<SEC-DOCUMENT>0001055726-20-000012.txt : 20200312
<SEC-HEADER>0001055726-20-000012.hdr.sgml : 20200312
<ACCEPTANCE-DATETIME>20200312155713
ACCESSION NUMBER:		0001055726-20-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200312
DATE AS OF CHANGE:		20200312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		20708685

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ino-12312019x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA0676BC6D8565EA89634FCDB2BA90CAF"></a></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#32;FOR THE FISCAL YEAR ENDED </font><font style="font-family:inherit;font-size:8pt;color:#000000;font-weight:bold;text-decoration:none;">DECEMBER&#160;31, 2019</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">OR</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">COMMISSION FILE NO.&#160;001-14888</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;">&#160;</font><font style="font-family:inherit;font-size:14pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:51%;"></td><td style="width:4%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">DELAWARE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">33-0969592</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Identification No.)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">660 W. GERMANTOWN PIKE, SUITE 110</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">PLYMOUTH MEETING,&#160;PENNSYLVANIA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">19462</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (267)&#160;440-4200</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</font></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:43%;"></td><td style="width:15%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Trading Symbol(s)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">COMMON STOCK, $0.001 PAR VALUE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">INO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nasdaq Global Select Market</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;No&#160;&#160;&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:23%;"></td><td style="width:3%;"></td><td style="width:47%;"></td><td style="width:24%;"></td><td style="width:3%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:Wingdings;font-size:8pt;">&#168;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">&#168;</font><font style="font-family:inherit;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</font><font style="font-family:Wingdings;font-size:8pt;">x</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June&#160;28, </font><font style="font-family:inherit;font-size:8pt;">2019</font><font style="font-family:inherit;font-size:8pt;">&#32;was approximately $279,656,181 based on $2.94, the closing price on that date of the Registrant&#8217;s Common Stock on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was </font><font style="font-family:inherit;font-size:8pt;">145,803,086</font><font style="font-family:inherit;font-size:8pt;">&#32;as of </font><font style="font-family:inherit;font-size:8pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:8pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2020 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended </font><font style="font-family:inherit;font-size:8pt;color:#000000;text-decoration:none;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:8pt;">.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s47DB1AB2FBB45AAD952F50BF153AFA52"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:83%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s18A11B75F2165A0F87A74A4D2F58CF1A"><font style="font-family:inherit;font-size:10pt;">PART I</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s18A11B75F2165A0F87A74A4D2F58CF1A">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEAD46D742BBE59EA94C99ACDB6B4D283"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;1. BUSINESS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sEAD46D742BBE59EA94C99ACDB6B4D283">2</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC56466F36F875D3597E05B0C20DE9A8D"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;1A. RISK FACTORS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC56466F36F875D3597E05B0C20DE9A8D">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1FE495A5E83955F5A4BC16EC6765CC39"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1FE495A5E83955F5A4BC16EC6765CC39">62</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s150B49A5408A5427A501C16D50591D4C"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;2. PROPERTIES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s150B49A5408A5427A501C16D50591D4C">63</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9747623C098F5379BE26D36817DB48F3"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;3. LEGAL PROCEEDINGS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9747623C098F5379BE26D36817DB48F3">63</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68CE1EFC87185C3B9E94E567F3B49A6C"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;4. MINE SAFETY DISCLOSURES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s68CE1EFC87185C3B9E94E567F3B49A6C">63</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s263CF4CC2F275661A8C63101B67916FD"><font style="font-family:inherit;font-size:10pt;">PART II</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s263CF4CC2F275661A8C63101B67916FD">64</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD4204899D6725A72927A72ED6B29BA9F"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD4204899D6725A72927A72ED6B29BA9F">64</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1191792FC3785B6F907274EB532DADCF"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;6. SELECTED FINANCIAL DATA</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1191792FC3785B6F907274EB532DADCF">65</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC0C5D793231D504A884D4A60A018E649"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC0C5D793231D504A884D4A60A018E649">67</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s950191C412FF5579A05932FB295BF00A"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;7A. QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s950191C412FF5579A05932FB295BF00A">76</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85802ED77D02552CA73DC6A0D54542A6"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s85802ED77D02552CA73DC6A0D54542A6">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2972D74C188A56C5B0DB4C0CAE1F7B9A"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2972D74C188A56C5B0DB4C0CAE1F7B9A">77</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s20A6DDC7A3525D66A25EFB92A47AC0A5"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;9A. CONTROLS AND PROCEDURES</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s20A6DDC7A3525D66A25EFB92A47AC0A5">77</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sb4d1fe50ce8645c4893c7fe6cef6193a"><font style="font-family:inherit;font-size:10pt;">ITEM 9B. OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sb4d1fe50ce8645c4893c7fe6cef6193a"><font style="font-family:inherit;font-size:10pt;">76</font></a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A0703D8358B53B2976BD396B9E4594A"><font style="font-family:inherit;font-size:10pt;">PART III</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8A0703D8358B53B2976BD396B9E4594A">80</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AD57C3FFFCD5AA09E9887449F898019"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AD57C3FFFCD5AA09E9887449F898019">80</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF975FB98BF665B43BD0DD2F8887F93CC"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;11. EXECUTIVE COMPENSATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF975FB98BF665B43BD0DD2F8887F93CC">80</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6D4420CC12105C39B30A25FAFFF8F053"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6D4420CC12105C39B30A25FAFFF8F053">80</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s491E816111E35BB0962FBA70543DFA40"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s491E816111E35BB0962FBA70543DFA40">80</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sECD9FCCE0A6F5DFBABA846C2A9B60E29"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sECD9FCCE0A6F5DFBABA846C2A9B60E29">80</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE43480E06B9F55D6BE7C581FA4964864"><font style="font-family:inherit;font-size:10pt;">PART IV</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE43480E06B9F55D6BE7C581FA4964864">81</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3C4C60F06E8D571ABB74A9DA03E3F51C"><font style="font-family:inherit;font-size:10pt;">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3C4C60F06E8D571ABB74A9DA03E3F51C">81</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBB440CAF63A751F79FCA1122D5E12938"><font style="font-family:inherit;font-size:10pt;">ITEM 16. FORM 10-K SUMMARY</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBB440CAF63A751F79FCA1122D5E12938">84</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8559EEA445AE5F89852791CBA75F5868"><font style="font-family:inherit;font-size:10pt;">SIGNATURES</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8559EEA445AE5F89852791CBA75F5868">85</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s314A53240F59593D98C67F842AF6B856"><font style="font-family:inherit;font-size:10pt;">CONSOLIDATED FINANCIAL STATEMENTS</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s314A53240F59593D98C67F842AF6B856">F-1</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless stated to the contrary, or unless the context otherwise requires, references to &#8220;Inovio,&#8221; &#8220;the company,&#8221; &#8220;our company,&#8221; &#8220;our,&#8221; or &#8220;we&#8221; in this report include Inovio Pharmaceuticals, Inc. and its subsidiaries.</font></div><div style="line-height:120%;padding-bottom:22px;padding-top:22px;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></div><hr style="page-break-after:always"><div><a name="s18A11B75F2165A0F87A74A4D2F58CF1A"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="sEAD46D742BBE59EA94C99ACDB6B4D283"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This Annual Report on Form 10-K (including the following section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This Annual Report includes trademarks and registered trademarks of Inovio Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;Inovio&#8221; or the &#8220;Company&#8221; refer to Inovio Pharmaceuticals, Inc. and its subsidiaries. References herein to &#8220;DNA medicine&#8221; refers to Inovio&#8217;s product candidates for cancer and infectious diseases in development.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Description of Business </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, we have demonstrated that DNA medicine can be delivered directly into cells in the body through our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our novel DNA medicine candidates are made using our proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person&#8217;s immune system recognize and destroy cancerous or virally infected cells.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our hand-held CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device in more than 6,000 administrations across more than 2,000 patients.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate Strategy </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate strategy is to advance, protect, and once approved, commercialize our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and clinically validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated diseases, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; Human Immunodeficiency Virus (HIV); Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and COVID-19 (coronavirus).  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Differentiated DNA Medicines Platform </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Overview of our platform </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe that stimulating the immune system specifically to treat or prevent cancers and infections is a compelling concept. We also believe the opportunity for immune-activating DNA medicines has become especially promising in the wake of recent technology advancements, such as checkpoint inhibitors, which have had a significant impact on the way certain cancers are treated. Still, despite promising results in clinical trials and drug approvals in limited indications, there remains a critical need and opportunity for further advancements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our DNA medicines platform is comprised of precisely designed DNA plasmids -- circular strings of DNA that contain an optimized genetic sequence of an antigen or monoclonal antibody specific to a targeted disease to be produced independently inside a cell. The proprietary design and optimization process of our DNA plasmids is called SynCon</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. These plasmids are delivered directly into cells in the body by our proprietary CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices, which apply transient electrical energy to facilitate significant cellular uptake of the plasmids. Once inside the cell, the plasmids enhance the ability of the body&#8217;s intracellular machinery to temporarily produce the target antigen or monoclonal antibody. We believe that together, these technologies may have versatile capabilities both in terms of myriad disease targets as well as product opportunities. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The characteristics and core components of our DNA medicines platform include: </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SynCon</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Design Process:</font><font style="font-family:inherit;font-size:10pt;">&#32;Our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;optimized plasmids have shown the ability to help break the immune system&#8217;s tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;Smart Device:</font><font style="font-family:inherit;font-size:10pt;">&#32;Our DNA medicines are injected directly into the cells of the body using our hand-held CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices. Our application allows the patient&#8217;s body to facilitate cellular uptake of the plasmids, which then enhances the ability of the intracellular machinery to temporarily produce the target antigen or monoclonal antibody. Our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices facilitate optimized cellular uptake of our DNA medicines, overcoming a key limitation of DNA-based immunotherapies. An antigen produced in this manner induces the immune system to generate polyclonal antibodies or T cells with the ability to perform their preventive or therapeutic functions. Similarly, DNA-encoded monoclonal antibodies, or dMAbs&#8482; generated in this manner can also trigger desired immune system functions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Our DNA medicines have generated best-in-class in vivo immune responses: </font><font style="font-family:inherit;font-size:10pt;">With our core platform technologies, we have developed a pipeline of clinical-stage product candidates that have generated best-in-class in vivo immune responses, in particular CD8+ T cells that are fundamental in eliminating cancerous or infected cells. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Our DNA medicines work more naturally with the immune system: </font><font style="font-family:inherit;font-size:10pt;">Our DNA medicines are non-live and non-replicating, and therefore do not cause the underlying disease. Compared to other technologies, our DNA medicines are designed to work more naturally with the immune system and within its controls to reduce or minimize the risk of unwanted inflammatory responses. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our mechanism of action for our DNA medicines process is shown in the figures below. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;involves the proprietary design and optimization of our DNA based plasmids, which are delivered directly into cells in the body by our proprietary CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:30px;"><img src="a10kimage.jpg" alt="a10kimage.jpg" style="height:597px;width:466px;"></div><div style="line-height:120%;padding-top:6px;"><img src="moa.jpg" alt="moa.jpg" style="height:301px;width:648px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DNA Medicine Platform in Detail: Delivery Science  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goal of our DNA medicines platform is to generate and deliver safe and effective therapeutics and vaccines. Our technology allows us to enable in vivo generation of functional immune responses to achieve desired therapeutic and preventive outcomes. Historically, we have focused primarily on in vivo production of disease-specific antigens directly in the body to stimulate prophylactic or therapeutic immune responses. More recently, we have explored an additional new application for the platform: in vivo generation of monoclonal antibodies to achieve preventive and therapeutic outcomes complementary to our antigen-generating immunotherapies. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With these core technologies, we have developed a robust pipeline of over 10 clinical-stage product candidates that have generated robust in vivo immune responses, in particular responses of CD8+ T cells, which have been observed to be fundamental in eliminating cancerous or infected cells. Clinical results to date have shown a favorable safety profile of our DNA medicines in more than 6,000 administrations across more than 2,000 patients to date. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are two components to our DNA medicines platform. The first is our biological component, known as the SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;immunotherapy platform, where we encode antigens into close-circular DNA plasmids. These DNA plasmids are highly optimized antigens or transgene proteins that have been optimized to drive increased expression intracellularly while also driving immune responses. All of our DNA plasmids are facilitated by our proprietary CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices technology which is the second component of our platform. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">SynCon</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;DNA Medicines</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;DNA medicines are designed to treat an existing disease (therapeutic) or prevent a disease (prophylactic) by activating and magnifying an immune response to one or more disease-specific antigens (proteins associated with a cancer or infectious disease that the body will recognize as foreign or not normal). Our DNA medicine candidates are able to direct the patient&#8217;s immune system to fight specific organisms or cells in a highly targeted and robust fashion, without the potential cost and quality control and manufacturing challenges of medicines involving </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ex vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;processes, such as T cells with chimeric antigen receptors, or CAR-Ts. We do this by introducing the specific genetic code for a target antigen into the cells of the body that will serve as a temporary antigen production facility.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our DNA medicines consist of one or more DNA plasmids encoding one or more selected antigens. Our proprietary smart devices enables significant uptake of the DNA plasmids by cells in localized tissue, which is typically muscle in the arm, to cause a therapeutic response and for the skin to induce a protective response, as described below.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the DNA code for the targeted antigen(s) is introduced into cells, the cells&#8217; natural machinery for producing proteins temporarily produce the selected antigen(s) encoded by the DNA sequences. The antigenic proteins manufactured through this process are then presented to the immune system and trigger one or both of two arms of the immune system:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the production of preventive antibodies, through a process known as a humoral immune response; and/or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the activation of therapeutic CD8+ T cells, through a process known as a cellular or cell-mediated immune response. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These responses then neutralize or eliminate infectious agents, such as&#160;viruses, bacteria, and other microorganisms, or abnormal cells, such as&#160;malignant tumor or infected cells. T cells can be immediately &#8220;trafficked&#8221; to parts of the body where cells are displaying the target antigen. Memory cells are also created for durable effects.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;DNA medicines are designed to generate antigen-specific antibody and T cell responses. First, we identify one or more antigens that we believe are the best targets, based on extensive due diligence, pre-clinical and clinical data that we have evaluated to direct the immune system toward a particular cancer or infectious disease. We then apply our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;precision design process, which uses the genetic make-up of the selected antigens from multiple variants of a cancer or strains of a virus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For each antigen we create a new genetic sequence that represents a consensus of the slightly different DNA from multiple variants or strains of the targeted antigen. We can create a differentiated SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;variant to help the immune system better recognize a cancer self-antigen (a cell and antigen grown in the body) and &#8220;break the tolerance&#8221; of cancer cells in the body. In human clinical trials, we have generated immune responses with SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;DNA medicines that were not matched to different strains of an infectious disease, such as influenza or HIV, indicating that such immunotherapies may have more universal protective capabilities against unmatched strains of a circulating virus. As a result, these SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;constructs may provide a solution to broadly cover the genetic &#8220;shift&#8221; and &#8220;drift&#8221; that is typical of many infectious diseases. This new engineered sequence is similar to the originating sequences but does not match any, so we believe it is patentable. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;sequence is inserted into a circular DNA plasmid with its own promoter. The plasmid is optimized at the DNA level for codon usage, improved stability of messenger RNA, or mRNA, and provided with enhanced and proprietary leader sequences for ribosome loading; it is optimized at the genetic level to enable high expression in human cells. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of the coded antigen to enhance the overall ability of the immunotherapy to induce the desired immune response.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The plasmids are then manufactured in a bacterial fermentation process using scalable technology. These manufactured DNA medicines can be stable under normal environmental conditions for extended periods of time.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our DNA medicine product development platform also allows for rapid design, pre-clinical testing, manufacturing, and clinical development of our DNA vaccine and DNA immunotherapy product candidates. Speed is an important feature, particularly as it relates to developing a response to globally emerging infectious diseases. Responses to emerging infectious diseases that we have been involved in are described in more detail below. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Delivery Technology</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our DNA medicines are delivered directly into cells of the body in a small local area of tissue using our proprietary CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device. CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;uses controlled, locally applied millisecond electric pulses to create temporary and reversible permeability, or pores, in the cell membrane, all of which we believe is necessary for the effective delivery of nucleic acids into the cell. Through this process, the cellular uptake of the DNA plasmids increases by more than 1,000 fold compared to the injection of a DNA plasmid alone without other delivery mechanisms. This improved cellular uptake has enabled the immune responses that we have observed in our clinical trials along with the efficacy results generated by these immune responses.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Alternative delivery approaches based on the use of viruses, bacteria, nanoparticles and lipids are complex and expensive and have generated safety concerns. Because the vector itself possesses many additional antigens specific to the vector, it can attract unwanted immune responses that are believed to compromise the vectors&#8217; ability to deliver their DNA &#8220;payload&#8221; and provide protection. In contrast, DNA plasmid vectors possess no antigens of its own; the plasmid results in production of only the target antigen.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have published preclinical data in which we observed improved immune responses generated by our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;DNA medicines delivered using CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;compared to a leading viral vector-based approach (Adenovirus type 5). We are not aware of any published data indicating the capability of alternative technologies focused on using genetic code to generate preventive or therapeutic antigens to exceed our immune response data obtained to date, nor to match the efficacy and immune response data generated in our controlled Phase 2b study of our product candidate VGX-3100, described below, based on </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;production of such immune responses.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The delivery of our synthetic DNA medicines using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices to date has shown a favorable safety profile in clinical trials, without serious adverse events and only transient mild local injection-related side effects such as redness and swelling. Our delivery is designed to be tolerable without the need for an anesthetic, and because it does not induce unwanted immune responses, it can be repeatedly administered for booster vaccinations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices provide a straightforward, cost-effective method for delivering our DNA medicines into cells with high efficiency, minimal complications and the ability to enable what we believe to be clinically relevant levels of gene expression, immune responses, and efficacy.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Choice of Tissue for DNA Medicine Delivery</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Skeletal muscle has been a core focus for delivery of DNA medicines via CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;because it is mainly composed of large elongated cells that are non-dividing, meaning that longer-term expression can be obtained without integration of the gene of interest into the genome. We have generated pre-clinical and clinical evidence that muscle cells may have a capacity for secretion of proteins into the blood stream. Secreted therapeutic proteins may therefore act systemically and produce therapeutic effects in distant tissues of the body. In this respect, the muscle functions as a factory for the production of the biopharmaceutical needed by the body. We envision that delivery of DNA medicines by CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;to muscle cells will circumvent the costly and complicated production procedures of viral gene delivery vectors, bacterial gene delivery vectors, protein-based drugs, conventional vaccines and monoclonal antibodies. This approach may provide long-term stable expression of a therapeutic protein or monoclonal antibody at a sustained level.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to generating pre-clinical and clinical evidence that intramuscular DNA delivery can be effective for a number of immunotherapies, we are also exploring delivery to the skin as a relevant route of administration for DNA vaccines. Skin or intradermal administration is important and is becoming an attractive site for immunization given its high density of antigen presenting cells (APCs). Unlike muscle, skin is the first line of defense against most pathogens and is therefore rich in immune cells and molecules. Skin specifically contains certain cells that are known to help in generating a robust immune response. With intradermal delivery, we may be able to demonstrate a comparable immune </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">response to muscle delivery. DNA medicine delivery into skin, or dermal tissue, is attractive given that the skin is the largest, most accessible, and most easily monitored organ of the human body, and it is highly immuno-competent, meaning that it is able to recognize antigens and mount an immune response to them.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Smart Delivery Systems</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are several configurations in the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device family. The first configuration covers intramuscular (IM) delivery of DNA medicines; the second covers intradermal/subcutaneous delivery (ID) of DNA medicines. Smart devices with these configurations have been validated, manufactured under Current Good Manufacturing Practices (cGMP) and are being used in human clinical trials. We have filed device master files (MAF) with the U.S. Food and Drug Administration (FDA) covering the use of the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart devices in human clinical trials. These devices are intended to be used in combination with our DNA medicines.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">-</font><font style="font-family:inherit;font-size:10pt;">SP smart devices combine the functionality of our current generation of skin and intramuscular devices in clinical testing with enhanced form, design and portability. All components of the pulse generator and applicator are integrated into a cordless, rechargeable device. The rechargeable battery can enable immunization of several hundred subjects, making the device useful for mass vaccinations. The devices are designed to accommodate different electrode arrays to meet the requirements of the particular DNA medicine and targeted tissue for delivery.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Next-Generation Smart Device Development</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also advancing a new generation of ID delivery devices called CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-3P. Currently used ID devices penetrate no more than 3 mm into the target tissue, compared to IM devices that go deeper. All of our current vaccine clinical studies are using these CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-3P smart devices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been researching other avenues for needle-free, contactless technology for DNA medicine delivery. With the advancement of these devices our aim is to make DNA delivery amenable to mass prophylactic vaccination by decreasing dose levels, increasing tolerability of the vaccination, increasing the breadth of viable immunotherapy targets, and enhancing portability. Based on our data from preclinical studies of influenza, HIV, malaria, and smallpox antigens, we believe that DNA delivery with this newer generation of ID delivery, including surface electroportation (SEP) devices, has the potential to yield levels of immunogenicity in terms of both antibody and T cell responses and/or efficacy against a virus challenge that are comparable to IM delivery devices currently in clinical development.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016,&#160;we acquired needle-free jet injection technology, devices and intellectual property from Bioject Medical Technologies Inc. We are developing an integrated non-invasive delivery device combining Bioject&#8217;s jet injection technology with our needle-free SEP technology. Bioject&#8217;s needle-free devices, which use high pressure gas or springs to propel liquid medicine into skin, have been observed to have desirable utility, safety and tolerability attributes in preclinical studies and clinical trials. Under a prior research agreement, we had assessed the combination of Bioject technology with our new delivery system and generated compelling antigen expression and immune responses in animal studies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2019, we announced that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of our new commercial ID delivery device. DTRA will provide $8.14 million of grant funding to support us in developing a small, portable, battery-powered ID device to be branded as CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;-3PSP, which will be used in the administration of our vaccines and therapies, including DTRA-developed products. In addition to the development of CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; _</sup></font><font style="font-family:inherit;font-size:10pt;">3PSP, this award will fund the investigation of DNA vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the new device.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our DNA Medicines Development</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary focus is to advance and potentially commercialize our DNA medicine product candidates developed from our optimized plasmid design and delivery integrated technology platform. Using this platform, we are currently developing a number of DNA medicines for the prevention or treatment of HPV-associated diseases, cancer and infectious diseases. The table below summarizes the status of our product development programs.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active DNA Medicines Development Programs</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><img src="inoviopipelinefor10k21920.jpg" alt="inoviopipelinefor10k21920.jpg" style="height:524px;width:648px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DNA Medicines and Immuno-Oncology </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Background</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been multiple technology advancements and product approvals that have highlighted the potential of immunotherapies to usher in a new era of cancer therapeutics. Monoclonal antibodies (mAbs) such as Herceptin</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and dendritic cell therapy Provenge</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;for prostate cancer have had varying degrees of success. While a significant step forward, suitable monoclonal antibodies with desired characteristics have been difficult to design or identify and expensive to produce, and the technology does not lend itself to designing mAbs for many diseases. Dendritic or other cell-based therapy is a highly personalized medicine involving removing cells from the patient, modifying them, multiplying them, and then returning them to the body. In addition to the high cost and complex processes to manufacture products, a weakness of this approach is that it has not been shown to generate high levels of cancer-specific T cells.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progress in the field of immune checkpoint inhibitors (CIs) has resulted in optimism regarding the potential for new immunotherapies against a spectrum of cancers. The immune system relies on a safeguard system of checkpoint </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mechanisms to prevent excessive or incorrectly directed immune responses. Many cancer cells have the ability to &#8220;hijack&#8221; these checkpoints and neutralize T cells sent by the immune system to eliminate them. Checkpoint inhibitors prevent cancer cells&#8217; ability to interfere with these checkpoints and enable T cells (especially CD8+ killer T cells) to complete their appropriate and intended killing function against cancer cells. Clinical trials of checkpoint inhibitors have shown notable therapeutic impact against melanoma and other cancers, but with response rates in the 15-20% range (and only in the case of melanoma going up to the 40% range or higher), there remains a significant opportunity. Observations suggest CIs may be less effective if there is not a high enough pre-existing level of antigen-specific CD8+ T cells in the tumor micro-environment, meaning that the tumor is &#8220;cold&#8221; rather than &#8220;hot&#8221; (with a significant level of CD8+ T cells). More recently, scientists have recognized that a strong CD8+ T cell generating &#8220;active&#8221; immunotherapy may be able to transform a "cold" tumor into a "hot" tumor and in combination with CIs may possess significant therapeutic potential to fight cancers.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">More recently, a new category of immunotherapies called adoptive cell transfer, for example CAR-T technology, has provided further evidence of the merit of providing an enhanced T cell presence to fight cancer. CAR-T therapies have achieved dramatic results in B cell cancers. Unfortunately, they have also been associated with significant side effects. When this technology has been applied to solid tumors, it has generated significant cytokine storms that have resulted in severe side effects, including deaths. Moreover, adoptive cell transfer such as CAR-T, like dendritic cell therapy, involves removing T cells from a patient, modifying them to better target a cancer cell, multiplying the T cells, then returning them to the patient. These complex therapeutic products need to be manufactured and released for each patient, leading to expensive manufacturing and increased supply chain complexity.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even though there have been promising technology advancements in recent years that better harness or activate capable killer T cells, we believe there is still significant untapped potential to develop &#8220;ideal&#8221; immunotherapies to fight cancers and infectious diseases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">What is an &#8220;ideal&#8221; active immunotherapy? We seek to advance product candidates that are effective, efficient and safe, specifically those that:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">target disease-specific antigens or proteins unique to a cancer or infectious disease;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">do not depend on complex manufacturing processes such as removal of dendritic cells or T cells from the patient that are then modified in the laboratory, amplified and then re-introduced in the patient as autologous or allogeneic cell based therapies;</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-top:6px;text-align:left;text-indent:29px;"><font style="padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">activate functional</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;">&#32;</font><font style="font-family:inherit;font-size:10pt;">killer T cells with the necessary killing tools, such as granzyme and perforin;</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">generate robust T cell responses or a significant number of T cells that are persistent and durable over time (memory response);</font></div></td></tr></table><div style="line-height:120%;padding-left:0px;padding-top:6px;text-align:left;text-indent:29px;"><font style="padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">do not induce unwanted immune responses;</font></div><div style="line-height:120%;padding-left:0px;padding-top:6px;text-align:left;text-indent:29px;"><font style="padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">do not induce toxic inflammatory responses; and</font></div><div style="line-height:120%;padding-left:0px;padding-top:6px;text-align:left;text-indent:29px;"><font style="padding-top:6px;text-align:left;font-family:inherit;font-size:10pt;padding-right:18px;">&#8226;</font><font style="font-family:inherit;font-size:10pt;">are capable of &#8220;breaking tolerance&#8221; of cancer cells grown in the body.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Data from our Phase 2b data of VGX-3100, discussed below, show that our product candidates are capable of achieving these characteristics with our approach to activating significant antigen-targeted T cells. Based on this approach, we are advancing a growing pipeline of pre-clinical and clinical immunotherapy product candidates.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Platform Progress to Date</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">VGX-3100 for the Treatment of HPV-related Precancerous Lesions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview and Background</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human papillomavirus, or HPV, is a sexually-transmitted, persistent infection with one or more high-risk (HR) genotypes of that virus can lead to, and thus are the causative agents responsible for, cervical pre-cancers (cervical dysplasia), cervical cancer, other anogenital cancers, and head &amp; neck cancer, which is one of the most rapidly growing cancers in men. Scientific literature estimates that, at any given time, approximately 43% of the U.S. and world&#8217;s adult population is infected with HPV, and about 25% of adult men and 20% of adult women in the U.S. have a genital infection with one or more HR-HPV genotypes. The lifetime risk for acquiring an HPV infection of any genotype is about 70% in sexually active U.S. adults and about 80% worldwide.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HPV is the most common viral infection of the reproductive tract and is the major cause of cervical cancers. Almost 300 million women globally are estimated to be infected with HPV, with another 30 million additional cases that have progressed to the pre-cancerous stage. In the United States, an estimated 13,800 new cases of cervical cancer will occur in 2020, and an estimated 4,290 women will die of cervical cancer in 2020. Nearly 570,000 new cases of cervical cancer are diagnosed annually world-wide, and more than 311,000 women die from this cancer each year. Virtually all </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">cases are linked with persistent infection with HPV. Challenges with acceptance, accessibility and compliance of vaccines to prevent HPV infection and the resulting pre-cancers and cancers have resulted in only about 40% to 60% of adolescent to young women being vaccinated in the United States, and even lower proportions have been vaccinated in some of the other countries around the world which have access to those vaccines.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While approximately 90% of HPV infections are ultimately cleared naturally by the body's own immune system, persistent cervical infection with one or more HR-HPV genotypes can lead to cervical high-grade squamous intraepithelial lesions (HSILs) and, if untreated, eventually invasive cervical cancer. Researchers have estimated the global prevalence of clinically pre-cancerous cervical HSILs at between 28 and 40 million. HPV-16 and HPV-18 are the two most prevalent high-risk types of HPV worldwide, causing the significant majority of HPV-related cancers. In the United States, HPV-16/18 are found in about 45% to 50% of all cervical HSILs and about 70% of invasive cervical cancers.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated annual incidence of cervical HSIL caused by HPV-16 and/or HPV-18 is approximately 195,000 persons in the United States and 233,000 persons in Europe. We believe these patients represent a significant market opportunity for our product candidates. Cervical HSIL can currently only be treated by an invasive surgical procedure.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To prevent HPV infection, there is currently one FDA-approved preventive vaccine available in the United States, called Gardasil</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;9. That vaccine protects against infection by nine total HPV genotypes, consisting of seven genotypes that confer high risk for cancer and two that confer risk for genital warts. However, preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes, which is a large population. In addition, many girls and women eligible to be vaccinated have not been receiving these vaccines. In 2017, a U.S. national survey found that only 57% of girls aged 13-17 years were up to date with the HPV vaccine series. Currently there is no viable immunotherapy or drug to fight established HPV infection or treat cervical dysplasia and/or cancer caused by HPV.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current management options for cervical HSIL are unappealing. The &#8220;watch-and-wait&#8221; process associated with low grade squamous intraepithelial lesions (LSIL, formerly called low-grade dysplasia or CIN 1) and in some young women with higher grade lesions (CIN 2) is a stressful approach. The only available treatment option for cervical HSIL is surgery, which involves ablating or cutting a women&#8217;s cervix to remove the pre-cancerous lesions. While surgical procedures are generally initially effective in removing lesions, they can lead to short-term adverse effects including cervical scarring, excess bleeding and infection, and to longer-term reproductive risks such as pre-term birth, miscarriage, and perhaps infertility. Current excisional and ablative procedures nearly double the overall risk of pre-term births from 5.4% to 10.7%, according to Kyrgiou et al in a major meta-analysis published June 2016 in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">British Medical Journal. </font><font style="font-family:inherit;font-size:10pt;">Anticipation of these procedures produces significant anxiety for patients, despite their doctor&#8217;s reassurances, and full recovery from surgery can take up to several weeks. Because surgery does not clear the underlying HPV infection, there is a 10-16% chance of high-grade pre-cancer lesion recurrence after surgery as a result of persistent HPV infection and/or incomplete removal of the lesion, with the persistent HPV infection being the better predictor of recurrence.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidate VGX-3100 is designed to significantly increase T cell immune responses against the E6 and E7 antigens of high-risk HPV types 16 and 18 that are present in both precancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into precancerous and cancerous cells, thus making them appealing targets for T cell directed immunotherapy. The goal of VGX-3100 is to stimulate the body's immune system to mount a killer T cell response strong enough to cause the killing of cells producing the E6/E7 protein. The potential of such an immunotherapy would be to treat precancerous dysplasias caused by these HPV types.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">VGX-3100 for the Treatment of Cervical High-Grade Squamous Intraepithelial Lesion (HSIL)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 2b</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Study Results</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, we published clinical data from our randomized, placebo-controlled, double-blind Phase 2b study of VGX-3100 in The Lancet in a paper entitled, &#8220;Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled Phase 2b trial.&#8221; We initiated this study in March 2011 using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;device in women with HPV type 16 or 18 and diagnosed with, but not yet treated for, cervical HSIL (also called high grade cervical intraepithelial neoplasia (CIN 2/3)).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This paper reported further details regarding the characteristics of T cells generated and their association with efficacy outcomes. Analyses of patient immune responses showed that overall antigen-specific T cell levels in women treated with VGX-3100 were greater than those treated by placebo at all observation periods. At week 14, levels of CD8+ T cells specific to the E6 and E7 HPV antigens in women treated with VGX-3100 were ten times greater than those in the placebo group. This response increased with each of the three immunizations, then declined modestly to a sustained and durable level of T cells (memory T cells) measured through 36 weeks (24 weeks post-treatment).</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients whose lesions regressed had higher frequencies of HPV-specific CD8+ T cells which co-expressed key molecules important in the T cell killing cascade and directly correlated with clinical efficacy. Specifically, higher levels of CD8+ killer T cells co-expressing checkpoint molecule CD137 on their surface, as well as the cytolytic protein perforin, were observed to be a predictive tool for efficacy. As a strong activation marker for CD8+ T cells, stimulation through CD137 has been shown in some systems to confer resistance of CD8+ T cells to the suppressive activity of regulatory T cells, indicating that its presence can identify tumor reactive T cells. Perforin is a pore-forming protein deployed by killer T cells to bore holes into the target cell's plasma membrane and destroy the cell. The difference in frequencies of CD8+ T cells expressing CD137 and perforin was greatest in patients who had both regressed their lesions and cleared HPV as compared to patients who did not.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To our knowledge, this was the first published study from which a direct correlation between antigen-specific CD8+ T cells generated </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;and clinical efficacy was observed. We have identified several key biomarkers of killer T cells that we believe can be used to predict the clinical efficacy of VGX-3100, as well as other immunotherapies, which we will seek to confirm in our ongoing Phase 3 trial.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 2b</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Trial Design </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The women in the Phase 2b study received either 6 mg of VGX-3100 or a placebo. VGX-3100 and placebo were administered using the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;device at months 0, 1 and 3. The study assessed efficacy by measuring regression of cervical lesions from CIN 2/3 to CIN 1 or normal in the treated versus control subjects. Immunological responses were also measured in this clinical study to assess the ability of this therapy to generate strong T cell responses in a larger, controlled study. Safety was also assessed.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary endpoint of the trial, histologic regression, was evaluated 36 weeks after the first treatment. In the per protocol analysis of this three-immunization regimen, CIN 2/3 resolved to CIN 1 or no disease in 53 of 107 (49.5%) women treated with VGX-3100, compared to 11 of 36 (30.6%) who received placebo. This difference was statistically significant (p=0.017). Intent to treat results were also similar and statistically significant.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There was also a high level of complete clearance of CIN 2/3 to that of a normal cervix. In a post-hoc analysis, CIN 2/3 resolved to no disease in 43 of 107 (40.2%) women treated with VGX-3100, compared to 6 of 36 (16.7%) who received placebo (p=0.006).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A secondary endpoint of the trial was virological clearance of HPV 16 or 18 from the cervix in conjunction with histopathological regression of cervical dysplasia to CIN 1 or no disease. This endpoint was achieved in 43 of 107 (40.2%) VGX-3100 recipients, compared to 5 of 35 (14.3%) placebo recipients (p=0.001). We believe this is an important outcome, as persistence of the HPV virus is associated with recurrence of cervical dysplasia.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All Phase 2b patients were monitored for an additional 52 weeks for a safety follow up. No significant safety issues were observed through week 88 following treatment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preparation and Launch of VGX-3100 Phase 3 Study</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In preparation for pivotal Phase 3 development and commercialization, we completed a manufacturing technology-transfer to a commercial manufacturing facility and scaled up manufacturing of VGX-3100.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also designed and manufactured a new smart delivery device, CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-5PSP, which is being used in our global Phase 3 clinical trial of VGX-3100. This smart device is a fully automated, smaller and user-friendly hand-held device. The new CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-5PSP smart device is being used in our ongoing VGX-3100 Phase 3 trial, which started in June 2017, and is being developed for potential commercial use.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have conducted additional market research with physicians and patients that have further characterized the unmet medical needs relating to the treatment of CIN 2/3 cervical dysplasia. These include a preference for a non-invasive, non-surgical procedure for removing cervical lesions; a treatment that can clear HPV, the cause of the pre-cancer, throughout the body and not just in the limited area of the lesion; and a treatment that does not result in pre-term births or infertility. We believe that CIN 2/3 represents a unique market opportunity for a novel therapy capable of providing a first-line alternative to surgery and in some cases even an alternative to watchful waiting. This market research will help guide our communication and interaction with the physician, patient and support communities.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 3 Program for VGX-3100 (REVEAL)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Phase 3 program, named REVEAL, consists of a primary study (REVEAL 1) and confirmatory study (REVEAL 2), in accordance with the&#160;FDA's&#160;general guidance for Phase 3 programs, to be conducted in parallel. The studies will each enroll 198 patients.&#160;Mark Einstein, MD, MS, FACS, FACOG,&#160;Professor and Chair Department of Obstetrics, Gynecology and Women&#8217;s Health Assistant Dean, Clinical Research Unit,&#160;Rutgers New Jersey Medical School, is Principal Investigator for the studies.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The REVEAL studies are prospective, randomized (2:1), double-blind, placebo-controlled trials evaluating adult women with HPV 16/18 positive biopsy-proven cervical&#160;HSIL (CIN 2/3). The primary endpoint is regression of cervical HSIL </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">and</font><font style="font-family:inherit;font-size:10pt;">&#32;virologic clearance of HPV-16 and/or HPV-18 in the cervix, which was a secondary endpoint that was achieved in our Phase 2b trial described above. Overall, the Phase 3 studies will evaluate cervical tissue changes at approximately 9 months after beginning a three-dose regimen of VGX-3100 administered at months 0, 1 and 3. Secondary endpoints include safety; tolerability; regression of CIN 2/3 to CIN 1 or normal; virologic clearance of HPV; efficacy measured by non-progression to cancer; and clearance of HPV from non-cervical anatomic locations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2019, we completed enrollment of 198 patients for the primary REVEAL 1 trial. Enrollment for the confirmatory REVEAL 2 trial is ongoing.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2019, VGX-3100 was granted an Advanced Therapy Medicinal Product Certificate by the European Medicines Agency, or EMA, for quality and non-clinical data. The procedure of certification of quality and non-clinical data involves an assessment of the available data in view of future registration and the related European Scientific Data Requirements, not including any clinical data or benefit-risk assessment. The granted EMA's certificate confirms that our chemistry, manufacturing and controls (CMC) data and nonclinical results available to date overall comply with the scientific and technical standards for evaluating an EU Marketing Authorization.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">VGX-3100 for the Treatment of Vulvar High-Grade Squamous Intraepithelial Lesion (HSIL)</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-cancerous lesions of the vulva, or vulvar intraepithelial neoplasia, or VIN, has less than a 5% rate of spontaneous, or natural, regression and there are no&#160;FDA&#160;approved non-surgical treatments. Surgery, the most common treatment, is associated with high rates of disease recurrence and can cause disfigurement, long-term pain, and psychological distress for the women who undergo the procedure. VIN recurs in approximately one of every two patients who undergo surgical treatment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, we commenced a Phase 2 trial to evaluate the efficacy of VGX-3100 in patients with VIN. This randomized, open-label Phase 2 clinical trial will assess the efficacy of VGX-3100 in 33 women with high-grade HPV-related vulvar lesions. VGX-3100 will be administered with our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;intramuscular delivery smart device. The primary endpoint of the study is histologic clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue samples. The study will also evaluate safety and tolerability of VGX-3100.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">VGX-3100 for the Treatment of Anal or Perianal HSIL</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Left untreated, anal HSIL may progress to cancer. Spontaneous regression of anal HSIL may occur, but only in the range of 20% to 29% of patients after one year of follow-up. Persistent infection with a high-risk HPV genotype is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/18 specifically.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no validated screening tests or a general screening recommendation consensus for anal HSIL. Currently, the treatments for anal HSIL consist of excising or ablating the lesion(s). Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, treatment of anal HSIL represents a significant unmet medical need due primarily to the high recurrence rates up to 49% one year after treatment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, we commenced a Phase 2 clinical trial to evaluate VGX-3100 in patients who are HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV 16 and/or 18. The open-label trial enrolled 24 patients who received 3 doses of VGX-3100 delivered by our intramuscular CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;device. The primary endpoint of the study is histologic clearance of the high-grade lesions and virologic clearance of the HPV 16/18 virus in anal/perianal tissue samples.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, in partnership with the AIDS Malignancy Consortium (AMC), we commenced a Phase 2 clinical trial to evaluate VGX-3100 in patients who are HIV-positive with histologically confirmed anal or perianal HSIL associated with HPV 16 and/or 18. The open-label trial will enroll approximately 75 patients who will receive 4 doses of VGX-3100 delivered by our intramuscular CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device. The primary endpoint of the study is histological regression of high-grade anal lesions to low-grade or normal. The trial is being fully funded by AMC.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">VGX-3100 Immune Correlates and Biomarker Signatures</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, we announced that a post-hoc analysis of data generated from our Phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures that were predictive of potential treatment success.&#160;Details of the new biomarker and immunologic data are highlighted in the peer-reviewed journal&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Cancer Research&#160;</font><font style="font-family:inherit;font-size:10pt;">in the article, &#8220;Clinical and Immunologic Biomarkers for Histologic Regression of High-grade Cervical Dysplasia and Clearance of HPV-16 and HPV-18 after Immunotherapy,&#8221; by us and our academic collaborators.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2019, we entered into a collaboration with QIAGEN N.V. to co-develop a liquid biopsy-based companion diagnostic for the related immune correlates and biomarker signatures to identify patients most likely to respond to VGX-3100. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ApolloBio Collaboration Agreement for VGX-3100 within Greater China</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, we entered into an amended agreement providing&#160;ApolloBio Corporation with the exclusive right to develop and commercialize VGX-3100 within&#160;Greater China&#160;(defined as China,&#160;Hong Kong,&#160;Macao and&#160;Taiwan). Additional details on the ApolloBio Agreement are provided below under "Business-License, Collaboration and Supply Agreements." </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the closing of the transaction in March 2018, we received proceeds of $19.4 million which comprised the upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. We may also receive potential milestone payments of up to $20 million in the aggregate. In addition, we are entitled to receive double-digit tiered royalty payments on sales. This collaboration of VGX-3100 encompasses the treatment and/or prevention of precancerous HPV infections and HPV-driven dysplasias (including cervical, vulvar and anal precancers) and excludes HPV-driven cancers and all combinations of VGX-3100 with other immunostimulants. The agreement also provides for potential inclusion of the Republic of Korea during the first three years of the term of the agreement.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis (RRP)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RRP is a rare disease (estimated at 15,000 active cases in the United States, including both juvenile and adult cases) that is characterized by the growth of tumors in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes.  Epidemiologic data are limited, but published clinical reports suggest this disease occurs worldwide. Although benign, papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of this disease is the tendency for the papilloma to recur after surgical procedures to remove them. Left untreated, if RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In extremely rare cases (less than 1%), papillomas can become cancerous (malignant transformation) developing into squamous cell carcinoma. Additional symptoms of RRP can include hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults. In children, the disorder is most often diagnosed at or around the age of four years. In adults, the disorder occurs most often in the third or fourth decade.</font></div><div style="line-height:120%;padding-top:6px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 3, 2020, we announced the publication of clinical data from a pilot clinical study of INO-3106 (DNA medicine candidate targeting HPV 6-associated RRP) in the scientific journal </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vaccines (MDPI)</font><font style="font-family:inherit;font-size:10pt;">. Study results demonstrated that INO-3106 generated immunogenicity and engagement and expansion of an HPV 6-specific cellular response, including cytotoxic T cells. Two out of two patients receiving INO-3106 who previously required approximately two surgeries per year for several years to manage this disease delayed their need for surgery, with one patient able to delay surgery for over a year and a half (584 days surgery-free) and the second remaining surgery-free for over two and a half years (915 days surgery-free).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2020, we commenced an open-label, multicenter Phase 1/2 trial that will enroll approximately 63 subjects in the United States and will evaluate the efficacy, safety, tolerability and immunogenicity of INO-3107 (our new product candidate designed to treat both HPV 6 and 11-associated RRP) in subjects with HPV 6 and/or 11-associated RRP who have required at least two surgical interventions per year for the past three years for the removal of associated papilloma(s). For this study, adult subjects will first undergo surgical removal of their papilloma(s) and then receive four doses of INO-3107, one every three weeks. The primary efficacy endpoint will be a doubling or more in the time between surgical interventions following the first dose of INO-3107 relative to the frequency prior to study therapy. If we obtain sufficient safety and potential efficacy data in adults, we plan to expand the trial to include pediatric patients as well as a potential booster regimen.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to initiating this efficacy trial, we also plan to seek orphan disease designation for INO-3107 from the FDA's Office of Orphan Products Development (OOPD). The FDA grants orphan designation to drugs and biologic products that are intended for the safe and effective treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States. Orphan disease designation can provide a drug developer with several benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MEDI0457 (VGX-3100 + INO-9012) for the Treatment of HPV-Associated Cancers</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview and Background</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HPV is also associated with some head and neck cancers, especially those in the oropharynx and perhaps to some extent the larynx and oral cavity. The incidence of HPV-caused oropharyngeal squamous cell cancer (OPSCC) has </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased significantly within the last 30 years in the United States, including a 225% increase from 1988 to 2004, an average annual increase of 14%. More recently, from 1999 to 2015, HPV-associated OPSCC incidence in the United States increased among men at an annual average rate of 2.7% and among women at an annual average rate of 0.8%, and by approximately 2009 the incidence of these HPV-associated mouth and throat cancers in men exceeded that of cervical cancers in women. Oropharyngeal cancer is the fastest-rising cancer among young white men in the United States, and U.S. men in general are about four times more likely than women to be diagnosed with HPV-associated oropharynx cancer. Increasing trends of the cancer in the United States are projected to continue at least through the year 2030. The estimated U.S. prevalence of HPV-caused oral cavity and pharynx cancer was approximately 108,000 cases in 2015.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, OPSCC was the most common HPV-associated cancer in the United States, with nearly 19,000 new cases diagnosed that year (15,479 cases among men and 3,438 cases among women). An estimated 53,260 new cases of this cancer in general, whether or not HPV-associated, are estimated to occur in 2020 in the United States, and an estimated 10,750 persons will die of this cancer in 2020. Worldwide, an estimated nearly 93,000 new cases of oropharyngeal cancer overall occurred in 2018, and about 25,400 to 29,000 cases per year of this cancer are HPV-associated.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scientists have estimated that by 2030 OPSCC will constitute the majority of all head &amp; neck cancers. About 70% of cancers of the oropharynx are now caused by HPV, with HPV-16 being the most prevalent genotype and causing about 86% of those HPV-caused cancers.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Improvements in primary treatment modalities (surgery and radiation) have produced significant improvements in morbidity, but intensive radiation has a profound long-term impact on mortality and quality of life. Based on these factors, we believe there is a significant opportunity for an effective immunotherapy.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Considering the several known cancers caused by HPV, the relative and total burden of those in terms of the annual U.S. average annual incidence rates and portions attributable to the HPV-16/18 genotypes for the period of 2008 to 2010 (the latest time period for which such HPV association and attribution data are available) are shown in the table below. In total for that period, an average of more than 30,000 cases of HPV cancers per year were diagnosed in the United States, and 80% (nearly 25,000) of those per year were specifically due to HPV-16/18 genotypes.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual Incidence of HPV-Attributable Invasive Cancers by Site in the United States, 2008-2010</font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:79.71163748712668%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Invasive Cancer tissue site</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;padding-top:2px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Avg. n in Sites where HPV is often found </font><font style="font-family:inherit;font-size:10pt;">(i.e. HPV-associated cancers)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cancers Attributable to Any HPV</font></div><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n (% of HPV-pos.)</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:2px;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cancers Attributable to HPV-16/18</font></div><div style="padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n (% of any HPV-attributable)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Oropharynx</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,972</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,567 (100%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;9,118 (86.3%)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cervix</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,976 (100%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;8,018 (73.1%)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anus</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,715</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;5,203 (100%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;4,537 (87.2%)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vulva</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;2,840 (100%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;2,009 (70.8%)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Vagina</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;830 (100%)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;609 (73.4%)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Penis</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,183</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;749 (100%)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;567 (75.7%)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:2px solid #000000;border-right:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:2px solid #000000;border-right:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,221</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:2px solid #000000;border-right:2px solid #000000;border-top:2px solid #000000;"><div style="padding-bottom:16px;padding-top:2px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">31,164 </font><font style="font-family:inherit;font-size:10pt;">(100%)</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:2px solid #000000;border-right:2px solid #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24,858 (80.0%)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Worldwide data estimates for the year 2012 are shown in the table below. For that year, an estimated 630,000 cases of new HPV cancer cases occurred, and more than 70% (430,000) of those cases were specifically due to HPV-16/18 genotypes.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Annual Incidence of HPV-Attributable Cancers by Site Worldwide</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;"><img src="grapha07.jpg" alt="grapha07.jpg" style="height:294px;width:677px;"></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MEDI0457 for the Treatment of Head &amp; Neck Cancer</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2014, we initiated a Phase 1 clinical trial assessing the immunogenicity and safety of our product candidate INO-3112 (consisting of a combination of VGX-3100 and our product candidate INO-9012) in head &amp; neck cancer patients. INO-3112 is now called MEDI0457, following our collaboration with AstraZeneca, described below. We added INO-9012, a DNA-based IL-12 immune activator, to VGX-3100 for this cancer study because our prior HIV vaccine clinical study had indicated that the addition of IL-12 to our DNA medicine could enhance the activation of CD8+ T cells.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enrolled 22 adults with HPV16 and/or HPV18-positive head &amp; neck squamous cell carcinoma (HNSCC) in this open-label Phase 1 trial. Patients were treated with four doses of MEDI0457 and then followed for safety, immune and clinical responses. In one part of the study, six patients were treated once with MEDI0457 before and after resection of their tumor. These patients received three additional doses subsequent to surgery and chemoradiation therapies. In the second part of the study, 16 patients were recruited into the study after their surgery and completion of chemotherapy and radiation therapy. These patients were treated with four doses of MEDI0457 and followed. Each MEDI0457 treatment was administered using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery system.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, at the Annual Meeting of the&#160;Society for Immunotherapy of Cancer&#160;(SITC), we reported interim immunology results showing that in the group of six patients treated before resection (one dose averaging 14 days and ranging 7 to 28 days prior to definitive surgery) and post-surgery (three additional doses), MEDI0457 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood in four of five subjects who also showed increased T cell activation in resected tumor tissue samples. One subject withdrew consent after surgery, leaving five evaluable subjects in this group.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we announced a paper published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Cancer Research</font><font style="font-family:inherit;font-size:10pt;">, a major cancer journal, detailing results of a patient with head and neck cancer treated with MEDI0457 who achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor. In our sponsored study of 22 patients with head and neck squamous cell carcinoma we reported 91% (20/22) of patients showed T cell activity in the blood or tissue.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we announced that a second patient with HPV-related head and neck cancer treated with MEDI0457 in a Phase 1 trial achieved a sustained complete response (full remission) after subsequent treatment with a PD-1 checkpoint inhibitor.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Both patients who achieved full cancer remission were treated with four doses of synthetic DNA medicine as part of the Phase 1 trial. This response indicates that synthetic DNA medicine generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue samples.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Of the four patients who developed progressive disease and were subsequently administered a PD-1 checkpoint inhibitor, two patients rapidly exhibited a complete response. The most recent patient for which data was presented in January 2019 received pembrolizumab (KEYTRUDA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">), while the previously reported complete responder was treated with nivolumab (OPDIVO</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">). The patients moved from metastatic head and neck cancer to no evidence of disease and they remain alive two years after treatment.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increasing evidence suggests that response rates from checkpoint inhibitors can be enhanced when used in combination with cancer vaccines like MEDI0457 that generate tumor-specific T cells. Interim data from a MEDI0457 monotherapy study of head and neck cancer patients demonstrated that MEDI0457 generated robust HPV16/18 specific CD8+ T cell responses in peripheral blood and increased CD8+ T cell infiltration in resected tumor tissue samples.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration with AstraZeneca</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, we formed a strategic collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AstraZeneca), focused on cancer immunotherapies. Under this agreement AstraZeneca licensed INO-3112 (renamed MEDI0457), to be studied in combination with selected immunotherapy molecules within its pipeline in HPV-associated cancers. See &#8220;Business- License, Collaboration and Supply Agreements&#8221; for additional information about the collaboration agreement.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we announced that AstraZeneca will conduct a Phase 1/2 clinical trial investigating the combination of MEDI0457 and durvalumab, a PD-L1 checkpoint inhibitor. The combination trial will enroll patients with metastatic HPV-related HNSCC with persistent or recurrent disease after chemotherapy treatment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The open-label clinical trial is evaluating the safety and efficacy of the combination therapy in 35 subjects with metastatic head and neck cancer at multiple U.S. sites. Subjects will receive multiple doses of MEDI0457 and durvalumab. The primary endpoints of the trial are safety and objective response rate. The trial will also evaluate immunological impact, progression-free survival and overall survival. The Phase 2 portion of this study was initiated in December 2017, and this initiation triggered a $7 million milestone payment from AstraZeneca to us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2018, we announced the dosing of the first patient in an open-label, Phase 2 combination trial to evaluate MEDI0457, in combination with durvalumab, in patients with HPV-associated cervical, anal, penile and vulvar cancers. This trial, which is being funded by AstraZeneca, has an estimated total enrollment of 77 patients.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The first dosing of a cervical cancer patient in this trial resulted in an additional $2.0 million milestone payment from AstraZeneca to us in 2018. A first dosing of a patient with a third distinct HPV-associated cancers other than H&amp;N or cervical triggered another $2.0 million milestone payment in April 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our collaboration agreement, AstraZeneca will fund all of the costs of developing MEDI0457.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INO-5151 (INO-5150 + INO-9012) for the Treatment of Prostate Cancer</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States in 2020, there will be an estimated 191,930 new cases of prostate cancer and more than  33,330 deaths occurred due to this cancer. Worldwide in 2018, an estimated 1.28 million new cases of and nearly 360,000 deaths occurred due to this cancer.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, we initiated a Phase 1 trial to evaluate our DNA immunotherapy for prostate cancer, INO-5150, in men with biochemically relapsed prostate cancer. This study is evaluating the safety, tolerability and immunogenicity of INO-5150 alone or in combination with INO-9012. The multi-centered study is also evaluating changes in prostate specific antigen, or PSA, levels, an important biomarker in prostate cancer. We have fully enrolled 62 patients in the trial across 4 dose cohorts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An interim data analysis presented in September 2017 at the European Society of Medical Oncology (ESMO) meeting in Madrid, Spain showed that INO-5150 had generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent prostate cancer. Treatment with INO-5150 as a monotherapy generated PSA and prostate specific membrane antigen, or PSMA, specific T cell responses in peripheral blood in 60% (35/58) of the subjects. Patients with specific CD8+ T cell responses experienced dampening in the rise of PSA and significant increases in PSA Doubling Times (PSADT).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, additional prostate cancer data from the trial was presented at the American Society of Clinical Oncology (ASCO) annual meeting. The additional data showed clinically meaningful PSA stabilization after administration of INO-5150 in patients, with no documented disease progression during the study. Of note, this effect was also observed in the patients with the fastest PSA doubling at the time of study entry.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we announced new data from the trial in which a slowing of Prostate-Specific Antigen Doubling Time (PSADT) was observed in men with prostate cancer. Eighty-six percent (86%) of patients remained progression-free at Week 72 of the study, and immunogenicity was observed in 77% (47/61) of patients by multiple immunologic assessments. These data were presented in a poster entitled &#8220;Synthetic DNA immunotherapy in Biochemically Relapsed Prostate Cancer&#8221; at the 2018 European Society for Medical Oncology (ESMO) congress.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, we announced a clinical collaboration agreement with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) in which our prostate cancer immunotherapy candidate INO-5151 will be combined with an immune modulator (CDX-301, FLT3 ligand, a dendritic cell mobilizer) and a PD-1 checkpoint inhibitor (nivolumab) targeting metastatic castration resistant prostate cancer (mCRPC) in a PICI sponsored platform </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">study. INO-5151 is a combined formulation of INO-5150 (with SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;antigens encoding for PSA and PSMA) and INO-9012 (DNA vector expressing interleukin 12).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This combination trial is an open-label, non-randomized, exploratory platform study designed to assess the safety and antitumor activity of multiple immunotherapy based combinations in participants with mCRPC who have received prior secondary androgen inhibition. This study will evaluate biomarkers of immune activity and clinical outcomes using a multi-omic, multi-parameter approach. Our immunotherapy is one arm (Cohort C) of this broad PICI-supported study, which is a multi-arm, multi-stage platform design.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the agreement, PICI will design and execute the clinical study, working in collaboration with its established network of the most pre-eminent clinical academic and industry cancer centers, and with funding support from CRI. Based on PICI's novel approach to accelerating studies of cancer immunotherapies, we will provide financial contributions based on the actual costs of the study, if our product(s) studied under the collaboration reaches the initiation of a Phase 3 study.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INO-5401 for the Treatment of Glioblastoma Multiforme (GBM)</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INO-5401 is an immunotherapy consisting of three tumor-associated antigens: hTERT, Wilms' tumor gene (WT1) and PSMA. The National Cancer Institute previously highlighted WT1, hTERT and PSMA among a list of attractive cancer antigens, designating them as high priorities for cancer immunotherapy development. WT1 was at the top of the list. The hTERT antigen relates to 85% of cancers and WT1 and PSMA antigens are also widely prevalent in many cancers.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, we reported data indicating that our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;WT1 cancer antigen was capable of breaking immune tolerance, a major challenge to researchers striving to develop potent cancer therapies, and induced neo-antigen-like T cell responses to cause tumor regression in pre-clinical studies. The results were published in the scientific journal </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Molecular Therapy</font><font style="font-family:inherit;font-size:10pt;">&#32;in an article entitled, &#8220;A novel DNA vaccine platform enhances neo-antigen-like T cell responses against WT1 to break tolerance and induce anti-tumor immunity.&#8221;</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While mice in the preclinical study did not mount an immune response to native mouse WT1 antigens, mice immunized with our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;WT1 antigen broke tolerance and generated robust neo-antigen-like T cells. The immunized mice also exhibited smaller tumors and prolonged survival in a tumor challenge study. SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;WT1 DNA vaccination also broke tolerance and generated neo-antigen-like T cell immune responses in Rhesus monkeys, a species whose immune system closely resembles that of humans. The ability to overcome the immune system&#8217;s usual tolerance of WT1 antigen suggests the potential of our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;WT1 antigen to tackle any WT1-expressing cancer in humans, including pancreatic, brain, lung, thyroid, breast, testicular, ovarian, and melanoma.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We previously reported similar results for our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;hTERT and PSMA cancer antigens.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These attributes of breaking tolerance and having broader prevalence across different cancers create the potential for INO-5401 to be an effective universal cancer immunotherapy in combination with different checkpoint inhibitors.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing INO-5401 for the treatment of GBM, a devastating disease for both patients and caregivers. GBM is the most aggressive brain cancer and its prognosis is extremely poor, despite a limited number of new therapies approved over the last 10 years. The latest available U.S. data for GBM is for the period of 2011 to 2015, when an average annual number of reported new cases was 11,229. The median overall survival for patients receiving standard of care therapy is approximately 15 months, and the average five-year survival rate is only 5.8% for urban residents and only 3.9% for rural residents.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we dosed the first patient as part of a Phase 1/2 immuno-oncology trial in patients with newly diagnosed GBM. The trial is designed to evaluate INO-5401 and INO-9012, in combination with cemiplimab (REGN2810 or Libtayo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">), a PD-1 inhibitor developed by Regeneron Pharmaceuticals.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The open-label trial of 50 newly diagnosed GBM patients is being conducted at approximately 25 U.S. sites, and the primary endpoint is safety and tolerability. The study will also evaluate immunological impact, progression-free survival and overall survival.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2019, we provided interim results from the Phase 2 study of newly diagnosed GBM patients. Key interim data from the 52-patient clinical trial showed that 80% (16 of 20) of MGMT gene promoter methylated patients and 75% (24 of 32) of unmethylated patients were progression-free at six months (PFS6) measured from the time of their first dose, substantially exceeding historical standard-of-care data.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This immunotherapy combination with a PD-1 checkpoint inhibitor also exhibited supportive safety, tolerability, and immunogenicity data and suggested a safety profile consistent with that of Libtayo</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and our other product candidates. The majority of patients tested had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401. Immune responses to all three tumor-associated antigens were demonstrated in this study.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, we announced the discontinuation of our Phase 1/2 study of INO-5401 in advanced bladder cancer. Although the bladder trial had yet to provide evaluable data, we decided to discontinue the study primarily due to several new therapeutic alternatives that have been approved, or that we believe are likely to be approved, for patients since the trial's design and inception.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Infectious Disease Product Candidates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product development platform also allows for rapid design, pre-clinical testing, manufacturing and clinical development of our vaccine and immunotherapy product candidates. In 2016, we were the first entity able to advance a Zika vaccine into human clinical trials, just 4.5 months after World Health Organization, or WHO, declared the emerging Zika infections to be a Pandemic Health Emergency of International Concern. Previously, we led the development of the first MERS vaccine in human clinical trials. More recently, our product platform and SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">sequencing capabilities allowed us to rapidly respond to the coronavirus outbreak of 2020, as we began preclinical testing in January 2020 and have started preparations for clinical product manufacturing. We believe that our development platform is well positioned to support global health agencies in order to develop preparedness countermeasures against bioterrorism and/or emerging pandemic agents.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">HIV</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since its discovery in 1981, HIV, the virus which causes AIDS, has killed an estimated 23.6 million to 43.8&#160;million people. Worldwide in 2018, there were an estimated 1.4 million to 2.3 million new HIV infections and 570,000 to 1.1 million deaths due to HIV. That year worldwide, an estimated 32.7 million to 44.0 million people were living with HIV worldwide. In 2018 in the United States and dependent areas (including Washington, DC and Caribbean and Pacific territories), 37,832 people received an HIV diagnosis. At the end of 2017, about one million people in the United States were living with HIV.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective vaccines have been actively pursued for over 30&#160;years, without significant success. HIV represents one of the most confounding targets in medicine. The virus's high mutagenicity (ability to mutate) has made effective vaccine development very challenging. Its outer envelope, swathed in sugar molecules, is difficult to attack, and HIV strikes the very cells that the immune system launches to thwart such an infection. Although several drugs (anti-retrovirals) are available to treat the patients once they are infected, vaccines and immunotherapies are necessary to stop the spread of disease and perhaps reduce the need for anti-retroviral treatment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noting that many long-term survivors have high counts of killer CD8+ T cells, the HIV vaccine and immunotherapy field has turned to stimulating the immune system to generate those cells. Recent HIV vaccine candidates used an adenovirus (a common human cold virus) genetically modified to contain code for HIV antigens to prevent viral replication. These vaccines have proven to not be effective. Somewhat recently, the RV-144 trial, which employed an ALVAC&#8482; (canary pox) vaccine prime followed by a protein vaccine boost, demonstrated 30% efficacy in preventing acquisition of infection amongst the vaccinated population compared to the control group. Although the efficacy was relatively modest, the finding for the first time showed that an immunotherapy may be able to combat spread of HIV and has spurred the development of newer immunotherapy candidates. However, quite recently the HVTN 702 Uhambo trial, which was assessing a prime-boost vaccine based on the regimen tested in the RV144 trial, was halted for new administrations of vaccine due to a non-safety finding of non-efficacy by the trial&#8217;s independent data and safety monitoring board (DSMB). Therefore, we continue to believe, that a different approach is needed to develop an effective vaccine or immunotherapy for HIV.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical and Clinical Development - HIV</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">PENNVAX</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">-GP - Preventive and Therapeutic Immunotherapies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP is a developmental vaccine intended to prevent and treat HIV strains present in Africa, Asia, Europe, and North America. Using&#160;our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology, it has been optimized to target two env antigens, as well as gag and pol antigens. This comprehensive targeting gives PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP the potential to provide global coverage against HIV-1 subtypes. PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP is delivered intramuscularly using our&#160;CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;smart delivery device. The development of the PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP program was funded by a seven-year, $25 million&#160;NIAID contract to us and our collaborators.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2015, the first patient was dosed in a Phase 1 trial to evaluate the safety and tolerability of PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP. This trial was conducted in collaboration with the HIV Vaccine Trials Network (HVTN). The trial measured immune responses following administration of the vaccine in four groups of healthy subjects receiving the vaccine with and without an immune activator (IL-12) and delivered into muscle or skin using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">smart delivery technology.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we announced results from the trial, in which PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP produced among the highest overall levels of immune response rates (cellular and humoral) ever observed in a human clinical trial by an HIV vaccine.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Overall, 71 of 76 (93%) evaluable vaccinated participants showed a CD4+ or CD8+ T cells cellular immune response to at least one of the four vaccine antigens. Similarly, 62 of 66 (94%) evaluated participants had an env specific antibody response. None of the placebo recipients (0 of 9) had either a cellular or an antibody response in the study. Notably, amongst the participants receiving PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP vaccine and IL-12 with intradermal immunization, 27 of 28 (96%) participants achieved a cellular response and 27 of 28 (96%) achieved an HIV env specific antibody response.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amongst the evaluated participants receiving PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP and IL-12 via intramuscular vaccination, 27 of 27 (100%) achieved a cellular response and 19 of 21 (90%) achieved an env specific antibody response. Similar immune responses and response rates were achieved via both intradermal and intramuscular administration of the vaccine, even though participants vaccinated via intradermal administration received 1/5th&#160;of the dose of vaccine compared to those vaccinated via intramuscular administration.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to our NIAID contract that funded our Phase 1 clinical trial of PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP, in 2015, we and our collaborators were awarded an additional $16 million Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) grant from the NIAID. We are using this additional grant to design and test new PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;envelope constructs with our DNA-based immune activator encoding novel cytokine genes in a prime-boost strategy with recombinant HIV envelope proteins. Our collaborators are assessing different combinations in preclinical models with the goal of generating high levels of neutralizing antibodies mirroring the robust CD8+ T cell responses generated by our PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-B DNA vaccine in previously published clinical studies. The overall goal of this project is to further build upon this important HIV vaccine approach as well as to gain fundamental insight into new technologies to improve vaccination outcomes.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we and our collaborators received an additional multi-year&#160;$7.0 million&#160;grant from NIAID&#160;to develop a single or combination therapy using PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP, with the goal of attaining long-term HIV remission in the absence of antiviral drugs. This is a two-step clinical study in HIV-positive subjects to assess PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP with INO-9012 alone and with the addition of a PD-1 checkpoint inhibitor. All trials will be randomized, double-blind, placebo-controlled assessments of PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP and will be conducted at the&#160;University of California in San Francisco&#160;and&#160;Los Angeles.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, we announced that the first participant had been dosed with PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP in a Phase 1/2 clinical trial designed to evaluate its ability to drive remission of HIV infection. This Phase 1/2 HIV trial is a randomized, double-blinded, placebo-controlled study. The trial is divided into two cohorts and all vaccines are being delivered via the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device. In the main study (Cohort A), 45 HIV-infected adults who initiated antiretroviral therapy during chronic infection will receive either PENNVAX-GP, another vaccine formulation that contains only Gag/Pol antigens, or a placebo. Both vaccines are also co-administered with INO-9012. In the single arm and uncontrolled second study (Cohort B), individuals who initiated antiretroviral therapy during acute HIV infection will receive PENNVAX-GP together with INO-9012.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we announced preliminary results from the Phase 1/2 trial, in which PENNVAX</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-GP delivered via intradermal route resulted in durable and robust antibody and T cell immune responses measured throughout the duration of the study. In this study, PENNVAX-GP plasmids were delivered intradermally or intramuscularly with CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device in healthy volunteers. PENNVAX-GP delivered intradermally (ID) with CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;generated equivalent or superior immune responses compared to the delivery via intramuscular (IM) route using the same delivery device, with ID delivery using only one-fifth of the dose compared to IM delivery.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">HIV dMAb</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we announced that our DNA-based monoclonal antibody technology will be deployed to develop product candidates that could be used alone and in combination with other immunotherapies in the pursuit of new ways to treat and potentially cure infection from HIV. See the section below titled "Synthetic DNA-based Monoclonal Antibodies" for more details on this technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Ebola Virus Disease (EVD)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Ebola virus causes one of the most virulent viral diseases, with case fatality rates averaging 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. Ebola can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within two to twenty-one days of exposure. In November 2019, the first conditional approval was issued for a preventive vaccine against Ebola Virus Disease (EVD). This approval was from </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the European Medicines Agency (EMA) for the vaccine ERVEBO</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">. That same month, the World Health Organization (WHO) pre-qualified that vaccine for use in high-risk countries. In the next month, the FDA approved that vaccine. However, there are no proven effective therapeutic treatments for Ebola. In addition, various experimental approaches have already been associated with undesirable side effects and limited ability to scale manufacturing.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">According to the U.S. Centers for Disease Control and Prevention (CDC), the 2014 West Africa Ebola epidemic was the largest in history, resulting in 28,610 suspected and confirmed cases and 11,308 deaths as of June 2016, when it was declared over.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, two Ebola outbreaks occurred, both in the Democratic Republic of Congo (DRC). The first of these outbreaks was declared in May and was relatively well-contained and short-lived, with a total of 54 cases and 33 deaths through the declared end of the outbreak in July. However, the second outbreak (the North Kivu outbreak), which was declared in August, persisted and continues into 2020. This second outbreak became the second largest Ebola outbreak in history, with a total of 3,444 cases, 2,264 deaths, and many thousands of contacts having been followed as of February 2020. On that date, approximately 620 contacts were being followed. This particular outbreak has a 66% case fatality rate as of February 2020. Of the confirmed plus 134 probable cases through that date, about 172 (5%) have been health care workers. As of January 2019, of the 63 health workers which had become infected with Ebola virus 21 of them have died.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical and Clinical Development - Ebola</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we entered into a collaboration with GeneOne to advance a DNA immunotherapy for Ebola into clinical development. The decision to advance our Ebola immunotherapy was based on positive results observed in preclinical studies, in which 100% of immunized guinea pigs and mice were protected from death after being exposed to the Ebola virus. Unlike the non-immunized animals, immunized animals were also protected from weight loss, a measure of morbidity. Researchers found significant increases in neutralizing antibody titers and strong and broad levels of immunotherapy-induced T cells, including "killer" T cells, suggesting that DNA immunotherapy could provide both preventive and treatment benefits. This data was published in 2013 in the peer-reviewed journal </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Molecular Therapy</font><font style="font-family:inherit;font-size:10pt;">&#32;in a paper titled, "Induction of Broad Cytotoxic T Cells by Protective DNA Vaccination Against Marburg and Ebola."</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, we received a contract from the Defense Advanced Research Projects Agency (DARPA) to lead a consortium to develop multiple treatment and prevention approaches against Ebola. Other collaborators are AstraZeneca; GeneOne and its manufacturing subsidiary, VGXI, Inc.; and David B. Weiner, Ph.D., a director of our company, who also serves as executive vice president at the Wistar Institute and retired professor of Pathology and Laboratory Medicine at The Perelman School of Medicine at the University of Pennsylvania, Emory University and Vanderbilt University. A previous collaboration agreement with GeneOne for Ebola was incorporated into this consortium funded by DARPA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are taking a multi-faceted approach to develop products to prevent and treat Ebola infection. These programs include development and early clinical testing of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:58px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a therapeutic DNA-based monoclonal antibody product against the Ebola virus infection, which we believe has properties that best fit a response to the outbreak in that they could be designed and manufactured expediently on a large scale using common fermentation technology, are thermal-stable, and may provide more rapid therapeutic benefit;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:58px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a highly potent conventional protein-based therapeutic monoclonal antibody (mAb) product against Ebola virus infection; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:58px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:34px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a DNA-based vaccine against Ebola.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contract with DARPA covers the pre-clinical development costs for the dMAb products and protein mAb candidates, as well as GMP manufacturing costs and the Phase 1 clinical trial costs for the three product candidates described above.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, we and our collaborators initiated a Phase 1 clinical trial of INO-4212, an Ebola DNA vaccine to evaluate its safety, tolerability and immune responses in 75 healthy subjects divided into five study arms. INO-4212 consists of two optimized SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;DNA plasmids coding for the Ebola glycoprotein antigen from circulating Ebola strains from 1975-2014. The study was designed to evaluate INO-4212 and its components INO-4201 and INO-4202, alone or in combination with INO-9012, delivered into muscle or skin using our proprietary DNA smart delivery technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, we reported initial results from the trial. Of 69 evaluated subjects, 64 (92.8%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 48 subjects (69.6%) seroconverted after only two doses.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the study arm using intradermal (skin) administration, 13 of 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses, and all remained seropositive after three immunizations. Similarly, in the study arm receiving the vaccine with intramuscular administration in combination with plasmid IL-12, 13 of 13 evaluable subjects (100%) produced strong antibody responses after three immunizations, and 12 of 13 (92.3%) achieved strong antibody responses after only two immunizations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Ebola glycoprotein specific geometric mean antibody titers measured in the five cohorts ranged from over 2,000 to greater than 46,000. Significantly, a majority of vaccinated subjects in each of the five cohorts produced strong Ebola antigen specific T cell responses as measured by interferon gamma ELISpot analysis.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INO-4212 was well tolerated, with no systemic serious adverse effects observed. Side effects, such as fever, joint pain, and low white blood cell counts have previously been reported following treatment with some viral vector based Ebola vaccines currently in development. Moreover, unlike the viral vectored vaccines which must be kept frozen, the INO-4212 formulation used in the trial was kept in a solution which was refrigerated at 2-8 degrees Celsius.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, we announced that enrollment of this study was being expanded to up to 200 subjects to further characterize and identify in humans the most optimal immunization regimen using intradermal (skin) delivery of the Ebola DNA vaccine.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, we reported preliminary results from the expanded Phase 1 trial. Across both stages of the trial, including both intramuscular and intradermal delivery, 95% (170/179) of evaluable subjects generated an Ebola-specific antibody immune response, with the mean antibody titer comparable or superior to those reported from viral vector-based Ebola vaccines. Our Ebola vaccine was also well tolerated in the second stages of the trial, with a favorable safety profile compared to viral vector-based Ebola vaccines, some of which have been associated with serious adverse events including myalgia, arthralgia, fever, and rash.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we announced that INO-4212 provided 100% protection following a challenge with a lethal dose of the Ebola virus in a preclinical study. An article in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Journal of Infectious Diseases</font><font style="font-family:inherit;font-size:10pt;">&#32;highlights that regimens of the INO-4212 vaccine delivered by intramuscular administration provided 100% protection against a lethal Ebola challenge in all preclinical animals. In a separate study, two injections by intradermal administration generated strong immunogenicity and provided 100% protection against a lethal Ebola challenge. In the study, scientists observed that vaccination induced long-term immune responses in monkeys that were detectable for at least one year after the final vaccination.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, Phase 1 clinical data of our Ebola vaccine candidate INO-4201 was published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Infectious Diseases</font><font style="font-family:inherit;font-size:10pt;">, in the article entitled, "Intradermal SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;Ebola GP DNA Vaccine is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers." We believe that this study, which is being fully funded by U.S. Defense Advanced Research Projects Agency (DARPA), further supports the advancement of the intradermal delivery platform for emerging infectious diseases. Significantly, intradermal (skin) administration with our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery device resulted in 100% of evaluable subjects in the study generating antigen-specific antibody responses that persisted for more than one year in most subjects and generated T cell responses equivalent to or better than the group that received intramuscular delivery. We believe these published data further validate the tolerability, potency, and product stability advantages of our vaccine and immunotherapy platform.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Ebola vaccine candidate was evaluated in five groups of healthy subjects. Of 70 evaluated subjects, 67 (96%) seroconverted and mounted a strong antibody response to the Ebola glycoprotein antigen following the three dose immunization regimen; 52 subjects (74%) seroconverted after only two doses.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significantly, in the study arm using intradermal (skin) administration, 13 of 13 evaluable subjects (100%) generated antigen-specific antibody responses after only two doses and all remained seropositive after three immunizations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date INO-4201 has been well-tolerated and has not demonstrated systemic serious adverse effects, such as fever, joint pain, and low white blood cell counts, reported in association with some viral vector-based Ebola vaccines currently in development.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Middle East Respiratory Syndrome (MERS)</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MERS is a viral respiratory illness first reported in&#160;Saudi Arabia&#160;in 2012. MERS appears to have been transmitted from an animal reservoir to humans but human to human transmission has been confirmed. This communicable virus has not been shown to spread in a sustained way in communities, but rapid spread in the nosocomial setting, such as emergency rooms and/or hospitals without adherence to state-of-the-art infection control practices, can result in outbreaks with many cases, including super-spreading events. Like the severe acute respiratory syndrome (SARS) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">outbreak in 2003, which made approximately 8,000 people ill and was fatal in nearly 10% of those cases, MERS is caused by a coronavirus and appears to cause a severe lung infection. However, the case-fatality rate (death rate) of MERS has typically been between 30% and 40%, which is significantly higher than that of SARS. While the SARS epidemic in 2003 killed 10% of those who became ill from the SARS virus, MERS has killed approximately 34% of people who people who became ill from the MERS virus from 2012 to January 2020. MERS differs in that it also causes rapid kidney failure. Its high death rate has caused serious concern among global health officials.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Despite the continuing threat of MERS outbreaks, there are no licensed vaccines or treatments for MERS. Since the virus was first identified in&#160;Saudi Arabia&#160;in 2012, the&#160;World Health Organization&#160;reports 2,519 laboratory-confirmed cases of MERS and 866 deaths from MERS worldwide as of January 2020. Twenty-seven countries have reported cases, including Korea where an outbreak in the summer of 2015 resulted in 186 cases and 38 deaths. The majority of MERS cases reported in the world by country have been reported from the Kingdom of Saudi Arabia, with a total of 2,121 cases, 788 associated deaths, and a case-fatality rate of 37% from 2012 through January 2020. Of those cases to date in Saudi Arabia, nearly 20% have been in healthcare workers.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical and Clinical Development - MERS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2013,&#160;we announced that preclinical testing of our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;MERS vaccine candidate, INO-4700 (GLS-5300), had induced robust and durable immune responses in mice, demonstrating the potential for such a&#160;vaccine to prevent and treat this deadly virus. DNA medicine constructs targeting multiple MERS antigens were designed using our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;vaccine platform with the goal to universally protect against multiple strains of MERS, which has been shown to have diverse genetic variants. These SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;constructs were administered via our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A consensus MERS "spike" protein vaccine construct was created based on multiple strains of the MERS virus.&#160; Our MERS DNA medicine was immunogenic in mice and seroconversion was observed in all animals. The antibodies generated by the vaccine in 100% of mice (20 of 20) were able to neutralize or completely block actual infection of MERS virus in the cells, demonstrating the protective potential of this vaccine. In contrast, none of the 10 unvaccinated mice in the control group generated neutralizing antibodies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The vaccinations were also highly T cell immunogenic, generating robust and broad T cell responses as extensively analyzed by the standardized T cell ELISPOT assay. The vaccine produced robust CD8+ and CD4+ T cell responses against multiple epitopes of the MERS spike protein. This increased diversity and magnitude of cellular responses may be critical for effectively mitigating MERS infection.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe these preclinical findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015,&#160;we announced that our MERS vaccine had induced 100% protection from a live virus challenge in a preclinical study in mice, camels and monkeys, or non-human primates. In all three species, the vaccine induced robust immune responses capable of preventing the virus from infecting cells. We believe the data from camels is an important finding because camels represent not only a host reservoir of the disease, but also act as a mode of transmission to humans. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS disease when challenged with a live MERS virus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preclinical results appeared in the peer-reviewed journal&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Science Translational Medicine</font><font style="font-family:inherit;font-size:10pt;">&#160;in an article entitled, "A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East Respiratory Syndrome Coronavirus in non-human primates."</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016,&#160;we and our collaborator GeneOne commenced a Phase 1, dose-escalation clinical trial of INO-4700 (GLS-5300) in 75 healthy volunteers at the Walter Reed Army Institute of Research&#160;(WRAIR) in&#160;Maryland. The primary and secondary goals of this first-in-man Phase 1 trial are to obtain safety and immunogenicity data. This trial represents the first MERS vaccine to be tested in humans for this disease that has no approved vaccines or treatments.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016,&#160;we announced that the&#160;International Vaccine Institute&#160;(IVI) will provide new funding and support to further advance the clinical development of INO-4700 (GLS-5300). IVI will add technical, laboratory and financial support for INO-4700 (GLS-5300) clinical trials in&#160;Korea with the goal to advance clinical testing toward emergency use authorization by the Korean government as well as authorities of other countries. This collaborative funding is part of a grant from the&#160;Samsung Foundation&#160;to IVI to support the development of a MERS vaccine for emergency use in&#160;Korea&#160;and internationally.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, we announced a collaboration with The Coalition for Epidemic Preparedness Innovations (CEPI) under which we will develop vaccine candidates against MERS. CEPI will fund up to $56 million of costs to support our </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pre-clinical and clinical advancement through Phase 2 of INO-4700. The goal of the collaboration is for the MERS vaccine to be available as soon as possible for emergency use.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, we announced positive results from the Phase 1 trial of INO-4700 (GLS-5300) for MERS. In the trial, treatment with INO-4700 (GLS-5300) was well tolerated and resulted in overall high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Antibody responses were observed in 94% of subjects at week 14 (two weeks after the third dose). Additionally, there were no statistically significant dose-dependent differences in antibody response rates (91%, 95%, and 95% at doses of 0.67, 2, and 6 mg, respectively). Durable antibody responses were also maintained through 60 weeks following dosing. These results were published in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Lancet Infectious Diseases</font><font style="font-family:inherit;font-size:10pt;">&#32;in a peer-reviewed article entitled, "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial." </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, we announced the dosing of the first subject in a Phase 1/2a study of INO-4700 (GLS-5300) for MERS in South Korea funded by IVI.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Zika Virus</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First identified in the late 1940s in&#160;Uganda, Zika virus subsequently spread to equatorial&#160;Asia&#160;in 1969 and then rapidly spread through the Pacific,&#160;and still later, in the 2014-2016 period, to and through South America,&#160;Central America and the Caribbean. In the end of that period, Zika virus emerged in two portions of the continental United States (extreme Southeastern Florida and extreme South Texas). Zika virus is a flavivirus, a family of viruses including yellow fever, dengue, and West Nile virus, which are introduced to people through mosquito bites. Because the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Aedes</font><font style="font-family:inherit;font-size:10pt;">&#32;species of mosquitoes that spread Zika virus are found in much of the world, there is concern that the virus will spread to new countries and cause additional outbreaks. There is also concern that Zika spreads sexually in humans, at least by males to females, as has been reported for some returning travelers and documented in multiple studies. In&#160;February 2016, the&#160;WHO stated that 39 countries had reported locally acquired circulation of the Zika virus since&#160;January 2007. Geographical distribution of the virus since expanded, though the incidence of infections declined significantly since the 2014-2016 emergence in the Americas. In 2019, there were no confirmed Zika virus disease cases in the United States. However, currently the CDC still lists at least 92 countries and territories as having risk of Zika virus infection and notes that the virus has potential risk in those areas. No vaccine or drug therapy currently exists for the Zika virus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most common symptoms of Zika virus are fever, rash, joint pain, and conjunctivitis. More seriously, health authorities have observed neurological and autoimmune complications potentially associated with Zika virus, including microcephaly in newborn children and Guillain-Barre syndrome. Microcephaly is a rare condition marked by an abnormally small head and incomplete brain development. There may also be a link with Guillain-Barr&#233; syndrome, a disease in which the body's immune system mistakenly attacks peripheral nerves. Symptoms start with muscle weakness. In severe cases the person is almost totally paralyzed and the disorder can be life threatening.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, we and GeneOne announced a joint research collaboration with academic collaborators of a SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;Zika vaccine known as INO-4600 (GLS-5700).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Studies - Zika Virus</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016,&#160;we announced that INO-4600 (GLS-5700) administered using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery device resulted in seroconversion, or the development of detectable specific antibodies in the blood, in all vaccinated mice. The vaccinations also generated robust and broad T cell responses as analyzed by the standardized T cell ELISPOT assay. In data reported in May 2016, two doses of INO-4600 (GLS-5700) delivered either intramuscularly or intradermally resulted in seroconversion, in all vaccinated non-human primates and broad T cell responses as analyzed by the standardized T cell ELISPOT assay.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These results were later published in&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nature Partner Journals (npj) Vaccines</font><font style="font-family:inherit;font-size:10pt;">&#32;in November 2016. Additional data indicated that, in the study, INO-4600 (GLS-5700) protected animals from infection, brain damage and death. No INO-4600 (GLS-5700) vaccinated animals were infected with Zika after exposure to the virus. In addition, vaccinated mice were protected from degeneration in the cerebral cortex and hippocampal areas of the brain while unvaccinated mice showed significant degeneration of the brain after Zika infection.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In another preclinical study, the results of which were published in June 2017, INO-4600 (GLS-5700) was observed to have protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tract of all vaccinated male mice challenged with a high dose of the Zika virus. This preclinical study data was published in&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Nature Communications</font><font style="font-family:inherit;font-size:10pt;">&#160;in an article entitled, &#8220;DNA Vaccination Protects Mice Against Zika Virus-Induced Damage to the Testes.&#8221;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 1: 40 Patient Zika Study in U.S. &amp; Canada</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, we were the first to commence a human Zika trial in healthy adult volunteers, with sites in the U.S. and&#160;Canada, with the first subject dosed in July. This Phase 1, open-label, dose-ranging study of 40 healthy adult volunteers was designed to evaluate the safety, tolerability and immunogenicity of INO-4600 (GLS-5700) administered with CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-3P, our intradermal smart delivery device.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In this Phase 1 trial, a total of 40 participants (two groups of 20 each) received INO-4600 (GLS-5700) in a 1 mg or 2 mg dose. The vaccine was administered in 0.1 ml intradermal injections. In October 2017, we announced positive safety and immune response results from the Phase 1 trial. The INO-4600 (GLS-5700) Zika vaccine induced binding antibodies in 100% of the participants after a three-dose vaccination regimen and in 95% after two doses of vaccine. In addition, neutralizing antibodies were observed in more than 95% of the serum samples that were assayed on neuronal-cell targets. Serum samples from vaccinated subjects when subsequently transferred to mice were found to be protective from death and illness in more than 90% of animals after they were challenged with a lethal dose of the Zika virus. These results appeared in the</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;New England Journal of Medicine</font><font style="font-family:inherit;font-size:10pt;">&#160;in the article, &#8220;Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine.&#8221;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Phase 1: 160 Patient Zika Study in Puerto Rico</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2017, we and GeneOne initiated a second clinical trial of INO-4600 (GLS-5700). In this second trial, we have enrolled 160 subjects in&#160;Puerto Rico, where the Zika virus outbreak was declared a public health emergency. In this placebo-controlled, double-blind trial involving healthy adult volunteers, 80 subjects received INO-4600 (GLS-5700) and 80 subjects received placebo. The study is evaluating the safety, tolerability and immunogenicity of INO-4600 (GLS-5700) administered with our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-3P smart device. We are also assessing differences in Zika infection rates in participants given either placebo or vaccine as part of an exploratory endpoint. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Zika dMAb</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup>&#160;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, we received a&#160;sub-grant through&#160;The Wistar Institute to develop a DNA-based monoclonal antibody designed to provide a fast-acting treatment against Zika infection and its debilitating effects. The goal of this program, which was funded by the&#160;Bill &amp; Melinda Gates Foundation, is to develop a Zika dMAb</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">through human clinical trials. In the first quarter of 2019, we dosed our first subject with a Zika dMAb. See the section below entitled "Synthetic DNA-based Monoclonal Antibodies" for further information on our DNA-based monoclonal antibody program.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lassa Fever</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lassa fever, also known as Lassa hemorrhagic fever, is an acute viral disease which occurs mostly in West Africa. The disease can cause a range of outcomes including fever, vomiting, and swelling of the face, pain in the chest, back and abdomen, bleeding of various parts of the body including the eyes and nose, and death.&#160;This infection is spread through contact with infected rodents. Person to person transmission is also possible, via bodily fluids, albeit less common. Lassa virus infection in West Africa is estimated to affect 300,000 people annually, resulting in approximately 5,000 deaths, as disease and infection surveillance has been poor.&#160;Because of difficulties in diagnosing Lassa fever and the remoteness of many areas in which the disease occurs, the numbers of cases and deaths are likely under-reported.&#160;Though the majority (about 80%) of Lassa virus-infected persons are asymptomatic or have mild symptoms, the infection can be quite serious to fatal in others. There are no licensed vaccines or treatments specifically for Lassa. The case-fatality among patients hospitalized for Lassa fever is about 15% to 20%, and in some epidemics case-fatality has reached 50% in hospitalized patients, such as in the 2015-2016 Nigeria portion of the West Africa outbreak. Of the survivors of Lassa fever, about one-third have sudden-onset hearing loss. In Nigeria, an unprecedented outbreak occurred in 2018, with more cases recorded and reported in the first two months than in any previous full year there.&#160;From January 1 to December 31, 2018, a total 633 confirmed and 20 probable cases were reported to the Nigeria Centre for Disease Control with 171 deaths among confirmed cases and 20 in probable cases, yielding a 27% case-fatality rate in confirmed cases.&#160;In 2019 in Nigeria, 810 confirmed cases were reported, and among those 167 died -- yielding a case-fatality rate of 20.6% that year.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Studies</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2019, we dosed our first patient in our Phase 1, first-in-human clinical trial to evaluate INO-4500, a DNA candidate vaccine to prevent infection from the Lassa virus. In 2019, we fully enrolled 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This trial represents the first Lassa candidate vaccine to enter the clinic. Our sponsored trial, as well as our INO-4500 program, is fully funded through the global partnership with CEPI that we entered into in April 2018.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the results of this study are positive, we expect to advance INO-4500 into both Phase 1b and Phase 2 field trials in endemic countries of West Africa. If satisfactory Phase 2 data are achieved, CEPI, in cooperation with local regulatory authorities and the WHO, could be able to stockpile the vaccine for future use throughout the region. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">COVID-19 (Coronavirus Disease 2019), Caused by the SARS-CoV-2 Virus</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A novel Coronavirus emerged in the human population in Wuhan City, China in November-December 2019. On December 31, 2019 the WHO China Office was informed of a number of pneumonia cases of unknown etiology appearing in the previous few days in Wuhan, China. On January 8, 2020, Chinese scientists announced the identification of a new Coronavirus associated with this pneumonia outbreak, and on January 11, they publically shared the genetic sequence of that new virus. The new virus was temporarily referred to as &#8220;2019-nCoV&#8221; and &#8220;2019 novel coronavirus,&#8221; among other names, but subsequently was named SARS-CoV-2 due to the large similarity of its genetic sequence with that of the original severe acute respiratory syndrome coronavirus (SARS coronavirus or SARS-CoV). The new virus is a member of the genus of Coronaviruses, which is comprised of seven known viruses that can infect and make humans ill, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV). This novel coronavirus is part of the Coronaviridae family of viruses that include the high risk viruses MERS-CoV and SARS-CoV, and four other lower risk coronaviruses which can cause the common cold. The disease caused by the SARS-CoV-2 novel coronavirus was subsequently named &#8220;COVID-19&#8221; (coronavirus disease, 2019).  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since the emergence of this novel virus, the virus has quickly spread throughout China and on to many other countries. As of February 28, 2020, a total of 53 countries/areas had reported at least one confirmed case, with at least one case from all continents of the world except for Antarctica. A total of 83,694 confirmed cases had been reported by that date worldwide to the WHO, with a total of 2,861 deaths reported of the confirmed cases. Also as of that date, about 94% of the cases cumulatively were reported from mainland China, but the nearly 4,900 cases had been reported from other countries/areas including the United States (59 cases), Japan, South Korea, several countries in Europe including Germany, France, the UK, and Spain, India, several countries in the Middle East, Australia, three countries in Africa including Egypt and Nigeria, and Brazil. In several of the countries outside of mainland China, as of that date very rapid spread and a high case count have occurred including in South Korea (2,337 cases), Japan (about 900 cases including on land and a cruise ship), Italy (650 cases), and Iran (245 cases). During this emergence, the WHO declared a Public Health Emergency of International Concern (PHEIC) and the U.S. declared a Public Health Emergency.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preliminary data on the case fatality for COVID-19 indicate it is about 3.8%, which is significantly lower than that of SARS (10%) and MERS (about 34%), but significantly higher than for seasonal influenza (0.1%). Preliminary estimates of the reproductive number (R</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">0</sub></font><font style="font-family:inherit;font-size:10pt;">), or the average number of persons one infected person in turn infects, of SARS-CoV-2 range from 2.2 to somewhat above 4.0, with an average of about 3.8. The R</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">0</sub></font><font style="font-family:inherit;font-size:10pt;">&#32;for this novel coronavirus thus appears to be significantly higher than that of MERS-CoV (&lt; 1.0) and SARS-CoV (about 2.0). It is the combination of the significant R</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">0 </sub></font><font style="font-family:inherit;font-size:10pt;">and significant case fatality rate that makes this new coronavirus and disease a very significant, acute international threat. On February 28, 2020 the WHO raised its risk assessment level for spread and impact to &#8220;very high at a global level&#8221; - the highest such level the WHO declares for an infectious disease. </font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Development</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2020, CEPI awarded us a grant of up to $9 million to develop a vaccine against SARS-CoV-2/COVID-19. We anticipate this initial CEPI funding will support our preclinical and clinical development through Phase 1 human testing in the United States of INO-4800, our new coronavirus vaccine candidate matched to the outbreak strain. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also collaborating with Beijing Advaccine Biotechnology Co. to advance the development of INO-4800 in China. The goal of this collaboration is to leverage Beijing Advaccine's expertise to run a Phase 1 trial in China in parallel with our clinical development efforts in the United States. We will also work with Beijing Advaccine to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe we may be in a position to begin human clinical trials in the United States in April 2020, subject to approval from the FDA, and soon thereafter in China and South Korea subject to approval of applicable regulatory authorities.  Our goal is to produce up to one million doses of a potential vaccine by the end of 2020, with our existing capacity and contract resources, for further clinical trials or emergency use.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Development Candidates</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">INO-1400 for the Treatment of Multiple Solid Tumor Types (hTERT antigen)</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human telomerase reverse transcriptase (hTERT) is a significant cancer immunotherapy target. High levels of hTERT have been detected in more than 85% of all human cancers, including breast, lung, and pancreatic cancers, while normal cells showed undetectable levels of telomerase expression. Immunological analysis indicated that hTERT is a widely applicable target recognized by T-cells and can be potentially used as a universal cancer immunotherapy. In  2020, over 565,000 new cases of breast, lung, or pancreatic cancers are estimated to collectively occur in&#160;the United States&#160;and about 225,000 people are estimated to die from these cancers collectively. Worldwide in 2018, more than 4.6 million new cases of these cancers occurred and more than 2.8 million people died from these cancers collectively. Despite available treatments, mortality rates remain unacceptably high in these tumor types. In addition, many existing treatment modalities are associated with significant adverse events.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2014, we initiated a Phase 1 clinical trial of INO-1400 alone or in combination with INO-9012 in adults with breast, lung or pancreatic cancer at high risk of relapse after surgery and other cancer treatments. This open label, dose escalation study is evaluating the safety, tolerability, and immunogenicity of INO-1400, as well as another hTERT construct called INO-1401. To date, we have treated 90 patients with nine different types of solid tumors. All patients received treatment using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;delivery device.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2017, in poster presentations at the&#160;SITC Annual Meeting, we reported additional results from the ongoing Phase 1 trial in which that INO-1400 generated hTERT-specific IFN-gamma secreting T cells, suggesting an ability to break immune tolerance.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">INO-1800 for the Treatment of Hepatitis B Virus</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although an effective preventive vaccine against hepatitis B virus, or HBV, infection has existed for over three decades, HBV remains a major epidemic, especially among people of Asian and African descent. The World Health Organization estimates that 2 billion people globally are or have been infected with HBV, with over 257 million people chronically infected with the virus and at risk of developing the major complications of cirrhosis or liver cancer. It is estimated that over two million people in the United States are chronically infected with the virus, including those who were foreign-born. Currently, the only therapies available for chronically infected individuals are interferon-alpha and nucleoside analog treatments, which function by controlling viral replication, but they do not clear infection. Interferon can prevent viral replication in only 30% of patients and does so with undesirable side effects.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liver cancer is the fourth most common cause of death from cancer worldwide, and it kills the vast majority of patients within five years of diagnosis in the U.S. An estimated more than 841,000 new cases arose in 2018 worldwide. Liver cancer is estimated to have 42,810 new cases and kill more than 30,000 persons in the U.S. in 2020. One of the major causes and risk factors for liver cancer is infection by hepatitis B. Chronically infected individuals may develop a permanent scarring of the liver, a condition called cirrhosis. Liver cirrhosis can evolve into hepatocellular carcinoma, which claimed an estimated 780,000 lives worldwide in 2018.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">INO-1800 is encoded for the HBcAg antigen and represents a consensus of the unique HBcAg DNA sequences of all major HBV genotypes (A through E). When delivered by CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, in a preclinical study, INO-1800 elicited strong HBcAg-specific T cell and antibody responses in the periphery (outside of the liver) as measured by ELISpot, ICS and cell proliferation assays. Researchers observed that the immunization could also induce antigen-specific CD8+ and CD4+ T cells that produced both IFN-y and TNF-a in the liver, indicating that a strong immunotherapy-induced T cell response was also present in the liver.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the preclinical study, the antigen-specific T cells exhibited a killing function and were able to migrate to and stay in the liver and cause clearance of target cells without any evidence of liver injury. This was the first study to provide evidence that intramuscular immunization could induce killer T cells that can migrate to the liver and eliminate target cells.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, we initiated a Phase 1 trial to evaluate INO-1800 in patients chronically infected with HBV. This randomized, open-label, active-controlled, dose escalation study was designed to evaluate the safety, tolerability and immunogenicity of INO-1800 alone or in combination with INO-9012. This international study enrolled patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. Secondary endpoints are evaluating the cellular and humoral immune response to INO-1800 and its effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, we announced interim results from the trial, in which INO-1800 was well-tolerated and generated virus-specific T cells, including CD8+ killer T cells, meeting the objectives of the clinical study. Preliminary immunology data from the trial revealed that treatment of patients with INO-1800 resulted in the generation of T cells that recognized key components of the hepatitis B virus and reacted by making antiviral cytokines such as Interferon gamma, a protein believed to be linked to clearance of HBV from the liver. In the trial, INO-1800 was also able to activate and expand CD8+ killer T cells that displayed markers believed to be important for retention in the liver as well as multiple potential mechanisms for killing virally infected cells.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently seeking a collaboration partner in order to further advance the clinical development of INO-1800.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">INO-8000 (GLS-6150) for the Treatment of Hepatitis C Virus</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hepatitis C virus can cause both acute and chronic infection, ranging in severity from mild, short-term illness to a serious lifelong illness. This virus can cause liver cancer, for which annual incidence and mortality rates are provided above. Worldwide, an estimated 71 million persons have chronic hepatitis C infection, and a significant portion of those persons will develop liver cirrhosis or liver cancer. It is estimated that nearly 400,000 people died worldwide in year 2016 alone from hepatitis C.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Antiviral medications can cure most persons with this infection, but access to such treatment worldwide is low. Unfortunately, no effective vaccine exists for hepatitis C.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2018, we announced the dosing of the first patient in a Phase 1 study designed to evaluate a preventive vaccine candidate, GLS-6150, against hepatitis C infection. Recruitment has begun in South Korea, where our collaborator GeneOne is responsible for conducting and funding this Phase 1 trial to assess the ability of GLS-6150 to boost immunity in people who have been treated and cleared of the virus. We believe that the vaccine could potentially be employed to prevent infection and re-infection.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This jointly developed, open-label, Phase 1 study of GLS-6150 will evaluate a total of 24 patients who have a sustained virologic response (SVR) following treatment for Hepatitis C (n=8 per group) and an additional 8 healthy controls to compare immune responses. Subjects will receive one of two doses of vaccine, 1 or 2 mg, administered intra-dermally and followed by electroporation with our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">-3P delivery device. Vaccinations will occur as a three-dose priming series (at 0, 4, 12 weeks) or as a two-dose priming series (at 0 and 8 weeks) and followed by a booster dose at 6 months. The final study visit is 4 weeks following the 6-month booster vaccination.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Universal Influenza Immunotherapy</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conventional vaccines are strain-specific and have limited ability to protect against genetic shifts in the influenza strains they target. They are therefore modified annually in anticipation of the next flu season&#8217;s new strain(s). If a significantly different, unanticipated new strain emerges, such as the 2009 swine-origin pandemic strain, then the current vaccines provide little or no protective capability. In contrast, we believe that our design approach to characterize a broad consensus of antigens across variant strains of each influenza sub-type creates the ability to protect against new strains that have common genetic roots, even though they are not perfectly matched. By formulating a single immunotherapy with some or all of the key sub-types, protection may be achieved against seasonal as well as pandemic strains such as swine flu or pandemic-potential strains, such as avian influenza. We are focused on developing DNA-based influenza immunotherapies able to provide broad protection against known as well as newly emerging, unknown seasonal and pandemic influenza strains.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Instead of targeting a specific strain or strains, we have developed a universal vaccine strategy to deal with ever-changing flu threats. Using our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;process, our scientists have designed immunotherapies targeting an optimal consensus of HA, NA, and NP proteins derived from multiple strains of each of the Type A sub-types H1N1, H2N2, H3N2 (these three influenza sub-types having been responsible for the majority of seasonal and pandemic influenza outbreaks in humans during the last century), as well as H5N1. In theory, consensus HA vaccine constructs from each sub-type, delivered using our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;device, could potentially protect immunized subjects from 90-95% of all human seasonal and pandemic influenza concerns. Additionally, we have also developed an optimal consensus of HA sequences derived from influenza Type B strains. Type B is one of three components of current seasonal influenza vaccinations. Using our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;constructs, we have now developed immunotherapy elements that can target both pandemic-risk (H5N1, H7N9, H1N1) as well as seasonal influenza strains (H3N2, H1N1, influenza B).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, using our approach the immunotherapies might not have to be administered annually after the first few priming sessions. Rather, the same combination could be used to boost the immune system every few years.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, we announced results from a preclinical study in which our synthetic vaccine approach, using a collection of synthetic DNA antigens, generated broad protective antibody responses against all major deadly strains of H1 influenza viruses from the last 100 years, including the virus that caused &#8220;Spanish Flu&#8221; in 1918 in multiple animal models, including mice, guinea pigs and non-human primates. The vaccine also protected 100% of immunized ferrets from a lethal virus challenge. The preclinical results were detailed in a paper published in the journal&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vaccine </font><font style="font-family:inherit;font-size:10pt;">entitled, &#8220;Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine."</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are seeking additional grant and/or collaboration funding to further advance this program.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Immunotherapies for Biodefense and Biosecurity</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A number of infectious agents that are relatively rare today are poised for an upsurge in incidence by either &#8220;natural&#8221; or terrorism-related means. For example, natural threats are posed by the influenza strains H5N1 and H7N9. At the same time, an engineered influenza virus for intentional release would pose a significant human threat.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since 2001, the United States government has spent or allocated over a billion dollars in funding to address the threat of biological weapons. United States funding for bioweapons-related activities focuses primarily on research for and acquisition of medicines for defense. Biodefense funding also goes toward stockpiling protective equipment, increased surveillance and detection of biological agents, and improving state and hospital preparedness. The increase in this type of funding is mainly due to the Project BioShield Act adopted in 2004.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are opportunities to secure development funding and for proof-of principle immunotherapy studies for bio-warfare pathogens. We have secured funding from the U.S. government for these projects.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continue to actively pursue grant and contract funding from the NIH, Department of Defense and other government funding agencies as a source of non-dilutive funding to support development of specific technologies that are broadly applicable across multiple product development programs in the areas of cancer, infectious diseases and biodefense. Based on various initiatives and with the support of NIH funding we are an active collaborator with the Department of Defense (U.S. Army) and continue research and development of DNA-based immunotherapies delivered via our proprietary CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;delivery system. Specifically, our projects are focused on identifying immunotherapy candidates with the potential to provide rapid, robust immunity to protect against bio-warfare and bioterror attacks as well as development of our CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;devices.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, DARPA awarded $12.2 million to our scientists and those from the Perelman School of Medicine at the University of Pennsylvania and AstraZeneca to develop and assess dMAb products for influenza and antibiotic resistant bacteria in preclinical studies. This collaboration aims to demonstrate that DNA plasmids can activate sufficient quantities of disease-specific monoclonal antibodies in the body to be protective against a pathogen challenge. See the section below titled "Synthetic DNA-based Monoclonal Antibodies" for more details on our dMAb programs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Synthetic DNA-based Monoclonal Antibodies Program</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mAbs have become one of the most valuable therapeutic technologies of recent years. In 2012, global sales of mAbs exceeded $50 billion. Among the top 10 best-selling drugs in 2012, six were monoclonal antibodies, each with annual sales exceeding $5 billion.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mAbs are designed to enhance the immune system's ability to regulate cell functions. They are designed to bind to a very specific epitope (area) of an antigen or cell surface target and can bind to almost any selected target. They have the ability to alert the immune system to attack and kill specific cancer cells (as in the case of Yervoy</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">) or block certain biochemical pathways (such as those leading to rheumatoid arthritis, as in the case of Humira</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">). However, mAb technology has limitations. As a passive immunotherapy, meaning they are manufactured outside the body, mAbs require costly large-scale laboratory development and production. Additional limitations include high cost to develop and manufacture, their limited duration of </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;potency, and a pharmacokinetic profile that can result in toxicity. We have created DNA based monoclonal antibodies that we believe overcome many of the limitations associated with conventional mAb technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Using our core platform technology, we encode the DNA sequence for a specific monoclonal antibody in a DNA plasmid. We deliver the plasmid directly into cells of the body using CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, enabling these cells to manufacture the mAbs </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">, - unlike conventional mAb technology that requires manufacture outside of the body. We believe this approach provides potentially significant advantages in terms of lower production costs, as well as the ability to target a pharmacokinetic profile that provides control in terms of dosing regimen, peak responses, duration of responses and toxicity.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to design dMAb product candidates not only for new disease targets not currently addressable with conventional mAbs, but also targets of existing, commercially available mAb products. We have already designed and produced dMAb product candidates targeting cancer mechanisms including checkpoint inhibition, anti-cancer pathways and anti-Tregs, as well as prophylactic and therapeutic dMAb product candidates for infectious diseases including Ebola, influenza, antibiotic resistant bacteria, dengue and Chikungunya. When the mAb binds to an infectious disease receptor, the immune system then generates natural killer cells and macrophages to clear the virus or bacteria-bound mAbs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Proof of Concept</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our first published research on a DNA-based monoclonal antibody was presented in October 2013 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Human Vaccines &amp; Immunotherapeutics</font><font style="font-family:inherit;font-size:10pt;">&#32;in a paper entitled, &#8220;Optimized and enhanced DNA plasmid vector based </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.&#8221; In a preclinical study, a single administration in mice of a highly optimized dMAb</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;HIV immunotherapy generated antibody molecules in the bloodstream that possessed desirable functional activity, including high antigen-binding and HIV-neutralization capabilities, against diverse strains </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of HIV viruses. In the study, this delivery strategy resulted in an increase in Fab levels in as little as 48 hours, when compared with protein-based immunization.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A second paper was published in July 2015 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Scientific Reports,&#160;</font><font style="font-family:inherit;font-size:10pt;">a&#160;Nature Publishing Group&#160;journal, in the paper, "Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy." In this study, a single intramuscular injection of a DNA plasmid encoding a monoclonal antibody targeting dengue protected mice subsequently exposed to the dengue virus. The protection conferred by the monoclonal antibodies expressed by these dMAb product candidates was very rapid, with 100% survival in mice challenged with lethal enhanced dengue disease less than a week after dMAb administration. While conventional vaccine and monoclonal antibody technologies have shown limited ability to provide an effective solution to dengue to date, the unique attributes and data generated by dMAb immunotherapies show their potential to provide a needed solution. Furthermore, this short time frame to achieve full protection is significantly more rapid than vaccine-driven protection, which can take weeks to months to reach peak efficacy levels.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A paper published in March 2016 in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Journal of Infectious Diseases</font><font style="font-family:inherit;font-size:10pt;">&#160;entitled, &#8220;Rapid and long-term immunity elicited by DNA encoded antibody prophylaxis and DNA vaccination against Chikungunya virus,&#8221; discussed the results of our preclinical study in which animals transfected with our DNA-based mAb targeting Chikungunya virus (CHIKV) exhibited the specific ability to bind to the CHIKV envelope antigen, and this serum possessed CHIKV-neutralizing activity. CHIKV is a serious mosquito-borne alpha-virus responsible for several recent epidemics in tropical Africa and Asia. In mid-2015, the CDC reported that suspected or confirmed cases of Chikungunya had reached 1.74&#160;million in 45 countries or territories in the Americas. There is currently no vaccine or therapeutic against this virus. In the study, the treatment of the animals with anti-CHIKV mAb plasmids protected 100% of the treated animals from a lethal injection of CHIKV virus while 100% of the control animals died. The treated animals were also spared virus-related morbidity, as measured by dramatic weight loss and lethargy.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Next Steps</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, DARPA awarded a $12.2 million grant to our scientists and those from the Perelman School of Medicine at the University of Pennsylvania and AstraZeneca in order to develop and assess dMAb product candidates in preclinical studies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This collaboration aims to demonstrate that DNA plasmids can activate sufficient quantities of disease-specific monoclonal antibodies in the body to be protective against a pathogen challenge. Using the capabilities and advantages of DNA plasmids delivered using CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, the team is constructing and evaluating multiple dMAb product candidates focused on influenza virus and antibiotic resistant bacteria, such as Pseudomonas aeruginosa and Staphylococcus aureus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we expanded the collaboration to include The Wistar Institute after the collaborating investigator, Dr. David Weiner, a member of our board of directors, moved to the Institute.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depending on the outcome of the preclinical studies, we and our collaborators may seek to advance a dMAb product candidate into clinical trials, if we are able to obtain additional governmental or non-governmental funding to do so.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described above, in April 2015, we received a grant from DARPA to lead a consortium to develop multiple treatment and prevention approaches against Ebola. The aim of the research funded by this grant is to compare combinations of a DNA vaccine with conventional or DNA-based monoclonal antibodies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, we announced that our DNA-based monoclonal antibody technology will be deployed to develop product candidates which could be used alone and in combination with other immunotherapies in the pursuit of new ways to treat and potentially cure infection from HIV. Funding for this research is part of a&#160;$23 million&#160;grant from the&#160;National Institutes of Health&#160;to&#160;our collaborator, The Wistar Institute.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described above, we have also received a&#160;sub-grant through&#160;The Wistar Institute&#160;to develop a DNA-based monoclonal antibody designed to provide a fast-acting treatment against Zika infection and its debilitating effects.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, we announced that in collaboration with The Wistar Institute and the University of Pennsylvania, the first subject was dosed as part of the first-ever human study of our dMAb technology. Funded fully by the Bill &amp; Melinda Gates Foundation, this trial's focus is on evaluating our dMAb's ability to prevent or treat Zika virus infection. This open-label trial is a single center, dose escalation trial that will enroll up to 24 healthy volunteers who will receive up to four doses of dMAbs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">License, Collaboration, Supply and Other Agreements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into various arrangements with corporate, academic, and government collaborators, licensors, licensees and others. These arrangements are summarized below.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, we entered into a strategic cancer vaccine collaboration and license agreement with AstraZeneca. Under the agreement, AstraZeneca acquired exclusive rights to our immunotherapy candidate INO-3112 (renamed MEDI0457), which targets cancers caused by human papillomavirus (HPV) types 16 and 18.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the agreement, AstraZeneca made an upfront payment of $27.5 million to us in the third quarter of 2015. AstraZeneca will fund all development costs. The agreement also calls for potential future payments totaling up to $700 million upon reaching specified development and commercial milestones. We are entitled to receive up to double-digit tiered royalties on MEDI0457 product sales.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AstraZeneca is studying MEDI0457 in combination with its PD-L1 checkpoint inhibitor, durvalumab, in a Phase 1/2 clinical trial in patients with recurrent or metastatic head and neck squamous cancer associated with HPV. On December 28, 2017, we received a $7.0 million milestone payment from AstraZeneca, which was triggered by the initiation of the Phase 2 portion of this ongoing clinical trial. In December 2018, we received a $2.0 million milestone payment upon the dosing of the first cervical cancer patient in the trial. In January 2019, we received a $2.0 million milestone payment upon the initiation of a Phase 2 combination trial to evaluate MEDI0457 in combination with durvalumab targeting a broad array of cancers associated with HPV.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">GeneOne</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2014, we and GeneOne announced a collaboration in which the companies will co-develop our DNA-based Ebola vaccine through a Phase 1 clinical trial. In April 2015, the collaborators received an award from DARPA to further advance the Ebola project. The previous collaboration agreement with GeneOne for Ebola vaccine was incorporated into this consortium funded by DARPA. In May 2015, a Phase 1 study of the DNA vaccine part of the project was initiated. Enrollment of this study has been completed. Details of this project are provided under "Ebola" above.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, we announced that we will advance a DNA vaccine for MERS into a Phase 1 clinical trial in healthy volunteers in a collaboration with GeneOne. Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a 35% milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;In January 2016, the collaborators announced the initiation of recruitment for the Phase 1 study in partnership with the Walter Reed Army Institute of Research (WRAIR) in Maryland, where the trial was conducted. We announced results from the trial in June 2018. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, we and GeneOne expanded the collaboration agreement to test and advance our DNA-based vaccine for preventing and treating Zika virus.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ApolloBio</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, we entered into an Amended and Restated License and Collaboration Agreement with Beijing Apollo Saturn Biological Technology Limited, a corporation organized under the laws of China, or ApolloBio. Under the terms of this License and Collaboration Agreement, which became effective in March 2018, we granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, our DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao and Taiwan. The territory may be expanded to include Korea in the event that no patent covering&#160;VGX-3100&#160;issues in China within the first three years of the term of the agreement.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the License and Collaboration Agreement, we have granted to ApolloBio an option to negotiate an exclusive license to research, develop and commercialize MEDI0457 in the event of termination of our current collaboration with AstraZeneca for the development of&#160;MEDI0457 in the territory covered by the License and Collaboration Agreement. As part of the collaboration, ApolloBio will fund all clinical development costs within the licensed territory, and the parties will discuss in good faith the inclusion of clinical trial sites in China as part of our ongoing Phase 3 clinical development program for&#160;VGX-3100.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the License and Collaboration Agreement, we received proceeds of $19.4 million in March 2018, which comprised an upfront payment of $23.0 million less $2.2 million in foreign income taxes and $1.4 million in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations during the year ended December 31, 2018.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the upfront payment, we are entitled to receive up to an aggregate of $20.0&#160;million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100&#160;is approved for marketing in these territories, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. The License and Collaboration Agreement, once effective, will continue in force until ApolloBio has no remaining royalty obligations.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Agreements Focused on Advancing Immuno-Oncology</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we entered into a supply agreement with Genentech to obtain supply of TECENTRIQ</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;(atezolizumab) for use in our clinical trials evaluating INO-5401 and INO-9012, an immune activator encoding IL-12, in combination with TECENTRIQ</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, in approximately 80 patients with advanced bladder cancer. We will manage and fund the costs of the multi-center, open-label trial.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, we&#160;entered into a clinical study and supply agreement with Regeneron to provide its PD-1 inhibitor, REGN2810, for use in our clinical trials evaluating INO-5401 and INO-9012, in combination with REGN2810, in patients with newly diagnosed GBM. Under the terms of the agreement, we will conduct and fund the trial based upon a mutually agreed upon study design.</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2018, we entered into a Clinical Collaboration Agreement with the PICI to undertake clinical evaluation of novel combination regimens within the field of immuno-oncology. We expect to benefit from the PICI's innovative research model, which brings together leading academic cancer institutions and companies to share resources, data and technology, accelerate research through unifying and managing clinical trial design, and conduct multi-center clinical trials. The goal of our collaboration is to design studies that have the potential to address cancers with high unmet need. The initial trial under consideration would address muscle-invasive bladder cancer with INO-5401 in combination with other immunotherapies.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the agreement, the&#160;PICI&#160;will have responsibility for clinical study execution, working in collaboration with its established network of clinical academic and industry cancer centers. We will contribute a portion of the development costs in an amount to be determined if the product candidate studied under the collaboration reaches the initiation of a Phase 3 clinical trial.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Geneos Therapeutics </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, we incorporated a subsidiary, Geneos Therapeutics, Inc., to develop and commercialize neoantigen based personalized cancer therapies. As of December 31, 2018, we owned 100% of the outstanding equity of Geneos. In February 2019, Geneos raised capital from the issuance of equity to us and other third parties, which reduced our ownership percentage. While we leverage our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;immunotherapy and CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;delivery technologies&#160;to break tolerance and create cancer products targeting shared tumor specific antigens, Geneos is focusing exclusively on leveraging our immunotherapy technology platform to advance the field of patient-specific neoantigen therapies for cancer. We believe that our clinically validated DNA-based platform is well suited for advancing individualized therapies due to its rapid product design and manufacturing benefits, ability to combine multiple neoantigens into formulations, and generation of potent killer T cell responses that are needed to drive clinical efficacy. We have exclusively licensed our SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;immunotherapy and CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology platform to Geneos to be used in the field of personalized, neoantigen based therapy for cancer. The license agreement provides for potential royalty payments to us in the event that Geneos commercializes any products using the licensed technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Core DNA Immunotherapy Technology and Product License</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016,&#160;we entered into a collaborative research agreement with the&#160;Wistar Institute&#160;for preventive and therapeutic DNA-based immunotherapy applications and products for cancers and infectious diseases developed by&#160;David B. Weiner, Ph.D., and his Wistar laboratory. We will have the exclusive right to in-license new intellectual property developed in this collaboration. In January 2020, we signed a license agreement with the Wistar Institute, attaining exclusive worldwide rights to develop multiple DNA plasmids and constructs with the potential to treat and/or prevent cancer and infectious diseases.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have license agreements for intellectual property relating to DNA-based immunotherapy technology and multiple products developed at the University of Pennsylvania, or UPenn. Under the terms of the license agreement with UPenn, we have obtained exclusive worldwide rights to develop multiple DNA plasmids and constructs with the potential to treat and/or prevent cancer and infectious diseases. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Both Wistar and UPenn license agreements, as amended to date, provide for royalty payments, based on future sales of licensed products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major pharmaceutical companies, broadly engaged in vaccine/immunotherapy research and development. These include Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline&#160;plc, Merck, Pfizer, and our collaborator AstraZeneca. There are also various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies including Aduro Biotech, Advaxis, Bavarian Nordic, BioNTech, CureVac, Dynavax, Hookipa, Iovance, Moderna, Nektar, Novavax, Translate Bio and Vir Biotechnology. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low grade cervical dysplasias. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is the current standard of care for treating high-grade cervical dysplasia. Advaxis and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to GBM, prostate, breast, lung and other cancers we are targeting.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other DNA delivery technologies such as viral vectors or lipid vectors to induce </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vivo</font><font style="font-family:inherit;font-size:10pt;">&#32;generated antigen production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their unique obstacles to overcome.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Viral DNA Delivery</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This technology utilizes a virus as a carrier to deliver genetic material into target cells. The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy. The greatest limitation of the technology stems from problems with unwanted immune responses against the viral vector, limiting its use to patients who have not been previously exposed to the viral vector and making repeated administration difficult. In addition, complexity and safety concerns increase their cost and complicate regulatory approval.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Lipid DNA Delivery</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies. These work by either increasing uptake of the DNA/RNA into cells or by acting as an adjuvant, alerting the immune system. While there has been progress in this field, lipid delivery tends to be less efficient than viral vectors and is hampered by concerns regarding toxicity and increased complexity.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">DNA Immunotherapy Delivery with Electroporation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are other companies with electroporation intellectual property and devices. We believe we have significant competitive advantages over other companies focused on electroporation for multiple reasons:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA-based agents. This experience has been validated with multiple sets of interim data from multiple clinical studies assessing DNA-based immunotherapies and vaccines against cancers and infectious disease. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a broad product line of electroporation instruments designed to enable DNA delivery in tumors, muscle, and skin.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our competitive position will be affected by the disease indications addressed by our product candidates and those of our competitors, the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include the efficacy, safety, ease of use, reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Review and Approval of Combination Products in the United States</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects. Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action, with the device component reviewed under a Device Master File.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">U.S. Biological Product Development</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations. Biologics are also subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">submission to the FDA of a BLA;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The clinical stage of development involves the administration of the product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand subjects) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may condition approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials to further assess the biologic&#8217;s safety and effectiveness after BLA approval.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;">&#32;testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">BLA and FDA Review Process</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Once a BLA has been accepted for filing, which occurs, if at all, sixty days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA&#8217;s review process again, including the initial sixty day review to determine if the application is sufficiently complete to permit substantive review.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is no assurance that the FDA will ultimately approve a product for marketing in the United States and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Post-Marketing Requirements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drug products </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and pharmaceutical samples must comply with the U.S. Prescription Drug Marketing Act, or the PDMA, a part of the FDCA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Coverage and Reimbursement</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs. Accordingly, a pharmaceutical company&#8217;s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Healthcare Reform</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably.&#160;In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expanded the entities eligible for discounts under the Public Health program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created a licensure framework for follow on biologic products.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. On January 31, 2019, the U.S. Department of Health and Human Services, Office of Inspector General, proposed modifications to the federal healthcare program Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. While some of these and other proposed measures may require additional authorization to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Healthcare Laws</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company&#8217;s ability to operate include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Physician Payments Sunshine Act, created under the ACA, which requires pharmaceutical companies to record any transfers of value made to doctors and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and to annually report such data to CMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other Regulations</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercialization and Manufacturing</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the broad potential applications of our technologies, we intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as infectious diseases and cancer. Where appropriate, we intend to rely on strategic marketing and distribution alliances.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable clinical investigations.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Relationship with GeneOne </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We acquired an equity interest in GeneOne in 2005. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we owned 7.5% of the outstanding capital stock of GeneOne and GeneOne owned 73,590 shares of our common stock. To our knowledge, none of our current officers, directors, or key employees beneficially owns, directly or indirectly, any securities of GeneOne.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, we sold our manufacturing operations (including patent rights to certain manufacturing technology) to VGXI, Inc., a wholly-owned United States subsidiary of GeneOne. In connection with this transfer we entered into a Supply Agreement pursuant to which VGXI,&#160;Inc., a cGMP contract manufacturer, produces and supplies the DNA plasmids for all of our research and early clinical trials. The price of the plasmids we purchase from VGXI,&#160;Inc. is determined by us and GeneOne at the time of order placement or, with respect to product supplied in connection with a grant contract, based on the contracted bid provided by the applicable agency. We agreed to treat GeneOne and its subsidiary as our most favored supplier for DNA plasmids and GeneOne and its subsidiary agreed to treat us as their most favored customer. Before we can manufacture DNA plasmids on our own behalf or engage a third party other than GeneOne or its subsidiary to manufacture DNA plasmids for us, we must first offer such manufacturing work to GeneOne or its subsidiary.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we entered into a Collaborative Development Agreement with GeneOne to co-develop an Ebola vaccine through Phase 1 clinical trials. In 2015, we amended the agreement to provide that we would have control over the development program, in return for the payment of certain development fees.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2015, we entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials. Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to 35% milestone-based ownership interest in the MERS immunotherapy upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;The collaborative research program will terminate upon the completion of activities under the development plan, unless sooner terminated.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, we and GeneOne expanded the collaboration agreement to test and advance our DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a 35% milestone-based ownership interest in the Zika immunotherapy upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, we completed the sale of certain assets related to our compound VGX-1027 to GeneOne for $1.0 million.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from GeneOne consists of patent and device maintenance fees from the influenza, HCV and Zika collaborations. For the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized revenue from GeneOne of </font><font style="font-family:inherit;font-size:10pt;">$127,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$342,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. Operating expenses recorded from transactions with GeneOne relate primarily to biologics manufacturing. These operating expenses for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we had an accounts payable and accrued liability balance of </font><font style="font-family:inherit;font-size:10pt;">$511,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$372,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to GeneOne and its subsidiaries. At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$284,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$381,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, of prepayments made to GeneOne were classified as long-term other assets on our consolidated balance sheet. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets. Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our intellectual property portfolio covers our proprietary technologies, including CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">delivery as well as immunotherapy and vaccine construct related technologies. As of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, our patent portfolio included approximately 90 issued United States patents and over 500 issued foreign counterpart patents. In addition, we have numerous patent applications pending in the United States and various foreign jurisdictions.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us. These third-parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third-party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system. We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights. Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Customers and Research and Development</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we derived 78% of our revenue from AstraZeneca. During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, we derived 75% of our revenue from ApolloBio and 23% of our revenue from AstraZeneca. During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we derived 53% of our revenue from AstraZeneca, 24% of our revenue from DARPA and 14% of our revenue from Roche. Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $</font><font style="font-family:inherit;font-size:10pt;">88.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$95.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and $98.6 million in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Information </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our revenue for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was earned in the United States. All of our long-lived assets are located in the United States.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Corporate History and Headquarters </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have been a leader in advancing the capabilities of DNA-based immunotherapies to treat infectious diseases and cancers going back to the original incorporation of Viral Genomix, Inc. under the laws of Delaware on April 17, 2000. We were renamed VGX Pharmaceuticals, Inc. on May 31, 2006. On February 21, 2007, VGX Pharmaceuticals acquired Advisys, Inc., a company possessing DNA and electroporation technology, through an asset purchase agreement. On April 14, 2007, VGX Pharmaceuticals entered into an exclusive license agreement with the Trustees of the University of Pennsylvania related to therapeutic and prophylactic DNA vaccines developed by Professor David B. Weiner at the University of Pennsylvania School of Medicine. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recognizing the value of electroporation delivery technology, devices, and patents in advancing DNA-based immunotherapy products, on June 1, 2009, VGX Pharmaceuticals completed a merger with Inovio Biomedical Corporation, a publicly listed company focused on electroporation delivery technology. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio Biomedical Corporation started as Biotechnologies &amp; Experimental Research, Inc. and was incorporated on June 29, 1983 in California to create products for the research marketplace. The company changed its corporate name to BTX, Inc. on December 10, 1991, and to Genetronics, Inc. on February 8, 1994. On April 14, 1994, Genetronics, Inc. became a public company through a share exchange agreement with Consolidated United Safety Technologies, Inc., a company listed on the Vancouver Stock Exchange under the laws of British Columbia, Canada. The company changed its name to Genetronics Biomedical Ltd. on September 29, 1994. Genetronics, Inc. remained as a wholly owned operating subsidiary. On September 2, 1997, the company listed on the Toronto Stock Exchange. On December 8, 1998, the company listed on the American Stock Exchange (now NYSE MKT) and voluntarily de-listed from the Toronto Stock Exchange on January 17, 2003. On June 15, 2001, Genetronics Biomedical Ltd. completed a change in jurisdiction of incorporation from British Columbia, Canada, to the state of Delaware and became Genetronics Biomedical Corporation. On January 25, 2005, Genetronics Biomedical Corporation acquired Inovio AS, a gene delivery technology company located in Norway. On March 31, 2005, Genetronics Biomedical Corporation was renamed Inovio Biomedical Corporation. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The merger between VGX Pharmaceuticals and Inovio Biomedical Corporation was effected pursuant to the terms of an Amended and Restated Agreement and Plan of Merger dated December 5, 2008, as further amended on March 31, 2009. On May 14, 2010, the combined entity changed its corporate name to Inovio Pharmaceuticals, Inc. We conduct our business through our United States wholly-owned subsidiaries, VGX Pharmaceuticals, LLC and Genetronics, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our telephone number is (267) 440-4200. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Internet website address is </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">www.inovio.com</font><font style="font-family:inherit;font-size:10pt;">. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, our Corporate Governance Policy and information for contacting our board of directors is available on our website.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 6, 2020, we employed 190 people on a full-time basis and 4 people under consulting and project employment agreements. Of the combined total, 153 were in product research, which includes research and development, quality assurance, clinical, engineering, and manufacturing, and 41 were in general and administrative functions, which includes corporate development, information technology, legal, investor relations, finance and corporate administration. None of our employees are subject to collective bargaining agreements. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="sC56466F36F875D3597E05B0C20DE9A8D"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and Industry</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred losses since inception, expect to incur significant net losses in the foreseeable future and may never become profitable.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have experienced significant operating losses to date. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;our accumulated deficit was $</font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">739.8 million</font><font style="font-family:inherit;font-size:10pt;">. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA vaccine and DNA immunotherapy product candidates or electroporation-based synthetic vaccine delivery technology and thus may never have any significant future revenues or achieve and sustain profitability. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have limited sources of revenue and our success is dependent on our ability to develop our DNA vaccines and DNA immunotherapies and electroporation equipment. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developing and securing United States and/or foreign regulatory approvals for our product candidates, including securing regulatory approval for conducting clinical trials with product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developing our electroporation-based DNA delivery technology; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our electroporation equipment and product candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our electroporation equipment and product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of electroporation equipment and products, and we may not be able to continue our operations. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">None of our human vaccine and immunotherapy product candidates have been approved for sale, and we may not develop commercially successful vaccine products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our human vaccine and immunotherapy programs are in the early stages of research and development, and currently include product candidates in discovery, preclinical studies and Phase&#160;1, 2 and 3 clinical trials. There are limited data regarding the efficacy of synthetic vaccine and immunotherapy candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before any regulatory authority will approve any of our vaccine product candidates. The success of our efforts to develop and commercialize our product candidates could fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our product candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances. The products, if safe and effective, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our substantial indebtedness could limit the cash flow available for our operations and could expose us to risks that could adversely affect our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2019, we sold $78.5 million aggregate principal amount of 6.50% convertible senior notes due 2024, or the Notes, as well as $15.0 million and $4.1 million aggregate principal amount of 1.0% convertible bonds due August 2024 and December 2024, respectively, or the August 2019 Bonds and the December 2019 Bonds, respectively. We may also incur </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional indebtedness to meet future financing needs. Our indebtedness could have significant negative consequences for our security holders and our business, results of operations and financial condition by, among other things:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increasing our vulnerability to adverse economic and industry conditions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limiting our ability to obtain additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">requiring the dedication of a substantial portion of our cash flow from operations to service our indebtedness, which will reduce the amount of cash available for other purposes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limiting our flexibility to plan for, or react to, changes in our business;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diluting the interests of our existing stockholders if we issue shares of our common stock upon conversion of the Notes, the August 2019 Bonds and the December 2019 Bonds in accordance with their respective terms; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">placing us at a possible competitive disadvantage with competitors that are less leveraged than us or have better access to capital.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our business may not generate sufficient funds, and we may otherwise be unable to maintain sufficient cash reserves, to pay amounts due under the Notes, the August 2019 Bonds and the December 2019 Bonds and any additional indebtedness that we may incur. In addition, our cash needs may increase in the future. In addition, any future indebtedness that we may incur may contain financial and other restrictive covenants that limit our ability to operate our business, raise capital or make payments under our other indebtedness. If we fail to comply with these covenants or to make payments under our indebtedness when due, then we would be in default under that indebtedness, which could, in turn, result in that and our other indebtedness becoming immediately payable in full.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The conditional conversion features of the Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert their Notes into shares of our common stock at any time during specified periods at their option. If one or more of the holders of the Notes elects to convert their Notes, unless we satisfy our conversion obligation by delivering only shares of our common stock, we would be required to settle all or a portion of our conversion obligation through the payment of cash, which could adversely affect our liquidity. The conditional convertibility of the Notes will be monitored at each quarterly reporting date and analyzed dependent upon market prices of our common stock during the prescribed measurement periods.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Conversion of the Notes, the August 2019 Bonds and/or the December 2019 Bonds will dilute the ownership interest of existing stockholders, and may otherwise depress the price of our common stock.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The conversion of some or all of the Notes, the August 2019 Bonds and/or December 2019 Bonds will dilute the ownership interests of existing stockholders to the extent we deliver shares of our common stock upon conversion of any of the Notes. The Notes may become in the future convertible at the option of the holders of the Notes prior to November 1, 2023 under certain circumstances as provided in the indenture governing the Notes. The August 2019 Bonds and December 2019 Bonds may become in the future convertible at the option of the holders of the August 2019 Bonds and December 2019 Bonds starting August 1, 2020 and December 31, 2020, respectively, until the date that is one month prior to maturity date of the August 2019 Bonds and December 2019 Bonds. Any sales in the public market of the common stock issuable upon such conversion could adversely affect prevailing market prices of our common stock. In addition, the existence of the Notes may encourage short selling by market participants because the conversion of the Notes could be used to satisfy short positions, or anticipated conversion of the Notes into shares of our common stock could depress the price of our common stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;font-weight:bold;">We may not have the ability to raise the funds necessary to settle conversions of the Notes in cash, to repurchase the Notes or the August 2019 Bonds or the December 2019 Bonds upon a fundamental change or to repurchase the August 2019 Bonds and the December 2019 Bonds from and including July 31, 2022 and December 31, 2022 up to the date falling one month prior to the maturity date of the August 2019 Bonds and December 2019 Bonds, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the Notes.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Subject to certain conditions, holders of the Notes or the August 2019 Bonds or the December 2019 Bonds may require us to repurchase for cash all or a portion of their Notes or August 2019 Bonds or December 2019 Bonds, respectively, upon the occurrence of a fundamental change (as defined in the indenture governing the Notes or the August 2019 Bonds or the December 2019 Bonds, respectively) at a repurchase price equal to 100% of</font><font style="font-family:inherit;font-size:10pt;">&#160;t</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">he principal amount of the Notes or the August 2019 Bonds or the December 2019 Bonds, as applicable, to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the fundamental change repurchase date. In addition, if a make-whole fundamental change (as defined in the indenture for the Notes) occurs prior to the maturity date of the Notes, we will in some cases be required to increase the conversion rate for a holder that elects to convert its Notes in connection with such make-whole fundamental change. The August 2019 Bonds and December 2019 Bonds will be subject to repurchase by us at the option of the holders thereof from and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">including July 31, 2022 and December 31, 2022, respectively, up to the date falling one month prior to the maturit</font><font style="font-family:inherit;font-size:10pt;">y date</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">&#32;at a repurchase price equal to the principal of the August 2019 Bonds and December 2019 Bonds to be repurchased plus a premium on such August 2019 Bonds and December 2019 Bonds in order to provide an internal rate of return with respect to such August 2019 Bonds and December 2019 Bonds of 6.00%. Upon a conversion of the Notes, unless we elect to deliver solely shares of our common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the Notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of Notes or August 2019 Bonds or December 2019 Bonds surrendered for repurchase or pay cash with respect to Notes being converted.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">In addition, our ability to repurchase or to pay cash upon conversion of the Notes may be limited by law, regulatory authority or agreements governing our future indebtedness. Our failure to repurchase the Notes at a time when the repurchase is required by the indenture governing the Notes or to pay cash upon conversion of the Notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under our August 2019 Bonds and December 2019 Bonds or agreements governing our future indebtedness. If the payment of the related indebtedness were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the Notes or the August 2019 Bonds or the December 2019 Bonds or to pay cash upon conversion of the Notes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need substantial additional capital to develop our DNA vaccine and immunotherapy programs and electroporation delivery technology.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Conducting the costly and time-consuming research, pre-clinical and clinical testing necessary to obtain regulatory approvals and bring our product candidates and delivery technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the progress of our current and new product development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the progress, scope and results of our pre-clinical and clinical testing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the time and cost involved in obtaining regulatory approvals; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of manufacturing our products and product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">debt service obligations on the Notes, the </font><font style="font-family:inherit;font-size:10pt;color:#231f20;">August 2019 Bonds and December 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#231f20;">Bonds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competing technological and market developments; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability and costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility and turmoil, making it more difficult to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities or we issue securities in connection with another transaction, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Fluctuating interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our product candidates. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face intense and increasing competition and many of our competitors have significantly greater resources and experience. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive, or result in treatments or cures superior to ours.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many other companies are pursuing other forms of treatment or prevention for diseases that we target. For example, many of our competitors are working on developing and testing cancer vaccines and immunotherapies and several products such as the CAR-Ts developed by our competitors have been approved for human use. Our competitors and potential competitors include large pharmaceutical and more established biotechnology companies. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, pre-clinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. Small companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our product candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to enter into agreements with other highly-regarded organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate and implement a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A small number of licensing partners and government contracts account for a substantial portion of our revenue. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have agreements with government agencies, which are subject to termination and uncertain future funding. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into agreements with government agencies, such as the NIAID and DARPA, and we intend to continue entering into these agreements in the future. Our business is partially dependent on the continued performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our quarterly operating results may fluctuate significantly.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">variations in the level of expenses related to our electroporation equipment, product candidates or future development programs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expenses related to corporate transactions, including ones not fully completed; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">addition or termination of clinical trials or funding support; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any intellectual property infringement lawsuit in which we may become involved; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any legal claims that may be asserted against us or any of our officers; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory developments affecting our electroporation equipment and product candidates or those of our competitors; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">debt service obligations on the Notes, the August 2019 Bonds and the December 2019 Bonds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the fair value of the derivative liability associated with the August 2019 Bonds;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the fair value of our investments, including investments in affiliated entities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if any of our products receives regulatory approval, the levels of underlying demand for our products. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain FDA approval of our products, we will not be able to commercialize them in the United States.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We need FDA approval prior to marketing our electroporation equipment and products in the United States. If we fail to obtain FDA approval to market our electroporation equipment and product candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This regulatory review and approval process, which includes evaluation of pre-clinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">from well-controlled clinical trials that our electroporation equipment and product candidates are both safe and effective for each indication for which approval is sought. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our electroporation equipment and any of our product candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our electroporation equipment and product candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, pre-clinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is possible that none of our products or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of pre-clinical studies and early clinical trials of our products may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products. </font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products could fail to complete the clinical trial process for many reasons, including the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our electroporation equipment and a product candidate are safe and effective for any indication; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be successful in enrolling a sufficient number of participants in clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate that our electroporation equipment and a product candidate's clinical and other benefits outweigh its safety risks; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be unable to demonstrate that our electroporation equipment and a product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of us or third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></div></td></tr></table><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the QSR or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Delays in the commencement or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delays in the commencement or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining regulatory approval to commence a clinical trial; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">future bans or stricter standards imposed on clinical trials of gene-based therapy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing sufficient quantities of our electroporation equipment and product candidates for use in clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining institutional review board, or IRB, approval to conduct a clinical trial at a prospective site; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collecting, reviewing and analyzing our clinical trial data; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">global unrest, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of adequate funding to continue the clinical trial. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our electroporation equipment and our product candidates may be harmed and our ability to generate product revenues will be delayed. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement or completion of clinical trials may adversely affect the trading price of our common stock. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our product candidates.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our electroporation equipment and product candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our product candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if United States regulatory approval is obtained, the FDA may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issue Warning Letters or untitled letters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impose civil or criminal penalties; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspend regulatory approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspend any ongoing clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refuse to approve pending applications or supplements to applications filed by us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impose restrictions on operations, including costly new manufacturing requirements; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seize or detain products or require us to initiate a product recall. </font></div></td></tr></table><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market any electroporation equipment and product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our product candidates may not </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">be approved for all indications requested, which could limit the uses of our product candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of our electroporation equipment and synthetic vaccine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment of our business reputation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of related litigation; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">distraction of management's attention from our primary business; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to patients or other claimants; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenues; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to commercialize our products. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have no marketing and sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenues.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently do not have a sales organization for the marketing, sales and distribution of our electroporation equipment and product candidates. In order to commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our product candidates which would negatively impact our ability to generate product revenues. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any of our products for which we receive regulatory approval does not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The commercial success of our electroporation equipment and product candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to provide acceptable evidence of safety and efficacy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the relative convenience and ease of administration; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of any actual or perceived adverse side effects; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability of alternative treatments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pricing and cost effectiveness; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effectiveness of our or any future collaborators' sales and marketing strategies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the willingness of patients to pay out of pocket in the absence of third-party coverage. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our electroporation equipment and product candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our product candidates, could hinder or prevent our products' commercial success. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our electroporation equipment and product candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that drug products have been approved for marketing by the FDA. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our product candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our product candidates or procedures using our product candidates, could reduce physician utilization of our products once approved.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Coverage and reimbursement policies for drug products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</font></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare reform measures could hinder or prevent our products' commercial success. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably.&#160;In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA.   Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. Under the Consolidated Appropriations Act of 2016, the excise tax was suspended through December&#160;31, 2017, and under the continuing resolution on appropriations for fiscal year 2018, or 2018 Appropriations Resolution, signed by President Trump on January&#160;22, 2018, was further suspended through December&#160;31, 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">expanded the entities eligible for discounts under the Public Health program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">created a licensure framework for follow on biologic products.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the provisions of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect through 2027 unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of drug products paid by consumers. On January 31, 2019, the U.S. Department of Health and Human Services, Office of Inspector General, proposed modifications to the federal healthcare program Anti-Kickback Statute discount safe harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. While some of these and other proposed measures may require additional </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to set a price we believe is fair for our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to generate revenues and achieve or maintain profitability; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the availability of capital; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain timely approval of our products. </font></div></td></tr></table><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Physician Payments Sunshine Act, created under the ACA, which requires pharmaceutical companies to record any transfers of value made to doctors and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and to annually report such data to CMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we and the contract manufacturers upon whom we rely fail to produce our systems and product candidates in the volumes that we require on a timely basis, or fail to comply with stringent regulations, we may face delays in the development and commercialization of our electroporation equipment and product candidates. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manufacture some components of our electroporation systems and utilize the services of contract manufacturers to manufacture the remaining components of these systems and our product supplies for clinical trials. The manufacture of our systems and product supplies requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and product candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our electroporation equipment to our partners and products to patients in our clinical trials or to commercially launch a product would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, future acquisitions may entail numerous operational and financial risks, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">exposure to unknown liabilities; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">higher than expected acquisition and integration costs; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased amortization expenses; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to retain key employees of any acquired businesses. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to stockholder litigation, which would harm our business and financial condition. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. Any such actions could give rise to substantial damages, and thereby have a material adverse effect on our consolidated financial position, liquidity, or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with stockholder actions could harm our business, financial condition and reputation. Litigation can be costly, time-consuming and disruptive to business operations. The defense of lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption in or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information, and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction or interruption of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. The ever-increasing use and evolution of technology, including cloud-based computing, creates </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in tax laws could adversely affect our business and financial condition.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;22, 2017, President Trump signed into law new legislation, known as the Tax Cuts and Jobs Act of 2017, that significantly revised the Internal Revenue Code of 1986, as amended, or the Code.&#160;The new federal income tax law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions).&#160;Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected.&#160;In addition, it is uncertain if and to what extent various states will conform to the federal tax law.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in funding for the FDA and other government agencies could hinder our ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The&#160;coronavirus&#160;outbreak could adversely impact our business.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2019, it was first reported that there had been an outbreak of a novel strain of&#160;coronavirus, SARS-CoV-2,&#160;in China. The&#160;coronavirus&#160;has since spread to a number of other countries, including countries in which we have planned or ongoing clinical trials. The number of cases globally is increasing daily and in an effort to halt the outbreak, many governments, including the Chinese government, and many business have placed significant restrictions on travel and closed businesses. Two of our collaborators, ApolloBio and Beijing Advaccine, are based in China and their operations, including development of VGX-3100 and INO-4800, could be adversely impacted by the restrictions on travel and business disruptions.</font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As the&#160;coronavirus&#160;continues to spread outside of China, including throughout the United States, we may experience disruptions that could severely impact our business and clinical trials, including:  </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays or difficulties in enrolling patients in certain of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of healthcare resources away from the conduct of certain of our clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of certain of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; and</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The global outbreak of coronavirus continues to rapidly evolve. The extent to which the&#160;coronavirus&#160;impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the&#160;coronavirus, the ultimate geographic spread of the&#160;coronavirus, the duration of the outbreak, travel restrictions imposed by China and other countries, business closures or business disruption in China and other countries, a reduction in time spent out of home and the actions taken throughout the world, including in our markets, to contain the&#160;coronavirus&#160;or treat its impact.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our electroporation equipment and product candidates, as well as successfully defending these intellectual property rights against third-party challenges. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pending patent applications may not result in issued patents; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issued patents may be challenged and invalidated, or rendered unenforceable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not develop or acquire additional proprietary technologies that are patentable; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our trademarks may be invalid or subject to a third party's prior use; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these events occur, our business could suffer and the market price of our common stock may decline. </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Common Stock</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not be sustained.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although our common stock is listed on the Nasdaq Global Select Market, we cannot assure you that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The price of our common stock may be volatile, and an investment in our common stock could decline substantially in value. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price may be highly volatile and can be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, in addition to the other risk factors described in this annual report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fluctuating public or scientific interest in the potential for influenza pandemic or other applications for our vaccine or other product candidates; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">fluctuations in our operating results; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements of technological innovations; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">new products or services that we or our competitors offer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:174%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">conditions or trends in bio-pharmaceutical or other healthcare industries; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory developments in the United States and other countries; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">negative perception of gene-based therapy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales or other transactions involving our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in our capital structure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales or other transactions by executive officers or directors involving our common stock; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in accounting principles; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">global unrest, terrorist activities, and economic and other external factors; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">catastrophic weather and/or global disease pandemics, such as the recent coronavirus outbreak. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The stock market in general has recently experienced relatively large price and volume fluctuations, particularly in response to the coronavirus outbreak. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of the common stock, which could cause a decline in the value of the common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:64px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:38px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the elimination of cumulative voting. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we are governed by the provisions of Section&#160;203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant costs and demands upon management as a result of being a public company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1FE495A5E83955F5A4BC16EC6765CC39"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s150B49A5408A5427A501C16D50591D4C"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We own no real property and have no plans to acquire any real property in the future. </font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">San Diego Leases</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2013, we entered into a lease, or the First San Diego Lease, for office space in San Diego, California. The term of the First San Diego Lease commenced on December 1, 2013. The initial term of the First San Diego Lease is ten years, with an option to extend the term by five years, subject to specified conditions. In June 2015, we amended the First San Diego Lease to increase the total leased space to 31,207 square feet and occupy the entire building. The commencement of the amended First San Diego Lease was in January 2016. As of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, rent payments under the First San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. We had an option to terminate the First San Diego Lease on December 1, 2019, which we did not exercise.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2016, we entered into an office lease, or the Second San Diego Lease, for a second property in San Diego, California. The total space under the Second San Diego Lease is approximately 51,000 square feet. We are using the facility for office, manufacturing and research and development purposes. The term of the Second San Diego Lease commenced on June&#160;1, 2017. The initial term of the Second San Diego Lease is ten years, with a right to terminate on November&#160;30, 2023, subject to specified conditions.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The base rent adjusts periodically throughout the term of the Second San Diego Lease. As of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, rent payments under the Second San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plymouth Meeting Lease </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2014, we entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We occupied the space in June 2014. The initial term of the Plymouth Meeting Lease was 11.5 years, with a right to extend the term by five years, subject to specified conditions. We use the space for office purposes.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The base rent adjusts periodically throughout the term of the Plymouth Meeting Lease. As of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately 2 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $49,000. In July 2015, we amended the Plymouth Meeting Lease to increase the total leased space to 27,583 square feet. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, we entered into another amendment to the Plymouth Meeting Lease to increase the total leased space to 57,361 square feet and extend the lease term through December 31, 2029. In connection with this amendment, we paid the landlord an additional security deposit of $75,000.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, we entered into two agreements to sublease a total of approximately 13,500 square feet in our Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9747623C098F5379BE26D36817DB48F3"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we are subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s68CE1EFC87185C3B9E94E567F3B49A6C"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><a name="s263CF4CC2F275661A8C63101B67916FD"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="sD4204899D6725A72927A72ED6B29BA9F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Market Information</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of March 6, 2020, we had approximately 480 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The closing price per share of our common stock on March 6, 2020 was $14.09, as reported on the Nasdaq Global Select Market.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividends</font></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&amp;P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. The graph assumes a $100 investment on December 31, 2014 in our common stock and in each index, with the reinvestment of all dividends, if any.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;text-indent:29px;"><img src="chart-4f4c561ec95bdab3028.jpg" alt="chart-4f4c561ec95bdab3028.jpg" style="height:400px;width:558px;"></div><div style="line-height:120%;padding-left:144px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">*$100 invested on 12/31/14 in stock or index, including reinvestment of dividends.<br>Fiscal year ending December 31.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:23%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">12/14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">12/15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">12/16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">12/17</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">12/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">12/19</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Inovio Pharmaceuticals, Inc.&#160;&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">73.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">75.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35.95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NYSE American</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">73.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87.62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">88.68</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74.91</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85.42</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Nasdaq Composite</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">106.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">116.45</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">150.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">146.67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">200.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">S&amp;P SuperCap Biotechnology Index</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">100.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">104.97</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">88.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">111.77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">123.27</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Sales of Unregistered Securities </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchases of Equity Securities by the Issuer and Affiliated Parties </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1191792FC3785B6F907274EB532DADCF"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.&#160;&#160;&#160;&#160;SELECTED FINANCIAL DATA</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following selected consolidated financial data should be read together with &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and related notes included elsewhere in this report. The selected consolidated balance sheet data at December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and the selected consolidated statements of operations data for the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited consolidated financial statements that are included elsewhere in this report. The selected consolidated balance sheet data at December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and the selected consolidated statements of operations data for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited consolidated financial statements not included in this report. Historical results are not necessarily indicative of the results to be expected in the future.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, <br>2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, <br>2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Operations Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research&#160;and development arrangements, including from affiliated entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,872,594</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,310,309</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,173,216</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,891,341</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,655,700</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants&#160;and miscellaneous revenue, including from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,046,870</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,477,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,916,411</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111,930</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,481,897</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,220,086</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,368,361</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,572,111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,108,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,091,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,642,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,235,937</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,283,702</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,846,358</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">920,891</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,612,974</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,257,257</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">806,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">177,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,763,652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) on investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,090,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,988,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,982,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,110,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,600,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Provision for) benefit from income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,335</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,097,766</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,551,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,740,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,102,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net (income) loss attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,192,558</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84,769</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(73,740,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,187,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per common share attributable to common stockholders</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.01</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.44</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,196,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,693,633</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,786,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,136,472</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,632,693</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">103,638,844</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,629,412</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,357,277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143,951,597</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131,113,265</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,239,270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,707,166</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">213,840,859</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,989,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,299,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,405,426</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,823,027</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,466,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncurrent liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,557,418</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,781,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,345,035</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,505,719</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,441,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(739,785,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(620,426,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(523,356,317</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(434,838,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(361,097,896</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,404,858</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,032,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">142,488,809</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">123,378,420</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175,933,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><a name="sC0C5D793231D504A884D4A60A018E649"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;I of this Annual Report under the Caption &#8220;Risk Factors.&#8221;</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our electroporation technology and DNA vaccines may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture vaccine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFD27BEA6C9B450479090C07F7B70B750"></a></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Our DNA medicine pipeline is comprised of three types of product candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, we have demonstrated that a DNA medicine can be delivered directly into cells in the body via our proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our novel DNA medicine candidates are made using our proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our hand-held CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery devices provide optimized uptake of our DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of our DNA medicines delivered directly into cells in the body using the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart device in more than 6,000 administrations across more than 2,000 patients.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our corporate strategy is to advance, protect, and provide our novel DNA medicines to meet urgent and emerging global health needs. We continue to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. We aim to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We or our collaborators are currently conducting or planning clinical studies of our DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis, or RRP; glioblastoma multiforme, or GBM; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome, or MERS; Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our product candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, we announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, we reduced approximately </font><font style="font-family:inherit;font-size:10pt;">28%</font><font style="font-family:inherit;font-size:10pt;">&#32;of our workforce and discontinued our immuno-oncology Phase 1/2 clinical trial of our product candidate INO-5401 in patients with advanced bladder cancer. In the third quarter of 2019, we incurred a personnel-related restructuring charge of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with one-time employee termination costs, including severance and other benefits.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of $</font><font style="font-family:inherit;font-size:10pt;">739.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities. </font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8891BEBFA90C5127A2D996891B93FE74"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The SEC defines critical accounting policies as those that are, in management&#8217;s view, important to the portrayal of our financial condition and results of operations and require management&#8217;s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. Our critical accounting policies include:</font></div><div style="line-height:174%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, we adopted Accounting Standards Update (&#8220;ASU&#8221;) 2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;Topic 606&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy our performance obligations. At contract inception, we assess the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. We evaluate whether we are the principal or agent in the arrangement. We have determined that we are the principal in current arrangements as we control the product supply before it is transferred to the customer. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our or our collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have determined that as of January 1, 2018, accounting for our various grant agreements falls under the contributions guidance under Subtopic 958-605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">, which is outside the scope of Topic 606, as the government agencies granting us funds are not receiving reciprocal value for their contributions. Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We adopted ASU 2016&#8209;02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842), </font><font style="font-family:inherit;font-size:10pt;">or</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;"</font><font style="font-family:inherit;font-size:10pt;">Topic 842", on January 1, 2019. For our long-term operating leases, we recognized an operating lease right-of-use asset and an operating lease liability on our consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that we would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. We determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed rent expense for our operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate our debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in our financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</font></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from our independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. We review and accrue clinical trial expense based on work performed, relying on estimates of total costs incurred based on patient enrollment, completion of studies and other events. We follow this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s5249264091795F8D9C85A0715324F7BD"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Information regarding recent accounting pronouncements is contained in Note&#160;2 to the consolidated financial statements, included elsewhere in this report.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBBF67479CFA15CB5B7636CC7D545FED1"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial data for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;is presented in the following table and the results of these periods are used in the discussion thereafter.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,  </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/(Decrease)          2019 vs. 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase/(Decrease)          2018 vs. 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Revenue under collaborative research and development arrangements, including from affiliated entity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,872,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,310,309</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,173,216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,437,715</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(87</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,137,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Grants and miscellaneous revenue, including from affiliated entity (1)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">239,336</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">171,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,046,870</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,748</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12,875,282</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(99</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,111,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">30,481,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">42,220,086</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,369,967</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(87</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,738,189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">88,017,319</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">95,257,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,572,618</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,240,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,314,742</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,203,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,315,159</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,290,369</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,112,003</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,024,790</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gain on sale of assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,220,475</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">124,573,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">125,862,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,352,560</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,289,952</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(111,108,545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(94,091,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(83,642,901</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,017,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,448,237</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,605,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,264,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,836,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">341,234</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">428,296</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,948,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(25,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,948,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">360,795</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">806,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(360,795</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(446,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,763,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,763,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Gain (loss) on investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,090,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,988,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,982,664</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,101,990</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(55</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,994,097</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">496,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,343,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(197,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,840,056</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(137</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,146,312</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(580</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss before income tax benefit/(provision for income tax) </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120,809,112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(94,798,019</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,011,093</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,592,247</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit/(provision for income taxes)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">257,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,427,146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(120,551,777</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,583,947</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,762,058</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net income attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,192,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,192,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net loss attributed to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,391,389</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,762,058</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:45%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Years Ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2019</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue primarily consisted of revenues under collaborative research and development arrangements, including arrangements with affiliated entities for the years ended December 31, 2019 and 2018. Our year over year total revenue decreased </font><font style="font-family:inherit;font-size:10pt;">$26.4 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">87%</font><font style="font-family:inherit;font-size:10pt;">. The decrease was primarily due to the recognition of a one-time upfront payment of $23.0 million from ApolloBio during the second quarter of 2018. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;decrease in research and development expenses for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to a decrease in expenses related to our collaboration with AstraZeneca of $2.9 million, a decrease in employee compensation expense of $2.6 million due to lower employee headcount and an increase in contra-research and development expense recorded from grant agreements of $2.4 million, as well as no sub-license fee expense in 2019 as compared to $1.9 million recorded in 2018 related to the ApolloBio collaboration. These decreases were offset by an increase in clinical trial related expenses of $3.5 million and the one-time personnel-related restructuring charge of approximately $1.9 million in connection with the employee termination costs incurred during the third quarter of 2019, among other variances.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contributions received from current grant agreements and recorded as contra-research and development expense were $11.9 million and $9.5 million for the years ended December 31, 2019 and 2018, respectively. The increase year over year was primarily due to an increase of $1.9 million earned from the CEPI grant, an increase of $1.9 million from the Bill &amp; Melinda Gates Foundation grant and an increase of $890,000 from the MCDC grant, offset in part by decreases of $1.1 million and $963,000 from various Wistar sub-grants and the DARPA Ebola grant, respectively, among other variances.  </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;decrease in general and administrative expenses for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily related to the $1.4 million of foreign non-income taxes withheld from the ApolloBio upfront payment we received in 2018 and the associated advisory fees of $960,000, among other variances.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$9.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">, of which </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was included in research and development expenses and </font><font style="font-family:inherit;font-size:10pt;">$3.9</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was included in general and administrative expenses, respectively. The slight decrease for 2019 compared to 2018 was primarily due to the reversal of previously recognized stock-based compensation expense due to the reduction in our workforce in July 2019 and a lower weighted average grant date fair value for the awards granted in 2019, offset by an option modification expense recorded in the second quarter of 2019. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there was $</font><font style="font-family:inherit;font-size:10pt;">3.4</font><font style="font-family:inherit;font-size:10pt;">&#32;million of total unrecognized compensation cost related to unvested stock options, which we expect to recognize over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years, as compared to </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$4.3</font><font style="font-family:inherit;font-size:10pt;">&#32;million of total unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.6</font><font style="font-family:inherit;font-size:10pt;">&#32;years, as compared to </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years. Total stock-based compensation for options granted to non-employees for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$970,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$302,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Income </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The $341,000 increase in interest income for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as compared to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily related to the interest earned on our higher short-term investments holdings in 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest Expense </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest expense for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily relates to our 6.5% convertible senior notes due 2024, or the Notes, which were issued during the first quarter of 2019, as well as our 1.0% convertible bonds due August 2024, or the August 2019 Bonds, which were issued during the third quarter of 2019.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Fair Value of Common Stock Warrants</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in fair value of common stock warrants for the year ended December&#160;31, 2018 was $361,000. The warrants were exercised during the quarter ended September 30, 2018, eliminating the associated fair value re-measurement in subsequent periods.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Fair Value of Derivative Liability</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in fair value of derivative liability for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">. We determined that our August 2019 Bonds included an embedded conversion feature that is considered to be a derivative liability requiring bifurcation from the debt instrument and separate recognition in our financial statements. The conversion option is revalued at each reporting period with&#160;the resulting changes in fair value reflected in the consolidated&#160;statements of operations.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss on Investment in Affiliated Entity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loss on investment in affiliated entity for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, resulting from the change in the fair market value of our investments in GeneOne and PLS. We record our investments in GeneOne and PLS at their market values based on the closing prices of those securities on the applicable stock exchange at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Tax Benefit/Provision for Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax benefit of $257,000 for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;reflected our application of the intraperiod tax allocation rules under which we are required to record a tax benefit in continuing operations to offset the tax provision we recorded directly to other comprehensive income (loss) related to unrealized gains on our short-term investments. The provision for income taxes of $2.2 million for the year ended December 31, 2018 was related to foreign income taxes on the upfront payment received from ApolloBio in 2018.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of </font><font style="font-family:inherit;font-size:10pt;">$483.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$68.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$80.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. We also had U.S. federal and state research and development tax credits of </font><font style="font-family:inherit;font-size:10pt;">$17.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of the federal research and development credits that will expire due to IRC Section&#160;383 limitations. The net operating losses and credits began to expire during </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comparison of Years Ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2018</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2017</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:45%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue primarily consisted of revenue under collaborative research and development arrangements for the year ended December 31, 2018, and revenue under collaborative research and development arrangements, grants and government contracts for the year ended December 31, 2017. Our year over year total revenue decreased $11.7 million, or 28%.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of January 1, 2018, accounting for our various grant agreements falls under the contributions guidance under Subtopic 958-605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;">, which is outside the scope of Topic 606, as the government agencies granting us funds are not receiving equivalent value for their contributions. Beginning on January 1, 2018, after adopting Topic 606 using the modified retrospective transition method, all contributions received from current grant agreements are being recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The $1.1 million increase in revenue under collaborative research and development arrangements for the year ended December&#160;31, 2018 as compared to 2017 was primarily due to the recognition of the gross upfront payment of $23.0 million from ApolloBio during the second quarter of 2018. This increase was offset by an overall decrease in revenue from the AstraZeneca collaboration of $15.4 million, primarily related to previously deferred revenue recognized during the second quarter of 2017, upon selection of the first cancer research collaboration product candidate by AstraZeneca, among other variances. There was also no revenue recognized in 2018 from Roche compared to $6.1 million for 2017, due to the termination of the agreement in 2017. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended December&#160;31, 2018, grant funding received and recorded as contra-research and development expense was $9.5 million, as compared to $13.0 million recorded as grant and miscellaneous revenue, including arrangements with affiliated entities, for the year ended December 31, 2017. The decrease in grant funding recorded for the year over year was primarily due to a decrease from our DARPA Ebola grant of $8.8 million, partially offset by an increase from our CEPI grant of $4.3 million.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The $3.3 million decrease in research and development expenses for the year ended December&#160;31, 2018 as compared to 2017 was primarily due to the $9.5 million contra-research and development expense recorded from grant agreements as discussed above, as well as a decrease of $8.9 million in expenses related to the DARPA Ebola grant and a decrease of $2.0 million in expenses related to our Hepatitis B program. These decreases were partially offset by an increase of $4.0 million related to increased employee headcount to support clinical trials and partnerships, an increase of $3.1 million for drug manufacturing related to our collaboration with AstraZeneca, an increase in expenses related to our GBM clinical trial of $2.8 million, an increase in expenses of $2.6 million related to our VGX-3100 Phase 3 clinical trial, an increase in expenses of $2.6 million related to our CEPI grant and an increase in depreciation expense of $2.3 million, among other variances. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The $1.0 million increase in general and administrative expenses for the year ended December&#160;31, 2018 as compared to 2017 was primarily related to the $1.4 million of foreign non-income taxes withheld from the ApolloBio upfront payment we received in 2018 and the advisory fee of $960,000 incurred in connection with receiving the upfront payment. There were also increases in legal expense and personnel costs from increases in employee headcount of $1.3 million and $1.2 million, respectively, partially offset by a decrease in non-cash stock-based compensation expense of $2.8 million and depreciation expense of $1.4 million, among other variances.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the years ended December&#160;31, 2018 and 2017 was $10.2 million and $12.9 million, of which $5.9 million and $5.8 million was included in research and development expenses and $4.3 million and $7.1 million was included in general and administrative expenses, respectively. The year over year decrease was primarily due to a lower weighted average grant date fair value for the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">awards granted in 2018, as well as higher expenses recorded for certain stock option modifications which occurred in 2017. At December&#160;31, 2018, there was $5.2 million of total unrecognized compensation cost related to unvested stock options, which we expect to recognize over a weighted-average period of 1.7 years, as compared to $5.9 million for the year ended December&#160;31, 2017 expected to be recognized over a weighted-average period of 1.8 years. At December&#160;31, 2018, there was $5.1 million of total unrecognized compensation cost related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of 1.7 years, as compared to $5.3 million for the year ended December&#160;31, 2017 expected to be recognized over a weighted-average period of 1.8 years.  Total stock-based compensation for options granted to non-employees for the years ended December&#160;31, 2018 and 2017 was $302,000 and $201,000, respectively.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Gain on Sale of Assets </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The gain on sale of assets for the year ended December 31, 2017 related to the sale of our compound VGX-1027 to GeneOne for a purchase price of $1.0 million. These assets had a carrying value of zero, resulting in the full proceeds being recognized as a gain on sale. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Interest and Other Income, net</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net, decreased by $692,000 for the year ended December&#160;31, 2018 as compared to 2017 primarily due to an increase in net realized loss recorded on short-term investments, partially offset by higher interest earned on short-term investments during the year.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Change in Fair Value of Common Stock Warrants</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The change in fair value of common stock warrants for the years ended December&#160;31, 2018 and 2017 was $361,000 and $807,000, respectively. The variance is due to the revaluation of the warrants to their fair value at each balance sheet date; in addition, the warrants were exercised during the quarter ended September 30, 2018, eliminating the associated warrant liability.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loss on Investment in Affiliated Entity</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loss on investment in affiliated entity for the years ended December&#160;31, 2018 and 2017 was $2.0 million and $7.0 million, respectively, resulting from the change in the fair market value of the investments in GeneOne and PLS. After the adoption of ASU No. 2016-01 on January 1, 2018, unrealized gains and losses on PLS are recorded on the consolidated statement of operations as a gain (loss) on investment in affiliated entity rather than the consolidated statement of comprehensive income (loss). </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Provision for Income Taxes</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes of $2.2 million for the year ended December 31, 2018 was related to foreign income taxes on the upfront payment received from ApolloBio in 2018.  There was no income tax provision or benefit recorded for the year ended December 31, 2017.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFF49022776E45BC3B282A78AFD257867"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities in the oncology, DNA vaccines and other immunotherapy areas of our business. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Working Capital and Liquidity</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had cash and short-term investments of $</font><font style="font-family:inherit;font-size:10pt;">89.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and working capital of $</font><font style="font-family:inherit;font-size:10pt;">62.2 million</font><font style="font-family:inherit;font-size:10pt;">, as compared to </font><font style="font-family:inherit;font-size:10pt;">$81.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$52.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. The increase in cash and short-term investments during the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to the net proceeds of $75.7 million received from the issuance of the Notes and net proceeds of $14.5 million and $4.0 million received from the issuance of the August 2019 Bonds and December 2019 Bonds, respectively, offset by expenditures related to our research and development activities, clinical trials and various general and administrative expenses related to legal, consultants, accounting and audit, and corporate development. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$97.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of net loss of&#160;</font><font style="font-family:inherit;font-size:10pt;">$120.6 million</font><font style="font-family:inherit;font-size:10pt;">&#160;less use of net cash in operating assets and liabilities of&#160;</font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, partially offset by net non-cash adjustments of&#160;</font><font style="font-family:inherit;font-size:10pt;">$26.2 million</font><font style="font-family:inherit;font-size:10pt;">. The primary non-cash expenses added back to net loss included stock-based compensation of&#160;</font><font style="font-family:inherit;font-size:10pt;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;">, interest expense of </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">, depreciation and amortization of&#160;</font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;">, loss on investment in affiliated entities of </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and change in fair value of derivative liability of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities for the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$73.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of net loss of&#160;</font><font style="font-family:inherit;font-size:10pt;">$97.0 million</font><font style="font-family:inherit;font-size:10pt;">&#160;less use of net cash in operating assets and liabilities of&#160;</font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;">, partially offset by net non-cash adjustments of&#160;</font><font style="font-family:inherit;font-size:10pt;">$18.7 million</font><font style="font-family:inherit;font-size:10pt;">. The primary non-cash expenses added back to net loss included stock-based compensation of&#160;</font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;">, depreciation and amortization of&#160;</font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and loss on investment in affiliated entities and short-term investments of&#160;</font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash (used in) provided by investing activities was $</font><font style="font-family:inherit;font-size:10pt;">(9.0) million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$42.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was $</font><font style="font-family:inherit;font-size:10pt;">105.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. The variance was primarily due to the net proceeds received from our issuance of the Notes, August 2019 Bonds and December 2019 Bonds (described below), as well as the $3.0 million acquisition of a non-controlling interest in Geneos, all of which occurred in 2019.</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Notes and Bonds</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, we completed a private placement of our 1.0% convertible bonds due December 2024, or the December 2019 Bonds, to an institutional investor in Korea for an aggregate principal amount of 4.7 billion Korean Won (KRW) (approximately USD $4.1 million based on the exchange rate on the date of issuance). Net proceeds from the offering were $4.0 million, after deducting the offering expenses payable by us. See Note 10 to the consolidated financial statements included in this report for further discussion. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the third quarter of 2019, we completed a private placement of aggregate principal amount of 18 billion Korean Won (KRW) (approximately USD $15.0 million based on the exchange rate on the date of issuance) of August 2019 Bonds issued to institutional investors led by Korea Investment Partners. Net proceeds from the offering were $14.5 million, after deducting the offering expenses payable by us. See Note 10 to the consolidated financial statements included in this report for further discussion. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2019, we completed a private placement of $78.5 million aggregate principal amount of Notes, sold to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million, after deducting the initial purchasers' discount and offering expenses payable by us. See Note 10 to the consolidated financial statements included in this report for further discussion. </font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Issuances of Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, we entered into an At-the-Market Equity Offering Sales Agreement (the "Sales Agreement"), with an outside placement agent (the "Placement Agent"), to sell shares of our common stock with aggregate gross proceeds of up to $100.0 million, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2018, we sold 3,340,678 and 5,354,075 shares of common stock under the Sales Agreement for aggregate net proceeds of $9.1 million and $27.7 million, respectively. During the years ended December 31, 2018 and 2017, we had a prior sales agreement with the same Placement Agent pursuant to which we sold 314,950 and 2,937,406 shares of common stock for aggregate net proceeds of $1.6 million and $24.2 million, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;7, 2020 and March 9, 2020, we entered into a first and second amendment to the&#160;Sales Agreement, respectively, which amendments increased the amount of our common stock that could be sold through the Placement Agent under the Sales Agreement from an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to an aggregate offering price of up to $250.0 million. During the period from January 1, 2020 to </font><font style="font-family:inherit;font-size:10pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;we sold an additional </font><font style="font-family:inherit;font-size:10pt;">43,148,952</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the Sales Agreement for aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$208,200,000.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million. Following these sales, as of March 11, 2020, there is no remaining capacity under the Sales Agreement.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2017, we closed an underwritten public offering of 12,500,000 shares of our common stock at a public offering price of $6.00 per share. The net proceeds, after deducting the underwriters&#8217; discounts and commissions and other offering expenses, were $70.1 million.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, stock options to purchase 42,969 shares of common stock were exercised for aggregate net proceeds of $113,000, offset by tax payments made related to net share settlement of RSU awards of $893,000. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, stock options and warrants to purchase 756,853 shares of common stock were exercised for aggregate net proceeds of $2.4 million, offset by tax payments made related to net share settlement of RSU awards of $612,000. During the year ended December&#160;31, 2017, stock options to purchase 452,973 shares of common stock were exercised for aggregate net proceeds of $2.3 million.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost Reductions</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, we announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, we also reduced approximately 28% of our workforce and discontinued our immuno-oncology Phase 1/2 clinical </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">trial of our product candidate INO-5401 in patients with advanced bladder cancer. During 2019, we incurred a personnel-related restructuring charge of $2.2 million in connection with one-time employee termination costs, including severance and other benefits.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of $</font><font style="font-family:inherit;font-size:10pt;">739.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. These activities will require additional financing. If these activities are successful and if we receive approval from the FDA to market our DNA vaccine and DNA immunotherapy product candidates, then we will need to raise additional funding to market and sell the approved products and equipment. We cannot predict the outcome of the above matters at this time. We are evaluating potential collaborations as an additional way to fund operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Contractual Obligations</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum payments due under our contractual obligations are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.03288201160542%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Payments Due by Period</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Less than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1&#160;year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">1&#160;&#8211;&#160;3&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">3&#160;&#8211;&#160;5&#160;years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">More&#160;than</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">5&#160;years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible senior notes (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,463,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,206,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,154,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible bonds (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,035,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">187,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">394,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,454,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease obligations (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,897,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,031,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,024,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,951,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under our Notes, including interest based on the fixed rate of 6.5% per year. Although these Notes mature in March 2024, they may be converted into shares of our common stock prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. See Note 10, "Convertible Debt&#8221; in the Consolidated Financial Statements section of this report for further discussion.</font></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under our August 2019 and December 2019 Bonds, including interest based on the fixed rate of 1% per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of 6% at maturity. Although these bonds mature in August 2024 and December 2024, respectively, they may be converted into KDRs, if we have any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock, if KDRs are not listed on KOSDAQ at that time or the converting holder requests delivery of shares of common stock, prior to maturity if certain conditions are met. Any conversion prior to maturity can result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. See Note 10, "Convertible Debt&#8221; in the Consolidated Financial Statements section of this report for further discussion.</font></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3) We have entered into operating leases for our facilities, which expire from 2023 to 2029, and operating leases for office equipment, which expire in 2021 and 2022. In the fourth quarter of 2019, we entered into two subleases for a portion of our Plymouth Meeting corporate headquarters facility through December 31, 2022 and March 31, 2025. As of December&#160;31, 2019, we expect to receive aggregate future minimum lease payments totaling $1.5 million (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above.&#160;</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s950191C412FF5579A05932FB295BF00A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A.&#160;&#160;&#160;&#160;QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market risk represents the risk of loss that may impact our consolidated financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and rates. We are exposed to market risk primarily in </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the area of changes in United States interest rates and conditions in the credit markets, and the recent fluctuations in interest rates and availability of funding in the credit markets primarily impact the performance of our investments. We do not have any material foreign currency or other derivative financial instruments. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in investment grade securities. Due to the short-term maturities of our cash equivalents and the low risk profile of our investments at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest rate on our indebtedness, consisting exclusively of the Notes and Bonds, is fixed and not subject to fluctuations in interest rates.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The investment in affiliated entities represents our ownership interest in the Korean-based companies, GeneOne and PLS. We report these investments at fair value on the consolidated balance sheet using the closing price of GeneOne and PLS shares of common stock as reported on the date of determination on the Korean Stock Exchange and Korea New Exchange Market, respectively. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Risk</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have operated primarily in the United States and most transactions during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of the issuance of the August 2019 and December 2019 Bonds, which are denominated in South Korean Won, and the valuation of our equity investments in GeneOne and PLS, each of which is denominated in South Korean Won and then translated into United States dollars. We do not have any foreign currency hedging instruments in place. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s85802ED77D02552CA73DC6A0D54542A6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item&#160;8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page&#160;F-1 of this report.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s2972D74C188A56C5B0DB4C0CAE1F7B9A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s20A6DDC7A3525D66A25EFB92A47AC0A5"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;at the reasonable assurance level.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management&#8217;s Report on Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Attestation Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The independent registered public accounting firm that audited the consolidated financial statements that are included in this Annual Report on Form 10-K has issued an audit report on the effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">. The report appears below.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></div><hr style="page-break-after:always"><div><a name="s19A0B58F2EDD53869CEBE6B67A234CB9"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Stockholders of Inovio Pharmaceuticals,&#160;Inc.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited Inovio Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control-Integrated Framework</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission 2013 framework (the COSO criteria). In our opinion, Inovio Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, based on the COSO criteria.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and related notes and our report dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:46%;"></td><td style="width:54%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Diego, California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></div><hr style="page-break-after:always"><div><a name="sb4d1fe50ce8645c4893c7fe6cef6193a"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="s8A0703D8358B53B2976BD396B9E4594A"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="s1AD57C3FFFCD5AA09E9887449F898019"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item&#160;10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;fiscal year, under the captions &#8220;Election of Directors&#8221; and &#8220;Executive Officers and Other Information.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sF975FB98BF665B43BD0DD2F8887F93CC"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item&#160;11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;fiscal year, under the captions &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Compensation of Directors&#8221; and &#8220;Director Compensation Table.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s6D4420CC12105C39B30A25FAFFF8F053"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item&#160;12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;fiscal year, under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="s491E816111E35BB0962FBA70543DFA40"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director independence and other information required by this Item&#160;13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;fiscal year, under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors.&#8221;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><a name="sECD9FCCE0A6F5DFBABA846C2A9B60E29"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this Item&#160;14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;fiscal year, under the caption &#8220;Ratification of Appointment of Registered Public Accounting Firm.&#8221;</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></div><hr style="page-break-after:always"><div><a name="sE43480E06B9F55D6BE7C581FA4964864"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><a name="s3C4C60F06E8D571ABB74A9DA03E3F51C"></a></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statements</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated financial statements required to be filed hereunder are indexed on Page&#160;F-1 hereof.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.</font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following exhibits are filed as part of this annual report on Form&#160;10-K:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exhibit</font></div><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description of Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm"><font style="font-family:inherit;font-size:10pt;">3.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit&#160;3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm"><font style="font-family:inherit;font-size:10pt;">3.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August&#160;10, 2011 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Form&#160;8-K current report filed on August&#160;12, 2011).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm"><font style="font-family:inherit;font-size:10pt;">4.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm"><font style="font-family:inherit;font-size:10pt;">Indenture, dated as of February 19, 2019, by and between the registrant and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on February 20, 2019).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm"><font style="font-family:inherit;font-size:10pt;">4.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm"><font style="font-family:inherit;font-size:10pt;">Form of Note representing the registrant&#8217;s 6.50% Convertible Senior Notes due 2024 (included as Exhibit A to the Indenture filed as Exhibit 4.1).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm"><font style="font-family:inherit;font-size:10pt;">4.3</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm"><font style="font-family:inherit;font-size:10pt;">Convertible Bonds Subscription Agreement, dated July 31, 2019, by and among the registrant and the Purchasers named therein (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on August 6, 2019).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm"><font style="font-family:inherit;font-size:10pt;">4.4</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex41.htm"><font style="font-family:inherit;font-size:10pt;">Form of Bond representing the registrant&#8217;s 1% Convertible Bonds due 2024 (included as Exhibit A to the Convertible Bonds Subscription Agreement filed as Exhibit 4.3).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex991.htm"><font style="font-family:inherit;font-size:10pt;">4.5</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519214088/d595826dex991.htm"><font style="font-family:inherit;font-size:10pt;">Registration Rights Agreement, dated July 31, 2019, by and among the registrant and the Purchasers named therein (incorporated by reference to Exhibit 99.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on August 6, 2019).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm"><font style="font-family:inherit;font-size:10pt;">4.6</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm"><font style="font-family:inherit;font-size:10pt;">Convertible Bonds Subscription Agreement, dated December 26, 2019, by and between the registrant and the Purchaser named therein (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on January 2, 2020).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm"><font style="font-family:inherit;font-size:10pt;">4.7</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex41.htm"><font style="font-family:inherit;font-size:10pt;">Form of Bond representing the registrant&#8217;s 1% Convertible Bonds due 2024 (included as Exhibit A to the Convertible Bonds Subscription Agreement filed as Exhibit 4.6).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex101.htm"><font style="font-family:inherit;font-size:10pt;">4.8</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312520000651/d863139dex101.htm"><font style="font-family:inherit;font-size:10pt;">Registration Rights Agreement, dated December 26, 2019, by and between the registrant and the Purchaser named therein (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on January 2, 2020).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10xkex49.htm"><font style="font-family:inherit;font-size:10pt;">4.9</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10xkex49.htm"><font style="font-family:inherit;font-size:10pt;">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm"><font style="font-family:inherit;font-size:10pt;">10.1&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm"><font style="font-family:inherit;font-size:10pt;">R&amp;D Alliance Agreement dated December&#160;19, 2005 by and between Ganial Immunotherapeutics,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by Novation and Amendment Agreement by and between VGX Pharmaceuticals, Inc., Ganial Immunotherapeutics, Inc., and Onconox (incorporated by reference to Exhibit&#160;10.31 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm"><font style="font-family:inherit;font-size:10pt;">10.2&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm"><font style="font-family:inherit;font-size:10pt;">R&amp;D Collaboration and License Agreement dated December&#160;18, 2006 by and between VGX International,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated October&#160;31, 2007 and as amended by Second Amendment dated August&#160;4, 2008 (incorporated by reference to Exhibit&#160;10.39 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm"><font style="font-family:inherit;font-size:10pt;">10.3&#8224;&#160;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm"><font style="font-family:inherit;font-size:10pt;">Patent License Agreement dated April&#160;27, 2007 by and between The Trustees of the University of Pennsylvania and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated June&#160;12, 2008 (incorporated by reference to Exhibit&#160;10.50 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm"><font style="font-family:inherit;font-size:10pt;">10.4&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm"><font style="font-family:inherit;font-size:10pt;">License Agreement dated May&#160;9, 2007 by and between Baylor University and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.34 as filed with the registrant&#8217;s registration statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_44.htm"><font style="font-family:inherit;font-size:10pt;">10.5&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_44.htm"><font style="font-family:inherit;font-size:10pt;">CELLECTRA&#174; Device License Agreement dated April&#160;16, 2008 by and between VGX International and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.44 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm"><font style="font-family:inherit;font-size:10pt;">10.6&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm"><font style="font-family:inherit;font-size:10pt;">License and Collaboration Agreement dated March&#160;24, 2010 between Inovio Pharmaceuticals, Inc. and VGX International, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended March&#160;31, 2010 filed on May&#160;17, 2010).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm"><font style="font-family:inherit;font-size:10pt;">10.7&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm"><font style="font-family:inherit;font-size:10pt;">Collaborative Development and License Agreement dated October 7, 2011 between VGX International, Inc. and Inovio Pharmaceuticals, Inc., as amended by First Amendment dated August 21, 2013, and Second Amendment dated October 7, 2013 (incorporated by reference to Exhibit 10.1 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended September&#160;30, 2011 filed on November&#160;7, 2011).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572615000015/ino-9302015x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">10.8&#8224;</font></a><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572615000015/ino-9302015x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">DNA Cancer Vaccine Collaboration and License Agreement dated August 7, 2015 by and between MedImmune, Limited and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2015 filed on November 9, 2015).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm"><font style="font-family:inherit;font-size:10pt;">10.9</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm"><font style="font-family:inherit;font-size:10pt;">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm"><font style="font-family:inherit;font-size:10pt;">10.10</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm"><font style="font-family:inherit;font-size:10pt;">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm"><font style="font-family:inherit;font-size:10pt;">10.11&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated License and Collaboration Agreement, dated December 29, 2017, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.12 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2017 filed on March 14, 2018).</font></a></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">10.15</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">Lease dated April 9, 2013 by and between BMR-Wateridge LP and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to registrant's quarterly report for the quarter ended March 31, 2013, filed on May 10, 2013).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">10.16</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">Office Lease Agreement dated October 10, 2016 by and between 6759 Mesa Ridge Road Holdings, LLC and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2016 filed on November 9, 2016).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm"><font style="font-family:inherit;font-size:10pt;">10.17</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm"><font style="font-family:inherit;font-size:10pt;">Lease Agreement dated as of March 5, 2014 between Brandywine Operating Partnership L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.36 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2014 filed on March 17, 2014).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">10.18</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm"><font style="font-family:inherit;font-size:10pt;">Second Amendment to the Lease Agreement dated June 22, 2017 between Brandywine Operating Partnership, L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</font></a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm"><font style="font-family:inherit;font-size:10pt;">10.19</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm"><font style="font-family:inherit;font-size:10pt;">Sublease dated June 21, 2017 between Accolade, Inc. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm"><font style="font-family:inherit;font-size:10pt;">10.20+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement dated March&#160;31, 2008 by and between J. Joseph Kim, Ph.D. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment of Employment Agreement dated March&#160;31, 2008 (incorporated by reference to Exhibit&#160;10.43 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm"><font style="font-family:inherit;font-size:10pt;">10.21+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and J. Joseph Kim, PhD. (incorporated by reference to Exhibit&#160;10.41 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572619000029/exhibit101.htm"><font style="font-family:inherit;font-size:10pt;">10.22+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572619000029/exhibit101.htm"><font style="font-family:inherit;font-size:10pt;">Separation Agreement dated March 26, 2019 between Inovio Pharmaceuticals, Inc. and Mark L. Bagarazzi (incorporated by reference to Exhibit 10.1 to the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2019 filed on May 9, 2019).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm"><font style="font-family:inherit;font-size:10pt;">10.23+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement dated as of December&#160;27, 2010 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Form 10-K report for the year ended December&#160;31, 2010 filed on March&#160;16, 2011).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm"><font style="font-family:inherit;font-size:10pt;">10.24+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm"><font style="font-family:inherit;font-size:10pt;">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit&#160;10.42 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm"><font style="font-family:inherit;font-size:10pt;">10.25+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm"><font style="font-family:inherit;font-size:10pt;">Second Amendment to Employment Agreement dated November 7, 2014 by and between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.2 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2014 filed on November 10, 2014).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino1231209x10kex1026.htm"><font style="font-family:inherit;font-size:10pt;">10.26+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino1231209x10kex1026.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement dated March 8, 2019 between Inovio Pharmaceuticals, Inc. and Jacqueline E. Shea (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino12312019x10kex1027.htm"><font style="font-family:inherit;font-size:10pt;">10.27+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino12312019x10kex1027.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement dated as of March 4, 2019 between Inovio Pharmaceuticals, Inc. and Laurent M. Humeau (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm"><font style="font-family:inherit;font-size:10pt;">10.28</font></a><font style="font-family:inherit;font-size:10pt;">+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement for Directors and Officers of Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 to the registrant&#8217;s Form&#160;10-Q quarterly report for the quarterly period ended June&#160;30, 2009, filed on August&#160;19, 2009).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm"><font style="font-family:inherit;font-size:10pt;">10.29+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated 2007 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.12 to the registrant's Form 10-K report for the year ended December 31, 2015 filed on March 14, 2016).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d3.htm"><font style="font-family:inherit;font-size:10pt;">10.30+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d3.htm"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Award Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.3 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm"><font style="font-family:inherit;font-size:10pt;">10.31+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm"><font style="font-family:inherit;font-size:10pt;">Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.4 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm"><font style="font-family:inherit;font-size:10pt;">10.32+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm"><font style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on May 10, 2019).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm"><font style="font-family:inherit;font-size:10pt;">10.33+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option Agreement under 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.55 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm"><font style="font-family:inherit;font-size:10pt;">10.34+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm"><font style="font-family:inherit;font-size:10pt;">Form of Nonqualified Stock Option Agreement under 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.56 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</font></a></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:90%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm"><font style="font-family:inherit;font-size:10pt;">10.35+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Units Award Agreement under 2016 Omnibus Incentive Plan. (incorporated by reference to Exhibit 10.54 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex211.htm"><font style="font-family:inherit;font-size:10pt;">21.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex211.htm"><font style="font-family:inherit;font-size:10pt;">Subsidiaries of the registrant (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex231.htm"><font style="font-family:inherit;font-size:10pt;">23.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex231.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Independent Registered Public Accounting Firm (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8559EEA445AE5F89852791CBA75F5868"><font style="font-family:inherit;font-size:10pt;">24.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s8559EEA445AE5F89852791CBA75F5868"><font style="font-family:inherit;font-size:10pt;">Power of Attorney (included on signature page).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex311.htm"><font style="font-family:inherit;font-size:10pt;">31.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex311.htm"><font style="font-family:inherit;font-size:10pt;">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex312.htm"><font style="font-family:inherit;font-size:10pt;">31.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex312.htm"><font style="font-family:inherit;font-size:10pt;">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex321.htm"><font style="font-family:inherit;font-size:10pt;">32.1&#94;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="ino-12312019x10kex321.htm"><font style="font-family:inherit;font-size:10pt;">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designates management contract, compensatory plan or arrangement.</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#94;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBB440CAF63A751F79FCA1122D5E12938"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</font></div><div style="line-height:120%;text-align:left;padding-left:33px;text-indent:-32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84</font></div></div><hr style="page-break-after:always"><div><a name="s8559EEA445AE5F89852791CBA75F5868"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March&#160;12, 2020</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J. J</font><font style="font-family:inherit;font-size:8pt;">OSEPH</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:8pt;">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">J. Joseph Kim</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;font-style:italic;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints J. Joseph Kim and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form&#160;10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:29%;"></td><td style="width:1%;"></td><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;J. JOSEPH KIM</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Director (Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">J. Joseph Kim</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;SIMON X. BENITO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Simon X. Benito</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;PETER KIES</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Peter Kies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;ANGEL CABRERA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Angel Cabrera</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/    ANN MILLER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Ann Miller</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;JAY SHEPARD</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Jay Shepard</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;DAVID WEINER</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">David Weiner</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;WENDY YARNO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Wendy Yarno</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">/s/&#160;&#160;&#160;&#160;LOTA ZOTH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Lota Zoth</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></div><hr style="page-break-after:always"><div><a name="s314A53240F59593D98C67F842AF6B856"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</font></div><div><a name="s23D4D6927C755E0FB8E44CEC03B83C65"></a></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Index to Consolidated Financial Statements</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s7187EFF4E4A553A3A4FBA7B38651E444"><font style="font-family:inherit;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s7187EFF4E4A553A3A4FBA7B38651E444">F-2</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s823664833FE151EFAFFA658167AC10C3"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets as of December&#160;31, 2019 and December&#160;31, 2018</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s823664833FE151EFAFFA658167AC10C3">F-3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s891C100E55095607BB8560EB4899D283"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations for each of the years ended December&#160;31, 2019, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s891C100E55095607BB8560EB4899D283">F-4</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3AA0946924035711BCC1440275A9CAFB"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Comprehensive Loss for each of the years ended December&#160;31, 2019, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s3AA0946924035711BCC1440275A9CAFB">F-5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s897C5B23CBAA525ABF71B6BFAC2B22BC"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders' Equity for each of the years ended December 31, 2019, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s897C5B23CBAA525ABF71B6BFAC2B22BC">F-6</a></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD4B8A424D26C530CA85B35CDE49E1A1D"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for each of the years ended December&#160;31, 2019, 2018 and 2017</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#sD4B8A424D26C530CA85B35CDE49E1A1D">F-7</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1EFEF2F57DEA50D9BA0DDED5BACB4B2C"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;text-align:center;" href="#s1EFEF2F57DEA50D9BA0DDED5BACB4B2C">F-8</a></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-1</font></div></div><hr style="page-break-after:always"><div><a name="s7187EFF4E4A553A3A4FBA7B38651E444"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Board of Directors and Stockholders of Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:24px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows, for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and the results of its operations and its cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, in conformity with US generally accepted accounting principles.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Internal Control-Integrated Framework</font><font style="font-family:inherit;font-size:10pt;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) and our report dated </font><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;expressed an unqualified opinion thereon.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of ASU No. 2014-09</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), using the modified retrospective method effective January 1, 2018.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Adoption of ASU No. 2016-02</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 2 to the consolidated financial statements, the Company recognized an operating lease right-of-use asset and an operating lease liability as a result of the adoption of Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), using the modified retrospective method effective January 1, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:46%;"></td><td style="width:54%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young&#160;LLP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company's auditor since 2002.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Diego, California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></div><hr style="page-break-after:always"><div><a name="s823664833FE151EFAFFA658167AC10C3"></a></div><div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22,196,097</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,693,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">67,338,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">57,538,852</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">700,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,316,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts receivable from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,332,044</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">738,583</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,584,598</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,406,590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid expenses and other current assets from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,050,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,120,805</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">94,200,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,814,824</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fixed assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,773,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,949,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Investments in affiliated entities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,315,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,693,851</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,760,145</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,513,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,513,371</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,783,009</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,672,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,669,998</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,951,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,113,265</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,237,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,134,733</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accounts payable and accrued expenses due to affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">729,729</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">977,792</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued clinical trial expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,049,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,671,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92,353</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">223,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred revenue from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,065,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,074,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Grant funding liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,065,212</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,165,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Grant funding liability from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">708,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">31,989,321</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35,299,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">150,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Convertible senior notes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">64,180,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Convertible bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,842,592</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,819,023</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred rent, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,518,207</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease liability, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">20,409,922</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">32,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,766</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Grant funding liability from affiliated entity, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">135,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,943</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">138,546,739</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,080,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December&#160;31, 2019 and December&#160;31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2019 and December 31, 2018, issued and outstanding: 101,361,034 at December&#160;31, 2019 and 97,225,810 at December&#160;31, 2018</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">101,361</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97,226</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">742,646,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">707,794,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(739,785,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(620,426,436</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">472,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(528,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,435,099</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86,936,138</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,969,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,404,858</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">87,032,407</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,951,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">131,113,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></div><hr style="page-break-after:always"><div><a name="s891C100E55095607BB8560EB4899D283"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.6328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,636,945</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,860,785</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,407,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">235,649</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">449,524</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">765,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants and miscellaneous revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">237,536</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171,588</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,474,539</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grants and miscellaneous revenue from affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,572,331</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,481,897</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,220,086</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,017,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95,257,876</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,572,618</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,203,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,315,159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,290,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain on sale of assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,220,475</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124,573,035</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,862,987</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(111,108,545</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,091,138</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(83,642,901</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,605,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,264,747</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,836,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,948,539</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,933</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">360,795</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">806,819</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,763,652</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,090,557</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,988,567</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,982,664</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">496,200</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,343,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197,544</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before income tax benefit/(provision for income tax)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,809,112</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(94,798,019</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit (provision for income taxes)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">257,335</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,551,777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,192,558</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average number of common shares outstanding </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,777,493</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,918,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></div><hr style="page-break-after:always"><div><a name="s3AA0946924035711BCC1440275A9CAFB"></a></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(120,551,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Other comprehensive income (loss):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Unrealized loss on investment in affiliated entity, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,452,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;Unrealized gain (loss) on short-term investments, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,001,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(180,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,458</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,550,302</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,148,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89,650,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,192,558</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(118,357,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(97,148,326</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89,650,745</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></div><hr style="page-break-after:always"><div><a name="s897C5B23CBAA525ABF71B6BFAC2B22BC"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:21%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">paid-in</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">capital</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">deficit</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">other</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">comprehensive</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">income (loss)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Non-</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">controlling</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">interest</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">stockholders&#8217;</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">equity</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">of&#160;shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Number</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">of shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74,062,370</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">74,062</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">556,718,356</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(434,838,235</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,327,968</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,269</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">123,378,420</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cumulative effect of accounting change (1)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">312,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(312,310</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash, net of financing costs of $4.9 million</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,437,406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,437</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">94,332,485</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">94,347,922</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options for cash and vesting of RSUs, net of tax payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">857,868</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">859</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,341,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,342,250</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,070,962</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,070,962</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on short-term investments, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,458</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,458</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on investment in affiliated entity, net of tax</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,452,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,452,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,357,644</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">90,358</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">665,775,504</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(523,356,317</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(117,005</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,269</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">142,488,809</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cumulative effect of accounting change (2)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">231,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(231,366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,669,025</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,669</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29,222,107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29,227,776</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,199,141</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,808,327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,809,526</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,988,277</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(333,655</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,654,622</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized loss on short-term investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(180,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(180,496</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">97,225,810</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">97,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">707,794,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(620,426,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(528,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">96,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87,032,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock for cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,340,678</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,340</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,085,669</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,089,009</font></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercise of stock options for cash and vesting of RSUs, net of tax payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">794,546</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(781,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(780,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity component of issuance of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,752,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,752,698</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,795,403</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">105,917</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,901,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Acquisition of non-controlling interest in Geneos, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,960,131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,960,131</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss attributable to common stockholders</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,192,558</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(120,551,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on short-term investments, net of tax</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,001,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,001,475</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">101,361,034</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">101,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">742,646,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(739,785,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">472,608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,969,759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,404,858</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Upon adoption of ASU 2016-09 on January 1, 2017, the Company elected to remove the forfeiture rate from the calculation of stock-based compensation and recorded a cumulative catch-up adjustment to accumulated deficit with a corresponding offset to additional paid-in-capital of </font><font style="font-family:inherit;font-size:10pt;">$312,000</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a </font><font style="font-family:inherit;font-size:10pt;">$231,000</font><font style="font-family:inherit;font-size:10pt;">&#32;cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in PLS from accumulated other comprehensive loss to accumulated deficit.</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></div><hr style="page-break-after:always"><div><a name="sD4B8A424D26C530CA85B35CDE49E1A1D"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For the Year ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(120,551,777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,598,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,747,183</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,850,376</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amortization of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,066,294</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,249,584</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,618,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amortization of operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">851,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(360,795</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(806,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,763,652</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,901,320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10,654,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,070,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,230,954</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amortization of premiums on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">72,561</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">319,845</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(150,027</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss (gain) on short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(476,368</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,342,005</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">215,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss on disposal of fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,889</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Loss on equity investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,090,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,988,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,982,664</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Gain on sale of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,000,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Tax benefit from other unrealized gains on short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(266,215</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized transaction loss on foreign-currency denominated debt</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">471,172</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,616,288</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,686,844</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,818,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(593,461</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(251,964</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">261,736</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(178,008</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,194,316</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(851,847</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other current assets from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">70,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">725,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(333,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,026</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(30,644</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(526,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable and accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(4,337,829</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">550,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,829,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued clinical trial expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,622,037</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,940,128</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,243,503</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable and accrued expenses due to affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(248,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50,849</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(145,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(180,450</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,016,836</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(13,689,322</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,800</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(140,535</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(319,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(398,357</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,608,881</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Operating lease right-of-use assets and liabilities, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,733,599</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Grant funding liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,899,364</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,165,848</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Grant funding liability from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">816,342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(48,507</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">87,333</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(97,850,136</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(73,550,156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(63,208,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Purchases of investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(100,950,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(88,155,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(95,700,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from sale of or maturity of investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">92,893,232</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">132,659,976</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">77,162,902</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Purchases of capital assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(987,926</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,085,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10,293,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from sale of intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,000,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net cash (used in) provided by investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,044,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">42,419,908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(27,831,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from issuances of convertible senior notes and convertible bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">97,443,617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Costs related to issuances of convertible senior notes and convertible bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(3,314,757</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from issuance of common stock and warrants, net of issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,089,010</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29,227,776</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">94,347,922</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from stock option and warrant exercises, net of tax payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,809,526</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,342,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(780,406</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Acquisition of non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,960,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">105,397,595</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">31,037,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">95,690,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Increase (decrease) in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,497,536</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(92,946</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4,650,107</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,693,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,786,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19,136,472</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,196,097</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,693,633</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,786,579</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Supplemental disclosure:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Amounts accrued for purchases of property and equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">559,646</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,254,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest paid</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,717,585</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Equity component of issuance of convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15,752,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Right-of-use assets obtained in exchange for lease obligations </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14,634,769</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></div><hr style="page-break-after:always"><div><a name="s1EFEF2F57DEA50D9BA0DDED5BACB4B2C"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="sD38CFC39EB03596C856FAC680736A63F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. The Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's novel DNA medicines are made using its proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio's hand-held CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of Inovio&#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;smart delivery device in more than 6,000 administrations across more than 2,000 patients.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9F28F45D27E857F4B5852981DFBDFA4C"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio incurred a net loss attributable to common stockholders of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$119.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. Inovio had working capital of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$62.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$739.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. During the year ended December 31, 2019, the Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from a private placement of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from the private placement of </font><font style="font-family:inherit;font-size:10pt;">18 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;Korean Won (KRW) (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the exchange rate on the date of issuance) aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;convertible bonds due August 2024 (the "August 2019 Bonds"), net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from the private placement of  </font><font style="font-family:inherit;font-size:10pt;">4.7 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;KRW (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the exchange rate on the date of issuance) aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;convertible bonds due December 2024 (the "December 2019 Bonds" and, collectively with the August 2019 Bonds, the &#8220;Bonds&#8221;) and net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from sales of common stock under its At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp; Company (the &#8220;Sales Agreement&#8221;). As described in Note 19 below, the Sales Agreement was amended subsequent to December 31, 2019. From January 1, 2020 through </font><font style="font-family:inherit;font-size:10pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">43,148,952</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the Sales Agreement, as amended, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$208.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million. These proceeds, in addition to the Company&#8217;s cash, cash equivalents and short-term investments of $</font><font style="font-family:inherit;font-size:10pt;">89.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and long-term investments of $</font><font style="font-family:inherit;font-size:10pt;">6.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-8</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">are sufficient to support the Company's operations for a period of at least 12 months from the date it issued these financial statements. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements and/or future public or private debt or equity financings including use of its Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, the Company announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, the Company reduced its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">28%</font><font style="font-family:inherit;font-size:10pt;">&#32;and discontinued its Phase 1/2 clinical trial of its immuno-oncology product candidate INO-5401 in patients with advanced bladder cancer. In the third quarter of 2019, the Company incurred a personnel-related restructuring charge of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with one-time employee termination costs, including severance and other benefits, all of which have been paid as of December 31, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s consolidated financial statements as of and for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. ("VGX"), and records a non-controlling interest for </font><font style="font-family:inherit;font-size:10pt;">39%</font><font style="font-family:inherit;font-size:10pt;">&#32;of its subsidiary Geneos Therapeutics, Inc. ("Geneos") as well as </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">&#32;of VGX Animal Health, Inc., a subsidiary of VGX. All intercompany accounts and transactions have been eliminated upon consolidation. </font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Reporting </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;segment operating primarily within the United States.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has contracts with certain of its customers that have represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company's total revenues, as discussed in Note 7.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. After the adoption of Accounting Standards Update ("ASU") No. 2016-01 on January 1, 2018, unrealized gains and losses on the Company's equity investment in its affiliated entity Plumbline Life Sciences, Inc. ("PLS") are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. The Company&#8217;s investment in GeneOne, an affiliated entity, is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) from investment in affiliated entity. The Company carries convertible notes and bonds at face value less unamortized debt </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-9</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds and equity investments in the Company&#8217;s affiliated entities, PLS and GeneOne, at December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. Investments included mutual funds, United States corporate debt securities and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;allowance for doubtful accounts was deemed necessary at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fixed Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;">&#32;recognized any losses on long-lived assets through December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful lives ranging from </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">18 years</font><font style="font-family:inherit;font-size:10pt;">. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or </font><font style="font-family:inherit;font-size:10pt;">17 years</font><font style="font-family:inherit;font-size:10pt;">, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective as of the acquisition of VGX in 2009, all new patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#8217;s intangible assets resulting from the acquisition of VGX, as well as the acquisitions of two other companies, Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-10</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;9 for further discussion of the Company&#8217;s goodwill and intangible assets.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowances against the Company&#8217;s deferred tax assets were </font><font style="font-family:inherit;font-size:10pt;">$137.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$115.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Topic 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company adopted ASU 2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;Topic 606&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-11</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that as of January 1, 2018, accounting for the Company&#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, </font><font style="font-family:inherit;font-size:10pt;">which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra- expense as opposed to revenue on the consolidated statement of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-12</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options, restricted stock units and warrants and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. For the year ended December 31, 2019, the dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 10) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables reconcile the components of the numerator and denominator included in the calculations of diluted net loss per share:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-13</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Numerator</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment for decrease in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator for use in diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89,012,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Denominator</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding (denominator for use in basic net loss per share)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,777,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,529</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for use in diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,918,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:59%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,752,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,694,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069,936</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688,017</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234,168</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,585,653</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2019 Bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,799,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2019 Bonds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,737,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,449,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,937,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016&#8209;02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">&#32;(&#8220;Topic 842&#8221;) on January 1, 2019. For long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC&#160;840, Leases (Topic 840). See &#8220;Recent Accounting Pronouncements - Recently Adopted&#8221; below, for more information about the impact of the adoption of Topic 842.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-14</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:53%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:53%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:15%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.45%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.71%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements - Recently Adopted</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-02</font><font style="font-family:inherit;font-size:10pt;">. In February 2016, the FASB issued Topic 842,&#160;which requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets and to disclose key information about leasing arrangements.&#160;The Company adopted the new lease standard on January 1, 2019 using the modified retrospective approach. The Company elected the available package of practical expedients upon adoption, which allowed the Company to carry forward its historical assessment of whether existing agreements contained a lease and the classification of its existing operating leases. Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its consolidated balance sheet of approximately </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$24.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company also classified deferred rent of </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as an offset to the Company&#8217;s operating right-of-use asset upon adoption. There were no adjustments to the Company&#8217;s opening accumulated deficit balance upon adoption.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 840</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Topic 842</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,518,207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,518,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-07</font><font style="font-family:inherit;font-size:10pt;">. In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;">&#32;that simplifies the accounting for stock-based payments granted to non-employees for services by generally aligning it with the accounting for stock-based payments granted to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-15</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employees. The Company adopted the standard on January 1, 2019 and there was no material impact to its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-13</font><font style="font-family:inherit;font-size:10pt;">. In August 2018, the FASB issued ASU 2018-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements (see Note 6 for more information about the Company&#8217;s fair value classifications). ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its disclosures.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements - Not Yet Adopted</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-13</font><font style="font-family:inherit;font-size:10pt;">. In June 2016, the FASB issued ASU 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</font><font style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. ASU 2016-13 is effective beginning in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-18</font><font style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued ASU 2018-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:inherit;font-size:10pt;">, which clarified the interaction between Topic 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. ASU&#160;2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the financial statements.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU 2017-04.</font><font style="font-family:inherit;font-size:10pt;">&#32;In January 2017, the FASB issued ASU 2017-04,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its consolidated financial statements or related disclosures.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAA362886A7B7512D92604009331809E8"></a></div><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Revenue Recognition  </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized total revenue under collaborative research and development and other agreements determined to be contracts with a customer of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from AstraZeneca and </font><font style="font-family:inherit;font-size:10pt;">$917,000</font><font style="font-family:inherit;font-size:10pt;">&#32;from various other contracts. The Company defers revenue when a contract is entered into with a collaborator and cash payments are received prior to satisfaction of the related performance obligation. Of the total revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$293,000</font><font style="font-family:inherit;font-size:10pt;">&#32;was in deferred revenue as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that was included in deferred revenue at December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. Performance obligations are generally satisfied within 12 months of the initial contract date. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s48807958801D55E98E2DCF3220796B66"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Collaborative Agreements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ApolloBio Corporation </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and may include Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years following the effective date of the ApolloBio Agreement.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the ApolloBio Agreement, the Company received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in March 2018, which comprised the upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;less </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in foreign income taxes and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations during the quarter ended March 31, 2018. The Company also incurred advisory fees of </font><font style="font-family:inherit;font-size:10pt;">$960,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in connection with receiving the upfront payment from ApolloBio. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-16</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;">&#32;after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the terms of the ApolloBio Agreement under Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;year after the effective date for any reason upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;">&#32;days written notice to the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Topic 606, the entire transaction price of </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2018.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$27.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to </font><font style="font-family:inherit;font-size:10pt;">$125 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and potential future commercial event-based payments totaling up to </font><font style="font-family:inherit;font-size:10pt;">$115 million</font><font style="font-family:inherit;font-size:10pt;">, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Within the broader collaboration, AstraZeneca had rights to co-develop up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company had recognized all of the </font><font style="font-family:inherit;font-size:10pt;">$27.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized total revenues of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from AstraZeneca primarily for manufacturing services, for which the Company determined it was the principal in the arrangement as it controlled the product supply before it is transferred to the customer, and the milestone achieved as discussed above. As of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-17</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$161,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the collaboration agreement with AstraZeneca.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Coalition for Epidemic Preparedness Innovations </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$56 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of costs over a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company received funding of </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the CEPI grant and recorded those payments as contra-research and development expense. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had a grant funding liability balance related to the CEPI grant of </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;">&#32;million recorded as grant funding liability on the consolidated balance sheet related to the CEPI grant. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB2BBEB9B3C7D5ED4A0F46297C9F1792F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Short-term Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of mutual funds. Short-term investments at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of mutual funds and United States corporate debt securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.&#160;During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, gross realized gain on investments of </font><font style="font-family:inherit;font-size:10pt;">$594,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and gross realized loss on investments of </font><font style="font-family:inherit;font-size:10pt;">$118,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, was recorded. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2019,&#160;2018&#160;and&#160;2017. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">&#160;available-for-sale securities in a gross unrealized loss position, of which </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;">&#32;with an aggregate total unrealized loss of </font><font style="font-family:inherit;font-size:10pt;">$11,000</font><font style="font-family:inherit;font-size:10pt;">&#32;were in such position for longer than 12 months. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:   </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:26%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,599,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:26%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,842,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,633</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,067,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528,736</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE11D4FF7CA8D58E5912F7E6D2877EF92"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-18</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349,729</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349,729</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,003,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,665,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liability (Note 10)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:35%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,646,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,646,507</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,591,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,052,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 assets at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of money market funds held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investments in its affiliates, GeneOne and PLS. The Company accounts for its investment in </font><font style="font-family:inherit;font-size:10pt;">1,644,155</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares of GeneOne based on the closing price of the shares on the Korean Stock Exchange on the applicable balance sheet date. The Company accounts for its investment in </font><font style="font-family:inherit;font-size:10pt;">395,758</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares of PLS as an equity investment with a fair value based on the closing price of the shares on the Korea New Exchange (KONEX) Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of mutual funds. Level 2 assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of U.S. corporate debt securities and mutual funds. Level 2 assets held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-19</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, August 2019 and December 2019, the Company issued the Convertible Notes, August 2019 Bonds and December 2019 Bonds, respectively. The carrying value of the Notes and Bonds approximates the fair value as December 31, 2019. See Note 10 for additional information.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;Level 3 assets held as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 liabilities held at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 10 below for more information). The derivative liability was recorded at fair value of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;include the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Initial fair value upon issuance of the August 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,055,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,763,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;Level 3 liabilities held as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s393A1C43C3B1512DA635F17925500CD5"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. Major Customers and Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Customer</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ApolloBio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AstraZeneca</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,850,424</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,269,773</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DARPA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,983,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,107,254</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other, including affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">917,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,859,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111,930</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,481,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,220,086</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from various license fees and collaborative research and development agreements. The Company has determined that as of January 1, 2018, accounting for the Company&#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#333333;">,</font><font style="font-family:inherit;font-size:10pt;">&#32;which is outside the scope of Topic 606. Beginning on January 1, 2018, all contributions received from current grant agreements have been recorded as a contra-expense as opposed to revenue on the consolidated statements of operations, as discussed in Note 2. During the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$469,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$161,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">23%</font><font style="font-family:inherit;font-size:10pt;">, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, $</font><font style="font-family:inherit;font-size:10pt;">3.2 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;">, of the Company's accounts receivable was attributable to AstraZeneca. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sDA1ED6D3AD19561A9067B1D7A15197DD"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. Fixed Assets</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-20</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consist of the following:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Depreciation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31, 2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,007,935</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,996,777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,011,158</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,229,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,048,053</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,944,293</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,781,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,996,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,939,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,166,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,773,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,909,341</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,464,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,444,897</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,031,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,425,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,606,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,198,803</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,767,653</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431,150</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,808,824</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,341,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,466,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,948,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,999,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,949,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented.  During the year ended December 31, 2019 the Company disposed of fixed assets with a net book value of </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and accumulated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$432,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s1E0A552FD3BC5A4C8834CDE08B0EAE29"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Goodwill and Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following sets forth goodwill and intangible assets by major asset class:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:15%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Useful</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Yrs)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite lived:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,528</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,802,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,528</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,742,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,449</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,248,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,219,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-indent:24px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">CELLECTRA</font><font style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:inherit;font-size:9.5pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,106,270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,106,270</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,106,270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,679,190</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GHRH(b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioject (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,175,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,924,444</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,100,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,882,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217,778</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other(d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,050,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,356,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,050,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,131,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">918,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,717,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,024,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693,851</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,717,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,957,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,760,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total goodwill and intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,231,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,024,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,207,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,231,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,957,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,273,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;and GHRH are developed technologies which were recorded from the acquisition of VGX.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-21</font></div></div><hr style="page-break-after:always"><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate amortization expense on intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense related to intangible assets at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is expected to be incurred as follows: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,414</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,760</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604,445</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment or impairment indicators present and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;losses were recorded during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9c6623b75be1460aa1ac3e4cc52214fa"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Convertible Debt</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 19, 2019 and March 1, 2019, the Company completed a private placement of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$75.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be </font><font style="font-family:inherit;font-size:10pt;">185.8045</font><font style="font-family:inherit;font-size:10pt;">&#32;shares per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount of Notes (equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.38</font><font style="font-family:inherit;font-size:10pt;">&#32;per share), subject to adjustment upon the occurrence of specified events.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the conversion price on (i) each of at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;trading days (whether or not consecutive) during the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was </font><font style="font-family:inherit;font-size:10pt;">$62.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;are allocated to the liability and equity component in the same proportion as the issuance proceeds. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-22</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the Notes at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount on the liability component</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,082,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,938,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,700,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,180,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is </font><font style="font-family:inherit;font-size:10pt;">13.1%</font><font style="font-family:inherit;font-size:10pt;">. For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of interest expense related to the Notes, of which </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the contractual interest coupon. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there have not been any conversions or redemptions of the Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">August 2019 Convertible Bonds </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">18 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;Korean Won (KRW) (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ Market of the Korea Exchange (KOSDAQ) in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The August 2019 Bonds, which are unsecured obligations of the Company, were issued on August 1, 2019 and will accrue interest at a coupon rate of </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum, payable quarterly. The August 2019 Bonds will mature on July 31, 2024, unless earlier converted or repurchased. The outstanding August 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. Commencing on August 1, 2020, the August 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock, if KDRs are not listed on KOSDAQ at that time or the converting holder requests delivery of shares of common stock. The initial conversion rate is </font><font style="font-family:inherit;font-size:10pt;">211.0595</font><font style="font-family:inherit;font-size:10pt;">&#32;shares per KRW</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;in principal amount (equivalent to an initial conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate is subject to reset on January 2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed </font><font style="font-family:inherit;font-size:10pt;">351.7658</font><font style="font-family:inherit;font-size:10pt;">&#32;shares per KRW</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;(equivalent to a conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$2.40</font><font style="font-family:inherit;font-size:10pt;">&#32;per share based on the exchange rates as of July 30, 2019). </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The August 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including July 31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the August 2019 Bonds to be repurchased plus a premium in order to provide an internal rate of return with respect to the August 2019 Bonds of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. In addition, upon the occurrence of a fundamental change (as defined in the August 2019 Bonds), the Company will be required to offer to repurchase the August 2019 Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon but excluding the applicable repurchase date. Upon the occurrence of an event of default (as defined in the August 2019 Bonds), with the approval of at least </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the bondholders, the Company will be required to offer to repurchase the August 2019 Bonds at a repurchase price equal to the principal amount thereof plus a premium in order to provide an internal rate of return with respect to the August 2019 Bonds of </font><font style="font-family:inherit;font-size:10pt;">8.00%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature is considered a derivative requiring bifurcation from the August 2019 Bonds as it does not meet the equity scope exception due to the fact that it is denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded as a reduction to the carrying value of the debt. This debt discount is being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option is accounted for as a derivative liability, which is revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-23</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the August 2019 Bonds at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,578,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,764,346</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the August 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,322</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,946</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,824,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represents the point at which the August 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds is </font><font style="font-family:inherit;font-size:10pt;">29.4%</font><font style="font-family:inherit;font-size:10pt;">. For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$982,000</font><font style="font-family:inherit;font-size:10pt;">&#32;of interest expense related to the August 2019 Bonds, of which </font><font style="font-family:inherit;font-size:10pt;">$65,000</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the contractual interest coupon. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there have not been any conversions or redemptions of the August 2019 Bonds.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The derivative liability is valued at </font><font style="font-family:inherit;font-size:10pt;">$8.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">. The change in fair value of the derivative liability was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">December 2019 Convertible Bonds </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">4.7 billion</font><font style="font-family:inherit;font-size:10pt;">&#32;KRW (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;">&#32;per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate will be </font><font style="font-family:inherit;font-size:10pt;">214.7766</font><font style="font-family:inherit;font-size:10pt;">&#32;shares per KRW</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;principal amount of Bonds (equivalent to an initial conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed </font><font style="font-family:inherit;font-size:10pt;">357.961</font><font style="font-family:inherit;font-size:10pt;">1 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$2.40</font><font style="font-family:inherit;font-size:10pt;">&#32;per share based on the exchange rate as of December&#160;19, 2019).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-24</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency doesn&#8217;t impact the settlement of the conversion option. Further, as there is no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the December 2019 Bonds at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,067,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the December 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,017,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is </font><font style="font-family:inherit;font-size:10pt;">6.2%</font><font style="font-family:inherit;font-size:10pt;">. For the year ended December&#160;31, 2019,&#160;the Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;interest expense related to the December 2019 Bonds. As of December&#160;31, 2019, there have not been any conversions or redemptions of the December 2019 Bonds.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum payments due under the Company's convertible debt instruments are as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Notes (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">August 2019 Bonds (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 2019 Bonds (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,290,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,051,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,021,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,236,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,308,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,463,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,645,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,390,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,498,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year. </font></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;">&#32;per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;at maturity. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0BC7E3429ADF5F29A721D54A097AB447"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Accounts Payable and Accrued Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;consist of the following:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,919,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,043,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,967,897</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,466,821</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued subcontract costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,076,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,540,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,237,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,134,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-25</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9988F17DDB9458B4BC8E5427788A8C2F"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Outstanding as of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares      Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series&#160;C Preferred Stock, par $0.001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares of the Company&#8217;s Series&#160;C Preferred Stock have the following pertinent rights and privileges, as set forth in the Company&#8217;s Amended and Restated Certificate of Incorporation and its Certificates of Designations, Rights and Preferences related to the various series of preferred stock.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rights on Liquidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a &#8220;liquidation event&#8221;), before any distribution of assets of the Company shall be made to or set apart for the holders of common stock, the holders of Series&#160;C Preferred Stock, pari passu, are entitled to receive payment of such assets of the Company in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of such series of preferred stock, plus any accumulated and unpaid dividends thereon (whether or not earned or declared).</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the assets of the Company available for distribution to stockholders exceed the aggregate amount of the liquidation preferences payable with respect to all shares of each series of preferred stock then outstanding, then, after the payment of such preferences is made or irrevocably set aside, the holders of the Company&#8217;s common stock are entitled to receive a pro rata portion of such assets based on the aggregate number of shares of common stock held by each such holder. The holders of the Company&#8217;s outstanding preferred stock shall participate in such a distribution on a pro-rata basis, computed based on the number of shares of common stock which would be held by such preferred holders if immediately prior to the liquidation event all of the outstanding shares of the preferred stock had been converted into shares of common stock at the then current conversion value applicable to each series.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Change of Control of the Company (as defined in the Certificates of Designations, Rights and Preferences) is not a liquidation event triggering the preferences described above, and is instead addressed by separate terms in the Series&#160;C Certificates of Designations, Rights, and Preferences.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the liquidation preferences are in excess of the par value of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;">&#32;per share of the Company&#8217;s preferred stock, these preferences are equal to or less than the stated value of such shares based on their original purchase price.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voting Rights</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of Series C Preferred Stock have full voting rights and powers equal to the voting rights and powers of holders of the Company&#8217;s common stock and are entitled to notice of any stockholders&#8217; meeting in accordance with the Company&#8217;s Bylaws. Holders are entitled to vote on any matter upon which holders of the Company&#8217;s common stock have the right to vote, including, without limitation, the right to vote for the election of directors together with the holders of common stock as one class. Series C Preferred holders are entitled to </font><font style="font-family:inherit;font-size:10pt;">368</font><font style="font-family:inherit;font-size:10pt;">&#32;votes for each share of Series C Preferred Stock held. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Holder Optional Conversion Right </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holder of any share or shares of Series&#160;C Preferred Stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the Preferred Stock into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i)&#160;the aggregate Liquidation Preference applicable to the particular series of preferred shares, plus accrued and unpaid dividends thereon by (ii)&#160;the applicable Conversion Value (as defined in the relevant series&#8217; Certificate of Designations, Rights and Preferences) then in effect for such series of preferred shares. As of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the Conversion Value was </font><font style="font-family:inherit;font-size:10pt;">$27.20</font><font style="font-family:inherit;font-size:10pt;">, such that the outstanding shares of Series C Preferred Stock were convertible into </font><font style="font-family:inherit;font-size:10pt;">8,456</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock. The Company is not obligated to issue any fractional shares or scrip representing fractional shares upon such conversion and instead shall pay the holder an amount in cash equal to such fraction multiplied by the current market price per share of the Company&#8217;s common stock.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Company Mandatory Conversion Option</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has the option upon </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;">&#32;(30)&#160;days prior written notice, to convert all of the outstanding shares of the Series&#160;C Preferred Stock into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i)&#160;the aggregate Liquidation Preference of the shares of the relevant series of preferred stock to be converted, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series&#8217; Certificate of Designations, Rights and Preferences) then in effect, if the following triggering events have occurred:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-26</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) the price of the Company&#8217;s common stock exceeds </font><font style="font-family:inherit;font-size:10pt;">$72.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;out of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days; and</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) the average daily trading volume (subject to adjustment for stock dividends, subdivisions and combinations) of the common stock exceeds </font><font style="font-family:inherit;font-size:10pt;">6,250</font><font style="font-family:inherit;font-size:10pt;">&#32;shares for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;out of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;consecutive trading days.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, the Company entered into the Sales Agreement with Stifel, Nicolaus and Company (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">3,340,678</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the Sales Agreement. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$2.78</font><font style="font-family:inherit;font-size:10pt;">&#32;per share resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company may sell up to an additional </font><font style="font-family:inherit;font-size:10pt;">$62.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in shares of its common stock under the Sales Agreement. The registration statement that registered with the SEC the shares that may be sold under the Sales Agreement expires on June 8, 2021.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in Note 19 below, subsequent to December 31, 2019, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement to increase the amount of common stock that may be sold under the Sales Agreement from </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company also sold shares of common stock under the Sales Agreement subsequent to December 31, 2019.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company entered into an At-the-Market Equity Offering Sales Agreement (the &#8220;Prior Sales Agreement&#8221;) with the same placement agent. The registration statement that registered with the SEC the shares sold under the Prior Sales Agreement expired on June 5, 2018, and no further sales can be made under the Prior Sales Agreement. The Company sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,911,104</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the Prior Sales Agreement resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$32.1 million</font><font style="font-family:inherit;font-size:10pt;">. During the period from January 1, 2018 to June 5, 2018, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">314,950</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the Prior Sales Agreement. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$5.07</font><font style="font-family:inherit;font-size:10pt;">&#32;per share resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">. During the year ended December 31, 2017, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">2,937,406</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the Prior Sales Agreement. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$8.41</font><font style="font-family:inherit;font-size:10pt;">&#32;per share resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$24.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2018, warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">284,091</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock were exercised, with net proceeds to the Company of </font><font style="font-family:inherit;font-size:10pt;">$902,000</font><font style="font-family:inherit;font-size:10pt;">. As of December 31, 2019 and 2018, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;common stock warrants outstanding. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options and Restricted Stock Units</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed </font><font style="font-family:inherit;font-size:10pt;">16,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;</font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued was increased by </font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">16,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">8,214,032</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock available for future grant under the 2016 Incentive Plan, </font><font style="font-family:inherit;font-size:10pt;">2,069,936</font><font style="font-family:inherit;font-size:10pt;">&#32;shares underlying outstanding but unvested restricted stock units and options outstanding to purchase </font><font style="font-family:inherit;font-size:10pt;">4,497,736</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years and have a maximum contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-27</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had options outstanding to purchase </font><font style="font-family:inherit;font-size:10pt;">4,767,654</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;years and have a maximum contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million was included in research and development expenses and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was included in general and administrative expenses, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of total unrecognized compensation expense related to unvested stock options, which are each expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$4.3</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.6</font><font style="font-family:inherit;font-size:10pt;">&#32;years and </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years, respectively.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$970,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$302,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$201,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, options to purchase </font><font style="font-family:inherit;font-size:10pt;">952,500</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock granted to non-employees remained outstanding.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes total stock options outstanding at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted    Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48-$3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">848,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3.01-$6.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,066,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.90</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,844,977</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.01-$9.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,454,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,210,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.01-$12.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,880</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,880</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.01-$15.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,745,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of options outstanding was </font><font style="font-family:inherit;font-size:10pt;">$918,000</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of options exercisable was </font><font style="font-family:inherit;font-size:10pt;">$881,000</font><font style="font-family:inherit;font-size:10pt;">, and the weighted average remaining contractual term of options exercisable was </font><font style="font-family:inherit;font-size:10pt;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#32;years.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of unvested restricted stock units was </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, options to purchase </font><font style="font-family:inherit;font-size:10pt;">9,265,390</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">2,069,936</font><font style="font-family:inherit;font-size:10pt;">&#32;restricted stock units were expected to vest.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity under the Company&#8217;s equity incentive plans during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was as follows: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:71%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,752,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596,468</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,040,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.49</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-28</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:85%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,491,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,003,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106,634</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average exercise price per share was </font><font style="font-family:inherit;font-size:10pt;">$6.27</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">324,502</font><font style="font-family:inherit;font-size:10pt;">&#32;options which expired during the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.17</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">119,091</font><font style="font-family:inherit;font-size:10pt;">&#32;options which expired during the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.67</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">200,501</font><font style="font-family:inherit;font-size:10pt;">&#32;options which expired during the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share was </font><font style="font-family:inherit;font-size:10pt;">$2.19</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.86</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.33</font><font style="font-family:inherit;font-size:10pt;">&#32;for options granted during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value was </font><font style="font-family:inherit;font-size:10pt;">$3.09</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.31</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.66</font><font style="font-family:inherit;font-size:10pt;">&#32;per share for restricted stock units granted during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company received </font><font style="font-family:inherit;font-size:10pt;">$113,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in proceeds from the exercise of stock options during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The aggregate intrinsic value of options exercised was </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$910,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$519,000</font><font style="font-family:inherit;font-size:10pt;">&#32;during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s4A6E045156EE5897B3329B38DB34D2E6"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Leases </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases approximately </font><font style="font-family:inherit;font-size:10pt;">82,200</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of office, laboratory, and manufacturing space in San Diego, California and </font><font style="font-family:inherit;font-size:10pt;">57,360</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms of </font><font style="font-family:inherit;font-size:10pt;">3.9</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">9.9</font><font style="font-family:inherit;font-size:10pt;">&#32;years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all of its leases and determined that, effective upon the adoption of Topic 842, they were all operating leases. The Company performed an evaluation of its other contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</font></div><div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the maturities of the Company's operating lease liabilities were as follows:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-29</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,052,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,023,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,951,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total remaining lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,897,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: present value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,412,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,764</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,074,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,409,922</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2 years</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease costs included in operating expenses in the consolidated statements of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;agreements to sublease a total of approximately </font><font style="font-family:inherit;font-size:10pt;">13,500</font><font style="font-family:inherit;font-size:10pt;">&#32;square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, prior to the adoption of Topic 842, annual future minimum lease payments under non-cancelable operating leases were as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:83%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,756,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,052,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,023,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,952,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,653,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s906B2723B260543C8AE290BB5B52AB0B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Investments in Affiliated Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company held </font><font style="font-family:inherit;font-size:10pt;">1,644,155</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares, representing a </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">7.8%</font><font style="font-family:inherit;font-size:10pt;">&#32;ownership interest in GeneOne as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">395,758</font><font style="font-family:inherit;font-size:10pt;">&#32;common shares, representing a </font><font style="font-family:inherit;font-size:10pt;">15.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">15.1%</font><font style="font-family:inherit;font-size:10pt;">&#32;ownership interest in PLS as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. Please see further information as discussed in Note 2 and Note 6.</font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sB39EE239D4A0575FBE98AD3905533B04"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are presented in the following table: </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-30</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;">&#32;statutory tax rate for December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">&#32;statutory tax rate for December 31, 2017, is as follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (benefit) taxes at statutory rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,370,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,908,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,872,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income tax, net of federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,457,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,965,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,838,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,456,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(282,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,332,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,537,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,268,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">846,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired NOLs and credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,176,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited NOLs and credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(616,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,176,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,019,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,093,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax benefit recorded during the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;is principally due to a requirement under Accounting Standards Codification ("ASC") 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes</font><font style="font-family:inherit;font-size:10pt;">, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;are shown below:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-31</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,300,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,408,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOL carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,788,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,399,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development and other tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,737,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,432,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">985,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,013,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,408,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,852,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,722,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,413,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,693,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,229,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,250,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,159,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115,007,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,070,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,243,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(142,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right of use asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,894,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,862,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible note</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,381,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,121,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$483.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$68.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$80.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The federal net operating loss generated in 2018 and 2019 of </font><font style="font-family:inherit;font-size:10pt;">$186.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;will carryforward indefinitely and be available to offset up to </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;">&#32;of future taxable income each year. The federal NOL carryforward began to expire in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">, and the California and Pennsylvania NOL carryforwards will begin to expire in 2028 and </font><font style="font-family:inherit;font-size:10pt;">2021</font><font style="font-family:inherit;font-size:10pt;">, respectively, unless previously utilized. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, as of December 31, 2019, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$17.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Federal NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">State NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Federal R&amp;D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">State R&amp;D</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-32</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis, regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2019. As a result of the analysis, the Company estimates that approximately </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to the Company's unrecognized tax benefits:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,632,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,313,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,855,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,575,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,319,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases (decreases) related to prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,204,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,632,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,313,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2016 and state and local income tax examinations before 2015. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (&#8220;IRS&#8221;), state or local tax examination.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s963C9056EC0E54169D1400B2E42389C9"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">16. 401(k) Plan</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of its employees&#8217; contributions, up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6%</font><font style="font-family:inherit;font-size:10pt;">&#32;of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$822,000</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s98F94A3411395FC49A309AB478370A87"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">17. Related Party Transactions</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">GeneOne Life Sciences </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company owned </font><font style="font-family:inherit;font-size:10pt;">1,644,155</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in GeneOne as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to GeneOne. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2010, the Company entered into a collaboration and license agreement (the &#8220;GeneOne Agreement&#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#8220;Product&#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into a collaborative development and license agreement (the &#8220;Hep Agreement&#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#8217;s </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-33</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;therapeutic vaccines for hepatitis B and C infections (the &#8220;Hep Products&#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;">&#32;years after the effective date.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone-based ownership interest in the MERS immunotherapy asset upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone-based ownership interest in the Zika immunotherapy asset upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company completed the sale of certain assets related to its compound VGX-1027 to GeneOne for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from GeneOne for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;consisting of</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:10pt;">patent, device maintenance and licensing fees was </font><font style="font-family:inherit;font-size:10pt;">$127,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$342,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$551,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses recorded from transactions with GeneOne relate primarily to biologics manufacturing and were </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$128,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </font><font style="font-family:inherit;font-size:10pt;">$511,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$372,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to GeneOne and its subsidiaries. At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$284,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$381,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, of prepayments made to GeneOne were classified as long-term other assets on the consolidated balance sheets.  </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plumbline Life Sciences, Inc.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company owned </font><font style="font-family:inherit;font-size:10pt;">395,758</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from PLS consists of license fees. For the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from PLS of </font><font style="font-family:inherit;font-size:10pt;">$111,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$107,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$589,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$478,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to PLS.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Wistar Institute</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Two of the Company's directors as of December 31, 2019, Dr.&#160;David B. Weiner and Dr. Morton Collins, were directors of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar. Dr. Collins retired from the Company's Board of Directors effective January 14, 2020.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreement. The Company will have the exclusive right to in-license new intellectual property developed in this agreement.  </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the Company received a&#160;</font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through July 2020. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2020.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-34</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A grant funding liability recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense from Wistar. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;were </font><font style="font-family:inherit;font-size:10pt;">$1.5</font><font style="font-family:inherit;font-size:10pt;">&#32;million and </font><font style="font-family:inherit;font-size:10pt;">$1.8</font><font style="font-family:inherit;font-size:10pt;">&#32;million, respectively. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$616,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$258,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </font><font style="font-family:inherit;font-size:10pt;">$219,000</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$554,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to Wistar. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$843,000</font><font style="font-family:inherit;font-size:10pt;">&#32;recorded as grant funding liability on its consolidated balance sheet related to Wistar.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC3A80E4364815882B08C194DA5F398B7"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18. Quarterly Financial Information (Unaudited)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;(unaudited):</font></div><div style="line-height:120%;padding-top:6px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br>2019</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Statements of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">617,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,770,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,665</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,014</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,390</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,579</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous revenue, including from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,488</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">866,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,905</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,003,955</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,137,209</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,486,266</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,389,888</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,696,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,681,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,850,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,975,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,700,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,818,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,336,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,364,917</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,421,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,951,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,200,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,535,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">587,679</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,438</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755,330</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625,535</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,668,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,428,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,194,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,315,105</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551,453</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,681,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(750,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,512</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before income tax benefit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,235,146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,536,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,685,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,351,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,771</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,147,382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,536,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,579,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,288,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">445,759</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,662,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,090,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,387,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,219,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-35</font></div></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Statements of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,372,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,813,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,385,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,289,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,207</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,008</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,817</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502,624</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000,868</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,448,761</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529,644</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,365,647</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,851,858</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,462,620</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,577,751</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,636,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,791,693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,189,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,698,015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,001,788</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,643,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,651,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,275,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,499,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,642,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,203,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,746,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380,987</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,681</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,523</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) from investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293,741</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,017,359</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,092,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,380,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,962,205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,015,672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,639,125</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,181,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,962,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,015,672</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,639,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,350,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7719B53DAB8D57AA878FDEDC376A7841"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">19. Subsequent Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;7, 2020, the Company entered into an amendment to the Sales Agreement, which amendment increased the amount of common stock that could be sold by the Company under the Sales Agreement from an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">. On March&#160;9, 2020, the Company entered into a second amendment to the&#160;Sales Agreement, which amendment increased the amount of common stock that could be sold by the Company under the Sales Agreement from an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;">. Under the Sales Agreement, as amended, the Company set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales were requested to be made, limitation on the number of shares that could be sold in any one trading day and any minimum price below which sales could not be made. The Sales Agreement provided that the Placement Agent is entitled to compensation for its services in an amount equal to up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From January 1, 2020 through </font><font style="font-family:inherit;font-size:10pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">43,148,952</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under its Sales Agreement for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$208.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$4.92</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. As of the date these financial statements were issued, there is no remaining capacity under the Sales Agreement, as amended.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company will receive shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares, the Company will hold a </font><font style="font-family:inherit;font-size:10pt;">19.9%</font><font style="font-family:inherit;font-size:10pt;">&#32;ownership interest in PLS.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-36</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>ino-12312019x10xkex49.htm
<DESCRIPTION>EXHIBIT 4.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2C4272459A2886CDE052C5E7B0494308"></a></div><div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 4.9</font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following description summarizes selected information regarding our capital stock, as well as relevant provisions of: (i) our certificate of incorporation; (ii) our amended and restated bylaws; and (iii) the General Corporation Law of the State of Delaware, or the DGCL. The following summary is qualified in its entirety by, and should be read in conjunction with, the certificate of incorporation and the amended and restated bylaws, copies of which have been filed as exhibits to our Annual Report on Form 10-K to which this exhibit is a part, and the applicable provisions of the DGCL. All references to &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221; refer to Inovio Pharmaceuticals, Inc. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">General</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of preferred stock, $0.001 par value per share. Our board of directors may establish the rights and preferences of the preferred stock from time to time. As of December 31, 2019, 1,091 shares of preferred stock were designated Series C Cumulative Convertible Preferred Stock, of which 23 shares were outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The holders of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders and do not have any cumulative voting rights. Any election at a meeting of stockholders is determined by a plurality of the votes cast by the stockholders entitled to vote at the election, and all other matters are generally determined by a majority of the votes cast on the matter. Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our board of directors out of funds legally available. In the event of we liquidate, dissolve or wind up, after payment of all of our debts and liabilities, and subject to the preferential rights, if any, of any outstanding preferred stock, the holders of our common stock are entitled to share ratably in all assets. Our common stock has no preemptive or conversion rights or other subscription rights, and there are no redemptive or sinking funds provisions applicable to our common stock. The rights, preferences and privileges of the holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate in the future.</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Pursuant to our certificate of incorporation, our board of directors has the authority, without further action by the stockholders (unless such stockholder action is required by applicable law or stock exchange listing rules), to designate and issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the designations, powers, preferences, privileges and relative participating, optional or special rights and the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of the common stock, and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our board of directors, without stockholder approval, can issue preferred stock with voting, conversion or other rights that could adversely affect the voting power and other rights of the holders of common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our board of directors will fix the designations, voting powers, preferences and rights of each series, as well as the qualifications, limitations or restrictions thereof, of the preferred stock of each series. </font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Anti-Takeover Provisions</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Section 203 of the DGCL</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested stockholder, with the following exceptions:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">before such date, the board of directors of the corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">on or after such date, the business combination is approved by the board of directors and authorized at an annual or special meeting of the stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock that is not owned by the interested stockholder.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In general, Section 203 defines a &#8220;business combination&#8221; to include the following:</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">subject to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:8%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder; or</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits by or through the corporation.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">In general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the entity or person&#8217;s affiliates and associates, beneficially owns, or is an affiliate or associate of the corporation and within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;background-color:#ffffff;">&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-style:italic;font-weight:bold;">Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Our certificate of incorporation provides that our board of directors may issue shares of undesignated preferred stock and determine the rights, preferences and privileges of these shares, without stockholder approval and that all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent. Our certificate of incorporation also does not provide for cumulative voting.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">The authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our control. These provisions are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of delaying changes in our control or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. We believe that the benefits of these provisions, including increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure our company, outweigh the disadvantages of discouraging takeover proposals, because negotiation of takeover proposals could result in an improvement of their terms.</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Agent and Registrar </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transfer agent and registrar for our common stock is Computershare. The transfer agent&#8217;s address is 3rd Floor &#8212; 510 Burrard St., Vancouver, BC V6C 3B9, and its telephone number is (604) 661-0258. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Listing on the Nasdaq Global Select Market </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed on the Nasdaq Global Select Market under the symbol </font><font style="font-family:inherit;font-size:10pt;">&#8220;</font><font style="font-family:inherit;font-size:10pt;">INO.</font><font style="font-family:inherit;font-size:10pt;">&#8221;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:13.5pt;"><font style="font-family:inherit;font-size:13.5pt;background-color:#ffffff;">&#160;&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>ino1231209x10kex1026.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF5F4E9B480DA306E86129CB9B87E9721"></a></div><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 10.26</font></div><div style="line-height:100%;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:131%;padding-top:17px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Employment Agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), dated as of March 8, 2019 is made by and between Inovio Pharmaceuticals, Inc., a Delaware corporation having offices at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and Jacqueline E. Shea, Ph.D. (&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Executive</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div><div style="line-height:116%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RECITALS</font></div><div style="line-height:131%;padding-top:16px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS, </font><font style="font-family:inherit;font-size:11pt;">the Company desires to employee Executive and to have the benefit of her skills and services, and the Executive desires to accept employment with the Company on the terms and conditions set for herein; and</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS, </font><font style="font-family:inherit;font-size:11pt;">as a condition to her employment by the Company, Executive agrees to execute and shall be bound by the terms and conditions of the Employee Non-Disclosure, Inventions, Non-Competition, and Non-Solicitation Agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Proprietary Information Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) attached hereto collectively as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOW, THEREFORE, </font><font style="font-family:inherit;font-size:11pt;">in consideration of the mutual promises, terms, covenants and conditions set forth herein and in the Proprietary Information Agreement, and the performance of each, the parties hereto, intending legally to be bound, hereby agree as follows:</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Employment; Term.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;">The Company hereby agrees to employ Executive as Ex. Vice President, and COO, and Executive hereby agrees to accept such employment with the Company in accordance with the terms and conditions of this Agreement.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;">The &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11pt;">&#8221; of this Agreement shall commence on the date hereof (the</font></div><div style="line-height:129%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Commencement Date</font><font style="font-family:inherit;font-size:11pt;">&#8221;) and shall continue in effect until terminated as provided in Section 7 below.</font></div><div style="line-height:108%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Position and Duties.</font></div><div style="line-height:131%;padding-left:0px;padding-top:18px;text-align:left;text-indent:42px;"><font style="padding-top:18px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive shall serve as Exec VP and COO and shall report to Dr. J. Joseph Kim, Ph.D., or such other executive officer as is designated by the Company or the Board of Directors (the &#8220;Board&#8221;).  Executive shall perform such duties and responsibilities as are normally related to such position, and such other duties as may, from time to time, be assigned to Executive by the Company or the Board.  Executive shall perform Executive&#8217;s duties from the Company&#8217;s office located Plymouth Meeting, PA, and will travel as reasonably necessary to perform Executive&#8217;s duties under this Agreement..</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;">Executive shall faithfully devote her full business/working time, attention and energy to the business and affairs of the Company and the performance of her duties hereunder and to use reasonable efforts to perform such responsibilities faithfully and efficiently.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;padding-left:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:132%;padding-left:0px;padding-top:1px;text-align:left;text-indent:42px;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">c.</font><font style="font-family:inherit;font-size:11pt;">Without limiting the generality of the foregoing paragraph, during the Term, upon prior written consent of the Chief Executive Officer of the Company, Executive shall be permitted to serve on other Boards of Directors, professional associations and otherwise be involved with any family business or trust to the extent that, in the reasonable judgment of the Chief Executive Officer, such other business pursuits and activity do not materially (i) interfere with Executive's ability to discharge Executive's duties and responsibilities to the Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage, or (ii) cause Executive to violate any provision of the Proprietary Information Agreement or the Confidentiality Agreement.</font></div><div style="line-height:132%;padding-top:1px;text-align:left;padding-left:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;padding-left:0px;padding-top:1px;text-align:left;text-indent:42px;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">d.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Guaranty of Employment</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement does not constitute a guarantee of continued employment but instead provides for certain rights and benefits for the Executive during Executive&#8217;s employment with the Company, and in the event such employment with the Company terminates under circumstances described herein.  The employment of Executive shall be &#8220;at will&#8221; at all times.  The Company or Executive may terminate Executive&#8217;s employment with the Company at any time, without any advance notice (except as provided below), for any reason or no reason at all, notwithstanding anything to the contrary contained in or arising from any statements, policies or practices of the Company relating to the employment, discipline or termination of its employees.   </font></div><div style="line-height:132%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Compensation.</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;text-indent:48px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">a.</font><font style="font-family:inherit;font-size:11pt;">Executive shall be entitled to receive as compensation for her employment a base annual salary at a rate of $400,000 per annum (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:11pt;">&#8221;), which shall be paid to Executive by the Company or any of its affiliates in accordance with the Company&#8217;s standard payroll practices, as in effect from time to time.</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;text-indent:48px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">b.</font><font style="font-family:inherit;font-size:11pt;">Increases in the Base Salary shall be reviewed annually by the Company's Board of Directors (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:11pt;">&#8221;) or it&#8217;s Compensation Committee during the Term, and any such increases will be at the Board's or Compensation Committee's sole discretion and will otherwise be consistent with the Company's annual policies and budget for payroll increases.</font></div><div style="line-height:104%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bonus.</font></div><div style="line-height:132%;padding-top:16px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the Term, Executive shall be eligible to receive an incentive cash bonus up to the amount, based upon the criteria, and payable at such times, as may be determined by the Board or its Compensation Committee. The amount shall be determined by the Board or Compensation Committee, in its sole and absolute discretion, which shall be binding and final, and shall be paid in a one-time lump sum payment (less payroll taxes). To the extent that such cash bonus is to be determined in light of financial performance during a specified fiscal period and the Agreement commences on a date after the start of such fiscal period, any cash bonus payable in respect of such fiscal period's results may be prorated. In addition, if the period of Executive&#8217;s employment hereunder expires before the end of a fiscal period, and if Executive is eligible to receive a cash bonus at such time (such eligibility being subject to the restrictions set forth in Section 7 below), any cash bonus payable in respect of such fiscal period&#8217;s results may be prorated. Notwithstanding the foregoing, all bonuses on account a particular year shall be paid on or before March 15</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;of the following year.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:132%;padding-top:14px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Benefits; Stock Options.</font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to the salary and cash bonus referred to above, Executive shall be entitled during the Term to participate in such employee benefits plans or programs of the Company, and shall be entitled to such other fringe benefits, as are from time to time adopted by the Board and made available by the Company generally to employees of Executive's position, tenure, salary, and other qualifications. Without limiting the generality of the foregoing, Executive shall be eligible for such awards and benefits, if any, under the Company's employee benefits plans or programs as shall be granted to Executive in the sole discretion of the Board or its Compensation Committee and as shall be provided pursuant to the terms of the plans or programs. Executive acknowledges and agrees that the Company does not guarantee the adoption or continuance of any particular employee benefits plan or program or other fringe benefits during the Term, and participation by Executive in any such plan or program shall be subject to the rules and regulations applicable thereto.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:134%;padding-left:0px;padding-top:1px;text-align:left;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">6.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Expenses.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company will reimburse Executive, in accordance with the practices in effect from time to time for other officers or staff personnel of the Company, for all reasonable and</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">necessary business and traveling expenses and other disbursements incurred by Executive for or on behalf of the Company in the performance of Executive&#8217;s duties hereunder, upon presentation by Executive to the Company of appropriate vouchers and supporting documentation.  All reimbursements provided under this Agreement shall be made in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;Section 409A&#8221;), including, where applicable, the requirement that (i) any reimbursement shall be for expenses incurred during Executive&#8217;s employment, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">7.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive&#8217;s employment by the Company pursuant hereto is subject to termination as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Death or Disability.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive&#8217;s employment shall be deemed to terminate automatically on the date of Executive&#8217;s death, and the Company may by written notice to Executive terminate Executive&#8217;s employment on account of her Total Disability effective as of the date of such notice.  For purposes hereof, Executive shall be deemed to experience a &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Total Disability</font><font style="font-family:inherit;font-size:11pt;">&#8221; if Executive either: is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be  expected to last for a continuous period of not less than 12 months or is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under any group disability or accident and health plan covering Executive.  In the event of any dispute under this Section 7(a), Executive shall submit to al physical examination by a licensed physician mutually satisfactory to the Company and Executive, the cost of such examination to be paid by the Company, and the determination of such physician shall be determinative.  In the case of a Total Disability, until the Company shall have terminated Executive&#8217;s employment hereunder in accordance with the foregoing, Executive shall be entitled to receive compensation provided for herein notwithstanding any such Total Disability. In the event of the termination of Executive&#8217;s employment on </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">account of her death or Total Disability, neither Executive nor her personal representative will have any rights or claims against the Company under this Agreement except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive (or her estate or representative, as applicable) shall be paid (A) any unpaid portion of her Base Salary computed on a pro rata basis through the date of her termination and (B) any unreimbursed expenses;</font></div><div style="line-height:120%;text-align:left;padding-left:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">All other of Executive's accrued but unpaid rights shall be as determined under any incentive compensation, stock option, retirement, employee welfare or other employee benefits plan or program of the Company in which Executive is then participating at the time of her termination; and</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">in the case of Executive&#8217;s Total Disability only, (A) the Company shall continue Executive&#8217;s medical benefits coverage existing at the time of her termination for as long as permissible under the Company&#8217;s health benefits policies (not to exceed 60 days) and the Company further agrees to pay Executive&#8217;s COBRA premiums for twelve months thereafter, with such premiums to provide for coverage at the same level and subject to the same terms and conditions (including, without limitation, any applicable co-pay obligations of Executive, but excluding any applicable tax consequences for Executive) as in effect for Executive at the time of termination, and (B) Executive shall further receive a lump-sum payment, within 30 days after the effective date of termination, equal to the aggregate amount of Executive&#8217;s Base Salary as in effect immediately prior to such termination that would be payable over a period of twelve months following the effective date of such termination.</font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Involuntary Termination for Cause.</font><font style="font-family:inherit;font-size:11pt;">&#32;In the event the Company terminates</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive&#8217;s employment for </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:11pt;">&#32;(as such term is defined below), such termination shall be effective immediately upon notice thereof, in which case Executive will have no rights or claims against the Company under this Agreement except as follows:</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive shall be paid (A) any unpaid portion of her Base Salary computed on a pro rata basis through the date of her termination and (B) any unreimbursed expenses; and</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">All other of Executive's accrued but unpaid rights shall be as determined under any incentive compensation, stock option, retirement, employee welfare or other employee benefits plan and program of the Company in which Executive is then participating at the time of her termination.</font></div><div style="line-height:130%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall mean: (1) conviction of Executive of any felony; (2) participation by Executive in any fraud or act of dishonesty against the Company; (3) material violation by Executive of (i) any contract between the Company and Executive, or (ii) any statutory, contractual or common law duty of Executive to the Company; (4) conduct of Executive that, based upon a good faith and reasonable factual investigation and determination by the Board, demonstrates Executive&#8217;s gross unfitness to serve; or (5) the continued, willful refusal or failure by Executive to follow the instructions of or perform any material duties reasonably requested by the Board or the Chief Executive Officer that are not illegal.</font></div><div style="line-height:124%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">c.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Involuntary Termination Without Cause.</font><font style="font-family:inherit;font-size:11pt;">&#32;The Company may terminate</font></div><div style="line-height:131%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive&#8217;s employment, other than on account of death, Total Disability or for Cause, on 30 days&#8217; prior written notice, in which case Executive will have no rights or claims against the Company under this Agreement except as follows:</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive (or her estate or representative, as applicable) shall be paid (A) any unpaid portion of her Base Salary computed on a pro rata basis through the date of her termination, and (B) any unreimbursed expenses;</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">All other of Executive's accrued but unpaid rights shall be as determined under any incentive compensation, stock option, retirement, employee welfare or other employee benefits plan and program of the Company in which Executive is then participating at the time of her termination;</font></div><div style="line-height:131%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:53px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">Executive shall receive severance payments in the amount of twelve (12)  months&#8217; of Executive&#8217;s Base Salary (as in effect immediately prior to such termination) which will be payable on the date specified in Section 7(h).</font></div><div style="line-height:131%;text-align:left;padding-left:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:11pt;">The Company shall pay Executive's COBRA premiums for twelve (12) months thereafter, with such premiums to provide for coverage at substantially the same level and subject to the same terms and conditions (including, without limitation, any applicable co-pay obligations of Executive, but excluding any applicable tax consequences for Executive) as in effect for Executive at the time of termination, provided that Executive timely elects COBRA continuation coverage.</font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">d.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Voluntary Termination For Good Reason.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive may terminate her</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">employment for good reason (&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination For Good Reason</font><font style="font-family:inherit;font-size:11pt;">&#8221;) by providing 30 days&#8217; prior written notice to the Company of a breach constituting Good Reason, which notice shall be provided within 45 days after the initial existence of the breach, and further provided that such breach is not cured in all material respects to the reasonable satisfaction of Executive within 30 days after such notice. In the event of Termination for Good Reason, Executive shall be entitled to receive the payments and other rights provided in Section 7(c) hereof. For purposes of this Agreement, termination for &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall mean voluntary termination by Executive of her employment with the Company based on one of the following events:</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">(i)</font><font style="font-family:inherit;font-size:11pt;">the material diminution in Executive&#8217;s position, title, responsibilities or authority from those in effect at the Commencement Date; provided, however, that a material diminution shall not be deemed to have occurred upon a change of control of the Company solely by virtue of the Company's having been acquired and made part of a larger organization;</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">a relocation of Executive&#8217;s principal executive offices more than fifty miles from its location at the Commencement Date; or</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">the breach by the Company of any of its material obligations under this Agreement;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">e.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Other Voluntary Termination.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive may otherwise terminate her</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">employment without Good Reason upon 30 days&#8217; prior written notice to the Company, in which case Executive (or her estate or representative, as applicable) shall be paid (A) any unpaid portion of her Base Salary on a pro rata basis through the date of the termination, and (B) any unreimbursed expenses.</font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">f.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Forfeiture of Rights.</font><font style="font-family:inherit;font-size:11pt;">&#32;In the event that, subsequent to the termination of Executive&#8217;s employment hereunder, Executive breaches any of the provisions of the Proprietary Information Agreement in any material respect, all payments and benefits to which Executive may otherwise have been entitled to pursuant to this Section 7 hereof shall immediately terminate and be forfeited.  </font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">g.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Release.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive shall not be entitled to any compensation under this Section 7 unless Executive executes and delivers to the Company a Separation of Employment Agreement and General Release (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in form and substance satisfactory to the Company, by which Executive releases the Company from any obligations and liabilities of any type whatsoever, except for the Company&#8217;s obligation to provide the compensation and benefits specified in this Section 7. The parties hereto acknowledge that the payments to be provided under this Section 7 are to be provided in consideration for the Release.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:96px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:37px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive shall execute and return the Release to the Company within the maximum period of time specified within the Release for its execution and return; provided, however, in no event shall that date be more than sixty (60) days following Executive&#8217;s termination of employment. If the Executive fails to return an executed Release within the earlier of the foregoing dates, the Executive shall forfeit all amounts that would have been payable to her pursuant to this Section 7 whose payment was contingent upon execution of a Release of claims. </font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:96px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:37px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">If the Executive executes and returns the Release to the Company  within the foregoing periods, then the amounts described in this Section 7 that would be payable to Executive in a single sum shall be payable to  executive on the seventy-fourth (74</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) day following her termination of employment.</font></div><div style="line-height:107%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">8.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Remedies.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to other remedies provided by law or equity, upon a breach by Executive of any of the covenants contained herein or in the Proprietary Information Agreement, the Company shall be entitled to have a court of competent jurisdiction enter an injunction against Executive enjoining Executive and prohibiting any further breach of the covenants contained herein. Executive acknowledges that a breach or threatened breach by Executive of the provisions of this Agreement will cause irreparable damage to the Company because Executive&#8217;s services to be performed hereunder are of a unique, special and extraordinary character. Thus, the Company shall be entitled to injunctive relief without the necessity of proving actual damages and the Company shall not be required to post a bond or other security in support of such injunctive relief.</font></div><div style="line-height:112%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">9.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Arbitration.</font></div><div style="line-height:131%;padding-top:18px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any claim, dispute or controversy arising out of or in connection with Executive&#8217;s employment by the Company, her separation from the Company, this Agreement, or any breach thereof, shall be arbitrated by the parties before a sole neutral arbitrator (who shall be a retired superior court judge) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-top:18px;text-align:left;padding-left:5px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">conducted by the AAA or any other nationally or locally recognized alternative dispute resolution organization in accordance with the Arbitration Rules and Mediator Procedures of the American Arbitration Association then in effect.  A copy of these rules may be obtained from the AAA website, https://www.adr.org/sites/default/files/Employment%20Rules.pdf.  The claims subject to mandatory arbitration under the terms of this agreement include, but are not limited to, claims that have been or could be asserted under: (a) any law, statute, or constitution, or based on contract, or in tort, or based on common law; and (b) any and all Claims based on or arising under any civil rights laws, labor laws and/or employment laws including, but not limited to, the civil rights laws, labor laws and/or employment laws of any state, municipality or jurisdiction, including, but not limited to, Title VII of the Civil Rights act of 1964, the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), the Age Discrimination in Employment Act, including the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act, 42 U.S.C. &#167; 1981, the Fair Labor Standards Act, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the California Fair Employment and Housing Act, the California Family Rights Act, the California Labor Code, or California Constitution; (c) any other federal, state or local law, constitution, regulation, ordinance, decision or common law claim concerning employment discrimination or termination of employment; (d) any and all claims for personal injury, emotional distress, libel, slander, defamation, and other physical, economic, or emotional injury; and (e) all claims for attorney&#8217;s fees and costs.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The arbitrator shall have the authority to order discovery sufficient for both parties to adequately arbitrate any and all claim(s) and defense(s) at issue. Such discovery shall include access to relevant documents and witnesses, but shall not have the authority to add to, detract from or modify any provision hereof nor to award damages or other remedies not otherwise available under statue(s), contract(s) or common law relevant to the claim(s) and defense(s) at issue. Following the close of all evidence at the conclusion of the arbitration hearing, the neutral arbitrator shall issue a written award that reveals his or her essential findings and conclusions. The neutral arbitrator&#8217;s decision shall be final and binding. Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction. The direct expense of any arbitration proceeding shall be borne by the Company. Each party shall bear its own attorney&#8217;s fees and costs unless such fees are awarded as a measure of damages under the applicable contract or statute at issue. Such arbitration shall take place in San Diego, California at a location and date mutually agreeable to the parties. The parties hereto consent to the jurisdiction of the state and federal courts located in the State of California with respect to any action arising under this Agreement. Notwithstanding the foregoing, the Company shall be entitled to seek injunctive or other equitable relief, as contemplated by Section 8 hereof, from any court of competent jurisdiction, without the need to resort to arbitration.</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">10.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Assignment; Binding Nature.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors, heirs (in the case of Executive) and permitted assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred to the successor of the Company or its business if the assignee or transferee assumes all of the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law. If any such successor of the Company or its business does not agree to so assume such liabilities, obligations and duties, Executive may immediately resign, which shall be deemed a Termination For Good Reason under the provisions of this Agreement. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-top:14px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No rights or obligations of Executive under this Agreement may be assigned or transferred by Executive other than Executive's rights to compensation and benefits, which may be transferred only by will or operation of law, except as otherwise specifically provided or permitted hereunder.</font></div><div style="line-height:104%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">11.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notice.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any notice which a party is required or may desire to give pursuant to this Agreement shall be given in writing by personal delivery, by registered or certified mail, return receipt requested, postage prepaid, or by overnight courier, at the following addresses:</font></div><div style="line-height:133%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">If to the Company:</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inovio Pharmaceuticals, Inc.</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1787 Sentry Parkway West</font></div><div style="line-height:131%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Building 18, Suite 400</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Blue Bell, PA 19422</font></div><div style="line-height:131%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: Chief Executive Officer</font></div><div style="line-height:133%;padding-top:17px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">If to Executive:</font></div><div style="line-height:130%;padding-top:17px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Jacqueline E. Shea Ph.D.  </font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any notice personally delivered shall be deemed received when given, or if given by overnight courier shall be deemed received on the next business day and any notice mailed shall be deemed received on the third business day thereafter.</font></div><div style="line-height:134%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">12.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement and the Proprietary Information Agreement (</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;">) constitute the complete agreements and understandings between the Company and Executive concerning Executive&#8217;s employment by the Company, and supersede any and all previous agreements or understandings concerning such employment, whether written or oral, between Executive and the Company.</font></div><div style="line-height:111%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">13.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Modification.</font></div><div style="line-height:132%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement may only be amended or superseded by a written document signed by Executive and by the CEO of the Company.</font></div><div style="line-height:105%;padding-left:5px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">14.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Waiver.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as set forth herein, no delay or omission to exercise any right, power or remedy accruing to any party shall impair any such right, power or remedy or shall be construed to be a waiver of or an acquiescence to any breach hereof. No waiver by either party of any breach by the other party of any condition or provision contained in this Agreement to be performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by Executive and the Chief Executive Officer or other duly authorized officer of the Company.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:105%;padding-left:5px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">15.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 409A.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All amounts payable under this Agreement are intended to comply with the &#8220;short term deferral&#8221; exception from Section 409A specified in Treas. Reg. &#167; 1.409A-1(b)(4) (or any successor provision) or the &#8220;separation pay plan&#8221; exception specified in Treas. Reg. &#167; 1.409A-1(b)(9) (or any successor provision), or both of them, and shall be interpreted in a manner consistent with the applicable exceptions. Notwithstanding the foregoing, to the extent that any amounts payable in accordance with this Agreement are subject to Section 409A, this Agreement shall be interpreted and administered in such a way as to comply with Section 409A to the maximum extent possible.&#160;&#160; Each installment payment of compensation under this Agreement shall be treated as a separate payment of compensation for purposes of applying Section&#160;409A.&#160;&#160; The severance amounts described in this Agreement shall be paid only upon the occurrence of an involuntary &#8220;separation from service,&#8221; as defined in Section 409A.  If&#160;payment of any amount subject to Section 409A is triggered by a separation from service that occurs while the Employee is a &#8220;specified employee&#8221; (as defined by Section 409A), and if such amount is scheduled to be paid within six (6) months after such separation from service, the amount shall accrue without interest and shall be paid the first business day after the end of such six-month period, or, if earlier, within 15 days after the appointment of the personal representative or executor of the Employee&#8217;s estate following the Employee&#8217;s death.&#160; &#8220;Termination of employment,&#8221; &#8220;resignation&#8221; or words of similar import, as used in this Agreement shall mean, with respect to any payments subject to Section 409A, the&#160;Employee&#8217;s &#8220;separation from service&#8221; as defined by Section 409A.&#160; If any payment subject to Section 409A is contingent on the delivery of a release by Employee and could occur in either of two years, the payment will occur in the later year.  Nothing in this Agreement or the Plan shall be construed as a guarantee of any particular tax treatment to the Employee.&#160; The Employee shall be solely responsible for the tax consequences with respect to all amounts payable under this Agreement, and in no event shall the Company have any responsibility or liability if this Agreement does not meet any applicable requirements of Code section 409A.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, to the extent that any Internal Revenue Service guidance issued under Section 409A would result in Executive being subject to the payment of interest or any additional tax under Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in order to avoid the imposition of any such interest or additional tax under Section 409A, which amendment shall have the minimum economic effect necessary to the Executive and shall not result in any additional cost to the Company, unless it agrees otherwise to incur such cost, and shall be reasonably determined in good faith by the Company and Executive.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Invalidity of Any Provision.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">If any portion of this Agreement is held invalid or inoperative, the other portions of this</font><font style="font-family:inherit;font-size:11pt;">&#32;Agreement shall be deemed valid and operative and, so far as is reasonable and permitted by the law, effect shall be given to the intent manifested by the portion held invalid or inoperative.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Applicable Law.</font></div><div style="line-height:132%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to the principles of conflict of laws thereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts.</font></div><div style="line-height:132%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Headings.</font></div><div style="line-height:130%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Section headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Effect.</font></div><div style="line-height:132%;padding-bottom:48px;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The provisions of this Agreement will be binding upon, and will inure to the benefit of, the respective heirs, legal representatives and successors of the parties thereto.</font></div><div><a name="s21E8F93442913886CEA69CB9B8AE5433"></a></div><div style="line-height:131%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[SIGNATURES ON FOLLOWING PAGE]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s5FC094DE6FC82AA72A4D9CB9B8D11422"></a></div><div></div><div><br></div><div style="line-height:137%;padding-top:1px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="line-height:111%;padding-top:13px;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ J. Joseph Kim</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  J. Joseph Kim, Ph.D.</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: President and CEO</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTIVE</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Jacqueline E. Shea</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Jacqueline E. Shea, Ph.D.</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: March 11, 2019</font></div><div style="line-height:120%;text-align:right;padding-left:312px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">32129851.4</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>4
<FILENAME>ino12312019x10kex1027.htm
<DESCRIPTION>EXHIBIT 10.27
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s39BAC4D7DEE9FAB38CE19CB745DF9233"></a></div><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:100%;padding-top:1px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit 10.27</font></div><div style="line-height:100%;padding-top:1px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;padding-top:1px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EMPLOYMENT AGREEMENT</font></div><div style="line-height:131%;padding-top:17px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Employment Agreement (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), dated as of  March 4, 2019 is made by and between Inovio Pharmaceuticals, Inc., a Delaware corporation having offices at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;), and Laurent Michel Paul Francois Humeau, Ph.D.(Executive).</font></div><div style="line-height:116%;padding-top:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RECITALS</font></div><div style="line-height:131%;padding-top:16px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS, </font><font style="font-family:inherit;font-size:11pt;">the Company and Executive entered into an Employment Agreement dated December 1, 2017 (&#8220;Prior Agreement&#8221;) and the Company desires to amend the Executive&#8217;s title to be Chief Scientific Officer and Executive Vice President and to have the benefit of his skills and services, and the Executive desires to accept employment with the Company on the terms and conditions set for herein; and </font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">WHEREAS, </font><font style="font-family:inherit;font-size:11pt;">as a condition to his employment by the Company, Executive agrees to execute and shall be bound by the terms and conditions of the Employee Non-Disclosure, Inventions, Non-Competition, and Non-Solicitation Agreement and the California Addendum (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Proprietary Information Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;) attached hereto collectively as </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">NOW, THEREFORE, </font><font style="font-family:inherit;font-size:11pt;">in consideration of the mutual promises, terms, covenants and conditions set forth herein and in the Proprietary Information Agreement, and the performance of each, the parties hereto, intending legally to be bound, hereby agree as follows:</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Employment; Term.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;">The Company hereby agrees to employ Executive as Chief Scientific Officer &amp; Executive Vice President and Executive hereby agrees to accept such employment with the Company in accordance with the terms and conditions of this Agreement.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;">The &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:11pt;">&#8221; of this Agreement shall commence on the date hereof March 4, 2019</font></div><div style="line-height:129%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">and shall continue in effect until terminated as provided in Section 7 below.</font></div><div style="line-height:108%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Position and Duties.</font></div><div style="line-height:131%;padding-left:0px;padding-top:18px;text-align:left;text-indent:42px;"><font style="padding-top:18px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive shall serve as Chief Scientific Officer and Executive Vice President and shall report to Dr. J. Joseph Kim, Ph.D., or such other executive officer as is designated by the Company or the Board of Directors (the &#8220;Board&#8221;).  Executive shall perform such duties and responsibilities as are normally related to such position, and such other duties as may, from time to time, be assigned to Executive by the Company or the Board.  Executive shall perform Executive&#8217;s duties from the Company&#8217;s office located San Diego, California, and will travel as reasonably necessary to perform Executive&#8217;s duties under this Agreement.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;">Executive shall faithfully devote his full business/working time, attention and energy to the business and affairs of the Company and the performance of his duties hereunder and to use reasonable efforts to perform such responsibilities faithfully and efficiently.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-top:14px;text-align:left;padding-left:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;padding-left:0px;padding-top:1px;text-align:left;text-indent:42px;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">c.</font><font style="font-family:inherit;font-size:11pt;">Without limiting the generality of the foregoing paragraph, during the Term, upon prior written consent of the Chief Executive Officer of the Company, Executive shall be permitted to serve on other Boards of Directors, professional associations and otherwise be involved with any family business or trust to the extent that, in the reasonable judgment of the Chief Executive Officer, such other business pursuits and activity do not materially (i) interfere with Executive's ability to discharge Executive's duties and responsibilities to the Company, whether or not such activity is pursued for gain, profit or other pecuniary advantage, or (ii) cause Executive to violate any provision of the Proprietary Information Agreement or the Confidentiality Agreement.</font></div><div style="line-height:132%;padding-top:1px;text-align:left;padding-left:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:132%;padding-left:0px;padding-top:1px;text-align:left;text-indent:42px;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">d.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Guaranty of Employment</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement does not constitute a guarantee of continued employment but instead provides for certain rights and benefits for the Executive during Executive&#8217;s employment with the Company, and in the event such employment with the Company terminates under circumstances described herein.  The employment of Executive shall be &#8220;at will&#8221; at all times.  The Company or Executive may terminate Executive&#8217;s employment with the Company at any time, without any advance notice (except as provided below), for any reason or no reason at all, notwithstanding anything to the contrary contained in or arising from any statements, policies or practices of the Company relating to the employment, discipline or termination of its employees.   </font></div><div style="line-height:132%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Compensation.</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;text-indent:48px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">a.</font><font style="font-family:inherit;font-size:11pt;">Executive shall be entitled to receive as compensation for his employment a base annual salary at a rate of $400,000.00 per annum (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Base Salary</font><font style="font-family:inherit;font-size:11pt;">&#8221;), which shall be paid to Executive by the Company or any of its affiliates in accordance with the Company&#8217;s standard payroll practices, as in effect from time to time.</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;text-indent:48px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">b.</font><font style="font-family:inherit;font-size:11pt;">Increases in the Base Salary shall be reviewed annually by the Company's Board of Directors (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Board</font><font style="font-family:inherit;font-size:11pt;">&#8221;) or it&#8217;s Compensation Committee during the Term, and any such increases will be at the Board's or Compensation Committee's sole discretion and will otherwise be consistent with the Company's annual policies and budget for payroll increases.</font></div><div style="line-height:104%;padding-top:14px;text-align:left;text-indent:9px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bonus.</font></div><div style="line-height:132%;padding-top:16px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">During the Term, Executive shall be eligible to receive an incentive cash bonus up to the amount, based upon the criteria, and payable at such times, as may be determined by the Board or its Compensation Committee. The amount shall be determined by the Board or Compensation Committee, in its sole and absolute discretion, which shall be binding and final, and shall be paid in a one-time lump sum payment (less payroll taxes). To the extent that such cash bonus is to be determined in light of financial performance during a specified fiscal period and the Agreement commences on a date after the start of such fiscal period, any cash bonus payable in respect of such fiscal period's results may be prorated. In addition, if the period of Executive&#8217;s employment hereunder expires before the end of a fiscal period, and if Executive is eligible to receive a cash bonus at such time (such eligibility being subject to the restrictions set forth in Section 7 below), any cash bonus payable in respect of such fiscal period&#8217;s results may be prorated. Notwithstanding the foregoing, all bonuses on account a particular year shall be paid on or before March 15</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">&#32;of the following year.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:132%;padding-top:14px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Benefits; Stock Options.</font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to the salary and cash bonus referred to above, Executive shall be entitled during the Term to participate in such employee benefits plans or programs of the Company, and shall be entitled to such other fringe benefits, as are from time to time adopted by the Board and made available by the Company generally to employees of Executive's position, tenure, salary, and other qualifications. Without limiting the generality of the foregoing, Executive shall be eligible for such awards and benefits, if any, under the Company's employee benefits plans or programs as shall be granted to Executive in the sole discretion of the Board or its Compensation Committee and as shall be provided pursuant to the terms of the plans or programs. Executive acknowledges and agrees that the Company does not guarantee the adoption or continuance of any particular employee benefits plan or program or other fringe benefits during the Term, and participation by Executive in any such plan or program shall be subject to the rules and regulations applicable thereto.  </font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:134%;padding-left:0px;padding-top:1px;text-align:left;"><font style="padding-top:1px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">6.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Expenses.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company will reimburse Executive, in accordance with the practices in effect from time to time for other officers or staff personnel of the Company, for all reasonable and</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">necessary business and traveling expenses and other disbursements incurred by Executive for or on behalf of the Company in the performance of Executive&#8217;s duties hereunder, upon presentation by Executive to the Company of appropriate vouchers and supporting documentation.  All reimbursements provided under this Agreement shall be made in accordance with the requirements of Section 409A of the Internal Revenue Code (&#8220;Section 409A&#8221;), including, where applicable, the requirement that (i) any reimbursement shall be for expenses incurred during Executive&#8217;s employment, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during a calendar year may not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year in which the expense is incurred, and (iv) the right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">7.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination.</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive&#8217;s employment by the Company pursuant hereto is subject to termination as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:48px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">a.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Death or Disability.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive&#8217;s employment shall be deemed to terminate automatically on the date of Executive&#8217;s death, and the Company may by written notice to Executive terminate Executive&#8217;s employment on account of his Total Disability effective as of the date of such notice.  For purposes hereof, Executive shall be deemed to experience a &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Total Disability</font><font style="font-family:inherit;font-size:11pt;">&#8221; if Executive either: is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be  expected to last for a continuous period of not less than 12 months or is, by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, receiving income replacement benefits for a period of not less than three months under any group disability or accident and health plan covering Executive.  In the event of any dispute under this Section 7(a), Executive shall submit to al physical examination by a licensed physician mutually satisfactory to the Company and Executive, the cost of such examination to be paid by the Company, and the determination of such physician shall be determinative.  In the case of a Total Disability, until the Company shall have terminated Executive&#8217;s employment hereunder in accordance with the foregoing, Executive shall be entitled to receive compensation provided for herein notwithstanding any such Total Disability. In the event of the termination of Executive&#8217;s employment on </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:120%;padding-left:0px;text-align:left;"><font style="font-family:inherit;font-size:11pt;">account of his death or Total Disability, neither Executive nor his personal representative will have any rights or claims against the Company under this Agreement except as follows:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive (or his estate or representative, as applicable) shall be paid (A) any unpaid portion of his Base Salary computed on a pro rata basis through the date of his termination and (B) any unreimbursed expenses;</font></div><div style="line-height:120%;text-align:left;padding-left:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">All other of Executive's accrued but unpaid rights shall be as determined under any incentive compensation, stock option, retirement, employee welfare or other employee benefits plan or program of the Company in which Executive is then participating at the time of his termination; and</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">in the case of Executive&#8217;s Total Disability only, (A) the Company shall continue Executive&#8217;s medical benefits coverage existing at the time of his termination for as long as permissible under the Company&#8217;s health benefits policies (not to exceed 60 days) and the Company further agrees to pay Executive&#8217;s COBRA premiums for twelve months thereafter, with such premiums to provide for coverage at the same level and subject to the same terms and conditions (including, without limitation, any applicable co-pay obligations of Executive, but excluding any applicable tax consequences for Executive) as in effect for Executive at the time of termination, and (B) Executive shall further receive a lump-sum payment, within 30 days after the effective date of termination, equal to the aggregate amount of Executive&#8217;s Base Salary as in effect immediately prior to such termination that would be payable over a period of twelve months following the effective date of such termination.</font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">b.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Involuntary Termination for Cause.</font><font style="font-family:inherit;font-size:11pt;">&#32;In the event the Company terminates</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive&#8217;s employment for </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:11pt;">&#32;(as such term is defined below), such termination shall be effective immediately upon notice thereof, in which case Executive will have no rights or claims against the Company under this Agreement except as follows:</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive shall be paid (A) any unpaid portion of his Base Salary computed on a pro rata basis through the date of his termination and (B) any unreimbursed expenses; and</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">All other of Executive's accrued but unpaid rights shall be as determined under any incentive compensation, stock option, retirement, employee welfare or other employee benefits plan and program of the Company in which Executive is then participating at the time of his termination.</font></div><div style="line-height:130%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Cause</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall mean: (1) conviction of Executive of any felony; (2) participation by Executive in any fraud or act of dishonesty against the Company; (3) material violation by Executive of (i) any contract between the Company and Executive, or (ii) any statutory, contractual or common law duty of Executive to the Company; (4) conduct of Executive that, based upon a good faith and reasonable factual investigation and determination by the Board, demonstrates Executive&#8217;s gross unfitness to serve; or (5) the continued, willful refusal or failure by Executive to follow the instructions of or perform any material duties reasonably requested by the Board or the Chief Executive Officer that are not illegal.</font></div><div style="line-height:124%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">c.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Involuntary Termination Without Cause.</font><font style="font-family:inherit;font-size:11pt;">&#32;The Company may terminate</font></div><div style="line-height:131%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Executive&#8217;s employment, other than on account of death, Total Disability or for Cause, on 30 days&#8217; prior written notice, in which case Executive will have no rights or claims against the Company under this Agreement except as follows:</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive (or his estate or representative, as applicable) shall be paid (A) any unpaid portion of his Base Salary computed on a pro rata basis through the date of his termination, and (B) any unreimbursed expenses;</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">All other of Executive's accrued but unpaid rights shall be as determined under any incentive compensation, stock option, retirement, employee welfare or other employee benefits plan and program of the Company in which Executive is then participating at the time of his termination;</font></div><div style="line-height:131%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:53px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">Executive shall receive severance payments in the amount of twelve (12)  months&#8217; of Executive&#8217;s Base Salary (as in effect immediately prior to such termination) which will be payable on the date specified in Section 7(h).</font></div><div style="line-height:131%;text-align:left;padding-left:90px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:131%;padding-left:0px;text-align:left;text-indent:90px;"><font style="text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">(iv)</font><font style="font-family:inherit;font-size:11pt;">The Company shall pay Executive's COBRA premiums for twelve (12) months thereafter, with such premiums to provide for coverage at substantially the same level and subject to the same terms and conditions (including, without limitation, any applicable co-pay obligations of Executive, but excluding any applicable tax consequences for Executive) as in effect for Executive at the time of termination, provided that Executive timely elects COBRA continuation coverage.</font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">d.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Voluntary Termination For Good Reason.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive may terminate his</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">employment for good reason (&#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Termination For Good Reason</font><font style="font-family:inherit;font-size:11pt;">&#8221;) by providing 30 days&#8217; prior written notice to the Company of a breach constituting Good Reason, which notice shall be provided within 45 days after the initial existence of the breach, and further provided that such breach is not cured in all material respects to the reasonable satisfaction of Executive within 30 days after such notice. In the event of Termination for Good Reason, Executive shall be entitled to receive the payments and other rights provided in Section 7(c) hereof. For purposes of this Agreement, termination for &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Good Reason</font><font style="font-family:inherit;font-size:11pt;">&#8221; shall mean voluntary termination by Executive of his employment with the Company based on one of the following events:</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">(i)</font><font style="font-family:inherit;font-size:11pt;">the material diminution in Executive&#8217;s position, title, responsibilities or authority from those in effect at the Commencement Date; provided, however, that a material diminution shall not be deemed to have occurred upon a change of control of the Company solely by virtue of the Company's having been acquired and made part of a larger organization;</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">a relocation of Executive&#8217;s principal executive offices more than fifty miles from its location at the Commencement Date; or</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:90px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">(iii)</font><font style="font-family:inherit;font-size:11pt;">the breach by the Company of any of its material obligations under this Agreement;</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">e.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Other Voluntary Termination.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive may otherwise terminate his</font></div><div style="line-height:130%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">employment without Good Reason upon 30 days&#8217; prior written notice to the Company, in which case Executive (or his estate or representative, as applicable) shall be paid (A) any unpaid portion of his Base Salary on a pro rata basis through the date of the termination, and (B) any unreimbursed expenses.</font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">f.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Forfeiture of Rights.</font><font style="font-family:inherit;font-size:11pt;">&#32;In the event that, subsequent to the termination of Executive&#8217;s employment hereunder, Executive breaches any of the provisions of the Proprietary Information Agreement in any material respect, all payments and benefits to which Executive may otherwise have been entitled to pursuant to this Section 7 hereof shall immediately terminate and be forfeited.  </font></div><div style="line-height:131%;padding-left:5px;padding-top:14px;text-align:left;text-indent:42px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">g.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Release.</font><font style="font-family:inherit;font-size:11pt;">&#32;Executive shall not be entitled to any compensation under this Section 7 unless Executive executes and delivers to the Company a Separation of Employment Agreement and General Release (the &#8220;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Release</font><font style="font-family:inherit;font-size:11pt;">&#8221;) in form and substance satisfactory to the Company, by which Executive releases the Company from any obligations and liabilities of any type whatsoever, except for the Company&#8217;s obligation to provide the compensation and benefits specified in this Section 7. The parties hereto acknowledge that the payments to be provided under this Section 7 are to be provided in consideration for the Release.</font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:96px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:37px;">(i)</font><font style="font-family:inherit;font-size:11pt;">Executive shall execute and return the Release to the Company within the maximum period of time specified within the Release for its execution and return; provided, however, in no event shall that date be more than sixty (60) days following Executive&#8217;s termination of employment. If the Executive fails to return an executed Release within the earlier of the foregoing dates, the Executive shall forfeit all amounts that would have been payable to his pursuant to this Section 7 whose payment was contingent upon execution of a Release of claims. </font></div><div style="line-height:131%;padding-left:0px;padding-top:14px;text-align:left;text-indent:96px;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:37px;">(ii)</font><font style="font-family:inherit;font-size:11pt;">If the Executive executes and returns the Release to the Company  within the foregoing periods, then the amounts described in this Section 7 that would be payable to Executive in a single sum shall be payable to  executive on the seventy-fourth (74</font><font style="font-family:inherit;font-size:11pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">th</sup></font><font style="font-family:inherit;font-size:11pt;">) day following his termination of employment.</font></div><div style="line-height:107%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">8.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Remedies.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition to other remedies provided by law or equity, upon a breach by Executive of any of the covenants contained herein or in the Proprietary Information Agreement, the Company shall be entitled to have a court of competent jurisdiction enter an injunction against Executive enjoining Executive and prohibiting any further breach of the covenants contained herein. Executive acknowledges that a breach or threatened breach by Executive of the provisions of this Agreement will cause irreparable damage to the Company because Executive&#8217;s services to be performed hereunder are of a unique, special and extraordinary character. Thus, the Company shall be entitled to injunctive relief without the necessity of proving actual damages and the Company shall not be required to post a bond or other security in support of such injunctive relief.</font></div><div style="line-height:112%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">9.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Arbitration.</font></div><div style="line-height:131%;padding-top:18px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any claim, dispute or controversy arising out of or in connection with Executive&#8217;s employment by the Company, his separation from the Company, this Agreement, or any breach thereof, shall be arbitrated by the parties before a sole neutral arbitrator (who shall be a retired superior court judge) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-top:18px;text-align:left;padding-left:5px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">conducted by the AAA or any other nationally or locally recognized alternative dispute resolution organization in accordance with the Arbitration Rules and Mediator Procedures of the American Arbitration Association then in effect.  A copy of these rules may be obtained from the AAA website, https://www.adr.org/sites/default/files/Employment%20Rules.pdf.  The claims subject to mandatory arbitration under the terms of this agreement include, but are not limited to, claims that have been or could be asserted under: (a) any law, statute, or constitution, or based on contract, or in tort, or based on common law; and (b) any and all Claims based on or arising under any civil rights laws, labor laws and/or employment laws including, but not limited to, the civil rights laws, labor laws and/or employment laws of any state, municipality or jurisdiction, including, but not limited to, Title VII of the Civil Rights act of 1964, the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA), the Age Discrimination in Employment Act, including the Older Workers Benefit Protection Act, the Employee Retirement Income Security Act, 42 U.S.C. &#167; 1981, the Fair Labor Standards Act, the Americans with Disabilities Act, the Civil Rights Act of 1991, the Family and Medical Leave Act, the California Fair Employment and Housing Act, the California Family Rights Act, the California Labor Code, or California Constitution; (c) any other federal, state or local law, constitution, regulation, ordinance, decision or common law claim concerning employment discrimination or termination of employment; (d) any and all claims for personal injury, emotional distress, libel, slander, defamation, and other physical, economic, or emotional injury; and (e) all claims for attorney&#8217;s fees and costs.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The arbitrator shall have the authority to order discovery sufficient for both parties to adequately arbitrate any and all claim(s) and defense(s) at issue. Such discovery shall include access to relevant documents and witnesses, but shall not have the authority to add to, detract from or modify any provision hereof nor to award damages or other remedies not otherwise available under statue(s), contract(s) or common law relevant to the claim(s) and defense(s) at issue. Following the close of all evidence at the conclusion of the arbitration hearing, the neutral arbitrator shall issue a written award that reveals his or his essential findings and conclusions. The neutral arbitrator&#8217;s decision shall be final and binding. Judgment may be entered on the arbitrator&#8217;s award in any court having jurisdiction. The direct expense of any arbitration proceeding shall be borne by the Company. Each party shall bear its own attorney&#8217;s fees and costs unless such fees are awarded as a measure of damages under the applicable contract or statute at issue. Such arbitration shall take place in San Diego, California at a location and date mutually agreeable to the parties. The parties hereto consent to the jurisdiction of the state and federal courts located in the State of California with respect to any action arising under this Agreement. Notwithstanding the foregoing, the Company shall be entitled to seek injunctive or other equitable relief, as contemplated by Section 8 hereof, from any court of competent jurisdiction, without the need to resort to arbitration.</font></div><div style="line-height:132%;padding-left:0px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">10.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Assignment; Binding Nature.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors, heirs (in the case of Executive) and permitted assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred to the successor of the Company or its business if the assignee or transferee assumes all of the liabilities, obligations and duties of the Company, as contained in this Agreement, either contractually or as a matter of law. If any such successor of the Company or its business does not agree to so assume such liabilities, obligations and duties, Executive may immediately resign, which shall be deemed a Termination For Good Reason under the provisions of this Agreement. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:131%;padding-top:14px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">No rights or obligations of Executive under this Agreement may be assigned or transferred by Executive other than Executive's rights to compensation and benefits, which may be transferred only by will or operation of law, except as otherwise specifically provided or permitted hereunder.</font></div><div style="line-height:104%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">11.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notice.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any notice which a party is required or may desire to give pursuant to this Agreement shall be given in writing by personal delivery, by registered or certified mail, return receipt requested, postage prepaid, or by overnight courier, at the following addresses:</font></div><div style="line-height:133%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">If to the Company:</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Inovio Pharmaceuticals</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">660 W. Germantown Pike, Suite 110</font></div><div style="line-height:130%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Plymouth Meeting, PA 19462</font></div><div style="line-height:131%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Attention: Chief Executive Officer</font></div><div style="line-height:133%;padding-top:17px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">If to Executive:</font></div><div style="line-height:133%;padding-top:17px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Laurent Humeau</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any notice personally delivered shall be deemed received when given, or if given by overnight courier shall be deemed received on the next business day and any notice mailed shall be deemed received on the third business day thereafter.</font></div><div style="line-height:134%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">12.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement and the Proprietary Information Agreement (</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:11pt;">) constitute the complete agreements and understandings between the Company and Executive concerning Executive&#8217;s employment by the Company, and supersede any and all previous agreements or understandings concerning such employment, whether written or oral, between Executive and the Company.</font></div><div style="line-height:111%;padding-left:5px;padding-top:14px;text-align:left;"><font style="padding-top:14px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">13.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Modification.</font></div><div style="line-height:132%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement may only be amended or superseded by a written document signed by Executive and by the CEO of the Company.</font></div><div style="line-height:105%;padding-left:5px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">14.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Waiver.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Except as set forth herein, no delay or omission to exercise any right, power or remedy accruing to any party shall impair any such right, power or remedy or shall be construed to be a waiver of or an acquiescence to any breach hereof. No waiver by either party of any breach by the other party of any condition or provision contained in this Agreement to be performed by such other party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by Executive and the Chief Executive Officer or other duly authorized officer of the Company.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:105%;padding-left:5px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:42px;">15.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 409A.</font></div><div style="line-height:131%;padding-top:17px;text-align:left;padding-left:5px;text-indent:42px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All amounts payable under this Agreement are intended to comply with the &#8220;short term deferral&#8221; exception from Section 409A specified in Treas. Reg. &#167; 1.409A-1(b)(4) (or any successor provision) or the &#8220;separation pay plan&#8221; exception specified in Treas. Reg. &#167; 1.409A-1(b)(9) (or any successor provision), or both of them, and shall be interpreted in a manner consistent with the applicable exceptions. Notwithstanding the foregoing, to the extent that any amounts payable in accordance with this Agreement are subject to Section 409A, this Agreement shall be interpreted and administered in such a way as to comply with Section 409A to the maximum extent possible.&#160;&#160; Each installment payment of compensation under this Agreement shall be treated as a separate payment of compensation for purposes of applying Section&#160;409A.&#160;&#160; The severance amounts described in this Agreement shall be paid only upon the occurrence of an involuntary &#8220;separation from service,&#8221; as defined in Section 409A.  If&#160;payment of any amount subject to Section 409A is triggered by a separation from service that occurs while the Employee is a &#8220;specified employee&#8221; (as defined by Section 409A), and if such amount is scheduled to be paid within six (6) months after such separation from service, the amount shall accrue without interest and shall be paid the first business day after the end of such six-month period, or, if earlier, within 15 days after the appointment of the personal representative or executor of the Employee&#8217;s estate following the Employee&#8217;s death.&#160; &#8220;Termination of employment,&#8221; &#8220;resignation&#8221; or words of similar import, as used in this Agreement shall mean, with respect to any payments subject to Section 409A, the&#160;Employee&#8217;s &#8220;separation from service&#8221; as defined by Section 409A.&#160; If any payment subject to Section 409A is contingent on the delivery of a release by Employee and could occur in either of two years, the payment will occur in the later year.  Nothing in this Agreement or the Plan shall be construed as a guarantee of any particular tax treatment to the Employee.&#160; The Employee shall be solely responsible for the tax consequences with respect to all amounts payable under this Agreement, and in no event shall the Company have any responsibility or liability if this Agreement does not meet any applicable requirements of Code section 409A.</font></div><div style="line-height:130%;padding-top:1px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, to the extent that any Internal Revenue Service guidance issued under Section 409A would result in Executive being subject to the payment of interest or any additional tax under Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in order to avoid the imposition of any such interest or additional tax under Section 409A, which amendment shall have the minimum economic effect necessary to the Executive and shall not result in any additional cost to the Company, unless it agrees otherwise to incur such cost, and shall be reasonably determined in good faith by the Company and Executive.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">16.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Invalidity of Any Provision.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">If any portion of this Agreement is held invalid or inoperative, the other portions of this</font><font style="font-family:inherit;font-size:11pt;">&#32;Agreement shall be deemed valid and operative and, so far as is reasonable and permitted by the law, effect shall be given to the intent manifested by the portion held invalid or inoperative.</font></div><div style="line-height:131%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">17.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Applicable Law.</font></div><div style="line-height:132%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement shall be governed by and construed in accordance with the laws of the State of California, without regard to the principles of conflict of laws thereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-indent:576px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font></div></div><div><br></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">18.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts.</font></div><div style="line-height:132%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">This Agreement may be executed simultaneously in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same agreement.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">19.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Headings.</font></div><div style="line-height:130%;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Section headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="line-height:105%;padding-left:0px;padding-top:16px;text-align:left;"><font style="padding-top:16px;text-align:left;font-family:inherit;font-size:11pt;padding-right:48px;">20.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Effect.</font></div><div style="line-height:132%;padding-bottom:48px;padding-top:14px;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The provisions of this Agreement will be binding upon, and will inure to the benefit of, the respective heirs, legal representatives and successors of the parties thereto.</font></div><div><a name="s0C621987FF46BEDB96439CB74617C93F"></a></div><div style="line-height:131%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[SIGNATURES ON FOLLOWING PAGE]</font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s8983C7B3230EBB18598E9CB74630AF94"></a></div><div></div><div><br></div><div style="line-height:137%;padding-top:1px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">IN WITNESS WHEREOF, the parties hereto have executed this Employment Agreement as of the date first written above.</font></div><div style="line-height:111%;padding-top:13px;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC.</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;/s/ J. Joseph Kim</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:  J. Joseph Kim, Ph.D.</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title: President and CEO</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EXECUTIVE</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">/s/ Laurent Humeau</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Laurent Michel Paul Francois Humeau, Ph.D.</font></div><div style="line-height:120%;text-align:left;padding-left:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: 12.10.2017</font></div><div style="line-height:120%;text-align:right;padding-left:312px;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">32129851.4</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>ino-12312019x10kex211.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5F6F7AA62EBA5C7A86B065E7B54B13BD"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 21.1 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INOVIO PHARMACEUTICALS, INC. </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsidiaries </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:66%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Subsidiary Name(1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><font style="font-family:inherit;font-size:7.5pt;font-weight:bold;">Jurisdiction of Organization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genetronics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">California</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VGX Pharmaceuticals, LLC</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:6px;padding-bottom:6px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">VGX Animal Health, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;padding-left:16px;text-indent:-16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GENEOS Therapeutics, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>ino-12312019x10kex231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sA52018CEEC0B521A9B3710EE20669CBA"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 23.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-3 No. 333-236202) of Inovio Pharmaceuticals, Inc.,  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 Nos. 333-142938, 333-150769, and 333-161559) pertaining to Inovio Biomedical Corporation 2007 Omnibus Incentive Plan, </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;Registration Statement (Form S-8 Nos. 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to Inovio Pharmaceuticals, Inc&#8217;s 2007 Omnibus Incentive Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, and 333-231872) of Inovio Pharmaceuticals, Inc.&#8217;s 2016 Omnibus Incentive Plan, and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-236201) of Inovio Pharmaceuticals, Inc.&#8217;s 2016 Omnibus Incentive Plan, as amended.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated March 12, 2020, with respect to the consolidated financial statements of Inovio Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2019.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">San Diego, California</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 12, 2020</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ino-12312019x10kex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s96B929586307532EAD2C2DCFFC396F1C"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.1 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of CEO Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as Adopted Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, J. Joseph Kim, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:47%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J. J</font><font style="font-family:inherit;font-size:7pt;">OSEPH</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">J. Joseph Kim</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">President, Chief Executive Officer and Director</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ino-12312019x10kex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s99C08082B94756A492640E3DA70F3404"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;31.2 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of CFO Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">as Adopted Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Peter Kies, certify that: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:47%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:1px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;P</font><font style="font-family:inherit;font-size:7pt;">ETER</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Peter Kies</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ino-12312019x10kex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s857F065FACEA5A90B989B67FD6609B67"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;32.1 </font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">18 U.S.C. Section&#160;1350, </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As Adopted Pursuant to </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ending December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:4pt;"><font style="font-family:inherit;font-size:4pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:6%;"></td><td style="width:47%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;J. J</font><font style="font-family:inherit;font-size:7pt;">OSEPH</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">J. Joseph Kim</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">President, Chief Executive Officer and Director</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March&#160;12, 2020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/&#160;&#160;&#160;&#160;P</font><font style="font-family:inherit;font-size:7pt;">ETER</font><font style="font-family:inherit;font-size:10pt;">&#160;K</font><font style="font-family:inherit;font-size:7pt;">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Peter Kies</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">Chief Financial Officer</font></div><div style="padding-bottom:1px;text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>ino-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:C79EFCB3F1325243B7D9F51A12A54A98,x:c89aba60464a401a9e3871fe4e2c4756-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2018-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2018-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2018-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2018-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ino="http://www.inovio.com/20191231" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="ino-20191231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q2June28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2020Q1March11">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_ino_GrantwithAffiliatedRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:GrantwithAffiliatedRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_ino_GrantwithAffiliatedRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:GrantwithAffiliatedRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_ino_GrantwithAffiliatedRevenueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:GrantwithAffiliatedRevenueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1_srt_RestatementAxis_srt_RestatementAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q1Jan1March11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-03-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3July1July30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_OwnershipAxis_ino_VGXAnimalHealthIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:VGXAnimalHealthIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:OtherCounterpartyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-11</xbrli:startDate>
			<xbrli:endDate>2018-04-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec1Dec31_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q1_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Aug7_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-08-07</xbrli:startDate>
			<xbrli:endDate>2015-08-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sept1Sept30_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-01</xbrli:startDate>
			<xbrli:endDate>2015-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DomesticCorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MCDCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MCDCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_MajorCustomersAxis_ino_MCDCMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MCDCMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_MajorCustomersAxis_ino_MedImmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_MajorCustomersAxis_ino_MedImmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:HoffmanLaRocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DefenseAdvancedResearchProjectsAgencyDARPAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DefenseAdvancedResearchProjectsAgencyDARPAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:HoffmanLaRocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:HoffmanLaRocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:HoffmanLaRocheMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DefenseAdvancedResearchProjectsAgencyDARPAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:HoffmanLaRocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DefenseAdvancedResearchProjectsAgencyDARPAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DefenseAdvancedResearchProjectsAgencyDARPAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:MedImmuneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DefenseAdvancedResearchProjectsAgencyDARPAMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:HoffmanLaRocheMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:ApolloBioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2009Q2_us-gaap_IncomeStatementLocationAxis_ino_VgxPharmaceuticalsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:VgxPharmaceuticalsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2009-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2005Q1Jan31_us-gaap_IncomeStatementLocationAxis_ino_InovioAsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:InovioAsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2005-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2Apr_us-gaap_IncomeStatementLocationAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:GhrhMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:GhrhMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:CellectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:CellectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:CellectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:GhrhMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-19</xbrli:startDate>
			<xbrli:endDate>2019-03-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-26</xbrli:startDate>
			<xbrli:endDate>2019-12-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_EventOfDefaultMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:EventOfDefaultMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug1Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q3Aug1Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJanuary22020ConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-08-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:InitialConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-26</xbrli:startDate>
			<xbrli:endDate>2019-12-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-19</xbrli:startDate>
			<xbrli:endDate>2019-03-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">ino:AfterJuly22020ConversionPriceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-26</xbrli:startDate>
			<xbrli:endDate>2019-12-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q2June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorATMSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-05</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q1March9_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-03-09</xbrli:startDate>
			<xbrli:endDate>2020-03-09</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2June1June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorATMSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2Jan1June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorATMSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-06-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2020Q1Jan1_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_EmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorATMSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_EmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_EmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:EmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:PriorATMSalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_PlymouthMeetingPennsylvaniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_SanDiegoCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q1_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_ino_CaliforniaIncomeTaxAuthorityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_ino_PennsylvaniaStateIncomeTaxAuthorityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec1Dec31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-01-01</xbrli:startDate>
			<xbrli:endDate>2010-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-03-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2May_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-05-01</xbrli:startDate>
			<xbrli:endDate>2015-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Nov1Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-11-01</xbrli:startDate>
			<xbrli:endDate>2016-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q1Jan_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:GeneOneLifeSciencesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q1QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LicensewithAffiliatedEntitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2020Q1Feb7_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-02-07</xbrli:startDate>
			<xbrli:endDate>2020-02-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2020Q1Feb20_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-20</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2020Q1March11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-03-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="investment">
		<xbrli:measure>ino:investment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="segment">
		<xbrli:measure>ino:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="krw">
		<xbrli:measure>iso4217:KRW</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="product">
		<xbrli:measure>ino:product</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="day">
		<xbrli:measure>ino:day</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="lease">
		<xbrli:measure>ino:lease</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="vote">
		<xbrli:measure>ino:vote</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2019Q4YTD" id="Fact-0342DB0491D3CF9A928F8ED5FB03FDB1">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q4YTD" id="Fact-16005C4D6FEEC140AB2D8ED5FB1349A4">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q4YTD" id="Fact-9B64A993B35A0A040B5C8ED5FB1A368C">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q4YTD" id="Fact-8FD2F1A6978C86CEA6518ED5FB1270F1">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q4YTD" id="Fact-E9CEB90827EC9C1467B68ED5FB058BBA">2019-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q4YTD" id="Fact-25EB12E3E86E7EC7F7368ED5FB033C91">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q4YTD" id="Fact-D3ACE229E8D95ADD9F9C8ED5FAFFA073">0001055726</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2020Q1March11" decimals="INF" id="Fact-4E16ECCC3B47AC88A2128ED5FB14E2B4" unitRef="shares">145803086</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q4YTD" id="Fact-8720B84A366272FC027B8ED5FB0438EF">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q4YTD" id="Fact-9749F970AEA6067C9E1F8ED5FAFF0B09">false</dei:EntityEmergingGrowthCompany>
	<dei:EntityFilerCategory contextRef="FD2019Q4YTD" id="Fact-8082D0A13E6A82A4F3388ED5FB0043EE">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="I2019Q2June28" decimals="0" id="Fact-2B5EFFFFBA6583336B668ED5FA6FCF1E" unitRef="usd">279656181</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2019Q4YTD" id="Fact-E465E14F8DFEC05C594B8ED5FB188692">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q4YTD" id="Fact-68912870C5F2349A022E8ED5FB081EC4">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2019Q4YTD" id="Fact-765CD0F473521A4899698ED5FB0ACA0B">false</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2019Q4YTD" id="Fact-DA53EDD93EB8EBA45F888ED5FB0958D6">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2019Q4YTD" id="Fact-96A20771B48A5F542DEE8ED5FB16D4F0">No</dei:EntityWellKnownSeasonedIssuer>
	<ino:AccruedClinicalTrialExpenseCurrent contextRef="FI2018Q4" decimals="0" id="Fact-2268B33BEE613F9BDBB28ED5FABAA4C7" unitRef="usd">5671764</ino:AccruedClinicalTrialExpenseCurrent>
	<ino:AccruedClinicalTrialExpenseCurrent contextRef="FI2019Q4" decimals="0" id="Fact-42DD2BC2707266F2C5358ED5FB3A7CCE" unitRef="usd">4049727</ino:AccruedClinicalTrialExpenseCurrent>
	<ino:AccruedSubcontractExpenses contextRef="FI2018Q4" decimals="0" id="Fact-C4827F802F45C3B89BFE8ED5FB129CC5" unitRef="usd">83812</ino:AccruedSubcontractExpenses>
	<ino:AccruedSubcontractExpenses contextRef="FI2019Q4" decimals="0" id="Fact-18B9AC763B209CCC332A8ED5FB144CDA" unitRef="usd">273508</ino:AccruedSubcontractExpenses>
	<ino:AdjustmentForChangeInFairValueOfWarrantLiability contextRef="FD2017Q4YTD" decimals="0" id="Fact-0E1EA1A2A89290FD5E5E8ED5FB1DCA8F" unitRef="usd">-806819</ino:AdjustmentForChangeInFairValueOfWarrantLiability>
	<ino:AdjustmentForChangeInFairValueOfWarrantLiability contextRef="FD2018Q4YTD" decimals="0" id="Fact-1EF6C5EF15670963774E8ED5FB1DDF3F" unitRef="usd">0</ino:AdjustmentForChangeInFairValueOfWarrantLiability>
	<ino:AdjustmentForChangeInFairValueOfWarrantLiability contextRef="FD2019Q4YTD" decimals="0" id="Fact-64B8A5CD17C0E48560CC8ED5FB1E87A2" unitRef="usd">0</ino:AdjustmentForChangeInFairValueOfWarrantLiability>
	<ino:AmortizationOfOperatingLeaseRightOfUseAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-00EB3215B3975FC29847CF14FF83C68F" unitRef="usd">851760</ino:AmortizationOfOperatingLeaseRightOfUseAssets>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2017Q4YTD" decimals="0" id="Fact-D938DFE3D6259992BCFB8ED5FA88275D" unitRef="usd">806819</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2018Q1QTD" decimals="0" id="Fact-05396FEACA57B5B3DB558ED5FAAB4A33" unitRef="usd">-127841</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2018Q2QTD" decimals="0" id="Fact-02BC108E2295179E6A908ED5FB2B17DE" unitRef="usd">259971</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2018Q3QTD" decimals="0" id="Fact-8443EBF9A0A4FFE124E88ED5FB33791C" unitRef="usd">228665</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2018Q4QTD" decimals="0" id="Fact-FD8F436EB7B9BC1A8D448ED5FB347F74" unitRef="usd">0</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2018Q4YTD" decimals="0" id="Fact-00F7C74CC146514D9F4A8ED5FA75F8BB" unitRef="usd">360795</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInFairValueOfCommonStockWarrants contextRef="FD2019Q4YTD" decimals="0" id="Fact-42697E63DC52FDB782938ED5FA82444B" unitRef="usd">0</ino:ChangeInFairValueOfCommonStockWarrants>
	<ino:ChangeInValueOfCommonStockWarrants contextRef="FD2017Q4YTD" decimals="0" id="Fact-1095629EB50D1AA6B4388ED5FB27E511" unitRef="usd">-806819</ino:ChangeInValueOfCommonStockWarrants>
	<ino:ChangeInValueOfCommonStockWarrants contextRef="FD2018Q4YTD" decimals="0" id="Fact-EC12C06557508B59B1D38ED5FB2826F6" unitRef="usd">-360795</ino:ChangeInValueOfCommonStockWarrants>
	<ino:ChangeInValueOfCommonStockWarrants contextRef="FD2019Q4YTD" decimals="0" id="Fact-4F300B1D580430325D478ED5FAC3F455" unitRef="usd">0</ino:ChangeInValueOfCommonStockWarrants>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2017Q4YTD" decimals="0" id="Fact-543A96EA17F3783FA2248ED5FA76DEA0" unitRef="usd">-6982664</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2018Q1QTD" decimals="0" id="Fact-1A643739159660012AFC8ED5FB2DAB2A" unitRef="usd">2380423</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2018Q2QTD" decimals="0" id="Fact-4013104DBC6B94ED8DE48ED5FB3CBA13" unitRef="usd">-2092608</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2018Q3QTD" decimals="0" id="Fact-C5A7FF184DE67948C54C8ED5FB414C97" unitRef="usd">1017359</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2018Q4QTD" decimals="0" id="Fact-3616F008A9151475D28A8ED5FAA89667" unitRef="usd">-3293741</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2018Q4YTD" decimals="0" id="Fact-85CA51C91D8A722E67808ED5FA7D7F57" unitRef="usd">-1988567</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2019Q1QTD" decimals="0" id="Fact-406DAF7A9E9A10CF2ACA8ED5FAFF6953" unitRef="usd">-750103</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2019Q2QTD" decimals="0" id="Fact-431FF6EB2E2B9806D3F28ED5FB0B766C" unitRef="usd">-173212</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2019Q3QTD" decimals="0" id="Fact-8935CFCF08373DF930708ED5FAFE55C4" unitRef="usd">-485841</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2019Q4QTD" decimals="0" id="Fact-DC536AF47644DD9A5AF48ED5FB154C66" unitRef="usd">-1681401</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:ChangeInValueOfInvestmentsInAffiliatedCompany contextRef="FD2019Q4YTD" decimals="0" id="Fact-2FC25B4A2B0D71F3EDCE8ED5FA87AC0E" unitRef="usd">-3090557</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
	<ino:CollaborationAgreementAdditionalRevenueToBeAchieved contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-07C44064C8B8C46AC53B8ED5FA442BA3" unitRef="usd">20000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
	<ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-6" id="Fact-4DD149BEA3D37FE45582F713786F2F08" unitRef="usd">115000000</ino:CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones>
	<ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-6" id="Fact-C1C7D04AAF3AEA8666D6F71602C9F545" unitRef="usd">125000000</ino:CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones>
	<ino:CollaborationAgreementRoyaltyPeriod contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-E74C5711A9DD453A9D328ED5FA4B009C">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
	<ino:CollaborationAgreementTerritoryExpansionOptionPeriod contextRef="D2017Q4Dec29_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-6F634BC78E7F822D8CE08ED5FA46DB75">P3Y</ino:CollaborationAgreementTerritoryExpansionOptionPeriod>
	<ino:CollaborativeAgreementAdvisoryFees contextRef="FI2018Q1_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-D17CA9B278E9980DB4138ED5FAEE2E93" unitRef="usd">960000</ino:CollaborativeAgreementAdvisoryFees>
	<ino:CollaborativeAgreementCorporateIncomeTax contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-92C18D95E94386159E598ED5FA492B23" unitRef="usd">2200000</ino:CollaborativeAgreementCorporateIncomeTax>
	<ino:CollaborativeAgreementExpensesToReimburse contextRef="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-5" id="Fact-430AF30FDA4DB6C8C7E48ED5FA604159" unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
	<ino:CollaborativeAgreementForeignNonIncomeTaxes contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-E49C220B8A0F7537947D8ED5FAEC26D4" unitRef="usd">1400000</ino:CollaborativeAgreementForeignNonIncomeTaxes>
	<ino:CollaborativeAgreementFundingToBeReceived contextRef="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-6" id="Fact-502CB83AFA09E60D10958ED5FA456E8D" unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
	<ino:CollaborativeAgreementMilestonePaymentRevenueRecognized contextRef="D2017Q4Dec1Dec31_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-D0E0309DC32B9F97C5A68ED5FA45F9B5" unitRef="usd">2000000</ino:CollaborativeAgreementMilestonePaymentRevenueRecognized>
	<ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-7D4B9559B70D7B75842C8ED5FA4457A7">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
	<ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-0FB755E9C808ADEC7B288ED5FA462476">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
	<ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment contextRef="D2018Q2April11_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" id="Fact-55CAAA25452C36514D7F8ED5FA454F59">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
	<ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="D2015Q3Sept1Sept30_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-6A5D72556005A12EF4858ED5FAEB59BE" unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
	<ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-AE004CEE724324B570738ED5FAED67EF" unitRef="usd">23000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
	<ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-989A46675DCA91F6EAA08ED5FA4729C6" unitRef="usd">27500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
	<ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-6B6243E3BFE06F31F563123EF9C0F0A3" unitRef="usd">4300000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
	<ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-62D485AB64065A6A66EA8ED5FA4C5AD0" unitRef="usd">23000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
	<ino:CollaborativeAgreementsUpfrontPaymentReceived contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-D54A58062D0D4D64AAE58ED5FA459837" unitRef="usd">6300000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
	<ino:CollaborativeArrangementTerm contextRef="D2016Q1March1March31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" id="Fact-08C751094F31A15A292D8ED5FA5FA52C">P5Y</ino:CollaborativeArrangementTerm>
	<ino:CollaborativeArrangementTerm contextRef="FD2013Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" id="Fact-685FC2BC575A5DFFEFF18ED5FA5D9A8F">P20Y</ino:CollaborativeArrangementTerm>
	<ino:ComprehensiveIncomeLossTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C618A3E5AD1CA27333768ED5FA6EFDC4" unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
	<ino:ComprehensiveIncomeLossTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-6BBD7DD6269A6FB608A18ED5FA961086" unitRef="usd">2170000</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
	<ino:ComprehensiveIncomeLossTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-8159D1B9ACBAA1F22C858ED5FA97EF6B" unitRef="usd">-257000</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
	<ino:ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" decimals="INF" id="Fact-1C5F9679F2FE739030008ED5FA9DC4C5" unitRef="shares">6250</ino:ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion>
	<ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare contextRef="FD2019Q4YTD" decimals="2" id="Fact-F80460FF314218C19E5D8ED5FA944E82" unitRef="usdPerShare">27.20</ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare>
	<ino:ConvertiblePreferredStockThresholdConsecutiveTradingDays contextRef="FD2019Q4YTD" decimals="INF" id="Fact-6755F59812AFE75A5ECF8ED5FAA6C65C" unitRef="day">30</ino:ConvertiblePreferredStockThresholdConsecutiveTradingDays>
	<ino:ConvertiblePreferredStockThresholdTradingDays contextRef="FD2019Q4YTD" decimals="INF" id="Fact-4770F410F5AFC1B64B5E8ED5FAA79105" unitRef="day">20</ino:ConvertiblePreferredStockThresholdTradingDays>
	<ino:DebtInstrumentAccretionOfPremium contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-C355FB04F8A6FDCA57620B6B3F5FA1C4" unitRef="usd">227322</ino:DebtInstrumentAccretionOfPremium>
	<ino:DebtInstrumentAccretionOfPremium contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-B829356D4988C38E395D0B6D52C8E0CB" unitRef="usd">0</ino:DebtInstrumentAccretionOfPremium>
	<ino:DebtInstrumentConvertibleInternalRateOfReturn contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-BCF0F65CE281A6CE07C8CA441FA78B29" unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
	<ino:DebtInstrumentConvertibleInternalRateOfReturn contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-F3FC35D6CD81B662A44BCA4DDC2409FC" unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
	<ino:DebtInstrumentConvertibleInternalRateOfReturn contextRef="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_EventOfDefaultMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-66B163F13A2450171565889C40A95377" unitRef="number">0.08</ino:DebtInstrumentConvertibleInternalRateOfReturn>
	<ino:DebtInstrumentConvertibleInternalRateOfReturn contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-3559838C84B3F8A7A415889B89C38E96" unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
	<ino:DebtInstrumentConvertibleInternalRateOfReturn contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-5A985F9461FD5892444088AFAFACFC3A" unitRef="number">0.06</ino:DebtInstrumentConvertibleInternalRateOfReturn>
	<ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage contextRef="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-E7873CCAD3E78FD0B1A5889C24C0470C" unitRef="number">0.25</ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage>
	<ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-C78D6199299B26210EC688AFF1730AFE" unitRef="number">0.25</ino:DebtInstrumentConvertibleRequiredBondholderApprovalPercentage>
	<ino:DebtSecuritiesAvailableforSaleContractualMaturity contextRef="FD2018Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember" id="Fact-6922BD437332360337B28ED5FAC93F5C">P2Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
	<ino:DebtinstrumentAccruedInterest contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-FBB60C4AA5164EBCC8000B69CC0B9A19" unitRef="usd">1700833</ino:DebtinstrumentAccruedInterest>
	<ino:DebtinstrumentAccruedInterest contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-E9E9EB3C017BF82576C90B6C68D7F15F" unitRef="usd">38946</ino:DebtinstrumentAccruedInterest>
	<ino:DebtinstrumentAccruedInterest contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-85F6B14539212742B78C0B6D5FF34B1B" unitRef="usd">0</ino:DebtinstrumentAccruedInterest>
	<ino:DeferredGrantFundingCurrent contextRef="FI2018Q4" decimals="0" id="Fact-B6AAC360A363A27D6B3C8ED5FB375409" unitRef="usd">4165848</ino:DeferredGrantFundingCurrent>
	<ino:DeferredGrantFundingCurrent contextRef="FI2019Q4" decimals="0" id="Fact-2B16988AA95B941E86728ED5FA5AF1BD" unitRef="usd">6065212</ino:DeferredGrantFundingCurrent>
	<ino:DeferredGrantFundingCurrent contextRef="FI2019Q4_srt_CounterpartyNameAxis_ino_CoalitionforEpidemicPreparednessInnovationsMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-199AAB42C81EE4E3B38B8ED5FA4A85B1" unitRef="usd">5000000</ino:DeferredGrantFundingCurrent>
	<ino:DeferredGrantFundingFromAffiliate contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-3" id="Fact-0B417619DCB59ABF1CAD12B7A89C60C8" unitRef="usd">843000</ino:DeferredGrantFundingFromAffiliate>
	<ino:DeferredGrantFundingFromAffiliateCurrent contextRef="FI2018Q4" decimals="0" id="Fact-1343F8978F7C856745EA8ED5FAB34AC4" unitRef="usd">27083</ino:DeferredGrantFundingFromAffiliateCurrent>
	<ino:DeferredGrantFundingFromAffiliateCurrent contextRef="FI2019Q4" decimals="0" id="Fact-67CAE91B230AB7516A718ED5FAA81CDF" unitRef="usd">708425</ino:DeferredGrantFundingFromAffiliateCurrent>
	<ino:DeferredGrantFundingFromAffiliateNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-355F4C67674C38B6D766F583201E0F5D" unitRef="usd">0</ino:DeferredGrantFundingFromAffiliateNoncurrent>
	<ino:DeferredGrantFundingFromAffiliateNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-F92DAB9062F776626CE8F583202D63C1" unitRef="usd">135000</ino:DeferredGrantFundingFromAffiliateNoncurrent>
	<ino:DeferredRevenueFromAffiliatedEntityCurrent contextRef="FI2018Q4" decimals="0" id="Fact-0B88E7F8DB560CA11EFA8ED5FA5F68BB" unitRef="usd">33575</ino:DeferredRevenueFromAffiliatedEntityCurrent>
	<ino:DeferredRevenueFromAffiliatedEntityCurrent contextRef="FI2019Q4" decimals="0" id="Fact-99C51B2DA548930567F08ED5FAB0BF62" unitRef="usd">31775</ino:DeferredRevenueFromAffiliatedEntityCurrent>
	<ino:DeferredTaxAssetInterestExpense contextRef="FI2018Q4" decimals="-3" id="Fact-F6A7A44230BC21364F28AC13C1424AB9" unitRef="usd">0</ino:DeferredTaxAssetInterestExpense>
	<ino:DeferredTaxAssetInterestExpense contextRef="FI2019Q4" decimals="-3" id="Fact-C6D9FA65F86D4CDB3144AC13C123E031" unitRef="usd">1122000</ino:DeferredTaxAssetInterestExpense>
	<ino:DeferredTaxAssetsIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-2DBE25B56D777813B5988ED5FAF7DB4B" unitRef="usd">912000</ino:DeferredTaxAssetsIntangibleAssets>
	<ino:DeferredTaxAssetsIntangibleAssets contextRef="FI2019Q4" decimals="-3" id="Fact-F21ABD194A8CE0209A438ED5FADFE85C" unitRef="usd">889000</ino:DeferredTaxAssetsIntangibleAssets>
	<ino:DeferredTaxAssetsOperatingLeaseLiability contextRef="FI2018Q4" decimals="-3" id="Fact-C7342227153FFC54E73B8845D13F1B43" unitRef="usd">0</ino:DeferredTaxAssetsOperatingLeaseLiability>
	<ino:DeferredTaxAssetsOperatingLeaseLiability contextRef="FI2019Q4" decimals="-3" id="Fact-801B4FBF1E8F002C71678845D11FFAB6" unitRef="usd">4722000</ino:DeferredTaxAssetsOperatingLeaseLiability>
	<ino:DeferredTaxLiabilitiesFinancingArrangementDiscount contextRef="FI2018Q4" decimals="-3" id="Fact-F9AB269EDE2E000A988EAC17211895BB" unitRef="usd">0</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
	<ino:DeferredTaxLiabilitiesFinancingArrangementDiscount contextRef="FI2019Q4" decimals="-3" id="Fact-98F076C5E55382DCB059AC1720FF4164" unitRef="usd">2862000</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
	<ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-3" id="Fact-C326C3CB6044BA618846884506065737" unitRef="usd">0</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
	<ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset contextRef="FI2019Q4" decimals="-3" id="Fact-8C2DF80D1BCE03FD68F28845060A560B" unitRef="usd">2894000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
	<ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A4A4C3775551FF0E441B8ED5FA62DFAE" unitRef="usd">454000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
	<ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C66FF912B6918ADEA12E8ED5FAA0B24F" unitRef="usd">2176000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
	<ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F4E1CCF1882EE800DA308ED5FA9CC857" unitRef="usd">616000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
	<ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8243EAE4BF34193BD10B8ED5FAA22F25" unitRef="usd">0</ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount>
	<ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-89EA7BC6680B9D41BCE98ED5FA9D88BC" unitRef="usd">2170000</ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount>
	<ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A4ADFA811A41E805CC728ED5FA6C7565" unitRef="usd">0</ino:EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount>
	<ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AE6D499C3BE7B3331CEB8ED5FA6C483A" unitRef="usd">-165000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
	<ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4C9D234CD4D651A63C748ED5FA9E23C1" unitRef="usd">-2176000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
	<ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A655D1E43269B847B56D8ED5FA6403ED" unitRef="usd">-616000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
	<ino:EquityComponentOfConvertibleDebtIssued contextRef="FD2017Q4YTD" decimals="0" id="Fact-A38DC2A2204AF2BFFC77C031FABBA1DD" unitRef="usd">0</ino:EquityComponentOfConvertibleDebtIssued>
	<ino:EquityComponentOfConvertibleDebtIssued contextRef="FD2018Q4YTD" decimals="0" id="Fact-54B012892D0AC012B77BC031FAB60F9A" unitRef="usd">0</ino:EquityComponentOfConvertibleDebtIssued>
	<ino:EquityComponentOfConvertibleDebtIssued contextRef="FD2019Q4YTD" decimals="0" id="Fact-B6D6D474E4FAE816BEBAC03153FD54EE" unitRef="usd">15752698</ino:EquityComponentOfConvertibleDebtIssued>
	<ino:GoodwillAndIntangibleAssetsGross contextRef="FI2018Q4" decimals="0" id="Fact-15FCE6DFF7ADCD6B0D908ED5FAD759F4" unitRef="usd">35231244</ino:GoodwillAndIntangibleAssetsGross>
	<ino:GoodwillAndIntangibleAssetsGross contextRef="FI2019Q4" decimals="0" id="Fact-DDC061D099E6696C24138ED5FAC683CC" unitRef="usd">35231244</ino:GoodwillAndIntangibleAssetsGross>
	<ino:GoodwillAndIntangibleAssetsNet contextRef="FI2018Q4" decimals="0" id="Fact-ED7B2E1702004483DD2C8ED5FADAB35D" unitRef="usd">15273516</ino:GoodwillAndIntangibleAssetsNet>
	<ino:GoodwillAndIntangibleAssetsNet contextRef="FI2019Q4" decimals="0" id="Fact-563359EF6DE6572762F08ED5FACBC037" unitRef="usd">14207222</ino:GoodwillAndIntangibleAssetsNet>
	<ino:GrantProceedsReceived contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-5" id="Fact-BC1894FEBFFF62FF141D0AB28FC3432A" unitRef="usd">3300000</ino:GrantProceedsReceived>
	<ino:GrantProceedsReceived contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-5" id="Fact-D97A8D62B75F59BD7BA58ED5FA5C1218" unitRef="usd">2200000</ino:GrantProceedsReceived>
	<ino:IncomeTaxReconciliationFairValueWarrant contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D639B164BD56017AC7658ED5FA61E611" unitRef="usd">-282000</ino:IncomeTaxReconciliationFairValueWarrant>
	<ino:IncomeTaxReconciliationFairValueWarrant contextRef="FD2018Q4YTD" decimals="-3" id="Fact-209F7E99D629927BD1928ED5FA9F6EDB" unitRef="usd">-76000</ino:IncomeTaxReconciliationFairValueWarrant>
	<ino:IncomeTaxReconciliationFairValueWarrant contextRef="FD2019Q4YTD" decimals="-3" id="Fact-BE7B72941E5C05738CF08ED5FAA48A0A" unitRef="usd">0</ino:IncomeTaxReconciliationFairValueWarrant>
	<ino:IncomeTaxReconciliationStatuteLimitations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C4AF59AB693A77DE993E8ED5FA9A68E3" unitRef="usd">-3456000</ino:IncomeTaxReconciliationStatuteLimitations>
	<ino:IncomeTaxReconciliationStatuteLimitations contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E23876C405EFAD0553078ED5FA646235" unitRef="usd">-3170000</ino:IncomeTaxReconciliationStatuteLimitations>
	<ino:IncomeTaxReconciliationStatuteLimitations contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F347C642618AB82EC7108ED5FA623B3A" unitRef="usd">-3838000</ino:IncomeTaxReconciliationStatuteLimitations>
	<ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-9617466DFFA6D3C5C0618ED5FAC5252D" unitRef="usd">2243503</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
	<ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-7C258F236309DBC67D4D8ED5FA8D63AE" unitRef="usd">-2940128</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
	<ino:IncreaseDecreaseInAccruedClinicalTrialExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-597B2094FA937FD3FD848ED5FAABDAA2" unitRef="usd">-1622037</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
	<ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties contextRef="FD2017Q4YTD" decimals="0" id="Fact-81F8141698362D7A575B8ED5FA9C7FC2" unitRef="usd">-319876</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
	<ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties contextRef="FD2018Q4YTD" decimals="0" id="Fact-A568DB3ABD677D480A3E8ED5FAC13E84" unitRef="usd">-140535</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
	<ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties contextRef="FD2019Q4YTD" decimals="0" id="Fact-495EBEFA129427F003F48ED5FAC24F90" unitRef="usd">-1800</ino:IncreaseDecreaseInDeferredRevenueFromRelatedParties>
	<ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet contextRef="FD2019Q4YTD" decimals="0" id="Fact-BDC43A0A2B2434759359F64ABDCFB7D0" unitRef="usd">-1733599</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
	<ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="FD2017Q4YTD" decimals="0" id="Fact-17DF506C01E5A4AF9E498ED5FAC162BE" unitRef="usd">333583</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
	<ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="FD2018Q4YTD" decimals="0" id="Fact-464EEA0B68BC863825F98ED5FAAA90FB" unitRef="usd">-725202</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
	<ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="FD2019Q4YTD" decimals="0" id="Fact-5EA3A245856DEB0895218ED5FA8DDAA8" unitRef="usd">-70665</ino:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
	<ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="FD2017Q4YTD" decimals="0" id="Fact-FF661B6EEF5B86BC266E8ED5FB24AE60" unitRef="usd">0</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
	<ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="FD2018Q4YTD" decimals="0" id="Fact-4096817D6548892710A48ED5FAADF547" unitRef="usd">4165848</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
	<ino:IncreaseDecreaseinDeferredGrantFundingCurrent contextRef="FD2019Q4YTD" decimals="0" id="Fact-B1B73B525528295E975C8ED5FACF33FE" unitRef="usd">1899364</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
	<ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent contextRef="FD2017Q4YTD" decimals="0" id="Fact-A5A609350E67DBAB0DC68ED5FAAF66D3" unitRef="usd">0</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
	<ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent contextRef="FD2018Q4YTD" decimals="0" id="Fact-84209FAF48CCB1A24FEA8ED5FB26F241" unitRef="usd">27083</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
	<ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent contextRef="FD2019Q4YTD" decimals="0" id="Fact-60ABA9EBD4C59D8216608ED5FAC60263" unitRef="usd">816342</ino:IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent>
	<ino:IssuanceOfCommonStockForCashFinancingCosts contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D14E51DD4E92653144DE8ED5FB227472" unitRef="usd">4900000</ino:IssuanceOfCommonStockForCashFinancingCosts>
	<ino:LesseeNumberOfLeaseAgreementsEnteredInto contextRef="FD2019Q4QTD" decimals="INF" id="Fact-6A894AE8CDFED3CB76EAAC61832BB1C0" unitRef="lease">2</ino:LesseeNumberOfLeaseAgreementsEnteredInto>
	<ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="FD2019Q4QTD" decimals="-2" id="Fact-EBA44B0B43070F6FE383AC5E50B8C541" unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
	<ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="FD2019Q4YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_PlymouthMeetingPennsylvaniaMember" decimals="0" id="Fact-A0B758F3DEDDA704105F0A7BB64DA755" unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
	<ino:LesseeOperatingLeaseAreaofLandUnderLease contextRef="FD2019Q4YTD_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_ino_SanDiegoCaliforniaMember" decimals="0" id="Fact-72D61946C94D938F88F50A79687876A8" unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
	<ino:MilestoneBasedOwnershipTarget contextRef="D2015Q2May_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="INF" id="Fact-12CEEAF2B5AF15DD72F48ED5FA621C66" unitRef="number">0.35</ino:MilestoneBasedOwnershipTarget>
	<ino:MilestoneBasedOwnershipTarget contextRef="D2016Q1Jan_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="INF" id="Fact-B0CABC6B6581436EABAE8ED5FA5E172A" unitRef="number">0.35</ino:MilestoneBasedOwnershipTarget>
	<ino:NonCashInterestExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-E38921E3DFEBE9B78FA98ED5FA75C8C8" unitRef="usd">0</ino:NonCashInterestExpense>
	<ino:NonCashInterestExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-EDDF2C9122327EFAD5FC8ED5FA749906" unitRef="usd">0</ino:NonCashInterestExpense>
	<ino:NonCashInterestExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-B76CCD72B29DEE65A56E8ED5FA70F1C3" unitRef="usd">5230954</ino:NonCashInterestExpense>
	<ino:NumberOfAdditionalProducts contextRef="D2015Q3Aug7_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="INF" id="Fact-B26C404CBA56834A17218ED5FA491913" unitRef="product">2</ino:NumberOfAdditionalProducts>
	<ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan contextRef="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" decimals="INF" id="Fact-72809CECAF703A348B118ED5FA9C99B7" unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
	<ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" decimals="INF" id="Fact-45A3C182D3E146D5F54A8ED5FA94A851" unitRef="shares">2069936</ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan>
	<ino:NumberofVotesPerShare contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-E7AE282A7A2820C9AF568ED5FA9908A8" unitRef="vote">368</ino:NumberofVotesPerShare>
	<ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_ino_CaliforniaIncomeTaxAuthorityMember" decimals="-5" id="Fact-EA2695E3C56C8DC5D7CA8ED5FA588411" unitRef="usd">68600000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
	<ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_ino_PennsylvaniaStateIncomeTaxAuthorityMember" decimals="-5" id="Fact-7B31FD7D349B2DAB75108ED5FA5C56A3" unitRef="usd">80500000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
	<ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-E97713DCDB829187C2608ED5FAE95CA9" unitRef="usd">483300000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
	<ino:OperatingLossCarryforwardsExpiringinFiveYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-DFB4118F8619EC29DC4A8ED5FA5D6D23" unitRef="usd">282300000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
	<ino:OperatingLossCarryforwardsExpiringinFiveYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-1FD2DE42C1EBC081E9BF8ED5FA614A01" unitRef="usd">148100000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
	<ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-FC5222BD352BE9F36B3A8ED5FA6BDEBC" unitRef="usd">4500000</ino:OperatingLossCarryforwardsExpiringinFourYears>
	<ino:OperatingLossCarryforwardsExpiringinFourYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-ED53729124B998EC4D918ED5FA6C6BB7" unitRef="usd">400000</ino:OperatingLossCarryforwardsExpiringinFourYears>
	<ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-3D45819E49FE8D6C14BA8ED5FA6BD3E1" unitRef="usd">6000000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
	<ino:OperatingLossCarryforwardsExpiringinThreeYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-051DB6A3FBD3461523638ED5FAE99070" unitRef="usd">300000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
	<ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-C8915473CC9B7A11ECB88ED5FA602DBD" unitRef="usd">2300000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
	<ino:OperatingLossCarryforwardsExpiringinTwoYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-0C58083D8E3A1FA37DB28ED5FAC42F96" unitRef="usd">300000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
	<ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-949D30B39BA76F7F5D108ED5FAC342C9" unitRef="usd">1600000</ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths>
	<ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-80A1CDEEE04E7129C1ED8ED5FA63B771" unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringintheNextTwelveMonths>
	<ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-F03DEF79AA0C784DD23B8ED5FA647B62" unitRef="usd">186600000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
	<ino:OperatingLossCarryforwardsIndefinitelyCarryforward contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-11A26D359CBC1229EE628ED5FA64FBC3" unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
	<ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-ED95838722FC8508CFF38ED5FAC54530" unitRef="usd">-1452431</ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax>
	<ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-FC8F0A0899C04A8549848ED5FAD556F9" unitRef="usd">-1452431</ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax>
	<ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax contextRef="FD2018Q4YTD" decimals="0" id="Fact-C272F617D9B11170D3768ED5FAC69A57" unitRef="usd">0</ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax>
	<ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax contextRef="FD2019Q4YTD" decimals="0" id="Fact-F5E4AB02C5553C481DC28ED5FAC438A2" unitRef="usd">0</ino:OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax>
	<ino:PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion contextRef="FD2019Q4YTD" decimals="INF" id="Fact-E1F9742D89F3A596609F8ED5FA9818A2" unitRef="usdPerShare">72.00</ino:PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion>
	<ino:PreferredStockConversionNoticePeriod contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" id="Fact-5A0D05A7BA412C321C448ED5FA8BE5D1">P30D</ino:PreferredStockConversionNoticePeriod>
	<ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="FI2018Q4" decimals="0" id="Fact-915FE56413AE4050D4B98ED5FB35592F" unitRef="usd">1120805</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
	<ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity contextRef="FI2019Q4" decimals="0" id="Fact-581AA99FAEB5D0B307818ED5FAC02D3B" unitRef="usd">1050140</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
	<ino:ProceedsFromCollaborativeAgreement contextRef="D2018Q1March1March31_srt_CounterpartyNameAxis_ino_ApolloBioMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-1F072557A9BFE04CBCE48ED5FA46630D" unitRef="usd">19400000</ino:ProceedsFromCollaborativeAgreement>
	<ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="FD2017Q4YTD" decimals="0" id="Fact-73FEA8BF89695739526CF64E0598BF23" unitRef="usd">0</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
	<ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="FD2018Q4YTD" decimals="0" id="Fact-213414522567581224B3F64E05A2E9AC" unitRef="usd">0</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
	<ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings contextRef="FD2019Q4YTD" decimals="0" id="Fact-E85E3518D2116DACE8D0F64E059D728E" unitRef="usd">-780406</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
	<ino:ProceedsFromSubGrant contextRef="D2016Q4Nov1Nov30_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-5" id="Fact-2F9F3A5CFF06AAE791908ED5FA5D7F52" unitRef="usd">6100000</ino:ProceedsFromSubGrant>
	<ino:ProceedsfromStockOptionandWarrantExercises contextRef="FD2017Q4YTD" decimals="0" id="Fact-D0E854BA2F51D27593298ED5FB23A6BA" unitRef="usd">1342250</ino:ProceedsfromStockOptionandWarrantExercises>
	<ino:ProceedsfromStockOptionandWarrantExercises contextRef="FD2018Q4YTD" decimals="0" id="Fact-141D7DA33B4CC1B7DDD48ED5FAC17EC4" unitRef="usd">1809526</ino:ProceedsfromStockOptionandWarrantExercises>
	<ino:ProceedsfromStockOptionandWarrantExercises contextRef="FD2019Q4YTD" decimals="0" id="Fact-7E3935E3A6ABCD1A32C98ED5FABA7CFD" unitRef="usd">0</ino:ProceedsfromStockOptionandWarrantExercises>
	<ino:RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent contextRef="D2019Q3July1July30" decimals="2" id="Fact-E9FABEE2BC48779B2DB211A906CA6A83" unitRef="number">0.28</ino:RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent>
	<ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember" id="Fact-78BE016438AB470CB5768ED5FAA256D3">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
	<ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" id="Fact-6F1D1C4246E6B44729EB8ED5FAA6B727">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
	<ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm contextRef="FD2019Q4YTD" id="Fact-B8A0475550B439F3C5208ED5FAA5D1CA">P5Y8M0D</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm>
	<ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue contextRef="FD2019Q4YTD" decimals="-3" id="Fact-7CEA02FDBBE8E09913578ED5FA9A7814" unitRef="usd">918000</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue>
	<ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized contextRef="I2020Q1Jan1_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="INF" id="Fact-E8C017CF23C3F29E96AE8ED5FA9E9A01" unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
	<ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber contextRef="FI2019Q4" decimals="INF" id="Fact-E855DB1C45D630B9755D8ED5FA9E37DE" unitRef="shares">9265390</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber>
	<ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-139AE0FA529136C684DC8ED5FA8D76C1" unitRef="shares">2069936</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber>
	<ino:StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod contextRef="FD2018Q4YTD" decimals="INF" id="Fact-9971DFA786D43C3BBB638ED5FA9E1516" unitRef="shares">284091</ino:StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod>
	<ino:StockSaleAgreementAggregateNumberofSharesIssued contextRef="D2018Q2Jan1June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="INF" id="Fact-92368EA290267BB2E6F588310F709808" unitRef="shares">314950</ino:StockSaleAgreementAggregateNumberofSharesIssued>
	<ino:StockSaleAgreementAggregateNumberofSharesIssued contextRef="D2018Q2June1June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="INF" id="Fact-8D26927C451EDA2BC4318ED5FAA3942A" unitRef="shares">3911104</ino:StockSaleAgreementAggregateNumberofSharesIssued>
	<ino:StockSaleAgreementAggregateNumberofSharesIssued contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="INF" id="Fact-BC8A7525F3383947CDEE88312C1551FF" unitRef="shares">2937406</ino:StockSaleAgreementAggregateNumberofSharesIssued>
	<ino:StockSaleAgreementAggregateNumberofSharesIssued contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="INF" id="Fact-3CFD78B15518B96AB0BA8ED5FA8B72FD" unitRef="shares">3340678</ino:StockSaleAgreementAggregateNumberofSharesIssued>
	<ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="D2018Q2Jan1June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="-5" id="Fact-66CBA33030E9602FB19E88316AD2FFEE" unitRef="usd">1600000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
	<ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="D2018Q2June1June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="-5" id="Fact-A139C9777D502FD1F7FC8ED5FA7F90F9" unitRef="usd">32100000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
	<ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="FD2017Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="-5" id="Fact-436D238FDA23FF8339CD883168408664" unitRef="usd">24200000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
	<ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="-5" id="Fact-5B88C85730B6D08E529D8ED5FAA5D149" unitRef="usd">9100000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
	<ino:StockSalesAgreementAgentFee contextRef="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="3" id="Fact-B39A003E84B27FE4834A8ED5FA98F8D0" unitRef="number">0.030</ino:StockSalesAgreementAgentFee>
	<ino:StockSalesAgreementAgentFee contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="INF" id="Fact-BC92F055C3869E73E10EC5362387992B" unitRef="number">0.03</ino:StockSalesAgreementAgentFee>
	<ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="D2018Q2May1May31_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="INF" id="Fact-B21F48E295D1C20A10E08ED5FA934C1F" unitRef="usd">100000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
	<ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="D2020Q1Feb7_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="INF" id="Fact-1ED5408BAB931BD985E6C5351BE7B916" unitRef="usd">200000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
	<ino:StockSalesAgreementMaximumAuthorizedAmount contextRef="D2020Q1March9_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="INF" id="Fact-782206D9F42F12967089AC432964EC44" unitRef="usd">250000000.0</ino:StockSalesAgreementMaximumAuthorizedAmount>
	<ino:StockSalesAgreementRemainingAuthorizedSalesAmount contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="-5" id="Fact-C08DADF6EF3F18587AAE8ED5FAA02195" unitRef="usd">62800000</ino:StockSalesAgreementRemainingAuthorizedSalesAmount>
	<ino:TaxBenefitsExpired contextRef="FI2019Q4" decimals="-5" id="Fact-57B5787311EABB97576A8ED5FAEE6B0F" unitRef="usd">10600000</ino:TaxBenefitsExpired>
	<ino:TaxCreditCarryforwardCarryforwardIndefinitely contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-A2CE2058BB18830E1C698ED5FA654668" unitRef="usd">0</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
	<ino:TaxCreditCarryforwardCarryforwardIndefinitely contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-5E5E4D4F288675BAEEDA8ED5FAF518C5" unitRef="usd">3200000</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
	<ino:TaxCreditCarryforwardExpiringinFiveYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-786FD7F2F1011CE4828C8ED5FAEC3895" unitRef="usd">17300000</ino:TaxCreditCarryforwardExpiringinFiveYears>
	<ino:TaxCreditCarryforwardExpiringinFiveYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-43726C5DE9C242FECED58ED5FAE7FF22" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFiveYears>
	<ino:TaxCreditCarryforwardExpiringinFourMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-26D3740878F2B739B5358ED5FA6D997A" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFourMonths>
	<ino:TaxCreditCarryforwardExpiringinFourMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-59A5167919A5FEA977F88ED5FA6B55F6" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFourMonths>
	<ino:TaxCreditCarryforwardExpiringinThreeMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-BAF17A004E592A2684BE8ED5FACB59F2" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinThreeMonths>
	<ino:TaxCreditCarryforwardExpiringinThreeMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-9C7268A85163978ABC1E8ED5FA656EE2" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinThreeMonths>
	<ino:TaxCreditCarryforwardExpiringinTwoYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-63176BC9EC12549EF0DB8ED5FA655137" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
	<ino:TaxCreditCarryforwardExpiringinTwoYears contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-8B72F9143246F6F42B808ED5FAE66BB3" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
	<ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-931E14AB3C321C3C36BE8ED5FADE57D2" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths>
	<ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-145F438E5E45AD257F338ED5FA6CE15A" unitRef="usd">0</ino:TaxCreditCarryforwardExpiringintheNextTwelveMonths>
	<ino:WorkingCapital contextRef="FI2019Q4" decimals="-5" id="Fact-AC8FF575BDF2141D7D8B8ED5FAA6BFA4" unitRef="usd">62200000</ino:WorkingCapital>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-AC0CB0ED325B1BBF837B8ED5FA947A84" unitRef="usd">23134733</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2019Q4" decimals="0" id="Fact-E2B4EE3D787C373F5B988ED5FAB0F09E" unitRef="usd">18237258</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-7D04476F6F3562D992BD8ED5FB1508CF" unitRef="usd">10043816</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
	<us-gaap:AccountsPayableTradeCurrentAndNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-775B7AFCDE1E3955F1D68ED5FB113D3F" unitRef="usd">6919081</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
	<us-gaap:AccountsReceivableNet contextRef="FI2018Q4_srt_MajorCustomersAxis_ino_MedImmuneMember" decimals="-5" id="Fact-F281AF3216BAB71D5AAB8ED5FA4E819B" unitRef="usd">3200000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNet contextRef="FI2019Q4_srt_MajorCustomersAxis_ino_MCDCMember" decimals="-3" id="Fact-61FEDCCD87CF058526B888200A8DF7CA" unitRef="usd">469000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNet contextRef="FI2019Q4_srt_MajorCustomersAxis_ino_MedImmuneMember" decimals="-3" id="Fact-5DB1FFDB92C705A75ED78ED5FA4EB44B" unitRef="usd">161000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="0" id="Fact-CA6957BA53CD673EBF088ED5FB2DD029" unitRef="usd">3316361</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2019Q4" decimals="0" id="Fact-C03D0AE933ABB8573B648ED5FAB20D99" unitRef="usd">700073</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableRelatedParties contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="INF" id="Fact-005B0FFAA3C6A402CAE412B4EFEB3DE3" unitRef="usd">0</us-gaap:AccountsReceivableRelatedParties>
	<us-gaap:AccountsReceivableRelatedParties contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember" decimals="-3" id="Fact-AE609F49EBB7511737CC8ED5FA5F8A8E" unitRef="usd">478000</us-gaap:AccountsReceivableRelatedParties>
	<us-gaap:AccountsReceivableRelatedParties contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-3" id="Fact-F903BD077262E4BBD6758ED5FA5FAE06" unitRef="usd">258000</us-gaap:AccountsReceivableRelatedParties>
	<us-gaap:AccountsReceivableRelatedParties contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-F1F3DD5CFE2DE50324E512B4EFB36ADF" unitRef="usd">128000</us-gaap:AccountsReceivableRelatedParties>
	<us-gaap:AccountsReceivableRelatedParties contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember" decimals="-3" id="Fact-6507C3EF522A932D843B8ED5FA5D22EC" unitRef="usd">589000</us-gaap:AccountsReceivableRelatedParties>
	<us-gaap:AccountsReceivableRelatedParties contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-3" id="Fact-4911FFE948731595E3448ED5FA600DF4" unitRef="usd">616000</us-gaap:AccountsReceivableRelatedParties>
	<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-3084F619D0FC413AEEAC8ED5FA599FEC" unitRef="usd">738583</us-gaap:AccountsReceivableRelatedPartiesCurrent>
	<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="FI2019Q4" decimals="0" id="Fact-92B7693E170D5A89E8518ED5FABCE06C" unitRef="usd">1332044</us-gaap:AccountsReceivableRelatedPartiesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-D88EC0F9A16E895B5B728ED5FB12F389" unitRef="usd">9466821</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccruedSalariesCurrent contextRef="FI2019Q4" decimals="0" id="Fact-1D7B13F71FE36F8B1FBE8ED5FB13EB7F" unitRef="usd">8967897</us-gaap:AccruedSalariesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="0" id="Fact-97909CF5D9CBE29C0EA38ED5FAD1598A" unitRef="usd">9999919</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="0" id="Fact-31F145BE8C5B75EB01478ED5FAD571FA" unitRef="usd">1767653</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="0" id="Fact-9EEBAFD3EE73F275409F8ED5FACE9F1D" unitRef="usd">3464444</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" decimals="0" id="Fact-5466B2F303EC80ABF8828ED5FAD5ECCE" unitRef="usd">2425854</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" decimals="0" id="Fact-8E8B0E84C3BECBF5954C8ED5FAD501F0" unitRef="usd">2341968</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q4" decimals="0" id="Fact-CCA9747ACDA14F7FE31F8ED5FAD2163D" unitRef="usd">13166458</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="0" id="Fact-3997F43C26F3FC613EA88ED5FAD0FA24" unitRef="usd">1944293</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="0" id="Fact-FAEC08E69E2EB5F9355A8ED5FACBF9F8" unitRef="usd">4996777</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" decimals="0" id="Fact-54433D7632AEA4CFAAF68ED5FAD551F0" unitRef="usd">3229357</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" decimals="0" id="Fact-BCDD9A3B66CFAEA5742C8ED5FACC71EA" unitRef="usd">2996031</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1 contextRef="FD2019Q4YTD" decimals="-3" id="Fact-6DAAB864C35FA2974C04CA1BCC552152" unitRef="usd">432000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="0" id="Fact-AFAEE841D39F4E29C89D8ED5FABA9C0C" unitRef="usd">-528867</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q4" decimals="0" id="Fact-0A522738498D27C0C5FE8ED5FA60142F" unitRef="usd">472608</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="0" id="Fact-0F4AD2BC5E883CBBAF4E8ED5FB3E51CA" unitRef="usd">707794215</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2019Q4" decimals="0" id="Fact-EF62133A018654AF80598ED5FB405F52" unitRef="usd">742646785</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2019Q4YTD" decimals="0" id="Fact-08B4B14267DBEE17E95AF6306A3250BF" unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-5E838D12A39E01BE44C9F62F976B62B7" unitRef="usd">15752698</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="0" id="Fact-40DC23698502C23E74D18ED5FAEAFC03" unitRef="usd">13070962</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-A118F0B3DFF95E9B78EB8ED5FAEA5F8C" unitRef="usd">13070962</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD" decimals="0" id="Fact-502CF76EC1CFCA5B1BC78ED5FADF9AA2" unitRef="usd">10654622</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-265C4EC7C4ECFB58EDC68ED5FADCE0FB" unitRef="usd">10988277</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-740345A85019D93686938ED5FAD8D6C8" unitRef="usd">-333655</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q4YTD" decimals="0" id="Fact-66A7EE009B91CFF149C8F61DB2479BFA" unitRef="usd">10901320</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-62520935A62CE3572B10F61D14D87B99" unitRef="usd">10795403</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-A4B72D7314CF7FD60B2DF61DC4B23D89" unitRef="usd">105917</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember" decimals="-3" id="Fact-D3C7D8204572AD6847028ED5FA9BA07A" unitRef="usd">201000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember" decimals="-3" id="Fact-C49C331C7BCFFF80CDC88ED5FAA140A8" unitRef="usd">302000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember" decimals="-3" id="Fact-D372CFC385C85E13556C8ED5FA9C866C" unitRef="usd">970000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2018Q4" decimals="INF" id="Fact-E41A7955FE4DD8BEABAB8ED5FADBD88D" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="FI2019Q4" decimals="INF" id="Fact-96C6166B6C361EAADC9A8ED5FAA0E682" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-74DB7294D45292E2D6FA8ED5FAC49730" unitRef="usd">1618665</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="0" id="Fact-C9CEEAE771481FDF0B118ED5FB266EFE" unitRef="usd">1249584</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-BA163618900475949EBD8ED5FB281D15" unitRef="usd">1066294</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD" decimals="0" id="Fact-9E859F55075E295BF03A8ED5FA55153E" unitRef="shares">8937494</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-D8A42536A44048123492F6A70C8BE49B" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-1D25AEC8F9F330DBF612F6A70C466E2E" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-4965CDCAC20C49894189F6A70C4052DC" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-9F3B7E31D83C0F4F493D8ED5FA556596" unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-CC885E96500A97F8BE478ED5FA55DE81" unitRef="shares">7694870</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-31602FD61CBEA53E0A198ED5FA56DE47" unitRef="shares">1234168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD" decimals="0" id="Fact-6D24129AAE51C8E64DA78ED5FA53023D" unitRef="shares">10449150</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-68D14F26B975BFDC87F3F6A70C541089" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-1A2BF5DADDC8D4E76676F6A70C5D509C" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-FBBFB3071C21C4408615F6A70C6A53AD" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-6AB5D6862E08CF8625E88ED5FA55B55B" unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-3F29B880D5A511DDC2E78ED5FA548188" unitRef="shares">8752677</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-FADCB57FDF9F982797948ED5FA546712" unitRef="shares">1688017</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD" decimals="0" id="Fact-5D3B478B2E2A6D2F24828ED5FA56697C" unitRef="shares">30737956</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-99559A6DB9FD292B5900F6A70C3C954D" unitRef="shares">14585653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-9831CCBEA147762D2C30F6A70C7A2A72" unitRef="shares">3799071</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-749F4C5572AB8A8F5774F6A70C4C8882" unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertiblePreferredStockMember" decimals="0" id="Fact-809A49B1B07D777D47D58ED5FA5467AD" unitRef="shares">8456</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-97B04ED2FBC3A054FF698ED5FA54A851" unitRef="shares">9265390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-2CBB5852C12351D48AF68ED5FA567B4D" unitRef="shares">2069936</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="0" id="Fact-B585A41C53B5ED4F21378ED5FABC371A" unitRef="usd">131113265</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q4" decimals="0" id="Fact-A71E8CBBE5849FA7CCB88ED5FAB25591" unitRef="usd">143951597</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="0" id="Fact-F4A52F2B3C58252B68218ED5FAB3A5F3" unitRef="usd">87814824</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q4" decimals="0" id="Fact-6AB33885DE888E0F794C8ED5FAAB4F0A" unitRef="usd">94200969</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-BDE1E82F29EC44F1A1CE8ED5FB3F6BF7" unitRef="usd">19052420</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-CFC0851BF9166C709F848ED5FB4169CE" unitRef="usd">57538852</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-D69F231BE34FD6D7EDC08ED5FB40F00B" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-BF8D14A44FC98DA788C28ED5FB40BD78" unitRef="usd">76591272</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-85B9FA9049698730394C8ED5FB359567" unitRef="usd">8665085</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-F047D7A3B5DCFEF15CD08ED5FAEC2BF0" unitRef="usd">67338017</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-0A2C16FD03C4446A6E958ED5FAF071DF" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-87A6E08ACD116F28F8388ED5FB374A91" unitRef="usd">76003102</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4" decimals="0" id="Fact-D1BA3CB50314FA6EEDE28ED5FAFE328C" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-295C1666BE3A617C3DE78ED5FACBAFB5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember" decimals="0" id="Fact-7842C0127C01C8E8081A8ED5FB00DDCC" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-DCBB15684888A6AD04C38ED5FA8718F6" unitRef="usd">754709</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4" decimals="0" id="Fact-B31564413D7A765359C58ED5FAFE7613" unitRef="usd">528736</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-E53B4DD06C4715C2655B8ED5FB00727B" unitRef="usd">528084</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember" decimals="0" id="Fact-41860C5CC82F2AA5A0C18ED5FAFEA9B9" unitRef="usd">652</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-55BD717F627D988CAEA28ED5FA8AE46A" unitRef="usd">15911</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4" decimals="0" id="Fact-F0B58B8F6CB45D9F20248ED5FAFD8811" unitRef="usd">58067588</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-2257637D45ADDED1B1738ED5FA80670B" unitRef="usd">57842955</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember" decimals="0" id="Fact-B3E57C8102386F09CAE48ED5FAFC6B9A" unitRef="usd">224633</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-8023854716D44F93A0648ED5FA957BFA" unitRef="usd">66599219</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4" decimals="0" id="Fact-2B4B068238252D5303D28ED5FB0093E4" unitRef="usd">57538852</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-6BCEAD42EEA5C3C84DAB8ED5FB3EEB62" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-01431A5269CBEF3CE45B8ED5FB3E055C" unitRef="usd">223981</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-3F7CD0FC0D0B68EDDA058ED5FB3E7F46" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-E05311763C4A9AF18AD18ED5FB4112A9" unitRef="usd">223981</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-F019FEBEC47FA2C3B7D68ED5FA7D9758" unitRef="usd">57314871</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_DomesticCorporateDebtSecuritiesMember" decimals="0" id="Fact-56C85409E97725C813BD8ED5FB0103BD" unitRef="usd">223981</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-6251E409E241E76528AE8ED5FA89242C" unitRef="usd">67338017</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2017Q4YTD" decimals="0" id="Fact-412D48020924EBD605068ED5FB287D6F" unitRef="usd">1254117</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2018Q4YTD" decimals="0" id="Fact-8C55E6CDE816A0ACC4788ED5FB2766D1" unitRef="usd">559646</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2019Q4YTD" decimals="0" id="Fact-2F934AC1AF35A884690F8ED5FAADA033" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="0" id="Fact-A753060EFBEDF495CCF58ED5FAB250D1" unitRef="usd">23693633</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q4" decimals="0" id="Fact-142A1E23FC3BDE2557B38ED5FABACD0F" unitRef="usd">22196097</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-0AF10C374C71B33EB2568ED5FA571EDD" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-FD7DB86F7A65EE8C66C28ED5FB3E4BFE" unitRef="usd">9646507</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-96D53AA449AB9F73B45F8ED5FB422453" unitRef="usd">57314871</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-FA2A394DFDEBB3A35BCE8ED5FB40E310" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-671B3FDBCA44D992E8E98ED5FB3FBA72" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-F56E3555E625CC7049A78ED5FA57FD12" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-ED941AF44D751B0B0A928ED5FA5885DD" unitRef="usd">57314871</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-7E4C79B1C657E78D2B448ED5FB4054D3" unitRef="usd">9646507</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-10050E3982050E77375C8ED5FAE8C641" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-F04336DE98EFDEAFDDF28ED5FB360BEF" unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-4BA535666DE4E5E26D488ED5FAEE4B58" unitRef="usd">67338017</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-67A6581AE33EA653FBE98ED5FB35D3D4" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-7DD76CC3DECA722F834F8ED5FB3735AE" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-959AE40BD7D4951A107C8ED5FB36D9DB" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_ino_MutualFundsMember" decimals="0" id="Fact-69E507BB3DEC030ADE848ED5FB363EA8" unitRef="usd">67338017</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" decimals="0" id="Fact-0823CA1ED5F203C4AA948ED5FAEDF83D" unitRef="usd">2349729</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="FI2019Q4" decimals="-5" id="Fact-A457C6CC7CDB839BEC9E8ED5FAAA4B34" unitRef="usd">89500000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2016Q4" decimals="0" id="Fact-602CD03E59FA1E4C92178ED5FB244868" unitRef="usd">19136472</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="0" id="Fact-E8FE3EA7077775315F188ED5FA9D73AF" unitRef="usd">23786579</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="0" id="Fact-85994481A79CE76EA1D98ED5FAC18FCA" unitRef="usd">23693633</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q4" decimals="0" id="Fact-390EE5906ECAE2DF29328ED5FA9FE73B" unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2017Q4YTD" decimals="0" id="Fact-7D316C49112C42FE7B4F8ED5FB2949FE" unitRef="usd">4650107</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2018Q4YTD" decimals="0" id="Fact-8863262586501B8EE4998ED5FB2398F9" unitRef="usd">-92946</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="FD2019Q4YTD" decimals="0" id="Fact-8438DDB42A90C5AD9B2D8ED5FB26A611" unitRef="usd">-1497536</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-1937DD14C4A535B4A44012842EB1B381" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-3D7B665D0E191EB42E818ED5FA8DDC38" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-DDFC5B715EED2050046E8ED5FB3C28CE" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q4" id="Fact-06CA4853413AEAE516478ED5FABDE5E7" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockOtherSharesOutstanding contextRef="FI2019Q4_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember" decimals="INF" id="Fact-5E28968E927490CE5CD48ED5FAA126B1" unitRef="shares">4767654</us-gaap:CommonStockOtherSharesOutstanding>
	<us-gaap:CommonStockOtherSharesOutstanding contextRef="FI2019Q4_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" decimals="INF" id="Fact-1DDD9376ABEEC82118A28ED5FA99399D" unitRef="shares">4497736</us-gaap:CommonStockOtherSharesOutstanding>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-76757C4553174010AC2C8ED5FA86AB84" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q4" decimals="INF" id="Fact-2E9E7C4E6EFCEE71E5A18ED5FA8688CE" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-EFC9F182A8A1B07081658ED5FA8604C9" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q4" decimals="INF" id="Fact-9D654174BCF26EED8F148ED5FA83EBA9" unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-810A18F99DE3A3675E378ED5FA7DD989" unitRef="shares">97225810</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-1AB41D36FA309F4D5DF28ED5FA7CB74D" unitRef="shares">101361034</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-6CB87B36FC6BE0A23EE88ED5FA867C82" unitRef="shares">97225810</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-BE5E0C2EA8093E9CEC668ED5FA7A3861" unitRef="shares">101361034</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="0" id="Fact-0D0A4B533C1B8BBB7C308ED5FAACF6C2" unitRef="usd">97226</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q4" decimals="0" id="Fact-DED9A91268193C623D5C8ED5FA615039" unitRef="usd">101361</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-57D21322E22869F741668ED5FB239C24" unitRef="usd">-89650745</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="0" id="Fact-ED8E99EC00A28C3BCD0E8ED5FB210C01" unitRef="usd">-97148326</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q4YTD" decimals="0" id="Fact-D22703D3A90B7996FC698ED5FB1F2205" unitRef="usd">-118357744</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="0" id="Fact-D3EA55D04D7D99D08B088ED5FB222CA8" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="0" id="Fact-BA4A6CFF9D5393D545708ED5FB225B88" unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="FD2019Q4YTD" decimals="0" id="Fact-EA30257920EAA170975B8ED5FB227FD9" unitRef="usd">-1192558</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="0" id="Fact-56DF9297EE32A283A82F8ED5FAC65135" unitRef="usd">-89650745</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="0" id="Fact-2D7B6E8DC36AED6793828ED5FAC7EA5A" unitRef="usd">-97148326</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="FD2019Q4YTD" decimals="0" id="Fact-235BE10FE82277315F618ED5FAC3D936" unitRef="usd">-119550302</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-95B7B7076518D45112F58ED5FA553111" unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-B0A8031A36DFAF8B96A18ED5FA54F246" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-067EAD4E2A0BFF7D966D8ED5FA56A355" unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-B48D7D290C40FFA1E86F8ED5FAA7C7DD" unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-786FA110627B6705F4818ED5FA9708BC" unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-86B666115B8556A24CBA8ED5FA57EFEB" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-A27DD36478EB92611C018ED5FA934A3F" unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-06226889048D597999188ED5FA975075" unitRef="number">0.75</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-30639BF6157A640228748ED5FA96C11C" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-23B2017BF984D1EB784E8ED5FA523D6C" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-93BD21D58E7361A877458ED5FA4FBEE2" unitRef="number">0.98</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-E852EE495B6F47F245668ED5FA52419B" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2018Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-EA2E18FB9147CCB0C1088ED5FA8D7058" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-EF660B32AB79F299CCFC8ED5FA562C85" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-260E8B0493C40B6568EE8ED5FA5268C6" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-AD8ACD71B650452A9F058ED5FA5477D2" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-2FF4DCACE91B2852DA398ED5FA9747D6" unitRef="number">0.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MCDCMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-A6E9004580CFE105566888202EAFF742" unitRef="number">0.67</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-2B03A0977CC5705C12D28ED5FA4E00D7" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-B64DF750C1017371E75F8ED5FA533CA5" unitRef="number">0.78</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2019Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" decimals="2" id="Fact-CC5608A7C0CCF1ED15B18ED5FAA47AD5" unitRef="number">1.00</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ContractWithCustomerAssetNet contextRef="FI2018Q4_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-FF9A6A44C6631FC3A5ED8ED5FA47D64D" unitRef="usd">3200000</us-gaap:ContractWithCustomerAssetNet>
	<us-gaap:ContractWithCustomerAssetNet contextRef="FI2019Q4_srt_CounterpartyNameAxis_ino_MedImmuneMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-B7AAE06D3563EB01ACAD8ED5FA4C402D" unitRef="usd">200000</us-gaap:ContractWithCustomerAssetNet>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2018Q4" decimals="0" id="Fact-5346A8BE5D1AA94CC05A8ED5FB39F4AC" unitRef="usd">223577</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="FI2019Q4" decimals="0" id="Fact-1B4BD53D02350DED1C2F8ED5FAC042C1" unitRef="usd">92353</us-gaap:ContractWithCustomerLiabilityCurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-ACD8D318CD41F834A1D08ED5FB33287A" unitRef="usd">150793</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-6F6C828BF041E21D93A28ED5FB2B4011" unitRef="usd">101567</us-gaap:ContractWithCustomerLiabilityNoncurrent>
	<us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="FD2018Q4YTD" decimals="-5" id="Fact-7DFB0B5C11A33E9B85188ED5FAC15BE3" unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
	<us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="FD2019Q4YTD" decimals="-3" id="Fact-98287A0CFC17C2F80F468ED5FAC08FBC" unitRef="usd">293000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
	<us-gaap:ConvertibleDebt contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-6285147F90D0925D4EE1F1EA3194B56B" unitRef="usd">0</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertibleDebt contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember" decimals="0" id="Fact-CC046512ECA12FA6501DF1F4659E0A83" unitRef="usd">0</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertibleDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-CF48D78725FC10608642F1EA31AC407A" unitRef="usd">64180325</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertibleDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_ConvertibleBondsMember" decimals="0" id="Fact-46087F88E19C501DAFE3F1F465A57130" unitRef="usd">12842592</us-gaap:ConvertibleDebt>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-07359CAF0F424E7F79C28ED5FAA0A831" unitRef="shares">8456</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2017Q1Jan1" decimals="0" id="Fact-D55CA09D740D957CB4C28ED5FAE94514" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-60AB4B23715EDA06D6FBCF2E873DEDF0" unitRef="usd">312000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-C93B91485819D997ABDB8ED5FADE0EEC" unitRef="usd">312310</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-88EA0BE9D5CBC2CA36D68ED5FAFB3360" unitRef="usd">-312310</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2017Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B3C58BEE54A93E3D557CCF2A702F25B0" unitRef="usd">-312000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Jan1" decimals="0" id="Fact-6465C62ED180DBC0DCD28ED5FAE8722F" unitRef="usd">0</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-8EBC099A7DE4E2D7396A8ED5FAD83B10" unitRef="usd">-231366</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-1EF64ACC9D2D6FD32A9ACF2B0477770C" unitRef="usd">-231000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-6EBF28763E8A0B91F4838ED5FAFABFD5" unitRef="usd">231366</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="I2018Q1Jan1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-5EF2202F49B0DEEC52A6CF2EF1A0D749" unitRef="usd">231000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F794D2CC8622B44F05BC8ED5FAADE926" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-14944B1814E0184B25A68ED5FAB043BA" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-063EDC0F7A21C82DDCB58ED5FA501DA2" unitRef="usd">4000</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CCF0618CD40E66C5E7C38ED5FAB444DD" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3FBFC0D79E141A976CE68ED5FA71B1A1" unitRef="usd">2170000</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D4E2C1DC6FC50667CE598ED5FA51EE2E" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AC51C6720A65FF364F038ED5FB052470" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-76A137F03514254E04808ED5FB18C7F7" unitRef="usd">2170000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-3B2DB3DD3088AA60C01A8ED5FA4C37CC" unitRef="usd">6000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-60512C1F9BDF8606856C8ED5FB04CCEC" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D17E0D9F8313273B8FAA8ED5FAA5009B" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-05A1ED36E472F8F9588F8ED5FA4E00E2" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-523B5133C4A1228BA6A6889C60E8EDD3" unitRef="usd">7100000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="FI2019Q4" decimals="2" id="Fact-A5792A60BA9EC2F6CD6E0B7CD8347989" unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2019Q3Aug1_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="2" id="Fact-9AA72CEB73801A22019B889BDD4B529E" unitRef="usdPerShare">2.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2019Q3Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="2" id="Fact-A1790B1B828C9898B2B9889BB98096D6" unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2019Q4Dec26_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="2" id="Fact-9E1D349E4DEB4119075A88B17A7C273B" unitRef="usdPerShare">2.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="I2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="2" id="Fact-EE3C0015A861EE4463B988B0F9E2F6D0" unitRef="usdPerShare">4.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="7" id="Fact-87A66DA9EB88E0584CF588CB9683D726" unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2019Q3Aug1Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJanuary22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="10" id="Fact-550AB7207E3918B3109788CB58E8ECB6" unitRef="number">0.0003517658</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2019Q3Aug1Aug1_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="10" id="Fact-AD8E837A80A2BC3E6DC288CB5092387B" unitRef="number">0.0002110595</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_AfterJuly22020ConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="10" id="Fact-E703AEEA73F4162D29F488CCDE5A5F28" unitRef="number">0.0003579611</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleConversionRatio1 contextRef="D2019Q4Dec26_us-gaap_DebtConversionByUniqueDescriptionAxis_ino_InitialConversionPriceMember_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="10" id="Fact-7C37C4126037631C561988CCDAD459DF" unitRef="number">0.0002147766</us-gaap:DebtInstrumentConvertibleConversionRatio1>
	<us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 contextRef="FD2019Q4YTD" decimals="INF" id="Fact-5E9B6BC8D39904007F100B818990CD6D" unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
	<us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="FD2019Q4YTD" decimals="INF" id="Fact-79A0C1FD59F887D073B20B7D7DAD0C25" unitRef="number">1.3</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
	<us-gaap:DebtInstrumentConvertibleThresholdTradingDays contextRef="FD2019Q4YTD" decimals="INF" id="Fact-CBAC04F22CFC7E64D76E0B7DF4CF7BCC" unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="INF" id="Fact-1B774E2BACB17F6E30740B688E8A9DC9" unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-27015276633909545FE58ED5FABB99C9" unitRef="usd">78500000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="INF" id="Fact-41284DBAB32E6252E8EA0B6AC2D535FC" unitRef="usd">15578211</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-51A6E46C1D621262374A889A70876E2A" unitRef="krw">18000000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-1929F7C71D0EECE216AA889A92B23551" unitRef="usd">15000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="INF" id="Fact-7F5868AB7B30614187320B6D270D0974" unitRef="usd">4067644</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-61DE36E8B6C57506271188ADB7AD02E9" unitRef="krw">4700000000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-111B37C95F6E9C3F0D4F88AE6050F719" unitRef="usd">4100000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="INF" id="Fact-ED2A05C38E569D2D1B4E0B71B6E2B383" unitRef="usd">78500000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-AFF2A1267BA0A7B01A0A88964181E7B2" unitRef="usd">78500000.0</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2019Q4" decimals="3" id="Fact-C7C14B2AAA13A54AD4880B8598DB1B57" unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="3" id="Fact-7EF050C0D14DD26972C9889CC2522F2F" unitRef="number">0.294</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="3" id="Fact-C75D0F2EE4F834E82813CAD08F12A9A9" unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="INF" id="Fact-8C8F3C4DDDAE9C8FC0D2888C995FEDA0" unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-CAFEBECD567FA7C041A18ED5FABE8E52" unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-CF73B37D865704F096BE11A8B00D1E10" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-749629E02C727D3C5F208811276776F6" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2019Q1March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="INF" id="Fact-73F55C929D182F2E24A60B77495C2C13" unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-5963EAD93D7FB4123C30889AD4E77F1A" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="INF" id="Fact-726489DE2AF5E42F20F288AED7335F35" unitRef="number">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="FD2019Q4YTD" decimals="INF" id="Fact-92A4EFB0CA4C6A5036480B825CDD5E37" unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2019Q4" decimals="-5" id="Fact-F3E1149A282F3F6CAA930B850C74DCF6" unitRef="usd">18600000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-1DAB25911EDAC790D1E20B693EA57094" unitRef="usd">14082302</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-FCACC8FE95E8AF6E31E20B6AF1AF0493" unitRef="usd">6764346</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="I2019Q3Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-9DAB8FF9F050D21E22FE889CA16957F7" unitRef="usd">7300000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="FI2019Q4" decimals="-3" id="Fact-71DF883A61938B26C7918ED5FA46CC5D" unitRef="usd">11000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions contextRef="FI2019Q4" decimals="INF" id="Fact-191B7C102A29D8675A728ED5FA4893B9" unitRef="investment">2</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7B0E3BC6AB85381027448ED5FA47FA45" unitRef="usd">20000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C0C7A80E3025AD5BC34E8ED5FA471C4F" unitRef="usd">594000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="FD2018Q4YTD" decimals="-5" id="Fact-8CD2D0D7E545AC4E3E47CA162B018D0B" unitRef="usd">1300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="FD2019Q4YTD" decimals="-3" id="Fact-965B669FF6C7E2C021F2CA162A1E9BD1" unitRef="usd">118000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
	<us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions contextRef="FI2019Q4" decimals="INF" id="Fact-2D2C0BC1032CB92A509D8ED5FA48EB66" unitRef="investment">4</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" id="Fact-F40FE0631D1C4650A7238ED5FAB03448" unitRef="usd" xsi:nil="true" />
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B678AE365CA99F5B61348ED5FA4B9DA9" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C9D6BB42D39A39C831718ED5FA506F63" unitRef="usd">-263000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2019Q4" decimals="-5" id="Fact-70E8CF5BE743377849CA0B8481AB5216" unitRef="usd">2800000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-745A507C75706A3C7AD40B6970AF81F3" unitRef="usd">1938206</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-9724EF14AFE4E552673D0B6B1C05E69D" unitRef="usd">255185</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-AA295DCC051456A811890B6D43AAD520" unitRef="usd">50000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D594D49A28E66528E5AF8ED5FA50DC96" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9C4DA59BBBC010AEFB778ED5FA4DFCB0" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-3A6A9957385BCAEA6BE98ED5FA4E82B6" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9490F1502180B3F9EDA28ED5FB0ADDC3" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A004088E7A5C4597571C8ED5FB192FC0" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D51AEE58A98692CDEE978ED5FA548A89" unitRef="usd">-263000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="0" id="Fact-49497A72A583411C316E8ED5FAB3F47C" unitRef="usd">24766</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2019Q4" decimals="0" id="Fact-5D5EDDD08E13BF56B8D48ED5FA625FC3" unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredRentCredit contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-5" id="Fact-26AA7EC10B19FC0756C811B2ACEAE063" unitRef="usd">-9600000</us-gaap:DeferredRentCredit>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2018Q4" decimals="0" id="Fact-E2EE43B851BD3EA4E0988ED5FAA6125A" unitRef="usd">1065387</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2019Q4" decimals="0" id="Fact-A8A8867EF9C7FDB166FC8ED5FA5D0E32" unitRef="usd">0</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="0" id="Fact-A36EF49CED3810B4380DF6C559AE643F" unitRef="usd">-1065387</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" decimals="0" id="Fact-9808383E7A8F3F2062DAF6C55979DE95" unitRef="usd">1065387</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-AA9E5B54039312C116E28ED5FAB92DB9" unitRef="usd">8518207</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-0B6F2A8A48DD9EA188568ED5FABB0F21" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="0" id="Fact-A8EEEA54B36C79C24988F6C6339A0FBC" unitRef="usd">-8518207</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_ScenarioPreviouslyReportedMember" decimals="0" id="Fact-26ABD21892117EB9CFB4F6C633A07633" unitRef="usd">8518207</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D399364DD91738D0932B8ED5FA52F62D" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-37DFC1B5471E9F9CBFC88ED5FA9DFA5C" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-FCB2F519FEA9AB8493268ED5FA8D0D47" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2018Q4" decimals="-3" id="Fact-E91DB82323D6B17CC90A8ED5FAFEDE3E" unitRef="usd">985000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2019Q4" decimals="-3" id="Fact-CD9BE61432A3DFBC66108ED5FA59A444" unitRef="usd">1506000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="FI2018Q4" decimals="-3" id="Fact-088BDE035EA48C731923AC0F5BD3CCBF" unitRef="usd">0</us-gaap:DeferredTaxAssetsDerivativeInstruments>
	<us-gaap:DeferredTaxAssetsDerivativeInstruments contextRef="FI2019Q4" decimals="-3" id="Fact-6522AC1E5065A09FAC0CAC0F5BD8CE0C" unitRef="usd">1852000</us-gaap:DeferredTaxAssetsDerivativeInstruments>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2018Q4" decimals="-3" id="Fact-DCBBFB57A30E4A2183048ED5FA5C4623" unitRef="usd">116250000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2019Q4" decimals="-3" id="Fact-1288D5044D0BF61FF4BC8ED5FAFDBAA3" unitRef="usd">145229000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2018Q4" decimals="-3" id="Fact-43EE31323F7D4E96625B8ED5FB16B7E9" unitRef="usd">7408000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="FI2019Q4" decimals="-3" id="Fact-B69BFECB2349D8D45EA68ED5FB1769FA" unitRef="usd">6300000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
	<us-gaap:DeferredTaxAssetsInvestments contextRef="FI2018Q4" decimals="-3" id="Fact-DFC9201072CA84D84794AC104ADEF31A" unitRef="usd">0</us-gaap:DeferredTaxAssetsInvestments>
	<us-gaap:DeferredTaxAssetsInvestments contextRef="FI2019Q4" decimals="-3" id="Fact-58C50346E4DE305ADC51AC104AF15CA0" unitRef="usd">645000</us-gaap:DeferredTaxAssetsInvestments>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-A329AAC8554C4DE6A8D48ED5FAE69B99" unitRef="usd">1243000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2019Q4" decimals="-3" id="Fact-7B192B92416B46F04EA48ED5FACF8692" unitRef="usd">8070000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-B25CFE19C12F3E9305AC8ED5FB173F6E" unitRef="usd">89399000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2019Q4" decimals="-3" id="Fact-639BC9D6938856DC15998ED5FB0800B7" unitRef="usd">110788000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2018Q4" decimals="-3" id="Fact-31EEB58D91A9BE78F4F68ED5FB16C9E6" unitRef="usd">2693000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2019Q4" decimals="-3" id="Fact-C253C3BF1ED8C87E53D88ED5FB18B819" unitRef="usd">2413000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-CE4F562402C7297B48BC8ED5FACDD481" unitRef="usd">9432000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
	<us-gaap:DeferredTaxAssetsOtherTaxCarryforwards contextRef="FI2019Q4" decimals="-3" id="Fact-282FF707764AABD5DFF88ED5FB179A7E" unitRef="usd">11737000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q4" decimals="-3" id="Fact-AC4A0A538C376F8695518ED5FAFBFCC6" unitRef="usd">3408000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2019Q4" decimals="-3" id="Fact-7ADF98FDECBD9274C4778ED5FAEA0262" unitRef="usd">3255000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2018Q4" decimals="-3" id="Fact-FF69FF0FABB9532F6A438ED5FADE4F58" unitRef="usd">2013000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2019Q4" decimals="-3" id="Fact-AB20FD2D7F290F2894438ED5FAFC2944" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-02B934C80C812CDABF788ED5FABBF943" unitRef="usd">115007000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2019Q4" decimals="-3" id="Fact-B6CC8B3B6A64C27F79A68ED5FAA8FD1F" unitRef="usd">137159000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-5BB6DBCD593E0BCF18358ED5FA59511D" unitRef="usd">24000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2019Q4" decimals="-3" id="Fact-CD3001ACA8E2238B606B8ED5FB06A3E8" unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="FI2018Q4" decimals="-3" id="Fact-1D05335F250B0931124A88440A4B097A" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
	<us-gaap:DeferredTaxLiabilitiesFinancingArrangements contextRef="FI2019Q4" decimals="-3" id="Fact-42C5AD719D3337F8187688440A534A63" unitRef="usd">1381000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-DFE783AC0AB1BCA18E4A8ED5FAF7B84C" unitRef="usd">142000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2019Q4" decimals="-3" id="Fact-D9D61909776CFA24C5168ED5FB06E985" unitRef="usd">160000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates contextRef="FI2018Q4" decimals="-3" id="Fact-A7249513E5FE39720F9B8ED5FB04F8D8" unitRef="usd">4000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
	<us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates contextRef="FI2019Q4" decimals="-3" id="Fact-33299B4B303AD83C5D178ED5FAE1B0F9" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-83006852254D8271EC3B8ED5FADF43BE" unitRef="usd">1121000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2019Q4" decimals="-3" id="Fact-3126BA618D48691B3D9C8ED5FA5958EA" unitRef="usd">805000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2017Q4YTD" decimals="-3" id="Fact-75017844B5919B700C508ED5FA95B230" unitRef="usd">822000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2018Q4YTD" decimals="-5" id="Fact-26A0E94D24B6ADD1B98B8ED5FA947D2A" unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2019Q4YTD" decimals="-5" id="Fact-E29B41EF6835AA23FD9D8ED5FA94A4CD" unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="FD2019Q4YTD" decimals="INF" id="Fact-05707C045F754337FAA48ED5FA93B93A" unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
	<us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch contextRef="FD2019Q4YTD" decimals="INF" id="Fact-261CA43C1A3678207D158ED5FAC1B1B8" unitRef="number">0.5</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="0" id="Fact-C04B0B2EB6E2CCD6F57C8ED5FAC29057" unitRef="usd">1850376</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2018Q4YTD" decimals="0" id="Fact-2A7E6309949E5CFFD7308ED5FB23DD87" unitRef="usd">3747183</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2019Q4YTD" decimals="0" id="Fact-D310377FC5B9CA80E4758ED5FAA9D3C1" unitRef="usd">3598388</us-gaap:Depreciation>
	<us-gaap:DerivativeLiabilities contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-C663379C55B238DAD14C889D24E13402" unitRef="usd">8800000</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilities contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-5" id="Fact-D49842D9AA15F546B44987EC39D1D84B" unitRef="usd">7100000</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilities contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-F1DA69473FF5F4DC868E8ED5FAA7CD63" unitRef="usd">0</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilities contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-87ED4BA598F38C1FDFB08ED5FAAE0B96" unitRef="usd">0</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilities contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-AE34C762D950AD2C800B8ED5FAA12C1D" unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilities contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-2EC22D207968734408678ED5FAB0D7EE" unitRef="usd">8819023</us-gaap:DerivativeLiabilities>
	<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-78F38D2D2C1DA1DE2973F57F0BF5F9D5" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
	<us-gaap:DerivativeLiabilitiesNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-87E48AD9E33A8DD69EB7F57F0BFC709A" unitRef="usd">8819023</us-gaap:DerivativeLiabilitiesNoncurrent>
	<us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-752529F39BF3EEBA82A38ED5FA609153" unitRef="usd">372000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-8A576E28DF00D9BB33128ED5FA6171A5" unitRef="usd">511000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-F7AB3D02A9058ABDEF808ED5FB2C0C29" unitRef="usd">977792</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrent contextRef="FI2019Q4" decimals="0" id="Fact-7E34D2B39CB34DBF16458ED5FA5BCE40" unitRef="usd">729729</us-gaap:DueToRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-3" id="Fact-82D24297D53852AAF84A8ED5FA5DA236" unitRef="usd">554000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-3" id="Fact-6C4D20F268AB1FB7B2808ED5FA5DEA8E" unitRef="usd">219000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4YTD" decimals="2" id="Fact-F5F95D45A58E0C6BF0238ED5FA8987FB" unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q1QTD" decimals="2" id="Fact-B87605C80642D16221658ED5FB3DB5D4" unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q2QTD" decimals="2" id="Fact-0076B4A7BB22B77FFE068ED5FB351CA3" unitRef="usdPerShare">-0.07</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q3QTD" decimals="2" id="Fact-62AD90887DBD05A91B388ED5FB35E5A3" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q4QTD" decimals="2" id="Fact-D44179324B34E7C5E37A8ED5FB369428" unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2018Q4YTD" decimals="2" id="Fact-2392C7CAFCA75A5C70DA8ED5FA7FEB54" unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2019Q1QTD" decimals="2" id="Fact-B13B0DCF7FBE9D117B278ED5FB08C8BE" unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2019Q2QTD" decimals="2" id="Fact-6458597C8C96665D96988ED5FB0AC4FA" unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2019Q3QTD" decimals="2" id="Fact-B443FFD4B2E4D94820C28ED5FAC4CA4E" unitRef="usdPerShare">-0.23</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2019Q4QTD" decimals="2" id="Fact-1CC3BD28EE1FDE3D3BCE8ED5FB067B14" unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2019Q4YTD" decimals="2" id="Fact-AF6E17E1F12C859E7D808ED5FA7F078E" unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-B2E00885479D352F1B738ED5FA857B56" unitRef="usdPerShare">-1.09</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q1QTD" decimals="2" id="Fact-7E15AA98F9B2C4892C208ED5FAA76602" unitRef="usdPerShare">-0.36</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q2QTD" decimals="2" id="Fact-5F208CFB1A9C6F27926B8ED5FB3D7D97" unitRef="usdPerShare">-0.08</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q3QTD" decimals="2" id="Fact-37BA0E21250C17C3E0548ED5FA75B9A4" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q4QTD" decimals="2" id="Fact-7E96C7D7A5115E519ABC8ED5FB398C0A" unitRef="usdPerShare">-0.34</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-20E3C9020D30210D9E628ED5FA86530E" unitRef="usdPerShare">-1.05</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2019Q1QTD" decimals="2" id="Fact-9340A7F243B75782B4378ED5FAC501E0" unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2019Q2QTD" decimals="2" id="Fact-9718F9C0E163D63AAF788ED5FB149540" unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2019Q3QTD" decimals="2" id="Fact-F160A48E59A1F012D1A28ED5FB027414" unitRef="usdPerShare">-0.25</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2019Q4QTD" decimals="2" id="Fact-EC1CE6B49B5B6E539A6B8ED5FB0A702B" unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2019Q4YTD" decimals="2" id="Fact-F4E1D5AA1C53200437948ED5FA88667B" unitRef="usdPerShare">-1.21</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2017Q4YTD" decimals="0" id="Fact-6E0945AD5FC6D1464A26F64961BB43EE" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2018Q4YTD" decimals="0" id="Fact-0DE43C27D48DD3062BF2F64961C05FB5" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FD2019Q4YTD" decimals="0" id="Fact-C5BB4B6992754C8457B8F64961C5BBFA" unitRef="usd">471172</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2017Q4YTD" decimals="0" id="Fact-19C496B4FA392FF20069F5CF0D3417F2" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2018Q4YTD" decimals="0" id="Fact-5A8E774B7ED4E111FC9BF5CF0D3E59DE" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2019Q1QTD" decimals="0" id="Fact-C748D7743F48B80E29A20ACDA91B8B6A" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2019Q2QTD" decimals="0" id="Fact-E965B5C0AD244A426BCD0ACDA9230908" unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2019Q3QTD" decimals="0" id="Fact-B2AA4ECF174AD2FC869A0ACDA905BA10" unitRef="usd">2551453</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2019Q4QTD" decimals="0" id="Fact-3403A1712E0480F7C44A0ACDA913E9FA" unitRef="usd">-4315105</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2019Q4YTD" decimals="0" id="Fact-B47C0E71CF402FF0F794F5CF0D44305C" unitRef="usd">-1763652</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-91507F15546AAC792B8F889D4270055F" unitRef="usd">1800000</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4" decimals="-5" id="Fact-442786C4BF02E9D47CBC8ED5FA8E9BE2" unitRef="usd">5200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-77ADC88EE18353C447318ED5FA7A7D58" unitRef="usd">5100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2019Q4" decimals="-5" id="Fact-C13D84E1D07538D6DB0F8ED5FA9622F6" unitRef="usd">3400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-DFFA3F6236D5B29AAD128ED5FA806FFC" unitRef="usd">4300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD" id="Fact-CCA4F8CA0007AD74B996CA6CF0E18870">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-3072821B254D7E10C3848ED5FA9CF33E">P1Y8M0D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2019Q4YTD" id="Fact-22D61F10D4534275ADE28ED5FA7A02F4">P1Y7M31D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-19F7D3ABFA6A3A5716518ED5FAA3BFD9">P1Y6M31D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="3" id="Fact-4E4BE4D5091415F6D62C00B6534EFD1C" unitRef="number">0.078</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember" decimals="3" id="Fact-BAA22740CA94733C5E918ED5FAA33297" unitRef="number">0.151</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="3" id="Fact-CB7821026C12821B9F778ED5FAA2D586" unitRef="number">0.075</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember" decimals="3" id="Fact-ABDC38B791F2EE3FBDCB8ED5FAA26959" unitRef="number">0.150</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="I2020Q1Feb20_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="3" id="Fact-846C7BC28554FF56DD37AC23425CC499" unitRef="number">0.199</us-gaap:EquityMethodInvestmentOwnershipPercentage>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2018Q4" decimals="0" id="Fact-3518073C8E4D4EF20E278ED5FABD88C3" unitRef="usd">9405913</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-68B1760601279E5568B28ED5FB4217D4" unitRef="usd">9405913</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-406C9E1ABCCACB28DCFE8ED5FB40A772" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-828403D421EBF200CB7A8ED5FB3E53C6" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-A0CB9F094761E612886E8ED5FB420628" unitRef="usd">9405913</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2019Q4" decimals="0" id="Fact-028AF398D2632077CBFB8ED5FA6E1B72" unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-E5809DB2BBF145A63D338ED5FABE084C" unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-A756929E88E90C9E0BAF8ED5FB352090" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-CB858C1C73325F9EDA918ED5FAE7EF6B" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:EquitySecuritiesFvNi contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-1FE4E006682C9C06C7308ED5FB3503ED" unitRef="usd">6315356</us-gaap:EquitySecuritiesFvNi>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="FD2019Q4YTD" decimals="0" id="Fact-6F97C26328CAC57C1C3687EDC04CF22F" unitRef="usd">1763652</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="FD2019Q4YTD" decimals="0" id="Fact-CD71A3AD42EA3BCE9B7E87EDC037CD06" unitRef="usd">7055371</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4" decimals="0" id="Fact-5C176AFF4BF4E087758D87EDC047B556" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4" decimals="-3" id="Fact-E6945F0820FAA2A2A0920B41F345D7E1" unitRef="usd">8819000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-1353EC54EB902DDDE521CB56A3914C03">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-32DFAEFD8EE1FEADA490CB56A3577176">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember" id="Fact-78A92BBE8762D5C7B718CA1D2884FE1A">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" id="Fact-2C88E136EBEB771B0A0BCA1D287F23EA">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" id="Fact-AC0BFC138A81F6BB6C98CA1D0B692ABF">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" id="Fact-4269859D95C826E84F7B8ED5FAD82A57">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" id="Fact-D518BA4146EE1AB60D1FCA1D0B833977">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" id="Fact-362E99CE3136CA0994F88ED5FADAE990">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" id="Fact-A24FB16E342AF21877A4CA1D0BD816F5">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" id="Fact-78A7D9DD0245C7719604CA0E30081F60">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4" decimals="0" id="Fact-DAE1C21E7637F7AFF1D08ED5FAC72DC5" unitRef="usd">19957728</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" decimals="0" id="Fact-BC94C7F1FECA682EF4588ED5FADAB1BF" unitRef="usd">1882222</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" decimals="0" id="Fact-C2EF4626D78FA3E798038ED5FAC906B2" unitRef="usd">7679190</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" decimals="0" id="Fact-A502646F168F6BC047358ED5FAD93F36" unitRef="usd">303630</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="0" id="Fact-1AEB9998177B0C1F44888ED5FAC7D284" unitRef="usd">1219357</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="0" id="Fact-532E7D97996ADA15089E8ED5FACD43A7" unitRef="usd">3131250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" decimals="0" id="Fact-4FF4A0B4A05E6C7C0C5F8ED5FAD3FD33" unitRef="usd">5742079</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4" decimals="0" id="Fact-7B1E97B8BC55D0219D068ED5FACC073A" unitRef="usd">21024022</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" decimals="0" id="Fact-BB0F5286D8A68D9659C58ED5FAD87715" unitRef="usd">2175556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" decimals="0" id="Fact-CC4F277DFD97DBC8FAE58ED5FAD112F3" unitRef="usd">8106270</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" decimals="0" id="Fact-A3073AC89A887EC0565E8ED5FACEE1AA" unitRef="usd">335314</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="0" id="Fact-CC3FDBFA215966B05E3B8ED5FACE2D00" unitRef="usd">1248104</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="0" id="Fact-C49CFC740EE83EB5A4D68ED5FADAA9A7" unitRef="usd">3356250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" decimals="0" id="Fact-4D86BDBC1BDD4D2D2C398ED5FACD7637" unitRef="usd">5802528</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="FI2019Q4" decimals="0" id="Fact-271F08AF81B56BEDD3F78ED5FB1EEE27" unitRef="usd">1604445</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2019Q4" decimals="0" id="Fact-24701CDE7D71159FCDF08ED5FB1F8EFB" unitRef="usd">547081</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2019Q4" decimals="0" id="Fact-D406E80FA117DC8B6A708ED5FB208903" unitRef="usd">253333</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2019Q4" decimals="0" id="Fact-628B84FB2BA35B1227768ED5FB1E879C" unitRef="usd">275760</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2019Q4" decimals="0" id="Fact-4A3C204C2053095C17468ED5FB1F9055" unitRef="usd">492818</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2019Q4" decimals="0" id="Fact-0F33E4520350208BA2FF8ED5FB1F25DA" unitRef="usd">520414</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4" decimals="0" id="Fact-B1B04585D06767FBA2608ED5FADB8D8E" unitRef="usd">24717873</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" decimals="0" id="Fact-CB80884B1027E3AF0D6D8ED5FAD54313" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" decimals="0" id="Fact-E9E08981D5E2544F113B8ED5FAD06B7E" unitRef="usd">8106270</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" decimals="0" id="Fact-741CB92759135746D5748ED5FACE5062" unitRef="usd">335314</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="0" id="Fact-892A59988672A3EA98558ED5FACC7ED4" unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="0" id="Fact-D5D6B6966B56B841B5498ED5FAD673CB" unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" decimals="0" id="Fact-09F57B8FC814726178EA8ED5FAD7209F" unitRef="usd">5802528</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4" decimals="0" id="Fact-DA5006992C47BBC065928ED5FAD9FDF1" unitRef="usd">24717873</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" decimals="0" id="Fact-80E10C4CC5D1A164FE2C8ED5FADC8462" unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" decimals="0" id="Fact-4AE2772DE38ACB4E804A8ED5FAD7409A" unitRef="usd">8106270</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" decimals="0" id="Fact-24794E6499AED16FDEF48ED5FAD385D1" unitRef="usd">335314</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="0" id="Fact-5AEB49020B94D87BEEF68ED5FAD6CCED" unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="0" id="Fact-EEB70F5942CE4D6AB9D38ED5FAC6028F" unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" decimals="0" id="Fact-D935ED529CC337AB14ED8ED5FAD388B0" unitRef="usd">5802528</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4" decimals="0" id="Fact-12B4D4EB131B822FFF5E8ED5FADB6B0E" unitRef="usd">4760145</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4" decimals="-5" id="Fact-B4D31422043D95A90CB0CA0D61B854F8" unitRef="usd">4800000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" decimals="0" id="Fact-86FC457669754A71388B8ED5FACF67E4" unitRef="usd">3217778</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" decimals="0" id="Fact-9CD4B3B43D64AE482FBF8ED5FAD81E21" unitRef="usd">427080</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" decimals="0" id="Fact-1EF97C1301A74C1FAE5A8ED5FACCF632" unitRef="usd">31684</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="0" id="Fact-CC0AD9EC602D5AA0551F8ED5FAD77E35" unitRef="usd">104404</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="0" id="Fact-AD9D4967E7806BE3E5DF8ED5FACA8FB7" unitRef="usd">918750</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" decimals="0" id="Fact-AA32D8D3ABB06891EFC38ED5FAD267A2" unitRef="usd">60449</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4" decimals="-5" id="Fact-2FF159C44A82B1DA4CA0CA0D61BC4210" unitRef="usd">3700000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4" decimals="0" id="Fact-9C77868DFBE33DA83AF08ED5FACD411C" unitRef="usd">3693851</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_BiojectMember" decimals="0" id="Fact-0FD3EC288A24097FC55E8ED5FAC70546" unitRef="usd">2924444</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_CellectraMember" decimals="0" id="Fact-446B7B33B43F9C7D0E708ED5FAC70E60" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ino_GhrhMember" decimals="0" id="Fact-C47B657191F1F3713A918ED5FAD84253" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" decimals="0" id="Fact-2BFD3A369BAA95C885618ED5FADB5ADD" unitRef="usd">75657</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_OtherIntangibleAssetsMember" decimals="0" id="Fact-DCF7C4641DA66A79D45B8ED5FAD536CC" unitRef="usd">693750</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember" decimals="0" id="Fact-EB6D739C8981E7F675108ED5FAD66BD8" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-568B955472F82CD1979C8ED5FA82F411" unitRef="usd">1000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="0" id="Fact-53EA3CB145128FEDA9EB8ED5FA7D8009" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-1AB625851A50E4A74CAF8ED5FA836F6B" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
	<us-gaap:GainLossOnInvestments contextRef="FD2017Q4YTD" decimals="0" id="Fact-0F99676802A9FF6824528ED5FAB12A4F" unitRef="usd">-215423</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnInvestments contextRef="FD2018Q4YTD" decimals="0" id="Fact-C9EADA5F3418842902848ED5FB2529A5" unitRef="usd">-1342005</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnInvestments contextRef="FD2019Q4YTD" decimals="0" id="Fact-0A421E01C53BEBC0D29B8ED5FB26FA37" unitRef="usd">476368</us-gaap:GainLossOnInvestments>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2017Q4YTD" decimals="0" id="Fact-6C70407B23682677F6CB8ED5FB24B3B5" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2018Q4YTD" decimals="0" id="Fact-D1A4BCF1D38DC70AFB528ED5FAAE1FA0" unitRef="usd">-14529</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="FD2019Q4YTD" decimals="0" id="Fact-9403D6F19314C0485D798ED5FB244454" unitRef="usd">-5889</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-AE2B0C83D774B79CE0758ED5FA8017BC" unitRef="usd">28290369</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q1QTD" decimals="0" id="Fact-1F7F9163A8FDED3238C48ED5FB3A6FC7" unitRef="usd">9698015</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q2QTD" decimals="0" id="Fact-9E72AD1A5A9FF137C07F8ED5FA44DDD0" unitRef="usd">7189310</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q3QTD" decimals="0" id="Fact-518AAF7BA3FB709BFBED8ED5FB353C46" unitRef="usd">6791693</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4QTD" decimals="0" id="Fact-1CDCC8C4563039CBF6758ED5FB3F0009" unitRef="usd">5636141</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-D41F3FC7FF78997CC79B8ED5FA790EB3" unitRef="usd">29315159</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q1QTD" decimals="0" id="Fact-1A83124EB4F539CE1CCB8ED5FB2AAE8D" unitRef="usd">6975029</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-AADBB8D7605BC2D70FCA8ED5FACE6661" unitRef="usd">5850101</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q3QTD" decimals="0" id="Fact-84B290150C65A04711898ED5FAF685BF" unitRef="usd">5681441</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q4QTD" decimals="0" id="Fact-35369EBD7F2BA1CC67608ED5FACA790B" unitRef="usd">8696586</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-EA817210D2C8979EAAF38ED5FA872593" unitRef="usd">27203156</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="0" id="Fact-161886A987D4BB7DCC7F8ED5FAC0A0E6" unitRef="usd">10513371</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2019Q4" decimals="0" id="Fact-B8AB3D41BB0D4B717AAD8ED5FA578D24" unitRef="usd">10513371</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2005Q1Jan31_us-gaap_IncomeStatementLocationAxis_ino_InovioAsMember" decimals="-5" id="Fact-BAFF0BC6F609922406738ED5FAC9B2E5" unitRef="usd">3900000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2009Q2_us-gaap_IncomeStatementLocationAxis_ino_VgxPharmaceuticalsMember" decimals="-5" id="Fact-63E36AAAAE9FB22117BA8ED5FAE70469" unitRef="usd">6200000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="I2016Q2Apr_us-gaap_IncomeStatementLocationAxis_ino_BiojectMember" decimals="-3" id="Fact-8FFD99A4A4E2BA8A978E8ED5FAD7C0A7" unitRef="usd">400000</us-gaap:Goodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2017Q4YTD" decimals="INF" id="Fact-24C6D1BED2E123E7A7448ED5FA779F88" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2018Q4YTD" decimals="INF" id="Fact-D38C45094DA81379D8758ED5FA7732E8" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2019Q4YTD" decimals="INF" id="Fact-2DDE7A94C103E77F16D48ED5FADEB83A" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="0" id="Fact-A2027F7A78C7E31511388ED5FA89083D" unitRef="usd">-88205772</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q1QTD" decimals="0" id="Fact-960D7F9E9FC701CD04A58ED5FB33A1EC" unitRef="usd">-30181017</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q2QTD" decimals="0" id="Fact-51348AEB4681AE493D588ED5FAC3AD49" unitRef="usd">-6639125</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q3QTD" decimals="0" id="Fact-61204E45982B921422008ED5FAE0D642" unitRef="usd">-25015672</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q4QTD" decimals="0" id="Fact-F8FA48909A2446C989558ED5FA65EB8D" unitRef="usd">-32962205</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="0" id="Fact-66191E117B4DDA2BD0DC8ED5FA84CFE0" unitRef="usd">-94798019</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q1QTD" decimals="0" id="Fact-FEBE7F8EDD7241A5FF1E8ED5FAF8BB3F" unitRef="usd">-29351667</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q2QTD" decimals="0" id="Fact-ED5465049E4487C574248ED5FAF3F293" unitRef="usd">-29685847</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q3QTD" decimals="0" id="Fact-82F8A99873E1093DCEFA8ED5FAFA7282" unitRef="usd">-23536452</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q4QTD" decimals="0" id="Fact-5BE9E29071A253D453698ED5FB090648" unitRef="usd">-38235146</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q4YTD" decimals="0" id="Fact-E5CC285765AFBDE49F1F8ED5FA7A57F7" unitRef="usd">-120809112</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F1E070E534FC4627778A8ED5FA49CF73" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="0" id="Fact-1CC346B16C8006AF8A618ED5FA78740E" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q1QTD" decimals="0" id="Fact-BB779E7FFA40D593F82B8ED5FAC7FA01" unitRef="usd">2169811</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q2QTD" decimals="0" id="Fact-9F750F54C4702F2BD9448ED5FB38D996" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q3QTD" decimals="0" id="Fact-10ABB2C7A9B08271FB9E8ED5FB011E96" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4QTD" decimals="0" id="Fact-1FDDC84CAA99185808EE8ED5FA5C31B1" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0AB7CFCE5228438219D28ED5FA4D4DA5" unitRef="usd">2170000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="0" id="Fact-E42382343E92927549468ED5FA88A963" unitRef="usd">2169811</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q1QTD" decimals="0" id="Fact-8653FCF85E82ACB7F5008ED5FB03FB87" unitRef="usd">-62800</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q2QTD" decimals="0" id="Fact-3BB9582E001A3017B0118ED5FB0086A4" unitRef="usd">-106771</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q3QTD" decimals="0" id="Fact-8C7D5FF495BCF2EC8BA38ED5FAFFAD26" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q4QTD" decimals="0" id="Fact-C2855F56EFB2DDA733FB8ED5FB0566E1" unitRef="usd">-87764</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-5" id="Fact-5CAD45D48B68D258E34F8ED5FA5AE674" unitRef="usd">-300000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="0" id="Fact-337194E622DC1EBC55528ED5FA7ED031" unitRef="usd">-257335</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-708B80AB929CD4B83C038ED5FA4B0386" unitRef="usd">-257000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A24C421493D30DC14C878ED5FA64FDAE" unitRef="usd">-20965000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="-3" id="Fact-71FBF8C805DD34DE1F848ED5FA639F54" unitRef="usd">20898000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2019Q4YTD" decimals="-3" id="Fact-732D7919ADB5EC30252F8ED5FA8E1954" unitRef="usd">25457000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B96F4F544B1F351546F38ED5FAA35DB1" unitRef="usd">50019000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D9FDD918D0DAE8E141608ED5FA6B12D1" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2019Q4YTD" decimals="-3" id="Fact-FE7DC66A227AA6089FA98ED5FA8DEB46" unitRef="usd">12000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C760BA15DFB6B2171C6F8ED5FA63D5F1" unitRef="usd">-30872000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3A3A8610511F6FCD19A98ED5FA9F7406" unitRef="usd">-19908000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2019Q4YTD" decimals="-3" id="Fact-7A4F8DF7AB27F7FAE2538ED5FA62D0BA" unitRef="usd">-25370000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EAE05F99DEEA26EC7DAA8ED5FA602A45" unitRef="usd">2332000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0883E36504A65A48F0AC8ED5FAA33330" unitRef="usd">1094000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2019Q4YTD" decimals="-3" id="Fact-E52C47EB24DD0D0389088ED5FA6FA3A7" unitRef="usd">1114000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-308AAC2F17AD0FCDAF3D8ED5FA9F0EAF" unitRef="usd">2093000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CD7C1CACB2A9179AB25C8ED5FA6E07CA" unitRef="usd">-102000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D0BCEB128C91BDD2BC5A8ED5FA9E2A14" unitRef="usd">831000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="-3" id="Fact-07E70B4411F3135107FC8ED5FA991A91" unitRef="usd">-4000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5000E6F8B4F35ABC16058ED5FAA73EAD" unitRef="usd">-4000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2019Q4YTD" decimals="-3" id="Fact-50A426132B3D21072ADD8ED5FA9B09E8" unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4CCCD851330F544A07558ED5FA96A8EC" unitRef="usd">846000</us-gaap:IncomeTaxReconciliationTaxContingencies>
	<us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5FF06878035E2A32F42C8ED5FA65E61B" unitRef="usd">1268000</us-gaap:IncomeTaxReconciliationTaxContingencies>
	<us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="FD2019Q4YTD" decimals="-3" id="Fact-63E8ED24167D3A48BF5E8ED5FA6AA3CE" unitRef="usd">1537000</us-gaap:IncomeTaxReconciliationTaxContingencies>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2017Q4YTD" decimals="0" id="Fact-6EBA368EF5DF795B9BBC8ED5FAB3E11E" unitRef="usd">2829807</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2018Q4YTD" decimals="0" id="Fact-C871A6CAE92CD0A543BF8ED5FAC32D33" unitRef="usd">550407</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="FD2019Q4YTD" decimals="0" id="Fact-C711031BB6B661F110418ED5FABBD4C0" unitRef="usd">-4337829</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="FD2017Q4YTD" decimals="0" id="Fact-F323641D3100C622854E8ED5FB2327F1" unitRef="usd">-145636</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
	<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="FD2018Q4YTD" decimals="0" id="Fact-DEC808EAED4FA26CA4D58ED5FAAEFB57" unitRef="usd">50849</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
	<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="FD2019Q4YTD" decimals="0" id="Fact-4A71A793ECB5A9A3EA078ED5FAC04968" unitRef="usd">-248063</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="0" id="Fact-DF6AAC8585EF4E7DDE1D8ED5FAC4BD8A" unitRef="usd">-9818306</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q4YTD" decimals="0" id="Fact-73E875ECB2894632D0818ED5FA9E163E" unitRef="usd">-2686844</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q4YTD" decimals="0" id="Fact-1E616E563745D288160B8ED5FA979441" unitRef="usd">-2616288</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="FD2017Q4YTD" decimals="0" id="Fact-12924EEB8DCC275DC8C08ED5FB26C0B6" unitRef="usd">-261736</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
	<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="FD2018Q4YTD" decimals="0" id="Fact-286A2BDF9B4C054116488ED5FAC251E7" unitRef="usd">251964</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
	<us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties contextRef="FD2019Q4YTD" decimals="0" id="Fact-BD00D8126F64AA020A568ED5FB24FA52" unitRef="usd">593461</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2017Q4YTD" decimals="0" id="Fact-19F9DAF6FDD833A0FAD28ED5FA95FD75" unitRef="usd">-13689322</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2018Q4YTD" decimals="0" id="Fact-2D6B21578F2867D9E9BD8ED5FAA5FCA4" unitRef="usd">-1016836</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="FD2019Q4YTD" decimals="0" id="Fact-B636A4BC8B68B5C6B5828ED5FA9D28A7" unitRef="usd">-180450</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
	<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="FD2017Q4YTD" decimals="0" id="Fact-D87848FA8AFB9E37D53B8ED5FABC795B" unitRef="usd">150027</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
	<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="FD2018Q4YTD" decimals="0" id="Fact-528E8D9B76A01B5EE0E88ED5FAC3690F" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
	<us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="FD2019Q4YTD" decimals="0" id="Fact-6D9621303CAD2354BA9C8ED5FAB29BFC" unitRef="usd">-5397</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
	<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="FD2017Q4YTD" decimals="0" id="Fact-92679BA7665D35C3AA1E8ED5FADBE378" unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
	<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="FD2018Q4YTD" decimals="0" id="Fact-EBD154D8586F78B061308ED5FA73F6C2" unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
	<us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="FD2019Q4YTD" decimals="0" id="Fact-EA019EFB0B1CA70B87338ED5FA72E969" unitRef="usd">1763652</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-1BE142148A66A5F1F6BF8ED5FABBA7FE" unitRef="usd">526207</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2018Q4YTD" decimals="0" id="Fact-547B74F4A1FBD0A347618ED5FACCC99D" unitRef="usd">30644</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-7943808A8E2EC280EA408ED5FAA17A7A" unitRef="usd">2026</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2017Q4YTD" decimals="0" id="Fact-3FB3B281272AC7322E478ED5FB254557" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2018Q4YTD" decimals="0" id="Fact-0212F34728C8B5787DE48ED5FAABBF94" unitRef="usd">87333</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="FD2019Q4YTD" decimals="0" id="Fact-191DC8EF97E7CBCA45F58ED5FAABDDE6" unitRef="usd">-48507</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-7C7E5E8284898DAB09328ED5FA9ABAD2" unitRef="usd">851847</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q4YTD" decimals="0" id="Fact-DDFCC5B52404412D0F4A8ED5FB276012" unitRef="usd">-1194316</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-54C41A2F377814D95FE98ED5FA99382E" unitRef="usd">178008</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2017Q4YTD" decimals="0" id="Fact-74C92214CADA163BED3D8ED5FB1CADA1" unitRef="shares">140529</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2018Q4YTD" decimals="0" id="Fact-99FFACFB8718B28956BD8ED5FB1C6123" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="FD2019Q4YTD" decimals="0" id="Fact-A19A1E9A9710438932C68ED5FB1C9B1C" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="0" id="Fact-F291C02F46001C618EE08ED5FA9A696D" unitRef="usd">4760145</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q4" decimals="0" id="Fact-9A4B5D00F794444085A98ED5FAB3DF84" unitRef="usd">3693851</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:InterestExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-6165F48453587C06C2A2F5CCF6BE06D9" unitRef="usd">25933</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-3A83579B1398DF30A4B0F5CCF6D1AAC7" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q1QTD" decimals="0" id="Fact-7B225044BCEE32C23B820AC91834CDA3" unitRef="usd">656248</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-16A5EF0D8A95646F042A0AC91830DF9F" unitRef="usd">2194783</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q3QTD" decimals="0" id="Fact-67F7A18CB30AA292D4A50AC9183D5E4E" unitRef="usd">2428671</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q4QTD" decimals="0" id="Fact-FB2E6317BAAE029FF5290AC9183895C3" unitRef="usd">2668837</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-13F771C5EEF51B13EE26F5CCF6EF9DDE" unitRef="usd">7948539</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-FD21DFCF980E943F9B8B889748CE6D02" unitRef="usd">7000000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-B02E7FAA16898920DEDB889CE76B3B3B" unitRef="usd">982000</us-gaap:InterestExpense>
	<us-gaap:InterestExpense contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="INF" id="Fact-639F1DF5BFC5443A8EEECAD455DBBACC" unitRef="usd">0</us-gaap:InterestExpense>
	<us-gaap:InterestExpenseDebt contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-3F6FE5F10D07D60C1997889A09EDE666" unitRef="usd">4400000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestExpenseDebt contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-3" id="Fact-3BDDF6BAC1EB1611990C889D034B9D3D" unitRef="usd">65000</us-gaap:InterestExpenseDebt>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q1QTD" decimals="0" id="Fact-B1BE4BF1BE995C198BA58ED5FB3BB8BD" unitRef="usd">312523</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q2QTD" decimals="0" id="Fact-664314BD7F90DC11204D8ED5FB340D10" unitRef="usd">396681</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q3QTD" decimals="0" id="Fact-42BEDCAE0360FA6D5EE98ED5FB341685" unitRef="usd">380987</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeExpenseNet contextRef="FD2018Q4QTD" decimals="0" id="Fact-6EF0AE9CF27FA778BD4E8ED5FA74B443" unitRef="usd">-169300</us-gaap:InterestIncomeExpenseNet>
	<us-gaap:InterestIncomeOperating contextRef="FD2017Q4YTD" decimals="0" id="Fact-2AA1B7D4E8A47D3DE25C8ED5FA783051" unitRef="usd">1836451</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestIncomeOperating contextRef="FD2018Q4YTD" decimals="0" id="Fact-574A390481F43142668C8ED5FA82C65D" unitRef="usd">2264747</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestIncomeOperating contextRef="FD2019Q1QTD" decimals="0" id="Fact-20C5B770D93AD60295608ED5FAEA0494" unitRef="usd">625535</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestIncomeOperating contextRef="FD2019Q2QTD" decimals="0" id="Fact-00C07D5952FEE2EF2E0A8ED5FB072C68" unitRef="usd">755330</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestIncomeOperating contextRef="FD2019Q3QTD" decimals="0" id="Fact-E8FCDD16DA79CC28D2868ED5FB11F465" unitRef="usd">637438</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestIncomeOperating contextRef="FD2019Q4QTD" decimals="0" id="Fact-0DF3A8D688C552C865138ED5FB031FEB" unitRef="usd">587679</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestIncomeOperating contextRef="FD2019Q4YTD" decimals="0" id="Fact-DA2F96F503D1C20E6B308ED5FA7DE961" unitRef="usd">2605981</us-gaap:InterestIncomeOperating>
	<us-gaap:InterestPaidNet contextRef="FD2017Q4YTD" decimals="0" id="Fact-33C1864C4755738940C18ED5FB2903AB" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="0" id="Fact-EDD7D6957CD760DA89A58ED5FABB7E15" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2019Q4YTD" decimals="0" id="Fact-82579B686C3B40BA37A98ED5FABDCDA0" unitRef="usd">2717585</us-gaap:InterestPaidNet>
	<us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="FD2017Q4YTD" decimals="0" id="Fact-49C3B6750F4A7599DB458ED5FABEE792" unitRef="usd">319845</us-gaap:InvestmentIncomeAmortizationOfPremium>
	<us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="FD2018Q4YTD" decimals="0" id="Fact-9B1D9ACEA79650DC96618ED5FACC80D7" unitRef="usd">72561</us-gaap:InvestmentIncomeAmortizationOfPremium>
	<us-gaap:InvestmentIncomeAmortizationOfPremium contextRef="FD2019Q4YTD" decimals="0" id="Fact-646816E0F91129550A088ED5FAA97DC0" unitRef="usd">1962</us-gaap:InvestmentIncomeAmortizationOfPremium>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="INF" id="Fact-E2E2DC29CEC1E7F1D42E8ED5FA5B84D8" unitRef="shares">1644155</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2018Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember" decimals="INF" id="Fact-F583612AE888FA35AA608ED5FA5C259C" unitRef="shares">395758</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-14B6DA368ADAD2BD20D58ED5FAB03877" unitRef="shares">395758</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="INF" id="Fact-D7C5EDB4DBC10A56B7B58ED5FAA39F75" unitRef="shares">1644155</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2019Q4_us-gaap_InvestmentTypeAxis_us-gaap_CommonStockMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PlumblineLifeSciencesMember" decimals="INF" id="Fact-BB5A2DCEFE44FA6B25908ED5FAA1D002" unitRef="shares">395758</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="INF" id="Fact-D73FDEFFC04FE796A9BD8ED5FA5F2743" unitRef="shares">1644155</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentOwnedBalanceShares contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember" decimals="INF" id="Fact-8FFF1EAF07F05D4678FF8ED5FA5E9D8B" unitRef="shares">395758</us-gaap:InvestmentOwnedBalanceShares>
	<us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="INF" id="Fact-73FAD5A6832F93AE5F638ED5FAAF5689" unitRef="shares">1644155</us-gaap:InvestmentsInAndAdvancesToAffiliatesBalanceShares>
	<us-gaap:LeaseCost contextRef="FD2017Q4YTD" decimals="-5" id="Fact-A9C0A1F019982AB5426B0B9B5B2852E9" unitRef="usd">2500000</us-gaap:LeaseCost>
	<us-gaap:LeaseCost contextRef="FD2018Q4YTD" decimals="-5" id="Fact-A1EE6503B0D0C10C983E0B9B4C9F5C8D" unitRef="usd">3400000</us-gaap:LeaseCost>
	<us-gaap:LeaseCost contextRef="FD2019Q4YTD" decimals="-5" id="Fact-81654FA15E68C0A5D17D0B98F34A5A22" unitRef="usd">3200000</us-gaap:LeaseCost>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q4" decimals="0" id="Fact-CAA675CC048428585E2C0BAA046398EA" unitRef="usd">31897000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2019Q4" decimals="0" id="Fact-59CE95EE7F9363FB8EB00BA9E73341A2" unitRef="usd">12951000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2019Q4" decimals="0" id="Fact-C1980A87124CCA9CCF590BA9CA304461" unitRef="usd">3001000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2019Q4" decimals="0" id="Fact-9819F6F8BA5FB98286720BA991937EFE" unitRef="usd">4023000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q4" decimals="0" id="Fact-06EC48FBE13E4AA19D070BA979088EFF" unitRef="usd">4052000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q4" decimals="0" id="Fact-97F15E714DA7C166BB7D0BA95C5B4CF4" unitRef="usd">3979000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="FI2019Q4" decimals="0" id="Fact-072141B22623DA1303EC0BA939E6E791" unitRef="usd">3891000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q4" decimals="0" id="Fact-E872DBF92286A6968B0A0BAA3F963540" unitRef="usd">9412236</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="0" id="Fact-ADF5F1BD9971896901D68ED5FA64CF90" unitRef="usd">44080858</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q4" decimals="0" id="Fact-F063732179CEB54B3A4F8ED5FB2AF639" unitRef="usd">138546739</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="0" id="Fact-FAF4C1240FA39AFE91128ED5FA6DC8F6" unitRef="usd">131113265</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q4" decimals="0" id="Fact-810B050B43B75FA40CB98ED5FAC0AF52" unitRef="usd">143951597</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="0" id="Fact-722999F068E1F9D0A60D8ED5FA657CA2" unitRef="usd">35299759</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q4" decimals="0" id="Fact-9E300FB2E49276D3EA288ED5FA984264" unitRef="usd">31989321</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-C7C6E9FAC5A87591E2F38ED5FACEC286" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-B44EEA09B527B9CAB0C98ED5FAAD8B52" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-8F6ADC0E2D60057290078ED5FAABD13C" unitRef="usd">8819023</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LiabilitiesFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" decimals="0" id="Fact-9481F38C2AF5E96DDAE68ED5FAA3E7DF" unitRef="usd">8819023</us-gaap:LiabilitiesFairValueDisclosure>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="0" id="Fact-E6B7D3DF6E71AB1788640B6A271AAD22" unitRef="usd">64180325</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-93706EB7552AC339DCE7CA28B03A5550" unitRef="usd">101463000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember" decimals="0" id="Fact-C647DBAEA530219F18460B6C953C0039" unitRef="usd">8824948</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-2BDA9CA9097176C12561CA28B046EDEC" unitRef="usd">20645000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember" decimals="0" id="Fact-DF41326F1313E94A926F0B6D6E2477CC" unitRef="usd">4017644</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-EEF5D1E19691AB7BF602CA28B0502308" unitRef="usd">5390000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebt contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-8E7DE79784C882A3B63ECA28B05BE713" unitRef="usd">127498000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtFairValue contextRef="FI2019Q4" decimals="-5" id="Fact-E555DDE43AABD17B67390B839B5C421B" unitRef="usd">62200000</us-gaap:LongTermDebtFairValue>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-4E8DEB186AADB2D21674CA2741D18FD8" unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-BA76EA3DC3133AC9C1FCCA2741AA9CDF" unitRef="usd">156000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-AB19C09AE457D2762142CA27419ADD87" unitRef="usd">31000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-260D7EDAA12AA7837DD4CA2742493114" unitRef="usd">5290000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-67A5658C9D4AF9734949CA28766D3611" unitRef="usd">81051000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-49983829CABBECB01673CA2876654807" unitRef="usd">20021000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-DB76EC31A3DFEE2C12D0CA28765E8DEE" unitRef="usd">5236000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-D56C91179C595C83C72CCA28765A5406" unitRef="usd">106308000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-48002EE6B6DE544A2904CA281D995737" unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-9C9524B3BCEC6EFA8FECCA281E3EB95D" unitRef="usd">156000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-D7C12F20B65C8DA9D181CA281DCBD019" unitRef="usd">41000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-69BC7A1C6A8B5A000C46CA281D77440A" unitRef="usd">5300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-E3F42465569304910905CA27E7EE77FC" unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-45E5599E8AAC1B2BA691CA27E7A08223" unitRef="usd">156000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-14AAE2CAD281CAAC824CCA27E83BEE60" unitRef="usd">41000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-580FCD15DCAC58F1B2F2CA27E7B0676F" unitRef="usd">5300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-9F4CDCAA3C9258E5EF81CA27ADBEBEFA" unitRef="usd">5103000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-2B59502A3267ACFD88DDCA27ADDBE429" unitRef="usd">156000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-91270247739C68BD3E5DCA27ADC80EDB" unitRef="usd">41000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="0" id="Fact-128F3F15733B5978D598CA27ADB516B5" unitRef="usd">5300000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:MinorityInterest contextRef="FI2018Q4" decimals="0" id="Fact-0A0403CBED9064E453D18ED5FAACA99F" unitRef="usd">96269</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterest contextRef="FI2019Q4" decimals="0" id="Fact-B08A0614174C55BF2F548ED5FA616932" unitRef="usd">1969759</us-gaap:MinorityInterest>
	<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="FI2019Q4_srt_OwnershipAxis_ino_GeneosTherapeuticsInc.Member" decimals="2" id="Fact-B642D3FCF198D6FA43DC11AA1B7C513A" unitRef="number">0.39</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
	<us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="FI2019Q4_srt_OwnershipAxis_ino_VGXAnimalHealthIncMember" decimals="2" id="Fact-9191E34B51B036DC6F168ED5FAB1F430" unitRef="number">0.15</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-F1C456CC00500B5181C38ED5FA9B2AA5" unitRef="usd">95690172</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-533406E4575146736EF48ED5FB230386" unitRef="usd">31037302</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-B36B456E249010AA0C438ED5FB28656D" unitRef="usd">105397595</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-574D3E64C752978411F58ED5FAAFFD91" unitRef="usd">-27831144</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-A9AE69675CE2F6E91DDF8ED5FB247625" unitRef="usd">42419908</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-C91EC2F2B0C534DD6A588ED5FAA9D1B0" unitRef="usd">-9044995</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q4YTD" decimals="0" id="Fact-279F79A3878118DEED488ED5FB271507" unitRef="usd">-63208921</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="0" id="Fact-8A137714DC617B52F1138ED5FA985BFD" unitRef="usd">-73550156</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q4YTD" decimals="0" id="Fact-AF30A3EC75555725EF658ED5FB246761" unitRef="usd">-97850136</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-344FC075EB46E71697EF8ED5FAF90C02" unitRef="usd">-88205772</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="0" id="Fact-4969C5151A8C7D60F67C8ED5FAFBD1A7" unitRef="usd">-96967830</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q1QTD" decimals="0" id="Fact-395D58E3526558F56B0E8ED5FB090A27" unitRef="usd">-29219262</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q2QTD" decimals="0" id="Fact-3C6865E22A1F2E51955C8ED5FAB44AE2" unitRef="usd">-29387226</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q3QTD" decimals="0" id="Fact-9A85B8650985E94B13B08ED5FA738351" unitRef="usd">-23090693</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q4QTD" decimals="0" id="Fact-43EBE06CC43A12B706728ED5FAAFDDC2" unitRef="usd">-37662038</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q4YTD" decimals="0" id="Fact-2F9F17635787B95CBB5B8ED5FAFF3820" unitRef="usd">-119359219</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2017Q4YTD" decimals="0" id="Fact-74613BD2B5C5542256498ED5FAFC135B" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="0" id="Fact-1F0AAED2310ADF971B3A8ED5FB01AF9E" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q1QTD" decimals="0" id="Fact-05E4F6ECF0235F0AF2F68ED5FB37E1B7" unitRef="usd">-69605</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q2QTD" decimals="0" id="Fact-A79E03F26EF99F30CC278ED5FA75E4E0" unitRef="usd">-191850</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q3QTD" decimals="0" id="Fact-913D09FB8718CB4797218ED5FAAA838B" unitRef="usd">-445759</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q4QTD" decimals="0" id="Fact-CE85FCCBF15E47AA63308ED5FAA5171B" unitRef="usd">-485344</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="FD2019Q4YTD" decimals="0" id="Fact-8AFC2729732F8C2B7DCF8ED5FAF5C8ED" unitRef="usd">-1192558</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q4YTD" decimals="0" id="Fact-3BA706097311919D01C08ED5FB217EF0" unitRef="usd">-89012591</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2018Q4YTD" decimals="0" id="Fact-1A09B99CDB5F221000528ED5FB1DE43C" unitRef="usd">-96967830</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2019Q4YTD" decimals="0" id="Fact-221990EB9676C5BF80C68ED5FB1CF55F" unitRef="usd">-119359219</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="FD2019Q4YTD" decimals="0" id="Fact-2EB98E09C0FE76323584F62111F603D5" unitRef="usd">2960131</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
	<us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-07E5F8CE292391799F24F62111F9BB4D" unitRef="usd">2960131</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2019Q4YTD" decimals="INF" id="Fact-3346BB7F46A8C270F1A88ED5FAB0228E" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2017Q4YTD" decimals="0" id="Fact-3D3010675F4C6FB645478ED5FA7AE76A" unitRef="usd">125862987</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q1QTD" decimals="0" id="Fact-53D9AE7BF7941A4055478ED5FA4615C0" unitRef="usd">34275766</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q2QTD" decimals="0" id="Fact-B361190CCC01117889DC8ED5FB2C3105" unitRef="usd">29651930</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q3QTD" decimals="0" id="Fact-C2E6FC35B8B184D631D78ED5FB339D03" unitRef="usd">28643551</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4QTD" decimals="0" id="Fact-4BDAC85BE678FDFC6AEF8ED5FB394748" unitRef="usd">32001788</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD" decimals="0" id="Fact-5DA537F5F919468BFD328ED5FA81EEE8" unitRef="usd">124573035</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q1QTD" decimals="0" id="Fact-C51AF894A21161DE82408ED5FAD33E9D" unitRef="usd">31364917</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q2QTD" decimals="0" id="Fact-476A86E1F74306B8BCD78ED5FACD4A51" unitRef="usd">28336367</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q3QTD" decimals="0" id="Fact-A687BF68F61ABC2D68898ED5FAFF1477" unitRef="usd">24818650</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q4QTD" decimals="0" id="Fact-E0C66E6D8D019BBF24FD8ED5FAF2AFA9" unitRef="usd">30700541</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q4YTD" decimals="0" id="Fact-4FB70DCCE847CC1AFB7F8ED5FA89391C" unitRef="usd">115220475</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-2EBE35E3A85185A4FEFD8ED5FA7FC175" unitRef="usd">-83642901</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q1QTD" decimals="0" id="Fact-406E2F730DCAAE006DF58ED5FB3E105E" unitRef="usd">-32746122</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q2QTD" decimals="0" id="Fact-79E9421F715221587BA28ED5FA459FF3" unitRef="usd">-5203169</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q3QTD" decimals="0" id="Fact-042C38FE9D8E89428C238ED5FAAE31D7" unitRef="usd">-26642683</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4QTD" decimals="0" id="Fact-390CD592C6EA04AC240B8ED5FB3CCE89" unitRef="usd">-29499164</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="0" id="Fact-45EABCC12FDFBD24E4A08ED5FA79ECEE" unitRef="usd">-94091138</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q1QTD" decimals="0" id="Fact-E3B8E2F0D22C789561F58ED5FAECE08E" unitRef="usd">-28535012</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q2QTD" decimals="0" id="Fact-1BDD1CC82B4CEDFC91C38ED5FAEEABFA" unitRef="usd">-28200694</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q3QTD" decimals="0" id="Fact-DAC9F8770BD2005F74AB8ED5FB0173C9" unitRef="usd">-23951787</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q4QTD" decimals="0" id="Fact-A6FD4164AF200812CC898ED5FAF5842E" unitRef="usd">-30421053</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q4YTD" decimals="0" id="Fact-1BFE15BBAA004DA003CF8ED5FA79ACC2" unitRef="usd">-111108545</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q4" decimals="0" id="Fact-D3ADBA78B8CC0FDB3ECF0BAA586A2BA4" unitRef="usd">22484764</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiability contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-5" id="Fact-583B0C2811210A0204EF11B290B87187" unitRef="usd">24200000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2018Q4" decimals="0" id="Fact-719169FE4F95438CC829F1E91A52BADB" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q4" decimals="0" id="Fact-C95A44287E82FD07A4FCF1E91A4AC374" unitRef="usd">2074842</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="I2019Q1Jan1" decimals="0" id="Fact-EC64FDF890CC06C3D69EF6C6C6B892E8" unitRef="usd">1733600</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="0" id="Fact-582ED839CEFE4696DEECF6C6C6B2789D" unitRef="usd">1733600</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-DAF5C00DCA1F08C5C551F58236E31465" unitRef="usd">20409922</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1Jan1" decimals="0" id="Fact-C0D143EB8DAF108C3093F6C71A46D72C" unitRef="usd">22484763</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="0" id="Fact-F0AF6BE8E50762CD4670F6C71A804FFF" unitRef="usd">22484763</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q4" decimals="0" id="Fact-9B911D77454A30E1FB748ED5FB1B285E" unitRef="usd">13783009</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan1" decimals="0" id="Fact-8C7DB19251E4F4E23F26F6C67854AC4F" unitRef="usd">14634769</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan1_srt_RestatementAxis_srt_RestatementAdjustmentMember" decimals="0" id="Fact-FA0562ABD77F73D31DEFF6C678A52BFF" unitRef="usd">14634769</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan1_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-5" id="Fact-575C18BE00FF72FE9C2611B25CF49FDA" unitRef="usd">14600000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2019Q4" decimals="3" id="Fact-6F7F54F8BB902191D9D30BAB0BCBC480" unitRef="number">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q1_srt_RangeAxis_srt_MaximumMember" id="Fact-740DBBF68FCF064C522E0B97977232A9">P9Y10M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q1_srt_RangeAxis_srt_MinimumMember" id="Fact-37938E6BF080C77279070B930D3D3713">P3Y10M31D
</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q4" id="Fact-B10AC31D5A7EF114FF700BAAF0061A15">P8Y2M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2019Q4" decimals="-3" id="Fact-9E5FBE7A672DBAB9DEFACAA538290E83" unitRef="usd">35653000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-3A1A0D3EA1FA19CFBE8FCA74DA54D70E" unitRef="usd">3756000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2019Q4" decimals="-3" id="Fact-A09F2147CA45429354C9CA7B66B1C11E" unitRef="usd">4023000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2019Q4" decimals="-3" id="Fact-F066295E6DB5DB87A9DACA7B30C9740E" unitRef="usd">4052000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2019Q4" decimals="-3" id="Fact-AAFF72262CA3A7FB92D8CA7A4AC7B25D" unitRef="usd">3979000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2019Q4" decimals="-3" id="Fact-1D5602655E09A4CAF0A7CA754551A6FD" unitRef="usd">3891000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2019Q4" decimals="-3" id="Fact-D5B996A93F8DA8CF5ED1CA7B9AD95403" unitRef="usd">15952000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-34369EAB702DE14777748ED5FA630A15" unitRef="usd">483300000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember" decimals="-5" id="Fact-8263E990E0B6E03248CD8ED5FA58F9AD" unitRef="usd">186600000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-5" id="Fact-94CB6507B66B68B6DC708ED5FA5C2D30" unitRef="usd">149100000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-7B27D7FBD77BA81403038ED5FB0C9832" unitRef="usd">3540284</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-9400A52F278A7A87CF2D8ED5FB18CD85" unitRef="usd">2076772</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-F0DFFA68A1C54C2146788ED5FB417415" unitRef="usd">2669998</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-077F40E279E8A380C7C78ED5FA627361" unitRef="usd">381000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-F90F050A5A7A987ADDAD8ED5FB42BD61" unitRef="usd">2672024</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q4_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-CE1BA45022B794E20DA48ED5FA5D232F" unitRef="usd">284000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-0F1E8C79DDD57321AD1B8ED5FA765660" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2018Q4YTD" decimals="0" id="Fact-7DC74123496AE4E85DE28ED5FA7FD455" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax contextRef="FD2019Q4YTD" decimals="0" id="Fact-DEE505B04691C9DBD0EC8ED5FAE0278C" unitRef="usd">-266215</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-D99A64AED16ABB8189408ED5FAC3D090" unitRef="usd">7458</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-DA1EA8BDD7C56079C6E38ED5FAE86EA8" unitRef="usd">7458</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="0" id="Fact-C657F70E161866879F1B8ED5FAC67A5E" unitRef="usd">-180496</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-163A299FAEAA9B1FC5D68ED5FAF66F12" unitRef="usd">-180496</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q4YTD" decimals="0" id="Fact-9DFB118F677E3AC822508ED5FAC4F569" unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-077F1A897AFB4A34E61BF627972D9702" unitRef="usd">1001475</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2018Q4" decimals="0" id="Fact-6FD56EA8027CB79CD4418ED5FA58BF52" unitRef="usd">87333</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2019Q4" decimals="0" id="Fact-99FDA2716282027346BA8ED5FABC5DFA" unitRef="usd">36943</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-CEAEE9431B86DBCB798DF5D3154B4CD6" unitRef="usd">-197544</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-1952ADEFF99EB6127724F5D3151BB372" unitRef="usd">-1343856</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q1QTD" decimals="0" id="Fact-0A4A79D1A16F5BD962560AD2E973B813" unitRef="usd">-35839</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-8F27AB04BED011D434190AD2E96DFA9F" unitRef="usd">127512</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q3QTD" decimals="0" id="Fact-151CA238228061A07B1A0AD2E96A5A92" unitRef="usd">140956</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q4QTD" decimals="0" id="Fact-455AF0CC00E6ACB2F12F0AD2E9709736" unitRef="usd">263571</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-704689D560A0C8F5DD16F5D31528AA77" unitRef="usd">496200</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2017Q4YTD" decimals="0" id="Fact-37ABBF00B6E0247065C3F64D7903130C" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2018Q4YTD" decimals="0" id="Fact-2DCA36BC0E411C19D04DF64D7907122A" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2019Q4YTD" decimals="0" id="Fact-78BCB41081720B6845B4F64D790C308D" unitRef="usd">3314757</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="0" id="Fact-CCE9A4BCF2AAE60E49008ED5FAAAC207" unitRef="usd">10293902</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="0" id="Fact-21BEB46886FB45390B668ED5FAC1B475" unitRef="usd">2085022</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q4YTD" decimals="0" id="Fact-E1116379C866345EDF1F8ED5FABBD302" unitRef="usd">987926</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2017Q4YTD" decimals="0" id="Fact-FEFBF759D28912ED833F8ED5FB26F569" unitRef="usd">95700144</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2018Q4YTD" decimals="0" id="Fact-50F9D2CE8DE18D22FAF08ED5FAC014C7" unitRef="usd">88155046</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="FD2019Q4YTD" decimals="0" id="Fact-61A1900175A0734020888ED5FAC12ED3" unitRef="usd">100950301</us-gaap:PaymentsToAcquireShortTermInvestments>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-07DDF9B0A79FFA5F76C28ED5FA828E53" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q4" decimals="INF" id="Fact-472962686B46245082728ED5FA7B1F73" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-3440FDE341B8B5F5C9F68ED5FA956FBA" unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockRedemptionPricePerShare contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-39AD4FE06A14F602318C8ED5FA8B9ABA" unitRef="usdPerShare">10000</us-gaap:PreferredStockRedemptionPricePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-D2F7356CEA1B408D69B38ED5FA833820" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q4" decimals="INF" id="Fact-D7E19BEECBA8D49B12778ED5FA78D374" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-A5126DCD0167EC5449D38ED5FB19E916" unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-EE66A148EC05EB9846768ED5FA7EE78F" unitRef="shares">23</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-20F8E20733FE844030458ED5FA846EF1" unitRef="shares">23</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-58EDBEBF84A93BB52F4B8ED5FB19CABB" unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-783C17676EA2D18FEA348ED5FA849107" unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-44F6D32451503BF7BA698ED5FB193FBE" unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-D83F93431576180F18318ED5FA81AE59" unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_SeriesCPreferredStockMember" decimals="INF" id="Fact-3EBDB52F0A9C37ED1D728ED5FB1906F9" unitRef="shares">23</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="0" id="Fact-5639F7ED2924980178608ED5FA5E13E5" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q4" decimals="0" id="Fact-4FD48F5E919BFBD51FBF8ED5FA63B091" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="0" id="Fact-6FACE7F565FFC67D640E8ED5FABDA6F0" unitRef="usd">1406590</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2019Q4" decimals="0" id="Fact-9AA9F166E8BB4714FDFE8ED5FB384D26" unitRef="usd">1584598</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-F50E9C34114885D7E5288ED5FAA556A3" unitRef="usd">75700000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
	<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-A96772A05CDA870D7EAD11A891B1CBA8" unitRef="usd">14500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
	<us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="FD2019Q4YTD_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-E18DEEA627057F81F5708810FD3F8722" unitRef="usd">4000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2020Q1Jan1March11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="-5" id="Fact-3F2ABA10245A4823356CAC19EA0D461D" unitRef="usd">208200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" decimals="0" id="Fact-6930ED62AED676EBB5848ED5FB258A9D" unitRef="usd">94347922</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q4YTD" decimals="0" id="Fact-4634ACAA99483120A2B48ED5FA962EA5" unitRef="usd">29227776</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q4YTD" decimals="0" id="Fact-D6169A2A4EAA1A4264A28ED5FACA53BE" unitRef="usd">9089010</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="-5" id="Fact-F81738F67BCFF916CD308811101FD3BD" unitRef="usd">9100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfDebt contextRef="D2019Q1Feb19March1_us-gaap_DebtInstrumentAxis_ino_A6.50ConvertibleSeniorNotesDue2024Member" decimals="-5" id="Fact-C2D6F7C51CE0A000528B0B78129305C4" unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
	<us-gaap:ProceedsFromIssuanceOfDebt contextRef="D2019Q3Aug1Aug1_us-gaap_DebtInstrumentAxis_ino_August2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-FC89A65863A03F516F44889AB132B7E5" unitRef="usd">14500000</us-gaap:ProceedsFromIssuanceOfDebt>
	<us-gaap:ProceedsFromIssuanceOfDebt contextRef="D2019Q4Dec26_us-gaap_DebtInstrumentAxis_ino_December2019ConvertibleBondsMember_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember" decimals="-5" id="Fact-FFA03E549C6EDFF882F688AE9EB9CB9A" unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2017Q4YTD" decimals="0" id="Fact-D5B04B06925DBB6E57CBF64CB408D0F7" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2018Q4YTD" decimals="0" id="Fact-9E855A32D80D622B0C4BF64CB3CFF077" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2019Q4YTD" decimals="0" id="Fact-76A1979A849C6FB27DC8F64CB3DE5C23" unitRef="usd">97443617</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromLicenseFeesReceived contextRef="D2010Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-5" id="Fact-DF5F30CA93DBB189C4C78ED5FA5E0561" unitRef="usd">3000000</us-gaap:ProceedsFromLicenseFeesReceived>
	<us-gaap:ProceedsFromMinorityShareholders contextRef="FD2017Q4YTD" decimals="0" id="Fact-02C55CA59AF8998C61C08ED5FAC24112" unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
	<us-gaap:ProceedsFromMinorityShareholders contextRef="FD2018Q4YTD" decimals="0" id="Fact-2E5FD3205F45A09CD9D08ED5FAC1FBD3" unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
	<us-gaap:ProceedsFromMinorityShareholders contextRef="FD2019Q4YTD" decimals="0" id="Fact-588A946031FFB43B08A08ED5FAAEB1C9" unitRef="usd">2960131</us-gaap:ProceedsFromMinorityShareholders>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="D2017Q4Dec1Dec31_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-5" id="Fact-25E60E5B69A351B5D71D8ED5FA5E7FE8" unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2017Q4YTD" decimals="0" id="Fact-CE287DB7003C404255378ED5FB25673B" unitRef="usd">1000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="0" id="Fact-C25AA085C199E8ACF4F78ED5FB2482D7" unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="FD2019Q4YTD" decimals="0" id="Fact-4F9C6E7A61540D72F0A08ED5FA9BEA9D" unitRef="usd">0</us-gaap:ProceedsFromSaleOfIntangibleAssets>
	<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="FD2017Q4YTD" decimals="0" id="Fact-452870A9B7829C9214118ED5FB272048" unitRef="usd">77162902</us-gaap:ProceedsFromSaleOfShortTermInvestments>
	<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="FD2018Q4YTD" decimals="0" id="Fact-D7DB8E75115D0788D00F8ED5FA9C500E" unitRef="usd">132659976</us-gaap:ProceedsFromSaleOfShortTermInvestments>
	<us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="FD2019Q4YTD" decimals="0" id="Fact-D0882E75FD3CA4C23F348ED5FAC18D9F" unitRef="usd">92893232</us-gaap:ProceedsFromSaleOfShortTermInvestments>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DE6927670360FFA624EB8ED5FA9A34D2" unitRef="usd">2300000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2018Q4YTD" decimals="-5" id="Fact-F28D29592A998F6FA11C8ED5FAA19A19" unitRef="usd">1500000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2019Q4YTD" decimals="-5" id="Fact-7ACF18B64283F28901368ED5FA807F09" unitRef="usd">100000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromWarrantExercises contextRef="FD2018Q4YTD" decimals="-3" id="Fact-49EE053FB880C2F0B8F38ED5FA8BCCEA" unitRef="usd">902000</us-gaap:ProceedsFromWarrantExercises>
	<us-gaap:ProfitLoss contextRef="FD2017Q4YTD" decimals="0" id="Fact-7D5542CA970805B13F928ED5FA78946B" unitRef="usd">-88205772</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-A2EC239AD86E75EC2D548ED5FAD4FEB1" unitRef="usd">-88205772</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q1QTD" decimals="0" id="Fact-21774C1880D6BE17F5C88ED5FAFD7B1C" unitRef="usd">-32350828</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q2QTD" decimals="0" id="Fact-5F7090B735182B0CBB048ED5FB3F3F28" unitRef="usd">-6639125</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q3QTD" decimals="0" id="Fact-4EFDDC18BC31250F8BA18ED5FB29375C" unitRef="usd">-25015672</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q4QTD" decimals="0" id="Fact-D485C88BB7194942B80C8ED5FB2B7948" unitRef="usd">-32962205</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q4YTD" decimals="0" id="Fact-A34B0274902AEE7452568ED5FA7B3505" unitRef="usd">-96967830</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-F59CA54363D5390693298ED5FAE9FF94" unitRef="usd">-96967830</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q1QTD" decimals="0" id="Fact-DE7595F563336E0103DF8ED5FAC626B5" unitRef="usd">-29288867</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q2QTD" decimals="0" id="Fact-23B70896B2C4F5A734218ED5FAFEC1D0" unitRef="usd">-29579076</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q3QTD" decimals="0" id="Fact-B125E4E2E218ADE11F9C8ED5FAD42BF0" unitRef="usd">-23536452</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q4QTD" decimals="0" id="Fact-B10B83AB02C53BB601A18ED5FB05B4CB" unitRef="usd">-38147382</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q4YTD" decimals="0" id="Fact-2319A8CA18E76405A3B68ED5FA82C1A3" unitRef="usd">-120551777</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-A0DBFB8DE3BA61CE9034F626B2C9BF51" unitRef="usd">-1192558</us-gaap:ProfitLoss>
	<us-gaap:ProfitLoss contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-A88766D1A62290F58920F625A0D09BEF" unitRef="usd">-119359219</us-gaap:ProfitLoss>
	<us-gaap:PropertyPlantAndEquipmentDisposals contextRef="FD2019Q4YTD" decimals="-3" id="Fact-799BBD8DEB02CC945AC6CA1A3466C159" unitRef="usd">6000</us-gaap:PropertyPlantAndEquipmentDisposals>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4" decimals="0" id="Fact-BFB844EB165A6D0C94AF8ED5FACDF133" unitRef="usd">25948933</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="0" id="Fact-245A2C8FF1CE1B58B8C08ED5FACE3900" unitRef="usd">3198803</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="0" id="Fact-077579A010874A065C6A8ED5FACC67FD" unitRef="usd">14909341</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" decimals="0" id="Fact-10392DCFC3BF8DFCEF2C8ED5FAD2A275" unitRef="usd">4031965</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" decimals="0" id="Fact-6EAF9E1A87393441A81E8ED5FAD07380" unitRef="usd">3808824</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q4" decimals="0" id="Fact-F41E9885908225134BA48ED5FAD23148" unitRef="usd">25939475</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="0" id="Fact-093F77BEE180106FB84C8ED5FACF3073" unitRef="usd">3048053</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="0" id="Fact-F97D1E25FF3DF02D7D5D8ED5FACD03D0" unitRef="usd">15007935</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" decimals="0" id="Fact-B62B5C14ABB9E600CAD98ED5FAD0C6BC" unitRef="usd">4102467</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" decimals="0" id="Fact-BEA119EAE712C3F0086C8ED5FACA628C" unitRef="usd">3781020</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="0" id="Fact-24EAF0ED8A5DB0153FFB8ED5FB3818F1" unitRef="usd">15949014</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="0" id="Fact-674B04E5CDB29EE3B4F18ED5FACB714A" unitRef="usd">1431150</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="0" id="Fact-415ED642DD49ED37FAB28ED5FACA261D" unitRef="usd">11444897</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" decimals="0" id="Fact-7B678471F82A88AF93A48ED5FAD4E94F" unitRef="usd">1606111</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" decimals="0" id="Fact-52E42E961AA06D4A09E18ED5FAD32CF8" unitRef="usd">1466856</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4" decimals="0" id="Fact-AF14C930CD641DE447B88ED5FB3B7142" unitRef="usd">12773017</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="0" id="Fact-8FA9B91B28AC0E536EBA8ED5FACC91E2" unitRef="usd">1103760</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="0" id="Fact-036DB32F1B06AED21A498ED5FAD477EA" unitRef="usd">10011158</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember" decimals="0" id="Fact-14DDD58AF05EBBA4FA968ED5FAC90F2D" unitRef="usd">873110</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" decimals="0" id="Fact-9382A8C51DFCDE6E87408ED5FAD18789" unitRef="usd">784989</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" id="Fact-472C41686CE01DE685278ED5FAB2EB14">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" id="Fact-F0F1B55CEE36E00709998ED5FAC1E475">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-5" id="Fact-D8E09D615D452065B6BA8ED5FA5EB607" unitRef="usd">2300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-5" id="Fact-422C96D823BB0C6A6B258ED5FA609352" unitRef="usd">7000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-5" id="Fact-80DD0E477979230F62338ED5FA5FF6E2" unitRef="usd">1800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-5" id="Fact-35EFF3E87B2B80920F008ED5FA5F70C3" unitRef="usd">2500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_TheWistarInstituteMember" decimals="-5" id="Fact-218150BC05F97C5777C48ED5FA5D3238" unitRef="usd">1500000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="0" id="Fact-1473B489B1543F62E44B8ED5FA80F4C9" unitRef="usd">98572618</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q1QTD" decimals="0" id="Fact-D800422EAE8E7026F35A8ED5FA7417AF" unitRef="usd">24577751</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q2QTD" decimals="0" id="Fact-AEA436F0D441D60E01AE8ED5FB3E1AD4" unitRef="usd">22462620</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q3QTD" decimals="0" id="Fact-C963F686D8306BAE46478ED5FB3DAF42" unitRef="usd">21851858</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4QTD" decimals="0" id="Fact-0AD8C93C688C1A1DACFA8ED5FB3CCE8D" unitRef="usd">26365647</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="0" id="Fact-D69616630D231742908E8ED5FA885973" unitRef="usd">95257876</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q1QTD" decimals="0" id="Fact-ED8B15FC5B65B2890BE88ED5FAC64143" unitRef="usd">24389888</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q2QTD" decimals="0" id="Fact-9F6C9BAC4E7689CD79428ED5FB2D1B59" unitRef="usd">22486266</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q3QTD" decimals="0" id="Fact-E3A42F591DFE1EE557BB8ED5FAC3B9F7" unitRef="usd">19137209</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q4QTD" decimals="0" id="Fact-E6EC8B3D639A75ACFC868ED5FB0694E4" unitRef="usd">22003955</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q4YTD" decimals="0" id="Fact-76DCAC410AEB27CF45B58ED5FA7740D3" unitRef="usd">88017319</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestructuringCharges contextRef="FD2019Q3QTD" decimals="-5" id="Fact-6C3EFE43741146D719D411A92221A3D0" unitRef="usd">2200000</us-gaap:RestructuringCharges>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="0" id="Fact-86147616C3323292CB2E8ED5FB365A0A" unitRef="usd">-620426436</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q4" decimals="0" id="Fact-4117D1ECA09D148B2A278ED5FABD9690" unitRef="usd">-739785655</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD" decimals="0" id="Fact-33E9CBAA48CE9E56C5E08ED5FA7D4CEF" unitRef="usd">42220086</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember" decimals="0" id="Fact-97F061F58FBBD8C6BA898ED5FA9865F3" unitRef="usd">3859132</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember" decimals="0" id="Fact-6662DFAC3B5C31BB34548ED5FA526D6A" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" decimals="0" id="Fact-B00742C9A983C35BA90A8ED5FA54757C" unitRef="usd">9983927</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember" decimals="0" id="Fact-2CD84B89D68743C6C1F18ED5FA551636" unitRef="usd">6107254</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember" decimals="0" id="Fact-FC7165F3B20D6F3C3FF58ED5FA8DE60E" unitRef="usd">22269773</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_ino_GrantwithAffiliatedRevenueMember" decimals="0" id="Fact-55E289029670EEEFB95B8ED5FA82A1B0" unitRef="usd">2572331</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-D3FBAC5EDE2E71E104288ED5FA767102" unitRef="usd">765828</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember" decimals="0" id="Fact-8ABA29E1CD8ECECE85F98ED5FA767686" unitRef="usd">10474539</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-2B4AB9A335F2F73D7EDA8ED5FA84F1B9" unitRef="usd">28407388</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q1QTD" decimals="0" id="Fact-B7AD7F5A18F0FBE72D088ED5FB39449B" unitRef="usd">1529644</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-DF11853860771436390B8ED5FB3A9CDF" unitRef="usd">148008</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-EA11B12ED165435631A18ED5FAAFE5E0" unitRef="usd">1289046</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-103A59291FD5AF8717EC8ED5FB32C163" unitRef="usd">92590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q2QTD" decimals="0" id="Fact-86F440B3CE072DBDBFB58ED5FA462097" unitRef="usd">24448761</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-C98964880FBEC4E66AAE8ED5FA45489D" unitRef="usd">60319</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-9722E818856B6F2F46EB8ED5FB3863CC" unitRef="usd">24385852</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-D1CAA2E53732CDB76BB88ED5FA77FF02" unitRef="usd">2590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD" decimals="0" id="Fact-5F9F916F211641C4EFBC8ED5FA72BFA6" unitRef="usd">2000868</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-CEC208517F0ADF9895208ED5FAA5D91F" unitRef="usd">184990</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-87A8116626983274755B8ED5FB3B1C50" unitRef="usd">1813287</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-4E595D9AF8F719521A698ED5FB391BE5" unitRef="usd">2591</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4QTD" decimals="0" id="Fact-A37102FEDA068370499D8ED5FA742863" unitRef="usd">2502624</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-695A336C5E8CA1343E7C8ED5FA76045F" unitRef="usd">56207</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-4DE763B2FD2CA05884F58ED5FB3D959B" unitRef="usd">2372600</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-957590DBAB8FF99630F18ED5FA7108AE" unitRef="usd">73817</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD" decimals="0" id="Fact-78D043DD357E9C735E0E8ED5FA7C6479" unitRef="usd">30481897</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember" decimals="0" id="Fact-050CF71E718C8A31ECA98ED5FA554BFD" unitRef="usd">631473</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember" decimals="0" id="Fact-7FCC0306E41A98D8B47409FD6EF3A08F" unitRef="usd">23000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" decimals="0" id="Fact-8CA6A1A14A2B25A43B408ED5FA97F44A" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember" decimals="0" id="Fact-CD387AD1431A601BBFEC8ED5FA9560F5" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember" decimals="0" id="Fact-BC486F3327F419C5B89C8ED5FA55DAF5" unitRef="usd">6850424</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_ino_GrantwithAffiliatedRevenueMember" decimals="0" id="Fact-EE21AD71F726A762C9828ED5FA8409FD" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-D2BD4C86C8E848E04DA48ED5FA8ADEA5" unitRef="usd">449524</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember" decimals="0" id="Fact-6750BE6F7F233AB90E618ED5FA866052" unitRef="usd">171588</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-094E149B837B538DD0B68ED5FA85BA8D" unitRef="usd">29860785</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q1QTD" decimals="0" id="Fact-8521F8010615B420CB9C8ED5FB030EEC" unitRef="usd">2829905</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-AF6FEE2091B06E2F209F8ED5FB2B1A88" unitRef="usd">55579</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-4917B1372231F51BD18A8ED5FACAC113" unitRef="usd">2770712</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q1QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-10643E0C5DE28B3AC8338ED5FB0859ED" unitRef="usd">3614</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q2QTD" decimals="0" id="Fact-C9C181C680A693EDB1808ED5FAFBB8F5" unitRef="usd">135673</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-C8BE91E4DFD14E48EE3D8ED5FAC7F749" unitRef="usd">71390</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-E0CAD1158ECC0BE355388ED5FAC51F1F" unitRef="usd">64283</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q2QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-C3A11F8E577E63EC4A178ED5FB2AFE93" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q3QTD" decimals="0" id="Fact-22001F4E081CB4CE906C8ED5FAFC21DA" unitRef="usd">866863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-C465CC4212AE37FE48C48ED5FB02AF7D" unitRef="usd">53014</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-E1993FDDCB9948F687528ED5FB29C986" unitRef="usd">617427</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-2DEB6835FB5138C950378ED5FAC53298" unitRef="usd">196422</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4QTD" decimals="0" id="Fact-EFD62F628A8047EC463A8ED5FAF6CC3B" unitRef="usd">279488</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-F519958CE127DB57B0888ED5FAF86390" unitRef="usd">55665</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-DECF6DE9F84879F34F2B8ED5FAC5B28A" unitRef="usd">184523</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4QTD_srt_ProductOrServiceAxis_us-gaap_ProductAndServiceOtherMember" decimals="0" id="Fact-D7F8CB2E24761C25E0698ED5FB036FED" unitRef="usd">39300</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD" decimals="0" id="Fact-F55515645D9D051D79218ED5FA86C725" unitRef="usd">4111930</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_MedImmuneMember" decimals="-5" id="Fact-9D1051E78126F6529CD58ED5FAC7E77F" unitRef="usd">3200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_ino_OtherCounterpartyMember" decimals="-3" id="Fact-D02AEFA0FEE7F88E2C568ED5FAC1A0D8" unitRef="usd">917000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_AllOtherCustomersMember" decimals="0" id="Fact-6E3C0CE6129B7D5712668ED5FA5250B1" unitRef="usd">917053</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_ApolloBioMember" decimals="0" id="Fact-DFC6995697AA7BFB2CE209FD6EE4A8DE" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" decimals="0" id="Fact-5A6CF8F012D43F82CCB78ED5FA9842C4" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_HoffmanLaRocheMember" decimals="0" id="Fact-C99A4EDC12343DFF856A8ED5FA52126B" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_ino_MedImmuneMember" decimals="0" id="Fact-6D372B3A9D077DB6F3788ED5FA53B7A1" unitRef="usd">3194877</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_ino_GrantwithAffiliatedRevenueMember" decimals="0" id="Fact-36A192A012C1A51A4B1E8ED5FA7636E2" unitRef="usd">1800</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_ino_LicensewithAffiliatedEntitiesMember" decimals="0" id="Fact-FA2E21816E70D02650DC8ED5FA796FCD" unitRef="usd">235649</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_GrantMember" decimals="0" id="Fact-3CCC273B4CD64B7922008ED5FA87EE46" unitRef="usd">237536</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" decimals="0" id="Fact-67E1B057A50F28B1C0828ED5FA8BAA6C" unitRef="usd">3636945</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2017Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-019609576B2C9559A1408ED5FA622F4E" unitRef="usd">551000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-889209D9D419F654D2628ED5FA61961B" unitRef="usd">342000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2018Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember" decimals="-3" id="Fact-1F0159A86D5CC7D50C9A8ED5FA622CBF" unitRef="usd">107000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_GeneOneLifeSciencesMember" decimals="-3" id="Fact-BC1D60D09668B3C86A298ED5FAC0351F" unitRef="usd">127000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RevenueFromRelatedParties contextRef="FD2019Q4YTD_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ino_PLSaffiliatedentityMember" decimals="-3" id="Fact-2B21CAFB99BF78A6F0FA8ED5FA5CDF6C" unitRef="usd">111000</us-gaap:RevenueFromRelatedParties>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q4YTD" decimals="0" id="Fact-D603249BC6AD15FD0A11CF166B3BF5C4" unitRef="usd">14634769</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2020Q1Jan1March11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="0" id="Fact-929D87C281CD95CA8B62AC198E1D802D" unitRef="shares">43148952</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="2" id="Fact-BC9BA918BE541B7B29CD883196097DE1" unitRef="usdPerShare">8.41</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="2" id="Fact-6A06B33018F90F8AE7DE8ED5FA94827E" unitRef="usdPerShare">2.78</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q2June5_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_ino_PriorATMSalesAgreementMember" decimals="2" id="Fact-14A72BA76FAAD8AB3E73883197D0A46D" unitRef="usdPerShare">5.07</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2020Q1March11_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_ino_SalesAgreementMember" decimals="2" id="Fact-D93FF9DB0AB94F93DFD5AC1A2B9D6D6E" unitRef="usdPerShare">4.92</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="0" id="Fact-FD203E0429089E2BE7D08ED5FABB7409" unitRef="usd">13070962</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_EmployeeMember" decimals="-5" id="Fact-D5047282498710F01B3E8ED5FA8C6A35" unitRef="usd">12900000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-5" id="Fact-749FF97B11757F59FC408ED5FA811217" unitRef="usd">7100000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-7BFEEE9245A72C3B08728ED5FA9893CA" unitRef="usd">5800000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="0" id="Fact-D0FDA06CB2AF8E033E458ED5FA95DF72" unitRef="usd">10654622</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_EmployeeMember" decimals="-5" id="Fact-DCD46B9F1283071ECE1E8ED5FA9E61D8" unitRef="usd">10200000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-5" id="Fact-1BA660D804F99E3A53D68ED5FAA00519" unitRef="usd">4300000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-B753A16027BFEE79D26C8ED5FAA409ED" unitRef="usd">5900000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q4YTD" decimals="0" id="Fact-F33F036ED2769D942FD88ED5FB2594EB" unitRef="usd">10901320</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_ino_EmployeeMember" decimals="-5" id="Fact-1597254287FF6AF6587D8ED5FA7AC5A4" unitRef="usd">9800000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-5" id="Fact-320D9753A6C60CA933978ED5FA9876EF" unitRef="usd">3900000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-5" id="Fact-9BC5E58B26A1AC0CA21B8ED5FA97A012" unitRef="usd">5900000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2007IncentivePlanMember" id="Fact-C5E06893C4936D2E6F008ED5FAA0B993">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" id="Fact-16BA889EDCB47774F0D88ED5FA993721">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-C44E278125FB4E5C4E248ED5FADEAE72" unitRef="shares">106634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-53746622F7538A09552E8ED5FAD8FA07" unitRef="shares">1491771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-94C77DECD9A92D3407A18ED5FA7CC6EA" unitRef="usdPerShare">6.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-C8709B9FDAA793E86A698ED5FAA09677" unitRef="usdPerShare">4.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-8323827EAECD502C1C938ED5FA9A2AA2" unitRef="usdPerShare">3.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-800615FDAE8DAA69A47D8ED5FADD6295" unitRef="shares">1688017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-E088ABA8AF5834B54F2E8ED5FAD0C51F" unitRef="shares">2069936</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-0C0B62BCC61E1B74CDFD8ED5FAE059B8" unitRef="shares">1003218</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-26EBADC75E9A2F077C0C8ED5FA4D6270" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-7E22BA543270552D94B48ED5FACA9991" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-59132A0D9D0D655BC8AE8ED5FA4D6B2A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-C64433BA2288AFF8648A8ED5FACBBF15" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-6BE1C9BD1AA0850F5B5E8ED5FA4E9B77" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-DC645749D381813D779F8ED5FACB9121" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-993B93805701F83BF5728ED5FA4F84D2" unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-491C262E1E6A55071F69CA081F26DA71" unitRef="number">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-3533BBE337C51F87AAE98ED5FA4D3365" unitRef="number">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-9D5EE30D5D5F0EC78D5DCA081723D77B" unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-036F5C6692689D64339D8ED5FA4C10A5" unitRef="number">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-487C7AFCE5341C23E517CA080F30AB5A" unitRef="number">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-BFB425928013505B57458ED5FA4F3167" unitRef="number">0.0220</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-54D3E4A5439EF728CD28CA080A14A512" unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-713C54CCDC63B2E755B38ED5FA4F1DE3" unitRef="number">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-6D99BADFD1E0507237CECA08005AA6C8" unitRef="number">0.0271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-2CEB19DD2EAC8E3976BE8ED5FA4CC202" unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-3E27F25CCA1071D93917CA07F6FF3D23" unitRef="number">0.0245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2019Q4_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" decimals="INF" id="Fact-04A93C04517640AE64398ED5FA80D269" unitRef="shares">16000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2016Q2May13_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" decimals="INF" id="Fact-843FFF3BD70499C9EE1F8ED5FA951215" unitRef="shares">16000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2019Q4_us-gaap_PlanNameAxis_ino_A2016IncentivePlanMember" decimals="INF" id="Fact-39A65F9062E1328538B48ED5FAA25A36" unitRef="shares">8214032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-FED04CE9440A7B7028708ED5FA9D8A01" unitRef="usd">519000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-595D2D6A170244EF0D478ED5FA8D5AA1" unitRef="usd">910000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2019Q4YTD" decimals="-3" id="Fact-03617E03E74D488C52C48ED5FAAEFF14" unitRef="usd">25000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-019E2A2C333BED8B43708ED5FA9E23F4" unitRef="shares">200501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2018Q4YTD" decimals="INF" id="Fact-37F437EA055656FA31378ED5FA9B045B" unitRef="shares">119091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="FD2019Q4YTD" decimals="INF" id="Fact-34666DEB2C2FDE92ED908ED5FA7E0DE8" unitRef="shares">324502</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="FD2019Q4YTD" decimals="INF" id="Fact-2FD522C6E05646E8AF728ED5FA5B9386" unitRef="shares">2040786</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-BFD22730FCFA405F156F8ED5FA5B559F" unitRef="usdPerShare">5.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2019Q4YTD" decimals="INF" id="Fact-36D11148701ADBE2250F8ED5FA595002" unitRef="shares">2596468</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-A8D6627D168128ED4C508ED5FA9C24CA" unitRef="usdPerShare">4.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2018Q4YTD" decimals="2" id="Fact-9BB17FC653DBCDCB148F8ED5FAA49C02" unitRef="usdPerShare">2.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q4YTD" decimals="2" id="Fact-D1372F3F5FA609E521428ED5FA9A08D6" unitRef="usdPerShare">2.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-679D5F5DE7384BA97ED68ED5FA5A537B" unitRef="shares">8752677</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q4" decimals="INF" id="Fact-6D1E6C0640C791C4BAC88ED5FA59334E" unitRef="shares">9265390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q4_us-gaap_IncomeStatementLocationAxis_ino_NonEmployeeMember" decimals="INF" id="Fact-64048EC8F5D10DA407718ED5FAA2D468" unitRef="shares">952500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-E262A7BC129D0414302B8ED5FA5A7248" unitRef="usdPerShare">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2019Q4" decimals="2" id="Fact-3C52BD17E903BB3A86068ED5FA5A140B" unitRef="usdPerShare">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-035B03D64D6E43A375308ED5FA5AB2E3" unitRef="usdPerShare">2.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-DED032D5AB410291FE558ED5FA8C3CE7" unitRef="usdPerShare">9.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2018Q4YTD" decimals="2" id="Fact-44B153080A6BD6FFF98A8ED5FA9EC546" unitRef="usdPerShare">5.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-F5A4E13AAC488E23E33B8ED5FA968665" unitRef="usdPerShare">6.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-A671CFB6F952017295E88ED5FA5AB16B" unitRef="usdPerShare">3.39</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" decimals="INF" id="Fact-82588B4C518E08CFCE018ED5FAAF0981" unitRef="usdPerShare">12.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" decimals="INF" id="Fact-3116671542B5C34E88A68ED5FA51CB26" unitRef="usdPerShare">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" decimals="INF" id="Fact-D4661DBB72DFE7CF61EB8ED5FAA18B59" unitRef="usdPerShare">1.48</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" decimals="INF" id="Fact-DE483F09521900833C448ED5FA561E93" unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" decimals="INF" id="Fact-C7BE53560801A331D7E08ED5FA450C70" unitRef="usdPerShare">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2019Q4" decimals="INF" id="Fact-D2493805D66D2BE65A628ED5FB1650A4" unitRef="shares">6745317</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" decimals="INF" id="Fact-4D12E58C1FF59FDDED2E8ED5FB0968EE" unitRef="shares">620043</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" decimals="INF" id="Fact-C7F364505B907FCB3CD28ED5FB098E35" unitRef="shares">220880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" decimals="INF" id="Fact-9380409C93827390978A8ED5FB0B2C2A" unitRef="shares">848969</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" decimals="INF" id="Fact-6FEE344F762AAE079EAD8ED5FB1937CE" unitRef="shares">3210448</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" decimals="INF" id="Fact-C6C0797A11A85A3BF5D78ED5FB09E259" unitRef="shares">1844977</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2019Q4" decimals="INF" id="Fact-86B7F604B80BEFB097708ED5FB130EF0" unitRef="shares">9265390</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" decimals="INF" id="Fact-F7B4F1675BF7C7AD41628ED5FB160E5E" unitRef="shares">620043</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" decimals="INF" id="Fact-4FA4D9C3D664F72381728ED5FB0A7710" unitRef="shares">220880</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" decimals="INF" id="Fact-7FACCF0B9F33C7B1F5148ED5FB054A49" unitRef="shares">903257</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" decimals="INF" id="Fact-D9398362462E8666FE008ED5FB120AAE" unitRef="shares">3454212</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" decimals="INF" id="Fact-6E3425CA922B22C5DF2B8ED5FB13CDCC" unitRef="shares">4066998</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" decimals="INF" id="Fact-36A13F5F650E9423A1998ED5FABA801F" unitRef="usdPerShare">15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" decimals="INF" id="Fact-D3C09B7743F2C89BD9D78ED5FA79109B" unitRef="usdPerShare">12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" decimals="INF" id="Fact-FADC1AA68A777D3645228ED5FB26A234" unitRef="usdPerShare">3</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" decimals="INF" id="Fact-8D711A9123397292F5E18ED5FA85CB12" unitRef="usdPerShare">9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" decimals="INF" id="Fact-E5A23D541D9654F0867D8ED5FA875CEA" unitRef="usdPerShare">6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-09DEFC33E2D1773C2C908ED5FAA012D0" unitRef="usd">6800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-5" id="Fact-C8C7AEF3C7FB031D40E78ED5FAA405E9" unitRef="usd">3500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B323D0DD8D205C8CA1048ED5FA4EBF79">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-531ACC7B81C09494DB24AC0D1AA2EFCF">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-8E49011D73674DB91BF38ED5FA4C81B3">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-CAC996464AB12C9717AFAC0CFB270B0A">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_EmployeesAndDirectorsMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-9AAC082217330C1399968ED5FA4EEF6E">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_ino_NonEmployeeMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-FE5A569B0993D1578A35F6B9058C4BD5">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2019Q4" decimals="-3" id="Fact-E5E2FB1B4FC5306C1B038ED5FA9B818E" unitRef="usd">881000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2019Q4" decimals="2" id="Fact-D9E4116A9A8605B09FBB8ED5FB12C79F" unitRef="usdPerShare">6.37</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" decimals="2" id="Fact-27A535273575A5AF7A548ED5FB070CBB" unitRef="usdPerShare">12.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" decimals="2" id="Fact-E8E0B5C55984277A33758ED5FB044854" unitRef="usdPerShare">9.83</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" decimals="2" id="Fact-31CE6B48F47BE2F878E58ED5FB077D3B" unitRef="usdPerShare">2.26</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" decimals="2" id="Fact-C989B85A286AD8C482EC8ED5FB14AC16" unitRef="usdPerShare">7.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" decimals="2" id="Fact-9A253788EACBED8A366A8ED5FB07C708" unitRef="usdPerShare">4.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2019Q4" decimals="2" id="Fact-4AE9E51F85C2F41FFC0F8ED5FB09DE32" unitRef="usdPerShare">5.72</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" decimals="2" id="Fact-AC3F355A6081DAB448D28ED5FB099460" unitRef="usdPerShare">12.96</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" decimals="2" id="Fact-FE0B38E10E224696321A8ED5FB06D5AC" unitRef="usdPerShare">9.83</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" decimals="2" id="Fact-115DA9E8BA268E716FF58ED5FB0BFA9D" unitRef="usdPerShare">2.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" decimals="2" id="Fact-23E6BD3CBD9B854337FF8ED5FB084FCF" unitRef="usdPerShare">7.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="FI2019Q4_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" decimals="2" id="Fact-D0A6F491B1F39ADB5A3C8ED5FB05BDBF" unitRef="usdPerShare">3.90</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD" id="Fact-67672BA15330F541E7D48ED5FB0ADBCC">P6Y5M31D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFiveMember" id="Fact-11DE0B0F5D835CBC2A118ED5FB111B73">P4Y2M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesFourMember" id="Fact-3F69758C87F5D2EE58238ED5FB11B855">P5Y9M30D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesOneMember" id="Fact-C6E0004846A0CFEB8EB18ED5FB1589A6">P3Y4M31D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesThreeMember" id="Fact-EBA30899AC00FE8FAC6C8ED5FB06E401">P6Y0M31D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ino_RangeOfExercisePricesTwoMember" id="Fact-9C22857FCDC978E069BC8ED5FB168F7D">P7Y10M30D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-195A785E06EE533C79A48ED5FAD0FB2A" unitRef="shares">74062370</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-5730FBC9CCFF7B6D7B668ED5FACFF6F1" unitRef="shares">23</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-31C6DD81AE8B47CE214E8ED5FAEBA517" unitRef="shares">90357644</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-DBF58D53353A2D268D698ED5FADAED47" unitRef="shares">23</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C242EBBB0DD0278EAEE48ED5FAF8DB1C" unitRef="shares">97225810</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-8168FF4340D4B5EBEE5A8ED5FAF87558" unitRef="shares">23</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-52CCDD23620747EC33B9F60F9D32286C" unitRef="shares">101361034</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-FE920EC18F5D946FA351F60EF575E115" unitRef="shares">23</us-gaap:SharesIssued>
	<us-gaap:ShortTermInvestments contextRef="FI2018Q4" decimals="0" id="Fact-E597D8D9526EDF8F49328ED5FABE195E" unitRef="usd">57538852</us-gaap:ShortTermInvestments>
	<us-gaap:ShortTermInvestments contextRef="FI2019Q4" decimals="0" id="Fact-BBDA93B1E104BEEAC4CD8ED5FAC2505D" unitRef="usd">67338017</us-gaap:ShortTermInvestments>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-EE97E92D3E220DF68F028ED5FAD37B2E" unitRef="shares">15437406</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6531F0DE29D135C0F5998ED5FAD432BC" unitRef="shares">5669025</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BC52706903B73EF31901F61360B3A72A" unitRef="shares">3340678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-0970752ECE4FEAB3E10A8ED5FAEC8B8E" unitRef="shares">857868</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-790F91A68A415CC3C83D8ED5FAF0F4CF" unitRef="shares">1199141</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-6F85F6E7939C8D193BE0F617AB1B54F2" unitRef="shares">794546</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q4YTD" decimals="INF" id="Fact-44D5382BBC8C50452B918ED5FA5922FB" unitRef="shares">42969</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="0" id="Fact-E1E427A968CF25E74F5A8ED5FAD96908" unitRef="usd">94347922</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-2F71A9F90E5BC9FD98BB8ED5FAF6DF60" unitRef="usd">94332485</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-ABF3B5021CC49BAD23818ED5FAF186C4" unitRef="usd">15437</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD" decimals="0" id="Fact-B32287E2785AAB622A968ED5FAE801C9" unitRef="usd">29227776</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-5A65DB925B2EA2DF3F908ED5FAD7F96E" unitRef="usd">29222107</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-2A359A7F581D3AF747258ED5FAD25BF0" unitRef="usd">5669</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD" decimals="0" id="Fact-EE11C07ACD3B5ECE808EF61360BA53D8" unitRef="usd">9089009</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-35EE6A21395B19A502C3F61360AE272D" unitRef="usd">9085669</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-7AFA7D682EFBD84B6638F61360AACB9B" unitRef="usd">3340</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD" decimals="0" id="Fact-44BAE2589A5D6DE61B7C8ED5FAD9BCAD" unitRef="usd">1342250</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-EF92B47BB3E9D972B5F48ED5FAEDD90E" unitRef="usd">1341391</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-9A1A0E3DA0FC627538D98ED5FAD5EF19" unitRef="usd">859</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2018Q4YTD" decimals="0" id="Fact-50D78C70ACD00C3ACCA68ED5FAEC4201" unitRef="usd">1809526</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-F774D9702B50A98364468ED5FAE0FD0B" unitRef="usd">1808327</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-6D83785884214036A2718ED5FACF345F" unitRef="usd">1199</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2019Q4YTD" decimals="0" id="Fact-050A3249B95F3E531AA5F61990A78A80" unitRef="usd">-780405</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-7A0F72A2543734D90BC7F6193ABD7272" unitRef="usd">-781200</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-57A34EE1991E5D2C3C20F6191163E5DC" unitRef="usd">795</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="0" id="Fact-EA109EC85173E504F6D78ED5FA6BDB83" unitRef="usd">86936138</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4" decimals="0" id="Fact-5034AF81F7CE522FFC998ED5FA5C0B08" unitRef="usd">3435099</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4" decimals="0" id="Fact-88E5A26DE5DD75C398918ED5FADD2274" unitRef="usd">123378420</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-1E601AA7084CA65BD7058ED5FAD680EC" unitRef="usd">1327968</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-3AD90F383CF2A5EAF9C18ED5FAF65CE8" unitRef="usd">556718356</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-173FB2F58A0B53F50F618ED5FACF6DC5" unitRef="usd">74062</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-BE30F94D03710A005E2F8ED5FAFA2407" unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-EA48E794627A99D9393A8ED5FAD76D8C" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-A1E5900341E20C3415908ED5FAF447CF" unitRef="usd">-434838235</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4" decimals="0" id="Fact-A7FDF3EE9A7017A631DB8ED5FAEB531B" unitRef="usd">142488809</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-376E97940F8293D5C0228ED5FAD5BA5A" unitRef="usd">-117005</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-6EB9DF88E71AEF14F9708ED5FAE755A7" unitRef="usd">665775504</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-A36C52214AECC5E0D38D8ED5FAF3E814" unitRef="usd">90358</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-0E6843DA45B6034D4DE08ED5FADB9373" unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-1097463C4ADE14A32C248ED5FAF3CF97" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-2FA052FEF59B128E07508ED5FAF400F7" unitRef="usd">-523356317</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4" decimals="0" id="Fact-372543E73753748EBB858ED5FB3D30B9" unitRef="usd">87032407</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-75EBCC51BE54EA85E5E08ED5FADD4234" unitRef="usd">-528867</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-39C4E44D06F61F7D1C908ED5FAF19FD6" unitRef="usd">707794215</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-6196017D4D513303199A8ED5FAD2C726" unitRef="usd">97226</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-8F3B37457648B17DAA0E8ED5FAF4C008" unitRef="usd">96269</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-BD5E04817225A84DF4AC8ED5FAE649B1" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-9AA8A2DF5B375A36527E8ED5FAE780FA" unitRef="usd">-620426436</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4" decimals="0" id="Fact-D115041CCAA3D00541828ED5FA5C8641" unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="0" id="Fact-940CA6509DC3759851C7F6108439011A" unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="0" id="Fact-AF2691AD4341AB7CBACEF61028123C66" unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-1022A8934011EF3E37D4F60FA0EF52D9" unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" decimals="0" id="Fact-33EC1B14FFC51E37D788F61086F10F39" unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="0" id="Fact-ADF70E4A617147DAC4C6F60EF951C0A1" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="0" id="Fact-0A9E28B48B4173310652F6102B01110F" unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
	<us-gaap:StraightLineRent contextRef="FD2017Q4YTD" decimals="0" id="Fact-23599FC761CE155EF6C48ED5FAA0379F" unitRef="usd">-3608881</us-gaap:StraightLineRent>
	<us-gaap:StraightLineRent contextRef="FD2018Q4YTD" decimals="0" id="Fact-E27E281149BAB85141BF8ED5FB25FA94" unitRef="usd">398357</us-gaap:StraightLineRent>
	<us-gaap:StraightLineRent contextRef="FD2019Q4YTD" decimals="0" id="Fact-81F67641A69742AF20BC8ED5FAC7C263" unitRef="usd">0</us-gaap:StraightLineRent>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-48A5CCB86DBC2CBCAFB28ED5FA634184" unitRef="usd">17300000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-AB740F3B6F350D3DB21F8ED5FA5FAB95" unitRef="usd">17300000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-5" id="Fact-06C0767ED2C7E4A768908ED5FA635028" unitRef="usd">3200000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-0B468A84B8B3E1689D108ED5FAF4761B" unitRef="usd">6855000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-2C48B21DAEA43AA183BF8ED5FAEAA14F" unitRef="usd">8313000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-8B71B3E355A3F4DC86F08ED5FAEFAFC9" unitRef="usd">9632000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2019Q4" decimals="-3" id="Fact-96BCE1BB15ABBB0476B88ED5FAEA20A9" unitRef="usd">11204000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6ADA14BBB9CEAB406F228ED5FAEB3970" unitRef="usd">74000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9F364A9EFFCE4F6E8ABA8ED5FAE73746" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2019Q4YTD" decimals="-3" id="Fact-688116998B3F297BEC798ED5FAF45406" unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-7F325D2EC255F529A4BE8ED5FAEEEDEA" unitRef="usd">1532000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C9E3CCABBED7428083C28ED5FAE99F4B" unitRef="usd">1319000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F0FA01CD19C118828D518ED5FAEEC258" unitRef="usd">1575000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2017Q4" decimals="-5" id="Fact-7CFD315CEC8C3A744D518ED5FAEF0346" unitRef="usd">7100000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2018Q4" decimals="-5" id="Fact-0F7260E3CC3F6FC6F9CE8ED5FAFC0E82" unitRef="usd">8300000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2019Q4" decimals="-5" id="Fact-76C33C0212276F2E1D138ED5FAEA8A07" unitRef="usd">9900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4YTD" decimals="0" id="Fact-11512DEC32C83E29FC0F8ED5FA7C3C54" unitRef="shares">81918022</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2018Q4YTD" decimals="0" id="Fact-95DC8486396357D9C2358ED5FA7FC2A5" unitRef="shares">92539997</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2019Q4YTD" decimals="0" id="Fact-934A7FB82DCC448786688ED5FA7B1FB0" unitRef="shares">98717999</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4YTD" decimals="0" id="Fact-A5BE2EE23071BC561F578ED5FA776CAB" unitRef="shares">81777493</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2018Q4YTD" decimals="0" id="Fact-1AAEE4F844FAE7813B028ED5FA7613ED" unitRef="shares">92539997</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2019Q4YTD" decimals="0" id="Fact-AED78654995589D50ADC8ED5FA7FA590" unitRef="shares">98717999</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<ino:GrantRevenuePolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-80F2BBDF4F213F2616068ED5FABD4E66">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has determined that as of January 1, 2018, accounting for the Company&amp;#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra- expense as opposed to revenue on the consolidated statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</ino:GrantRevenuePolicyTextBlock>
	<ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock contextRef="FD2019Q4YTD" id="Fact-9B8077E7AF2E55B642C08ED5FA5FABA9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration Date:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Federal NOLs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;State NOLs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Federal R&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;State R&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;282.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;186.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;149.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-6EFEAC1FB127C290F0268ED5FA50FC1E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Accounts Payable and Accrued Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued expenses at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,919,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,043,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,967,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,466,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued subcontract costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;273,508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,076,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,540,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,237,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,134,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-059B48CA06C62A557EB78ED5FAA19160">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inovio incurred a net loss attributable to common stockholders of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$119.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Inovio had working capital of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$62.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$739.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. During the year ended December 31, 2019, the Company received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from a private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$78.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2024 (the &amp;#8220;Notes&amp;#8221;), net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Korean Won (KRW) (approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due August 2024 (the "August 2019 Bonds"), net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the private placement of  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.7 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; KRW (approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due December 2024 (the "December 2019 Bonds" and, collectively with the August 2019 Bonds, the &amp;#8220;Bonds&amp;#8221;) and net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from sales of common stock under its At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp;amp; Company (the &amp;#8220;Sales Agreement&amp;#8221;). As described in Note 19 below, the Sales Agreement was amended subsequent to December 31, 2019. From January 1, 2020 through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;11, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,148,952&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the Sales Agreement, as amended, for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$208.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. These proceeds, in addition to the Company&amp;#8217;s cash, cash equivalents and short-term investments of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and long-term investments of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it issued these financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements and/or future public or private debt or equity financings including use of its Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2019, the Company announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, the Company reduced its workforce by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and discontinued its Phase 1/2 clinical trial of its immuno-oncology product candidate INO-5401 in patients with advanced bladder cancer. In the third quarter of 2019, the Company incurred a personnel-related restructuring charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with one-time employee termination costs, including severance and other benefits, all of which have been paid as of December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&amp;#8217;s consolidated financial statements as of and for the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-E00329A44EBA735B701B8ED5FAB3F5B5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementAccountingPolicy contextRef="FD2019Q4YTD" id="Fact-1BA49658D3AEAC802B1F87E45350C66E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaboration Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&amp;#160;Collaborative Arrangements&amp;#160;(&amp;#8220;Topic 808&amp;#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Topic 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-892FF309B156F554E98C8ED5FA4B362D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaborative Agreements &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;ApolloBio Corporation &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December&amp;#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&amp;#160;VGX-3100, its DNA immunotherapy product designed to treat&amp;#160;pre-cancers&amp;#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and may include Korea in the event that no patent covering&amp;#160;VGX-3100&amp;#160;is issued in China within the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years following the effective date of the ApolloBio Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the ApolloBio Agreement, the Company received proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$19.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in March 2018, which comprised the upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; less &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in foreign income taxes and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations during the quarter ended March 31, 2018. The Company also incurred advisory fees of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$960,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the upfront payment, the Company is entitled to receive up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&amp;#160;VGX-3100&amp;#160;in the United States, China and Korea. In the event that&amp;#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&amp;#160;low-&amp;#160;to&amp;#160;mid-teens,&amp;#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&amp;#8217;s obligation to pay royalties will continue for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; after the first commercial sale in a particular territory or, if later, until the expiration of the&amp;#160;last-to-expire&amp;#160;patent covering the licensed products in the specified territory. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the terms of the ApolloBio Agreement under Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; year after the effective date for any reason upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days written notice to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under Topic 606, the entire transaction price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;AstraZeneca&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$125 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and potential future commercial event-based payments totaling up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$115 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Within the broader collaboration, AstraZeneca had rights to co-develop up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2017, the Company had recognized all of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$27.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.&amp;#160;In both December 2018 and March 2019, the Company recognized as revenue &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in milestone payments from AstraZeneca triggered by AstraZeneca&amp;#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized total revenues of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from AstraZeneca primarily for manufacturing services, for which the Company determined it was the principal in the arrangement as it controlled the product supply before it is transferred to the customer, and the milestone achieved as discussed above. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$161,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the collaboration agreement with AstraZeneca.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Coalition for Epidemic Preparedness Innovations &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On April&amp;#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate&amp;#160;preclinical&amp;#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$56 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of costs over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company received funding of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to the CEPI grant and recorded those payments as contra-research and development expense. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had a grant funding liability balance related to the CEPI grant of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million recorded as grant funding liability on the consolidated balance sheet related to the CEPI grant.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-78955EB4697F890D8C638ED5FAC106B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2019Q4YTD" id="Fact-22608D7D9305B46A1DE98ED5FAACFEE5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-E1853F00D24EC1B174378ED5FA4F71DF">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Major Customers and Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Customer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019 Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;%&amp;#160;of&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018 Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;%&amp;#160;of&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017 Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;%&amp;#160;of&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ApolloBio&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,000,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;AstraZeneca&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,194,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,850,424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,269,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DARPA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,983,927&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Roche&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,107,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All other, including affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;917,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;631,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,859,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,111,930&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,481,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,220,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue from various license fees and collaborative research and development agreements. The Company has determined that as of January 1, 2018, accounting for the Company&amp;#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which is outside the scope of Topic 606. Beginning on January 1, 2018, all contributions received from current grant agreements have been recorded as a contra-expense as opposed to revenue on the consolidated statements of operations, as discussed in Note 2. During the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$469,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$161,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. As of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of the Company's accounts receivable was attributable to AstraZeneca. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
	<us-gaap:ConsolidationPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-B7660937462AC269E1648ED5FABA3C34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. ("VGX"), and records a non-controlling interest for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its subsidiary Geneos Therapeutics, Inc. ("Geneos") as well as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of VGX Animal Health, Inc., a subsidiary of VGX. All intercompany accounts and transactions have been eliminated upon consolidation. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
	<us-gaap:ConvertibleDebtTableTextBlock contextRef="FD2019Q4YTD" id="Fact-AAF26B4891B51A9756690A18097144D9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The balance of the Notes at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount on the liability component&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,082,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,938,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,700,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net carrying amount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,180,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The balance of the August 2019 Bonds at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,578,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,764,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(255,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the August 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net carrying amount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,824,948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The balance of the December 2019 Bonds at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,067,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(50,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net carrying amount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,017,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-4858F7E8EE5CA2B3E1B60A124FA20CED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Convertible Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Convertible Senior Notes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$78.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2024 (the &amp;#8220;Notes&amp;#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&amp;#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;185.8045&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares per &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount of Notes (equivalent to an initial conversion price of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.38&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share), subject to adjustment upon the occurrence of specified events.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the conversion price on (i) each of at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; trading days (whether or not consecutive) during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&amp;#160;The redemption price will be equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&amp;#8217;s own stock and classified in stockholders&amp;#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$78.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are allocated to the liability and equity component in the same proportion as the issuance proceeds. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The balance of the Notes at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,500,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount on the liability component&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14,082,302&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,938,206&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,700,833&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net carrying amount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,180,325&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&amp;#160;The effective interest rate of the liability component is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13.1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&amp;#160;the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of interest expense related to the Notes, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the contractual interest coupon. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there have not been any conversions or redemptions of the Notes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;August 2019 Convertible Bonds &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Korean Won (KRW) (approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ Market of the Korea Exchange (KOSDAQ) in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The August 2019 Bonds, which are unsecured obligations of the Company, were issued on August 1, 2019 and will accrue interest at a coupon rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum, payable quarterly. The August 2019 Bonds will mature on July 31, 2024, unless earlier converted or repurchased. The outstanding August 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Commencing on August 1, 2020, the August 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock, if KDRs are not listed on KOSDAQ at that time or the converting holder requests delivery of shares of common stock. The initial conversion rate is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;211.0595&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in principal amount (equivalent to an initial conversion price of approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate is subject to reset on January 2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;351.7658&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (equivalent to a conversion price of approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.40&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rates as of July 30, 2019). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The August 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including July 31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the August 2019 Bonds to be repurchased plus a premium in order to provide an internal rate of return with respect to the August 2019 Bonds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, upon the occurrence of a fundamental change (as defined in the August 2019 Bonds), the Company will be required to offer to repurchase the August 2019 Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon but excluding the applicable repurchase date. Upon the occurrence of an event of default (as defined in the August 2019 Bonds), with the approval of at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the bondholders, the Company will be required to offer to repurchase the August 2019 Bonds at a repurchase price equal to the principal amount thereof plus a premium in order to provide an internal rate of return with respect to the August 2019 Bonds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature is considered a derivative requiring bifurcation from the August 2019 Bonds as it does not meet the equity scope exception due to the fact that it is denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was recorded as a reduction to the carrying value of the debt. This debt discount is being amortized to&amp;#160;interest expense over the term of the debt using the effective interest method. The conversion option is accounted for as a derivative liability, which is revalued each reporting period with&amp;#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&amp;#160;statements of operations.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The balance of the August 2019 Bonds at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,578,211&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,764,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(255,185&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the August 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227,322&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,946&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net carrying amount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,824,948&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represents the point at which the August 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through August 1, 2022.&amp;#160;The effective interest rate of the August 2019 Bonds is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29.4%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&amp;#160;the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$982,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of interest expense related to the August 2019 Bonds, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$65,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the contractual interest coupon. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there have not been any conversions or redemptions of the August 2019 Bonds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The derivative liability is valued at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The change in fair value of the derivative liability was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;December 2019 Convertible Bonds &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December&amp;#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &amp;#8220;December 2019 Bonds&amp;#8221;) with an aggregate principal amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.7 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; KRW (approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&amp;#160;31, 2019 and will accrue interest at a coupon rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per annum, payable quarterly. The December 2019 Bonds will mature on December&amp;#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Commencing on December&amp;#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate will be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;214.7766&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares per KRW&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; principal amount of Bonds (equivalent to an initial conversion price of approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of December&amp;#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&amp;#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;357.961&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.40&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share based on the exchange rate as of December&amp;#160;19, 2019).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&amp;#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&amp;#8217;s own stock and classified in stockholders&amp;#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&amp;#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&amp;#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency doesn&amp;#8217;t impact the settlement of the conversion option. Further, as there is no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The balance of the December 2019 Bonds at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:27%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,067,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(50,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accretion of premium associated with the December 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net carrying amount &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,017,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. For the year ended December&amp;#160;31, 2019,&amp;#160;the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; interest expense related to the December 2019 Bonds. As of December&amp;#160;31, 2019, there have not been any conversions or redemptions of the December 2019 Bonds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, future minimum payments due under the Company's convertible debt instruments are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Convertible Notes (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;August 2019 Bonds (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 2019 Bonds (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,290,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81,051,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,021,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,236,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;106,308,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,463,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,645,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,390,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127,498,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at maturity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DerivativesPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-5C5BAEA4818311628681CAAD7464951F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivative Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-EC3D6CA49AD29D9E84EE8ED5FAAA2F25">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options, restricted stock units and warrants and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. For the year ended December 31, 2019, the dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 10) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-8321619FD5844529FFE68ED5FAA3B491">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Investments in Affiliated Entities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company held &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,644,155&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares, representing a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ownership interest in GeneOne as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;395,758&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares, representing a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15.1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ownership interest in PLS as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Please see further information as discussed in Note 2 and Note 6.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2019Q4YTD" id="Fact-92F5DA1AE01194422E7B8ED5FAB16C08">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level&amp;#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&amp;#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&amp;#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,349,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,349,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investments in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,315,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,315,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,003,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,665,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative liability (Note 10)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&amp;#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,646,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,646,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,314,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,314,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investments in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,405,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,405,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,591,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,052,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,538,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 assets at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of money market funds held by the Company that are valued at quoted market prices, as well as the Company&amp;#8217;s investments in its affiliates, GeneOne and PLS. The Company accounts for its investment in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,644,155&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares of GeneOne based on the closing price of the shares on the Korean Stock Exchange on the applicable balance sheet date. The Company accounts for its investment in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;395,758&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common shares of PLS as an equity investment with a fair value based on the closing price of the shares on the Korea New Exchange (KONEX) Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 assets at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of mutual funds. Level 2 assets at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of U.S. corporate debt securities and mutual funds. Level 2 assets held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2019, August 2019 and December 2019, the Company issued the Convertible Notes, August 2019 Bonds and December 2019 Bonds, respectively. The carrying value of the Notes and Bonds approximates the fair value as December 31, 2019. See Note 10 for additional information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Level 3 assets held as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 liabilities held at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 10 below for more information). The derivative liability was recorded at fair value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; include the Company&amp;#8217;s stock price on the valuation date; the expected annual volatility of the Company&amp;#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the derivative liability for the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Initial fair value upon issuance of the August 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,055,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Change in fair value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,763,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Level 3 liabilities held as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2019Q4YTD" id="Fact-9973E4F69FA28AE4994A8ED5FAB24292">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the changes in fair value of the derivative liability for the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Initial fair value upon issuance of the August 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,055,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Change in fair value &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,763,652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:1pt;"&gt;&lt;font style="font-family:inherit;font-size:1pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Level 3 liabilities held as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2019Q4YTD" id="Fact-1143908D3EAC98D7A9328ED5FABC372C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. After the adoption of Accounting Standards Update ("ASU") No. 2016-01 on January 1, 2018, unrealized gains and losses on the Company's equity investment in its affiliated entity Plumbline Life Sciences, Inc. ("PLS") are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. The Company&amp;#8217;s investment in GeneOne, an affiliated entity, is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) from investment in affiliated entity. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-051B11ACD1BFEF2DD74DCAAE7F7EBB83">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Foreign Currency Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-CD091F74E6B653103E378ED5FAD9D231">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Useful&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Yrs)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Indefinite lived:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Definite lived:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,802,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,802,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,802,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,742,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Licenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,323,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,248,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,323,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,219,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-indent:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:inherit;font-size:9.5pt;"&gt;CELLECTRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9.5pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,106,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,106,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,106,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,679,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;427,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;GHRH(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;335,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(335,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;335,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(303,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bioject (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,175,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,924,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,882,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,217,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,050,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,356,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;693,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,050,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,131,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;918,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,717,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,024,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,693,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,717,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,957,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,760,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total goodwill and intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,231,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,024,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,207,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,231,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,957,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,273,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;CELLECTRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and GHRH are developed technologies which were recorded from the acquisition of VGX.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Aggregate amortization expense on intangible assets was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Amortization expense related to intangible assets at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is expected to be incurred as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;492,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;275,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;253,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,604,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,693,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment or impairment indicators present and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; losses were recorded during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-74E4BE4BC01CB493AE5CCA06677A8B5E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective as of the acquisition of VGX in 2009, all new patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&amp;#160;31, 2019 and 2018, the Company&amp;#8217;s intangible assets resulting from the acquisition of VGX, as well as the acquisitions of two other companies, Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&amp;#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&amp;#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&amp;#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&amp;#160;31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&amp;#8217;s results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-493A5AE3FB2C1C1B57B48ED5FAB448E8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-F72119FBFB1038F0CDAB8ED5FAFDCC64">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of the provision for income taxes are presented in the following table: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(263,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(263,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(257,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; statutory tax rate for December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; statutory tax rate for December 31, 2017, is as follows:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (benefit) taxes at statutory rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,370,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,908,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,872,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State income tax, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,457,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,898,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,965,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,838,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,456,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(76,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(282,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,094,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,332,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Uncertain tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,537,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,268,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;846,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired NOLs and credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;616,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,176,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;454,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Limited NOLs and credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(616,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,176,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(165,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in tax rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,019,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;831,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(102,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,093,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(257,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The income tax benefit recorded during the year ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is principally due to a requirement under Accounting Standards Codification ("ASC") 740, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounting for Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and liabilities as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are shown below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,408,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;NOL carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110,788,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,399,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development and other tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,737,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,432,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,506,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;985,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,013,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,255,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,408,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;889,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;912,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,852,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,122,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;645,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,722,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,413,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,693,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145,229,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116,250,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,159,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(115,007,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,070,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,243,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(160,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(142,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right of use asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,894,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,862,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible note&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,381,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(805,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,121,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$483.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$68.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, net of the net operating losses that will expire due to IRC Section&amp;#160;382 limitations. The federal net operating loss generated in 2018 and 2019 of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$186.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will carryforward indefinitely and be available to offset up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of future taxable income each year. The federal NOL carryforward began to expire in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the California and Pennsylvania NOL carryforwards will begin to expire in 2028 and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, unless previously utilized. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, as of December 31, 2019, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration Date:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Federal NOLs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;State NOLs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Federal R&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;State R&amp;amp;D&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024 and thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;282.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Indefinite&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;186.6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;483.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;149.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&amp;#8217;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; occurs within a three-year period. The Company has completed an IRC Section&amp;#160;382/383 analysis, regarding the limitation of NOL and R&amp;amp;D credit carryforwards as of December&amp;#160;31, 2019. As a result of the analysis, the Company estimates that approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of tax benefits related to NOL and R&amp;amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;amp;D carryforwards.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,632,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,313,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,855,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases related to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,575,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,319,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,532,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases (decreases) related to prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,204,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,632,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,313,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&amp;#160;months of the reporting date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2016 and state and local income tax examinations before 2015. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (&amp;#8220;IRS&amp;#8221;), state or local tax examination.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-85F40E9913A0279EA7EE8ED5FABD714F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&amp;#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowances against the Company&amp;#8217;s deferred tax assets were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$137.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$115.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-C886755CCE6B777A14648ED5FAAA8CC4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds and equity investments in the Company&amp;#8217;s affiliated entities, PLS and GeneOne, at December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Investments included mutual funds, United States corporate debt securities and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-4E5EC44DE18D39E5C91F8ED5FA47BA3C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Short-term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Short-term investments at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of mutual funds. Short-term investments at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisted of mutual funds and United States corporate debt securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.&amp;#160;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, gross realized gain on investments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$594,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and gross realized loss on investments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$118,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, was recorded. No&amp;#160;material balances were&amp;#160;reclassified out of accumulated&amp;#160;other comprehensive income (loss) for the years ended&amp;#160;December&amp;#160;31, 2019,&amp;#160;2018&amp;#160;and&amp;#160;2017. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;available-for-sale securities in a gross unrealized loss position, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; with an aggregate total unrealized loss of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were in such position for longer than 12 months. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of available-for-sale securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&amp;#160;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Market&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;---&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,599,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;754,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&amp;#160;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Market&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;---&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,842,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(528,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,314,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less than 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;224,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,067,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(528,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,538,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-86AF926B061BDC833EB88ED5FAB1D12F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU 2016&amp;#8209;02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;Topic 842&amp;#8221;) on January 1, 2019. For long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC&amp;#160;840, Leases (Topic 840). See &amp;#8220;Recent Accounting Pronouncements - Recently Adopted&amp;#8221; below, for more information about the impact of the adoption of Topic 842.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q4YTD" id="Fact-6CB4B2618C5415154F930A78C422107F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the maturities of the Company's operating lease liabilities were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,891,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,979,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,052,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,023,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,951,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total remaining lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,897,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: present value adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,412,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,074,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,409,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:LesseeOperatingLeasesTextBlock contextRef="FD2019Q4YTD" id="Fact-9F9A7D85A5F0E0A4F3FD8ED5FB0BA8AD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Leases &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company leases approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82,200&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of office, laboratory, and manufacturing space in San Diego, California and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,360&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has evaluated all of its leases and determined that, effective upon the adoption of Topic 842, they were all operating leases. The Company performed an evaluation of its other contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the maturities of the Company's operating lease liabilities were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,891,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,979,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,052,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,023,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,001,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,951,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total remaining lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,897,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: present value adjustment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,412,236&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,074,842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,409,922&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average remaining lease term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.2 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted-average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease costs included in operating expenses in the consolidated statements of operations for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the fourth quarter of 2019, the Company entered into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; agreements to sublease a total of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2018, prior to the adoption of Topic 842, annual future minimum lease payments under non-cancelable operating leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,756,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,891,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,979,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,052,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,023,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,952,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,653,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
	<us-gaap:NatureOfOperations contextRef="FD2019Q4YTD" id="Fact-0A844B70D2BA1804D23C8ED5FAC22808">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;The Company&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inovio Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Inovio&amp;#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's novel DNA medicines are made using its proprietary SynCon&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inovio's hand-held CELLECTRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Human data to date have shown a favorable safety profile of Inovio&amp;#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; smart delivery device in more than 6,000 administrations across more than 2,000 patients.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp;amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&amp;#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp;amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-76FFE813E1D74CCFEB058ED5FAADE380">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements - Recently Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2016-02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In February 2016, the FASB issued Topic 842,&amp;#160;which requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets and to disclose key information about leasing arrangements.&amp;#160;The Company adopted the new lease standard on January 1, 2019 using the modified retrospective approach. The Company elected the available package of practical expedients upon adoption, which allowed the Company to carry forward its historical assessment of whether existing agreements contained a lease and the classification of its existing operating leases. Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its consolidated balance sheet of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company also classified deferred rent of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as an offset to the Company&amp;#8217;s operating right-of-use asset upon adoption. There were no adjustments to the Company&amp;#8217;s opening accumulated deficit balance upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 840&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Topic 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Impact of Adoption&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,065,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,065,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent, non-current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,518,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,518,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,634,769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,634,769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability, non-current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-07&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In June 2018, the FASB issued ASU 2018-07, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that simplifies the accounting for stock-based payments granted to non-employees for services by generally aligning it with the accounting for stock-based payments granted to employees. The Company adopted the standard on January 1, 2019 and there was no material impact to its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements (see Note 6 for more information about the Company&amp;#8217;s fair value classifications). ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2016-13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In June 2016, the FASB issued ASU 2016-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. ASU 2016-13 is effective beginning in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-18&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarified the interaction between Topic 808, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and Topic 606, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU&amp;#160;2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU 2017-04.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&amp;#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its consolidated financial statements or related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-6D7585F9A4F90945B0FC8ED5FA8CD97B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;401(k) Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its employees&amp;#8217; contributions, up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of their annual compensation. The Company&amp;#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$822,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-76FF09A842A8209F514F8ED5FB28516A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;and&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,007,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,996,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,011,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,102,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,229,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;873,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,048,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,944,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,103,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and other &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,781,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,996,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;784,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,939,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,166,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,773,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,909,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,464,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,444,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,031,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,425,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,606,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,198,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,767,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,431,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and other &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,808,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,341,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,466,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,948,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,999,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,949,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation expense for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented.  During the year ended December 31, 2019 the Company disposed of fixed assets with a net book value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and accumulated depreciation of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$432,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-11BB09BFF30D5D349A858ED5FAB37282">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2019Q4YTD" id="Fact-3351416087A1AAF314D88ED5FB28244E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;and&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,007,935&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,996,777&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,011,158&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,102,467&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,229,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;873,110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,048,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,944,293&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,103,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and other &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,781,020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,996,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;784,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,939,475&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(13,166,458&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,773,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,909,341&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,464,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,444,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,031,965&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,425,854&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,606,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Office furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,198,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,767,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,431,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment and other &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,808,824&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,341,968&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,466,856&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,948,933&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(9,999,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,949,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2019Q4YTD" id="Fact-B28FA1EEC57F5CE319D48ED5FA568A74">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarterly Financial Information (Unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the quarterly results of operations of the Company for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (unaudited):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consolidated Statements of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;617,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,770,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements with affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miscellaneous revenue, including from affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196,422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;279,488&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;866,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;135,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,829,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating Expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,003,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,137,209&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,486,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,389,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,696,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,681,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,850,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,975,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,700,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,818,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,336,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,364,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,421,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,951,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,200,694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,535,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;587,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;637,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;755,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,668,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,428,671&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,194,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(656,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of derivative liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,315,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,551,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss on investment in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,681,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(485,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(173,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(750,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;263,571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140,956&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss before income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,235,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,536,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,685,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,351,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;106,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,147,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,536,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,579,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,288,867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to non-controlling interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;485,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;445,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss attributable to Inovio Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,662,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,090,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,387,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,219,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consolidated Statements of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,372,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,813,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,385,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,289,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements with affiliated entity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miscellaneous revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,502,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000,868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,448,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,529,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating Expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,365,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,851,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,462,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,577,751&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,636,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,791,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,189,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,698,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,001,788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,643,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,651,930&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,275,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,499,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(26,642,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,203,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,746,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest and other income, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(169,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;380,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;396,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;312,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;259,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(127,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gain (loss) from investment in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,293,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,017,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,092,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,380,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss before provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,962,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,015,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,639,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,181,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,169,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,962,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,015,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,639,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,350,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-03AD49DAED3A16CB69768ED5FA6189A7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;GeneOne Life Sciences &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company owned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,644,155&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in GeneOne as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and one of the Company's directors, Dr.&amp;#160;David B. Weiner, acts as a consultant to GeneOne. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2010, the Company entered into a collaboration and license agreement (the &amp;#8220;GeneOne Agreement&amp;#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &amp;#8220;Product&amp;#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2011, the Company entered into a collaborative development and license agreement (the &amp;#8220;Hep Agreement&amp;#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&amp;#8217;s SynCon&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; therapeutic vaccines for hepatitis B and C infections (the &amp;#8220;Hep Products&amp;#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years after the effective date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&amp;#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&amp;#160;In return, GeneOne will receive up to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone-based ownership interest in the MERS immunotherapy asset upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&amp;#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&amp;#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&amp;#160;In return, GeneOne will receive up to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone-based ownership interest in the Zika immunotherapy asset upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2017, the Company completed the sale of certain assets related to its compound VGX-1027 to GeneOne for a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized from GeneOne for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consisting of&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#ff0000;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;patent, device maintenance and licensing fees was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$127,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$342,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$551,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating expenses recorded from transactions with GeneOne relate primarily to biologics manufacturing and were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$128,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and an accounts payable and accrued liability balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$511,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$372,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to GeneOne and its subsidiaries. At December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$284,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$381,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of prepayments made to GeneOne were classified as long-term other assets on the consolidated balance sheets.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Plumbline Life Sciences, Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company owned &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;395,758&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and one of the Company's directors, Dr.&amp;#160;David B. Weiner, acts as a consultant to PLS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue recognized from PLS consists of license fees. For the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue from PLS of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$111,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$107,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. At December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$589,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$478,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to PLS.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;The Wistar Institute&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Two of the Company's directors as of December 31, 2019, Dr.&amp;#160;David B. Weiner and Dr. Morton Collins, were directors of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar. Dr. Collins retired from the Company's Board of Directors effective January 14, 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the Company entered into collaborative research agreements with Wistar&amp;#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&amp;#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year term of the agreement. The Company will have the exclusive right to in-license new intellectual property developed in this agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2016, the Company received a&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through July 2020. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2020.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A grant funding liability recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recorded &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as contra-research and development expense from Wistar. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million, respectively. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accounts receivable balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$616,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$258,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, and an accounts payable and accrued liability balance of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$219,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$554,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, related to Wistar. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$843,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recorded as grant funding liability on its consolidated balance sheet related to Wistar.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2019Q4YTD" id="Fact-5CA98173A07BB616D3828ED5FAADB355">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-48354B7D090EA6A284D58ED5FAAB444F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective January 1, 2018, the Company adopted ASU 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;(&amp;#8220;Topic 606&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Fees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Supply Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&amp;#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&amp;#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="FD2019Q4YTD" id="Fact-8838EAB6D61AAC3023778ED5FAC14C4E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenue Recognition  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized total revenue under collaborative research and development and other agreements determined to be contracts with a customer of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from AstraZeneca and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$917,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from various other contracts. The Company defers revenue when a contract is entered into with a collaborator and cash payments are received prior to satisfaction of the related performance obligation. Of the total revenue recognized during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$293,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was in deferred revenue as of December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. During the year ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that was included in deferred revenue at December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Performance obligations are generally satisfied within 12 months of the initial contract date.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2019Q4YTD" id="Fact-58CEBBCEF268D41106CA8ED5FA515FB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts payable and accrued expenses at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consist of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Trade accounts payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,919,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,043,816&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,967,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,466,821&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued subcontract costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;273,508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83,812&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,076,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,540,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,237,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,134,733&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2019Q4YTD" id="Fact-C9D13CE0F9A1FF69559E8ED5FAAC4CE6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,752,677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,694,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,069,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,688,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,234,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,585,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;August 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,799,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,009,450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,737,956&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,449,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,937,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock contextRef="FD2019Q4YTD" id="Fact-BC024FB82062DF3AF0DB8ED5FA470256">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of available-for-sale securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&amp;#160;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Market&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;---&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;66,599,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;754,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(15,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="18" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:26%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Maturity&amp;#160;(in&amp;#160;years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&amp;#160;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair&amp;#160;Market&amp;#160;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;---&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,842,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(528,084&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,314,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less than 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;224,633&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(652&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total investments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;58,067,588&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(528,736&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,538,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2019Q4YTD" id="Fact-FD1D3DD1C6ED160ABCA28ED5FADFF57C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The components of the provision for income taxes are presented in the following table: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31, &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Current:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(263,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(263,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(257,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2019Q4YTD" id="Fact-020D5BD83B8F3285E3E38ED5FA57BC41">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets and liabilities as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are shown below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Capitalized research expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,408,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;NOL carryforwards&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;110,788,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89,399,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development and other tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,737,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,432,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,506,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;985,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,013,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,255,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,408,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;889,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;912,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,852,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,122,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;645,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lease liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,722,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,413,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,693,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145,229,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;116,250,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(137,159,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(115,007,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total deferred tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,070,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,243,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Acquired intangibles&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(160,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(142,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investment in affiliated entity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right of use asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,894,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Note discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,862,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible note&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,381,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(805,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,121,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2019Q4YTD" id="Fact-BF756B953158F71A52518ED5FAAA6EF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables reconcile the components of the numerator and denominator included in the calculations of diluted net loss per share:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Numerator&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(119,359,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(96,967,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(88,205,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment for decrease in fair value of warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(806,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator for use in diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(119,359,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(96,967,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(89,012,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Denominator&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of common shares outstanding (denominator for use in basic net loss per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98,717,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92,539,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81,777,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator for use in diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98,717,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92,539,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81,918,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2019Q4YTD" id="Fact-FB2BB5668EACC4893B1F8ED5FA59D7CD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; statutory tax rate for December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; statutory tax rate for December 31, 2017, is as follows:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income (benefit) taxes at statutory rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,370,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,908,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,872,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State income tax, net of federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Foreign income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,457,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,898,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,965,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development tax credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,838,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,456,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(76,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(282,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,114,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,094,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,332,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Uncertain tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,537,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,268,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;846,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expired NOLs and credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;616,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,176,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;454,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Limited NOLs and credits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(616,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,176,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(165,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in tax rates&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,019,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;831,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(102,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,093,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(257,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,170,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2019Q4YTD" id="Fact-6BE85B1DF361F39BFC748ED5FAB2A316">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&amp;#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,349,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,349,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investments in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,315,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,315,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,003,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,665,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67,338,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Derivative liability (Note 10)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,819,023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table presents the Company&amp;#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:35%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Fair Value Measurements at&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quoted Prices&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;in Active Markets&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Other Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Level&amp;#160;3)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,646,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,646,507&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mutual funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,314,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,314,871&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;US corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;223,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Investments in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,405,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,405,913&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;76,591,272&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,052,420&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;57,538,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2019Q4YTD" id="Fact-9F505E8DFD15DAAB932ACA708E230FF0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of December 31, 2018, prior to the adoption of Topic 842, annual future minimum lease payments under non-cancelable operating leases were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:83%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;text-decoration:underline;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,756,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,891,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,979,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,052,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,023,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,952,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,653,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="FD2019Q4YTD" id="Fact-73C9F74DF12737A8B7C78ED5FAC91F34">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="26" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Useful&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(Yrs)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Accumulated&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Net Book&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Indefinite lived:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,513,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Definite lived:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Patents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,802,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,802,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,802,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,742,079&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,449&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Licenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,323,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,248,104&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,657&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,323,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,219,357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;104,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-indent:24px;font-size:9.5pt;"&gt;&lt;font style="font-family:inherit;font-size:9.5pt;"&gt;CELLECTRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:9.5pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,106,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,106,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,106,270&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,679,190&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;427,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;GHRH(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;335,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(335,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;335,314&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(303,630&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bioject (c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,175,556&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,924,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,100,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,882,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,217,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,050,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,356,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;693,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,050,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,131,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;918,750&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,717,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,024,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,693,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,717,873&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,957,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,760,145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total goodwill and intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,231,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,024,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,207,222&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;35,231,244&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,957,728&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,273,516&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$400,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(b)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;CELLECTRA&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and GHRH are developed technologies which were recorded from the acquisition of VGX.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(c)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:0px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(d)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2019Q4YTD" id="Fact-E6835A76C9B4649F96AFCA2055FF581C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, future minimum payments due under the Company's convertible debt instruments are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Convertible Notes (1)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;August 2019 Bonds (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 2019 Bonds (2)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,290,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,103,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;41,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,300,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81,051,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,021,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,236,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;106,308,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;101,463,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,645,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,390,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127,498,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at maturity.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2019Q4YTD" id="Fact-E3B94522472CAC6C0B87F6601FFDB937">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 840&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Topic 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Impact of Adoption&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,065,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,065,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent, non-current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,518,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,518,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,634,769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,634,769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability, non-current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2019Q4YTD" id="Fact-3800B43B6408123075518ED5FA57758D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following is a summary of the quarterly results of operations of the Company for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (unaudited):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, &lt;br clear="none"/&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consolidated Statements of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;617,427&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64,283&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,770,712&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements with affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53,014&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;71,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;55,579&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miscellaneous revenue, including from affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;196,422&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,614&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;279,488&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;866,863&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;135,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,829,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating Expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,003,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,137,209&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,486,266&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,389,888&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,696,586&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,681,441&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,850,101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,975,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,700,541&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,818,650&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,336,367&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,364,917&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,421,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,951,787&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,200,694&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,535,012&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest income&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;587,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;637,438&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;755,330&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625,535&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,668,837&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,428,671&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,194,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(656,248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of derivative liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(4,315,105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,551,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Loss on investment in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,681,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(485,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(173,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(750,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other income (expense), net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;263,571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140,956&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;127,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(35,839&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss before income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,235,146&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,536,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,685,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,351,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;87,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;106,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;62,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(38,147,382&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,536,452&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,579,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,288,867&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to non-controlling interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;485,344&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;445,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;191,850&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;69,605&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss attributable to Inovio Pharmaceuticals, Inc.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,662,038&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(23,090,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,387,226&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,219,262&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.38&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.30&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Quarter&amp;#160;Ended&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;June&amp;#160;30, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;March&amp;#160;31, &lt;br clear="none"/&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Consolidated Statements of Operations:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Revenues:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,372,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,813,287&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,385,852&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,289,046&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue under collaborative research and development arrangements with affiliated entity&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;184,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60,319&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;148,008&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miscellaneous revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73,817&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92,590&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total revenues&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,502,624&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000,868&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,448,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,529,644&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Operating Expenses:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26,365,647&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,851,858&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,462,620&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,577,751&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,636,141&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,791,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,189,310&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,698,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,001,788&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28,643,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,651,930&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,275,766&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Loss from operations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(29,499,164&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(26,642,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(5,203,169&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,746,122&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Interest and other income, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(169,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;380,987&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;396,681&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;312,523&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in fair value of common stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;228,665&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;259,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(127,841&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gain (loss) from investment in affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,293,741&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,017,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,092,608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,380,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss before provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,962,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,015,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,639,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,181,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,169,811&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,962,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,015,672&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,639,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32,350,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.27&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.36&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="FD2019Q4YTD" id="Fact-E5FAA96ED078CEA10D218ED5FA7FA14F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock unit activity under the Company&amp;#8217;s equity incentive plans during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,688,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,491,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,003,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(106,634&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,069,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="FD2019Q4YTD" id="Fact-3B26907259867170FD578ED5FAA32BB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes total stock options outstanding at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Underlying Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Underlying Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted    Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.48-$3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;903,257&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;848,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.01-$6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,066,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,844,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.01-$9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,454,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,210,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.01-$12.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.01-$15.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;620,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;620,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,745,317&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2019Q4YTD" id="Fact-3B051FCF0661292E447F8ED5FA96A101">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock option activity under the Company&amp;#8217;s equity incentive plans during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,752,677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,596,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,040,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2019Q4YTD" id="Fact-0E7EE48E2182071688038ED5FAB10630">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.45%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.71%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockByClassTextBlock contextRef="FD2019Q4YTD" id="Fact-19CC1470051B94AB25EE8ED5FAA40204">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Outstanding as of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares      Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series&amp;#160;C Preferred Stock, par $0.001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2019Q4YTD" id="Fact-8506324EBB4A81CBDBFA8ED5FA5B4010">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at beginning of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,632,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,313,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,855,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases related to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,575,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,319,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,532,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases (decreases) related to prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(74,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance at end of the year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,204,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,632,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,313,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2019Q4YTD" id="Fact-FF144FE4C23B9EAD5A238ED5FADDDF70">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amortization expense related to intangible assets at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is expected to be incurred as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Year ending December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;547,081&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;520,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;492,818&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;275,760&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;253,333&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,604,445&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,693,851&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2019Q4YTD" id="Fact-896C4B8C82584C821E118ED5FA4F4221">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:32%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Customer&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2019 Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;%&amp;#160;of&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2018 Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;%&amp;#160;of&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017 Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;%&amp;#160;of&amp;#160;Total&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ApolloBio&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23,000,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;AstraZeneca&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,194,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,850,424&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,269,773&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;DARPA&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,983,927&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Roche&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,107,254&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All other, including affiliated entities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;917,053&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;631,473&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,859,132&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,111,930&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,481,897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;42,220,086&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-E2739CC198BE2DAF0DC88ED5FAAC2930">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segment Reporting &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment operating primarily within the United States.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q4YTD" id="Fact-FC9C86FC29BE19E38C858ED5FAABC17E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Inovio incurred a net loss attributable to common stockholders of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$119.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Inovio had working capital of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$62.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$739.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. During the year ended December 31, 2019, the Company received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from a private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$78.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible senior notes due 2024 (the &amp;#8220;Notes&amp;#8221;), net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the private placement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Korean Won (KRW) (approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due August 2024 (the "August 2019 Bonds"), net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from the private placement of  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.7 billion&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; KRW (approximately USD &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; based on the exchange rate on the date of issuance) aggregate principal amount of its &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; convertible bonds due December 2024 (the "December 2019 Bonds" and, collectively with the August 2019 Bonds, the &amp;#8220;Bonds&amp;#8221;) and net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from sales of common stock under its At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp;amp; Company (the &amp;#8220;Sales Agreement&amp;#8221;). As described in Note 19 below, the Sales Agreement was amended subsequent to December 31, 2019. From January 1, 2020 through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;11, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,148,952&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the Sales Agreement, as amended, for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$208.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. These proceeds, in addition to the Company&amp;#8217;s cash, cash equivalents and short-term investments of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;89.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and long-term investments of $&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, are sufficient to support the Company's operations for a period of at least 12 months from the date it issued these financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements and/or future public or private debt or equity financings including use of its Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2019, the Company announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, the Company reduced its workforce by approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;28%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and discontinued its Phase 1/2 clinical trial of its immuno-oncology product candidate INO-5401 in patients with advanced bladder cancer. In the third quarter of 2019, the Company incurred a personnel-related restructuring charge of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in connection with one-time employee termination costs, including severance and other benefits, all of which have been paid as of December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&amp;#8217;s consolidated financial statements as of and for the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. ("VGX"), and records a non-controlling interest for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of its subsidiary Geneos Therapeutics, Inc. ("Geneos") as well as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of VGX Animal Health, Inc., a subsidiary of VGX. All intercompany accounts and transactions have been eliminated upon consolidation. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Segment Reporting &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment operating primarily within the United States.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has contracts with certain of its customers that have represented more than &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company's total revenues, as discussed in Note 7.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. After the adoption of Accounting Standards Update ("ASU") No. 2016-01 on January 1, 2018, unrealized gains and losses on the Company's equity investment in its affiliated entity Plumbline Life Sciences, Inc. ("PLS") are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. The Company&amp;#8217;s investment in GeneOne, an affiliated entity, is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) from investment in affiliated entity. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds and equity investments in the Company&amp;#8217;s affiliated entities, PLS and GeneOne, at December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Investments included mutual funds, United States corporate debt securities and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&amp;#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allowance for doubtful accounts was deemed necessary at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fixed Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;not&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recognized any losses on long-lived assets through December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Valuation of Intangible Assets and Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective as of the acquisition of VGX in 2009, all new patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&amp;#160;31, 2019 and 2018, the Company&amp;#8217;s intangible assets resulting from the acquisition of VGX, as well as the acquisitions of two other companies, Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&amp;#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&amp;#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&amp;#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&amp;#160;31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&amp;#8217;s results of operations. See Note&amp;#160;9 for further discussion of the Company&amp;#8217;s goodwill and intangible assets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Income Taxes &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&amp;#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowances against the Company&amp;#8217;s deferred tax assets were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$137.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$115.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaboration Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&amp;#160;Collaborative Arrangements&amp;#160;(&amp;#8220;Topic 808&amp;#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Topic 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective January 1, 2018, the Company adopted ASU 2014-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;(&amp;#8220;Topic 606&amp;#8221;)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;License Fees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Product Supply Services&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&amp;#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Milestone Payments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&amp;#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Royalties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Grants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has determined that as of January 1, 2018, accounting for the Company&amp;#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#333333;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra- expense as opposed to revenue on the consolidated statement of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Derivative Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Foreign Currency Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Research and Development Expenses&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options, restricted stock units and warrants and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. For the year ended December 31, 2019, the dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 10) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables reconcile the components of the numerator and denominator included in the calculations of diluted net loss per share:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Numerator&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss attributable to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(119,359,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(96,967,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(88,205,772&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Adjustment for decrease in fair value of warrant liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(806,819&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator for use in diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(119,359,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(96,967,830&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(89,012,591&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Denominator&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average number of common shares outstanding (denominator for use in basic net loss per share)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98,717,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92,539,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81,777,493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive potential common shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;140,529&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator for use in diluted net loss per share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;98,717,999&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;92,539,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;81,918,022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.09&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,752,677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,694,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,069,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,688,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,234,168&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Convertible notes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,585,653&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;August 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,799,071&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2019 Bonds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,009,450&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30,737,956&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,449,150&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,937,494&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU 2016&amp;#8209;02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&amp;#8220;Topic 842&amp;#8221;) on January 1, 2019. For long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC&amp;#160;840, Leases (Topic 840). See &amp;#8220;Recent Accounting Pronouncements - Recently Adopted&amp;#8221; below, for more information about the impact of the adoption of Topic 842.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.20%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:15%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Year Ended December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.45%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.71%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;88%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;99%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected life in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements - Recently Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2016-02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In February 2016, the FASB issued Topic 842,&amp;#160;which requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets and to disclose key information about leasing arrangements.&amp;#160;The Company adopted the new lease standard on January 1, 2019 using the modified retrospective approach. The Company elected the available package of practical expedients upon adoption, which allowed the Company to carry forward its historical assessment of whether existing agreements contained a lease and the classification of its existing operating leases. Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its consolidated balance sheet of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The Company also classified deferred rent of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as an offset to the Company&amp;#8217;s operating right-of-use asset upon adoption. There were no adjustments to the Company&amp;#8217;s opening accumulated deficit balance upon adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;ASC 840&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Topic 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Impact of Adoption&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,065,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,065,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent, non-current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,518,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,518,207&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,634,769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,634,769&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability, current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,733,600&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Operating lease liability, non-current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,484,763&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-07&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In June 2018, the FASB issued ASU 2018-07, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation&amp;#8212;Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that simplifies the accounting for stock-based payments granted to non-employees for services by generally aligning it with the accounting for stock-based payments granted to employees. The Company adopted the standard on January 1, 2019 and there was no material impact to its consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In August 2018, the FASB issued ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements (see Note 6 for more information about the Company&amp;#8217;s fair value classifications). ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Recent Accounting Pronouncements - Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2016-13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In June 2016, the FASB issued ASU 2016-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. ASU 2016-13 is effective beginning in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU No. 2018-18&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In November 2018, the FASB issued ASU 2018-18, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which clarified the interaction between Topic 808, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Collaborative Arrangements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and Topic 606, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU&amp;#160;2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;ASU 2017-04.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; In January 2017, the FASB issued ASU 2017-04,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&amp;#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its consolidated financial statements or related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-68F5E3430DAF96B30B3B8ED5FA9AFA9F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Outstanding as of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Authorized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares      Issued&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Series&amp;#160;C Preferred Stock, par $0.001&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,091&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;23&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The shares of the Company&amp;#8217;s Series&amp;#160;C Preferred Stock have the following pertinent rights and privileges, as set forth in the Company&amp;#8217;s Amended and Restated Certificate of Incorporation and its Certificates of Designations, Rights and Preferences related to the various series of preferred stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Rights on Liquidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a &amp;#8220;liquidation event&amp;#8221;), before any distribution of assets of the Company shall be made to or set apart for the holders of common stock, the holders of Series&amp;#160;C Preferred Stock, pari passu, are entitled to receive payment of such assets of the Company in an amount equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of such series of preferred stock, plus any accumulated and unpaid dividends thereon (whether or not earned or declared).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If the assets of the Company available for distribution to stockholders exceed the aggregate amount of the liquidation preferences payable with respect to all shares of each series of preferred stock then outstanding, then, after the payment of such preferences is made or irrevocably set aside, the holders of the Company&amp;#8217;s common stock are entitled to receive a pro rata portion of such assets based on the aggregate number of shares of common stock held by each such holder. The holders of the Company&amp;#8217;s outstanding preferred stock shall participate in such a distribution on a pro-rata basis, computed based on the number of shares of common stock which would be held by such preferred holders if immediately prior to the liquidation event all of the outstanding shares of the preferred stock had been converted into shares of common stock at the then current conversion value applicable to each series.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A Change of Control of the Company (as defined in the Certificates of Designations, Rights and Preferences) is not a liquidation event triggering the preferences described above, and is instead addressed by separate terms in the Series&amp;#160;C Certificates of Designations, Rights, and Preferences.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Although the liquidation preferences are in excess of the par value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share of the Company&amp;#8217;s preferred stock, these preferences are equal to or less than the stated value of such shares based on their original purchase price.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Voting Rights&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The holders of Series C Preferred Stock have full voting rights and powers equal to the voting rights and powers of holders of the Company&amp;#8217;s common stock and are entitled to notice of any stockholders&amp;#8217; meeting in accordance with the Company&amp;#8217;s Bylaws. Holders are entitled to vote on any matter upon which holders of the Company&amp;#8217;s common stock have the right to vote, including, without limitation, the right to vote for the election of directors together with the holders of common stock as one class. Series C Preferred holders are entitled to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;368&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; votes for each share of Series C Preferred Stock held. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Holder Optional Conversion Right &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The holder of any share or shares of Series&amp;#160;C Preferred Stock has the right at any time, at such holder&amp;#8217;s option, to convert all or any lesser portion of such holder&amp;#8217;s shares of the Preferred Stock into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i)&amp;#160;the aggregate Liquidation Preference applicable to the particular series of preferred shares, plus accrued and unpaid dividends thereon by (ii)&amp;#160;the applicable Conversion Value (as defined in the relevant series&amp;#8217; Certificate of Designations, Rights and Preferences) then in effect for such series of preferred shares. As of December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Conversion Value was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$27.20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, such that the outstanding shares of Series C Preferred Stock were convertible into &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,456&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock. The Company is not obligated to issue any fractional shares or scrip representing fractional shares upon such conversion and instead shall pay the holder an amount in cash equal to such fraction multiplied by the current market price per share of the Company&amp;#8217;s common stock.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Company Mandatory Conversion Option&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has the option upon &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;thirty&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (30)&amp;#160;days prior written notice, to convert all of the outstanding shares of the Series&amp;#160;C Preferred Stock into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i)&amp;#160;the aggregate Liquidation Preference of the shares of the relevant series of preferred stock to be converted, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series&amp;#8217; Certificate of Designations, Rights and Preferences) then in effect, if the following triggering events have occurred:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:66px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(i) the price of the Company&amp;#8217;s common stock exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$72.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; out of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days; and&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:65px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ii) the average daily trading volume (subject to adjustment for stock dividends, subdivisions and combinations) of the common stock exceeds &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,250&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares for at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; out of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consecutive trading days.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2018, the Company entered into the Sales Agreement with Stifel, Nicolaus and Company (the &amp;#8220;Placement Agent&amp;#8221;) to sell shares of its common stock with aggregate gross proceeds of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, from time to time, through an &amp;#8220;at-the-market&amp;#8221; equity offering program under which the Placement Agent will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,340,678&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the Sales Agreement. The sales were made at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.78&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share resulting in aggregate net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company may sell up to an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in shares of its common stock under the Sales Agreement. The registration statement that registered with the SEC the shares that may be sold under the Sales Agreement expires on June 8, 2021.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As described in Note 19 below, subsequent to December 31, 2019, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement to increase the amount of common stock that may be sold under the Sales Agreement from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company also sold shares of common stock under the Sales Agreement subsequent to December 31, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2016, the Company entered into an At-the-Market Equity Offering Sales Agreement (the &amp;#8220;Prior Sales Agreement&amp;#8221;) with the same placement agent. The registration statement that registered with the SEC the shares sold under the Prior Sales Agreement expired on June 5, 2018, and no further sales can be made under the Prior Sales Agreement. The Company sold an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,911,104&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the Prior Sales Agreement resulting in aggregate net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$32.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. During the period from January 1, 2018 to June 5, 2018, the Company sold a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;314,950&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the Prior Sales Agreement. The sales were made at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.07&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share resulting in aggregate net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. During the year ended December 31, 2017, the Company sold a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,937,406&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the Prior Sales Agreement. The sales were made at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.41&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share resulting in aggregate net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the year ended December 31, 2018, warrants to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;284,091&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock were exercised, with net proceeds to the Company of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$902,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. As of December 31, 2019 and 2018, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; common stock warrants outstanding. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Stock Options and Restricted Stock Units&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&amp;#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, provided that commencing with the first business day of each calendar year beginning January&amp;#160;1, 2020, such maximum number of shares shall be increased by&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued was increased by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;16,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,214,032&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock available for future grant under the 2016 Incentive Plan, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,069,936&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares underlying outstanding but unvested restricted stock units and options outstanding to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,497,736&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and have a maximum contractual term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. The 2016 Incentive Plan terminates by its terms on March&amp;#160;9, 2026.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&amp;#160;31, 2007 and terminated by its terms on March&amp;#160;31, 2017. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had options outstanding to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,767,654&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and have a maximum contractual term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$10.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$12.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$5.8&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million was included in research and development expenses and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was included in general and administrative expenses, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of total unrecognized compensation expense related to unvested stock options, which are each expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.3&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, respectively.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$970,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$302,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$201,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. As of December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;952,500&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock granted to non-employees remained outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes total stock options outstanding at December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;font style="font-family:inherit;font-size:9pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Options Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Underlying Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Contractual Life&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares Underlying Options&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted    Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.48-$3.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;903,257&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.4&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.29&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;848,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.01-$6.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,066,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.90&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,844,977&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.01-$9.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,454,212&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,210,448&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.01-$12.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;220,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9.83&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.01-$15.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;620,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;620,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12.96&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,745,317&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.37&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the aggregate intrinsic value of options outstanding was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$918,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the aggregate intrinsic value of options exercisable was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$881,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and the weighted average remaining contractual term of options exercisable was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.7&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the aggregate intrinsic value of unvested restricted stock units was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At December 31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, options to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,069,936&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; restricted stock units were expected to vest.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock option activity under the Company&amp;#8217;s equity incentive plans during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was as follows: &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,752,677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.35&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,596,468&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.39&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(42,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,040,786&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.49&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,265,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.72&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Restricted stock unit activity under the Company&amp;#8217;s equity incentive plans during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:85%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,688,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,491,771&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,003,218&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cancelled&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(106,634&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance, December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,069,936&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average exercise price per share was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.27&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;324,502&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options which expired during the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$5.17&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;119,091&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options which expired during the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$9.67&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;200,501&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options which expired during the year ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant date fair value per share was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.19&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.86&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$4.33&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for options granted during the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted average grant date fair value was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.31&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.66&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share for restricted stock units granted during the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$113,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in proceeds from the exercise of stock options during the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The aggregate intrinsic value of options exercised was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$910,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;"&gt;$519,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the years ended December&amp;#160;31, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2019Q4YTD" id="Fact-73F1F9A431AEAFE6DE0A8ED5FB1B1C8A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Subsequent Events&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February&amp;#160;7, 2020, the Company entered into an amendment to the Sales Agreement, which amendment increased the amount of common stock that could be sold by the Company under the Sales Agreement from an aggregate offering price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$100.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to an aggregate offering price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. On March&amp;#160;9, 2020, the Company entered into a second amendment to the&amp;#160;Sales Agreement, which amendment increased the amount of common stock that could be sold by the Company under the Sales Agreement from an aggregate offering price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$200.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to an aggregate offering price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$250.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Under the Sales Agreement, as amended, the Company set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales were requested to be made, limitation on the number of shares that could be sold in any one trading day and any minimum price below which sales could not be made. The Sales Agreement provided that the Placement Agent is entitled to compensation for its services in an amount equal to up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From January 1, 2020 through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;March&amp;#160;11, 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,148,952&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under its Sales Agreement for net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$208.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million. The sales were made at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.92&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. As of the date these financial statements were issued, there is no remaining capacity under the Sales Agreement, as amended.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company will receive shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares, the Company will hold a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.9%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ownership interest in PLS.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2019Q4YTD" id="Fact-90FE500B53C1EA76053A8ED5FABE25C2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&amp;#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2019Q4YTD" id="Fact-D587E5791855B8A228EE8ED5FAB19A99">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
		<link:loc xlink:href="#Fact-6465C62ED180DBC0DCD28ED5FAE8722F" xlink:label="Fact-6465C62ED180DBC0DCD28ED5FAE8722F_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-6EBF28763E8A0B91F4838ED5FAFABFD5" xlink:label="Fact-6EBF28763E8A0B91F4838ED5FAFABFD5_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-88EA0BE9D5CBC2CA36D68ED5FAFB3360" xlink:label="Fact-88EA0BE9D5CBC2CA36D68ED5FAFB3360_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-8EBC099A7DE4E2D7396A8ED5FAD83B10" xlink:label="Fact-8EBC099A7DE4E2D7396A8ED5FAD83B10_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-C93B91485819D997ABDB8ED5FADE0EEC" xlink:label="Fact-C93B91485819D997ABDB8ED5FADE0EEC_lbl" xlink:type="locator" />
		<link:loc xlink:href="#Fact-D55CA09D740D957CB4C28ED5FAE94514" xlink:label="Fact-D55CA09D740D957CB4C28ED5FAE94514_lbl" xlink:type="locator" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6465C62ED180DBC0DCD28ED5FAE8722F_lbl" xlink:to="Footnote-6A2697EB30BD678C471AC9FCF00F1795_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-6EBF28763E8A0B91F4838ED5FAFABFD5_lbl" xlink:to="Footnote-6A2697EB30BD678C471AC9FCF00F1795_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-88EA0BE9D5CBC2CA36D68ED5FAFB3360_lbl" xlink:to="Footnote-160C359149823538668FC9FC652FBC0A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-8EBC099A7DE4E2D7396A8ED5FAD83B10_lbl" xlink:to="Footnote-6A2697EB30BD678C471AC9FCF00F1795_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-C93B91485819D997ABDB8ED5FADE0EEC_lbl" xlink:to="Footnote-160C359149823538668FC9FC652FBC0A_lbl" xlink:type="arc" />
		<link:footnoteArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Fact-D55CA09D740D957CB4C28ED5FAE94514_lbl" xlink:to="Footnote-160C359149823538668FC9FC652FBC0A_lbl" xlink:type="arc" />
		<link:footnote xlink:label="Footnote-160C359149823538668FC9FC652FBC0A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Upon adoption of ASU 2016-09 on January 1, 2017, the Company elected to remove the forfeiture rate from the calculation of stock-based compensation and recorded a cumulative catch-up adjustment to accumulated deficit with a corresponding offset to additional paid-in-capital of $312,000.</link:footnote>
		<link:footnote xlink:label="Footnote-6A2697EB30BD678C471AC9FCF00F1795_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a $231,000 cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in PLS from accumulated other comprehensive loss to accumulated deficit.</link:footnote>
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>ino-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20191231" xmlns:ino="http://www.inovio.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="A401KPlan" roleURI="http://www.inovio.com/role/A401KPlan">
        <link:definition>2122100 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401KPlanDetails" roleURI="http://www.inovio.com/role/A401KPlanDetails">
        <link:definition>2422401 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedExpenses" roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses">
        <link:definition>2117100 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedExpensesDetails" roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails">
        <link:definition>2417402 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableAndAccruedExpensesTables" roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables">
        <link:definition>2317301 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>2104100 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>2404401 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Company" roleURI="http://www.inovio.com/role/Company">
        <link:definition>2101100 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>1003000 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperations" roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>1004001 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceOfConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails">
        <link:definition>2415403 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>2415402 - Disclosure - Convertible Debt Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNotes" roleURI="http://www.inovio.com/role/ConvertibleDebtNotes">
        <link:definition>2115100 - Disclosure - Convertible Debt (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleOfMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails">
        <link:definition>2415404 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>2315301 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.inovio.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.inovio.com/role/FairValueMeasurements">
        <link:definition>2106100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2406402 - Disclosure - Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails">
        <link:definition>2406404 - Disclosure - Fair Value Measurements Marketable Securities and Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2406403 - Disclosure - Fair Value Measurements Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.inovio.com/role/FairValueMeasurementsTables">
        <link:definition>2306301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.inovio.com/role/FixedAssets">
        <link:definition>2113100 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.inovio.com/role/FixedAssetsDetails">
        <link:definition>2413402 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.inovio.com/role/FixedAssetsTables">
        <link:definition>2313301 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets">
        <link:definition>2114100 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails">
        <link:definition>2414404 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails">
        <link:definition>2414403 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails">
        <link:definition>2414402 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetailsCalc2" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetailsCalc2">
        <link:definition>2414402 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2314301 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>2121100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails">
        <link:definition>2421406 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2421404 - Disclosure - Income Taxes Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails">
        <link:definition>2421403 - Disclosure - Income Taxes Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2421405 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails">
        <link:definition>2421402 - Disclosure - Income Taxes Summary of the Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.inovio.com/role/IncomeTaxesTables">
        <link:definition>2321301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
        <link:definition>2421407 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInAffiliatedEntities" roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntities">
        <link:definition>2120100 - Disclosure - Investments in Affiliated Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInAffiliatedEntitiesDetails" roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails">
        <link:definition>2420401 - Disclosure - Investments in Affiliated Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.inovio.com/role/Leases">
        <link:definition>2119100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.inovio.com/role/LeasesNarrativeDetails">
        <link:definition>2419402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details">
        <link:definition>2419404 - Disclosure - Leases - Summary of Future Minimum Lease Payments Before Adoption of Topic 842 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" roleURI="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails">
        <link:definition>2419403 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetailsCalc2" roleURI="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetailsCalc2">
        <link:definition>2419403 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.inovio.com/role/LeasesTables">
        <link:definition>2319301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersAndConcentrationOfCreditRisk" roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk">
        <link:definition>2110100 - Disclosure - Major Customers and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersAndConcentrationOfCreditRiskDetails" roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails">
        <link:definition>2410402 - Disclosure - Major Customers and Concentration of Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersAndConcentrationOfCreditRiskTables" roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables">
        <link:definition>2310301 - Disclosure - Major Customers and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2125100 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedDetails" roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2425402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2325301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>2124100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2424401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.inovio.com/role/RevenueRecognition">
        <link:definition>2103100 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>2403402 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestments" roleURI="http://www.inovio.com/role/ShortTermInvestments">
        <link:definition>2105100 - Disclosure - Short-term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsNarrativeDetails" roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails">
        <link:definition>2405402 - Disclosure - Short-term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails">
        <link:definition>2405403 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShortTermInvestmentsTables" roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables">
        <link:definition>2305301 - Disclosure - Short-term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>2118100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2418403 - Disclosure - Stockholders' Equity Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryOfPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails">
        <link:definition>2418402 - Disclosure - Stockholders' Equity Summary of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails">
        <link:definition>2418406 - Disclosure - Stockholders' Equity Summary of RSU Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails">
        <link:definition>2418405 - Disclosure - Stockholders' Equity Summary of Stock Option Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryOfStockOptionsOutstandingDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails">
        <link:definition>2418404 - Disclosure - Stockholders' Equity Summary of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>2318301 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>2126100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>2426401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Impact of Recently Issued Accounting Standards - Impact of Adopting ASU 2016-02 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="ino_A2007IncentivePlanMember" name="A2007IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_A2016IncentivePlanMember" name="A2016IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_A6.50ConvertibleSeniorNotesDue2024Member" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_AccruedClinicalTrialExpenseCurrent" name="AccruedClinicalTrialExpenseCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_AccruedSubcontractExpenses" name="AccruedSubcontractExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_AdjustmentForChangeInFairValueOfWarrantLiability" name="AdjustmentForChangeInFairValueOfWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_AfterJanuary22020ConversionPriceMember" name="AfterJanuary22020ConversionPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_AfterJuly22020ConversionPriceMember" name="AfterJuly22020ConversionPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_AllOtherCustomersMember" name="AllOtherCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_AmortizationOfOperatingLeaseRightOfUseAssets" name="AmortizationOfOperatingLeaseRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_ApolloBioMember" name="ApolloBioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" name="AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_August2019ConvertibleBondsMember" name="August2019ConvertibleBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_BiojectMember" name="BiojectMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CaliforniaIncomeTaxAuthorityMember" name="CaliforniaIncomeTaxAuthorityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CellectraMember" name="CellectraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ChangeInFairValueOfCommonStockWarrants" name="ChangeInFairValueOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_ChangeInValueOfCommonStockWarrants" name="ChangeInValueOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CoalitionforEpidemicPreparednessInnovationsMember" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" name="CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" name="CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementRoyaltyPeriod" name="CollaborationAgreementRoyaltyPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborationAgreementTerritoryExpansionOptionPeriod" name="CollaborationAgreementTerritoryExpansionOptionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementAdvisoryFees" name="CollaborativeAgreementAdvisoryFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_CollaborativeAgreementCorporateIncomeTax" name="CollaborativeAgreementCorporateIncomeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementExpensesToReimburse" name="CollaborativeAgreementExpensesToReimburse" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementForeignNonIncomeTaxes" name="CollaborativeAgreementForeignNonIncomeTaxes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementFundingToBeReceived" name="CollaborativeAgreementFundingToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" name="CollaborativeAgreementMilestonePaymentRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_CollaborativeArrangementTerm" name="CollaborativeArrangementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_CommonStockEquivalentsAbstract" name="CommonStockEquivalentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ComprehensiveIncomeLossTaxExpenseBenefit" name="ComprehensiveIncomeLossTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_ConvertibleBondsMember" name="ConvertibleBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion" name="ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" name="ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays" name="ConvertiblePreferredStockThresholdConsecutiveTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ConvertiblePreferredStockThresholdTradingDays" name="ConvertiblePreferredStockThresholdTradingDays" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DebtInstrumentAccretionOfPremium" name="DebtInstrumentAccretionOfPremium" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DebtInstrumentConvertibleInternalRateOfReturn" name="DebtInstrumentConvertibleInternalRateOfReturn" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" name="DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DebtinstrumentAccruedInterest" name="DebtinstrumentAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_December2019ConvertibleBondsMember" name="December2019ConvertibleBondsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" name="DefenseAdvancedResearchProjectsAgencyDARPAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_DeferredGrantFundingCurrent" name="DeferredGrantFundingCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredGrantFundingFromAffiliate" name="DeferredGrantFundingFromAffiliate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredGrantFundingFromAffiliateCurrent" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredGrantFundingFromAffiliateNoncurrent" name="DeferredGrantFundingFromAffiliateNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredRevenueFromAffiliatedEntityCurrent" name="DeferredRevenueFromAffiliatedEntityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredTaxAssetInterestExpense" name="DeferredTaxAssetInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredTaxAssetsIntangibleAssets" name="DeferredTaxAssetsIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredTaxAssetsOperatingLeaseLiability" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" name="DeferredTaxLiabilitiesFinancingArrangementDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_DenominatorAbstract" name="DenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" name="EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" name="EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" name="EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_EmployeeMember" name="EmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_EmployeesAndDirectorsMember" name="EmployeesAndDirectorsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_EquityComponentOfConvertibleDebtIssued" name="EquityComponentOfConvertibleDebtIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_EventOfDefaultMember" name="EventOfDefaultMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_GeneOneLifeSciencesMember" name="GeneOneLifeSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_GeneosTherapeuticsInc.Member" name="GeneosTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_GhrhMember" name="GhrhMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_GoodwillAndIntangibleAssetsGross" name="GoodwillAndIntangibleAssetsGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_GoodwillAndIntangibleAssetsNet" name="GoodwillAndIntangibleAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_GoodwillAndIntangibleAssetsTextualAbstract" name="GoodwillAndIntangibleAssetsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_GrantProceedsReceived" name="GrantProceedsReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_GrantRevenuePolicyTextBlock" name="GrantRevenuePolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_GrantwithAffiliatedRevenueMember" name="GrantwithAffiliatedRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_HoffmanLaRocheMember" name="HoffmanLaRocheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_IncomeTaxReconciliationFairValueWarrant" name="IncomeTaxReconciliationFairValueWarrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncomeTaxReconciliationStatuteLimitations" name="IncomeTaxReconciliationStatuteLimitations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" name="IncreaseDecreaseInDeferredRevenueFromRelatedParties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" name="IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_InitialConversionPriceMember" name="InitialConversionPriceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_InovioAsMember" name="InovioAsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_IssuanceOfCommonStockForCashFinancingCosts" name="IssuanceOfCommonStockForCashFinancingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_LesseeNumberOfLeaseAgreementsEnteredInto" name="LesseeNumberOfLeaseAgreementsEnteredInto" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_LicensewithAffiliatedEntitiesMember" name="LicensewithAffiliatedEntitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_MCDCMember" name="MCDCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" name="MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_MedImmuneMember" name="MedImmuneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_MilestoneBasedOwnershipTarget" name="MilestoneBasedOwnershipTarget" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_MutualFundsMember" name="MutualFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NonCashInterestExpense" name="NonCashInterestExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_NonEmployeeMember" name="NonEmployeeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NumberOfAdditionalProducts" name="NumberOfAdditionalProducts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" name="NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_NumberofVotesPerShare" name="NumberofVotesPerShare" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_NumeratorAbstract" name="NumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" name="OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLossCarryforwardsExpiringinFiveYears" name="OperatingLossCarryforwardsExpiringinFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLossCarryforwardsExpiringinFourYears" name="OperatingLossCarryforwardsExpiringinFourYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLossCarryforwardsExpiringinThreeYears" name="OperatingLossCarryforwardsExpiringinThreeYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLossCarryforwardsExpiringinTwoYears" name="OperatingLossCarryforwardsExpiringinTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" name="OperatingLossCarryforwardsExpiringintheNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OperatingLossCarryforwardsIndefinitelyCarryforward" name="OperatingLossCarryforwardsIndefinitelyCarryforward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" name="OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_OtherCounterpartyMember" name="OtherCounterpartyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_PLSaffiliatedentityMember" name="PLSaffiliatedentityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_PennsylvaniaStateIncomeTaxAuthorityMember" name="PennsylvaniaStateIncomeTaxAuthorityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_PlumblineLifeSciencesMember" name="PlumblineLifeSciencesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_PlymouthMeetingPennsylvaniaMember" name="PlymouthMeetingPennsylvaniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion" name="PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_PreferredStockConversionNoticePeriod" name="PreferredStockConversionNoticePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_PriorATMSalesAgreementMember" name="PriorATMSalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ProceedsFromCollaborativeAgreement" name="ProceedsFromCollaborativeAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" name="ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_ProceedsFromSubGrant" name="ProceedsFromSubGrant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_ProceedsfromStockOptionandWarrantExercises" name="ProceedsfromStockOptionandWarrantExercises" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_RangeOfExercisePricesFiveMember" name="RangeOfExercisePricesFiveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_RangeOfExercisePricesFourMember" name="RangeOfExercisePricesFourMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_RangeOfExercisePricesOneMember" name="RangeOfExercisePricesOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_RangeOfExercisePricesThreeMember" name="RangeOfExercisePricesThreeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_RangeOfExercisePricesTwoMember" name="RangeOfExercisePricesTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent" name="RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_SalesAgreementMember" name="SalesAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_SanDiegoCaliforniaMember" name="SanDiegoCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" name="ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod" name="StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSalesAgreementAgentFee" name="StockSalesAgreementAgentFee" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="ino_StockSalesAgreementRemainingAuthorizedSalesAmount" name="StockSalesAgreementRemainingAuthorizedSalesAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxBenefitsExpired" name="TaxBenefitsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxCreditCarryforwardCarryforwardIndefinitely" name="TaxCreditCarryforwardCarryforwardIndefinitely" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxCreditCarryforwardExpiringinFiveYears" name="TaxCreditCarryforwardExpiringinFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxCreditCarryforwardExpiringinFourMonths" name="TaxCreditCarryforwardExpiringinFourMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxCreditCarryforwardExpiringinThreeMonths" name="TaxCreditCarryforwardExpiringinThreeMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxCreditCarryforwardExpiringinTwoYears" name="TaxCreditCarryforwardExpiringinTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" name="TaxCreditCarryforwardExpiringintheNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="ino_TheWistarInstituteMember" name="TheWistarInstituteMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_VGXAnimalHealthIncMember" name="VGXAnimalHealthIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="ino_VgxPharmaceuticalsMember" name="VgxPharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="ino_WorkingCapital" name="WorkingCapital" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>ino-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inovio.com/role/A401KPlan" xlink:href="ino-20191231.xsd#A401KPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/A401KPlanDetails" xlink:href="ino-20191231.xsd#A401KPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:href="ino-20191231.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:href="ino-20191231.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Company" xlink:href="ino-20191231.xsd#Company" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:href="ino-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ino-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfOperations" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNotes" xlink:href="ino-20191231.xsd#ConvertibleDebtNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:href="ino-20191231.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/DocumentAndEntityInformation" xlink:href="ino-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:href="ino-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:href="ino-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:href="ino-20191231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:href="ino-20191231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:href="ino-20191231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetailsCalc2" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:href="ino-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:href="ino-20191231.xsd#IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:href="ino-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:href="ino-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:href="ino-20191231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntities" xlink:href="ino-20191231.xsd#InvestmentsInAffiliatedEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails" xlink:href="ino-20191231.xsd#InvestmentsInAffiliatedEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:href="ino-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:href="ino-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:href="ino-20191231.xsd#LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:href="ino-20191231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetailsCalc2" xlink:href="ino-20191231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:href="ino-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:href="ino-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:href="ino-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:href="ino-20191231.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ino-20191231.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestments" xlink:href="ino-20191231.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:href="ino-20191231.xsd#ShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="ino-20191231.xsd#ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:href="ino-20191231.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:href="ino-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:href="ino-20191231.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:href="ino-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:href="ino-20191231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:href="ino-20191231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/A401KPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/A401KPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_5ab6bb81-691e-83b4-fd2b-b49296087bce" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_5ab6bb81-691e-83b4-fd2b-b49296087bce" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_972f0a2f-50fb-a5c8-edc5-b877723ca343" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedSalariesCurrent_972f0a2f-50fb-a5c8-edc5-b877723ca343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_3732af8b-2d10-e16f-836e-98c28ea9b92c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_3732af8b-2d10-e16f-836e-98c28ea9b92c" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedSubcontractExpenses" xlink:label="loc_ino_AccruedSubcontractExpenses_50b5ae81-dcfd-4a2f-f1e6-8ed614708161" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_ino_AccruedSubcontractExpenses_50b5ae81-dcfd-4a2f-f1e6-8ed614708161" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/Company" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_af83e23a-3410-1fdc-046a-00c6a71a25d6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_af83e23a-3410-1fdc-046a-00c6a71a25d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_5d3f3f8e-8f06-ee35-6076-a0312a3c4f12" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_5d3f3f8e-8f06-ee35-6076-a0312a3c4f12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_98F69C97FFC9877AA7713B0E88A62EBE" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_98F69C97FFC9877AA7713B0E88A62EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_0284b583-d70f-f751-948b-fa207d353c89" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ConvertibleDebt_0284b583-d70f-f751-948b-fa207d353c89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_6b87b7d6-b9a9-1bd7-ea2f-8ed61550d145" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_6b87b7d6-b9a9-1bd7-ea2f-8ed61550d145" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_68a2ece1-b79e-558c-a305-f3ccae8c21c3" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_BE81B545F8A87072989ECF6525A33DFE" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_BE81B545F8A87072989ECF6525A33DFE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_52f9f195-5f62-754f-ea14-d08f3a881035" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_52f9f195-5f62-754f-ea14-d08f3a881035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_bb5d27c0-1416-f5b3-6207-246aefdffa46" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_bb5d27c0-1416-f5b3-6207-246aefdffa46" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_6b45d205-e846-5977-fbf7-0a1a84b37e6b" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_ino_DeferredGrantFundingCurrent_6b45d205-e846-5977-fbf7-0a1a84b37e6b" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_82cdb06a-75f1-f799-a4a2-0a1a85157fd8" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_82cdb06a-75f1-f799-a4a2-0a1a85157fd8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_613b4462-2421-6647-a4af-0a1a84d2e6e2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_613b4462-2421-6647-a4af-0a1a84d2e6e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_96b88c28-1e98-9d45-1451-c49d58f81cb0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_96b88c28-1e98-9d45-1451-c49d58f81cb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsfromStockOptionandWarrantExercises" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_49480b15-a074-706a-c087-8ed6148bd181" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_49480b15-a074-706a-c087-8ed6148bd181" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_D68EC46480437581FAC45D59B472FF60" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_D68EC46480437581FAC45D59B472FF60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_b49014a6-fb91-48c3-1070-bd4e11610366" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_b49014a6-fb91-48c3-1070-bd4e11610366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_64589f54-c78b-3b4d-2741-1fc26cfb953a" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_64589f54-c78b-3b4d-2741-1fc26cfb953a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cfe928e9-32cc-877c-5be1-d45ac401869a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_cfe928e9-32cc-877c-5be1-d45ac401869a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_432de4b8-1ba2-acf3-4361-6eed332028b6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_432de4b8-1ba2-acf3-4361-6eed332028b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_848cd271-4e03-8c13-d21d-e6ec9c3916f7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_Depreciation_848cd271-4e03-8c13-d21d-e6ec9c3916f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_725ae160-1b15-a075-fa62-729d0bc8cda1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants_ed51d980-0e4a-156b-11a0-0a1a84484e31" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_ChangeInValueOfCommonStockWarrants_ed51d980-0e4a-156b-11a0-0a1a84484e31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_c29b0a8e-c690-86a3-16b6-6f0c242475a5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_c29b0a8e-c690-86a3-16b6-6f0c242475a5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NonCashInterestExpense" xlink:label="loc_ino_NonCashInterestExpense_FE635951AD7E394838D3185CEFE3ED12" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_NonCashInterestExpense_FE635951AD7E394838D3185CEFE3ED12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_bb9bf802-e6b4-8fac-4bbb-f6618f5d853b" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_bb9bf802-e6b4-8fac-4bbb-f6618f5d853b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_f36be4b0-50ba-fdde-d8c3-1df343692d30" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnInvestments_f36be4b0-50ba-fdde-d8c3-1df343692d30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ae064a9e-7563-5fa2-95b8-bfe0f620685d" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7ff3f6cf-b096-d01c-dff2-0a1a84ae329a" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7ff3f6cf-b096-d01c-dff2-0a1a84ae329a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_513c8407-64a8-bb1f-1e88-081ffd5da1ec" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_513c8407-64a8-bb1f-1e88-081ffd5da1ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="16" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9c560dfb-d3ee-5129-5a3f-0e84995641c7" xlink:type="locator" />
    <link:calculationArc order="17" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_9c560dfb-d3ee-5129-5a3f-0e84995641c7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="18" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_d69d511b-c8ab-12e7-acd0-0a1a853898b9" xlink:type="locator" />
    <link:calculationArc order="19" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_d69d511b-c8ab-12e7-acd0-0a1a853898b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5550ae9d-a6e2-fc35-fc50-54521e2bfb5d" xlink:type="locator" />
    <link:calculationArc order="20" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5550ae9d-a6e2-fc35-fc50-54521e2bfb5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="locator" />
    <link:calculationArc order="21" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7c1c3153-d95c-50b8-10ed-a75d1f3d7a68" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_B3617CDAD822C9C06F14CF6666F4C0D7" xlink:type="locator" />
    <link:calculationArc order="22" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_B3617CDAD822C9C06F14CF6666F4C0D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_b62d9ad7-27f1-1e68-6211-2d739fe9161a" xlink:type="locator" />
    <link:calculationArc order="23" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_b62d9ad7-27f1-1e68-6211-2d739fe9161a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="24" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_c8b690f5-16ee-d324-81ec-0a1a852a567b" xlink:type="locator" />
    <link:calculationArc order="25" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_c8b690f5-16ee-d324-81ec-0a1a852a567b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StraightLineRent" xlink:label="loc_us-gaap_StraightLineRent_37b39cf1-9f75-f5d5-bfd9-c8894d044ebb" xlink:type="locator" />
    <link:calculationArc order="26" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_StraightLineRent_37b39cf1-9f75-f5d5-bfd9-c8894d044ebb" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_6f4f99c3-751b-1824-e6ee-0a1a84646bbc" xlink:type="locator" />
    <link:calculationArc order="27" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_6f4f99c3-751b-1824-e6ee-0a1a84646bbc" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_3aeb2f18-f78a-e496-6fe7-0a1a855f6f5b" xlink:type="locator" />
    <link:calculationArc order="28" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_3aeb2f18-f78a-e496-6fe7-0a1a855f6f5b" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_e554f7dd-4414-586e-e04d-0a1a843a9cc3" xlink:type="locator" />
    <link:calculationArc order="29" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_e554f7dd-4414-586e-e04d-0a1a843a9cc3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="30" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_F952BBB33F13112E4111CF14F32A8749" xlink:type="locator" />
    <link:calculationArc order="31" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_F952BBB33F13112E4111CF14F32A8749" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" xlink:label="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_53907346-464d-c0fc-70b6-0a1a855d805a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_53907346-464d-c0fc-70b6-0a1a855d805a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_58462a12-ec5e-da2d-89ad-2d8b2ce76259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_513c8407-64a8-bb1f-1e88-081ffd5da1ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_513c8407-64a8-bb1f-1e88-081ffd5da1ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_268a7620-ecf1-70b7-f29b-722cf7efdb1c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InterestIncomeOperating_268a7620-ecf1-70b7-f29b-722cf7efdb1c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_4b940182-0fd0-2402-853c-0a1a849a5e90" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_4b940182-0fd0-2402-853c-0a1a849a5e90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bb8edfc7-c933-ca32-53e3-97c4fc9b3824" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_bb8edfc7-c933-ca32-53e3-97c4fc9b3824" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7ff3f6cf-b096-d01c-dff2-0a1a84ae329a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_7ff3f6cf-b096-d01c-dff2-0a1a84ae329a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_440d49bc-ab70-2673-3639-4fbbaa711932" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_440d49bc-ab70-2673-3639-4fbbaa711932" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_736d2dab-e6d0-241f-ea81-d597b26683aa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a0f3158e-b5db-b595-708a-09b10cc83fb2" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a0f3158e-b5db-b595-708a-09b10cc83fb2" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_D852951FFBF486D2B4342887A09FF0E2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_D852951FFBF486D2B4342887A09FF0E2" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_891be224-a29d-628a-abcf-0a1a85689eaa" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_ino_DebtinstrumentAccruedInterest_891be224-a29d-628a-abcf-0a1a85689eaa" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNotes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b14a8305-c528-44ac-6db7-45b0f6f6ddc6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_b14a8305-c528-44ac-6db7-45b0f6f6ddc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce3ac95b-761b-7fbc-3779-1bdfd056c71f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ce3ac95b-761b-7fbc-3779-1bdfd056c71f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_c498d065-e002-c8b0-aba8-6aaec8302ba7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_d2b58163-9b70-93d8-8da6-4d47d94fdd3f" xlink:to="loc_us-gaap_DerivativeLiabilities_c498d065-e002-c8b0-aba8-6aaec8302ba7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_554f95d2-cb4f-eb2c-68b3-7e12c8578a72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_a0a5801b-c8ce-1793-dd5f-edbcde4cc5a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cddb4eb0-3110-27ee-28d5-5d7adef4fa0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cddb4eb0-3110-27ee-28d5-5d7adef4fa0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_7c4f8e9c-edc6-6598-b4d4-0a1a84b07571" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_7c4f8e9c-edc6-6598-b4d4-0a1a84b07571" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_7c4f8e9c-edc6-6598-b4d4-0a1a84b07571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_b2906161-757d-7728-6d3a-0a1a851d2ddf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_b2906161-757d-7728-6d3a-0a1a851d2ddf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_b2906161-757d-7728-6d3a-0a1a851d2ddf" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_558D17DE2017A4329422CAA5A0BFF5C1_7c4f8e9c-edc6-6598-b4d4-0a1a84b07571" xlink:type="locator" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_558D17DE2017A4329422CAA5A0BFF5C1_b2906161-757d-7728-6d3a-0a1a851d2ddf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_558D17DE2017A4329422CAA5A0BFF5C1_7c4f8e9c-edc6-6598-b4d4-0a1a84b07571" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_558D17DE2017A4329422CAA5A0BFF5C1_b2906161-757d-7728-6d3a-0a1a851d2ddf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_558D17DE2017A4329422CAA5A0BFF5C1_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_558D17DE2017A4329422CAA5A0BFF5C1_7c4f8e9c-edc6-6598-b4d4-0a1a84b07571" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_558D17DE2017A4329422CAA5A0BFF5C1_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:type="locator" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_23974969-2584-d87f-9859-8ed6153718b5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_23974969-2584-d87f-9859-8ed6153718b5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_a0872d0f-d4ca-9ced-5731-8ed6154448dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_a0872d0f-d4ca-9ced-5731-8ed6154448dd" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_8e631208-a5a7-fe2e-4056-8ed614eeb98d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_8e631208-a5a7-fe2e-4056-8ed614eeb98d" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_7fd1c207-7f1b-f0b2-e7d3-8ed614b515e6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_7fd1c207-7f1b-f0b2-e7d3-8ed614b515e6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_4d77a9d3-c0e8-3c95-4463-8ed615b8e643" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_4d77a9d3-c0e8-3c95-4463-8ed615b8e643" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_6d46f7d9-6dda-7e10-04b3-8ed61577cb67" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_b4fc8037-648f-e410-eb0b-414180a1ba19" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_6d46f7d9-6dda-7e10-04b3-8ed61577cb67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:type="locator" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_4fe7862e-5a2f-59cf-ccc1-8ed615476a7f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_4fe7862e-5a2f-59cf-ccc1-8ed615476a7f" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_73b0a5a2-9910-fd68-33b7-8ed615bb3887" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_73b0a5a2-9910-fd68-33b7-8ed615bb3887" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_40bd23c1-2cd5-67ce-4295-8ed614b3b7f0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_40bd23c1-2cd5-67ce-4295-8ed614b3b7f0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_91fa91d9-bd6b-7a98-eba1-8ed6151b4c73" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_91fa91d9-bd6b-7a98-eba1-8ed6151b4c73" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4ca758fa-a6b1-6ac8-7759-8ed614be8de1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4ca758fa-a6b1-6ac8-7759-8ed614be8de1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_eb4b8063-e8a3-a25e-dabf-8ed615854e3a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_e4471146-5550-2e7e-6b62-9683693768a5" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_eb4b8063-e8a3-a25e-dabf-8ed615854e3a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="ino-20191231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncomeTaxReconciliationStatuteLimitations" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_99992bbd-b14c-6100-31aa-8ed6152e77a8" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_99992bbd-b14c-6100-31aa-8ed6152e77a8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncomeTaxReconciliationFairValueWarrant" xlink:label="loc_ino_IncomeTaxReconciliationFairValueWarrant_5da98f4e-f24f-d327-4ebe-8ed6161c1490" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_ino_IncomeTaxReconciliationFairValueWarrant_5da98f4e-f24f-d327-4ebe-8ed6161c1490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_4a8ae2b6-addf-f0c7-b540-8ed615524743" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_4a8ae2b6-addf-f0c7-b540-8ed615524743" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_d5826fb0-9fd5-6ea9-adca-8ed615a74ab7" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_d5826fb0-9fd5-6ea9-adca-8ed615a74ab7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_05cc23a1-95bf-5dfd-ffdf-58b097230187" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_05cc23a1-95bf-5dfd-ffdf-58b097230187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_49a08e86-47b2-01fa-94cc-0320e102ec63" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_49a08e86-47b2-01fa-94cc-0320e102ec63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_e51ba957-fbba-d1d2-7272-1520a4ba45da" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_e51ba957-fbba-d1d2-7272-1520a4ba45da" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_6dd89dcc-feee-b4e3-5a1e-8ed614cef9b7" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_b9878087-71ac-1a17-c393-8ed614bca409" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_6dd89dcc-feee-b4e3-5a1e-8ed614cef9b7" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ae7f5893-98a6-942d-2c2a-b900560a7b96" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_ae7f5893-98a6-942d-2c2a-b900560a7b96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_bde039cb-b9b3-01cb-27ac-11db66881ce3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_bde039cb-b9b3-01cb-27ac-11db66881ce3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_646908de-2c79-6268-8484-e0575f967d9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_4653140c-a494-1db4-9e71-1db68da07323" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_4653140c-a494-1db4-9e71-1db68da07323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_5f18d199-c4fe-4aaf-2d38-8ed61468eb81" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_5f18d199-c4fe-4aaf-2d38-8ed61468eb81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_6514ac48-3983-aa80-ceca-70754e132167" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_6514ac48-3983-aa80-ceca-70754e132167" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetInterestExpense" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_12FFCED33E288C0CD819AC13A16831E8" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_12FFCED33E288C0CD819AC13A16831E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_8238b72a-9466-2c8c-af2e-800965722912" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_8238b72a-9466-2c8c-af2e-800965722912" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_A6A569D3C91D211DE24F8845C750E68F" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_A6A569D3C91D211DE24F8845C750E68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_7b5330cc-8193-c814-bd66-50fd0d79ab5f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_7b5330cc-8193-c814-bd66-50fd0d79ab5f" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_548DABA1A7C23B3606888844FA3BC45D" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_548DABA1A7C23B3606888844FA3BC45D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_65623B88E2257189E767AC17184021B5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_65623B88E2257189E767AC17184021B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_b76016e9-67b0-a3ad-0aff-6c98fd9ca654" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_b76016e9-67b0-a3ad-0aff-6c98fd9ca654" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/InvestmentsInAffiliatedEntities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_832fb73d-9886-a0dd-5905-8e2ec54304d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_1f2c68db-a374-1412-5f1f-4edca1431bbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_e71cbb67-0324-15b7-66dc-376e90f3ca60" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5668F39382C388ABAA74CA6746D49350_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5668F39382C388ABAA74CA6746D49350_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5668F39382C388ABAA74CA6746D49350_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_5668F39382C388ABAA74CA6746D49350_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_5668F39382C388ABAA74CA6746D49350_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5668F39382C388ABAA74CA6746D49350_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_5668F39382C388ABAA74CA6746D49350_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9b5435a4-bf09-4c35-cca5-efd34c20356a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9b5435a4-bf09-4c35-cca5-efd34c20356a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AdjustmentForChangeInFairValueOfWarrantLiability" xlink:label="loc_ino_AdjustmentForChangeInFairValueOfWarrantLiability_482A5BC0CD2D0D8EFAD7EAB486DB53E9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_ino_AdjustmentForChangeInFairValueOfWarrantLiability_482A5BC0CD2D0D8EFAD7EAB486DB53E9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>ino-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inovio.com/role/A401KPlan" xlink:href="ino-20191231.xsd#A401KPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/A401KPlanDetails" xlink:href="ino-20191231.xsd#A401KPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:href="ino-20191231.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:href="ino-20191231.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Company" xlink:href="ino-20191231.xsd#Company" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:href="ino-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ino-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfOperations" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNotes" xlink:href="ino-20191231.xsd#ConvertibleDebtNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:href="ino-20191231.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/DocumentAndEntityInformation" xlink:href="ino-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:href="ino-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:href="ino-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:href="ino-20191231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:href="ino-20191231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:href="ino-20191231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:href="ino-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:href="ino-20191231.xsd#IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:href="ino-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:href="ino-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:href="ino-20191231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntities" xlink:href="ino-20191231.xsd#InvestmentsInAffiliatedEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails" xlink:href="ino-20191231.xsd#InvestmentsInAffiliatedEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:href="ino-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:href="ino-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:href="ino-20191231.xsd#LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:href="ino-20191231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:href="ino-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:href="ino-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:href="ino-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:href="ino-20191231.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ino-20191231.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestments" xlink:href="ino-20191231.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:href="ino-20191231.xsd#ShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="ino-20191231.xsd#ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:href="ino-20191231.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:href="ino-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:href="ino-20191231.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:href="ino-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:href="ino-20191231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:href="ino-20191231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/A401KPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/A401KPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226" xlink:to="loc_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_533F63D89E6D4644C337C530C4A471C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:to="loc_ino_ApolloBioMember_533F63D89E6D4644C337C530C4A471C8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_B11FE8BB34200BC40088C530C4A5B981" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:to="loc_ino_MedImmuneMember_B11FE8BB34200BC40088C530C4A5B981" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:to="loc_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromCollaborativeAgreement" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementCorporateIncomeTax" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementAdvisoryFees" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementRoyaltyPeriod" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfAdditionalProducts" xlink:label="loc_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementFundingToBeReceived" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/Company" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:to="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:to="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_709E4399A1471853E24CCEFCE982E75D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_709E4399A1471853E24CCEFCE982E75D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertibleBondsMember" xlink:label="loc_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:to="loc_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:to="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_D9DF83DB99E810F97288CEFCE989BFAC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_D9DF83DB99E810F97288CEFCE989BFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_EBE39B9A02D2663B7E43CEFCE98C34BE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_EBE39B9A02D2663B7E43CEFCE98C34BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_93B9E5CC9E26CF35B9B5CEFCE98C6E0C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_93B9E5CC9E26CF35B9B5CEFCE98C6E0C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87706164AB94E10176F7CEFCE98EB9BB" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87706164AB94E10176F7CEFCE98EB9BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EE643FD525C2D5531DC0CEFCE990D6E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EE643FD525C2D5531DC0CEFCE990D6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:to="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:to="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:to="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantwithAffiliatedRevenueMember" xlink:label="loc_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A91976E65386A6A57D67C530C60D47AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A91976E65386A6A57D67C530C60D47AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:to="loc_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E7BC0D446EBA707AE373CEFCE8FF25C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E7BC0D446EBA707AE373CEFCE8FF25C1" xlink:to="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:to="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:to="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_265EE4688098226FCEE2CEFCE8FEE778" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_CommonStockMember_265EE4688098226FCEE2CEFCE8FEE778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E7BC0D446EBA707AE373CEFCE8FF25C1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" xlink:label="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_35A9DB2F4B1BD25B6BC2CEFCE907FA5A" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_35A9DB2F4B1BD25B6BC2CEFCE907FA5A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_73DA7EFC51A3C06C9D92CAC7CBC72921" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_73DA7EFC51A3C06C9D92CAC7CBC72921" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_E156A0A38FE329D27C2CCAC7CBC77AE8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:to="loc_ino_August2019ConvertibleBondsMember_E156A0A38FE329D27C2CCAC7CBC77AE8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_BC97BC57B1B7A3C8A39BCAD123822844" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:to="loc_ino_December2019ConvertibleBondsMember_BC97BC57B1B7A3C8A39BCAD123822844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:to="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:to="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_615C73F35DFCC62D5DE6CAC7CBD32A8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC" xlink:to="loc_srt_MaximumMember_615C73F35DFCC62D5DE6CAC7CBD32A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:to="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:to="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_InitialConversionPriceMember" xlink:label="loc_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AfterJanuary22020ConversionPriceMember" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EventOfDefaultMember" xlink:label="loc_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AfterJuly22020ConversionPriceMember" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_010BBDD64AE0F94BEA63CAC7CBD56A7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7" xlink:to="loc_us-gaap_ConvertibleDebtMember_010BBDD64AE0F94BEA63CAC7CBD56A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_82212D93906BAADB2FD4CAC7CBD684BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_82212D93906BAADB2FD4CAC7CBD684BD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_0CA3736E3CCD862D0A85CAC7CBD69E8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:to="loc_ino_August2019ConvertibleBondsMember_0CA3736E3CCD862D0A85CAC7CBD69E8E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_8DBE3951D98476A0322ACAC7CBD63AD9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:to="loc_ino_December2019ConvertibleBondsMember_8DBE3951D98476A0322ACAC7CBD63AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A1D7046D7B400A308AA5CAC7CBD7D5F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_A1D7046D7B400A308AA5CAC7CBD7D5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B7D9E8983ADA54250485CAC7CBD76E19" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B7D9E8983ADA54250485CAC7CBD76E19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_F588B75D8EED5D47C12DCAC7CBDA7651" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_F588B75D8EED5D47C12DCAC7CBDA7651" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_E891933F5579B882ABBECAC7CBDA3304" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DerivativeLiabilities_E891933F5579B882ABBECAC7CBDA3304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_8F0F3941FE9563206ECBCAC7CBDA8474" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_8F0F3941FE9563206ECBCAC7CBDA8474" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNotes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_930535D6BC76DD4BD5A5CAC7CBBBF901" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258" xlink:to="loc_us-gaap_ConvertibleDebtMember_930535D6BC76DD4BD5A5CAC7CBBBF901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_CBEA4B5CC266AA3EA332CAC7CBBC1651" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_CBEA4B5CC266AA3EA332CAC7CBBC1651" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_66E6A3F75E8A34C245F6CAC7CBBD176F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:to="loc_ino_August2019ConvertibleBondsMember_66E6A3F75E8A34C245F6CAC7CBBD176F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_003B68314F30BEF4278DCAC7CBBD3702" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:to="loc_ino_December2019ConvertibleBondsMember_003B68314F30BEF4278DCAC7CBBD3702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_60ADFED2C454B3704CB0CAC7CBBEB19A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebt_60ADFED2C454B3704CB0CAC7CBBEB19A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_42B657395648BD7278DACAC7CBBEA977" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_42B657395648BD7278DACAC7CBBEA977" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_70CBC7F6F47F9B52B783C530C437D999" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_70CBC7F6F47F9B52B783C530C437D999" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_320FFD62DDF1C6F01E95C530C435A46A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_320FFD62DDF1C6F01E95C530C435A46A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:to="loc_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_70CBC7F6F47F9B52B783C530C437D999" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_39495B36A23CCE44B53BC530C438ABAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_39495B36A23CCE44B53BC530C438ABAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:to="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_487F22FAF26B03F8D7B0C530C4129118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:to="loc_us-gaap_CommonStockMember_487F22FAF26B03F8D7B0C530C4129118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DEA094AC9A9397FAD628C530C4131C7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_DEA094AC9A9397FAD628C530C4131C7B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="loc_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CellectraMember" xlink:label="loc_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GhrhMember" xlink:label="loc_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:to="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:to="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D" xlink:to="loc_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_InovioAsMember" xlink:label="loc_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:to="loc_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_VgxPharmaceuticalsMember" xlink:label="loc_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:to="loc_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_7EC023FDF0FDD5D6CE10CAA5A0C7BA5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:to="loc_ino_BiojectMember_7EC023FDF0FDD5D6CE10CAA5A0C7BA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D61EF503AAFC7D8D3E9DCAA5A0C89EDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D61EF503AAFC7D8D3E9DCAA5A0C89EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:to="loc_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6DE641AE1E237EB17334CAA5A0C95027" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6DE641AE1E237EB17334CAA5A0C95027" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:to="loc_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:to="loc_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_130054919D965C8F504FCA664D8D1F95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2" xlink:to="loc_us-gaap_ResearchMember_130054919D965C8F504FCA664D8D1F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_71CEE955C16536835313CA664D8F9609" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_71CEE955C16536835313CA664D8F9609" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CaliforniaIncomeTaxAuthorityMember" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxBenefitsExpired" xlink:label="loc_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/InvestmentsInAffiliatedEntities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:to="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:to="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:to="loc_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:to="loc_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:to="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_39FB5A16AC2EE28074EDC530C280411D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6" xlink:to="loc_us-gaap_CommonStockMember_39FB5A16AC2EE28074EDC530C280411D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_466C00D2A2C762E296B9C530C2815328" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_466C00D2A2C762E296B9C530C2815328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SanDiegoCaliforniaMember" xlink:label="loc_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:to="loc_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PlymouthMeetingPennsylvaniaMember" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:to="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:to="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:to="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D184668BE411882D03B8C5957A4E97AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:to="loc_srt_MinimumMember_D184668BE411882D03B8C5957A4E97AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1878D47C1C5BEA2E459EC5957A4E6320" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:to="loc_srt_MaximumMember_1878D47C1C5BEA2E459EC5957A4E6320" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2C18908D5B4AE5FAEB10C5957A4F0E4C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2C18908D5B4AE5FAEB10C5957A4F0E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_0BA70BACED6B8A3E236AC530C3BFEDC0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_MedImmuneMember_0BA70BACED6B8A3E236AC530C3BFEDC0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" xlink:label="loc_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_HoffmanLaRocheMember" xlink:label="loc_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AllOtherCustomersMember" xlink:label="loc_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MCDCMember" xlink:label="loc_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:to="loc_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:to="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:to="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:to="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_AF0ADA55BAB480F4EB10CEFCE592ABF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:to="loc_us-gaap_LicenseMember_AF0ADA55BAB480F4EB10CEFCE592ABF4" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_7BC0ACF469A622D23515CEFCE593A6BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_7BC0ACF469A622D23515CEFCE593A6BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19EAF65CCFB5EBB985B7CEFCE59300D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19EAF65CCFB5EBB985B7CEFCE59300D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6895EB8FF07921AEE0E5CEFCE59425F7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_OperatingExpenses_6895EB8FF07921AEE0E5CEFCE59425F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_403907F71AA3B7CC1FD9CEFCE594C4D4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_InterestExpense_403907F71AA3B7CC1FD9CEFCE594C4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E1031C25754116148414CEFCE5958F34" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E1031C25754116148414CEFCE5958F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_AD98DA97CF4A15CE5C0DCEFCE5964DD9" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_ProfitLoss_AD98DA97CF4A15CE5C0DCEFCE5964DD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1B186740C669F4E1D1DACEFCE596D5B8" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1B186740C669F4E1D1DACEFCE596D5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5414BC1FA3356440D1DFCEFCE596EBE6" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_NetIncomeLoss_5414BC1FA3356440D1DFCEFCE596EBE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C30C47C3124EF4BE44B8CEFCE5966D6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:to="loc_us-gaap_EarningsPerShareBasic_C30C47C3124EF4BE44B8CEFCE5966D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C17685FE658FFCB69F3BCEFCE597E1D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C17685FE658FFCB69F3BCEFCE597E1D8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:to="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:to="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:to="loc_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PLSaffiliatedentityMember" xlink:label="loc_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:to="loc_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TheWistarInstituteMember" xlink:label="loc_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:to="loc_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F89CB761450B31AE07F5C530C2165027" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_F89CB761450B31AE07F5C530C2165027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeArrangementTerm" xlink:label="loc_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MilestoneBasedOwnershipTarget" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementExpensesToReimburse" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromSubGrant" xlink:label="loc_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantProceedsReceived" xlink:label="loc_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliate" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:to="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:to="loc_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherCounterpartyMember" xlink:label="loc_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:to="loc_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:to="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:to="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:to="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_63AF9F2AE504A124AF16C530C45D0281" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4" xlink:to="loc_srt_MaximumMember_63AF9F2AE504A124AF16C530C45D0281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:to="loc_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_91472F803C33AA7C695BCEFCE65DAEA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D" xlink:to="loc_us-gaap_SubsequentEventMember_91472F803C33AA7C695BCEFCE65DAEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:to="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:to="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A2016IncentivePlanMember" xlink:label="loc_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:to="loc_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A2007IncentivePlanMember" xlink:label="loc_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:to="loc_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:to="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:to="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_92D3D1835A5A63CE43C4CEFCE65F7440" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:to="loc_us-gaap_CommonStockMember_92D3D1835A5A63CE43C4CEFCE65F7440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:to="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:to="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C" xlink:to="loc_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_CF36F858621F73BC14B4CEFCE6601E77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:to="loc_ino_SalesAgreementMember_CF36F858621F73BC14B4CEFCE6601E77" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PriorATMSalesAgreementMember" xlink:label="loc_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:to="loc_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EmployeeMember" xlink:label="loc_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5018AEB4D58F6F6B9BCBCEFCE663CB14" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5018AEB4D58F6F6B9BCBCEFCE663CB14" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberofVotesPerShare" xlink:label="loc_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PreferredStockConversionNoticePeriod" xlink:label="loc_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion" xlink:label="loc_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockThresholdTradingDays" xlink:label="loc_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays" xlink:label="loc_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion" xlink:label="loc_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementRemainingAuthorizedSalesAmount" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod" xlink:label="loc_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:type="locator" />
    <link:definitionArc order="42" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:type="locator" />
    <link:definitionArc order="43" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:type="locator" />
    <link:definitionArc order="44" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:type="locator" />
    <link:definitionArc order="45" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:to="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:to="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1884C8AD458B0F99EFF4C530C2F811C7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1884C8AD458B0F99EFF4C530C2F811C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0E2960E207E4B373A50EC530C2F8A6E9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0E2960E207E4B373A50EC530C2F8A6E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_73612ADA42517EB05F3EC530C2F99118" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_73612ADA42517EB05F3EC530C2F99118" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:to="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1D9EC30794F8983FCB83C530C2B7485B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1D9EC30794F8983FCB83C530C2B7485B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesOneMember" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesTwoMember" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesThreeMember" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesFourMember" xlink:label="loc_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesFiveMember" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:to="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:to="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_6C64CBB7523BBF568FB0C530C1EF0F8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E" xlink:to="loc_ino_PlumblineLifeSciencesMember_6C64CBB7523BBF568FB0C530C1EF0F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_A7488190CEE6FBCE60E6C530C1F05773" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A" xlink:to="loc_ino_SalesAgreementMember_A7488190CEE6FBCE60E6C530C1F05773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:to="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:to="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4E2422291F84D723B4B7C530C1F172D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB" xlink:to="loc_us-gaap_CommonStockMember_4E2422291F84D723B4B7C530C1F172D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D6385348EDAD94ADFE79C530C1F24D42" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C" xlink:to="loc_us-gaap_SubsequentEventMember_D6385348EDAD94ADFE79C530C1F24D42" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_FB1632EDAFC33926A5BAC530C1F2CE84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_FB1632EDAFC33926A5BAC530C1F2CE84" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_4BEF1724167C71154457C530C1F23766" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_ino_StockSalesAgreementAgentFee_4BEF1724167C71154457C530C1F23766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6E8924E415D8F8ADFBB8C530C1F36653" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6E8924E415D8F8ADFBB8C530C1F36653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5EA87AA46431D88C2020C530C1F3E8A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5EA87AA46431D88C2020C530C1F3E8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_680A4AF397BCB23332EBC530C1F3F23C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_680A4AF397BCB23332EBC530C1F3F23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5496209E5EC50C3BCA77C530C1F32CE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5496209E5EC50C3BCA77C530C1F32CE1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:to="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_91AB928F8ECB81298E6CC9F7DCB73168" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_91AB928F8ECB81298E6CC9F7DCB73168" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_28FF3A5CFFF15506BA07C9F7DCB73B5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:to="loc_ino_August2019ConvertibleBondsMember_28FF3A5CFFF15506BA07C9F7DCB73B5F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_9E24C153F8B043B6BCFAC9F7DCB8FD61" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:to="loc_ino_December2019ConvertibleBondsMember_9E24C153F8B043B6BCFAC9F7DCB8FD61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CommonStockEquivalentsAbstract" xlink:label="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:to="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:to="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:to="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:to="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:to="loc_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C086766ACC8D8728AE80C9F7DCA3A50D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C086766ACC8D8728AE80C9F7DCA3A50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:to="loc_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:to="loc_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:to="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:to="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:to="loc_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:to="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:to="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_VGXAnimalHealthIncMember" xlink:label="loc_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:to="loc_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:to="loc_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="loc_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="loc_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:to="loc_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:to="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:to="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:to="loc_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:to="loc_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_WorkingCapital" xlink:label="loc_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent" xlink:label="loc_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E80CBAE112256AF4343CAA5A29CB1B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E80CBAE112256AF4343CAA5A29CB1B8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EmployeesAndDirectorsMember" xlink:label="loc_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:to="loc_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_9294D4AE0C2E5E90A145CAA5A29A72D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:to="loc_ino_NonEmployeeMember_9294D4AE0C2E5E90A145CAA5A29A72D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:to="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:to="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AF90872F5DACEED073D9CAA5A29BA494" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:to="loc_srt_MinimumMember_AF90872F5DACEED073D9CAA5A29BA494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_574EDEE2FE414F49C88BCAA5A29CB3EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:to="loc_srt_MaximumMember_574EDEE2FE414F49C88BCAA5A29CB3EA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E80CBAE112256AF4343CAA5A29CB1B8" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>ino-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD_label_en-US" xlink:label="lab_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:to="lab_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:to="lab_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expirations of Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in the Next Twelve Months</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in the Next Twelve Months</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:to="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:to="lab_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expirations of Tax Credit Carryforwards [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:type="arc" />
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in the Next Twelve Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in the Next Twelve Months</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:to="lab_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:type="arc" />
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:type="arc" />
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Months</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:type="arc" />
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Months</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Months</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:type="arc" />
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:type="arc" />
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:to="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in Affiliated Entities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value ($ per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:to="lab_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value ($ per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:to="lab_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (benefit) taxes at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:type="arc" />
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign income taxes</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:type="arc" />
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncomeTaxReconciliationStatuteLimitations" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:to="lab_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:type="arc" />
    <link:label id="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrants</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Fair Value Warrant</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Fair Value Warrant</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncomeTaxReconciliationFairValueWarrant" xlink:label="loc_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:to="lab_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:type="arc" />
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:type="arc" />
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limited NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:type="arc" />
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A_totalLabel_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A_label_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A_documentation_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:to="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1_label_en-US" xlink:label="lab_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:to="lab_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:to="lab_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:to="lab_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:to="lab_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:to="lab_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0_label_en-US" xlink:label="lab_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:to="lab_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D_label_en-US" xlink:label="lab_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:to="lab_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:type="arc" />
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:to="lab_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:type="arc" />
    <link:label id="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04_terseLabel_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VGX Animal Health, Inc</link:label>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04_label_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VGX Animal Health, Inc [Member]</link:label>
    <link:label id="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04_documentation_en-US" xlink:label="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VGX Animal Health, Inc [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_VGXAnimalHealthIncMember" xlink:label="loc_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:to="lab_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:to="lab_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:to="lab_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:type="arc" />
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:type="arc" />
    <link:label id="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">August 2019 Convertible Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:to="lab_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:type="arc" />
    <link:label id="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2019 Convertible Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:to="lab_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:type="arc" />
    <link:label id="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0_label_en-US" xlink:label="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:to="lab_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:to="lab_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3_label_en-US" xlink:label="lab_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:to="lab_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4_terseLabel_en-US" xlink:label="lab_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4_label_en-US" xlink:label="lab_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:to="lab_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054_label_en-US" xlink:label="lab_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:to="lab_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4_label_en-US" xlink:label="lab_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:to="lab_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net loss from operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:to="lab_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:type="arc" />
    <link:label id="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3_verboseLabel_en-US" xlink:label="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3_label_en-US" xlink:label="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3_documentation_en-US" xlink:label="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net amount of current assets and current liabilities.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_WorkingCapital" xlink:label="loc_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:to="lab_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in affiliated entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:type="arc" />
    <link:label id="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700_terseLabel_en-US" xlink:label="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected number of positions to be eliminated, percent</link:label>
    <link:label id="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700_label_en-US" xlink:label="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent</link:label>
    <link:label id="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700_documentation_en-US" xlink:label="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent" xlink:label="loc_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:to="lab_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:to="lab_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:to="lab_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:to="lab_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent credit</link:label>
    <link:label id="lab_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA_label_en-US" xlink:label="lab_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:to="lab_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:to="lab_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:type="arc" />
    <link:label id="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF_terseLabel_en-US" xlink:label="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF_label_en-US" xlink:label="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MedImmune [Member]</link:label>
    <link:label id="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF_documentation_en-US" xlink:label="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MedImmune [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:to="lab_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:type="arc" />
    <link:label id="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC_terseLabel_en-US" xlink:label="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Counterparty</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC_label_en-US" xlink:label="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:label id="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC_documentation_en-US" xlink:label="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Counterparty [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherCounterpartyMember" xlink:label="loc_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:to="lab_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from deferred revenue beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial fair value upon issuance of the Bonds</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08_netLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="lab_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:to="lab_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:type="arc" />
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7_verboseLabel_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7_label_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7_documentation_en-US" xlink:label="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketable securities and fair value measurements.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="lab_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares held in an affiliated entity (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advances to Affiliates, Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:to="lab_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares owned (shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:to="lab_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2" xlink:type="arc" />
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12_verboseLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets (Textual) [Abstract]</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsTextualAbstract" xlink:label="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="lab_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247" xlink:type="arc" />
    <link:label id="lab_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23_label_en-US" xlink:label="lab_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23" xlink:to="lab_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="lab_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:to="lab_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="lab_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:type="arc" />
    <link:label id="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38_label_en-US" xlink:label="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38_documentation_en-US" xlink:label="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:to="lab_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:type="arc" />
    <link:label id="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779_terseLabel_en-US" xlink:label="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DARPA</link:label>
    <link:label id="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779_label_en-US" xlink:label="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defense Advanced Research Projects Agency (DARPA) [Member]</link:label>
    <link:label id="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779_documentation_en-US" xlink:label="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defense Advanced Research Projects Agency (DARPA) [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" xlink:label="loc_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:to="lab_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:type="arc" />
    <link:label id="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5_terseLabel_en-US" xlink:label="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5_label_en-US" xlink:label="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hoffman-La Roche [Member]</link:label>
    <link:label id="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5_documentation_en-US" xlink:label="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hoffman-La Roche [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_HoffmanLaRocheMember" xlink:label="loc_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:to="lab_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:type="arc" />
    <link:label id="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other, including affiliated entities</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AllOtherCustomersMember" xlink:label="loc_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:to="lab_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:type="arc" />
    <link:label id="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C_terseLabel_en-US" xlink:label="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MCDC</link:label>
    <link:label id="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C_label_en-US" xlink:label="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MCDC [Member]</link:label>
    <link:label id="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C_documentation_en-US" xlink:label="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MCDC [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_MCDCMember" xlink:label="loc_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:to="lab_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:to="lab_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:to="lab_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:type="arc" />
    <link:label id="lab_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:to="lab_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF_label_en-US" xlink:label="lab_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:to="lab_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment disposed of</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation written off due to disposal of property plant and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Sale or Disposal of Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:type="arc" />
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:type="arc" />
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:type="arc" />
    <link:label id="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_SanDiegoCaliforniaMember" xlink:label="loc_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:to="lab_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:type="arc" />
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PlymouthMeetingPennsylvaniaMember" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:type="arc" />
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, operating lease, area of land under lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF_label_en-US" xlink:label="lab_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:to="lab_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:type="arc" />
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F_terseLabel_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lease agreements entered into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F_label_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F_documentation_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:to="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of major customers and concentration risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30" xlink:to="lab_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:to="lab_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="lab_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount on the liability component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:type="arc" />
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of premium associated with the bonds</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C_label_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:label id="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C_documentation_en-US" xlink:label="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Accretion Of Premium</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:to="lab_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:type="arc" />
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C_terseLabel_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C_label_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C_documentation_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:to="lab_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:to="lab_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value of the financial liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:type="arc" />
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:to="lab_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Derivative Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:to="lab_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:type="arc" />
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21_label_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetInterestExpense" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:to="lab_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:type="arc" />
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:to="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:type="arc" />
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:to="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:type="arc" />
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Note discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:to="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:to="lab_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer matching contribution, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum annual contribution per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:to="lab_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:to="lab_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, par value ($ per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of components of income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:type="arc" />
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE_terseLabel_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of operating loss and tax credit carryforward expirations</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE_label_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE_documentation_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:to="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unrecognized tax benefits rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of shares authorized under stock option plans, by exercise price range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options, activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:to="lab_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:type="arc" />
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F_verboseLabel_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</link:label>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F_label_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Equivalents [Abstract]</link:label>
    <link:label id="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F_documentation_en-US" xlink:label="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock equivalents.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CommonStockEquivalentsAbstract" xlink:label="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:to="lab_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total antidilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:to="lab_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B" xlink:type="arc" />
    <link:label id="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130_terseLabel_en-US" xlink:label="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, financing costs</link:label>
    <link:label id="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130_label_en-US" xlink:label="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, financing costs</link:label>
    <link:label id="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130_documentation_en-US" xlink:label="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, financing costs.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IssuanceOfCommonStockForCashFinancingCosts" xlink:label="loc_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:to="lab_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance ($ per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:to="lab_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:type="arc" />
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0_terseLabel_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0_label_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0_documentation_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantRevenuePolicyTextBlock" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:to="lab_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements - Recently Adopted, Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:type="arc" />
    <link:label id="lab_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16_label_en-US" xlink:label="lab_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:label id="lab_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16_documentation_en-US" xlink:label="lab_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DocumentAndEntityInformationAbstract" xlink:label="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="lab_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2_terseLabel_en-US" xlink:label="lab_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2_label_en-US" xlink:label="lab_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:to="lab_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351_label_en-US" xlink:label="lab_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:to="lab_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:to="lab_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:to="lab_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:to="lab_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0_label_en-US" xlink:label="lab_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:to="lab_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:to="lab_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:to="lab_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7_label_en-US" xlink:label="lab_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:to="lab_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F_label_en-US" xlink:label="lab_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:to="lab_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:to="lab_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:to="lab_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:to="lab_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:to="lab_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A_label_en-US" xlink:label="lab_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:to="lab_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:type="arc" />
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, internal rate of return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Internal Rate Of Return</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:to="lab_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:to="lab_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:to="lab_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:type="arc" />
    <link:label id="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_A2016IncentivePlanMember" xlink:label="loc_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:to="lab_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:type="arc" />
    <link:label id="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_A2007IncentivePlanMember" xlink:label="loc_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:to="lab_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:to="lab_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:type="arc" />
    <link:label id="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F_terseLabel_en-US" xlink:label="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Sales Agreement</link:label>
    <link:label id="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F_label_en-US" xlink:label="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior ATM Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F_documentation_en-US" xlink:label="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior ATM Sales Agreement [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PriorATMSalesAgreementMember" xlink:label="loc_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:to="lab_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:type="arc" />
    <link:label id="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4_terseLabel_en-US" xlink:label="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee</link:label>
    <link:label id="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4_label_en-US" xlink:label="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4_documentation_en-US" xlink:label="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EmployeeMember" xlink:label="loc_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:to="lab_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:type="arc" />
    <link:label id="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2_label_en-US" xlink:label="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:to="lab_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, redemption price ($ per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC_label_en-US" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:type="arc" />
    <link:label id="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B_terseLabel_en-US" xlink:label="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B_label_en-US" xlink:label="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Votes Per Share</link:label>
    <link:label id="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B_documentation_en-US" xlink:label="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Votes Per Share</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberofVotesPerShare" xlink:label="loc_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:to="lab_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:type="arc" />
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion, conversion price ($ per share)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:to="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:type="arc" />
    <link:label id="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852_terseLabel_en-US" xlink:label="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notice period for mandatory conversion of preferred stock</link:label>
    <link:label id="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852_label_en-US" xlink:label="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Conversion, Notice Period</link:label>
    <link:label id="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852_documentation_en-US" xlink:label="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Conversion, Notice Period</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PreferredStockConversionNoticePeriod" xlink:label="loc_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:to="lab_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:type="arc" />
    <link:label id="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B_terseLabel_en-US" xlink:label="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Daily market price triggering mandatory conversion ($ per share)</link:label>
    <link:label id="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B_label_en-US" xlink:label="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Conversion, Daily Market Price Triggering Mandatory Conversion</link:label>
    <link:label id="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B_documentation_en-US" xlink:label="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Conversion, Daily Market Price Triggering Mandatory Conversion</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion" xlink:label="loc_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:to="lab_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:type="arc" />
    <link:label id="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Threshold Trading Days</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Threshold Trading Days</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockThresholdTradingDays" xlink:label="loc_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:to="lab_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:type="arc" />
    <link:label id="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays" xlink:label="loc_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:to="lab_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:type="arc" />
    <link:label id="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average daily trading volume triggering mandatory conversion (shares)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Average Daily Trading Volume Triggering Mandatory Conversion</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Average Daily Trading Volume Triggering Mandatory Conversion</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion" xlink:label="loc_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:to="lab_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:type="arc" />
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:type="arc" />
    <link:label id="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agent fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D_label_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:label id="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Agent Fee</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:to="lab_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:type="arc" />
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, aggregate number of shares issued (shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share ($ per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:type="arc" />
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sale agreement, aggregate proceeds from issuance of stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:type="arc" />
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sales agreement, remaining authorized sales amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Sales Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Sales Amount</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementRemainingAuthorizedSalesAmount" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:type="arc" />
    <link:label id="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A_terseLabel_en-US" xlink:label="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised in period (shares)</link:label>
    <link:label id="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A_label_en-US" xlink:label="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised In Period</link:label>
    <link:label id="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A_documentation_en-US" xlink:label="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised In Period</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod" xlink:label="loc_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:to="lab_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants (shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reserved number of shares under the Incentive Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:type="arc" />
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865_verboseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan (shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:type="arc" />
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in number of shares authorized (shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grants under the Incentive Plan (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:type="arc" />
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642_verboseLabel_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan (shares)</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642_label_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Shares of Vested Restricted Stock Outstanding Under Plan</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642_documentation_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:to="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of common stock shares outstanding under the Incentive Plan (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period of incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:type="arc" />
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13_verboseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual year term of incentive plan</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment  award maximum contractual term.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:to="lab_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding to purchase common stock (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:type="arc" />
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:type="arc" />
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, remaining contractual term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:type="arc" />
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options expected to vest (shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:type="arc" />
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSU's expected to vest (shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, expirations in period, weighted average exercise price ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, expirations in period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, grants in period, weighted average grant date fair value ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options, exercises in period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:to="lab_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B" xlink:to="lab_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF" xlink:type="arc" />
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6_terseLabel_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6_label_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6_documentation_en-US" xlink:label="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:to="lab_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B_label_en-US" xlink:label="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Common Stock Warrants</link:label>
    <link:label id="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net change during the reporting period in the fair value of common stock warrants, which are revalued at each balance sheet date subsequent to initial receipt or issuance.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:to="lab_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE" xlink:to="lab_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE" xlink:type="arc" />
    <link:label id="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A_terseLabel_en-US" xlink:label="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A_label_en-US" xlink:label="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A_documentation_en-US" xlink:label="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NonCashInterestExpense" xlink:label="loc_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:to="lab_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Amortization of Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:to="lab_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:to="lab_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from other unrealized gains on short-term investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized transaction loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C_negatedLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease in Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:to="lab_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80_verboseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase Decrease in Deferred Revenue From Related Parties</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:to="lab_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:type="arc" />
    <link:label id="lab_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD_label_en-US" xlink:label="lab_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Straight Line Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StraightLineRent" xlink:label="loc_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:to="lab_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:type="arc" />
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuances of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Costs related to issuances of convertible senior notes and convertible bonds</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30" xlink:type="arc" />
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087_verboseLabel_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option and warrant exercises, net of tax payments</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087_label_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087_documentation_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsfromStockOptionandWarrantExercises" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:to="lab_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:type="arc" />
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:to="lab_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:type="arc" />
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D_terseLabel_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D_label_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component Of Convertible Debt Issued</link:label>
    <link:label id="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D_documentation_en-US" xlink:label="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Component Of Convertible Debt Issued</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EquityComponentOfConvertibleDebtIssued" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:to="lab_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Annual Future Minimum Lease Payments Under Non-cancelable Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:to="lab_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:type="arc" />
    <link:label id="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE_label_en-US" xlink:label="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE_documentation_en-US" xlink:label="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:to="lab_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US corporate debt securities</link:label>
    <link:label id="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0_label_en-US" xlink:label="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Corporate, US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:to="lab_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:type="arc" />
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857_label_en-US" xlink:label="lab_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:to="lab_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:type="arc" />
    <link:label id="lab_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA_label_en-US" xlink:label="lab_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:to="lab_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:to="lab_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:type="arc" />
    <link:label id="lab_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67_terseLabel_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Adoption</link:label>
    <link:label id="lab_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67_label_en-US" xlink:label="lab_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Adjustment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:to="lab_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:to="lab_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, non-current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:to="lab_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:type="arc" />
    <link:label id="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6_verboseLabel_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">GeneOne Life Sciences</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6_label_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:label id="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6_documentation_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GeneOne Life Sciences [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:to="lab_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:type="arc" />
    <link:label id="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:to="lab_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of ownership</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:to="lab_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:type="arc" />
    <link:label id="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB_terseLabel_en-US" xlink:label="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investment in affiliated entity, net of tax</link:label>
    <link:label id="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB_label_en-US" xlink:label="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Investment In Affiliated Entity, Net Of Tax</link:label>
    <link:label id="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB_documentation_en-US" xlink:label="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Investment In Affiliated Entity, Net Of Tax</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" xlink:label="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:to="lab_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Eligible Item or Group for Fair Value Option [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:to="lab_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:to="lab_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:type="arc" />
    <link:label id="lab_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Mutual funds</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:to="lab_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">US corporate debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability (Note 10)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:to="lab_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:type="arc" />
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.48-$3.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesOneMember" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:to="lab_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:type="arc" />
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.01-$6.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesTwoMember" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:to="lab_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:type="arc" />
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$6.01-$9.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesThreeMember" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:to="lab_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:type="arc" />
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$9.01-$12.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesFourMember" xlink:label="loc_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:to="lab_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:type="arc" />
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$12.01-$15.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesFiveMember" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:to="lab_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, lower range limit ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price, upper range limit ($ per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Life (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price ($ per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average exercise price ($ per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of finite-lived intangible assets, future amortization expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67" xlink:type="arc" />
    <link:label id="lab_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155_terseLabel_en-US" xlink:label="lab_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GeneOne (affiliated entity)</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:to="lab_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:type="arc" />
    <link:label id="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6_terseLabel_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLS (affiliated entity)</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6_label_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6_documentation_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PLSaffiliatedentityMember" xlink:label="loc_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:to="lab_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:type="arc" />
    <link:label id="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TheWistarInstituteMember" xlink:label="loc_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:to="lab_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payment received for license granted</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeArrangementTerm" xlink:label="loc_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:to="lab_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:type="arc" />
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA_terseLabel_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership target</link:label>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA_label_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone-Based Ownership Target</link:label>
    <link:label id="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA_documentation_en-US" xlink:label="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone-Based Ownership Target</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_MilestoneBasedOwnershipTarget" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:to="lab_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Full payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:to="lab_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E_terseLabel_en-US" xlink:label="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable/accrued liability</link:label>
    <link:label id="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E_label_en-US" xlink:label="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Other Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:to="lab_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementExpensesToReimburse" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:type="arc" />
    <link:label id="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sub-grant</link:label>
    <link:label id="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451_label_en-US" xlink:label="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sub-Grant</link:label>
    <link:label id="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451_documentation_en-US" xlink:label="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Sub-Grant</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromSubGrant" xlink:label="loc_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:to="lab_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:type="arc" />
    <link:label id="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant proceeds received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1_label_en-US" xlink:label="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantProceedsReceived" xlink:label="loc_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:to="lab_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred grant funding from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliate" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B" xlink:to="lab_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9_label_en-US" xlink:label="lab_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:to="lab_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:to="lab_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="lab_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40_label_en-US" xlink:label="lab_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:to="lab_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:type="arc" />
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939_terseLabel_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue under collaborative research and development arrangements with affiliated entities</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939_label_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:label id="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939_documentation_en-US" xlink:label="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License with Affiliated Entities [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:to="lab_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous revenue, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0_label_en-US" xlink:label="lab_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:to="lab_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:type="arc" />
    <link:label id="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7_terseLabel_en-US" xlink:label="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grants and miscellaneous revenue from affiliated entity</link:label>
    <link:label id="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7_label_en-US" xlink:label="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant with Affiliated Revenue [Member]</link:label>
    <link:label id="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7_documentation_en-US" xlink:label="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grant with Affiliated Entities [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantwithAffiliatedRevenueMember" xlink:label="loc_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:to="lab_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="lab_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:to="lab_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="lab_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:to="lab_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:to="lab_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:to="lab_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B_label_en-US" xlink:label="lab_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:to="lab_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82_verboseLabel_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82_label_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value of Common Stock Warrants</link:label>
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82_documentation_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:to="lab_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on investment in affiliated entities</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income tax benefit/(provision for income tax)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit (provision for income taxes)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:to="lab_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:to="lab_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:to="lab_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic ($ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:to="lab_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted ($ per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:type="arc" />
    <link:label id="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertibleBondsMember" xlink:label="loc_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:to="lab_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:to="lab_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:to="lab_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:type="arc" />
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:to="lab_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed assets, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1_label_en-US" xlink:label="lab_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:to="lab_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7_label_en-US" xlink:label="lab_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:to="lab_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:type="arc" />
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:type="arc" />
    <link:label id="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632_verboseLabel_en-US" xlink:label="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632_label_en-US" xlink:label="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue from Affiliated Entity, Current</link:label>
    <link:label id="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632_documentation_en-US" xlink:label="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:to="lab_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:to="lab_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:to="lab_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:to="lab_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant funding liability from affiliated entity, net of current portion</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Noncurrent</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357_label_en-US" xlink:label="lab_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:to="lab_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:to="lab_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="lab_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2019 and December 31, 2018</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:to="lab_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2019 and December 31, 2018, issued and outstanding: 101,361,034 at December 31, 2019 and 97,225,810 at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:to="lab_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:to="lab_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:to="lab_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:to="lab_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of quarterly financial information (unaudited)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:type="arc" />
    <link:label id="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6_terseLabel_en-US" xlink:label="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator</link:label>
    <link:label id="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6_label_en-US" xlink:label="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:label id="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6_documentation_en-US" xlink:label="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Numerator [Abstract]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NumeratorAbstract" xlink:label="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:to="lab_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E" xlink:to="lab_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E" xlink:type="arc" />
    <link:label id="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1_terseLabel_en-US" xlink:label="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment for decrease in fair value of warrant liability</link:label>
    <link:label id="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1_label_en-US" xlink:label="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment For Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1_documentation_en-US" xlink:label="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustment For Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AdjustmentForChangeInFairValueOfWarrantLiability" xlink:label="loc_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:to="lab_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Numerator for use in diluted net loss per share</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:type="arc" />
    <link:label id="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B_terseLabel_en-US" xlink:label="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator</link:label>
    <link:label id="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B_label_en-US" xlink:label="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:label id="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B_documentation_en-US" xlink:label="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denominator [Abstract]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DenominatorAbstract" xlink:label="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:to="lab_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding (denominator for use in basic net loss per share) (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive potential common shares (shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Denominator for use in diluted loss per share (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted ($ per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE" xlink:to="lab_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic ($ per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2" xlink:to="lab_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="lab_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:to="lab_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:to="lab_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:to="lab_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD_label_en-US" xlink:label="lab_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:to="lab_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of accounting change (1)</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for cash, net of financing costs of $4.9 million</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity component of issuance of convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of non-controlling interest in Geneos, net</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:to="lab_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on short-term investments, net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E" xlink:to="lab_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:type="arc" />
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F_terseLabel_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F_label_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F_documentation_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CaliforniaIncomeTaxAuthorityMember" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:to="lab_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:type="arc" />
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A_terseLabel_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A_label_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A_documentation_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:to="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:type="arc" />
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:to="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:to="lab_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:type="arc" />
    <link:label id="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8_label_en-US" xlink:label="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8_documentation_en-US" xlink:label="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxBenefitsExpired" xlink:label="loc_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:to="lab_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:to="lab_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058_verboseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:type="arc" />
    <link:label id="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EmployeesAndDirectorsMember" xlink:label="loc_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:to="lab_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:to="lab_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:type="arc" />
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E_verboseLabel_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E_label_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E_documentation_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assumptions used in estimation of fair value of stock options.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miscellaneous revenue, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:to="lab_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:to="lab_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:to="lab_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:to="lab_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581_terseLabel_en-US" xlink:label="lab_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:to="lab_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB_verboseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:type="arc" />
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE_terseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on investment in affiliated entities</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989" xlink:to="lab_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="lab_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="lab_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:to="lab_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:to="lab_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:type="arc" />
    <link:label id="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE_verboseLabel_en-US" xlink:label="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">CELLECTRA</link:label>
    <link:label id="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE_label_en-US" xlink:label="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CELLECTRA [Member]</link:label>
    <link:label id="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE_documentation_en-US" xlink:label="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CELLECTRA.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CellectraMember" xlink:label="loc_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:to="lab_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:type="arc" />
    <link:label id="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9_verboseLabel_en-US" xlink:label="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">GHRH</link:label>
    <link:label id="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9_label_en-US" xlink:label="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GHRH [Member]</link:label>
    <link:label id="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9_documentation_en-US" xlink:label="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GHRH.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GhrhMember" xlink:label="loc_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:to="lab_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:type="arc" />
    <link:label id="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42_terseLabel_en-US" xlink:label="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42_label_en-US" xlink:label="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42_documentation_en-US" xlink:label="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:to="lab_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:type="arc" />
    <link:label id="lab_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642_label_en-US" xlink:label="lab_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:to="lab_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:type="arc" />
    <link:label id="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A_verboseLabel_en-US" xlink:label="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inovio AS</link:label>
    <link:label id="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A_label_en-US" xlink:label="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inovio As [Member]</link:label>
    <link:label id="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A_documentation_en-US" xlink:label="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inovio AS.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_InovioAsMember" xlink:label="loc_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:to="lab_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:type="arc" />
    <link:label id="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1_verboseLabel_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">VGX</link:label>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1_label_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VGX Pharmaceuticals [Member]</link:label>
    <link:label id="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1_documentation_en-US" xlink:label="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VGX pharmaceuticals.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_VgxPharmaceuticalsMember" xlink:label="loc_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:to="lab_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:to="lab_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:type="arc" />
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and intangible assets, Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:type="arc" />
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and intangible assets, Net Book Value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:to="lab_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:type="arc" />
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:to="lab_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:to="lab_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Territory expansion option period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8_label_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Territory Expansion Option Period</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:to="lab_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:type="arc" />
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaborative agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727_label_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:label id="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727_documentation_en-US" xlink:label="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Collaborative Agreement</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromCollaborativeAgreement" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:to="lab_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, corporate income tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6_label_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:label id="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Corporate Income Tax</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementCorporateIncomeTax" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:to="lab_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, foreign non-income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D_label_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Foreign Non-Income Taxes</link:label>
    <link:label id="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Non-Income Taxes</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:to="lab_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advisory fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Advisory Fees</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementAdvisoryFees" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:to="lab_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Obligation period to pay royalties</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementRoyaltyPeriod" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement, number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement anticipated development and regulatory event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:to="lab_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:type="arc" />
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement, anticipated commercial event based payment receivable milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A_label_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:label id="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:to="lab_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:type="arc" />
    <link:label id="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C_terseLabel_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional products</link:label>
    <link:label id="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C_label_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Additional Products</link:label>
    <link:label id="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C_documentation_en-US" xlink:label="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Additional Products</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfAdditionalProducts" xlink:label="loc_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:to="lab_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement, milestone payment, revenue recognized</link:label>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093_label_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Milestone Payment, Revenue Recognized</link:label>
    <link:label id="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Milestone Payment, Revenue Recognized</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:to="lab_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementFundingToBeReceived" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:type="arc" />
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:type="arc" />
    <link:label id="lab_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F_verboseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred grant funding</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:to="lab_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:to="lab_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:type="arc" />
    <link:label id="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965_terseLabel_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued subcontract costs</link:label>
    <link:label id="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965_label_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Subcontract Expenses</link:label>
    <link:label id="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965_documentation_en-US" xlink:label="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Subcontract Expenses</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedSubcontractExpenses" xlink:label="loc_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:to="lab_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5_label_en-US" xlink:label="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:to="lab_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917_label_en-US" xlink:label="lab_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="lab_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:type="arc" />
    <link:label id="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006_terseLabel_en-US" xlink:label="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Conversion Price</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006_label_en-US" xlink:label="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:label id="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006_documentation_en-US" xlink:label="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial Conversion Price [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_InitialConversionPriceMember" xlink:label="loc_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:to="lab_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:type="arc" />
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992_terseLabel_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After January 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992_label_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992_documentation_en-US" xlink:label="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After January 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AfterJanuary22020ConversionPriceMember" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:to="lab_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:type="arc" />
    <link:label id="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D_terseLabel_en-US" xlink:label="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Event Of Default</link:label>
    <link:label id="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D_label_en-US" xlink:label="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Event Of Default [Member]</link:label>
    <link:label id="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D_documentation_en-US" xlink:label="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Event Of Default [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_EventOfDefaultMember" xlink:label="loc_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:to="lab_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:type="arc" />
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B_terseLabel_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After July 2, 2020 Conversion Price</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B_label_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:label id="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B_documentation_en-US" xlink:label="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">After July 2, 2020 Conversion Price [Member]</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_AfterJuly22020ConversionPriceMember" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:to="lab_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, conversion price ($ per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:to="lab_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:to="lab_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:to="lab_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:type="arc" />
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779_terseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, required bondholder approval, percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Required Bondholder Approval, Percentage</link:label>
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:to="lab_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, convertible, carrying amount of equity component</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>ino-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.inovio.com/role/A401KPlan" xlink:href="ino-20191231.xsd#A401KPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/A401KPlanDetails" xlink:href="ino-20191231.xsd#A401KPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:href="ino-20191231.xsd#AccountsPayableAndAccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:href="ino-20191231.xsd#CollaborativeAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:href="ino-20191231.xsd#CollaborativeAgreementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Company" xlink:href="ino-20191231.xsd#Company" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:href="ino-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="ino-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfOperations" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="ino-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNotes" xlink:href="ino-20191231.xsd#ConvertibleDebtNotes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:href="ino-20191231.xsd#ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:href="ino-20191231.xsd#ConvertibleDebtTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/DocumentAndEntityInformation" xlink:href="ino-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurements" xlink:href="ino-20191231.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:href="ino-20191231.xsd#FairValueMeasurementsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:href="ino-20191231.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:href="ino-20191231.xsd#FixedAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:href="ino-20191231.xsd#FixedAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:href="ino-20191231.xsd#FixedAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="ino-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:href="ino-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:href="ino-20191231.xsd#IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:href="ino-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:href="ino-20191231.xsd#IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:href="ino-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:href="ino-20191231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntities" xlink:href="ino-20191231.xsd#InvestmentsInAffiliatedEntities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails" xlink:href="ino-20191231.xsd#InvestmentsInAffiliatedEntitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/Leases" xlink:href="ino-20191231.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:href="ino-20191231.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:href="ino-20191231.xsd#LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:href="ino-20191231.xsd#LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/LeasesTables" xlink:href="ino-20191231.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRisk" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables" xlink:href="ino-20191231.xsd#MajorCustomersAndConcentrationOfCreditRiskTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="ino-20191231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:href="ino-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:href="ino-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognition" xlink:href="ino-20191231.xsd#RevenueRecognition" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:href="ino-20191231.xsd#RevenueRecognitionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestments" xlink:href="ino-20191231.xsd#ShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:href="ino-20191231.xsd#ShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:href="ino-20191231.xsd#ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:href="ino-20191231.xsd#ShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:href="ino-20191231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:href="ino-20191231.xsd#StockholdersEquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:href="ino-20191231.xsd#StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:href="ino-20191231.xsd#StockholdersEquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:href="ino-20191231.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:href="ino-20191231.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="ino-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401KPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_72FC8861A3BB6B8BC5F5C530C2260088" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_72FC8861A3BB6B8BC5F5C530C2260088" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_FDA4C1A816647EC0602CC530C226542C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401KPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_6A80BF8127EFACF04332C530C2218784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_BEE4933997D7B4F84F7CC530C22263DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_DDFF2839453FA1D5D65CC530C2218643" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_3F501F504217E46CF80AC530C2223BDE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F1C4690546C30BA02FD8C530C30C355F" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_73835CAC6C05E8D759C9C530C30C011F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_F2CCF73116B74210F945C530C3064FB0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2CCF73116B74210F945C530C3064FB0" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_52AF7B040F21BB1DEEF0C530C306D629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2CCF73116B74210F945C530C3064FB0" xlink:to="loc_us-gaap_AccruedSalariesCurrent_E51C5E73103346127899C530C3063918" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedSubcontractExpenses" xlink:label="loc_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2CCF73116B74210F945C530C3064FB0" xlink:to="loc_ino_AccruedSubcontractExpenses_05079B3DEBFFE2759D3CC530C3062965" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2CCF73116B74210F945C530C3064FB0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_709B78230BD2AEE328BEC530C307FFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_F2CCF73116B74210F945C530C3064FB0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_649B5E30E605B524FCA8C530C30730AA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_267E800812FC454A52E3C530C30A10E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_267E800812FC454A52E3C530C30A10E8" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_15E3F6CF9E9BAACCB150C530C30A438A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_753330161042002A58BBC530C4B5CCC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_753330161042002A58BBC530C4B5CCC3" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_95EE90AC56E30636A613C530C4B5B70F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC31D683EB99EBF1477AC530C49D4428" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_EC31D683EB99EBF1477AC530C49D4428" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3ECA24C4352D023F193CC530C49DB6D9" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_34D05309DA8FF98C4E79C530C49E0226" xlink:to="loc_us-gaap_ForeignCountryMember_952D98BB4F3F2F5BD8C1C530C4A3441F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_977B810715647B98FDB3C530C4A4CBAD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_533F63D89E6D4644C337C530C4A471C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:to="loc_ino_ApolloBioMember_533F63D89E6D4644C337C530C4A471C8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_B11FE8BB34200BC40088C530C4A5B981" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:to="loc_ino_MedImmuneMember_B11FE8BB34200BC40088C530C4A5B981" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_479A63D57CCC9DFAFB98C530C4A45CD0" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_F50EC130B411516CDEA1C530C4A5F30D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2A5267F8FC650F1B7BB4C530C4A5C56F" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57BC21873F8E60302424C530C4A5E678" xlink:to="loc_us-gaap_CollaborativeArrangementMember_E3A17EEB346225C30BB4C530C4A60C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_72E8ED27E85B6075B159C530C49DC797" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementTerritoryExpansionOptionPeriod" xlink:label="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementTerritoryExpansionOptionPeriod_249866650C050F4E5190C530C4A66CB8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromCollaborativeAgreement" xlink:label="loc_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_ProceedsFromCollaborativeAgreement_11B4960537A8EB402488C530C4A60727" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_584C0218EA27CAC70D98C530C4A702AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementCorporateIncomeTax" xlink:label="loc_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementCorporateIncomeTax_1872FE0F3EF92B376F5CC530C4A73EB6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementForeignNonIncomeTaxes" xlink:label="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementForeignNonIncomeTaxes_551A61449D0B96AF267EC530C4A7809D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementAdvisoryFees" xlink:label="loc_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementAdvisoryFees_76103D1032587C086F98C530C4A79DE5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_560E834A8527DA12ED37C530C4A79CC2" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementRoyaltyPeriod" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_0F8B6BCD256078413E30C530C4A7A091" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_645367C54303D8C19C20C530C4A8A882" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_4098363398DD12AB927DC530C4A8DE17" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones_74874EED3B4DF35C49BAC530C4A8A739" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones" xlink:label="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones_6001BFB2AB11155BD4A2C530C4A8DB2A" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfAdditionalProducts" xlink:label="loc_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_NumberOfAdditionalProducts_71F51C4BDFA6663DA3DBC530C4A9888C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementMilestonePaymentRevenueRecognized" xlink:label="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized_C4A22C96095D30FA9EF4C530C4A9F093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19E69ABE91DBEF58FE9FC530C4A9D250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_3A7B98F099B7EE45B30AC530C4A9B8DA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementFundingToBeReceived" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_FAD40614C0DEC3C77BE4C530C4AA7DDE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_721F3E3A0C4BD414D058C530C4AA2DA9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_BEBADF9BC64E90DEC5EAC530C4A61270" xlink:to="loc_ino_DeferredGrantFundingCurrent_45252B4135C920ED56C9C530C4AAFD4F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Company" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1F4582A0E2CF50F72ED6C530C5C8B9FF" xlink:to="loc_us-gaap_NatureOfOperations_6EDD88E67F02B09EC85FC530C5C8891B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5CA56C5E1350F190B6EFCEFCE9805906" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5CA56C5E1350F190B6EFCEFCE9805906" xlink:to="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:to="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8E49BFBF78A2F5FE3454CEFCE981E3F9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_709E4399A1471853E24CCEFCE982E75D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_709E4399A1471853E24CCEFCE982E75D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertibleBondsMember" xlink:label="loc_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_F7658E6D82207F092E2CCEFCE9815E3E" xlink:to="loc_ino_ConvertibleBondsMember_A004943108B9C3EB7009CEFCE982189E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_B449533249C89C679AA2CEFCE980E6A4" xlink:to="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:to="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1C6999BF91BD32F20CE3CEFCE982BB08" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_81FF6F5140BEFFACC0B6CEFCE9832B90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_ShortTermInvestments_3309AFCF503DCF0707D9CEFCE9832599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_AF466DBAF1DC974ED880CEFCE98342E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_7C560D70286E0AC43127CEFCE983EC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_B6C50944CBF13E2CC524CEFCE984743F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_F12DDDEA77D63C47E4D9CEFCE9840681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_AssetsCurrent_703C53177DD5E67A0FAACEFCE9894DEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_52F7B7843EFB4807ED51CEFCE98911CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_D9DF83DB99E810F97288CEFCE989BFAC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_D9DF83DB99E810F97288CEFCE989BFAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8A45FA5AE24B4EB3980BCEFCE98A0B09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_Goodwill_075D3C2C1579645E11BDCEFCE98AD8E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C8A477A3389C1990DD00CEFCE98AF50F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1E2DEC04968970CF7E71CEFCE98A7AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1DA457C8AEB610C8DED3CEFCE982EFD7" xlink:to="loc_us-gaap_Assets_652BBC9722CFAB9D0866CEFCE98AAEA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_CE7FC13379869FE76493CEFCE9821934" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_227760F785AA1212C18ECEFCE98BEE9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_A3BE735692254ABD0B0ECEFCE98C5137" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AccruedClinicalTrialExpenseCurrent" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_C733D08606A161452D36CF6538AFA3F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_395B61A5F71496607051CEFCE98CBE75" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredRevenueFromAffiliatedEntityCurrent" xlink:label="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredRevenueFromAffiliatedEntityCurrent_7BAC85693F336AD4546DCEFCE98C3632" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_EBE39B9A02D2663B7E43CEFCE98C34BE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_EBE39B9A02D2663B7E43CEFCE98C34BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_93B9E5CC9E26CF35B9B5CEFCE98C6E0C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_93B9E5CC9E26CF35B9B5CEFCE98C6E0C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingCurrent" xlink:label="loc_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredGrantFundingCurrent_3AA749BCC806DF5A404BCEFCE98DB752" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_D6DCC3DFD1ED91B9A655CEFCE98DA9AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_LiabilitiesCurrent_92FAD4E5DEE63B6B2C0FCEFCE98DEFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_34BCDAA8279403B64AACCEFCE98D5E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_ConvertibleDebt_8C257B4BFEF32C63BC30CEFCE98DE839" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5469D09AC36CF27C6329CEFCE98EE638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_A2527C31F82F95A8C89ACEFCE98E004E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87706164AB94E10176F7CEFCE98EB9BB" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_87706164AB94E10176F7CEFCE98EB9BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_D2251C369A510DAA1E2DCEFCE98EE5CB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliateNoncurrent" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateNoncurrent_6CD720DC883408A33A27CEFCE98EBB72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4E625274F6DEF4411E32CEFCE98F6E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_39DA374D860466F8A8C6CEFCE98BF1D4" xlink:to="loc_us-gaap_Liabilities_46AD217ECC593B4240E4CEFCE98F4357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_CommitmentsAndContingencies_EF4AC96539A0928E617CCEFCE98F3BAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_PreferredStockValue_22FE939B5D14ED564641CEFCE98F4407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_CommonStockValue_F8D42C082EAFA62072A5CEFCE9904FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_AdditionalPaidInCapital_C5486F564BE8DD38421ECEFCE99011A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EE643FD525C2D5531DC0CEFCE990D6E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_EE643FD525C2D5531DC0CEFCE990D6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2C99ECDD39E435CD487CCEFCE9905E18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_StockholdersEquity_9F416A464946FFB9DE6CCEFCE99093F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_MinorityInterest_CC96C0B50700B3CB3345CEFCE991DEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_3C186ECD4DED8A26B173CEFCE98F05EB" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_B28A55F86CEB778CF9DBCEFCE991B1DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8380E4BCA144090353EDCEFCE98BC9AA" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_983AB2CCD64746DAD464CEFCE99147B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_0BA215AD216AD06D07C3C530C61B7DC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_CB7D4AF409F70F0B4FF8C530C61BFACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_PreferredStockSharesIssued_BBCB519A395ED8CD5CD7C530C61B3B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6189BE8F2840942B7CD2C530C61C18DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_77817D1BDBDF8B08E125C530C61CCC3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_38FA984610ABBB3D6B1CC530C61C8FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_CommonStockSharesIssued_D23518E900E4DD1A18FAC530C61C3B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_F08CEF89ADA55A6AC43BC530C61B8DCB" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7C76CF5451E92EE3F66BC530C61CA297" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:to="loc_us-gaap_ProfitLoss_1C6B6BB038B9005CA31BCEFCE8CE0ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_Depreciation_B4FB984994FD5A95112ECEFCE8CE542B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_C8B3E70148D9C4A7F011CEFCE8CFEBBF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AmortizationOfOperatingLeaseRightOfUseAssets" xlink:label="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_ino_AmortizationOfOperatingLeaseRightOfUseAssets_735667E234DF2D69EA52CF1503F0B6E6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_ino_ChangeInValueOfCommonStockWarrants_BC9FB338121C058D6356CEFCE8CFB25B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_70E6EC03F88328EC6BC9CEFCE8CFECB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_ShareBasedCompensation_E842CA0967E02EA4B593CEFCE8CF87BE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NonCashInterestExpense" xlink:label="loc_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_ino_NonCashInterestExpense_A3B421618D33E485FE22CEFCE8CF598A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeAmortizationOfPremium" xlink:label="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_InvestmentIncomeAmortizationOfPremium_8B258B5DE7CAE31D4967CEFCE8CFA5C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_1E215BC124329EEEAE2ACEFCE8CF4031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnInvestments" xlink:label="loc_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_GainLossOnInvestments_80273AE3C1E27CF8F5A1CEFCE8D07F47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_BFB226F9731A377CEEECCEFCE8D03FA1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_132EDB60C07756F2CA8FCEFCE8D014FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_869C0E9A9F72048902D8CEFCE8D07DE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_5CF04D2D235B412ED098CEFCE8D0C372" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_BDF4AABDF8C6D2F5A315CEFCE8CE63D9" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1735AC7CBFA198842B9FCEFCE8D12008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0029BBFE412376ED0723CEFCE8D1F384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_337BAECF5B5802DD326BCEFCE8D2D23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_673DE79F98B5165BC130CEFCE8D2B76D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:label="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_57F008A8A416012072C4CEFCE8D2B02C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_B114729324A823B2D6F5CEFCE8D2376D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_B7CCD70EA7D01D10FD40CEFCE8D33857" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_6D5D133947339CC44465CF6676B5B7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_15E09C2859963988DD75CEFCE8D32499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_86F56E0BF1475A3FFE87CEFCE8D34451" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties" xlink:label="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties_1FFA946BA9CAE085E45DCEFCE8D3FE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StraightLineRent" xlink:label="loc_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_StraightLineRent_7E0F932396C2E5332510CEFCE8D49BDD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_067A3D21BBE9966CAA71CEFCE8D456BE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_527F7326702F54486E4ACEFCE8D4254E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent_0525DEF927D566397782CEFCE8D45FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5A64B0E2D1AF70D64121CEFCE8D16E66" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_48CF2C62E02F3DADC79CCEFCE8D4C958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3A285AD48913E1E925A8CEFCE8CD95AC" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7FD9B4488759709F136ACEFCE8D476FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_4E29663BA380408940AECEFCE8D523FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_595C7FCD960CEE5F50E2CEFCE8D5DBAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_C0B01543EDB6A20B7A56CEFCE8D500D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_755BB084A040207C2374CEFCE8D6D276" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_01A7D76E0BA169D493B3CEFCE8D5E6E4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2159FF77066E24654089CEFCE8D6B120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7B3C7C4D15AF972751BBCEFCE8DBB1DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_71F03D574D07C97BA5F9CEFCE8DCBB13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_FCF650DD433720C64637CEFCE8DC6C30" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsfromStockOptionandWarrantExercises" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_CCCF063811E4BB580281CEFCE8DC8087" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_732BD823F36612B20A64CEFCE8DC50EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_2123C47CD2857A9FEFBDCEFCE8DCEADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_38259A2B130AC168DBBECEFCE8DB7820" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_30EEB9EB0E005CE37DDCCEFCE8DCA994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_AB6B5006F4FD302DE570CEFCE8DDA17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_434FFFD395B2AB444BA4CEFCE8DDFB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7432C85363196380C03CCEFCE8DDA291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_32E0483DF5AAC594B0CFCEFCE8CDB6B6" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_A5B5A89904FC14ACD0E6CEFCE8DDFC9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:to="loc_us-gaap_InterestPaidNet_18041E2026D480EA1455CEFCE8DE4A70" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EquityComponentOfConvertibleDebtIssued" xlink:label="loc_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:to="loc_ino_EquityComponentOfConvertibleDebtIssued_2FBB7A5A662491E8F43FCEFCE8DE842D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_226756BF548E644B3721CEFCE8DDEA10" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_1E0FA070BCC42C5AFB3ECF166AC90D8D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_5CEAEE4696102E4CB0D1C530C5FDC6B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:to="loc_us-gaap_ProfitLoss_5CEAEE4696102E4CB0D1C530C5FDC6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" xlink:label="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:to="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_7731B3BA5431A116D103C530C5FDB2EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_DEAA73B821F234B41CE9C530C5FD0514" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_95744CEB602292717D27C530C5FEF4BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_BC246DC04D25765466A4C530C5FE4F21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_BF5EF2F06D92F3B3B4AEC530C5FE08D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_488784B371A6AD6AEFC0C530C5FD4578" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_40767DBFC57F821DCCAAC530C5FEE884" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_C933C1AF15C8F4BD61B9C530C60B694B" xlink:to="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:to="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_C76632AE384BC5B8F9F6C530C60BFB8D" xlink:to="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_us-gaap_LicenseMember_56818687F8CB8B570D96C530C60C3E40" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_95DF034D83F13336BA45C530C60CF939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrantMember" xlink:label="loc_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_us-gaap_GrantMember_ABC884BFF5F6761790E7C530C60DE1F0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantwithAffiliatedRevenueMember" xlink:label="loc_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_12FC0DB8AD94FDBA1EA5C530C60CDF9E" xlink:to="loc_ino_GrantwithAffiliatedRevenueMember_41DD9C0A30C603CE94E2C530C60DE4A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_A009C2F1CC08AB835B0DC530C60B1DE9" xlink:to="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A91976E65386A6A57D67C530C60D47AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5358E71BF00423DACA83C530C60D298E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_A91976E65386A6A57D67C530C60D47AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_87B45BFF5FFF528F47D2C530C60ECCEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_EE196584F4EAD30A0194C530C60E8CBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_60BC04BA4110B939705EC530C60F2E80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_D530B874DBF81F3B1E2BC530C60EA050" xlink:to="loc_us-gaap_OperatingExpenses_B9BDE61973C6B74DC60AC530C60F1884" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_OperatingIncomeLoss_AE6B584FE5F906F77807C530C60F5AC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_InterestIncomeOperating_A0DC98650FA4625090AAC530C60F610B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_InterestExpense_9757388C780A0F750E18C530C610A25B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_D1B311D1CA574331C60FC530C6102E82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_29C997FA51ACC9E123C5C530C6103934" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_0C84CCA49F6D3C20C087C530C61047F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_AC0F35024ED32F09A2DFC530C60F413C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_D47D8D8A0F13FF2ADE2DC530C610C419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7B40B69CD7B097E4DA91C530C6103B6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_925054859DA0AB1CA403C530C611A517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_ProfitLoss_A7A37E93E65AFCD887BDC530C611469D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0A76D112526B38AF16DFC530C61153F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_NetIncomeLoss_DA9AE8E3F4199ABE65A3C530C6119472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:to="loc_us-gaap_EarningsPerShareBasic_D35852BB8CC3E589B13AC530C6129DC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9798743C51773620A810C530C6113919" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1943123245CF05A8F475C530C61286FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9A9A093D5141C2246883C530C60DAE6B" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_F3EBCCEEE69918E8DEE0C530C612BD4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_83F4156ADB2041563CC9C530C6126425" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2DF5C1784388BEF1EF13C530C6121121" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_63B721CA223389496CB6CEFCE8FC4789" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_63B721CA223389496CB6CEFCE8FC4789" xlink:to="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_EC6BE7B051BA6901E067CEFCE8FD99BC" xlink:to="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_PreferredStockMember_8A9908BF126CE70FDDC4CEFCE8FE0AB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_265EE4688098226FCEE2CEFCE8FEE778" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_CommonStockMember_265EE4688098226FCEE2CEFCE8FEE778" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9FED970EB39DD91DE31ACEFCE8FEC72D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_RetainedEarningsMember_03018B3E2AACAD6527B4CEFCE8FE5E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_679F3E9AE49A0ABB06AACEFCE8FF0AC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2B3662BDBA00FE92D7CBCEFCE8FD0381" xlink:to="loc_us-gaap_NoncontrollingInterestMember_9909F0213F18079F6BD8CEFCE8FFE27D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E7BC0D446EBA707AE373CEFCE8FF25C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D272C34C3E7553CAB186CEFCE8FDF27A" xlink:to="loc_us-gaap_StatementLineItems_E7BC0D446EBA707AE373CEFCE8FF25C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E7BC0D446EBA707AE373CEFCE8FF25C1" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_SharesIssued_23AB720BBFB7B72C7311CEFCE8FFF5FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_924C3A5141431B6A1D5DCEFCE900B77A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_CA8DFEC62E527FF1898BCEFCE9007D29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_A86512F1228B78CE5473CEFCE900712B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8A1739602CE88913336ECEFCE900BAFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_EB804C1EB7D4235614A2CEFCE900CF71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_DE6707657D08D01DBC69CEFCE901F44E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_56316E74A629E967C602CEFCE901BDD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_A3243F7084E1F905B124CEFCE901D48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_18CC40E7E071865B82E0CEFCE901D62F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_ProfitLoss_37ECA91B1947B55DED59CEFCE9067A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_86DC7A99650CD36DD489CEFCE907C586" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax" xlink:label="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_35A9DB2F4B1BD25B6BC2CEFCE907FA5A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax_35A9DB2F4B1BD25B6BC2CEFCE907FA5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_SharesIssued_2DBC5C69939553EF369BCEFCE907FE2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CB3FA1476D5294187727CEFCE8FFAD04" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_99B11C7FA7913F9AD5B5CEFCE9075C2B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B" xlink:type="locator" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IssuanceOfCommonStockForCashFinancingCosts" xlink:label="loc_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_988BD2CABCA5268624C7C530C5E7966B" xlink:to="loc_ino_IssuanceOfCommonStockForCashFinancingCosts_39563F6AB5EF8E800605C530C5E78130" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F32107105A8B1885523CCAC7CBC62D30" xlink:to="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9DEA2F76962116F11A0ACAC7CBC61C3F" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_73DA7EFC51A3C06C9D92CAC7CBC72921" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_73DA7EFC51A3C06C9D92CAC7CBC72921" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_E156A0A38FE329D27C2CCAC7CBC77AE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:to="loc_ino_August2019ConvertibleBondsMember_E156A0A38FE329D27C2CCAC7CBC77AE8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_BC97BC57B1B7A3C8A39BCAD123822844" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1011B19A9FE436BC14E4CAC7CBC65072" xlink:to="loc_ino_December2019ConvertibleBondsMember_BC97BC57B1B7A3C8A39BCAD123822844" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3236C8DD7D5A2C1400CFCAC7CBC62DB1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_48DFE8DF835754E582D4CAC7CBC8536D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_8611846660D46C16DCD2CAC7CBC8339B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5CC3976C248F3520ADE2CAC7CBC80C13" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentAccretionOfPremium" xlink:label="loc_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_ino_DebtInstrumentAccretionOfPremium_38CDCCFF892C4AB43E9ECAC7CBC8DC4C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtinstrumentAccruedInterest" xlink:label="loc_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_ino_DebtinstrumentAccruedInterest_C0016827CE7DC5A45AB2CAC7CBC8F24C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_445372F7540222E21919CAC7CBC7019B" xlink:to="loc_us-gaap_LongTermDebt_6086FC2976CCFE81D867CAC7CBC8470B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2D01E60A4CA93A7E97CCCAC7CBD2E857" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2D01E60A4CA93A7E97CCCAC7CBD2E857" xlink:to="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_36C54A700640FC5C2028CAC7CBD2D1D3" xlink:to="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_615C73F35DFCC62D5DE6CAC7CBD32A8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_323CF55C324C0F32C08DCAC7CBD2BDBC" xlink:to="loc_srt_MaximumMember_615C73F35DFCC62D5DE6CAC7CBD32A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionByUniqueDescriptionAxis_2B9C41A0719B0857A458CAC7CBD322A5" xlink:to="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_InitialConversionPriceMember" xlink:label="loc_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_InitialConversionPriceMember_4E325ED3C80E76A5DC8CCAC7CBD3D006" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AfterJanuary22020ConversionPriceMember" xlink:label="loc_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_AfterJanuary22020ConversionPriceMember_760B5929C0D33369F25BCAC7CBD4B992" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EventOfDefaultMember" xlink:label="loc_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_EventOfDefaultMember_1D83D54552DDD8E3E31FCAC7CBD4EF7D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AfterJuly22020ConversionPriceMember" xlink:label="loc_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtConversionNameDomain_7A0C32D7DA6F6C97193CCAC7CBD35917" xlink:to="loc_ino_AfterJuly22020ConversionPriceMember_2F77AD4C15EE36E081EBCAC7CBD45D2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_814666C851CAFBB0736BCAC7CBD4E3B8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_010BBDD64AE0F94BEA63CAC7CBD56A7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_A25F027C0A29FE873AA8CAC7CBD55EA7" xlink:to="loc_us-gaap_ConvertibleDebtMember_010BBDD64AE0F94BEA63CAC7CBD56A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_922238280972FAAA78C0CAC7CBD577F2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_82212D93906BAADB2FD4CAC7CBD684BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_82212D93906BAADB2FD4CAC7CBD684BD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_0CA3736E3CCD862D0A85CAC7CBD69E8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:to="loc_ino_August2019ConvertibleBondsMember_0CA3736E3CCD862D0A85CAC7CBD69E8E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_8DBE3951D98476A0322ACAC7CBD63AD9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DC64E2610C81D9610809CAC7CBD5A536" xlink:to="loc_ino_December2019ConvertibleBondsMember_8DBE3951D98476A0322ACAC7CBD63AD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1BA162777E201FBE8C30CAC7CBD2695B" xlink:to="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A1D7046D7B400A308AA5CAC7CBD7D5F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_A1D7046D7B400A308AA5CAC7CBD7D5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B7D9E8983ADA54250485CAC7CBD76E19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_B7D9E8983ADA54250485CAC7CBD76E19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_857A14E59FFBBC321862CAC7CBD736F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_996FA2266EC365267F00CAC7CBD76B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_FFB77D0691EEFAF90F2DCAC7CBD85018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_F5DDB44DEF5AE98E6451CAC7CBD826B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_A27B2FBFF17045C6DCB8CAC7CBD826E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_B86DCAF99B24EA1AD185CAC7CBD86D6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3047A1531748267525D1CAC7CBD9D36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_LongTermDebtFairValue_824B829205ECA9283B7BCAC7CBD92D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_F1105A85F9BA20A546DFCAC7CBD97B14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_5C585D294ED2D907F246CAC7CBD9F454" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_24C5AAEBA14AF164B913CAC7CBD99E46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_InterestExpense_57D21E868B992088788ECAC7CBD91148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_InterestExpenseDebt_19F5B2BC1BB92DD7AB3CCAC7CBDAC0D1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_F588B75D8EED5D47C12DCAC7CBDA7651" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_F588B75D8EED5D47C12DCAC7CBDA7651" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage" xlink:label="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage_FAF60E03473EBE9A519DCAC7CBDA4779" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_D097A9DBE2BB56E6F1ABCAC7CBDA08A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_E891933F5579B882ABBECAC7CBDA3304" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_DerivativeLiabilities_E891933F5579B882ABBECAC7CBDA3304" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_8F0F3941FE9563206ECBCAC7CBDA8474" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_879FEAC9FF12F1109C1ACAC7CBD6BADC" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_8F0F3941FE9563206ECBCAC7CBDA8474" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNotes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3271ADEB2DC5D1EF5566C530C334C6CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3271ADEB2DC5D1EF5566C530C334C6CA" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_30F4A6D317F57B54CB5BC530C3344857" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_136BEC69E7FE518C1B94CAC7CBBACB7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_136BEC69E7FE518C1B94CAC7CBBACB7E" xlink:to="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_D17B13631286A1648ADBCAC7CBBB8A5F" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_930535D6BC76DD4BD5A5CAC7CBBBF901" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_01C5973A750C4F17CCD3CAC7CBBB6258" xlink:to="loc_us-gaap_ConvertibleDebtMember_930535D6BC76DD4BD5A5CAC7CBBBF901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:to="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2ED78548957A6592A9B6CAC7CBBCCEF2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_CBEA4B5CC266AA3EA332CAC7CBBC1651" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_CBEA4B5CC266AA3EA332CAC7CBBC1651" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_66E6A3F75E8A34C245F6CAC7CBBD176F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:to="loc_ino_August2019ConvertibleBondsMember_66E6A3F75E8A34C245F6CAC7CBBD176F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_003B68314F30BEF4278DCAC7CBBD3702" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_AB17A16DC60ED6DE13D4CAC7CBBCC5D5" xlink:to="loc_ino_December2019ConvertibleBondsMember_003B68314F30BEF4278DCAC7CBBD3702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1CB98DF87D5016B163C0CAC7CBBBE004" xlink:to="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_2ED06F8EF96F8859E8A7CAC7CBBDFA89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_AFAB67A9D628C8FB4E70CAC7CBBD5539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_830B7BEAC645488540E1CAC7CBBEEAEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_A05B765F4A00E9D4F88DCAC7CBBECEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_7751063A7E0AD8A095AACAC7CBBE03E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_60ADFED2C454B3704CB0CAC7CBBEB19A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_LongTermDebt_60ADFED2C454B3704CB0CAC7CBBEB19A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_42B657395648BD7278DACAC7CBBEA977" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_42B657395648BD7278DACAC7CBBEA977" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtInstrumentConvertibleInternalRateOfReturn" xlink:label="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_DF96E62D6490DA641800CAC7CBBD1C6A" xlink:to="loc_ino_DebtInstrumentConvertibleInternalRateOfReturn_54DE52BBC2A2BADF2E51CAC7CBBE5358" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7DE42AE650E8C748A815CA25830F8B4B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7DE42AE650E8C748A815CA25830F8B4B" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_C22DDA81A249B8541D22CA25831018DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7DE42AE650E8C748A815CA25830F8B4B" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_DCD59F02B10A3954F385CA258310A76A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="ino-20191231.xsd#ino_DocumentAndEntityInformationAbstract" xlink:label="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_DocumentType_C619A9D8BEA7F8BDF9A9C530C6470DB2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_AmendmentFlag_C48A4809D257BCD9213DC530C647C351" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_DocumentPeriodEndDate_866C6D93F95F83242BD1C530C6478716" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_DocumentFiscalYearFocus_B7C5EEC56C01B23D4DBFC530C647393C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9BE7DA76085ED7A7FBF9C530C647A00C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityRegistrantName_2DE52D9715213C2CF09AC530C64858E0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityCentralIndexKey_586C76B913D103868F40C530C6489539" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_CurrentFiscalYearEndDate_451BAA12CB06BBF50675C530C648DC9C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityFilerCategory_8C1EE2759C2511D0CACDC530C648E6B7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_A6102868130CBE116968C530C649227B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_83DF9A17F5BE8DC4DFA8C530C649E81E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityPublicFloat_2C46F79FDCA871E6D904C530C6499E5F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityCurrentReportingStatus_A7F14235388404D366B6C530C64936E5" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityVoluntaryFilers_0294F9C158E5CC20E235C530C64ACD92" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntitySmallBusiness_19A53876C463964D0499C530C64A052E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityEmergingGrowthCompany_9323BEBAD2C1517534C2C530C64A7472" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DocumentAndEntityInformationAbstract_39E802805C6C035CDF86C530C646BC16" xlink:to="loc_dei_EntityShellCompany_741D7D4CAF544F22CDF9C530C64AE39A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D5BD30A692EA0DE91E90C530C44A92CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D5BD30A692EA0DE91E90C530C44A92CF" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_32C592E665BCF2485146C530C44BA81C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C87CAA72C6FACDF53B0BC530C42EF1C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C87CAA72C6FACDF53B0BC530C42EF1C8" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4BB69C8DDE57B397A45DC530C43434C2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_320FFD62DDF1C6F01E95C530C435A46A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_BC624A58B667FD35D789C530C435D242" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_320FFD62DDF1C6F01E95C530C435A46A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_95A68C352F89FBFCE2FDC530C43581E5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:to="loc_us-gaap_MoneyMarketFundsMember_0C91251B71EE1E74C7B3C530C4360515" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8B44E04D528FA5B05668C530C435DD21" xlink:to="loc_ino_MutualFundsMember_BBA8E92B7980C833D2E9C530C4364F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_779504F7F8D83DC63988C530C43674D4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_380AEF71063B6FECF0BAC530C43754B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_B319C1F1D5832C129F23C530C437AAB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7D87F5717EFC1AE973E3C530C43638C8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_07B2692FB5E58E72BB3FC530C4372CD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_70CBC7F6F47F9B52B783C530C437D999" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_4FCCB8AC49E0D3B2EA8EC530C434F214" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_70CBC7F6F47F9B52B783C530C437D999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_70CBC7F6F47F9B52B783C530C437D999" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7BD02C562C9580EE8208C530C4381639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_149DAF618067B3106D77C530C438C27F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_39495B36A23CCE44B53BC530C438ABAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_39495B36A23CCE44B53BC530C438ABAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7ABD4D5FE71DEEDC9130C530C438A2B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_DerivativeLiabilities_3AA127DC68D2868A820CC530C4393C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_9C86170CBF39E9B06067C530C4383A01" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_AFA4FAAA2B22298A2946C530C439836B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_D34435482E28C400FA98C530C400887B" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_96752B0A46FF0AA5A153C530C401B10A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_70ADCC3EB878163BC72BC530C40181EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_077D6D8B696581E3702BC530C4014E08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_ACD218595CBEB0CFBA68C530C4018602" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69496F1AF23576B5E2E1C530C4019CCB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_55BDBA5F507762BF438FC530C411A66C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_55BDBA5F507762BF438FC530C411A66C" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:to="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_57FE7C461C3573126369C530C411CF36" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_487F22FAF26B03F8D7B0C530C4129118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_7F618F510049027FA55BC530C4125830" xlink:to="loc_us-gaap_CommonStockMember_487F22FAF26B03F8D7B0C530C4129118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_71E7B5780831111F0DBDC530C412D124" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_DEA094AC9A9397FAD628C530C4131C7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4B702E130EBD416A0466C530C412EDD9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_DEA094AC9A9397FAD628C530C4131C7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8C82C14E4C0ED0B20330C530C4110C69" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract" xlink:label="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4FF68E57DDAC529D50B7C530C413BAF3" xlink:to="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares" xlink:label="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="loc_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares_8843DD20B08697157C3AC530C414185B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_5699ABB51AF95EF25C3BC530C419F761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract_F92B6A7B3F713162C654C530C41336A7" xlink:to="loc_us-gaap_DerivativeLiabilities_C51605FB7D0CC30FEBC6C530C419F37C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_91720C6F9E5438BF0DF8C530C4425A22" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_91720C6F9E5438BF0DF8C530C4425A22" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_54836771FEEEB24A2A7BC530C442CA5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_91720C6F9E5438BF0DF8C530C4425A22" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_2BBC76CFCF713B432B86C530C443CED0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4F0438214653F92523DBC530C3A752D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4F0438214653F92523DBC530C3A752D3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_9CE1EBAF1099FECEBE15C530C3A76D06" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_63ECE40B1182B5096752C9F7DBF698B6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_302EB68023C7FF55D559C9F7DBF68B1A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_B15F76D1C76CD2D7B77DC9F7DBF79329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_OfficeEquipmentMember_23CBDD106F99171AF6DFC9F7DBF74EBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_8915841E2FC6994630A0C9F7DBF7BF44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7E6F227C418ED845503DC9F7DBF6EBDF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_75F841AD3E3A6A101B48C9F7DBF886AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_D7772D2439A965627D1FC9F7DBF68BFA" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2AFD196C90A33576464DC9F7DBF838E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_AA2A8356D1978B04A6D3C9F7DBF8766D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9DF8486BA28BD0C4918AC9F7DBF83B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_Depreciation_95CAA511724B92F55CCAC9F7DBF886AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisposals" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_52A01DE8ED67AD6ACDCCCA1A34579728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3D4D743DACA99278E22EC9F7DBF8C47E" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1_38ABF2EDF3A0CECFE898CA1BCC471D00" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CF0D12A6283D8C391227C530C39D883A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_CF0D12A6283D8C391227C530C39D883A" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_B7DEAE9EE01DB6041E3AC530C39EDFEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2175928E7D0835BEABFEC530C37E6513" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2175928E7D0835BEABFEC530C37E6513" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_E2FFDF9E773A1E229D41C530C37F9EE9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DBE88C8DB25FC14DB2FCC530C337F141" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DBE88C8DB25FC14DB2FCC530C337F141" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4769A50D25E45D712DB8C530C33741CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_DBE88C8DB25FC14DB2FCC530C337F141" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_B3A0F871A974BDC46542C530C3381F26" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2" xlink:type="locator" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsTextualAbstract" xlink:label="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_F982E61F253E9D46016EC530C33D84A2" xlink:to="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_143EDFB447D942857C9EC530C33EED0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_FA081679A188BC2466F9C530C33E2C16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_B7A8C9828AFD8496CDA3C530C33E0A3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2EBE8FB74B401426A7E4C530C33FEF57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_EDA46EF03FA8A5A0CFB2C530C33FBE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_8766F62542CC89DD5CE0C530C33F48B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_GoodwillAndIntangibleAssetsTextualAbstract_247B3A9C40E51CC24156C530C33E6C12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_78EF1CE1450B75A56B04C530C33FA247" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_264585D7241E5887D7B1CAA5A0C416A9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_264585D7241E5887D7B1CAA5A0C416A9" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C471A342D1A389737C92CAA5A0C4B46E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_us-gaap_PatentsMember_39400E38F03F0B477A10CAA5A0C51039" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_us-gaap_LicensingAgreementsMember_B95AD1B8B1DFACFDAD15CAA5A0C57C24" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CellectraMember" xlink:label="loc_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_ino_CellectraMember_D9FD4584160E92300785CAA5A0C5D3AE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GhrhMember" xlink:label="loc_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_ino_GhrhMember_F8C8CC7267A8EC3D0847CAA5A0C58ED9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_BiojectMember" xlink:label="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIntangibleAssetsMember" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7E746BA01B93378C03F5CAA5A0C41D8B" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_1C6339EEEECDD68257FCCAA5A0C6179C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14BD08D23662A274222BCAA5A0C60958" xlink:to="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_WeightedAverageMember" xlink:label="loc_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6FECE504819A95DD30BDCAA5A0C63B8D" xlink:to="loc_srt_WeightedAverageMember_C866CE4C5F7BAE418142CAA5A0C62642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_052068F630277905AE07CAA5A0C6EA78" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_InovioAsMember" xlink:label="loc_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:to="loc_ino_InovioAsMember_A6BAEEB1A4F07070F9EBCAA5A0C7E62A" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_VgxPharmaceuticalsMember" xlink:label="loc_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:to="loc_ino_VgxPharmaceuticalsMember_82D969354CC01646FF26CAA5A0C776E1" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C1EA12B3F4D2D9A93084CAA5A0C7BF66" xlink:to="loc_ino_BiojectMember_408D6C6A85B704425A97CAA5A0C51A42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_AD37A1B3D9D0D6384B28CAA5A0C4CCE6" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_5F90716816CCD2B6C3A0CAA5A0C8790A" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D61EF503AAFC7D8D3E9DCAA5A0C89EDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D61EF503AAFC7D8D3E9DCAA5A0C89EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_623AC6B4622BFD1B46A0CAA5A0C88A0E" xlink:to="loc_us-gaap_Goodwill_2CD55C4E26FD1CF3EEA1CAA5A0C9977E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_CCBA3A5880D9D5249BB2CAA5A0C94D11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6D6E00525F114FF2F92FCAA5A0C966CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6DE641AE1E237EB17334CAA5A0C95027" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_FA1F29AAF1FAC8B23511CAA5A0C91748" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6DE641AE1E237EB17334CAA5A0C95027" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsGross" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_BB4B249DA5B54B09A61CCAA5A0CAD88D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GoodwillAndIntangibleAssetsNet" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_A726C777594171CE7828CAA5A0C864FB" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_A0AE42AA1CBC8D093A75CAA5A0CA0AB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_322830C021A4051CCDFEC530C375494D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_322830C021A4051CCDFEC530C375494D" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_2FB8D9121CB817387F42C530C375AA78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_322830C021A4051CCDFEC530C375494D" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7573500A545BA1F3440EC530C375A942" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_443CD51A5CE2553E6797C530C277321C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_443CD51A5CE2553E6797C530C277321C" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_4C6F393CCB068679E084C530C2787B34" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_BEFF81F4F96AC5AD9176C530C234BE5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_BEFF81F4F96AC5AD9176C530C234BE5F" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6ECC528C2E7F01B215C5C530C2343755" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_885BA1919D6A19933EB5C530C235DAFB" xlink:to="loc_us-gaap_ResearchMember_465A3627962140C918F4C530C2350CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_CA0A1AAADCAA9A4A8E0EC530C2358CF2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:to="loc_us-gaap_DomesticCountryMember_C8270F28FAF6CB46A3E1C530C236D0E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_85C065C9ECA5996E34BDC530C235CC07" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_24747D11BBC9026291C9C530C236825D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_98EA6279554AEEFD1C51C530C2340A91" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths_C798698B00C779ADC780C530C2379F8E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_C4472942BF685CA61922C530C237C833" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_7D6C78E9C88BBB71B986C530C237CE45" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_72679D96A24C630A6B72C530C2377AD9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_11F30592E235F5F92503C530C237F0B7" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_E2A4D8E3412815929A12C530C238DE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_C11413F6BFE10E9A4357C530C236EF37" xlink:to="loc_us-gaap_OperatingLossCarryforwards_B4161D9F7F025DC43F27C530C23896EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_A521F8E40F8E70A4C326C530C2362DC1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths_7230C09588690173E4D1C530C238F387" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_90DF5993ED7E0912AC70C530C238802E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinThreeMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinThreeMonths_3745DB0CAC146D1E1CA3C530C2396CE8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFourMonths" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFourMonths_E14233987AFA7BA63592C530C2399913" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_4BF78B451DCA4A5AE9A1C530C2395AB0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_E87792C745C31D8E1208C530C23905E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_EEF572B1E56025DFB0EAC530C2386CD3" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_C3E772B1A34EE2E962C7C530C239FBAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_612B486A4A454B912BF3CA664D8BF7D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_612B486A4A454B912BF3CA664D8BF7D3" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_C3981A5B841C2B761AF5CA664D8C8DCB" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_130054919D965C8F504FCA664D8D1F95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_D7816F7054EF26E8E4E4CA664D8D7CB2" xlink:to="loc_us-gaap_ResearchMember_130054919D965C8F504FCA664D8D1F95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8D3F411EE1EB14F36805CA664D8E1622" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6F625F3AEA750435A0ABCA664D8E19F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_71CEE955C16536835313CA664D8F9609" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_71CEE955C16536835313CA664D8F9609" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CaliforniaIncomeTaxAuthorityMember" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_43F926D0D624DADC4E42CA664D8F098F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_9968DAEA93CE3B1E5C28CA664D8E1D92" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_A458670358717F30B1FFCA664D8FD18A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_C690764224EC90263B83CA664D8C3DD0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_995400C15BB8839720D8CA664D906DA6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_8D34534C54380B68B093CA664D90596E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_OperatingLossCarryforwards_B70EAF5631525288A4E0CA664D90FD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_35BA85160B534C9B40C4CA664D9155B1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TaxBenefitsExpired" xlink:label="loc_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_ino_TaxBenefitsExpired_2A607DFE681B5AC1A570CA664D91FAE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_FF27E2F7AACF06DA86A7CA664D909E2C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_A388D6DC39F5E60228ECCA664D91F043" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_95CAEF43CC16F38F742BC530C25F22BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_95CAEF43CC16F38F742BC530C25F22BF" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_AB75AB7198FB41DA846DC530C260851B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_503573826E1587326F9FC530C2602CBE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount_DEA2CFE87F6C7A8719DEC530C26004C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_165136C047ED1F12777AC530C260EBFB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncomeTaxReconciliationStatuteLimitations" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_06C9C209646A975DA711C530C2610B78" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_IncomeTaxReconciliationFairValueWarrant" xlink:label="loc_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_ino_IncomeTaxReconciliationFairValueWarrant_6958BDD3587809853170C530C261FD6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_50A0CADF6AF477D54D7EC530C26140B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_704948FA003707944D03C530C261FD02" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_5F5E6CDC5ED02888CB01C530C2612218" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_EAD6D7C32EB8691B74D5C530C262C38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9BB2A1EF4EE4154A7221C530C262A438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_44FAB7C7E572FDAAD708C530C2627147" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_2889C3C3EA409C160547C530C25F7158" xlink:to="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_368B68599203D52573D8C530C2625E0A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7F1D2916E314F05A50F8C530C247EFA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7F1D2916E314F05A50F8C530C247EFA0" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_E2CD4CB9D6C9178E2675C530C2480CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_761D5C62DFB15680154DC530C248C87B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_261A56FFC4550643E407C530C248A08C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_DD5B5FEBA5360820F826C530C24830D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_8D34D02A7EC16C6A0303C530C248E97C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_866BA51B55C9FF1488E2C530C249A079" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetsIntangibleAssets" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_79A992DB84048B7676A9C530C249F229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDerivativeInstruments" xlink:label="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsDerivativeInstruments_0C22B70E505EA59E493FC530C249361D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetInterestExpense" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_9705212BD7D946957FA8C530C2498A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_D23C4DAB43C10BBB6CCFC530C249E57E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_259FCB739917B9857EE5C530C249E95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_B19EF2603278F7BE91EFC530C24AD3FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0DC47C21ABF747475086C530C24AC34E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_A2698F53237F8F35AE16C530C24A34EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_5CFC8026914AFE98B721C530C247CE3C" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_F77C265E64AA04E7AE95C530C24A501C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7F1D2916E314F05A50F8C530C247EFA0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_6E8BB63B2CEAD263070FC530C24A4355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_F76808F10969FEB494B2C530C24BC09F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_98D135F8D8C14FCFD37FC530C24B1EC1" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_AA667A7D7C54D96B617AC530C24BB0A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesFinancingArrangements_1E455C40E87AF09B97CAC530C24B1DDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_4F522C64A7FB4B052F1FC530C24C673B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_DCD2D576CCD7FF4FA1ACC530C24AD273" xlink:to="loc_us-gaap_DeferredTaxLiabilities_B99F892EBFAFFC74DFD3C530C24C5BAB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4947B0B39484D9DE4BD0C530C26AD6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_911C282C44B24CDA484AC530C26A3ED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_6F7CF21729DED03E593AC530C26AAB2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_561FEF1D7FB551966448C530C26A7FA1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_654B2623CF62F473CD2DC530C26B85A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_871429B490F8AF4499DEC530C26BEDE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_754D10B5505A407E1980C530C26B8460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_5A0E7947765F97272526C530C26BC0E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_297CE9C729F4F4F3FED0C530C26B6B9F" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_CCA68E284D970DF13D1BC530C26C7A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3F5C1CD00F7A3D5759A6C530C269E917" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_816568B14F17C3288466C530C26CD505" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_679007B98E9E13A0708AC530C271FF59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679007B98E9E13A0708AC530C271FF59" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_587EB6FD153C3CF4338EC530C271D63C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679007B98E9E13A0708AC530C271FF59" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_5A65E09027C67ED90279C530C272CE80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679007B98E9E13A0708AC530C271FF59" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A95BF7D9C3A143A30FCBC530C272645C" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679007B98E9E13A0708AC530C271FF59" xlink:to="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_01EBBF9D316550B0E624C530C273C7AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_679007B98E9E13A0708AC530C271FF59" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_E5E0FAB047416A6281EEC530C27367EB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A13611D840F2E93B8CDEC530C229419D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A13611D840F2E93B8CDEC530C229419D" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_99D3EB81413188E470E9C530C2298D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0C4E84991F455A02C767C530C22A686A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_26CABCF64D77A488B7A5C530C22A8FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_60241B5FBDA419CE6D65C530C22902E5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_7FA144921CFD9F14393EC530C22A0760" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/InvestmentsInAffiliatedEntities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_E3169EFA077FC5379C9AC530C2865EBE" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_9844CDE44D2550389C44C530C286267C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_292777ECE77A38C249CAC530C27E4C54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_292777ECE77A38C249CAC530C27E4C54" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1D584ED43BAB1A5DCEECC530C27E3430" xlink:to="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:to="loc_ino_GeneOneLifeSciencesMember_6A6CD49922D49140CE86C530C27FB4A6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_B07EC6D82CCEC024D9A6C530C27EACD9" xlink:to="loc_ino_PlumblineLifeSciencesMember_5C893E86A55351BDA708C530C27F3AD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:to="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_B64D65118ED49CDD7595C530C27F258D" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_39FB5A16AC2EE28074EDC530C280411D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_8A6E8B7E70ECB5AE9F54C530C280C8C6" xlink:to="loc_us-gaap_CommonStockMember_39FB5A16AC2EE28074EDC530C280411D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_009057E1A6FFD5562BE4C530C27E9286" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_466C00D2A2C762E296B9C530C2815328" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_466C00D2A2C762E296B9C530C2815328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_15DB758113A556A71C4DC530C280E522" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_E5652C17B92F7492411BC530C281B0DF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_40DAEFA1EAA92ABEAEA7C530C2AD9D91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_40DAEFA1EAA92ABEAEA7C530C2AD9D91" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_D7710020470E60771FE7C530C2AD6E75" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_6769D60AA0CE6AB06992C5957A4B99CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6769D60AA0CE6AB06992C5957A4B99CD" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_D936A9908C27CFF597C6C5957A4B3A65" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SanDiegoCaliforniaMember" xlink:label="loc_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:to="loc_ino_SanDiegoCaliforniaMember_82A47527C99F8762DAAFC5957A4CF710" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PlymouthMeetingPennsylvaniaMember" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_9309172FB36D0789F4C7C5957A4C0738" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_D8343AD1F6814CBE9302C5957A4DA816" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:to="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3BC0CFD94DBE56579197C5957A4D149F" xlink:to="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_D184668BE411882D03B8C5957A4E97AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:to="loc_srt_MinimumMember_D184668BE411882D03B8C5957A4E97AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1878D47C1C5BEA2E459EC5957A4E6320" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_042EEAFF42B68FDE13F7C5957A4D852F" xlink:to="loc_srt_MaximumMember_1878D47C1C5BEA2E459EC5957A4E6320" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_74565FD075D427937FC4C5957A4B8722" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_20E4166342E07497A38AC5957A4FD9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2C18908D5B4AE5FAEB10C5957A4F0E4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_2C18908D5B4AE5FAEB10C5957A4F0E4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_us-gaap_LeaseCost_90E467864C85D1227356C5957A4FBFEF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_47AE1478A93F5863B3CAC5957A4ECC37" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_2D1FBEFA7581E8EE6CCBC5957A4FFC9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_05E2C05C916D6944614ACAA507B6AAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C7C375161E4E2C428D5ACAA507B7BDC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_609D7D0E2C7AB8E92B8ACAA507B8A9EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_F71D2C177EB235B56B69CAA507B8A19B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_F3E6BE4276A90E8BAF49CAA507B85237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_E7B66B9C09B6B29F480BCAA507B8D314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6364E88614BD01D79FC8CAA5077D7E5C" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_1BC00304C48B47F5C97ECAA53A578EE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_E0618F20D25C4576278ACA6746DE77A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_BB79DA6A2709898C96E3CA6746E4C4C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_6226CD866C9761FCBB02CA6746E423A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_64A5ADC2A2525445BCD1CA6746E48C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_99A1BC9F1521E3E16129CA6746E43639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_4A331B58830E79D9D87DCA6746E412F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_362976FC372D383EE72DCA6746E45020" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_74996313F616D3F1CAE7CA6746E52AEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_4E8B60C706E335F98509CA6746E52E61" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_OperatingLeaseLiability_4E8B60C706E335F98509CA6746E52E61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_BA2037B04BDB2580FD9CCA6746E5338E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_BAFC7ED11D76FE05D71ECA6746E5C6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_54E829A891E05A7A3DAECA6746E52843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_50E852079C36F4E6149BCA6746DE07CF" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1BD9B766A32A803053FBCA6746E6C446" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_83DD62B6EE032891EADFCA67470ABC5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83DD62B6EE032891EADFCA67470ABC5F" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_E265D4F968D3BF1B1472CA67470AC6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_83DD62B6EE032891EADFCA67470ABC5F" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_8C569B7884494F2D0374CA70D390A296" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_2E1DE277A7A5ACF431E3C530C3D55C84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_2E1DE277A7A5ACF431E3C530C3D55C84" xlink:to="loc_us-gaap_ConcentrationRiskDisclosureTextBlock_AE04F4460FDB847E8180C530C3D542A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_30BE674ED59B3EE9CEDDC530C3BD5B23" xlink:to="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3AE2FAB513C3EAD50AD7C530C3BECF26" xlink:to="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ApolloBioMember" xlink:label="loc_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_ApolloBioMember_58A409F60458E2234DA4C530C3BE1F38" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_0BA70BACED6B8A3E236AC530C3BFEDC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_MedImmuneMember_0BA70BACED6B8A3E236AC530C3BFEDC0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DefenseAdvancedResearchProjectsAgencyDARPAMember" xlink:label="loc_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_DefenseAdvancedResearchProjectsAgencyDARPAMember_BE5854A5E50EEFD609B4C530C3BFE779" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_HoffmanLaRocheMember" xlink:label="loc_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_HoffmanLaRocheMember_CE8958D313FD849F70E9C530C3BF2FB5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AllOtherCustomersMember" xlink:label="loc_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_AllOtherCustomersMember_5247B195F829A37F2E81C530C3BFB59B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MCDCMember" xlink:label="loc_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7E008B77061FEB812E58C530C3BED0AD" xlink:to="loc_ino_MCDCMember_1E3690BDC67BF330ED81C530C3BF685C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_D4EB2E823071E307DDF8C530C3C0BBA7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_59D3BEDDFE42E754CCD3C530C3C0F764" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_14E2241B43DA9992506CC530C3C05AA7" xlink:to="loc_us-gaap_AccountsReceivableMember_057CA4FD4B9CAB5DA6DCC530C3C05394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_06EA5405A9865CF34261C530C3C1C0A1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_6F72040CE1A0B3D8741FC530C3C14A3D" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_A74BEFE0EADB24F2373FC530C3C19EEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_40F41ADCE4DCC7758928C530C3BD8136" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5DAF9ED4ECC66E259965C530C3C257CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_AB0C854E6FD5C408D38AC530C3C2807C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_19A55B9E09A194D3B744C530C3C2D2D9" xlink:to="loc_us-gaap_AccountsReceivableNet_C2EB7EA1BA25A5D4C645C530C3C328B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaap_RisksAndUncertaintiesAbstract_54130F1720DDA4DDD334C530C3CC395A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RisksAndUncertaintiesAbstract_54130F1720DDA4DDD334C530C3CC395A" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_4F71FB1E5C9D13B035EEC530C3CD8FCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_925FC76D48B8729EF181C530C20D7BB5" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_88D1D79D18D9A3B371E4C530C20E051B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_651445AE1669A0CE4337CEFCE5915FAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_651445AE1669A0CE4337CEFCE5915FAC" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:to="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1AB59892AE658E554BFBCEFCE591F13E" xlink:to="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_AF0ADA55BAB480F4EB10CEFCE592ABF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:to="loc_us-gaap_LicenseMember_AF0ADA55BAB480F4EB10CEFCE592ABF4" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_LicensewithAffiliatedEntitiesMember" xlink:label="loc_ino_LicensewithAffiliatedEntitiesMember_7BC0ACF469A622D23515CEFCE593A6BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:to="loc_ino_LicensewithAffiliatedEntitiesMember_7BC0ACF469A622D23515CEFCE593A6BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductAndServiceOtherMember" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_DF946852D8B9D2957B84CEFCE592C176" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_8B54F604ABAA0F80104FCEFCE593B9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_66625DD0C8CBF20794C8CEFCE5914535" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19EAF65CCFB5EBB985B7CEFCE59300D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19EAF65CCFB5EBB985B7CEFCE59300D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_55E8E51471927591C1C9CEFCE593E916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_EC676E193FC98E85F853CEFCE593903B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_6895EB8FF07921AEE0E5CEFCE59425F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_OperatingExpenses_6895EB8FF07921AEE0E5CEFCE59425F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_OperatingIncomeLoss_C73A3070AB770F1EBF93CEFCE5949D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_InterestIncomeOperating_8CD9EA7A7EF0DE0AF960CEFCE5948D85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_403907F71AA3B7CC1FD9CEFCE594C4D4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_InterestExpense_403907F71AA3B7CC1FD9CEFCE594C4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_8E3494CB258CBA31C4EFCF6AE289C142" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInFairValueOfCommonStockWarrants" xlink:label="loc_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_ino_ChangeInFairValueOfCommonStockWarrants_BE084FDDA66444626A84CEFCE5956581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_5522C5B704A34427C7F1CEFCE59529EB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_1F5B6E92556E1A4918BCCEFCE595B1CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_39F85A43E849A6E752A0CEFCE5953921" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E1031C25754116148414CEFCE5958F34" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_E1031C25754116148414CEFCE5958F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1CA2EF6519AD113A4B95CEFCE596BE27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_AD98DA97CF4A15CE5C0DCEFCE5964DD9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_ProfitLoss_AD98DA97CF4A15CE5C0DCEFCE5964DD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1B186740C669F4E1D1DACEFCE596D5B8" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1B186740C669F4E1D1DACEFCE596D5B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_5414BC1FA3356440D1DFCEFCE596EBE6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_NetIncomeLoss_5414BC1FA3356440D1DFCEFCE596EBE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_CE4FA1C6045B74FBAF6ECEFCE5933811" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_C30C47C3124EF4BE44B8CEFCE5966D6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:to="loc_us-gaap_EarningsPerShareBasic_C30C47C3124EF4BE44B8CEFCE5966D6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_C17685FE658FFCB69F3BCEFCE597E1D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_F38A522AE1B12415A265CEFCE5963FD0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_C17685FE658FFCB69F3BCEFCE597E1D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_852C8564F8D2CD6E5F3EC530C20AFEB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_852C8564F8D2CD6E5F3EC530C20AFEB3" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_4D8566E0503D3F40A2B3C530C20AE88A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_88B1D7F69F5A41599FA6C530C21D8D7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_88B1D7F69F5A41599FA6C530C21D8D7E" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_C9E02E72731494ABCE13C530C21DACFC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_7CB4F1137B31FAAE0EB6C530C2147F67" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_466D390F3F44256B032AC530C214F6F9" xlink:to="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneOneLifeSciencesMember" xlink:label="loc_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:to="loc_ino_GeneOneLifeSciencesMember_6BF6D3D1F19716A2DA30C530C2156155" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PLSaffiliatedentityMember" xlink:label="loc_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:to="loc_ino_PLSaffiliatedentityMember_7B2FE952994573141C80C530C2154AB6" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_TheWistarInstituteMember" xlink:label="loc_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_13B1D3FF82524C38EFC2C530C215270E" xlink:to="loc_ino_TheWistarInstituteMember_01975A5AFF6957E9E821C530C215A970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_47A0E136D1923DBCF323C530C214A9FD" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentOwnedBalanceShares" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_F89CB761450B31AE07F5C530C2165027" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_F89CB761450B31AE07F5C530C2165027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_DA79950872475AF8FA4CC530C216FC18" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeArrangementTerm" xlink:label="loc_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_CollaborativeArrangementTerm_F9210FF56E7CA2643500C530C21666D9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MilestoneBasedOwnershipTarget" xlink:label="loc_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_MilestoneBasedOwnershipTarget_211BF19085395A93D737C530C216E3BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_EB4BA24ED1384DBF1411C530C217CF93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_RevenueFromRelatedParties_0E2E7618A34609A14EA6C530C2178FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_65D26BBD31C296FD5D91C530C2175D39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_E2C6FB553EC626086D50C530C217E02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_558BE838008895444B14C530C21773EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_BBA4BA40DF97E1545840C530C217E739" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CollaborativeAgreementExpensesToReimburse" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_85D01DC322BBDF3F0FF6C530C218965E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ProceedsFromSubGrant" xlink:label="loc_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_ProceedsFromSubGrant_F48EC2056C85C25A577BC530C2189451" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantProceedsReceived" xlink:label="loc_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_GrantProceedsReceived_0DE366F8CCC5A2766982C530C2182ED1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_FE05B49F6B6F524761C3C530C2185FEC" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DeferredGrantFundingFromAffiliate" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_C86FF938A5FEB617AD90C530C216E9EF" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_EFE2532980203B58116EC530C2188960" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_38BE85269FCF9B33847BC530C4E8505E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_5FFE0CB2536B5BB6B110C530C4E87BEF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E5BB142F4A50D0220248C530C4C42B05" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E5BB142F4A50D0220248C530C4C42B05" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:to="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_C3A6C5EA23881AC13D22C530C4C4F282" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MedImmuneMember" xlink:label="loc_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:to="loc_ino_MedImmuneMember_CCDCF04DAEBACC6023C0C530C4C55FDF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_OtherCounterpartyMember" xlink:label="loc_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0EF99E9E34A249150541C530C4C575CE" xlink:to="loc_ino_OtherCounterpartyMember_AEE4043DC530C8327550C530C4C598AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_5996EE4318F7DC82FAF0C530C4C4C5AA" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9FD86C94D0A5DEA23B22C530C4C60000" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7D7814FD515FE860C8ECC530C4C5C89B" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_500DB665AC226FF3E22CC530C4C65699" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9F893091D8CCD8145C57C530C4844026" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_F0595E9204BC12B6C096C530C4842242" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B2FA0D42727BB7E47FFEC9F7DC561AD4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B2FA0D42727BB7E47FFEC9F7DC561AD4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ACB2A789730F8642E48BCA1593B5872B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B2FA0D42727BB7E47FFEC9F7DC561AD4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_E9FAED0603530F9C0F43CA162A0821DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B2FA0D42727BB7E47FFEC9F7DC561AD4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_C12331ED0374E67EC1A7C9F7DC563FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B2FA0D42727BB7E47FFEC9F7DC561AD4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_D057E04DF37BF89C1A52C9F7DC561FA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_B2FA0D42727BB7E47FFEC9F7DC561AD4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_CE222E0EA7BC21CCB692C9F7DC57EBD4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E0A083103021B6298A71C530C45C5FC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E0A083103021B6298A71C530C45C5FC1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:to="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_41FB3004029AF08943E6C530C45CEDB9" xlink:to="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_63AF9F2AE504A124AF16C530C45D0281" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08A6D1EE6504031F92BBC530C45DE5F4" xlink:to="loc_srt_MaximumMember_63AF9F2AE504A124AF16C530C45D0281" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:to="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_A243FB9FA9813D22F0D6C530C45D8D87" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_MutualFundsMember" xlink:label="loc_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:to="loc_ino_MutualFundsMember_AF909B9C0B63CA0E1A2AC530C45EB3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_CD4631CDCDA3CBA7C311C530C45D7987" xlink:to="loc_us-gaap_DomesticCorporateDebtSecuritiesMember_5F681F206A90B560A5BCC530C45EA5F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_963A873EFCA88B74294EC530C45CF46B" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_C930CF46278E38D5DCA4C530C45EB1B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_215FD40AAEA2B626808FC530C45FE607" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2E0F784AB5485CDCD8F6C530C4645169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4C77DD081232DFB57A91C530C464E11E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_ABCD051EC259BFFFF72AC530C45E7144" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01096F1CC0DA3A8A1687C530C4641873" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF75B3BC1632192270F9C530C47C6246" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF75B3BC1632192270F9C530C47C6246" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_515D8AA464DB9FDC27D7C530C47C850B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_93AEDDCE62437E56A115C530C30173B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_93AEDDCE62437E56A115C530C30173B0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6A58840A23080DB066B5C530C301A047" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_13BFE7453AF5A96CC71DCEFCE65BB244" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_13BFE7453AF5A96CC71DCEFCE65BB244" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_3C470EC4537329F8F577CEFCE65CFBE4" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_91472F803C33AA7C695BCEFCE65DAEA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_941781C47A792E6832BECEFCE65C4C2D" xlink:to="loc_us-gaap_SubsequentEventMember_91472F803C33AA7C695BCEFCE65DAEA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_BD1928EBA70560E63D37CEFCE65D6FED" xlink:to="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A2016IncentivePlanMember" xlink:label="loc_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:to="loc_ino_A2016IncentivePlanMember_33F485AA576AD46613C2CEFCE65D4082" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A2007IncentivePlanMember" xlink:label="loc_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_F538976394C447B98FB7CEFCE65D9500" xlink:to="loc_ino_A2007IncentivePlanMember_381F2B478377267E65C6CEFCE65EB8A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_72A9E19743641C55B46DCEFCE65E25B9" xlink:to="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_AFF08D3279A69B260742CEFCE65E426D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_92D3D1835A5A63CE43C4CEFCE65F7440" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4F384BE67CE3A6F546E4CEFCE65E9DA0" xlink:to="loc_us-gaap_CommonStockMember_92D3D1835A5A63CE43C4CEFCE65F7440" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_DDCDEAB9BBCFDDA77536CEFCE65FBF18" xlink:to="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_262D9FF1224F9C16F9FACEFCE65FB92C" xlink:to="loc_srt_MinimumMember_E3A75FBD035945B678CDCEFCE65F11E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7464656E7A4C0F37EFC5CEFCE65F0953" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_CF36F858621F73BC14B4CEFCE6601E77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:to="loc_ino_SalesAgreementMember_CF36F858621F73BC14B4CEFCE6601E77" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PriorATMSalesAgreementMember" xlink:label="loc_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_F18D4634E26AF03653D9CEFCE660B3BA" xlink:to="loc_ino_PriorATMSalesAgreementMember_E68601D308ABA48C919ECEFCE660666F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5DD4D04388F9EFBBDBCBCEFCE66031FD" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B88B09F5FB9CEFB4E70FCEFCE6611E03" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2DC67C98EE6EC1E6F529CEFCE661F48E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_B9194C1081756F355F5ACEFCE6612A37" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EmployeeMember" xlink:label="loc_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_ino_EmployeeMember_2F1418093701A711F100CEFCE66241A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6A0509093318DE4806B0CEFCE662DBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_3C54B152D27C8508E6B1CEFCE6625A0B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9FA4E6CB8122B27DB682CEFCE661EDC9" xlink:to="loc_ino_NonEmployeeMember_186F398E742F05D05961CEFCE662DEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_11C5FF9554E639262199CEFCE65CEECE" xlink:to="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_02148FA77C90BFF5EE1ACEFCE66302AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5018AEB4D58F6F6B9BCBCEFCE663CB14" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5018AEB4D58F6F6B9BCBCEFCE663CB14" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberofVotesPerShare" xlink:label="loc_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_NumberofVotesPerShare_EE42A0163838177C0BCCCEFCE6639C5B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_ED4754B0A05718D23A6CCEFCE663B9A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2A695FF2CB3D51978C1BCEFCE66350CA" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PreferredStockConversionNoticePeriod" xlink:label="loc_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_PreferredStockConversionNoticePeriod_E16F609EFE7B5C7A21B7CEFCE664A852" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion" xlink:label="loc_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion_153076514A6AB3E03A58CEFCE664331B" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockThresholdTradingDays" xlink:label="loc_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockThresholdTradingDays_9CC9A08E282568436469CEFCE6648EA9" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays" xlink:label="loc_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays_0160DEE96DD946EB249BCEFCE664CF3D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion" xlink:label="loc_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion_FE577DE18484F700F199CEFCE6646DD8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_140E17993FC3945C7046CEFCE66472D4" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSalesAgreementAgentFee_7A5F55E0336D50E00BA9CEFCE665CF1D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_A6E61BDD5A8613DD1ED4CEFCE665B343" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_8341CBC8A44033AA67ADCEFCE6656F74" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_91B5E5AB507E61409F98CEFCE665A00E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementRemainingAuthorizedSalesAmount" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedSalesAmount_9A6D828FD5668D850139CEFCE66502F0" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod" xlink:label="loc_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod_8FAD30072E21F77E236CCEFCE665BF2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_62B67E486BF3F998BEE2CEFCE6660856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7B3C1F9A742B75BD4E8FCEFCE66685ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_D856ECCC7D236A34FF37CEFCE666208E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_57A1CB3BA2AA63922DE6CEFCE666D865" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_BE91D242A7F8B6AE75F6CEFCE666CFFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_9E10ECB2AADD784CE00ACEFCE666818F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_67DDDE1DF6B33FBC0DC6CEFCE667D642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_92C7CF8EF75BA85A2FF3CEFCE667F44C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_74CB6DAF3717D77DF1ACCEFCE667CE75" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_98C0E0E71C086DFEF618CEFCE6678E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensation_D58111258C762A74F6B8CEFCE667AE66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_FB56C1EDD217E8371F18CEFCE66851B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_6136D48DC7BDE1948D34CEFCE6680B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_18BA7FEC290547C5645CCEFCE66803C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_854FD929AC76D3811E7DCEFCE66858AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_033DDC77A2F39CECA170CEFCE668203A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_D4B7D0E6A58E51222274CEFCE6697F24" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_265D3AF07F73785F57F0CEFCE669CB72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_B6754145A2F5A64F8CBDCEFCE669D740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_6CBB40A10FED3D180C11CEFCE66947DB" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_17DED0BC6D0383CCC9B7CEFCE6696EE7" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_F7AEE15E74889A218EDCCEFCE66A5084" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_C412CDB7378733154FCFCEFCE66A863D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_D1E48D60F9712A01FEFECEFCE66A8FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:type="locator" />
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0CB195DC8EAAB414B2D0CEFCE66A7F7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:type="locator" />
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214982BB52B1D7C8B402CEFCE66A437E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:type="locator" />
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5FFF563EE56EAB4EA7B4CEFCE66A8231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:type="locator" />
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_1C0CA32F7BA1816B2654CEFCE66251FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8B9E56BEB2F4375AD9D2CEFCE66BBA05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4FA15A9252C011EB73CDC530C2F68530" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_A4BAC1007F7E073484F7C530C2F64919" xlink:to="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_62F78E59AD68D4D8EF77C530C2F63150" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_D2D4DD9841C5DA431D97C530C2F77E1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D68D99C04333CFB509F4C530C2F646BE" xlink:to="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3C202C1E4B32F40460CCC530C2F7A517" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_96635D4EF7A6BA3078C0C530C2F8F9F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1884C8AD458B0F99EFF4C530C2F811C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1884C8AD458B0F99EFF4C530C2F811C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0E2960E207E4B373A50EC530C2F8A6E9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0E2960E207E4B373A50EC530C2F8A6E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_73612ADA42517EB05F3EC530C2F99118" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_3583E5F3BE9E34366D96C530C2F81EC2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_73612ADA42517EB05F3EC530C2F99118" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_B7C7FEF46DA61D84F93AC530C2B64ADE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_B7C7FEF46DA61D84F93AC530C2B64ADE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:to="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E308FEAC4A7B88CD3856C530C2B71CE4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1D9EC30794F8983FCB83C530C2B7485B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_370EBAB4C070F576228CC530C2B7AAB0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1D9EC30794F8983FCB83C530C2B7485B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6943503761CA37789526C530C2B67186" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E512738A6F802A53D90FC530C2B75535" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_21F8F6E506D354D9B375C530C2B8103E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1C15C8AF2EA6344D08B1C530C2B8C2FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6C4C927FF11D05F66BD0C530C2B8DEBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_D0C8F0E604F22D3C360CC530C2B97C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_BC3919FCA78F980A0E5AC530C2B8F7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_064471B29230D80248B4C530C2B9B121" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_99B904A18B4C1ED631FCC530C2BDF795" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_99B904A18B4C1ED631FCC530C2BDF795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12970A9210DBBF0BA533C530C2BD5A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E51994B99676B2B6C7ACC530C2BE0C9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7CB40BF307C5EBFF5BF5C530C2BED903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_FAEA0D5A66B22DACECF7C530C2BE08A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_E552651C3FA469CCBAD6C530C2BD71E1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FC26ADE82FAB43B98937C530C2BEBD87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_99B904A18B4C1ED631FCC530C2BDF795" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_B49C8131C8D33FDE7DB3C530C2BF7681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_C1166F91317008D798AEC530C2BF65F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_10D2C3D86E1FAFFABA47C530C2BF67BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_BBBEFB235041F333BEDDC530C2BF64BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_357049B4E04DD03C16D8C530C2BEC75F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_F9E46D58BB1B09450B32C530C2BFBED5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_00009D3B4130F95F461ECEFCE647BB9A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_00009D3B4130F95F461ECEFCE647BB9A" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_4A65D570FEB65CE889DECEFCE648C3AD" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesOneMember" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesOneMember_0582C5DE334C89A9C26CCEFCE649A7C5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesTwoMember" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_7251848D4F1E3E1E7C23CEFCE6491F16" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesThreeMember" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_65615657B9EC82D3C7D2CEFCE649DF00" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesFourMember" xlink:label="loc_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesFourMember_345890FD871D6737E555CEFCE649AA86" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RangeOfExercisePricesFiveMember" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_5CF751AD2476CF5A7E52CEFCE6489275" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_E083BC933863EF0C8FF2CEFCE6490AC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_368B4BBF5FB6B8C71C70CEFCE6474B2E" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_C8F7C09CF500486262BBCEFCE64ACF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_A8AD4536078F2D4D42E5CEFCE64A2827" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9772ACEE244AD7B44769CEFCE64AF547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_FAF95E9F4CA8BAA2F69ACEFCE64A72F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_1164E211E5035D77D939CEFCE64BE167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_AB0FA19D5C2EEC3310B7CEFCE64BB7F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_D010E4C521313A4D216BCEFCE64AFFF5" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_62A9ABAC7B8554FB9B46CEFCE64B059A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_004DA364EC42C6A88F68C530C2FD8B39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_004DA364EC42C6A88F68C530C2FD8B39" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_30599A50A460384057C0C530C2FD789D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_004DA364EC42C6A88F68C530C2FD8B39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_D98422203C94510648B9C530C2FDE803" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_004DA364EC42C6A88F68C530C2FD8B39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_85139E52BD1384DB47D2C530C2FE6E80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_004DA364EC42C6A88F68C530C2FD8B39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_415F00203C2CBCD3C199C530C2FE3C18" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_E75B447A2BE020F0B09AC530C1F76989" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3B98C0C7916F814596B9C530C1F78F65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_AC545BCC787711E76562C530C1EC4415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_AC545BCC787711E76562C530C1EC4415" xlink:to="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5CEECB9A09A423AC3CC9C530C1ED8B68" xlink:to="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_PlumblineLifeSciencesMember" xlink:label="loc_ino_PlumblineLifeSciencesMember_6C64CBB7523BBF568FB0C530C1EF0F8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_4BF00F2476D817B70181C530C1EE3C1E" xlink:to="loc_ino_PlumblineLifeSciencesMember_6C64CBB7523BBF568FB0C530C1EF0F8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_085BA3A7C37B0E67629CC530C1F0CD32" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_A7488190CEE6FBCE60E6C530C1F05773" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_BEE721233AEECCBD1582C530C1F02D2A" xlink:to="loc_ino_SalesAgreementMember_A7488190CEE6FBCE60E6C530C1F05773" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_B89FA87CA07B26A46BB9C530C1F1318E" xlink:to="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4E2422291F84D723B4B7C530C1F172D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0864B3F0199414380177C530C1F1A1EB" xlink:to="loc_us-gaap_CommonStockMember_4E2422291F84D723B4B7C530C1F172D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_47FBB8C5FF75E2A21D4CC530C1F12851" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_D6385348EDAD94ADFE79C530C1F24D42" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_D9C2E344E1AC9A9B4636C530C1F2859C" xlink:to="loc_us-gaap_SubsequentEventMember_D6385348EDAD94ADFE79C530C1F24D42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F3675376017A8168F06DC530C1ECB57D" xlink:to="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_FB1632EDAFC33926A5BAC530C1F2CE84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_FB1632EDAFC33926A5BAC530C1F2CE84" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_StockSalesAgreementAgentFee" xlink:label="loc_ino_StockSalesAgreementAgentFee_4BEF1724167C71154457C530C1F23766" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_ino_StockSalesAgreementAgentFee_4BEF1724167C71154457C530C1F23766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6E8924E415D8F8ADFBB8C530C1F36653" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6E8924E415D8F8ADFBB8C530C1F36653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5EA87AA46431D88C2020C530C1F3E8A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5EA87AA46431D88C2020C530C1F3E8A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_680A4AF397BCB23332EBC530C1F3F23C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_680A4AF397BCB23332EBC530C1F3F23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5496209E5EC50C3BCA77C530C1F32CE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_6B6635EAD1CE7125DADEC530C1F21751" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5496209E5EC50C3BCA77C530C1F32CE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7AF559CE9005701895CAC530C5C5C146" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7AF559CE9005701895CAC530C5C5C146" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2374FBE6FE078B859102C530C5C66FB2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B7581AAF5655D6207085C9F7DCB63B1C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B7581AAF5655D6207085C9F7DCB63B1C" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:to="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AA1C419CCDFD2F38A09C9F7DCB7E7C3" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_91AB928F8ECB81298E6CC9F7DCB73168" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_91AB928F8ECB81298E6CC9F7DCB73168" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_28FF3A5CFFF15506BA07C9F7DCB73B5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:to="loc_ino_August2019ConvertibleBondsMember_28FF3A5CFFF15506BA07C9F7DCB73B5F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_9E24C153F8B043B6BCFAC9F7DCB8FD61" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_CC9347E9CD2ADFA0FD7CC9F7DCB733FF" xlink:to="loc_ino_December2019ConvertibleBondsMember_9E24C153F8B043B6BCFAC9F7DCB8FD61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_E8E10B5AC58B3892CE99C9F7DCB8FAC7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_74181023A8052CEF6DD8C9F7DCB9488E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_BDAABA86EC3D587B08C9C9F7DCB9657E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_026EFF345B6602C98D7BC9F7DCB9072A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_A807A5333B74F9A21045C9F7DCB8A33D" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_78230B30648FABB4804FC9F7DCB93143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_A73887ECA591B0634904C9F7DCB6F860" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_CommonStockEquivalentsAbstract" xlink:label="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8FE24B012B1A6B98B66BC9F7DCB963AD" xlink:to="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CommonStockEquivalentsAbstract_AB240828FA7FB84DA240C9F7DCB9672F" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_ED8418E863A3BAAE7621C9F7DCBA42D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9BF92FEA42E11B43F235C9F7DCC1CAAA" xlink:type="locator" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NumeratorAbstract" xlink:label="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9BF92FEA42E11B43F235C9F7DCC1CAAA" xlink:to="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:to="loc_us-gaap_NetIncomeLoss_D948BCAD188BE627A4D5C9F7DCC1DE5E" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AdjustmentForChangeInFairValueOfWarrantLiability" xlink:label="loc_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:to="loc_ino_AdjustmentForChangeInFairValueOfWarrantLiability_30540E4D144D4C629241C9F7DCC2ACD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_NumeratorAbstract_2220FD0E9D38F27C183FC9F7DCC199F6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_AD31106A6234C86AED9DC9F7DCC29B35" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_DenominatorAbstract" xlink:label="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9BF92FEA42E11B43F235C9F7DCC1CAAA" xlink:to="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E6CBD19958DECF226AECC9F7DCC224C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_5243E148E191EE506E7BC9F7DCC2811E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_DenominatorAbstract_419D7C0A1402A90B68D2C9F7DCC2A27B" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5199F04DF31708C03C05C9F7DCC3B166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9BF92FEA42E11B43F235C9F7DCC1CAAA" xlink:to="loc_us-gaap_EarningsPerShareDiluted_782164CA56E5EF2FBDCEC9F7DCC393FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9BF92FEA42E11B43F235C9F7DCC1CAAA" xlink:to="loc_us-gaap_EarningsPerShareBasic_18BAF86D0E32939F5347C9F7DCC310C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9A27883B800E62998A42C9F7DCA13B4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9A27883B800E62998A42C9F7DCA13B4D" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAxis" xlink:label="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:to="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementDomain" xlink:label="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_C04BB188F60054E66251C9F7DCA25857" xlink:to="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_EB9B8EDC0D3E568003C4C9F7DCA25F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="loc_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_2D474FF1F9A5D6F6DF37C9F7DCA2B0AA" xlink:to="loc_srt_RestatementAdjustmentMember_56AD6A856602A5DEEFF9C9F7DCA32D67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_A6B6BD70D63E5CCAB221C9F7DCA17FF5" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_8F6C87B312F8A0155CE6C9F7DCA3A5CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_54AA5A6B40B9738559E9C9F7DCA39924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_C086766ACC8D8728AE80C9F7DCA3A50D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_C086766ACC8D8728AE80C9F7DCA3A50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_D5936C9DC42D73EE4081C9F7DCA495A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_423E596D74EC8A7F0C35C9F7DCA3CA63" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_82A0175B80F71C28A00EC9F7DCA457FF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C17B9E6CE2176EC27B9ECAC7CE654F25" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A0C6255F7283FC6E13ACCAC7CE666FCF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C3EEC59D339DFE24B49BCAC7CE66242E" xlink:to="loc_us-gaap_PatentsMember_5A1E98E59F1F11058BC2CAC7CE66EBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6B42E3B76667AC2125A5CAC7CE67CD92" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1A47D269D86E3539770CCAC7CE6797A8" xlink:to="loc_us-gaap_SubsequentEventMember_AF1C29C9AF536E3037D9CAC7CE670FA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_07BE9938CF23CC6BDC0BCAC7CE6799E0" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9CAF731BE5971304FDBECAC7CE683D10" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4FF8E1FBFD7755B2041ACAC7CE680FFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_AE06F3CDA073681AA75ECAC7CE68F219" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0B789860554B7D302FE1CAC7CE69A4FB" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_259B8E236A306C70D819CAC7CE696EA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_26FD897C656488F9BC3ECAC7CE698251" xlink:to="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_D3C7659FAFECD19C9AAACAC7CE695C08" xlink:to="loc_us-gaap_CommonStockMember_3A60CC1C3A08BE076222CAC7CE6A73F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_942F468F9F22926656CDCAC7CE6AF0F0" xlink:to="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GeneosTherapeuticsInc.Member" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_9E468786175EF7581657CAC7CE6AF18D" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_VGXAnimalHealthIncMember" xlink:label="loc_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_361970C1F3CDD124559BCAC7CE6A257D" xlink:to="loc_ino_VGXAnimalHealthIncMember_C290352792AE68A8455BCAC7CE6BAD04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A6581597C11C09029FCDCAC7CE6B5B35" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_E9F185E601F77DCD229FCAC7CE6B50D7" xlink:to="loc_us-gaap_ConvertibleDebtMember_30EE99FF3F288E0FB424CAC7CE6C4410" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_0887E0E5B3902E82BE69CAC7CE6C46E6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_BBB5C0382AEB57E0D3D6CAC7CE725BFF" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_August2019ConvertibleBondsMember" xlink:label="loc_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="loc_ino_August2019ConvertibleBondsMember_B9392C85F43D53D27DD5CAC7CE72FC51" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_December2019ConvertibleBondsMember" xlink:label="loc_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_DECC02B3DCF2981E2C9DCAC7CE7163A2" xlink:to="loc_ino_December2019ConvertibleBondsMember_987CAA3EC457F8E2BD7ECAC7CE7291BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8B57C98CE66EE7BC0B9ECAC7CE73CB9E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_SalesAgreementMember" xlink:label="loc_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0CD33EE074C72B34FD75CAC7CE7342D7" xlink:to="loc_ino_SalesAgreementMember_FE08E58C65581B08C3FCCAC7CE73E3D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_5AE2411D31DAFD4EAC50CAC7CE74CA4B" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_D95CC74A3D734571C443CAC7CE749A21" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_48DD01F5B400CAAEEBAFCAC7CE74FFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_B60EFEC4D5FD95204E36CAC7CE75A7B3" xlink:to="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:to="loc_srt_MinimumMember_A9732A58D06310CF3560CAC7CE75B054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_154862A765555EDC3D01CAC7CE7557B4" xlink:to="loc_srt_MaximumMember_99A8F49F2FE9881FBC5ACAC7CE761EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_935C00BF4A54ABA1B07ACAC7CE65B437" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_NetIncomeLoss_2FE04095980B21F0A10FCAC7CE76452F" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_WorkingCapital" xlink:label="loc_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_ino_WorkingCapital_136C64C58AB295E1CA46CAC7CE771CB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_FFBAD4435A5622D942E0CAC7CE778A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_88734C3AD7D49471EE46CAC7CE7730DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_F165325144E2E7FB8385CAC7CE7727EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_03A3FA321883B7EEEC4FCAC7CE7878C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_71E0DD5A31FCE5350F03CAC7CE78E342" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_B90963F3674BE914872CCAC7CE78736A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_BC51513DA269B13F1295CAC7CE78157D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F51D345FD4187154E82CAC7CE792CD5" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent" xlink:label="loc_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent_2DB3449CF61E14CBD045CAC7CE798700" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_RestructuringCharges_7186DE053CC31767AC68CAC7CE79E008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_40F68B771CF6A5EDDAE6CAC7CE7A7241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_NumberOfOperatingSegments_24F3ABD60ACC42A77C66CAC7CE7A01FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_20E2CD4431A7AAB5DD67CAC7CE7AE534" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3F1F6B032EE84AD7B675CAC7CE7A320B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_3670EB881EABB3E149A0CAC7CE7A265A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7C3CAA15DEFE9591C369CAC7CE7BB79E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_28AEDE8B70FD7A84AEFFCAC7CE7BEE85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_B5AEADB3004E61A88FF7CAC7CE7B3E44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_OperatingLeaseLiability_62174A2A51FC800F694DCAC7CE7CBBCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_DCA9BEB0E90AE5B4AB2FCAC7CE763649" xlink:to="loc_us-gaap_DeferredRentCredit_0982FBF3E9EBB2FF52DFCAC7CE7CCCCA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_CF510FF0A4E76BD2922CCAA5A2EDC79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_0D743B133320EF7DC52ECAA5A2EECE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_8EA2E32B84A999EF7B5ACAA5A2EEFCA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_UseOfEstimates_EECA1372868D5A2844C5CAA5A2EE3E13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_858B4616CACE1F1AEF9DCAA5A2EE7059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_5BEF97F1679E9137BBC5CAA5A2EE6A08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_58A6C675FB6B3096D83CCAA5A2EFE749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_229F72010F9679DADD04CAA5A2EFF02F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_F99F95A65362A55FA664CAA5A2EF3789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7113E3E21F7C2A4B8E14CAA5A2EF9ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_E74F8750FAB8E2816361CAA5A2EF069A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_7FC3408CBCCB35295AE3CAA5A2EF106D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_BFFBE530FACBDBAD65DDCAA5A2F0FB8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementAccountingPolicy" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_A227DF26919D2EE2BAADCAA5A2F04641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_D2A36B1F9B13AC1F6812CAA5A2F02AFD" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_GrantRevenuePolicyTextBlock" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_ino_GrantRevenuePolicyTextBlock_3ED4DE2D864A6FE3AA39CAA5A2F05DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_6B0B4A4735AA9E7C4810CAAD744FE33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_C3C32A8B35273B2BA977CAAE7F6C3843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_E9508D9F9ADBCCB35F9DCAA5A2F0FAB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_E24FA231B686A25CFFB3CAA5A2F01A8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_056E85338674960466A5CAA5A2F1E4BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_7ED6362EB2610D075BEACAA5A2F1CCCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_959465702CBBE02CF771CAA5A2ED7909" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_73B3D6A716AC45F3EF32CAA5A2F11BE4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4F564739A65493CC388FCAA5A2934424" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4F564739A65493CC388FCAA5A2934424" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_B352AA85380066DD343CCAA5A2948EBE" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_EmployeesAndDirectorsMember" xlink:label="loc_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:to="loc_ino_EmployeesAndDirectorsMember_019E86E3D7497C075154CAA5A299A424" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_NonEmployeeMember" xlink:label="loc_ino_NonEmployeeMember_9294D4AE0C2E5E90A145CAA5A29A72D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10A2D5A3159EBDEAF736CAA5A294C058" xlink:to="loc_ino_NonEmployeeMember_9294D4AE0C2E5E90A145CAA5A29A72D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_BD1C920F26535F4A289BCAA5A29AF588" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35B2A48F7C651E3F2656CAA5A29A25F9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3715516F2E42981484C9CAA5A29BF8B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_22DCD23877B15AC779EACAA5A29B963D" xlink:to="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AF90872F5DACEED073D9CAA5A29BA494" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:to="loc_srt_MinimumMember_AF90872F5DACEED073D9CAA5A29BA494" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_574EDEE2FE414F49C88BCAA5A29CB3EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8BD6E7CAA5A053EEE5FDCAA5A29B581A" xlink:to="loc_srt_MaximumMember_574EDEE2FE414F49C88BCAA5A29CB3EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E80CBAE112256AF4343CAA5A29CB1B8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F6C362EBD16EA10557CAA5A2933F93" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E80CBAE112256AF4343CAA5A29CB1B8" xlink:type="arc" />
    <link:loc xlink:href="ino-20191231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3E80CBAE112256AF4343CAA5A29CB1B8" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E89A011ACB1AF5C49298CAA5A29C49F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_995F73495D9C94DF6B1ACAA5A29D579D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_689257F3D1E0DAE55122CAA5A29DF709" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_7A9DE1A5DA2E8DDDE2A5CAA5A29CF59E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9CA27BF66E2755672CEECAA5A29DE16F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0AD4DC42300452C9A176C530C5B40B90" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AD4DC42300452C9A176C530C5B40B90" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0AE6C593E5C217544230C530C5B4E260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AD4DC42300452C9A176C530C5B40B90" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_DD3F8435BB59DFE46643C530C5B52453" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AD4DC42300452C9A176C530C5B40B90" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_57F08D6747DE3BB4E7F3C530C5B5C71C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0AD4DC42300452C9A176C530C5B40B90" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_063B4D1B1641BBBC4BABC530C5B5BD89" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>a10kimage.jpg
<TEXT>
begin 644 a10kimage.jpg
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MBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@
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M%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%%
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MFH2ZAI<9N=OVZ$F"Y"C \U>&('H>H]B*T9'\M2>I[#U-55TN!OWDD:M.<YE
M^;KZ^E>"58FT^>WC\QX\)T)!!Q]<=*]7\,?"[Q%XHU;6+86-GID>C/C5+K4P
MD4-G@X^:7&<YZ* 3]:N^+/@O>>!_"\7B*>]TSQ'X8NI#;B^T6]$J@YR XP&3
M\1S5O#U(QYFC-9CA)5?8QJ)RTZ]]5\VM4MVM;6+M-$BLV,\U ;;!!R_'3:Y
M_$9JC)>M?7D]K;.J7-MM+L5+*-P./K]/IZUYMI^GI8Z''?WLJP+/(?LZ;2S2
M <,>.@!K$U"Z6\NGD12JG &[KP,9/O6CXLO)KS5MSA4@6-5MXXQA4BQ\H K&
MKFN[69Z5E>Z)/[7$^KS6%O&TK01AIY 0%C)^ZI]6(YP.@QGJ*T(8S'&%)R?;
MI5#0=-BTNQ,499Y&D:2:20Y:20G+,3_G P*TJ****0!11111110 44444444
M %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%
M%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%
M% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1
M1111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !1115A
MK&>./S#$VT=?;Z^E%C"MQ<!7Y !.W.,X[5KPZU:0 S^2)Y"/F@E4[2>^2#T_
MSQ3['Q#ID=Q&\^A6J,K B2&65=ASUP6(/TJG9/342U&[UR!GD]*5C@>E5+JV
MFNHVB$K6^1@318W+Z$9!&?J,5CP^%]4MV!/BO5+Q/XH;J&TVN/3*0*1^!KJ?
M WA'Q)KKE_".@7NI7]D\=S*VGP/,R;6R"PYVC<._6OI=_@UH[6DWC36?#7B#
MQ#X[(BU.72K&X:TA;G.^-A&Q9U(Y3(/M7!?"W4/$6L?"[Q%HG@K4[C3_ !A:
M7PO9[&R<1/J-GMP0@_C*]=I[=*WO"7QJU+2[RTUS7+;QMI&M6 Q=V>CP.MGK
M.T84RJW",.C, <BOJ,#3A3BO:;2U[I?\%'Y3Q!6QF,G*.$=I4GRN*;C.2:32
M;33Y)[>[L]6]^77\Y([Y$DG!+@^6C$#)'7 [U:R<?TK/NM%L-8TX6]U")X6P
MXW$AE8="".5(]15](Q'&J<E0,98Y/XUZ/KF@ZQ\<-+BM+OX0:MX;TF:?[==1
MVNN6UE-=2$!1-*DR!F '=E_6N1^)&C_#'X8Z/>_#(7/BN+5-3D@,L<"+<C<>
MB*7$2$9/WE7\:\R\+_$+2_''A7QKH6M^*9/"&KZYJ*WW]J7JS3Q30C/^BR,N
MYP!G(XQQ7I6@Q^';?3]'\5)K!\41^%;)M-TO4+J)D-Y>G)W(C?-Y40Z;AUQ7
M;5G2E'GT>FK=MNNBL]O\CYJAE^,P%=89\T81?NTX*HE*5HR@W.<IQE[VEE9I
M+F>D;),G:?FQZ<9IL=ND<CR*BB1\;V Y;'3-3'CMFLCQ1XAB\,:+/J$L;2[,
M*D:_Q,3@#/;GO7S7\5? X\&^(-2T-9WNFTMEVR2($<QL 2& ) 92>Q/6O.J]
M,UK2]:C\3W-WJ).J)J$KR37#?Q,W+,?[IX[\5R,V@Z6TI6W\0VK#/'G0RI^N
MTBOC*DHRFW#8_=,/3JTZ,(UW>:2N^[MJ_O- ,([GVDX/^]_^K^56*Y72?&>F
M^*M/:6VF:VNX\$P2#$@.>..X)':I)/%.K0R%&\'ZM* <>;!/9E3[C=.K?I6#
M16[)H\*I)&&W,@8^>I.&P,YP>U851)<ING<Z:BJ_V@[(WY4MC,;8R,]N.]6*
M****0PHHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB
M@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HH
MHHHHHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHH
MHH ******** "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *
M******* "BBBBBBB@ HHHKJM/U"YDLX+^SGE@U"P(7SH7*2;?X7!!R,=.*^V
M)/B]XRM].T M-J6H_#;5-,AMFUG0V:2ZTN[ PSR.N6X;[ROP17PYX-MI)KZ>
M1BJ6,41:ZDD^ZJ?U)/05TGASQY=>#[R>Z\.^+M4T*27J+-Y(2W^\5)!_*O6P
M6-^K73ZGR'$.00SJ%-N,7*%[<R[]4]XM/5.SZIIW*J-]GNC&>$DRR^@/<?U_
M.IEC7[VT;O7%9^O:E'I\,"D-)=3RB*WA3[SOU_( $D]@#4ZR7?EJLEJI;'S;
M9 R_AG&:^B=5^%]W-)J*_&3[+;Z#8S(UCXP21+:ZO58@A$4+F8%3D\97GDXK
MJOB=IOQ T_5M!\,?"*TM+;P')91%9X?(GM7SRSRRR G&.N<9KPZZ^/=[JS#2
MO%XL/B%HZ%9TAU>XD%PCE>3'.!N7/]W/-<Y\1/BLOCS[-/!HMOH-EIMMY%O8
M6,KM&RALC>7)+$>OX8KT*F.I.FW"^OG[WI>VWXGRU'A[,9XF#QCBU"]ER\U&
M^EI*',FIZ-O115WRVO<M[NN#FHW19HV211(CC:RL,@@]B/2JNGS2M;*98)48
ML00P QS['I4?V%H=0FE$I_TD(C#)^4*#R/?FNN^(7B3PUI7C2[\/QW=O>P"-
M8Y;B-1]F>4C]X 23\N<X/2O*/&GPY?1U>^TW=/8CEXSRT0]?<?R_6N(DD::1
MI';<[')8]S7;^!OB"^D^7I^HL9+'[J2-R8O8^J_RKYJH^:3E%6OT/U;#Q=.C
M"E5DY.*2YGN_-GGGBCX:W%E=G5O#1:-XG\SR%8Y!'4Q^HQD;?RK=\#?$N'Q
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M444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110 44444444
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M>W4Y%M/<'R<^OEC"Y]\5QE6DTF^DCCD2SN&CDX1EB8AOH<<U"MO*T;.(G**
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M[RQ8Y0M+AT'7##'!_7V%(K?8\+_X3J^T?]G/3KM[Z=;V9UTPW^TR2Q*9C&9
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MX%^ /B'7?A= -1$DLD>H3M<&2?3[?&&\J/  "CCCH.<'K7@WC33KSX<Z;;^
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M'\HRWEDL)0..-N1WQ6AX2^%NI_#7PG;?$/XC^*YE\#V/^D6/A_Q-IZ_VG=7
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M[U.8U#PV?A/XB\/W>A:CJ)T?4M06PO=*OKV2ZB'F [9(S*S,A##H#@@]*O\
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MBEI%^Z*6BBBB@844444444 %%%%%%%% !11111110 44444444 %%%%%%%%
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M(+F&.X@D&UXI5#*P]"#P:EHK3_X2C6?^@M??^!+_ .-'_"4:S_T%K[_P)?\
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ML6NC/^F6ZASN:1%.[WP.?SIHQG[K3*>H0NP62,+E<[O4C';WX%.LY"RC)SD
M\U:JG_JF.!@*3Q[5SU%/DC:&0HW44RD;%RBD5MPR*6BBBI!'YF=F2>N#U_\
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M%%% !11111110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%%
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MW4:?DH_Q_G1+)YV(T&V%?NI_4^]0K)Y@$<?^K7_QX^IK3ACCT^W^T3+O9O\
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MQ]W^%/[QK+U"^>\F+,:?J6H->2>B+PB_W15&F*,>K$DD,C;$Z]SZ"IX81&H
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M%/$%A;">QFTSQ#$LGDW#:->+<?99/[LO3;_O<KQUJ+_A"]%\/ -X@U?SI_\
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M5_//M59KKQG> /!8Z1IZD?ZNZGDE<?78 /R)K6;XCP7RA;[3(+I?^FL22?\
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M'@<'->[V\46N:7IVIR6IOMEIY_V4$[96"XV':,]?3FO*Q5.52M24>O,OPO\
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M_$0R?=/TI]O_ *E/H*1NE%O_ *I:HT444C8FHHHHK4AYL;CV6LNM*(YL9O\
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M7E8JBJ%1Q3T-)<E2C2Q-.+C&I%22>ZOT?H.J.:=(5!8\GA5 R2?0"AM^UMF
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M\:V**["]7PM+$\MN\8G;YECD\U%&>H. >1VQQ2S0^%)(2\4HCFZB(F79NP,
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M110 44444444 %%%%%%%% !11111110 44444444 %%%%%%%% !11111110
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M6 ****I4445Q@%%%%%%%% !11111110 44444444 %%%%%%%% !11111110
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M@W>H3H@@E2,GYG*' %=+KNJ)H.GI:6@*/C8O_P 53])\2/?:D(&CPL@ZE_\
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M:LZ_+QTR3@Y/7&<?[-<MJL4$.HSI;,K0!CLVMN&/3/?]?J:J44#>I@F^U?S
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M:Z*X2>^CU:V>1@AO(XP0ZHG5\=>@'H:\*ANK!M)B>PM95A@G5KB&5PYY/!)
M&?RKZXU#5M3\(^)/$7Q1L96.BP^$[9='N%^:#S'*IY:]L@ALK[UT993C+FE+
M;9^C3U_ ^(XMQE>A3HT<,H\[DI1<KV<HRCRQ5FM9-[ZV2>CZ;%TQ;;"O60\_
M[O?_ #[U+P, <#I69IL=]#($U*YM[BY9>);>%HD;U 4LQ&/]XYK5P.F.*U/@
MK=3R>'?#AN988/!-II0>^U,7\<"65\DA91<(6SUP,8S4NGZI<:A)K]AX]M9[
M'QM=6$XT?Q7HUJEY)>Z>QRRPLIV.RKP#D-M]*\'O/#>@^*OCIX5N]31+#0_%
M0BOY[7<(T5V!W1Y& JLXZ_[5>V^%/B)=Z+:^)M/\9_#NT\'^&_"TOVO2I-/A
MELI8[@/A1'(Y*R,R\G PW<$&OH:<U91>B6GEM?MIIJM;GYGFN!E"JZU-<\ZB
M4K*T91O-JT6Y/G?-[M2/+R2BEHG:[(XTA4B-0N22<#J2>32\C  &*=VI#QSG
M/]:^?+SX7Z!J.B:GJ7@?Q)=>(/[)B+W^G:II[6EP(V."R*&8.!WZ$5Y!J5E$
MMF)A&L3JP7Y>AR.F*^P_&GCSP;X/\.ZQ\1O ,-W-=^*K6739X8G58]/E<9<2
M+U4MUV@!23D&OE#4M<M[6&W@NM,M[ZY5=^^1W 7/085ADXZU\ICH1IR25M>W
MX/7N?L'#^+K8W#N=3FT=O?24DU\47RI)V?6ROY[N*50RDL<#KGT]Z59/WVP-
MN&,U5OM'M=2F@DN8S+Y)W)&S'R]W!#%>A(QP3T[51N]$NM0=GM-:O=*CSC%K
M'"Q;'?\ >1O^E<Q#;R7#;8UW'ZXJ2:SGML>;#)&/]M2*U_[?M;[;')8VNGJI
MR&M8V&[_ 'LL2?K7?Z!XMTB'38;1=0C<XRZW&Y /;D8/YUZ60Y5A\XQ+P^(Q
M"HJS?-*UKZ65FU>_D>]B\1+#PYH0YC=+!>M"L& (.0>XK)TC1[O1XYO-U:]U
MAI&SNOO*!0>B^7&@Q]1^-:<<;*@!//?%>0UU?ACP'>:_MGGS:67_ #U8?,_^
MZ/Z]*]*M[/1M8'G):6-SL/\ K%1'_E_6J?BGQ7:^'XQ&S>9.R?);Q_>_$_PC
M]:_5<+P!EV51>9YSBXSP\=N6ZYGV;W^4=6>#4S:MB'['#PM-_.W]>9)29I.1
M0*Q_%WA'2K?P\SVJQV<MI_RT8\R?[+'N?2O+JU-9UZ[UR;?<2?(OW(4X1![#
M^M9=?F'$V98#-,=[;+L.J5-)*RTO;K;9::?F>W@:%6A2Y:LN9[BBEHHHHHKT
MS1U\+:EI-I:7!MI9T3:TC#R9"WUXS^9KDR7)WG565"->%.25USNR;[+K?Y,T
MQ.)^K14N5R7ET"BBDYKS.K\6D7LUC)>I;2-:Q_?FQ\M>H6W@'1-+D:\D$EQ&
MGSA+B0;%_EG\:R_$7Q#M4MY;*QACN59/+](U^GK^&!]:^SJ\%4\HH3KY[BHT
MG9\D8^]*3Z/TOVOIU1YL<REB)J.%I\W=O3^OZW%HIN32XKS2N\\%_"F7QYIJ
MMI7B+1?[;<L(=!N)WBNIMO9"R>66/8;^:X.NK^&.H:/HOC;3-3UVXNK:PL)!
M>8LX]\DKH=RQCD;=Q &[M7X_B_:*C*5)VDM=KW\K>?E9^9]3A?9NJHU5>+TW
MM;SO_P /Z"U%)-Y;?,C;,9+\8'ZYJ6FODJ0 "?>N_F^%_B/PKHNDKK5K'8WM
MN\A-CY\;W"Q/R&= 24YS]X"MFST+[59KLX/>O)M1^(%]<^.M1\30!8)[RX>9
MX>JE6;.QO4=*](T'XG:!?*'>Y;1[D_>AE4LG_ 6 QCZXKYK%4,9&"E)7;U=E
MLWJU:[?S/O<JQF7R;I\W+;3WFM4M$[V2O9+02.99<E#N'][L?I3J%7:H%%=I
MHNCKIL.Z;Y%KSGXV7$*Z1IT'_+5YWD3_ ', ?SQ6CK?Q>T:QC_T>6;5Y^R*I
MCC_%F&?R!KR'Q#XBO/$^I/>WLFZ0\*@X5%[*H["EEN!KNNJ]562[_P"1MGF;
M81826$P[4F]--4E>^^WW"$TM'Z4M9E%%%?9'YB%%%%%212O"VZ-RC?[)YJ.B
MG&3B[K< HHHK;M?$TT0Q.JS#UZ&M&'6K&YP"YA8]F%<G17TF&XAQU!*,VIK^
M]K^._P")RRP].6JT"BBBNX6-)@#$ZR#V-(UL?2N+CD,;;E)!]0<&IXM3NXC\
MMS(/QS7MPXEP\_XU!I^3_P TOS,'A9+:04445U?V<^E'D'TKFQKU\.D_Z"C^
MWK[_ )[?H*Z/[?RW^2?W+_,GZO5[H****Z7[.?2G"W(Z\5RKZS?2<&X?^55Y
M+F:7AY78?[3&LI<1X./\.BWZM+_,I8:?604445ULMW:6N?-G7/H.35&X\311
M96WA+'L9.E<U17E5^)L7-6H14%Y:O[W_ )&L<+!?%J%%%%7;S5+F^)$DA"_W
M5X%4J**^7K5JF(FYU9.3[O4ZHQ459(********Q*"BBBBBBB@ HHHHHHHH *
M******* "BBBBBBB@ HHHHHHHH ******** "BBBBBBB@ HHHHHHHH *****
M*** "BBBG*Q1@5.".XKI=)^(6L:6$5I_ML*G_5W/S?KU_6N8HKT<#F6,RVI[
M;!U94Y>3M]_?YF-6C3KKEJ1304E+17L_AGQQ9^))OLXADMKK9OV/AE/K@_\
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M76=1V4+DL>N>IXKLK86G3CS1J)ZM;]$KW]'KZ=3KEET91;P]13:OHO+KZ/\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>chart-4f4c561ec95bdab3028.jpg
<TEXT>
begin 644 chart-4f4c561ec95bdab3028.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &0 BX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*:GX:OKRTT71[O7/'UO>Z?;:';VNHW/AT7.JZ<7\1M:O<W%M0^ O[#'@_P"
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M07P_>^%-$3PM;:!I7BB#P_<P-K/B"74M2M)[Z&6TLY(HBS2OV'-)\/?M&_M
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M.<9XXY5A^60,_49%!./7TX!/7Z _GT'>@!:*** "BBD)P,G/'H"3^0!)_ 4
M+12$@<G/IP"?T )_'I02!Z\^@)_D#C\>G>@!:*0L <?-D^BL1_WT!M'XFEH
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MM8IYPXFFCMX4EE$C^9())4C62022?.X=FWO\S9;F@#^3?_@G5_P4M^,/PO\
M@-I?@'XH_$SX=7_@SPS^SM\)/C1H'Q+^*EO\2O%OBW3]3^,?_!5'X\_LFZMX
M"\3^(T\7:]JOBZ\U3PKI'@_3?AGK.JQ^&?#G@?Q9JN@MXZU"#X9PWVI:?]K?
ML@?\%'OVI_VK_BQ^S;\*8KOX ^ V^(?P;_:]^)7Q&UJY\%>)_$U_]L_8X_X*
M*^'?V7+W1O"]C:_%+1K+3=0^*WP=?7]8E-W)K-KX)\9M#XITZ+Q/X5TNX\.7
MG[T/H6BR1202:3ICP31B&6%]/LVBEB$L<WE21M 4>/SHHY=C*5\R-) -Z*PF
MBTO38'$D&GV,,@>XD#Q6EM&XDNY9IKIPR1*P>XEN;B6=@=TTD\SREWED9@#^
M2[0/^"X'[9E[X2\,>-]2L/V;9+;5O@O\"_C;?:)I_@/QK9E(/%/_  58O/V!
MO&?@J/4+GXKW[0/JWPQN]/\ B/9>(I8))?#'B_2;Q1I&K^%M0:/3_J/XW_\
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M_P#L77/B*+P'_P %"/V.?BA^T1XATY/^"8_C?X[^#?A1^ULWC?Q-XQ^*EIX
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M8> ';5YU\->(/"OCV[NO$&E:[H%\?Z1_@3\3/@C\*?V9/$?C/2?&OP_N]/\
M ES/-\5(O!GQBU+XC?#7PY\:M;T;PSJGB;X<^!?B!X\\0WP32;KQ5XCTG3/"
M^C3ZM86NFW7B*QTXZ;H%U-/I%E]#>#_%W@/7=&O'OO"-S\.?+\<ZMX1F\/?$
M/PWI7@^]U#Q9/<V\$TFDV\T\^E>)HO$LE_;OI6N^'KW5[+Q.LX:QO;UFVUV.
MEZU\/]4DD\*:-JGA#4)8+>ZO)?#NF7VA7DD-K9:B+&\NI-'LYI7CM[75L6ES
M.]J(X-1Q;RNET0E '\V^H?\ !2/]I?\ 8]\(_P#!33X3_$N^@UG]HWX&_&?X
M)_M)?L[V/[0#^'-;C\0_LL?ML?'+P!X4U#PQ=:7\)OB/J-O)I?[/GC_Q%\2_
M ^B_V5XSMI]+\&O\*;B]L(K2:2WFFC_X+ _M:^#]7^.L>K^%/@Y\7&^%'A+_
M (+4V_AGPGX,\'>*O#/B+QMXM_X)G?$3X16?PBU194\?>*I#;_$_P?\ %'5(
M?&OA;2--N;AV\&2^(O!VJ;[N[T:#]2_$W_!2_P#93\*?'WQU\!O'&D?$+P[X
MD^'_ ,?_ ('_ +,'C#QIJ?PR_M'X?Z;\:/VD?">B^+O@5X5NO$^B7VM7JVWQ
M%T76?#T6F>(;C1XO#NCZCJ6EZ/XIU/0+^>&WK[(^'OQ*\&>,])'B!-#O? [O
MXZ\;>!-(L_&VGZ'X<UG7M1\'^*-6\)/J_AR&WU.__M;0O%)TUM:\)7UG<FZU
MKPWJ.FZA)8V;WAM(P#\KM'_;;_:=^(/QV_9*^#/P[^(?[(E[X1_:N^'G[6WQ
M:\)_&3PY;^(OC!IO_"M_@1XA_9=U/X;W2V&C>-OA]HW_  G/BWPE\6OB/H/C
M+P[9:KJNCZ+?:+H'C72-6N8M&\3>#KKYN_X)O_\ !1#X@?$^V_9N^!<<OP8^
M"L&O?!SQ?^T%9WGC%OBWXUTWXS^'O#O[<G[2_P &?C9\-OA?XA\??%77O%:?
M$+X?_#[P1\/OB-*;CQ;\0&TO4OBCI!/A>V^'-GIVFQ?N[X&^*GP$\5KXEL_A
M[XX^&6M0_#3QQ?\ PN\41>&M8\-RVGA#X@0;)-3\$WS64J6VG>(HIM4:"]T>
M-ENAJ$M]82Q&_M]0@AXK]HS]HKX%_LO?#K7/BS\3I8&T3X:ZOX LM5M/"VC:
M?XF\6^&)OBYX\\.?"KPUJD7ANRF36;&QU+Q#XNTRSOM0M8HBNF/>W3BXMK2=
M  ?B+X&_X+&_&_X@66M2>#]1_9X\5:?)\9_^".7A7PI\1=)\*^.8_"7B/P+_
M ,%&_$]IX&^*WB'3O"^L>-]$\6Z?I?@V]LM<\6_#.3Q3/I'BS3-+DAT#XH^&
MX=9T?5TCC_:^_:]^+/Q__P"#<_\ :'_:CUO7K3P!\;?^%<_%S3+'Q/\ "'5/
M$G@"2R\8_"?]I'Q#\)=(\1^#I[3Q-=^(_#FK^(-+\'PZVVE6?B/4'M;G6+[3
MK.ZO=-\HR?T&KXM^#]AHUKK:^(_AQ9Z!>VLDEGJJZSX2M](NK/2-3ETN1[:_
M%TEC/;:=J^HRV#M#,\5EJ-]):,8;NZ>*2C\4OB9\._A-\/\ XD>,O$_V>[T?
MX3^ O%'Q3\5>'M"M--U;Q';^&/"&BWOB#5=0L?#(N(+BYN/L-C<?85*VXO;H
MQ6L$_G3QAP#\3?'/_!3#XW_##]M?2_V;/!ND_!W7/@EX?^/?[!/P0TJP@TKQ
M!?\ Q \1^&OVJ?V7/VE/B9J\NG^-#X_ET%M4T#QA\%?!5OX+O/\ A'KN'5[3
MQ5?Z1KC22W&E:S7R1\-_^"GGQ2TKQAKO[8?BG4_#=RGQ3_X)_P#_  1^\;_$
M_P !6/B+7-.^$O[/6I?M*_MP_M"_"+]H+QUJ?AW5O$6K1Z%J/P!\%W^F:/XW
M\0ZQ;V5\LW@KPN?B,MII%I<)'_3%\)OB?\+/C%X"^%_Q)\#W&FMHWQ6^&G@C
MXN>";+4[&QT;Q--X)\8>'=,\1^&M3NO#UR1JNFO'I>HV:3Q21?\ $MNEDLWD
M62!@-JQ\2_"749IK'3=>^'E]/KOVNUN+2RU7PK=2ZM_:BRZE?V\UO;7$DFH?
MV@L\U[>0NDXO%EDNIUE61Y& /RJC_;C_ &@OAU^TU^R3\*_C[XQ_99LOA=^T
MQ\/]=M)/'?P>G\0>.M/\*_M!^!V\1>.M,\ :EXHU3Q#HUK;>$?VE?@;X<\0^
M(O@SK,_AF&\T_P"(/PY^(/A&SG\>PWW@^2X[/]N7]LO51^R5^S%^T-^R'\:_
M".F>!/CG^UQ^PWX+;XQ2^&8?$WAJ3X*_'#]H;P7X"\8ZD\'B'4?#$.@6TVE:
MM+8ZM>:W)IU[IUO_ &EHLCZ!J]U%JVD_6'[0W[47P0_9BL_@!?\ C/1=9U:R
M_:,^.?PP_9O^%-Y\/?#&E>);>\^)7Q'AOS\.;"\N[;4M/BT;0;JWT+4'M_$W
MFOHFBPZ>K7-U9))9&;WG2+[X8&V;P-HU_P""IH-*L+G49O"]GJ.A7C6NGZ=K
M$D%]J5WI2W,\JP6VOQRK?:C=PD)K8E-W<#4O,- '\P_PU_X**?M'?LO:K^VS
M;:5'I7Q\T'2O&O\ P7E^-W@3X>>()/&&K>.M*\3_ +%'QV^"0^&_@O1?$4OC
M'59O^%9ZSX=^+OB@CP!H7A>PDT'PWX+@D\&WTS17UN?V&UWQ%#^U#^Q%\1)_
MB]\5/AQ%\/OBIX@30? 7QF_9F^-6I>'+K_A5?B[Q;X5LOA]XSTWXEV$VA6W@
MOXQV5CK+-<1^'-5U3P]:^(;2Q>"6\M=0O=#@^G/A7^TI\$OBKXP^.OACPI>P
MV6L_L\?$SP]\+?'VHZQ9:5I&DR>*/&GPT\$?%GPU-X7\0K?3V'B/3-?\#_$?
MPOJ%G?V5TLLD^H3:=-;1W=M<1#V+3M2^'D^WPAI5]X-E^QW5_8+X9L+K0)/L
MU[I,@N-3M%T2UD;R+K3I9A-?VPM$FLY)?,N8XF?<0#\:?V-_C!^T)\$-8_:*
M^$'[:6E:MXQ^/G[*/A7X-?"3X9?M$7NJ6?ASPO\ MS_#WXP>-OB!IO[,OC#0
M1X@\0Z1X4TKXT^(M3\.?\*U^.FC7=_$+/XBZ-_;0\1GP_KMN;/Y'^'WQN_:-
M\=_LX?M4_L+>.OVC-"^''[<'['_[:O@VS\)>)OVJM0AO_"?[1'P6^*_C67]H
MW]G+P3^T3JOP?\2:C8:7X4^+7@.Z\0_L^^/4^'GBF\B\/:EX+L-(E%[)J0\-
MZA_3Y<6EK=HL=U;07$:.LB)/#%,BR)]QU65'573^%@ R]B*K3:/I5PEW'<:;
MI\Z7\-Q;WR365K*EY!=C%S#=*\3"XAN  )XIA)',!B16% '\HMU^T#HOQ2_:
M3_X)%V_QWT[Q3^RIX4UAO^"MG@C]HCX=']J#QW/\,=0U_P"#=AX<L="\5>"O
MBSI7B_PO-XT^%4'C@^*O$7[/'B1FMI?!]M=3:#X'6PD\/QHG2:)^TO\ \%"=
M0_X(X_#'Q-8:Y\5-;_;1^!?A:Y_:[UM?$]WX)\*_$SQ_^S;\"_VB_$/B+X':
M1^TAX:\8>(? _B^TM/VJ?V?/A]?:=XDO?#FA:IXQ\1:E9;M?T**]\2ZKI]Q_
M4FFB:,B6<::5IJ1Z=#:6]A&MA:*EE!8$&QALU$(6UALRJFTB@$<=L0#"J$58
MDTZPE>666RM999X!;3RRV\,DDUN"&$,TDB,\L095;RY&9-P#;<C- 'X Z'\=
MO"/[6G[<_AKXB_%OQEJ\/_!/_P"*'_!,KX??&[]DZ+6/%>N>!?A/XC\=>,?B
M!J4_[0'B'Q#K6DZGH=G_ ,-$?"WP;=?#?2;#1-0UU?&'PP\/W^MZQX0TW3=3
MO?%VJ0>+WOQK_P""@>A_\&\7PY^*OC;7?C=I?[0=VG@>R^*?Q1ATK5[;]I;P
MW^QYJ?[3\?AS5/C3+I]II5SXEL/C!'^QY)I7C#Q/XC733XR\-RW^M?$*Y6Q\
M7:3/-:?T,?&+X$?![]H#X<ZM\)?C+\.O"WQ#^'6M7&G7U[X4\1Z9'<Z:NJZ-
MJMOKVAZYIY@:WNM'\0Z#KMG::YH'B+1KG3]=T/6;6VU72M1L[^".X7O?#7AS
M3_">A:=X=TJ?7+K3]+A:"VN/$GB?Q)XRUR5&EDF+ZCXG\7ZMKGB76+@O*X-W
MJ^K7UT8]D1F,<<:* ?EY\9OBE\/?V7O"GP9\6_LD6>B>,K3XJ_'G]E']F?Q;
MJVA_$3Q'\0/AE\,_A7\9_BL-"N?CCK>C6GB;6M!NO$RVM[=Z3I?CC4+V"\\1
M^)/$7AFX\>:MKF@Z7':M^8-[_P %HOVQK[PMX.\7K\/O@K\.W/P+_8F^+_B'
MP7XP\&^.+_6/$EU^T1_P4W\9?L+>*WT/4'^(&@2Z#X*U;X5:3H/QY\#3RZ1K
MFLZ2-8T^+4[[6/#UZMS7]0MEX<T#3=.N-'T[1-(L-*NWNI+K3;+3+&UT^YDO
MBQO7N+*WMX[6=[LLQNFEA=K@DF8N235J32]-E8-+864C*BQAI+2W=@B !$#/
M$Q"* JJ@(554!0  * /YH/B%_P %;OVL_!OPZ6]TM?@3K?BK0OA3_P %S?$V
MI:M-\/\ Q.NG>*?%O_!*/XUZ)X-^#2V&@V'Q1NGT33?CCX7U2"#QYH<&J:[?
MPW^HV6J^!-7M8YK:TG]<L_\ @J9^V3XJ^(OB_P ">%OV9O!WAWQ5=WG[9?A#
MPEX'^)VH:SX6C^'.M_L^?LB?L^_'?X.^./C5XYN[RRT?2? ?Q<^*7QBO/AWJ
MNJM#H^BV&CZU\/9M,UB#5=.\5W&I?LAXM_9D^$OC;XZ?"+]HG7M'OYOB1\#_
M  I\3O!?P_FM]6NK3P[8:!\89/!LWC^WU'PM"!HNMW.LS_#SP3/#?ZG;3WNE
M3>'+&32IK-I+S[3[L^GV,DL\\EG:R375LEG<RO;PO+<6D;2M':SR,A>:V1IY
MV2"5GA1II65 78D _D<_:,_X*B_M#7&D?&;XM_#CPW>? 7XN:=_P3O\ "_C+
M4+KXF>%O%"?$KX->)-$_X*?ZI^RY\5? GB#X<O\ %'4_@=J5OX,T:#Q-?V'Q
MDL/!5EJNO/I\/CNTUJT\!WFF^#] _:']DC]LCXQ_M"_M%_M"_"O6K3X-:)X9
M_9T^)_Q0^#GBW0+G7]4T;XWZT?#OA3X)>*/@O\;O"_@79JEM=_"OXTZ5XR^(
M_B"75Y]371+'3%^'&F>#]9\0:GIOCF:?]/&T;27@DM6TS3FMI; Z7);M8VI@
MDTUHO).GO"83&]B80(3:,IMS$!&8BO%21:9IT%[+J,-A91:A/:V]C-?16MO'
M>2V5H\LEK:2W21B>2UMI)YWM[=Y&A@>:5HD1I&) /YB_AS^UQ\3?@1\5OV^+
MKP#XJ\-^(M2\6_\ !=O]E_\ 9(TRW^)NK^*?'VB> _@E\>/!'[/OAGQ$O@K0
M8O'>DCPW;^'-?\5^./%V@VVFSVOAH^*8O$$&J6$T(U'^S_!_BC_P5'^/W[3'
M[(_A=/&-_P"#OA!KLGPV_P""=7QS3QG\.KSQ?X)U;QKXT\7?\%@8OV8_BY;^
M#M1'C"6?0_!WA+X;_"VQ;Q_X:BU'7I8X/C-?:3XGO6\*'3#JG]= T?207(TS
M3P9'$CD6-J"[JTKJ['R?F96GF8,V6#32D$&1RT<N@Z)/]G\_2-+F^R)<1VHE
MT^SD%NEW)#+=) '@80K<R6\$EPL6P3O!"\H=HHRH!^'$W_!0+]K_ .)/PV_;
M3\8_ K3?V6K+Q]^S-\0OVB_ACX?^!OQ'\1^()OBIKWQ.^!W[1>M>#OAS\.-2
M\)6NJ^'6LI/VI_@1IVE>(/AEXIN?$,$=K\4?''@==#T'QEX"U"]-O^@'[(/[
M;_P+_:G\(?#5O _Q>\+>-O'WQ!^ G@?]IF+POIVDWGA[6]-^%7Q-\1:[H/A^
MXU+1)KO5;>SU+PUXCT35_AYXML1K,VJZ3XP\/WJ:YI6@MJ%C9'[(;0M%>XN[
MM](TQ[J_DLY;VY;3[-KB\ETZ-XK"2ZG:$RW#V,4CQV;S.[6L;M';F-&*F.W\
M/:':ZG_;5OI5C#JHT]]*2^CMXUGATZ6\.HW%G;L%"VT%W?".[O4MUB%[<06L
MUWYSVEL80#^;KQ#_ ,%G/C+(WQA/PUU+]G+Q[9>%O#O[%OB3P1XLMO#OC^T\
M*:E/\=O^"I'Q*_8&^+6FR:'JGB[1?&]SH_A#P3X0T;Q5I^HZM;^&]9T[QW%K
M>K7>GZE\.?$'A&-/%?VO?^"E'[0GQ'_8D_:)^'>N7WA'P/KLO[&W_!9/Q1!\
M;_ 0\1^ [_Q%\4OV#?VNK7]FSX1>'_A>UIX[O;SP;XYU;X?W0^.'B2UT[Q'K
M^L"]&@7OA41>%8]7$W]62Z#HB/)(FD:6LDOF^9(NG62O)Y]U+>S;V6 ,_G7D
M\UU+N)\RYEDG?,TCNRS:'HUQ'%%/I6FS103R7,$<NGV<L<-Q+;2V<EQ$DD#)
M'/):336KRHJR/;RR0,QB=D(!^.W_  4JO_C+!X>_9I\=_ GX@?!#Q/XG\"^%
M_B7\1-<_95^/_P 3=<^$G@/]J?P#;>$O MCK^H^$/C1H-_';^!_C-\*I]4TW
M5/A?XAUJ/4O#D$OCG6M5U*.TCLH]=TO\M/VO/^"G&C:]XE_9WU,)^T7\(/V?
M?V</A=^S]JO[;_P5O_$6LZ5^U9H_PJ_:\^&_P9^-GP?_ &G/AGIYU1?&7C]O
MV3?'?PXTWX1_M ^/?#DWBCQ186'Q0^-%C%I=B;+4?$4W]:][H^DZE9II^H:9
MIU]81O:R1V5Y8VMU:(]C(DUFZ6T\,D"O:2QI+;,L8:WD17A*,H(2?1=(NKZ+
M4[G2]/N-2@M)["'4)[*VFOH;*Y(-S9Q7DD37,=I<D W%LDH@G(S+&Y)R ?S%
M?M,W/QI_;$_;7_9_^&WP9^/'@+P3XY_:$_X))_M"^,O#GQ)^$/[0GQ2D^$OP
MW^*__"_/@);>!/CW\*YO .H:;+\6/&7P[\.ZOXNA\"?:X?#=IXMT2Y\3I?:K
M9^%X[[3'_IN\.:=J6D:!HFEZQK=QXEU;3=(TRPU/Q#>6MK8W>NZA9V-O;7NL
MW-G8I'96EQJMU%+?SVMG&EK;RW#PVR+"B 68-(TJV-J;;3=/MS90PVUF8;*U
MB-K;V\+6\$-L8XE,$,-N[P0Q0[(XH6:)%5&*G1H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I""1@
M8ZC.?3(S^.,X]#BEHH _GI^/?_!'+QG\7[C]KCQ%\/+CX3_LX^-OVM?V7OVI
MO@]\>-/^&_BGXB77P-_:7^*WQ8M+6S^"7QA^)'P9U'0ET#P#X[^&US93>(?&
M/Q+\(0:QXW\2ZQK>KVJMJVFW=PS^5>//V'?CO\//VG_V?==\5> ?!'Q"?X\?
M\%,OVX?VE];LO >A>-O%WPQ^%_@_XW_\$M?%?[/>BZ!\8/&6I?#A(-'TN_\
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M<_OE10!_-!\9/^"*/QM^)O@;Q!X,M/$/[/%M9W1_X+DCPK8ZH_BZ;3/"*_\
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MKPWXMT*'5M,GU/0=8T^SU"U@U"SFDA$5S$[>TT %%%% !1110 4444 %%%%
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M^*MK^W;:_MN? .R\&?"SQS!X5\5:%\6[30/'^MZ#X/\ VT/"MAX \5:-\(?
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MJ?:9]WV3_A&/]$^P?9/LVWS_ /2?M'GY_=>77L%(W0_0_P J /PC_P""%O\
M;GE_\%<O^$F_LG_A(O\ A]9^V?\ V[_87V[^Q?[6_P"$2^!_V[^R?[3_ .)C
M_9_G[OLWVW_2=G^LYQ7[NU^''_!$S_D,?\%B?^TWO[;7_J,?!&OW'H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**,C_/7\NM !17FWBWXO_#7P/.++Q)XPTBTU5W$<6@VLLFK^(YY6("1V_AW1
MX[_6IF=B%798D%B!D5Q+?$_XF>*"\?P[^#VKP6CC;%XE^*FHQ^ ]*W94K+!X
M?A@UCQC>1/&=\?GZ7I0?!!D0X!^%S3Q*X,RS&U\J6;O.,[PTN7$9!PO@<PXK
MS["R:]WZ]E'#F%S/'9;2F_=6*S*CA,)!W=7$4XQE)?18/A3/<70IXQX+ZAE]
M57I9EF^(PV39=6BFN;ZOC<UK83#XN<4[^QPM2M6EHHTY-I/W_(]:YOQ'XQ\)
M^#[0WWBOQ+H7ANTV,ZW&N:K8Z7&X3[PB-Y/"TK9X"1*[L2%522!7DI^&OQ3\
M4L7\>_&+4M,LY3(9/#GPGTFW\&V2JZ@"%_$VI/KGBR<(=P,UK>:4[K@JD3$X
MZ7PY\#?A7X8O%U2Q\':;?ZX"KMXC\1FY\5>(WF"!&G_MSQ)/JFHQR2<L_P!G
MGAC+,Q5%W$5P+B#Q$SG3).!\+P[AI-1_M'CO/,+#%PB[-8K"<.\)OB"./I<K
MO]5S+B/AK&7?+4A1E%HZ/[,X8P.N8<0ULTJI7^K<.9=6E0DUHZ-;-<Y66O#S
MO_R]PF59K0LKQE.Z.?\ ^&A/"FJ'9X%\.?$'XDMN6,7'@[P;JC:.'?(C+>)/
M$(T#P\86.,S1:E-&%R^2@)$@\6?'?6P!HWPG\,>%8G*-'=>/?B#'-=+&X#'S
M=&\%Z-KB+*JD Q-K2E7RK$ ;J]T"J       .P X  Z  <    <4M6N$^-,?
M[^>>)>98>3]VIA.#.'>'^'\MJ0V:?^L&&XUSRE-I:U<+G^'E&5Y4^2Z44\YR
M'#:9?PGA:J5G&MGV:9EF>+A)6=U_9E7(,NG&]_<K9;55K*3EJWX4N@_M#:F$
M:_\ B%\,_#.0A>#P]\/-;UUEVN-ZK?>(/%]JLF]"1O.G1X8*1$ 6J2'X=_%A
MGB>_^/\ XA8*CK)'I7@#X=:='(Q+%''VS1M8D0J"H8&1PX7C83Q[C15Q\,\B
M<HU,1G/B!BJZLY59>)WB'A8U&G&5Y8/+N)L%E\;RC=PHX.E347*"@H-Q<OBS
M,4G&E@>&J-/7EA'A+ABJX)JUE7Q64U\4[+:4Z\Y[-R<DI+Q6X^'/Q)>(K:_'
MSQM!,2N))O"/PON4 !^8&)?!]N26'"GS0%/)##BJY\%?&^U+/9?&W2K_  2R
M0^(OA7HTZMB%E"23>']>\/OAIMLI=(@P&4 8<'W*BKGX:<.SES_VCQ["7NV]
MEXI^)M**<.;E;I0XNC2D_>=U.$HSM%34E&*2CQ9FD5R_5>&Y+7X^#^$IO7EO
M:<LD<U\"MRR3CKRVNSPHP_M)V>!'??!3Q"B @&?3O'/A2>;;$@!9X+_Q3!$S
MR[W;;"R(N$4'=NC<WC+XYV VWOP9\/ZSM/S2^%_BG8LTB[ILF.V\3>&M ^;8
ML15'NQN:7!=0K;?<Z*S7 6.P]UE7B+X@Y53>GL_K_#^?V5DDE6XPX;XDQ2M;
M?V]WK=L?^LF'J6>,X7X9QDE]KZMF>6W>EVZ>1YKE5'7M[.R[65CPT_&/7+$B
M/7?@C\8M/D#!7DTW1_#?BNU7+LA99?#/BC4+B11M+DK9[MF"%)9 0_M#_#JU
M!_MM/''AIPNYT\1?#+XA:8L>(!<.)+AO#<MJ/+C8;R)RN[A68$$^XX'H/RHQ
M]?S/^-/_ %?\0\)IE_B'@,8M$I<5<%87,ZME;XI<,YUP52<WNY*A&/\ <LV"
MS/ABMKBN&,30?59/G]?"0OI>RS? 9_-1T=DZC=OM;L\9M?VB/@C=.(Q\3O"-
MK(9(HO+U34UT>17F4/&K1ZLEDZ$J03O"[.C[370P?&#X372L]M\3OA[.BL49
MHO&?AQ@K@ E21J7!PP./0UWMQ9VEVNRZM;>X7<&VSP13+N *AL2HXW!20#C(
M!(S@FL"3P1X-F=I)?"?AF61V9GDDT#27=F8EF9F:S+,S,26)))))))-5'"^*
ME%I2SS@#,5=WE'A7B')VETM%\99W>RT;<H\UG91NK)UN#I[9?Q)AMK)YSEF.
M3>E[M9%E]D];63L8-Q\8?A+:*KW7Q/\ A[ K-M4R^,_#B[F +$+_ ,3++$ $
MD =*Y67]H_X+B0PV/C>TU^X^3;;>%-,UWQ;.YD"E-D?AO2]3+!MX .0N[*DA
ME8#TF'P5X.MY%F@\*>&H)4(9)8=!TF.1&'1E=+-64CL00171100P(L4$4<,:
M *J1(L2*HZ*$C"J !P   .U*6$\5J[]SB#@#+$G]KA#B'.I35H[27&V1*G+F
MYFGR58VLG%ZC5?@VFO>RSB7%MKIG>5X!1=^SX?S%S5M&N:GK>S2L>&-\8_$F
MK[4\$?!;XEZZSL"E_P");33/ASHIB)51,UQXJO8M:\L%E8K#X?EF,0=XXI&3
M88/[!^/_ (N(_MSQAX4^%NER E].\!:=)XM\3F,L 8G\5>*[:WTBTD*;LR67
MA:9XSM,<V<FO?L#KCGU[_GUI:QEP%FF:?\E3Q]Q;FM">M3*LDQ.&X*RE3]W6
MCB.&:&"XL5/1IX?%\68W#U$[5:=1-WM<1X/!_P#(GX;R7!5%I'&9A2JY_C''
MM.GF]3$9+S7U56ADN'JQ:4H3@TK>2^$_@GX#\*:H?$1LK[Q1XM8N6\9>-M2N
M?%7B8>8ZNPM;_4S)#I,991B#1K73H%4;5C"\5ZUC_/\ CZT45]=D7#>0<+X)
MY?P[D^79-@Y595ZM#+L)1PL:^)J)*KB\5*E",\5BZ[BI5\7B)5<17G[]:K.;
M<GXN8YKF6;UUB<TQV*Q]=0C2A4Q5>I6=.E'X*-%3DXT:%/:G1I*%*FM(0BDD
M%%%%>T>>%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C=#]#_*E
MI&Z'Z'^5 'X<_P#!$S_D,?\ !8G_ +3>_MM?^HQ\$:_<>OPX_P"")G_(8_X+
M$_\ :;W]MK_U&/@C7[CT %%%% !1110 4444 %%%% !129'J/SHR/4?G2NNZ
M^\+/M_7]-?>+129^OY'_  HR/?\ (_X477=?>.S[/^O^'7WBT4PR(OWG53UP
MS!3CGG!(/8_D:SYM:TBW+K/JFG0M&6$@EO[2,IL&6WAYE*[1RVX# Y.*RJXG
M#T%S5J]&C&]N:K4A3C>U[7FTMM=]KOHRX4JM1VITYS?:$92?X)]S3HKCKCXA
M^ ;1/,NO&_A"VCR%\RX\3:)"FY@2J[Y+Y5RP!(&<D D5A77QK^#UF9%N?BI\
M.X7BC,LD;>,_#ID5 "VXQIJ+.<@9 52QXP"2*\#%<9\'X+_?>*N&\':U_K6>
M99A[73:;]MBH:-*33[1D]HNWHT<BSS$?[ODV:U[[>QR_%U>W\E&7=?-I'IU%
M>*3_ +1OP/@(4?$OPQ=,T+3JFFW<VJN\29+,B:9;W;.<#(1078$%5.X9C'[0
M_P ,Y\C3+CQ?KDFV!ECT/X:_$74]XN'VQ%)(/"_DL&^]GS0-O.3T/B2\6/"V
M,G3_ .(D<"2J1WI0XMR&=9M1YK1HPQ\JDI<OO*,8.36J3/07!G%\DI?ZK<1*
M#M[\LES&--)M1NYRPR@E=I-MI)Z;GM]%>'_\+N6<XTOX3_&S5<F0(5^'\NBQ
MOY<JQ ^;XIU+044.6WIOP?*5G95 J-OB/\6+SG1_@%K\:,<)+XJ\=^!=!0?-
M,NZ6'2[_ ,37:*/+C8A;=G*2Y4$J T/Q2X-EK@\1GN<1LG[3AW@WC+B6C9I-
M2=?A_(,RHJ+3TESVWU*7!^>IVKTLNP,OY<TS[(<IG?:WL\RS+"SNNJY;_@>Z
M49 ZG%>%-/\ M(:F28=.^#GA&!\A3=ZEXQ\;WL8\P@YBM;'P?9EQ&-X(N'4L
MP0J ":8WPV^*^L$KXD^/&MVEM)N+V7P_\&>%_"80,,*L>I:PGB[5EV'G>MU&
MS# P&!8Q+CW,L5_R)/#GCS-J<M(8K$83(>&</%MI1E6P_%_$&09S"EUFZ.48
MBK!:JC)M)M<.82DTLPXIX<P4E\5*E6S+-JC2LY*G5R3+,RP,IZVBIXVG"3WF
ME=KW*XN;>UAEN;F:*WMX4,DT\\B0P11CDO)-*R1H@')9F '<UX[J_P"T#\*]
M.NY=+T[Q'_PF6N1GRQH'P_T^_P#'.KM/SBW>'PW;ZA;V<I(*YU"ZLXU8$/(N
M#BE#^SI\,9Y$N?%-EKOQ#OD<O]K^(GBG7_%RL67:1_9>HWYT)% .52+2HT1@
MK*H*(5]ATG0]%T"U6QT+2=,T6Q3:$LM)L+33;1 HVJ%MK*&"$!5 51LX P.*
MES\6,ULH4.!^"Z#U5:K7SGCO,:E.5[QE@Z=#@C 9;BH)Z3CF.?X935W"M#W)
M4H\&8+5U.(,^J+>G"G@>',+&:<=57G/B'$8JC+7W7A<MJN+MS4Y6:\6_X3/X
MW>*R!X0^&&F^"--E(:'7OBOKB#4# P_UL?@CPB^HWHF0?,+75=?TJ0DK'+Y6
M79#_ (4UXC\2A7^)WQ8\8^)H6$?G^'/"CQ_#CPE(O)EMIK?P[(?$FH6S%BA3
M4?$LWF(!O0' 7WVBDO#3 YC[W&'$'$_&[E\>#SG,H9?P_*G*SGAJ_"W#.'R+
MA[-,)=>Y'/\ +\YQ,8J*GBJLE*<C_6O$X73(\LRCA])+EKX#"2Q69QDMJU/.
M,VJYCFF$KM?%++<5@:3;;C1@K1CQ7A#X<^!/ 5N;?P=X3T+PZKJ5GGTW3X(K
MZ[!9G+7VI,KZC?.68DR7EU/)G^+'%=KC_/\ CZT45]UEF597DF"H99DV6X#*
M<NPL/9X;+\LP>'P&"P\/Y*&%PM.E0I1_NTZ<5Y'SV+QF,Q^(J8O'8K$XW%5G
MS5L3BZ]7$XBK+O4K5ISJ3?G*38444FX9QD9ZXSS^74UWG,+16'KOB;P[X7L)
M-5\2Z[H_A[3(A(TNHZ[J=CHUC$L2-+(TEWJ=Q:VZ*D:M([-( J*SL0H)'R9X
MM_X*)_L,>";M-/UO]J[X%2ZD[1HNE>'_ (A:'XQU??* 8D.E>#9_$&H*\A9%
MC5K<,[R1(H+RQJW9A<NS#'-K X#&8QK=87"U\0UZJC";6S.O#8#'8QM8/!XO
M%-;K#8>M7:]52A.Q]GT5\"VW_!2C]F/6Q;GP,OQ[^)BW<RPV\OPY_91_:9\5
MV4Q:Q_M /#J=I\*HM,FB-N5/F17C@.RH1G)$*?M_6=X;#^Q?V/\ ]OC6TU!I
M5CE7]E[7_#D=N8R0#>OXXU_PJ+5)2LGE22[4/EY=D$MOYW?_ *MY\G:IE6-P
M]M_K=%X.VC>OUKV-M$]^QV?V!G*TJ9;BZ'_832>%[_\ 03[+L_N/T HKX"O_
M -N?Q7;&(67[!7[>FK!PYD>V^&'PJLE@(*A%==6^-ED\AD!9@85=5"X<JQ I
M;#]N;Q3<B7[;^P;^WEI!0IY8NOA=\+;W[0&W;C&=)^-=Z(_+PH83^66WKY>\
M*^T_U=S;EYO84+=O[0RYRW2^#ZWS]5]G;78?]A9G;F]C0]/KV YM7;X/K7/_
M .2[:[:GWY17P!)^WO+;:@FGW_[%G[?=GNV&2]C_ &=(M9T^W21&97DN?#?C
MG6O-Y4(\5HES/$[*)8D&YEN6_P"W_P""_M\VGZI^SM^W%H4D,"S&>^_8V^.%
M_:2%RFR&*Y\-^'->229D<R$#]V@21))4F41,/AS.K7C@*M3W>;]S.C7]W37]
MS4G?=;:[.UFKK^P<W^S@JE32_P"ZG2K:.VO[JI/NOO7<^\Z*^ Q_P4K_ &8[
M?3I-3URW_:(\+V\5P;>0>(_V/OVJ].='+K%&S$?!^XA"SR'9#^^W.P(V#C,C
M_P#!3O\ 8A@O(=/O_C3)HEW<0-<PQ^)?AC\9?#"O A8&3SO$'PZTV!5+*T:;
MI 9)5:*,-(K*#_5KB+6V0YS)+F3<,LQLX^[K+WHT6M%JW>R6H?ZOY]TR7-7:
MZO'+\7):;ZQI-:7UU/OBBOA.P_X*;?L":@+O9^UC\%K,V,ABNTUGQ9'H$D$B
MAC(KQ:[;:;)^YV,)RJLMNZE)S&XVUUUA_P % _V%]2LX=0M/VQ?V8FM9U=HY
M)OCC\.+5BJ.T;%H;OQ#!/& R,/WL29 W#*D,<Y\/Y]3_ (F29O3U2]_+<;'5
MJZ7O45JUJEU6NQ$\CSJG\>49I#5+W\OQ<=6KI:T5JUJEU6I]?45\E?\ #?'[
M#?\ T>/^RU_X?WX6_P#S44O_  WO^P\59A^V)^R\RJ"6*?'KX828 !)R$\3,
M<X' QD] ":C^Q,Z_Z%&:?^$&+_\ E7FOO(_LC-O^A7F/_A%B?_E1]:45\*7G
M_!3?]@"SM1>?\-<_ N^@:>.V4Z-XYL->E::0E41;?0UU&X8[L*Q6(JC,H=E+
MJ&SXO^"G/[&5_-]F\/\ Q'\8^,KDWTNG+%X#^ O[0GCD27D,+SR113>%OA9J
M=M*OE*'CECF:&57C>-V1U8[+AOB*2<ED.=.*O>2RO'-*V]W["RM=7N].IJL@
MSUJZR7-FM=5EV,LK;W?L;*W7MU/ONBO@ ?\ !0;PSJB12^"?V7_VY_'\4\<$
MEO/I'[*?C_PG:3K<0W$Z%-0^*[?#RP10L C=YKB.-)9[=2Q\PE6/^U;^U-KI
M8^!/^"<OQU:(MB.[^*GQ>_9M^&%KL>*TEBDF@L/B1X^UJ('SYHY4CT>::&6V
M,9C=G;RG_J[FT?XU'#X1]LPS'+<METTY<?B\-)/5*UKW'_869K2K2H85]L=C
M\!@)=-XXW%4&GJM+7/T"HK\^Y/&__!3+Q2F_0?@#^R#\+(W48_X6!^T3\4/B
M/J$!:.ZP\FG> O@KX;L)S#*EMYEO'X@C69976.Z4H75TGPR_X*0>*XW.N?M4
M_LU?"[S#\MO\,?V6/%/C"[MTS?+B+6/B=\<);62<))8LLT_AHP^= Y:U,3/'
M,_[$5/\ WK.,CPKVM]=GF'XY-A\S7S3L/^R%"WUG-<GPS[?7)8ZWJ\IHY@ON
M9^@!91U91]2!_,T%@/[Q^BLWY8!S7Y_M^QS\>/$H/_"QO^"B/[5>HJXQ)9_#
M/0_V??@WIY FF?RX9?#GPAU3Q!;QF&8P;T\0&Z"QPRBY$T2, ?\ !-SX%ZN=
MWQ&\?_M5_%UF4+,/B-^UW^T+?6=R%N(+E/.T;PYX\\,:%L26#Y8(M,CMPDLT
M?E%&4(?4,EI6^L9][;O_ &9E>+Q-M%_T,9Y.+ZGE-/\ CYS[7_L7Y=B<1_ZG
MSRH^W_$'C#PIX3MC>>*/$N@>&[0*6-UK^M:9HMN%5HU9C-J=W:1A0TL:DE@
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M_9N^(GP?EM9GE:-(KK6?'_@"S\+F3)$CM;:_/&L#":241*S)^L!52<E03ZD
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MAYEWJKH,1^&'5F=70JB,SG< %SD"_)_P6'_8^FAMY="B^//BEKFX%ND7A_\
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M>JO\X/?D-D&O/M>^$7PI\5;O^$G^&G@#Q'N&UCKO@WPWJK$84#Y[W3)G& B
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M)P!)*?$-U<R$"61Y9B[R<[XAX^P.N:^'U#,:;^%\&<78#-J\5=1YZV'XLP/
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M  ^L::%X5\-Z*D0D$2Z3H6E::L8E9FE$:V5I $$C,S.% WL26R22>DV@8 R
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M?HKYC;]INW@6Y:_^!?[2^G_97".&^#>JZKY@(7YX'\/:CK$<\8+!2T;MR&8
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M*<>:*PO#'%.*;C9._P#LV354E9IINUUJKK4%G^5MI1JXB;:NO9Y?F-2ZWO\
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M[CU^''_!$S_D,?\ !8G_ +3>_MM?^HQ\$:_<>@ HHHH **** "BBB@ HHHH
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M^EFD;H?H?Y4#.!GK@9^O>O'_ (C'X[#4K0_"S_A4W]BC3<ZA_P )_P#\)O\
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M]JJB?#M])&F+)IY=]66\:_C6R-M=@']!E%?BP/V6O^"VQ /_  ]=_9?Y /\
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M= '[345^+/\ PRS_ ,%M_P#I*[^R_P#^*S[+_P"B;H_X99_X+;_])7?V7_\
MQ6?9?_1-T ?M-17XL_\ #+/_  6W_P"DKO[+_P#XK/LO_HFZ/^&6?^"V_P#T
ME=_9?_\ %9]E_P#1-T ?M-17\^OQ%^&W_!;#X?\ Q$^ 7@"3_@J#^S#JDGQT
M\>^+? T.IK_P3@LK,>&G\*_!_P"(GQ9;4Y+,_M&77]K)>Q^ 'T+[(+O36MWU
M9-2$]P+-K&X]D_X99_X+;_\ 25W]E_\ \5GV7_T3= '[345^+/\ PRS_ ,%M
M_P#I*[^R_P#^*S[+_P"B;H_X99_X+;_])7?V7_\ Q6?9?_1-T ?M-17XL_\
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MO[+_ /XK/LO_ *)N@#]IJ*_%G_AEG_@MO_TE=_9?_P#%9]E_]$W1_P ,L_\
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MQ>0:?I6CZ1IEM+>ZCJ>I7UR\=O9V-C:0RW-U<SR)%!#&\DC*JDU\I:[_ ,%
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MM-B5Y+7P_I_B7QIX:T,:A>M;Q7NIZB;33_M<EEJ(LP#T2BBB@ HHHH ****
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M1P01(   'DED9(88Y)71&\=UK]M']EWPY\5_@W\$->^,_A#1_BA^T#HD.O\
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MP1I'B;PQX-TOP+XNU+XS67PKNM.UGXM^'=,CUKP'!XI\5:?\/;5]3L8[#7K
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M\7?$'_!//P;\ _&WA#PYX#_:H\/>,/\ @HWX5\'?%JY^(PUOPK\)_A3^W_\
M$CXS3?$'7+K1/"QOK;XK2S?";XE:%+9_#;5[#2[2Z^*O@SP_+<^*/"^DZ?\
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M_#+1_P"CB_VI_P#P[Y_^9VC_ (9:/_1Q?[4__AWS_P#,[7@?ZR<??]&V[?\
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M\0M\4OA_X%\&_$KQ3I5QX.\4V>C6'@CXA:KXLT+P5KL'BZZTJ+PKJ<7B+6O
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M75X]XUU+]>T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)@>@YP3QU(Z'\.WI2T4 (0#V[Y]P<8R#U!QQ]..E+@<
M<#CI[8Z8HHH 0@'J/0_B.A^HP,'M@4H&.G^?\]Z** # QC QC&.V/3'I28'7
M'/KWXSW_ !/YGU-+10 F ,8'3@>P]![<#CV'I1@>@X&!QV]/IP./:EHH ,#.
M>Y_S_A^0]!2;5QC P>V!CZ8].IQZDGN:6B@!,#T'?]>N?7/?/4\FEP,8P,>G
M;\J** $P,YP,^N/;'/X<?0D=S1@>G7K[X]?4^_7@>E+10 8'^?\ /?OZT8'/
M Y&#[CT/MR?SHHH 3 /8?U^N?7WI>G2BB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ,#&,# Q@=ACI^7:D(!QD=.A[C(QP>W''%+10 F!Z#@DCCN>I
M^IR<^N:7 ].O6BB@ P#U'3D>Q]:,#T'_ .OK^=%% "8'H.@'3L#D?D>1Z<XZ
MTN!Z>_XYSG\^?K110 FT>@[G\2<DCTR1GCOSUI<#T]_Q]?U/YT44 '3I1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 453U%+Z2POH
M],GM[74I+.Y33[F[MWN[6WO7@D6TGN;6.:VDN;>&X,<DUNEQ \T:M$LT3,)%
M\1_X1[]HWC/Q+^%N<#/_ !:W7QSWP/\ A8!P,]!DXZ9/6OF,_P"(<=DM7#4\
M)PCQ-Q+'$0J3G5R%\.JGA7"48JGB/[<XAR2ISU%)RI_5Z=>%HM3G"3BGZ^69
M7A\PC5E7SO*<I=.4(QAF2S1SK*6\Z7]GY9CX\L-%+VLJ<KM<L9*[7O5%>"_\
M(]^T9_T4KX6_^&MU_P#^>!1_PCW[1G_12OA;_P"&MU__ .>!7S_^OF=?]&J\
M1?\ P+@#R_ZKSS_+OIZ?^K> _P"BRX7Z?9XEZ\O_ %3G][\#WJBO!?\ A'OV
MC/\ HI7PM_\ #6Z__P#/ JQ::#^T&EW:O>_$;X93V:7-N]W#!\,]=@GFM%FC
M:YA@G?QY*D$TL DCBF>*58I&61HI%4HU4^.LYG.$'X6^(=-3E&+J3EP%R04G
M%.<^3CJ<^6*?-+DA*5E[L9-I$RX=P$8RDN,.&)-1;48KB3FDTD^5<W#JC=WL
MKM*^[2U7N5<SI?C3P?K=KKU]HWBKPWJUEX6U&_TCQ+>:9KNE7]KX>U72[2WO
M]3TW7+BTNYHM(U#3K&[M;R^LM1>VNK2TN;>YN(HX9HG?IOK7XS_%;PCXF^"'
M[0O[17[<_P"S+I$GC[5O"?CWPOX-_;;_ &=/ <]IJFM_';X*:!\$/A7JUEXS
M\*^%;2Y>+_AJGX V6L:SXC^'MD\%EJGQI^&U[XF^">JK?ZSJ'PGUGP=^BGRY
M^NVF^+_"FL^'K+Q;I'B;P_JOA;4H8;C3_$FFZWIE]H%]!<3K:P36>LVMU+IE
MU%-<NMO%+!=2)).RPQLTA"E_B7Q7X7\&:3-K_C#Q'H/A70K>2"&XUKQ)K&G:
M%I-O+=2K!;1SZEJES:6<4EQ,RPP1O,'FE98XU9R!7X__ !KT#2OVN/V/O@U^
MR+\,=+B\5:'\1_V6_A]\2?%5MX1\:Z/\*_$G@;P?J'@FR'[/OC73M-U>TL]4
MT::'XK6>E_$;PSI\^G::)+[X0W>D:M;2VC:AI%SQ%M\6O$W[;7[)W['OQ"T3
M]HOX9?LW_MW_  A^-WBSPQ-I?C;2]"^(_P '=3_;.^ 7@GXL?!O]I/X"?$SP
M39:_HMS?^$?$MM;_ !.\0>&+OPMXD\-_$/0_#3>&?B;X'O9H[1K#50#]@]4^
M./P7T.RT/4M:^+?PQTC3_$QNU\.7VI_$#PAI]GKS6-Q+:7JZ+=7>LPP:J;2Z
M@FMKH:?)<FWGBDAFV21NJ^A:3J^E:]IUMJ^B:E8:OI5ZC26>I:7>VVH:?=1H
M[Q,]M>V<L]K<(LB/&SPRNJR(Z$AD8#^;K1/C/X4^(OQJ_P""2&M_%#X2_"K]
MGKQ'X3_;C_X*/>"/B3X6T+Q)H6N_!K5?B5X7_9F_::TKX@?$GX->+];TOPRW
MB/X;?$WQU<7WBS2=8NM"T?54UK6M3T3Q#;'Q)I^H2W'T5\!_B%I7PL_:=_X*
M=?$SX&0:2O[,6N-^RWX5^%>E0:GI_AOX/?$G_@H?KUE\0?"/Q9TSX/7AEM/"
M+MXL?5/V:_"/Q<UWPLLVAZA\5K/Q'->37GC;0_B"5 /W"M;VSOHY);*[MKR*
M&YN[*62UGBN$CO+"YEL[ZTD>%W5+FSNX)K6ZMV(FM[F*2"9$EC=%Y/2_B5\.
M]<\2ZAX,T7QYX,U?QAI'VS^UO"NE^*="U#Q)I8T^Y6SOCJ.A6=_-JMD+.[9;
M:[-S:1_9;@B&X\J4A#_/OH5_^T=^S[I?_!2C]B+X?VNH^!?V@?V@/V7OC=^V
MI^P;;7'Q'T?Q=XKUGX[^*/ VI^"_VC--\-ZY;W-I!9:^?VDI?!?Q[T?3#%]G
ML-?_ &@-?N+46_A_PZ]EIGK'QDTCPOXA_8!_X)XZ1^R18+8_&K0_C3^P==?L
MYV>DV\T/C+P9<:%\0?AQ<?M+'QY;11Q>(]%LM*_9['QSTW]H^T\5Q6U[=65S
MXIT'QE#/XDU2"QN0#]SM>\0Z#X5TF\U_Q-K6D^'=#T]8GO\ 6==U*RTC2;%)
MIXK:)[S4=1GMK.U22XGA@C:>>,/-+%"A:21$;,\*^._!'CNVGO?!/C#PMXPL
M[5H%N+OPMXAT?Q#;0&ZA^T6HFGTB\O(X3<P S0"5D::(&2,,GS5^9O[9M[=Z
M;^WE_P $T;_XFW,5E^S#!?\ [42:C>:[*EO\/K;]K6X\$>!8?V7CXXN-29-!
MMM2F\&/^T'9_"J;7'2U?XE7&G6>E-_PG-WX,1_4OVC/B7X1^!_C?X,7_ ,-X
M?!WP_D_:R_:4\$_!7XY?'[0M%\-WLGA:.S^$'Q5\1?#O4-?O;J*Y\-2^,/&/
MB?PAX/\ @;X,\0>,['6;'3[KQ[H&E3V6HWC^$M)F /T+HK\"&_:__:OUFWUO
MP?J7QF\)^ -3\/?!G_@J9J>A>/;#X=^ +B^^)S?L4_'7X->$O@K\<M(T?Q1>
MWVA6VC>+?"7C'Q'H7Q"T;3M,N?".M:[I6N:YX1NO#%DVD)I'%>.?^"A_[2GA
MOX0>.?B!9_%CX:IJ^O?L:?\ !,+]K;0HK[P9X4N=(^%^I?M4_M"ZK\*?C-X;
MLK:+6+"\UKX:KX:TRUU'P[JGB_4M1\0^&-4N-3N[GQ9J-E/I]AI@!_191TZU
M^*MC^US\>_#'Q[U7]GCQG\1K#4/AAKW[<EM\ _"O[6T?A3P)HLNA>'->_8PN
M_P!I.P^&=\RV=Q\*[CXBQ?%BUC^$WASQ;=^'&T^^TS4=*\'ZIX>O?BG=Z?J6
MJX/A+]M3]I-+?X1ZI\3M?T63P9#\6=6^$7C#QC\']*^'5[XEUZWT3]N;Q;^S
MC\+_ (X^,O@?XLOK[QI=_ /]I_P-X=\.VVD^-?@/X@N]3^%_C?6/%_C'_A&O
M%_PULM/OO#8!^UNA^)?#OB:+4)_#FNZ/KT.DZUK'AO5)=&U*SU*/3?$/A^^E
MTS7M#OGLYIEM-7T7489K#5=.G,=W87D3VUU#%,I0;=?A)H_[37QP\=_&']FJ
M"X^/3:;HUI_P4/\ ^"A_P*USPWX(TOX8Z-I'Q5T'X)Z%\7;GX1?#CQ"VM6FK
ML?$T5AX4M](B33=6TS5-;U&\N_%4]I'JNGZ/<:+]!_\ !/7]J3XQ?M47^G?$
MS7?BK^SKXC^&OC/X(>&O$>L_![P+XHN?$GQF^!OQM3Q!]G\6>$/%^G6WP_\
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M?XC\*Z[HWB7P_JT NM+USP_JEAK6CZC;%BHN+#5-,N+JQO("RLHEMKB6,L"
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MC&2A@*$BO!OVB_V3?AK^T9\)];^$FK"7P)I>OW7@&2]U_P ":%X-M/$BZ?\
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>grapha07.jpg
<TEXT>
begin 644 grapha07.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %3 PD# 2(  A$! Q$!_\0
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M<T?]H9V!"XD\Q!O'7<K=>17%?;/C#_T.'@?_ ,(^\_\ EK1]L^,/_0X>!_\
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MK,-E)X9M["QETGQ!=::)KE9;MG21;>>,N )(O]8"OS''\5)]L^,/_0X>!_\
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MY4\,M=:A=^*M/UFR\8>9;[;/3HHX5FM22XF4D1SQ^6J%6%QDGE\=1]L^,/\
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M6!YY7*D3>4!NF"(7D7.UB=HP37^V?&'_ *'#P/\ ^$?>?_+6C[9\8?\ H</
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M'].:_P#V[;J91NJ:O\5G]]G^MK?/R/4(U*QH&8NP !9L9/N<<5I:!_R%H/\
M@7_H)K/K0T#_ )"T'_ O_034C1V%%%%06%<_XL_Y=?\ @7]*Z"N?\6?\NO\
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M%%% !1110 4444 %%%% !1110 4444 %%%% %>;4;2WNX+66YABNKC<887D
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M^$;"QT^U$>K7*Z?J$.I6<EYK=Y<2V\T0*QA'DE+*@5F78#M(8@@YJA#^S/\
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M96W1_*5*G).:]8T?X,>'_#^F:O;Z?/JUM?:O*LU_K/\ :4SZA<,O"[KAF+X
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M/_[=0%F>@?M ZAXCL?A3K47A33[W4-;O56RB_L] \UNLK!))U4D9*(68#/)
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MN23DYKM= _Y"T'_ O_036DTHMI.YC!N23:L=A11161J%<=\0_#?BOQ!_9_\
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M1EW_ /+6C_A7'Q7_ .A^\&_^$9=__+6O8Z* /'/^%<?%?_H?O!O_ (1EW_\
M+6C_ (5Q\5_^A^\&_P#A&7?_ ,M:]CHH \<_X5Q\5_\ H?O!O_A&7?\ \M:/
M^%<?%?\ Z'[P;_X1EW_\M:]CHH \<_X5Q\5_^A^\&_\ A&7?_P M:/\ A7'Q
M7_Z'[P;_ .$9=_\ RUKV.B@#QS_A7'Q7_P"A^\&_^$9=_P#RUH_X5Q\5_P#H
M?O!O_A&7?_RUKV.B@#QS_A7'Q7_Z'[P;_P"$9=__ "UH_P"%<?%?_H?O!O\
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M?O!O_A&7?_RUKV.B@#QS_A7'Q7_Z'[P;_P"$9=__ "UH_P"%<?%?_H?O!O\
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M?O!O_A&7?_RUH_X5Q\5_^A^\&_\ A&7?_P M:]CHH \<_P"%<?%?_H?O!O\
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MX6M;:X-LJVEA*5^5"D*DNH0 .Y8GOFNKO/&S:?=6=K<:C%#<WCF.WA8+OE8
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M\*+!<["BN/\ [>O_ /GO_P".+_A1_;U__P ]_P#QQ?\ "BP7.PHKC_[>O_\
MGO\ ^.+_ (4?V]?_ //?_P <7_"BP7.PHKC_ .WK_P#Y[_\ CB_X4?V]?_\
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M_'%_PHL%SL**X_\ MZ__ .>__CB_X4?V]?\ _/?_ ,<7_"BP7.PHKC_[>O\
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M_P#GO_XXO^%']O7_ /SW_P#'%_PI6'<["BN/_MZ__P">_P#XXO\ A1_;U_\
M\]__ !Q?\*+!<["BN/\ [>O_ /GO_P".+_A1_;U__P ]_P#QQ?\ "BP7.PKS
M+Q-^SOX-\2^+M/\ $CV<UEJMMJR:Q/+:W$B"[F2%HE\Q=V,8*\@ _(HSC(K=
M_MZ__P">_P#XXO\ A3?^$CO!((S=*)""P7:N2!U.,>X_.BUFFM_Z87T:Z/\
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M_P#X1^^' M\#_?7_ !I?[ O_ /GA_P"/K_C0W<.K9GT5H?V!?_\ /#_Q]?\
M&C^P+_\ YX?^/K_C4@9]%:']@7__ #P_\?7_ !H_L"__ .>'_CZ_XT 9]<)\
M;O#\GB7X;ZG9IJ%GIR*\%Q,VHS>3:S11S)))!,^#MCD56C8X. YX/0^E_P!@
M7_\ SP_\?7_&J]YX1EU*$17>GPW408.(Y@CKN!R#@]P:3\AQ=G<^4]#^'S^.
M_AEX@FOHO#G@OPSJ'B2'5=.TO4;?[=I1MX8XP?W3?9P8YI(WDP-H(.X;MV3W
M>@^(K#QC\$[3PY:W&G^ -7UW2+Z#2K>Q40Q1Q1;H_M-N@QMBP4D'0A7'/>O<
M;SPC+J4(BN]/ANH@P8),$=<CH<'O2W7A&6_@:&YT^*XA92C1RA&4J>H(/;VI
MNSBX]'^BM^B\OO!-J2GU7^=SY[_9QTV=O$_B?5+'1-(T#PR+2STV"/0+EIK*
M_NH?,\ZYC/E1!N'2,N =VS!8E<#WNKT?AR\AC6..U5$4;5564  = !FG?V!?
M_P#/#_Q]?\:J4KDV_K\/Z[[F?16A_8%__P \/_'U_P :/[ O_P#GA_X^O^-2
M,SZ*T/[ O_\ GA_X^O\ C1_8%_\ \\/_ !]?\: ,^BM#^P+_ /YX?^/K_C1_
M8%__ ,\/_'U_QH SZ\+^+FB:3#\3O!6IV<>CRZRVMVOGV]G;*-:E #*7$^_(
M@1&#2(4P4#?,,XKZ$_L"_P#^>'_CZ_XU7C\(2PW<MU'I\*74H DF4('<#H"W
M4T+249=FF#UC*/=-?>?.WB?_ (1KP/\ '71O$"3:';6D=OJ%QJDNEVZPW=JG
MDAGN+^8.WFP[DV@%5(=DQNQ6'\:]0T74->\9WFJ3V\]Y-X5MIO!,I93(]TS3
M'=9=S,93:Y*?-@Q=J^F[KX>Q7EAJ%E)I4/V;4%9+M(]J><&!#;BI!.03^=6X
M_"<\,<$<=C&D=N L*KL C & %&>...*%HDNW_!_ST^92=I<UOZ5M_NU/DW7'
M0>)]<.HM#_PM+_A)]'72,[?M@L2MMO$'\7D;?MN_'R_ZW-6?!CVG_"<>&/L[
M1'XC-XLU4>(-FTWGV "YVB?'S>1M^Q>7N^7_ %6*^K3X;NS*)3:*95&T/N7(
M!ZC.:%\-W:RM(+11(P 9PRY('0$YJU*UO+_)+\;:][D_9:_KK^5_=[%*M#0/
M^0M!_P "_P#031_8%_\ \\/_ !]?\:N:1I%W:ZA%++%M1<Y.X'L1ZU '2444
M5)04444 <UXF\<6WA?Q+X6TF[MI2OB"YELH+M2/+CF2%IE1N_P ZQR8]UQWJ
MEX6^*FB^)YKZ,3QV+0W5[!;BXF4-=1VCK'<3H,_ZM9&VD^WN*K?&KP-JGC_P
M#<V6@7=OI_B:TGAU'2+R[W>3%=PR"2,R;06V'!5L G:[5P.K?!7Q+X=M_!'_
M  BZZ9JL^C^'K_0;O^U+R2VWR77D,UUN6*0L=\+$K@$^9UJ;M)OKK;[KK\59
M^3OZ6E%M)NR_J_X-->:9WUG\7='NO' T+S[5;.XTZQO]/U+[4"EZUT]PJ1QK
MCD[;<L""=P;H,<WM:^+7@OPY&9-4\5:1IZ">6VS<WB)^\BQYJ\G^#(W?W>^*
M\D;]GWQ,WAR"T2YTN'4[7PCH^GV5V9Y"MOJNG3231.0$R86=URP^;"L-O-1^
M+O@/XTN/ .D^%],O[.YM9M(OX-95-4N-,\[4[IED:[\R%#))&':?,1*AMZYR
M!QI4M%OEULW\UK;\K;=8O:Y,;2:OI=1^3LN;\7^#MT/:_''C.T\#^$;[7YT:
M[B@1/*AA89N)'94BC4GC+NZJ#T^:N<L/B;JNH^(I]#L?#3:O=:4T$.MW=I>1
MQV]I/(BR&*,R8:5E1T=N%X9<9)VB#XA>!=3USX)1Z#:0QOK%C!8W$5M'+\DL
MUK+%,(@[ <,T.T,0.N3BL_P]H?BSPWXJUS6?#6EZ;J.A>+;N#5;B+6KR;3[O
M3IO(BAE'EBWD\P%(58 E"&R#P=RNR4VK^GX6^3U^Y=R4[TU)[_U_7WF_H_Q:
MCUOQ%XBT^#PQKHTO0II;:ZU[;;/:O-&B.T<<:3M<.V' XAP2",UD1_':UU'P
M&WC.QTF]@T2QU273]4AU2/[/=6Z1SF"28("W"OABK$'8&X##;51/A;<?\+EM
M/%6D^'=+\*PVS74FHZA9R*MUK[21E(TG")RBDB3<[,P*J%&,FN67X>^-8?@_
MXN\(:QI6FIJOBO6KQ[=]%O9KV"WANYVED>9Y+>'9Y2L^.#O*C&"P%3#6U^R^
M^Z_/7M9?>.6B=N_X6?Y:>K^X^AJ6D5=J@>@Q2TA!1110,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .)\??%"#P-J6FZ9'H]_KFJ
M7\%Q=QVMB\$>V" (979YY(UX\Q %!));I@,0_5?BKI&E_"G_ (6 +>]N]';3
MH]2CMX8U6YEC=59$"NRJ'.X##,!D]:Y'X[?".[^)VI:.\VCZ;XJT.UM;J&31
M-3OI;)4N9 @CNDECC<[D42)T! E+*<C!?X/T?Q5>>!M;\(^.O#UCXOM=,@M+
M&&>Z<,FN@01M,TJ2IM $F1SD-CUS0M8/O_P6O\N_YI-VO&W];?\ ![?J=!JG
MQ8?1?#^DW5_X3UNQUS5[PV&G^')I+-KR>4*SGYH[AX541QNY)EX53WP#ER?M
M :5<:?I+Z1HFKZ[JVH+=NVBV:P+=6JVD@CNO-\R54!CD(CPK'<S#;D?,.3T7
MX*^)O#.EZ+JFEP:7#J.D>(KC5[#PPMVT=A:6<UNUNUG%*(CLP&,HQ'M#DJ %
M.:-%^#OC/P->:;XET?\ L?5?$TRZNNIV5U=R6]JC7UTMT&BD$3,PB=%3E%+J
M2?E.%IOR_IVT7WZ-W^[<%M_6UW=_=9I6Z]>GM?AGQ'I_B_P[INN:3<"ZTS4;
M>.ZMI@"-\;J&4X/(X/0]*TZY?X7^"Q\.?AWX<\,?:?MITFQBM&N=NWS650&;
M'8$Y..V:ZBJG92:CL2M@HHHJ!A1110 4444 %%%% !1110 4444 %%%% 'G?
MB_XO7'@WQ3IVD7/@7Q)>6NH7T.GVNK6<NG-;RR2#)(C:[6<J@W%CY7 1FY S
M5F3XL16/Q TWPOJ7A[6-+7599K?3=5N1 ;:\EBC,CHH25I%^178%T4'8W^SN
MDB\(ZCJ/Q<G\2:H86TO3=.6ST6%6)9)96+74S#H"0L*+W 5_[QKG['PSXZOO
MC++XAUW2/#MQH5G'+;:-+!K<YGLXV7YI#;FS"M+(0JLWG81.%!^8N1MI?S_X
M'SZ_/R'+K;R_K_/T\T=AXC\=P:+KUAH-G97&L:[>(9ULK4JODP*P5IY78@(@
M) [LQX53@XZ>OFCXA_L_^)_B'J]YXCU'1/#%QXEU?P_#I/GR7DI_X1Z[BDF9
M;NSD\G>QQ/GCRVW1J,X8D?2%C ]K9V\,LK7$D<:HTS=7(&"Q^O6G;W==]?Z_
MKO\ )*7Q:;?\!?JVOE]\]%%%( HHHH **** "LSQ+XDT[PAH-[K.K7*VFG6<
M9EFF8$X'H .6).  !DD@#DUIUY_\=/AO+\5OAW<Z# ;=IOM=I>I!>$BWN#;W
M$<WDRD*Q"/Y>PD*<;LX.,4G_ %_7D5&U]3J_#>L76N:2E[=Z3=:*TA)2TO&0
MS!.Q8(S!2?[N21WYXKAG^/>E:3JVL6/B71M6\)_V?I4VN)-JBPLES90L%ED3
MR99"I4LGR.%;#KQG('/>!/"GBWX4RK!I'AK2;?2M>\1*[Z#IURXM-"L1:A7>
M(B-4RTD6\H%5<RD#)Y-*3X1^-_'T/Q!C\:V7A^PO/$.FRZ;8ZMI.L3WC64()
M,,*P26D05029';S&+MV"[0M:7\K?C;_-^CLUO82[/NOS_P D_-:/8ZI?V@-*
MM=+U676-$UC0]6L5M'70[M8&N[H7<ACM?*\N5HR9) 8\%QM93NP.3U?@7QY;
M^.+;40+*ZTG5-+NC9:AIEZ8S-:S;%< F-F1@R.C!E8@AAT.0/*-9^#OC/QM>
M:EXIU<:/I?BB)-(&F:?:WDD]JS6%R]R3+,858"5Y&3A"44 \G('H/PO\'ZOH
M=]XLU[7UM8-7\2:BE[)964S316L<=O%!'&)"B%VVQ;F.T#+$#(&35EK?^MK?
M?[U^UNG6>WR^^VJ]$]GU\]SO:***@84444 %%%% !7/>/?&UE\/?#-QK=_#<
M7,,<D,"6]J%,DLLLJQ1HI=E4;G=1EF51G)('-=#7$?&3P=J/CSP#>:+IK6[O
M/+ T]G>2-'#?6ZRJTUL[JK,BRH&0L%.-W0TGT_K^ON?H]AJU]2A9_&"XU+0]
M2N[#P1X@U+4M+U%M,O\ 2+6:P6:WD$:R%_,ENHX63:Z<K(6RV"H(;&QX%^)%
MKXZ\ P^+5TK5-(L94EE6UOHHY+@QHS#>JV[RJZL%W*49MP((ZBO,]'^"_B72
M/AOKOA73A9Z#I6N:RC+I5K>R31Z3ICE/M<<4K*K%Y,3,% "H9L*<+FO798]7
MTW5=(LM(T_35\.1VTJ7#/.\<L+*%$"11JA4H?F!)(P , U3M;[OOM=_CMOK=
M"ZI>OW7T_P"#\NY2^&_Q$L/B=X?FU?3[+4-/AAO;FP>WU2 0SK)!*T;Y3)P,
MJ< X..H!XKJJ\V^!OA3Q3X/T/7;;Q3::1:7-[K=[JD(T?49;Q-EQ,TVUFDMX
M2"I?;P#G&>.E>DT/IZ+\M0?Q2MM=V]+Z?@%%%%( HHHH **** "O._%_Q>N/
M!OBG3M(N? OB2\M=0OH=/M=6LY=.:WEDD&21&UVLY5!N+'RN C-R!FO1*XB+
MPCJ.H_%R?Q)JAA;2]-TY;/1858EDEE8M=3,.@)"PHO<!7_O&A?$K[?U_PWXA
MT??^O^'-3QUX\TWX?:3;WVHK-+]INX;*"WMPIDEED8* -S*,*-SL20 J,3TK
MG/''QPTCP3JES:-IVH:M#I]BFJZM>:>(FBTRS=F5)I=SJS [)&VQAVVQL<=
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M2]W5][?,4?>V[7^6_P"AZW_PEG_3K_Y$_P#K4?\ "6?].O\ Y$_^M7AGP_\
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M $Z_^1/_ *U<_118#H/^$L_Z=?\ R)_]:C_A+/\ IU_\B?\ UJY^BBP'0?\
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M$_=Q!O*B1$ "HN]R.I)<DDUU%=HEO82321)%;-+'C>BJI9<],CMFI/[/M?\
MGVA_[]C_  HN*QP]%=Q_9]K_ ,^T/_?L?X4?V?:_\^T/_?L?X47'8X>BNX_L
M^U_Y]H?^_8_PH_L^U_Y]H?\ OV/\*+A8X>BNX_L^U_Y]H?\ OV/\*/[/M?\
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MO-6GURS>2/3K=#K=PFUE\Q+D29^SI&P:1"F"@;YANY]\_M"U_P"?F'_OX/\
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M,CO-;NT9RC,RDJ<8R/3BG_VA:_\ /S#_ -_!_C6DI<UW;=W_ *^_7N1V\O\
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M #\P_P#?P?XT?VA:_P#/S#_W\'^-0,L457_M"U_Y^8?^_@_QH_M"U_Y^8?\
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M8A&49)ZGZU)_:%K_ ,_,/_?P?XU<I<SO8SBK?U_6[U^98HJO_:%K_P _,/\
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MPA:S^ Y696D>[9YR6L.YG,QL\E/FP8NU?3>K1Z5KNEW>G7TD%Q97<30SPF7
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MZ\&[K^P\2ZKJ6H>+O,M#]IM9XKH0*#YGGG E@CV% %\OC( -5%)O7S_#_/\
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MT_#6RMZWL7))7M_6OXZ:W\^IZRWQ"\.KXVB\(#5(G\1R6[W0L(U9F6-=N2Q
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ME:ZM_6WZW^5NY-1110(**** "BBB@ JAK>M6WA_39K^[%PT$6,K:VTEQ*Q)
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MC+S/T2-!W9V*J!W+"DY65QJ-W9#?^$3_ .GK_P A_P#UZ/\ A$_^GK_R'_\
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M)Y:LK2E59F$2L&<J%4Y84F[%*/,[(UO^$3_Z>O\ R'_]>C_A$_\ IZ_\A_\
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M!D(!?CC KH?[>O\ _GO_ ..+_A56Z\9/8W%I;W.I06\]Y(8K:*5D5IW"ERJ
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M?P%T]K?4VU?7]8U[5-1GTZ2?5+LVZ3>78SB:WB"QQ*@0.&+?+N;S'Y'&-_\
MMZ__ .>__CB_X4?V]?\ _/?_ ,<7_"KYI7O?^KW_ #(5E:W3_@+]$<[KO[.?
MA3Q+:S6FI/J%U9SW^HZA+ TRJKO>PO#,A(0$*%D;;@@@@$DU?L_@W;KX4?0M
M3\0ZKK,)N[.[6XGBLX95-M-'-&O[F!%8%HUW%@2<M@KD8T_[>O\ _GO_ ..+
M_A1_;U__ ,]__'%_PI*\;)=+?AM]P[ZWZW;^;W-;PWX4M/"\VM2VLDTC:M?O
MJ,_G,"%D9$0A< 87$8ZY/)YK:KC_ .WK_P#Y[_\ CB_X4?V]?_\ /?\ \<7_
M  I6T2[:?=H+37^M]3L**X_^WK__ )[_ /CB_P"%']O7_P#SW_\ '%_PHL.Y
MV%%<?_;U_P#\]_\ QQ?\*/[>O_\ GO\ ^.+_ (46"YV%%<?_ &]?_P#/?_QQ
M?\*/[>O_ /GO_P".+_A18+G845Q_]O7_ /SW_P#'%_PH_MZ__P">_P#XXO\
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M_P".+_A1_;U__P ]_P#QQ?\ "F[O<G0["BN/_MZ__P">_P#XXO\ A1_;U_\
M\]__ !Q?\*5AW.PHKC_[>O\ _GO_ ..+_A1_;U__ ,]__'%_PHL%SL**X_\
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M@K#\36\MQ]F\J)Y,;L[%)QTIB/"/VF-&T_5/@[K\MY8VUW)!$AB>>%7,9,J
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MF7VJ]\:_%'Q M8M,?2YKC0=7BT+5]4;1]+DCO$NYK9K8P(7>'<5.\Y"!20Q
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MJ!Y;G/*YU)=8\0^(M6\&?%'3O!&J7BW?A^]TV;0&DMTO+1YI(9(G)DD5"C&
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M[?\ C#_T(O@?_P +2\_^5->ET4 >:?V_\8?^A%\#_P#A:7G_ ,J:/[?^,/\
MT(O@?_PM+S_Y4UZ710!YI_;_ ,8?^A%\#_\ A:7G_P J:/[?^,/_ $(O@?\
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M $(O@?\ \+2\_P#E31_;_P 8?^A%\#_^%I>?_*FO2Z* /-/[?^,/_0B^!_\
MPM+S_P"5-']O_&'_ *$7P/\ ^%I>?_*FO2Z* /-/[?\ C#_T(O@?_P +2\_^
M5-']O_&'_H1? _\ X6EY_P#*FO2Z* /-/[?^,/\ T(O@?_PM+S_Y4T?V_P#&
M'_H1? __ (6EY_\ *FO2Z* /-/[?^,/_ $(O@?\ \+2\_P#E31_;_P 8?^A%
M\#_^%I>?_*FO2Z* /-/[?^,/_0B^!_\ PM+S_P"5-']O_&'_ *$7P/\ ^%I>
M?_*FO2Z* /-/[?\ C#_T(O@?_P +2\_^5-']O_&'_H1? _\ X6EY_P#*FO2Z
M* /-/[?^,/\ T(O@?_PM+S_Y4T?V_P#&'_H1? __ (6EY_\ *FO2Z* /-/[?
M^,/_ $(O@?\ \+2\_P#E31_;_P 8?^A%\#_^%I>?_*FO2Z* /-/[?^,/_0B^
M!_\ PM+S_P"5-']O_&'_ *$7P/\ ^%I>?_*FO2Z* /-/[?\ C#_T(O@?_P +
M2\_^5-']O_&'_H1? _\ X6EY_P#*FO2Z* /-/[?^,/\ T(O@?_PM+S_Y4T?V
M_P#&'_H1? __ (6EY_\ *FO2Z* /-/[?^,/_ $(O@?\ \+2\_P#E31_;_P 8
M?^A%\#_^%I>?_*FO2Z* /-/[?^,/_0B^!_\ PM+S_P"5-']O_&'_ *$7P/\
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M@,,X(Z&HCI]]_P +?UZ>I5]GV_SO_74^7M0\>_$/6/BQ%ID/C.31=.D\51:
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MS%G^0D*!C;G</=?LL.V-?)CVQD%%VC"$="/2GLJM]Y0>W(INSLNG_ M^B?\
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M\* 0(VEQQ$QQ$J%\[+QHKEI&(;=E HKZ850J@*  .@%+6DI*4G)*RU_'^O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
&444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>inoviopipelinefor10k21920.jpg
<TEXT>
begin 644 inoviopipelinefor10k21920.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M  #VU@ !     -,M2% @(
M                        $6-P<G0   %0    ,V1E<V,   &$    ;'=T
M<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M%&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M  0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E
M>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M$G-21T(@245#-C$Y-C8M,BXQ
M                              !865H@        \U$  0    $6S%A9
M6B                      6%E:(        &^B   X]0   Y!865H@
M    8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6
M245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W
M=W<N:65C+F-H
M             &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M              !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M   !6%E:(       3 E6 %    !7'^=M96%S          $
M           "CP    )S:6<@     $-25"!C=7)V        !      %  H
M#P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\
M ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L
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MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#
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M\(*S)*3!PD/#1.1U5F8WHH.TI6.$)67QXV0)XL1%M78XE2>%)D?_V@ , P$
M A$#$0 _ -_@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MBTXOHH^L2D0
M
M
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M74LM,9/8W]O=QM9U]^MR.YNTY0BUUE2<L6YK#9AL>TL^&D#H8
M
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M)X]<L-F!DVE.<S*=79H\JLK>XI5E2E4QGN;N$7%-=;)O'KET"=PVR;(
M
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M[$Y=#[!0JT<\R_\ &5H7=#IR52'V7@3>U*X\'$$UAD#=[I<J.VR6.[3B+7J
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M.M3J.OBE4C*+:W([4I)/#$V'!JDST
M
M
M  *U>+]\W9L-_P"9+^O+&8W1_+U_W@RC_P":_P#17)H'^:'_ +%YY_\ )?\
M[PM#2!'TW/D.      !<SP*OEKNGYD)W^/X0.</YI/\ MI3_ .*4/[.L=6?R
M<_\ =NI_PBX_M+<W#Q\[SZE  =+F.2,=X[]S_A GL+@ONM?T44BONQE+'&/=
M-*'+G=KHW'^W:Y#VY?U_,KT*--TB@WDKS;*\@C@WP [H(
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MSZ.'F7%$R"%21FE3(<;92VZ\HIU8EJ] 899;?2M;:&5K2E:"7##A!VX
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M5N"=K0-QYQ]Q=M:%EDW5K[%*B.#PQZ ,@B
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MZ-S\YO%OS.Y;_%* 9_SO?,V?RBE[+,2YOOG''\S/V$;6/'Y^:3VQ_P#,)_\
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M -N_\G_6FXH- FV3^;K;;[;K+[;;[+[:VW6W4I=;=;=3DNMNMKRTK;6E?9H
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M[9?*Z/\ :1/5C'$1TV
M
M                                                          5J
M\7[YNS8;_P R7]>6,QNC^7K_ +P91_\ -?\ HKDT#_-#_P!B\\_^2_\ WA:&
MD"/IN?(<      "YG@5?+7=/S(3O\?P@<X?S2?\ ;2G_ ,4H?V=8ZL_DY_[M
MU/\ A%Q_:6YN'CYWGU*  I@XQ?\ \S\_;XPS_P#!(5*?1]0@RS;(VP^'L2Y
MQ#B[(4PI'IUGASD#-BEDN89.YVREQBI3,>_)[G5F97%E8:("I DK4QS4HRS.
ME_F[K^9?S9$FUBN!$2&V2^+KHWC>3NL.)R2^9*?6!51$_P!F(8/)L@M#0IKT
MUM"CY.TH:1=9=TB>^RM$BU36V^VZV[DK;=2DRA)C$D)KKN[K#M9&Y%)<'Y1;
M983#DG9TN93VYZ8I5&T?1&FVK'*+OC<@>[F\VA%]I:H@DY*<99=869=?;6VD
M'%KA!1OLUQ-=/9WOGH9EZ"YU6N&(\0^&#PN/1$%R\U)67W2QPA#&^RHZXPA
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M$LGTZXC6G.<B,18&QKF6Z5Y?NQRS)38O? ,JM%]ZV(PPA7)K;Y!(X0U1N^Y
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MM:4$ 1N\]36;S9O/$\)?_P![EXQ?<;/_ '_^"[_UT?<K[N__ %^_^@_\+_\
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MIW^C)?../?[->3OA5C89]SR?-*/RRG\&H8GS<_."7R>?PH&UCQO_ )J[;_\
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MJ;^/*;F'6I88;DL>#AQ]8M ^ME?]P3_V:C_Y7$89]!O_ -T_PW^\&2?2A_\
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MVR;>UMOA-QZ/OKO,<AI7=[-U+B4IXR:2X)M+@27!TBUH809.
M
M
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M;D@NN,3J$Q]UW1U.L*OL1>#Z0,/<%;YLW6K_ ,V3]?\ E41J>[81:6)
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M)DL*NS@'0+\-.=:8'@'$D4-0M+>[92F+$U2W+F5'!*F63/(4_D+>2YR9X=9
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M2%_8UK"I^3KT9TWZDXN+^PSGFTN)6EU3NH>[I5(S7JQ::]@]9W$&5H3G/%L
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MJUKRUJ/'5K5J\W5KSE.H^C)MOJO:>BG3ITH[E*,8P7022741S@IDX
M
M
M                          5J\7[YNS8;_P R7]>6,QNC^7K_ +P91_\
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M.4?8J%CYS_R]G^!4]F!4)PA.(O"^&UFW)F5)OCF49*;YWBPS'Z1JBKJTM*Q
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MXI[S3QWL>+U"T,869(
M
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M-G<N03/$&+I:_%7VF%/<G@$3?G<N^RZRZR\MR=6E6MLOMN*MK2M+^6E;:?\
M)01Q:!WTYD95"%*UJ&AK/;$-$]J)N.0)#4*.U(7T*2B5)>5<G3T2E?:E\RVG
M,M]BG)00!R@ Q1(L#8-F#W=)I;AC%$HDEYA9M\@D6.H@]O=YI-U+BC;G5S9U
M*^XPJZVE;;JF<MM:>P(XL&34*!"V(TS>VHTK>@1E6$)$*%.2D1I2"Z<EA*9,
MGL+)(*LI]BVVVE*" /INMMOMNMNMI=;=2MMUMU*5MNMK3DK;=2O+2M*TK[-
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MLKVUK&C7I2@W'E,4I+!M8S:Q]5&*6'-_EN7WM*^I5J\JE*:DD]S!M/';A%/
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M>PV;N/!@EQEE@P\R(
M
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M_P#O??H _P"VP/K>?]/?X_\ W,?4;_ZH_P#;?]_'U>/_ +WWZ /^VP/K>?\
M3W^/_P!S'U&_^J/_ &W_ '\F;HIPG/,JS8JS#X??"7V3!WV&^YWP6>XWF=NW
M!D7=LNV_A'E7.[&[3<WH>Q:<_I.7GV\WDNUOSI<_?TE::CIWR3X%NW4*W*>%
M<M[B,X[NYX/2X=_''>V8<#QV;6YG/Y:OHEU;+5/EKRAO6=2AR7@?(?E)4Y;V
M_P"%5N#D\-W<VX\*PVW#CG<ZE
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M3]TXO'>Y6?!N\&'1X2R4;M-L@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MR'E+FI\SW?=JG[P/)W.!YRM^Y0[R/.2XZ?I\8P^(W"?[O(>4N:GS/=]VJ?O
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MTIE?X5N [4T5\TLN^1TO@HYDU/\ .&]^4S^$R!0R<L(
M                7Y<)C_!C)'YS[_@K'ASOSQ?QRU^2?ZR9NKFS_A-Q\H_S
M(EJHU";(
M                    EQF'Y*VG'_GA?UC-@I0_*S];V"9^Y1$<524
M
M                    EOKK_A5MA^:-O^$:84JGNX>J17 R) JD
M                                            )<:*?*IQ9_\ =O\
MJYEXI5_R3];V2:/NB(XJDH                                    $M
M]S_\58Y^:/&'P<)%*C[A^JR,N$B0*I
M      ENS_(AF7[14=^ QHI/\NOP2/W/KD2!5(
M             $H-+_E.XF_M=W^"[Z*=;\DR,>$CM(/^//?]KN7WX<)UP(@<
M0(@                                   EQMI_[#-^R1AG_ .*04J7W
M7X;)I=#U"(XJDH
M                                                    1\VQ^31G
M3\V$N_%*@9)H_P"=.7_*Z?PD6/4OS?O/D\_@LV.N#U\V3IG^9UN_&[N/+K[Y
MY9A\H?L(:1^;=G^97LLLG&(&1@            !Y9_%*^<;W:_:4RO\ "MP'
M:FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
M      +\N$Q_@QDC\Y]_P5CPYWYXOXY:_)/]9,W5S9_PFX^4?YD2U4:A-D
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M,$UBB!0KDH      $N-M/_89OV2,,_\ Q2"E2^Z_#9-+H>H1'%4E
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M3C"3;"5%+ZD&WEWVEGT*OZ,RI-]U*6F4+OIS;N;6O)7V*@#\@
M $?-L?DT9T_-A+OQ2H&2:/\ G3E_RNG\)%CU+\W[SY//X+-CK@]?-DZ9_F=;
MOQN[CRZ^^>68?*'["&D?FW9_F5[++)QB!D8             >6?Q2OG&]VOV
ME,K_  K<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
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MJUW-M0JZ='?2E/\ IG_U%!1C&;JM*778</4)FUN\&PI-'M*8
M            !+C,/R5M./\ SPOZQFP4H?E9^M[!,_<HB.*I*
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MJ>[AZI%<#(D"J0                 L>X=F/J*);.,S.#8M<4&,XXL3LB5
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M!I?\IW$W]KN_P7?13K?DF1CPD=I!_P >>_[7<OOPX3K@1 X@1     !R\?\
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M/@@\?Z=(;JXSL61=C<491VJBCW[A)+ER&PF-JV"(L#"PENBV63-0M,67.I3
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M/X+-CK@]?-DZ9_F=;OQN[CRZ^^>68?*'["&D?FW9_F5[++)QB!D8
M     >6?Q2OG&]VOVE,K_"MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
M                               +\N$Q_@QDC\Y]_P %8\.=^>+^.6OR
M3_63-U<V?\)N/E'^9$M5&H39                         !:QOQ('YB@>
MK?:1[=V?LJ(R7LGM4Y+&_LGH&;&G0]/V(<3TW0]-?S>=R\WG5Y/LU'EH).4L
M>/VR>7 BKQT?GQ\N*O>GEU=[R+;K2+G1Q6.%Q-MU>6ZTJY6<;4NVZOV:4Y.4
M>I)+@)"Q6;?-HX?_ #BN?PRRB/,OUE^I_D1._<(YF$,U^S.DK;B6&*T*C)^'
MY3>_V1<]8G0JGE#V;(ZHS2+E-Y1%A*IJE1Q)9E]U"JK$M+#+BZ7TN!ODJV\_
M<M!=='!<)RVI.()/K<IGN?,Y(?<''V"'.#(U-KHK1=MGA:M6H59M4R-.I/OZ
M2^C51,F)OYIBHY3;4NVMMO+6%6:J84X;7B(K=VL_LQO<-N]0&)B@IJ!3E#%L
MP6/#W#ZK4R92N2JU,DH11%V5>07;1>W/!9I!IE2RKSDIY%*\^E _(U<9>Y:'
MNH[.%&0-!< SG%4EEDIR.@I%':01RYHCD77+45STX-:-V;53\^'-R<\XXA$@
M5W(2+;KN2O.45YU*4N+K?+7J1FDH[2,4UPF*L.1UQS%H5/L:P6TEUG+#-K7$
MR.]DIB%RHBUX8W\JXFT\XJEEJUO*46I[K^2TY0FO*MKSJ5Y)YM0KJ4O<M$$L
M8X+A.]:LX9G.)L)[/J)^VV1YWE$ ,O21Q2K1'/25K9XQ/;279P2)%"BY"E=5
M3D<4GH;6PR^Y&;7FTMYM;I:LXSG'=X$_:(Q32>)TA?&U^T>FV,6C&M4[QD'"
MZTAK?X98M1)W(UN)2+&DM218L/3V5O5MY:943=6ZVPZEIY5E;CK.8)L>2K-R
M]R^B0PWH[.%&%E6J+=C; LPR=GI4_P .FII]&[&4,0.S$6>ZN!I-"T][ZB,;
M'=0:55294XPDE0G.*2)S+KZVW7V<D_*[U11I[5T2&[@L7PF?W+'4PS1H'A"/
M8Q::2M[8YP8O=&Y(O;4AZ1.A/R,V*^EJY+$15#B%+RFK4OG<^I1M#*4K9]L*
M:DH5Y.6Q8>T1P;@L"I\>HD                         )<9A^2MIQ_P">
M%_6,V"E#\K/UO8)G[E$1Q5)0                            GCP\IA$H
M5FF3NLRE$=B36HQ>]-Y#E)GML84!Z\V5PI24B)6.JE(G,5F)TAIEI5MU;ZV%
MWW4IR6UK2A<)R@DDV\?;)H;&=\Q-/(.VX+W/:'&911 [2ETEID8;%LB:$KC(
MRU+<Z6)[V%$>L+4N]BB\RVEE4]IE+ZW4I3EY:"649;\'@\%@%P,Z'P\IA$H5
MFF3NLRE$=B36HQ>]-Y#E)GML84!Z\V5PI24B)6.JE(G,5F)TAIEI5MU;ZV%W
MW4IR6UK2:X3E!))MX^V(;&=]Q/,\9YHP3+-99U-FF O[3+W>2XWD[XI3D1Y9
MV4]+'@A/V<I4$I>R*KW)8485TEEYJ=9;>1TE]E]M)91E":J16*PVD5@UNF2]
M6L=XNUBR"M=<FYSQ.MFK^R+V)F;V"6)#&)B:*&I'1P<GY[>*,Y:)>X7H2"$I
M)A9=;J5OYE3>6ZI4M64JD<(Q>Z(I)[6C&;!/(.3J#M)&3IG%"I'(,R25T8(^
M9(FBQ[?&P]=CN\AQ:&JY91>Y(3K$1U;#B2[R[J$WUI7[2[DF<9<K!X/#!?Y2
M&*W6<U+BX-NGB[%RELR5"H'F;'C12.2!AG[MVD2OI-Z="2H7(E5"U:I2GO6(
M:*"+TY*CH^RKRCN;?2VM2WJ,GBFX/B([)+IG2Y:UZUX"B6,H6K41#+V3*9$C
M$DR3*(YR.R-HA[;(4+J],*-86H,35,7($5J(M/7^?,*O/--M(H879=%.I4;>
MU1PV>J0ZU>J9NV5A=^=Y$CR!&=K<9LN(%34VICFAXG2MM)9+R":7K^Q&!$88
MC=W99?3IKR5542RAG(1=3^;MY)*<MQ;K@]_U",MNW'8<#M@X0!ZQWK/.X'D.
M*R:)XC5DLZA':ZV%S!W27&PE&0H21_H+#K#T9<3-N66']C5)J:7S;;J7>Q&D
MI*4HR33?VQ+@6!S>?$>.Y?G?#&QC#FO%:N+M4IPX@6,ETH;R7\LI%D).I7N5
MZ8Q12U(@:VU?50LJIZ Q(609TEEM+*U$*>\H.FXO'!^P'ACCB?BNV0QM#-SL
MC+720LT@Q1DJ%QF*N\A87 F0,B56E86VB98>>RFK2UB,B^JE&HM*YUY/9%;J
M\E"[K:E3E*BL%UR8Q6]TC$\?U&QC&9ZAF[[L5B%?A9F>27U,:3*4)\H>$"!0
M6O2L2I$7;VKJ>II0L@XQ.H--,MNK4LBVZZVRD[JR<=U1>^0W5CPK SSA[9G'
M\[VTRA/7>6,$2A)&-$<,ACE,'E!&2W)$U2-N6U,+J^*D5+3G)<J6*RR.2TVP
MB^G/LI?;>*<Z4HTE%+%XDR:<L>@5Y:DOC+&]B<8O<B>&M@94#HZ&+W=Z<$C6
MUHBS(X\D%WJUZXXA(FLO/-MLI6^^VE;KJ4I[-:#T54W3:7"2+A.+V>>&E_S]
ME-Y871N>V=QE"A0WNK0M3.3:N3W)DUM#T:Y&:<E4DUNMK2EUEUUO+3[(C235
M-)\. ?"8'$Y                             );ZZ_P"%6V'YHV_X1IA2
MJ>[AZI%<#(D"J0                 LU<LLL^ONH$ A^)\@QTW*DX>B9'+U
M<0D#&[N\=JM+M=EQ3D6@5.-S:N3)"6]JK:92SI*%'<GLTNH/-N.I6;FNM1/C
MA'9PF$,7;DYL9<BPMRF62I"]Q$B1-MDF;'$Q.<D4,*E1:E=;[B[$UMU34R$^
M\TKDK3D-LMK_ "">5&#B\%M(*3Q)_)I%A2(Y5V8DS/EG%QK/E7&;0Z(^Q)]$
M3"[Y:6EEC<^-2>TIWOO/7JSK2%M;:4YU]ZZM+:5Y!0PFX133Q3XB;9B_4*\-
M(I)'8GL5$GN4OS+&F5,URLM0[R!T0LS608HCCD0GL.7N)Z9(5>>??;992Z^E
M;KZTI3EK4>BNFZ>"VLDCPDC]9LJX]BFX^?W602UA:V";/>228Y)E3HB+C;@8
M?D2CR@J6^5.[6VIG-M*O-3'U-H2=R6VVW5NOLI=3J0DZ,<%M27L$R:WF<QA-
MD@NOD;VFA+[FC$\@5RG%C&K8%C-,&<LIR5FMN7&ZC$F)6+2S5,@)MJE--2D]
M+<78O3^S7I;*W0FY5'&2B]C]H+!8K$Z-"IEB'8;7"*X,R-D%JQ5D#&CC0Z)2
M:1V6%L#HVE]G$)B#EZI0D1D$U;EU$R@F]209:8G)/+Z2REY5)I*=.HYQ6,6%
M@U@^$D)JY#\5XYA>>XG#,@MV3Y;6$F.LSE+ FJ7%$".C7)$[$PLJ^Y0IL=#"
MJ]E*%*@J[HJ]*7;7[:SDMIU7.3BY+!8[ L$FNB89BLOCNQ^O&/\ &*;+K?B/
M,.*+2VEKMD<A51ICEK F2V-J).6X)S2JGU[6DI:<TNU0I(-2&?S%2C*&4G:=
M.HY88P8QQ6'1,=9(B,&P_B1_;)QFY5E/-4A-O0,C! <@/3K%(\VF4*3KC9)=
M<<75451/<==T:HHF\\RXLJTFXNAQM)HMSFG&.$%QH@TDMO"?3O+-(=+677DJ
M*2R-2<UE@2U&\EQY]:WHQI5WI(M;:E<[&U4IN0*;KDYE*6&TLNK6R[V/M:\B
MA%IRQ36T2Z'J"7S2'*>'OBN%II9&E$Q;IXXK'")D/K6;)D*2^69'4V*EC"6J
MN=$R:].N(,I?>5;;6PZR[EY+[:U@HOPARP>&'^1!^XP*^AZ"4
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MF6FDS*>9$2V])C2U??)["EMUS!8AN0'T.JKH50JI)G.Y.9=R0C&6-38]N/\
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MS8ZX/7S9.F?YG6[\;NX\NOOGEF'RA^PAI'YMV?YE>RRR<8@9&
M  'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
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MK&;!2A^5GZWL$S]RB(XJDH
M                                              !+?77_  JVP_-&
MW_"-,*53W</5(K@9$@52                           $S,5["XO+Q,7A
M'/&.'&6Q%L=#'6.2&(*$J*5M!IRI8LO*OJI5MM%EQ![BHZ*^JJRWH3:DWEW6
M4MK2C*G+?WZ;P9,FL,&=AD&R^(H)C*98RUJQY)HQ;D5/<@F$RG*],H?U#88F
M/2&(TB5"YNY%EU$:Y005?0\NQ/8;>9:74XRIEL%3G*2E4:>'$,4E@B"0KDH
M                  !+C13Y5.+/_NW_ %<R\4J_Y)^M[)-'W1$<524
M                               "6^Y_^*L<_-'C#X.$BE1]P_59&7"1
M(%4@                                   2W9_D0S+]HJ._ 8T4G^77
MX)'[GUR) JD                                   "4&E_RG<3?VN[_
M  7?13K?DF1CPD=I!_QY[_M=R^_#A.N!$#B!$
M            $N-M/_89OV2,,_\ Q2"E2^Z_#9-+H>H1'%4E
M
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M8OW4#PBGQC=D/,"V=]YC1UQB_=0/"*?&-V0\P+9WWF-'7&+]U \(I\8W9#S
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MTLN^1TO@HYDU/\X;WY3/X3(%#)RP@
M !O2_17_ )'^P_[29WZKX".:N>O^/VGR/_63-W<V'\)N/E/^9$V@!IDV6
M
M        ! )M^<5D'YC2?OED%?\ V?\ K$GW9/T4"<
M
M       @%LC\J_3W^UY5_MM KT_R4R27ND3]% G
M                               CKMK\F[+_ .2*C[[2"I2_*+U267N3
ME]9?D]X:_-U%_P 6$"%3\H_5(QX#.8D(@
M
M
M    0#X=?^$N1_SYS#X-0@5[CW2_!1)#@]<GX*!.
M
M                  $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\ -Z]^
M33^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
M       \L_BE?.-[M?M*97^%;@.U-%?-++OD=+X*.9-3_.&]^4S^$R!0R<L(
M                                 ;TOT5_Y'^P_[29WZKX".:N>O^/V
MGR/_ %DS=W-A_";CY3_F1-H :9-E@
M                                        0";?G%9!^8TG[Y9!7_V?
M^L2?=D_10)P
M                                   " 6R/RK]/?[7E7^VT"O3_ "4R
M27ND3]% G
M CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_%A A4_*/U2,> SF)"(
M
M
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M<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M        #>E^BO\ R/\ 8?\ :3._5? 1S5SU_P ?M/D?^LF;NYL/X3<?*?\
M,B;0 TR;+
M                     @$V_.*R#\QI/WRR"O\ [/\ UB3[LGZ*!.
M
M                   0"V1^5?I[_:\J_P!MH%>G^2F22]TB?HH$X
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M5(QX#.8D(@
M
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M&CZ'Y1G&79[8PS#+*D:EM-=#A3][)<,9+HIG=!;BY@
M                            0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD
M6+4_S>O?DT_@LZ=P>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ
MR,             /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"CF34_P X;WY3
M/X3(%#)RP@                                !O2_17_D?[#_M)G?JO
M@(YJYZ_X_:?(_P#63-W<V'\)N/E/^9$V@!IDV6
M                                                 ! )M^<5D'YC
M2?OED%?_ &?^L2?=D_10)P
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M=].=R>P#)J>.$L.' [_BV1?1GY9DW',6Q,Q: N>5)+.XC'\:-L=QJT%2!PR
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M)QJ04X/&$EBGQI\!^HE)@
M     "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG
M^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@            !Y9_%*^<
M;W:_:4RO\*W =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
M                   WI?HK_P C_8?]I,[]5\!'-7/7_'[3Y'_K)F[N;#^$
MW'RG_,B;0 TR;+
M                          @$V_.*R#\QI/WRR"O_ +/_ %B3[LGZ*!.
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MRZ7U9I_6>5QSC3ES"YLF]UM8J4)8)N%2$DI0DDT\))8IIK%--Y[%D,C
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MG-]CF<O+['*#%)]>L3@MML$XYSOQ_-18WF?#<)S+BZG#_P H'N#!D_'C%D.
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M584]0&"$2>7DW<Z^E+EB*O)7EOM#HD%LACT66YB)(        $==M?DW9?\
MR14??:05*7Y1>J2R]R:%&8/\4I_^5;U]^FCZO<UG_;C)/^&T/@(^+'/1_P!V
M=1?\7N?[21C@9Z:R
M
M                            V+OH]O\ Z^.T'Y,XM_&DW''O\W/\.R/\
M]=?!H'=?\D'\5U%\GL_AW!L]#B(^A8                $ ^'7_ (2Y'_/G
M,/@U"!7N/=+\%$D.#UR?@H$X
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MZE+J5'-N;[OE.ONX8<K+@X\=OV3J3*83IY90A4V35*./4,A"W%P
M                                    ($\4OYN/=K]FS*WP57C)]%?.
MW+OEE+X2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?Y
ME>RRR<8@9&             'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J
M?YPWORF?PF0*&3EA                                 #>E^BO_ "/]
MA_VDSOU7P$<U<]?\?M/D?^LF;NYL/X3<?*?\R)M #3)LL
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M\NJ9KF,+2"C;0J*G*:E9*,FIN%3#<BW)]:\<,-G"6;^LNXD'\%G+G^8IK\B
MUU]'?-]_S?:_LK_>#;'TJ\Z/_(=[^VQ_=2F'AD8"F^Z6!^-1A-F,LQOD7*[U
M@!S;F]V<#:I627L>3<ZY!(AKZ[)4734:USNP49UZJQ-6M$QQAE":_P#BZ[=Y
MQL\L](9WH_.*W]XL+6%RFXK;*G*C;4N4C%OW2C+E(IOA26/1-%<T^G+_ %WI
MW7F04'X+F=Y4LY14GLA4A7NZRI3DECNN4.3G)1]RV]WH$LM:]T.(UPV\)0S7
M','"TR!/H5BA*ZM"&?XI/>RD-S<I?USL>ZOCS"8;E:$.[@8H7J+KE%JMN[-Y
MUAE]:7\^\S%M0Z0T!S@YQ6U!E6I:%"\NG&3I5E''%14=V,:E2C4BL$MF[+=V
MI;,$LRTKKOG0YK,@H:7SO2%S<V%FI15:W<\-US<G*<J5*XI2EBWUV]#>V-[<
M6_IUQV8X8FS6=MA\L0G$&3-<-Y9?B+.QJZ.RU^<DL1G3@;BN0I)VW,[8R/=\
M752&U"U'.;@F<&IL5'+23%EEIQ]IUULNH-.\X^G,EL,KO+NWS#1=*[ML)PBG
M.FN6BZ;DY1WU'&2A%QG.*BU!X1:QFTOJOFFU7J',\YL+*[ROG!KV5VW"I.2I
MU9.WFJT8QA/DW/"+J3C.G3DYIS6])2:@SK?_ .TW^_O[6\-^%.E S34'_P#,
M#D?_  JI\#,#7^EO_P"5S4G_ !JE_:96;0'"6^;?U!_-(W?C5V'.'.C_ -P<
MU^5/X,3K3F9_[79)\B7PI%B0P$V<                         0"V1^5?
MI[_:\J_VV@5Z?Y*9)+W2)^B@3@                               8_R
MMCU+EC'$RQHNDTOA[=.&%;&W.10%U3,4P0-3G91.Z6,+VJ;G2UG6+F^XQ/V4
M63V218==>082?:6;8(IX/$YJ%0V,8YAL2Q["&9+'89!(RPPV(Q]!TO8+%&(P
MU)&1@9D?3F'']BM;4A*(+Y]]UW,LIRUK7V0(<.T[,                (Z[
M:_)NR_\ DBH^^T@J4ORB]4EE[DT*,P?XI3_\JWK[]-'U>YK/^W&2?\-H? 1\
M6.>C_NSJ+_B]S_:2,<#/360
M
M                                  &Q=]'M_P#7QV@_)G%OXTFXX]_F
MY_AV1_GKKX- [K_D@_BNHOD]G\.X-GH<1'T+                 @'PZ_\
M"7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M            @OQ#7]=%=?*R-(2882TS:.G.9Q=M:]AH%*5X0=DF7TMKT179
MJLDNMWL4^WY*UY*C9O-+;4[S5G@DVE.I;5%%<<DX2PZ>Q-^L:FYZ+ZIEFC'?
MP6-.G=4W-\46IQQ?$MYQ7KFLUF3/K6ZM*U&XF(5R%189:>@6T3K4A]*TY.:<
MD46&D&?_ )UM1V7D&E:T*L7",E)=%;/LG 6LN<?+Z-K-U:D'L>S%/$J+ELE0
ML[VJ=8>27%[[C;C;;&,R]O3\[G5KSJHT]UB6G+7^2EE*#=UK8PA9JWNDJB2^
MZVG)]7.\PS3.)WUK*5*#ELW=CZO"=;5[Y[#8Z)N(C<S14Z*E:6&.#&TN)MO)
M2M:5YYZ?[;DK3^7E&'9YIS(*K<I44I=)R7^4WUHC/]3THQC*ZJ3@_?*+^SNX
M_9+$>&[IWNWQ;<H1'*.V,ZG2/27&,I:Y&L8G%#=%XKFET9UE%Z2(QMA:D[.A
MDC,4O;R;7)P444D)RKJEE5N.K6EO,_.;JS3^CK:IEF20IRS^M!QV/>=%/9O3
M>UJ6#>['8V]KV';_ #4::SW44X9KFKG#**;3Q:PY5K[F'!C'WTELZ'#B;Z=M
MMMEMMEEM+;;:4MMMMI2VVVVVG)2VVE.2E*4I3V*#D(ZM/]
M                                $">*7\W'NU^S9E;X*KQD^BOG;EWR
MRE\)%BU/\WKWY-/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO99
M9.,0,C             #RS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\X;
MWY3/X3(%#)RP@                                !O2_17_ )'^P_[2
M9WZKX".:N>O^/VGR/_63-W<V'\)N/E/^9$V@!IDV6
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MIYO\_P!>YYX7Z;Y/#*>2Y+D=VHJG*[W*<ICA.6&YNT^+'?Z.!/L8.;'
M                  " 6R/RK]/?[7E7^VT"O3_)3))>Z1/T4"<
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M&>FL@
M
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M17S2R[Y'2^"CF34_SAO?E,_A,@4,G+"
M    &]+]%?\ D?[#_M)G?JO@(YJYZ_X_:?(_]9,W=S8?PFX^4_YD3: &F398
M
M           $ FWYQ60?F-)^^605_P#9_P"L2?=D_10)P
M
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M9G<YE?V]Y&_IT(Q5*$X[O)2J-M[_  X[ZPPXF6RC09TL
M! /AU_X2Y'_/G,/@U"!7N/=+\%$D.#UR?@H$X
M             $?\T;4Z[:ZN\$8,WY?A6,WG)KI<S0)NE3K8WJ9.Y6*4*.],
MW65LOYU;53D196Z_FV4N,I3E%_R;2VH=0T:]QDEG7N:-M'>JNG'%0C@WB_63
M?K'CNLPLK*4(752%.51X13>&+Z75) "P'L   ##&:]A\)ZY,K!(\XY(C6-&.
M4R5##H\YR97<D2NLG<BSCD#*DOL*-K>M5%I[[K;>2E.2VOLB\Y+I[.M15JEO
MDEM5N:]*DZDU!8N,(\,GTEBCS75Y:V45.ZG&$)2W4WT6^@?K'=@<,2S+DUP-
M',BQQWS#CEJ;GN<8_1JKC)#&FEVL3&-JYS2U+I:40LL6%5LK2ZO+2^@EN,@S
MFTRFCGMS;U(91<3<:=5KK)RCCBHOC6#Z@A>6M2YG:0G%W,$G*/12?!B9B%H/
M20VS9Q"=*]<)R?C7.6QV-<93Q,VH'<^+RAV-1NA;8Z67F-ZRXFU,;2A*NPNZ
MME>7V:4&8Y+S?ZTU'8K,LCRZYNK%R<5.$<8[T>%8X\*+9=9SE=E5Y"[KPIUL
M,<&]N#X#O6"-OM8=GDKXKU_SECK*]D9M*,D!$0D*5P7,Y1]MUY)Z]NK4I>G3
M&TLK2TVI?1UNI6E+N6E:#P9[I'4VF9PAG]C<6CJ^XY2#2EAT$^!OI8XE:TS*
MPOTW9U85-WAW7CAZW"=PPSGW#>PS$]R?"F0X[D=@CDF<X:^.L;57*TC9*&:A
M-SHR*K[RRJV+D5%%E;[>2O)SJ>R/)G&0YQI^O"VSJWJ6U>I2C4C&:P<H2QW9
M+I/!X%2VO+:\@ZEK.,X1DXMKH-<*,OBT'I     ,)Y]S[ ]<8(DG<][<+BWJ
M:0;&T/BL61)G6:3W(F290VQ"%PF&,JI<VEN[^\O#G;7F5/**3I"CU)UY:<@X
MRP12Q(^; \0[!^!,GEX*11?-VP>>K(\EF#UA75_$TAS//(;$%U_,02;(%K-V
M)&8 V.=:TJCM>')$I6VW67)RC:&%UN8D5%M8\".'B7$XU8EN%-A\TT<\@13S
M3F%PD&QF(<@XXDL#SWB9(A95$@)LD^*9.F;GZVUY:4AIK<I(J>WN'1&6D*+[
MBC;;&(W7BEQDY(?*6F<Q*+39AO/,8IA'&24LIBHFY,IO:9 V)79NO4)[JUN3
MGW(U=E;[*UK6R[EI_(!+P'0<7YNB66Y#F",QILF*!?A/(Q^,)8=*(JYQUN<I
M G8F>0WK8>N7V6DRF.51/9-EJ]-RD5/M,+Y>=9<!%K S"!       # NPNR&
M,M88K$)CE14\)&6<97QMAAAO9&@UY4&3?*\D312(D*4Y)A=R9N.=U=E#U%:U
MM(+Y;JTK2@$4F^ ST! PU'LZP>19OR1KU91X:,F8UB4&R"K;'Q$0B22J 9 O
M>4#/-80J+6J+GY@026-N+,X7UL(.0N:.I9A="SDQIXCALQZ!F4"
M      ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^33^"SIW!Z^;)T
MS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P             \L_BE?
M.-[M?M*97^%;@.U-%?-++OD=+X*.9-3_ #AO?E,_A,@4,G+"
M                     &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_ -9,W=S8
M?PFX^4_YD3: &F398
M                            $ FWYQ60?F-)^^605_\ 9_ZQ)]V3]% G
M
M                         (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10)P
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MQ=TEZML7RA>R19M(:V]4_K69H8&E4ZG)R*5.O3HDI-U]:UM*LI[ $&\7BS-
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MW)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M     @'PZ_\ "7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
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M. V$1$I@              $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\
M-Z]^33^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
M           \L_BE?.-[M?M*97^%;@.U-%?-++OD=+X*.9-3_.&]^4S^$R!0
MR<L(                                 ;TOT5_Y'^P_[29WZKX".:N>
MO^/VGR/_ %DS=W-A_";CY3_F1-H :9-E@
M                                            0";?G%9!^8TG[Y9!
M7_V?^L2?=D_10)P
M                                       " 6R/RK]/?[7E7^VT"O3_
M "4R27ND3]% G
M     CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_%A A4_*/U2,> S
MF)"(
M
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M!0PWL$VDVMN.+D\$CTPRG/,ROJ%QG<J,;>V>]&-/%[TET7CP8_T1L2CGHS,
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MOR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&
M        'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3E
MA                                 #>E^BO_(_V'_:3._5? 1S5SU_Q
M^T^1_P"LF;NYL/X3<?*?\R)M #3)LL
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MJMG.%N&.<P.^%LCP1U/1*G**2R21-V9%JAM4V+$!RA"H<KBC#$BHNTRRM?\
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M7[2F5_A6X#M317S2R[Y'2^"CF34_SAO?E,_A,@4,G+"
M                &]+]%?\ D?[#_M)G?JO@(YJYZ_X_:?(_]9,W=S8?PFX^
M4_YD3: &F398
M                       %8<VQ=!<N[Z/L5R&Q^Z%@+P\@=K$';-X:>1P1
MF-I*=1V4QN#:MKT9:LRG,J9S*\[V:5K2G)Z8RE"AC'AQ*;6,]I(7S%-5O%9_
M??(W?>*?+U>/[")MV(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J
M\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35
M;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWA
MR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F
M*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N
M^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V
M(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WW
MR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^P
MANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S
M^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\
M?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;
MQ6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR
M]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*
M:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^
M\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(
M\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR
M-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PA
MNQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^
M^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?
MV$-V(\Q35;Q6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q
M6?WWR-WWAR]7C^PANQ'F*:K>*S^^^1N^\.7J\?V$-V(\Q35;Q6?WWR-WWAR]
M7C^PANQ(@YMUEPA$-@];H/'83VOB\^<9 1+6OW22Y7VV*17-M$MG9JY_4N*#
MHJ*+_93'$UNY?9Y>2@K0JS=.4F]J)6DI)$OO,4U6\5G]]\C=]XH\O5X_L(FW
M8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_?
M?(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/[
M"&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK
M/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>K
MQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5
MO%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'
M+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8
MIJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[
M[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8
MCS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??
M(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["
M&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/
M[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$POL1J!KK!<)9'ET5QYV
MKD+#'3E[2X>ZV<KNQ%=BA/9:;V(XR98A/Y+3*TYII5]OL_8$].M4E-)O9CTB
M$HI(Y'!>G.N$QPYC.523'/;%_D,,879W7^Z^=H^RW!:@*.4J.Q4$H2HD_2&7
M5KS"B[++?Y*4H$ZU13:3V8](**:,K^8IJMXK/[[Y&[[Q)R]7C^PB.[$>8IJM
MXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY
M>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%
M-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?
M>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$
M>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y
M&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80
MW8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_
M??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/
M["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMX
MK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>
MKQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-
M5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>
M'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>
M8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&
M[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W
M8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_?
M?(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/[
M"&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK
M/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>K
MQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5
MO%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'
M+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8
MIJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[
M[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8
MCS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??
M(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["
M&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/
M[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ
M_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O
M%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+
MU>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8I
MJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[
MPY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8C
MS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(
MW?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&
M[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[
M[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_
M80W8D0=,-9<(98QW-GW($)[?NK1E:21IN5>Z27-78[*@8XLL2(N@97]M3&]$
MI<CKNDOLN-NY_)==6E+:4K5JLXR2B]F!+&*:VDOO,4U6\5G]]\C=]XH\O5X_
ML(FW8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O
M%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+
MU>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8I
MJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[
MPY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8C
MS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(
MW?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&
M[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[
M[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_
M80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%
M9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U
M>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJ
MMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[P
MY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS
M%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W
M?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[
M$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[
MY&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_8
M0W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9
M_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>
M/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJM
MXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY
M>KQ_80W8CS%-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%
M-5O%9_??(W?>'+U>/["&[$>8IJMXK/[[Y&[[PY>KQ_80W8CS%-5O%9_??(W?
M>'+U>/["&[$A+Q)=.=<(;H)N!*HWCGM<_P >U]R8[-"_W7SM9V(X(HTM.3*.
MQ5\H5(E'1F6TKS#2[[*_RTK09/HRM4>K,N3>SPREQ>^18]3Q2T]>_)I_!9FK
M@]?-DZ9_F=;OQN[B?7WSRS#Y0_812TC\V[/\RO999.,0,C             #
MRS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\X;WY3/X3(%#)RP@
M                         !O2_17_ )'^P_[29WZKX".:N>O^/VGR/_63
M-W<V'\)N/E/^9$V@!IDV6
M                                ! )M^<5D'YC2?OED%?\ V?\ K$GW
M9/T4"<
M                               @%LC\J_3W^UY5_MM KT_R4R27ND3]
M% G                                                    CKMK\
MF[+_ .2*C[[2"I2_*+U267N3E]9?D]X:_-U%_P 6$"%3\H_5(QX#.8D(@
M
M
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M+37=Q'++ZW5IFDH.4<)[U.;6&,8XX24L-J3QQP>TV!1I(WB
M                                   $">*7\W'NU^S9E;X*KQD^BOG;
MEWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\ ,ZW?C=W'HU]\\LP^4/V$4=(_-NS_
M #*]EEDXQ R,             /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"CF
M34_SAO?E,_A,@4,G+"                                 &]+]%?^1_
ML/\ M)G?JO@(YJYZ_P"/VGR/_63-W<V'\)N/E/\ F1-H :9-E@
M
M 0";?G%9!^8TG[Y9!7_V?^L2?=D_10)P
M                                                        " 6R
M/RK]/?[7E7^VT"O3_)3))>Z1/T4"<          QB?FG$J;,"/7Y1D6($YN<
M(%=E)#BHQ[16SE7CFQZ51R^;$1VIO; R-6OR$Y'572SHNR"KK.7G4K0".#PQ
MZ S!FG$NOT#<\H9OR+$,58Z95+8C=IK.GM%'8VW*GE>G:VI.L=7 TE*0:X.2
MHL@FVZZE;S;[;:>S4 DV\%PF*,[[O:@:OR)GB.Q.R6',+2>0,M)&R,.1YTQQ
M5T=6&Y<K;*.Z%&Z*DYRAOJX(#B>EMI6WI"KK>7EI4 HR? CXL)[XZ5[(2>^$
M8%VKP%EJ:V)#U]L-@N4X>_RP] D*O/6+T<;1NM[RN0H2;*W'G$D&%D6\E3+K
M>6G*#C)<*9F#$.;L0Y^BJB;X4R/$,H1%(_.T75R&%O2-]:TDD83"RGIA5J41
MAEJ9W:C3K+5">_FFE5NISJ4Y0#37"?H\YIQ+'<I0W"#YD6(->8,A,KY)(1C1
M8^(BII)X]&B3SWY\:8_4WMBI:&HM,9TRBEG16ULNMYW.I6@#!X8] R<! ZDS
M3^"2.43*#QZ:Q)]FN.3& K(4/9I(S.DH@ALK:NWL6+F4?1+#W:,&25D_Z8WT
M7$D56)?YTGGE_; ,#%N<]K=9=8TS,JV)S_A_"14C-O)C]N3\A1>&*7V\JZEI
M]6=&^N2-6Y%):UITQA-E]A-/9OK;0"*3? C+4.F</R'%V.;P"5QJ<PN3MY+M
M&Y?#GUKDT7D+6HY:IW)C?V54M:79O/I2O,.3FF%W<GL5J! Q#GS;#6C5E)&E
M^Q^=,8X113)2YHXHJR5+FF*$2%4RE(CG9.TF.JA/:M-;BG)/<=;9RULH=96O
M_.H!%)O@1'UGXK_#2D#NUL#'O/K$ZO3VXH6AG:T.7(DH7.3HY*2D3>@1IRW"
MXP]4L5G6%EV6TK==?=2E/9J!'<GQ,D-G/:W676-,S*MB<_X?PD5(S;R8_;D_
M(47ABE]O*NI:?5G1OKDC5N126M:=,839?833V;ZVT @DWP(RU#IG#\AQ=CF\
M E<:G,+D[>2[1N7PY]:Y-%Y"UJ.6J=R8W]E5+6EV;SZ4KS#DYIA=W)[%:@0.
MR@"&^8.(;HQK]/'/%^;]L<#XJR*RIFQ8[0J=9&CL=DC<E>4"=U:E"QJ<5I*H
M@IP;519Y-UUM*7E7VW4]BH$RC)[4G@?SB?B(:*YVE)L(PWMM@+)4M(8WB3*(
M]$,EQEY<T\=CR7LU]?%"9*OON(:F='_.J3[^0LDNG.NK2GL@'&2VM,['Y]&D
MOIB:L?Y@\2]]PABANRXF9]A,ZA&2HPV3;',QBL_AKUV;VFEL)D+1*HP[=KG!
M6TN':Q^8EB]J7]@.J ],=T1M_1*"3"[N2^RZE(DN&'"<'BO+F-<WQ&R?8EF+
M//H4<^2B.)93'C3%;&N>(7(G.)2A*W.%Q1:=R+9I*S*T1IQ%3"*J$YEMM]W-
MJ ::X3(P       ".NVOR;LO_DBH^^T@J4ORB]4EE[DY?67Y/>&OS=1?\6$"
M%3\H_5(QX#.8D(@
M
M                                              0#X=?^$N1_SYS#
MX-0@5[CW2_!1)#@]<GX*!.
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MUI6E1\YY1E"3A--33P:>QIKH,^D$)QJ14X-.#6*:VII\#3XC]1*3
M                                       0)XI?S<>[7[-F5O@JO&3Z
M*^=N7?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;
ML_S*]EEDXQ R,             /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"C
MF34_SAO?E,_A,@4,G+"                                 &]+]%?\
MD?[#_M)G?JO@(YJYZ_X_:?(_]9,W=S8?PFX^4_YD3: &F398           $
M*]XM[L0</[&\:RQF^.Y-=H1)9<3""W7'$::I+5G?U;6X.[:2_$N4CC]R%,Z)
M&E30@ZVIME32:V75MNN+I?D6F],W^J;N=CELZ,;F%/?PJ2<<8II/=PC+'!M8
MK9L>/&6;.L\M,AMXW5[&HZ$I[N,$G@\&UCBUAC@\!H[OS@#B#8WDN3< K)11
MJB$N.A<D9)NS)(_*&IUM:V]X2J3VQ&ZO*>]I=$+C2J918?=8;>2=9[%Y5]M&
MI-+YII6[A9YHH;]2GOQ<&Y1:Q:>UI;4UM6'13Z*&2Y[89_;RN;!RW(3W6I+"
M2>"?!B]C3V/'CXB:@QTO)6)O1Q;M2^'O.8;C?.IF17.836*G31"T8ZC#5(S6
MN.VNJEE1+WRYSDL>M1T=W%O5V);;.FK?V&;6[F4I;S\RTUH7/=56U2[RSD8V
M].>XW4DXXRPQ:CA&6.":QX.%&-9WJO*L@KPM[[E'6G'>2A%/!8X8O%KA:>'J
M,FO@O-\6S[A& 9]CC5)HG"<CQ)-.6%+D% @CS^FBJ^PU4U/+PB2NKLA;TCJT
M6%KR+NRKZ=AGEWW\RZMUMN.YGEM?*\QJY76E"=S1J;DG!N4=Y;&DVDVT^M>S
MA3+S8WM*_LJ=_34H4:D-Y;Z2>Z^!M8M+%;5MX&5';)?2'^'?@"0+XC')%.=B
M9"VJ.Q%QV#61E>8:C56W7]+96=RB11:.O2<NRRG\^S&.I-U]]MM+O8,J7G>4
M<U&J\TI*O5A2M*36*Y9M3:_ C&4EZD]U_8QQ3,><#3]A4=*G*=Q47#R:3CV4
MG%/U8[Q$>+_2H]4UKD61,=;\_P =:KZVVWN+ MQY*U97.K6E;[VU=(XG9<79
M[%:\U1==R<O);6M*4K?:W,GGD88V]W:SGQ252*ZJC+V"TTN<_*Y2PK6]>,>-
M.$OL-Q]DO'U#WZU2WFCBY^UPRJUS!:QITA\JA;@E6QR?Q&BSDM*N?XB]$)'0
MM#<HK4FQ>FM4MAYUEUA*DRMM1K?/M+YYIJLJ6;T)4XR;W9IJ4)8>]DL5CT=U
MX22X4C-LISW*\[INIEU53E'W47BI1]6+VX=-8I]!LXK>'?'%.@,#C>3LU0S+
MCY I$_W1@V3XRBC/*6^,O9B?LIK1RJCA*(^H:K'XLHZU&=2PTB\U/<7??89<
M3:;/IO3%]JFZG99=4H1NH1WMVI)Q<EP-QPC+'=V8K8\'C@UCA)G6>6N0T(W-
M["K*A*6&]"*DD^AO8R6&/0?!LPX<,>OZ*<2C6+B'LTY<L .\G)<\<N+<CE40
MGK,BCDM1H7E.8<T2$AM0O#XF5Q]Q/3*$]AY9];K%":^PRRSE*J95U-I#.=*5
M*4,TC!PK)N,H-RBVN&.+4<)+8\,.!K#';A)DFH\MU!"<K!RWJ;6]&22E@^!X
M)O8]JQQX5ZA-"=SF(8QA<JR)/Y"VQ.$0A@=)1*Y*\'T3-C&P,J,U>YN2TWDN
MNH2E2D775I;2Z^^M*6VVW75I2N/6UM7O+B%I:P<[FI)1C%<+DW@DO59>*]>C
M;497%>2A1A%RDWP)+:V5':Q\<_47;[-,5P+@K'^RDHG4K.4WEWG8WBZ%@861
MN+Z=XE<H=S,AWV,D:9TOVYQ]]E3+[[BR"2S5)Q)!F=YSS:Y]D.73S/,ZMG"V
MA_\ $DY2;X(Q7)[9-\"]5MJ*;6*9;K;*<VO(V-C3N95Y?>1227#*3W]B7'ZR
MQ;2+G!KTS  #\5*E.C3GJU9Y*5(E)-4JE2DVPA.F3D67&G'GG&W6EDDDEVUN
MNNNK2VVVE:UKR"*3DU&*QDR#:2Q>Q(JNR]QMN&)A9]6Q>2[2QF12%N47)E:'
M&4;F^4D)1I=_1J+*RB"1I]AU34M_VIA=''I;;J5IS:UMNI3-K#FYUEF-)5J-
ME.%)K8ZDH4WV,Y1GM_!P,8N]9Z:LYNE4NHRJ+H04I_\ BBG'[)V+!7&-X;FQ
M4D:87CK9^)IIB^*+4;7&\@,DQQ<K7N!M]2TK6WN.0X[&X^Z.BZ^MMJ=,D6'G
M'F7VEV6W&5Y@HYGH#5V4T97%W95';Q6+E!PJ)+HMJG*4DET6TDN%["I8ZNT[
MF%14;>Y@JTN!24H8OB3FDFWT$F\2S48<9(=1G\[BF+H+,LE3MX31Z%0"+OTR
MEKZLK6B5HCD:;%+P\N)W-I6^ZQ(WHS+^;;2MUW)R6TK6M*"O:VU>]N:=G;1<
M[BK.,(Q7"Y2:27KME*O7I6M"=S7:C1IQ<I/B26+?4(NZ=;_ZP[XML\=M:9F[
MS!#C9<P-TM,=H=*(C<@528AU4L]A!<F:VR]=:H)95%;KB:7T+YE*7<G.IRWK
M/]+9SIF=*&<4XTY5E)QPG&6*CAC[EO#A7"6S*,^RW/(SGETW.--I2QC*.&..
M'"ECP,F"ZNK6Q-C@]/CD@9F9I1J7%U=G58G;FQL;T95ZA6N<%ZLPE*C1I2"[
MKS#3+[;+++:UNK2E.46"$)U9JG33E4D\$DL6V^!)+:V^(NTIQA%SFTH)8MO8
MDN-LJ:R1QU^%KC-Z4QYPV@:I6ZHSJ$J?!O",C9!9;;:T,_GTTNC$37PUS)YQ
M?-Y4C@HN^VI7DYM>49S:<VFM;RFJL+*4(-;.4G3@^QE)37KQ1BMSK?3%M/DY
M7*G)>\C.:[)1<7ZS9*K6'B#Z9[DG+$&N&?H9D1^;TER];$:V/42G)#>7=0L]
MRI!IPTQJ6J&M*;=;8:K*1F)B[K[*7&4Y]G.LF<Z5U#I]*6;VM2E2;P4MDH8\
M6_!RCB^@F\>EL+IEN?Y/G#<<NKPJ32Q<=L98<>[)*6'3PP)E#'R\$5-E=X=2
M]/D2-9LCG:#8N/<DAB]K8'-4M>)F[H"3.A.7LT#BZ)\FCNA*.^TN.3(#2Z&?
M:UNYWL"]Y/IO/<_DXY1;5:R3P<DDH)\3G)J"?2<D6O,<ZRK*(IYC7A2;6*3V
MR:XU&*<FO41".(<>SA6S%_MCJ;9JQA4'J;4J%RE^,<M1A@6W7&&64.N?G6#D
MM;0FYME+JF.)B*VEMU.7DKSJ4R.OS8:VMZ7*NSWDEBU&I2E)?U5/%_U<2RT=
M=:7K5.35SNO'8Y0G%/UW'!>O@6UQJ3QN:1]GED.D+'+(M(4"=U8)+&G9 ^Q]
M\:UA=#4CDSO+6H5-SF@5%5I<6<29>7?;7EMK6@P6M1K6]65"XA*%>#PE&2<9
M)KA33P::XF973JTZU-5:,HSI26*::::XTUL:.<%,G             " 3;\X
MK(/S&D_?+(*_^S_UB3[LGZ*!.
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M +$P^J'_ -0_X#_?!]>3_I?_ -R_W ?6'/\ N@_I_P#^Q,/JA_\ 4/\ @/\
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M /L3#ZH?_4/^ _WP?7D_Z7_]R_W ?6'/^Z#^G_\ [$P^J'_U#_@/]\'UY/\
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M7_\ <O\ <!]8<_[H/Z?_ /L3#ZH?_4/^ _WP?7D_Z7_]R_W ?6'/^Z#^G_\
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M +$P^J'_ -0_X#_?!]>3_I?_ -R_W ?6'/\ N@_I_P#^Q,/JA_\ 4/\ @/\
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M /L3#ZH?_4/^ _WP?7D_Z7_]R_W ?6'/^Z#^G_\ [$P^J'_U#_@/]\'UY/\
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M6SY??\+\(WOQD*>[N^#4=WW>.]O/@PPVXJV(:$.E0
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MW/+I8*+D\72?0P^\;X5T.%<1;B-!'18
M                 $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/
MX+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C
M    #RS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\ .&]^4S^$R!0R<L(
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M)QW7[UM/8EAB'-YG%S:9G+(+EOD9[V[%_<5(8N27$I)2Q7ODFN%X[PHYO-U
M            ! )M^<5D'YC2?OED%?\ V?\ K$GW9/T4"<
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MT>MQ-;<V7.38\YN4W&;6-M5M:=O<<BXU)1DV]R,\4X[,,)8>L6"#!39(
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MRZE.I.I+<Y*2A.E!J.$G/%NM%K&*V)]+&P08*;)
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M+'/1_P!V=1?\7N?[21C@9Z:R
M                                                         "^3
M@!?*2S+^8\WX>P\<K_S8_,S+?^*+^PK'9G\E'S]S7_A#_P#44#;$'!!]*@
M                                                    " ?#K_PE
MR/\ GSF'P:A KW'NE^"B2'!ZY/P4"<
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M:TN^S2M:5Y1S-FE.-+,:U."PBJCP7KXG564U)U<LH5*FV;I1QZAVP> N
M                                         ! GBE_-Q[M?LV96^"J\
M9/HKYVY=\LI?"18M3_-Z]^33^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(
M_-NS_,KV663C$#(P             \L_BE?.-[M?M*97^%;@.U-%?-++OD=+
MX*.9-3_.&]^4S^$R!0R<L(                                 ;TOT5
M_P"1_L/^TF=^J^ CFKGK_C]I\C_UDS=W-A_";CY3_F1-H :9-E@
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M]#<<IF_P             @$V_.*R#\QI/WRR"O\ [/\ UB3[LGZ*!.
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MKC_L3D'RJC_8W9DO-Q__ #*ZG^15_P"WLC: '-YUJ
M         $ MD?E7Z>_VO*O]MH%>G^2F22]TB?HH$X
M             '1,G8WBF8,?RS%\Z3NJR%SEG4QV5-S-(Y#$USM'U_-+=6:K
M_%'-FD"%"\HN>E5T3*B;SDIQA5;N;?=2H)X;3M#(RL\;9FB.QYK;V-@8&Q R
ML;*TI"&]K9V=J2E(6QK;4"6PI,B;V]$184227;:66792VVE*4I0 <F
M          (Z[:_)NR_^2*C[[2"I2_*+U267N30HS!_BE/\ \JWK[]-'U>YK
M/^W&2?\ #:'P$?%CGH_[LZB_XO<_VDC' STUD
M
M          %\G "^4EF7\QYOP]AXY7_FQ^9F6_\ %%_85CLS^2CY^YK_ ,(?
M_J*!MB#@@^E0
M      ! /AU_X2Y'_/G,/@U"!7N/=+\%$D.#UR?@H$X
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MEV.\WZFSU372W!Q)OEGR$3'B@;1PMV88ME7*<5A34N?6QPC!K@2^1J0K8Y?
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MVF             $ FWYQ60?F-)^^605_P#9_P"L2?=D_10)P
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M*^U<9V\Q;#<VG-\AT+UNS7DW+6*[5DNC#H?(.VBIC71M(?%D:F]^2&2YPAK
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M]I(QP,]-9
M                                          !?)P OE)9E_,>;\/8>
M.5_YL?F9EO\ Q1?V%8[,_DH^?N:_\(?_ *B@;8@X(/I4
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M_!,XH)8UHN,G[Y8*4'ZN#:]3!= U,1O(U4             &]+]%?^1_L/\
MM)G?JO@(YJYZ_P"/VGR/_63-W<V'\)N/E/\ F1-H :9-E@
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M,7U4D9>'@/6               0";?G%9!^8TG[Y9!7_ -G_ *Q)]V3]% G
M
M                        (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10)P
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M7GN][*/:CZ ^9S_E[+^QEVX]6SHIZ,F-?ZDX]T@^F;G2\]WO91[4?0'S.?\
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MO13]5$A1B)G
M      ! /AU_X2Y'_/G,/@U"!7N/=+\%$D.#UR?@H$X
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M_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M                                                       (!-OS
MBL@_,:3]\L@K_P"S_P!8D^[)^B@3@
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M9?\ R14??:05*7Y1>J2R]R<OK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M                         (!\.O\ PER/^?.8?!J$"O<>Z7X*)(<'KD_!
M0)P                                    -,OC7["[*Y^V^G&/=.I[)
MF%FX;."EF?,RJHL^/36D6S"V916BJ..1+6N2D/"UK:E*0ZB8REUM2"E=*_\
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M4R5*1^DDA?#I? 8X0],JM0H4'4O7R9;T:="7?T%D"9I822X$_M%_PB4P
M          "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U
M\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@            !Y9
M_%*^<;W:_:4RO\*W =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
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M (_:?(_]9,W=S8?PFX^4_P"9$V@!IDV6
M                                           ! )M^<5D'YC2?OED%
M?_9_ZQ)]V3]% G
M                                       (!;(_*OT]_M>5?[;0*]/\
ME,DE[I$_10)P
M   (Z[:_)NR_^2*C[[2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB
M0B
M
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M*_\ (_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M
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MO1'G:ZW>-^(_UA7^"!R53B8WHCSM=;O&_$?ZPK_! Y*IQ,;T1YVNMWC?B/\
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MO1'G:ZW>-^(_UA7^"!R53B8WHCSM=;O&_$?ZPK_! Y*IQ,;T1YVNMWC?B/\
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MO1'G:ZW>-^(_UA7^"!R53B8WHCSM=;O&_$?ZPK_! Y*IQ,;T1YVNMWC?B/\
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MW4IRTI4.2J<3([R7 SL?G:ZW>-^(_P!85_@@<E4XF0WHCSM=;O&_$?ZPK_!
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MYZ_X_:?(_P#63-W<V'\)N/E/^9$V@!IDV6
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M;+KWXFL==5VS[@'*5.-C=0\V77OQ-8ZZKMGW .4J<;&ZAYLNO?B:QUU7;/N
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M-EU[\36.NJ[9]P#E*G&QNH>;+KWXFL==5VS[@'*5.-C=0\V77OQ-8ZZKMGW
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M-EU[\36.NJ[9]P#E*G&QNH>;+KWXFL==5VS[@'*5.-C=0\V77OQ-8ZZKMGW
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MN4L-B6.W'!&*Z_S'*;K+;2URNM2J1I3:W824MV*BDNBWAT-IJ;#>1JL
M        -Z7Z*_\ (_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -
M,FRP
M               (!-OSBL@_,:3]\L@K_P"S_P!8D^[)^B@3@
M
M             $ MD?E7Z>_VO*O]MH%>G^2F22]TB?HH$X
M                                     $==M?DW9?\ R14??:05*7Y1
M>J2R]R<OK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M         (!\.O\ PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
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M^1'I#])@=F1>76<:K(5;3SZ=D713(:A,X6%<OVU2;'AB4)C#*4^Q2ZZRE?\
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M CFKGK_C]I\C_P!9,W=S8?PFX^4_YD3: &F398
M                                                 $ FWYQ60?F-
M)^^605_]G_K$GW9/T4"<
M                                             @%LC\J_3W^UY5_M
MM KT_P E,DE[I$_10)P
M          (Z[:_)NR_^2*C[[2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]
M4C'@,YB0B
M
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MJ#:F[B$7A[UM*2?2:X3U(!\[#Z-@
M               ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_ #>O?DT_
M@LZ=P>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,
M    /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"CF34_SAO?E,_A,@4,G+"
M        !MP_11/\0=T_R-PE^.\DC1//A^JY=^<K>Q3-K\UOZQ>?@4_9F3U]
M5;]'M\86'?\ .Z;Y4QC'IMSJ_%7'['_^*+[Z+Z!^,H_M/_Z8]5;]'M\86'?\
M[IOE3#TVYU?BKC]C_P#Q0]%] _&4?VG_ /3*4>-9J#PU=;,7X3>]&)+"'V5R
M6>R%JG144SY?F!01'DD>+5MIBMMNE\D[3DW.5:TM/YA727?:\ZOV!L7F[S[6
M&;WMS3U+"K&A"E%PWJ')=<Y8/![D<=G0,,UEE&G,NMJ,\DE"5651J6[5Y39A
MLV;SPV]$UUQM@U\             &]+]%?\ D?[#_M)G?JO@(YJYZ_X_:?(_
M]9,W=S8?PFX^4_YD3: &F398
M                                   $ FWYQ60?F-)^^605_P#9_P"L
M2?=D_10)P
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MK95I&ZJU[VA0Y6:E0JTDH;T88XU(13ZZ26">/1)CC71M0
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MHPC*DX;R7"O6?"NDU@8-S>ZISB\S2-&5>I;YEO[F\MC4D\-V:X&L=C33PZ?
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MW3_(W"7X[R2-$\^'ZKEWYRM[%,VOS6_K%Y^!3]F9J/#>QJ@
M     -Z7Z*_\C_8?]I,[]5\!'-7/7_'[3Y'_ *R9N[FP_A-Q\I_S(FT -,FR
MP
M            (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
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MJ=2/N91XUP;-AW,>,]X                             ! +9'Y5^GO\
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M/]I(QP,]-9
M                                           !?)P OE)9E_,>;\/8
M>.5_YL?F9EO_ !1?V%8[,_DH^?N:_P#"'_ZB@;8@X(/I4
M                                        0#X=?^$N1_SYS#X-0@5[
MCW2_!1)#@]<GX*!.                                        :]_T
M@'AN/&X^!V7.>)F4QYSKKLB<%"5@1677N<ZQHXJTZJ31UNLM]A0\,)EMSHC*
MN^V-H6H)+Y33K+;MT\R^MZ&F,]>5YG-0RB]DDY/@IU4L(R?%&7N)/H8IO8F:
M7YZ=%7&IM/\ E/+(N>;646U%<-2D]LXKCE'W:71P:6UHT2XXAO;S3"7 NY":
ME,N)5%K*=C7ISBS.C,*/M.YE2C+;Z<VMMW)6E?8'?N7*#BIIK<PX<=F''B?-
MK4,ZKG*DHR=7'##!X]3AV%WFKNUC_CW$A$/95Z9-86UE-*],;9;6^EA%EQ9"
MBS_W,I01S;N7V:5NI7^49W4T=I[5=.UO;_9=VL5'#'#@X'ZC7173.4LPUCS@
M\WN<9K9:<G'R3FU:57&4=[=E/W:3XU+'K7TGT2+F<)BOF:B^/,)!CS*)4?<A
M0(4ME##33UYE;#%1_)3F)D:>E];S3;^:6672MU:TI07?5&9VF6Y5X%0?!#=B
MO6PZA2YI=)WMSG,<ROVU1C5Y2K4>Q8X[SPXY-\$5PO!(MCU\B7:".1ACN,[(
MN9F9J:[CZ<[D.N0)"$MYU.=3G<AEQ?+3^7DJ.5,_KMREZI] ]*6REA-1P3V]
M5XEL&(VZXNY&87SK#"[R+R[[+JVW67V>S9?;=;[-MUMU.6E:?8J-.YW44E)2
MP:::.@,AI2CNR6*DL&B\B*N)KM&V5Q/NMO/5-R:]1?;R<ERBEE+#Z_:^Q2[I
M;:\M/Y*^P.8,PHQM[VK1A[B,VEZF.S[!U?EM>=U84;BI[N=.+?JX;3L \9[0
M                                            "!/%+^;CW:_9LRM\
M%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(
MHZ1^;=G^97LLLG&(&1@            !Y9_%*^<;W:_:4RO\*W =J:*^:67?
M(Z7P4<R:G^<-[\IG\)D"ADY80           -BCZ/GI!K_NG,=GFO/+/+G=)
MC^-8M7QJV)Y#FD ,(4R%TFZ=SN6G0UZ9C7.PPII)YEJBIEI5:5K92E;KN74_
M.IJ3-=.V]E/+)4XRJSJ*6]3A/W*AAAOIX<+X.$V#H+);#.:US&^4VJ<8-;LY
M0X7+''=:QX.B57<.C6^#[=[I8(URR2ZRMDA&4']_:G]T@ZYH;94C3M4)DTD3
MWLZY^8I*T)SKUS*59?4Y"HMJ5=?2E*75I=;FVK<WN<AT[<YO9QA*YHQBXJ:;
MB\9QCM491? WP-;3&-/9=0S;.:&7W+G&C5DTW%I2V1;V-IKA713.?XG>K6/]
M+-X\WZSXM>)B_P $QKX->T3M/W!D=):K]V.(8!/W/MLOCL>BK,?T#S*E!1'0
MH".:FL+MOY]]+C+Z6C<ZNM1:;MLXO8TXW-;E-Y0345N59P6"E*3X(K'&3VX\
M"V$^I<LM\FSNMEMJYRH4]S!R:<NNIQD\6E%<,GAL6PLRXM&B>JNLNAW#ZS/A
M#%GN)R5F^,P]PRA)/=OD:2>Z=8ZX;CDK7G=IY=+W]@9>G?UYI_-;DJ2VWG\R
MVE"Z6V4P[0VIL[SG4^:Y=F5?E+.VG-4X[E..ZE5E%;8PC)]:DNN;X^$R75>1
MY7EN1V%Y94MRYK1BYO>F][&FI/9*32VO'8D:ZXVP:]             #>E^B
MO_(_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M
M (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
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M#(D0<#4AZ^*SJ-,TMC:X] I+6H#EC&_HG!L4FHEA-AI-UY5U2S;*76\EU*5
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M9U%_Q>Y_M)&.!GIK(
M                                                  +Y. %\I+,O
MYCS?A[#QRO\ S8_,S+?^*+^PK'9G\E'S]S7_ (0__44#;$'!!]*@
M                                              " ?#K_ ,)<C_GS
MF'P:A KW'NE^"B2'!ZY/P4"<
M    5I2M*TK3EI7V*TK]BM/^2H I2WDX?.FK5-[=L';$,./E,DO7P.=1!PC<
M><\:9"ME;&O),?I1#7-N4M!DF1$M?+8M)L+--,NK>9SC>0RW>O-SK75.96DM
M$U+B<\LC#E82;ERE/DYQ>Y&:>.XW+W+Q2X%@MAH'G)T3I3);^GS@6]"-'.74
MY*6[@J<^4A-.<HX8*IA'W2P;^ZQ>TU]<V:5ZWMBU8\8=7R7#=3+SCJ1UA<KY
M)!D];KJWT)0QB1J3CFA#96O):2B6IB2[>2EME*4I2G4FD-1ZHR^,:$ZLJM%)
M+"3>.'2?0ZAQSSE:8T3J'?NKJWI4[QXMU*:4)-\<L,%)].6+Z9"9I<$N'Y&H
M[/2,LH+L,I8:],Y=[*YGE6W?_7TJPMRI6M.3EK915=;R_8&X*M&OG5FJDWR5
M9KH]=]G%,Y/MK^PT]G;MZ$J]U;4Y;$Y))>ILP3_J^N3'@^_>NL*(+,E9DS:S
M";?MR$\<L=*\MM>7DLO2KJ6W\O)['+R#5F?Z-SEM\E.A*/X37V''_*=,Z+U]
MDUQ%*I0NJ4^)J$EU8S]E(RC$.+1),^99@&K.@.$Y%*\P9/>28\GR=E-*D01/
M'""ZZWMM.ZPEE/>ULC11AKH>M,HO5MR>G06TNL.YU2ZZ@U+IVEDN7ULVS^XC
M"UI1;W8<,WT(*3PP<G@E@F]O"CIK1N8K/;VE89;2G*I.26+Z"Z,GABDDMKVO
MU#=0A$63P>'QB'I5R]T)C3$V,U'5U.[(=7<Q D*3GN[JHY*=D.CH?9<H4&?^
MIG&77?RCC^YN)W5Q.YG@ISDY8+@6+QP727 ND=>4*,+>C&A3V0A%)>L=H% J
M@                                            $">*7\W'NU^S9E;
MX*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_8
M11TC\V[/\RO999.,0,C             #RS^*5\XWNU^TIE?X5N [4T5\TLN
M^1TO@HYDU/\ .&]^4S^$R!0R<L(           &W#]%$_P 0=T_R-PE^.\DC
M1//A^JY=^<K>Q3-K\UOZQ>?@4_9F4Z\$'YU'4#\LIC^JF>C/^<?YDW_YN']K
M Q'1?SGM/PY? D=RX_'SM>V/_F$_^@TX;'GYKOF+8_\ G?\ J*I6UW\Z[K_R
MO[&F6K\>#YK[A2?D;C__ -!ZB PGFR^>F>?G)_V\C*-<_-K*_P "/]E$U'QO
M4U0             &]+]%?\ D?[#_M)G?JO@(YJYZ_X_:?(_]9,W=S8?PFX^
M4_YD3: &F398
M                       $ FWYQ60?F-)^^605_P#9_P"L2?=D_10)P
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MVDC' STUD
M                                          %\G "^4EF7\QYOP]AX
MY7_FQ^9F6_\ %%_85CLS^2CY^YK_ ,(?_J*!MB#@@^E0
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M]I\C_P!9,W=S8?PFX^4_YD3: &F398
M                                         $ FWYQ60?F-)^^605_]
MG_K$GW9/T4"<
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M1(3/LML<E!91!/8<,)-3Q]O((*(3$(&LJA95E;K^<0D\7LX"P<"4
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M_>!Z@+6[QS9O_I('WH!];'6?FW*^I7[\/J4:"\ZYOU;?O ]0%K=XYLW_ -)
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M6W[P/4!:W>.;-_\ 20/O0#ZV.L_-N5]2OWX?4HT%YUS?JV_>!Z@+6[QS9O\
MZ2!]Z ?6QUGYMROJ5^_#ZE&@O.N;]6W[P/4!:W>.;-_]) ^] /K8ZS\VY7U*
M_?A]2C07G7-^K;]X'J M;O'-F_\ I('WH!];'6?FW*^I7[\/J4:"\ZYOU;?O
M ]0%K=XYLW_TD#[T ^MCK/S;E?4K]^'U*-!>=<WZMOW@>H"UN\<V;_Z2!]Z
M?6QUGYMROJ5^_#ZE&@O.N;]6W[P/4!:W>.;-_P#20/O0#ZV.L_-N5]2OWX?4
MHT%YUS?JV_>!Z@+6[QS9O_I('WH!];'6?FW*^I7[\/J4:"\ZYOU;?O ]0%K=
MXYLW_P!) ^] /K8ZS\VY7U*_?A]2C07G7-^K;]X'J M;O'-F_P#I('WH!];'
M6?FW*^I7[\/J4:"\ZYOU;?O ]0%K=XYLW_TD#[T ^MCK/S;E?4K]^'U*-!>=
M<WZMOW@>H"UN\<V;_P"D@?>@'UL=9^;<KZE?OP^I1H+SKF_5M^\#U 6MWCFS
M?_20/O0#ZV.L_-N5]2OWX?4HT%YUS?JV_>!Z@+6[QS9O_I('WH!];'6?FW*^
MI7[\/J4:"\ZYOU;?O ]0%K=XYLW_ -) ^] /K8ZS\VY7U*_?A]2C07G7-^K;
M]X'J M;O'-F_^D@?>@'UL=9^;<KZE?OP^I1H+SKF_5M^\#U 6MWCFS?_ $D#
M[T ^MCK/S;E?4K]^'U*-!>=<WZMOW@>H"UN\<V;_ .D@?>@'UL=9^;<KZE?O
MP^I1H+SKF_5M^\#U 6MWCFS?_20/O0#ZV.L_-N5]2OWX?4HT%YUS?JV_>!Z@
M+6[QS9O_ *2!]Z ?6QUGYMROJ5^_#ZE&@O.N;]6W[P/4!:W>.;-_]) ^] /K
M8ZS\VY7U*_?A]2C07G7-^K;]X'J M;O'-F_^D@?>@'UL=9^;<KZE?OP^I1H+
MSKF_5M^\#U 6MWCFS?\ TD#[T ^MCK/S;E?4K]^'U*-!>=<WZMOW@>H"UN\<
MV;_Z2!]Z ?6QUGYMROJ5^_#ZE&@O.N;]6W[P/4!:W>.;-_\ 20/O0#ZV.L_-
MN5]2OWX?4HT%YUS?JV_>!Z@+6[QS9O\ Z2!]Z ?6QUGYMROJ5^_#ZE&@O.N;
M]6W[P3%TPX:&*=)9Y*9_ 9[D*6.4KB-T/6(I?=&[D*9#<\MCU54FHRL;6?V5
MT[799]O?=9S+KO8Y>2M-=<Y'/3GW.9E5#*<VM+.WHV]QRR='E-YRW)0P>_.2
MPPDWL6..&TVGS4<P&F^:/.;G.LEO;ZYKW-KR$HU^2W5'?A4Q7)TX/'&"6UM8
M-["R :;-\@
M    $ ^'7_A+D?\ /G,/@U"!7N/=+\%$D.#UR?@H$X
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MNYL/X3<?*?\ ,B;0 TR;+
M                                 @$V_.*R#\QI/WRR"O\ [/\ UB3[
MLGZ*!.
M                               0"V1^5?I[_:\J_P!MH%>G^2F22]TB
M?HH$X         !'3;O /G5:O9[UN]UGN#\.&+)CC/W9]H?=1[F/=8SJ6GMW
M[G>W,=[==K^R.D[&[.2=+R<WI;.7EH(Q>#3.<UEPUYN>MVOFO?NC]V/@(PAB
MC#7NN[3^Y[W5>#"!L$(]T?:#MH^=H^WG:/LKL/LU9V-TO1].;S>DN!O%M\9
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M%3\H_5(QX#.8D(@
M
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M9?BE*<)PJ*#? I[C>[MV;=F.S$]67ZBRC,ZW@]I5QK=!-.+?J8I8EDXUP7P
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M4TH'/+^M:AXHJ3$&%W'-[4T=+=4U%?;= F:V-=%,O'$20
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MX3<*L5]ZIX-=.4C'^<*QMJM.UU%9K"%U%*73QBI4Y/IN.*?J(U9QNHUB
M         &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_ -9,W=S8?PFX^4_YD3:
M&F398
M                $ FWYQ60?F-)^^605_\ 9_ZQ)]V3]% G
M
M             (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10)P
M                                     (Z[:_)NR_\ DBH^^T@J4ORB
M]4EE[DY?67Y/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M
M         0#X=?\ A+D?\^<P^#4(%>X]TOP420X/7)^"@3@
M                     '4I[-6#&T(EV094L+;XU"8V]2I]6FWVEV)FIA;E
M#DN-K??6EM*T3IKN3EK[->2@]=A97&8WM'+[6+E<UZD817'*327V64ZU6%"E
M*M4>$(1;?J)8FD+I;@WB<;CW[U[D8+A&O)D&WXE>28!);L^'O5'ZW'A[@O,3
M-$+H23RD,#8C=TJ8H^O.I<>U%\EM.AY!VOK//.;/1ZR+1V>5\P\.R&E1JP\%
MW=WEL%C*IMVSDXRDUQ3>W::LRNTSW,O"\SM(4>2O)2B^4QQW<>!=)8I>MTC"
M9.79O&^#'OKP^\UEFH\NZ99WQNV$-:A4<=5?!7[(A;?7M)V067>H:&21,AMM
MMY=O,H0XI;N2E3:4K>I938W//+D.O\E:>49S8UI.226%6-%OKL."4H26Q[<8
M3XCRJYJPTS>9/=?K-K5BL..+ET.DFOLHEKMAL3K+M[BOA,:SZ=,2E1LI!LTX
MG7J<>,L$>6*6X@8X\WH[YK=(>>RH>UB%>M3U<S+RS*DF)R+E5]:6TYXQ/2FG
M=3:1S35FI=832TW7LJZ5656,J=Q*;?)[G7/>:3W%BL4VHK;L+AF-[8YE;Y=8
MY8O[]"K![JBU*"2Z['9LX_4VF8=6M@]<^'YO1Q6F'B-4+BDZRU-KI9"Y;-H,
MZR)OR]BAR3N*PN,1%?:T.9;LG>DCDEYJ.AE$YMQ=2;ZT,376V6?5&G]1:_T-
MI6OS=XU;&TH<G4ITZL8.WKQ:6_46]'=<6I==ABL=Y;))OTV%Y99/FV80SOK:
MU2>,7*+:G!]!/!XXXK9ZW0*MY-CZ;QOA>X]F;A$W^&8OS!Q;D>2<#QA\;U3>
MH1XL<FAU3MB]&@46%7$-*R]-6A-]EEI1M"JF6UK;=2HVC:YA97/.?<6=.M3K
M9G9Z2=&ZG%IIUXRBY)M<,ECM6.*QP98:E&M#((591E&A5S'>IIK#K&GALXBS
MK.>/<I90XA/'C@>'"',_(LMT8BS5%T35T]KD^F71R'FNT;:ZDUM,.<9(R$J6
M\DNVO+>8II;_ "C6629AE>6<W^A+_.'%9=1SR<IN6&$>OJ;LY=*$L)M]!+$O
MMU1N*^<YO2M<>7E:I+#A>Q8I>JL5ZY#K+.T&FV3.!W@G1/'$/4OVZ:-W@\02
MX,:L=NY63(UF%ME:SW6S=9?VBLYGNBM4J*4-L.N4J:.%J>^VG(90O,,ITQK'
M+.>Z^UUF-94]&.-6H[J5:/(SMW!<G377?<8+9A@MQR70QMMS?Y97TK2RFC!O
M-$XQY-1>\II[9<'1ZKQP.+VFA&L,6XGV!85Q-U3O9CR(: Z]Q?);@D+D:]:9
ME*/XA(:S*F'1U&XN1QILJ2W\^^MM:75K6MU?9%72U[J>ZYL;^]YLU#RA6S^[
MG13W$N0G<.7W;2P4&B7,*5A#/J-+/<>1C9TU+A]VH8=#;PF:-''/"D1XNF-8
M]PC%>77K4J88M<+MJR']ID]D#1KVYJG5Z97V8]MJ!21V#95MJDJII;2JXXRP
MJMU+KZ6V;6]+.KOFEN;CG:5I#5E&Z7@+C*'*M.5+%81;3QZ_>P^Y2;PV'IRI
MVM/4<(:<=1Y=*F^5Q3W=BEQI=+#'HD6R8'.)#PFIW+F^)R&9XRQ-Q:Y+D'.4
M78F]6Y*%..$EK.@4N:YL3EFW*6A"I6T+.OOLN**[(I??S;*776Y/*_LK?G7H
M6E2K3HYG=Z3A2MIR:259[S45)\$FEBMN+PP6W8>"-&M/3LJD8RE0IYBY5$MO
M6[-N'$O\I9;LYL'K-Q ]Z>%8Q\/-%9.<AX?R$R3K)LXA$*=&!#CC"S.6R*%$
M/E;G>T-EZ(IB(3J"[T]U>QDABBA-M:WGTM&MM,Z?U+H#0VJ:_."^0R^\MY4J
M-*K4C)UKF6\E4A'>>.]BGBMLDL7LCB7R_O;'.,UR^&3+?K4IJ4I1BUNP6'6M
MX+@ZBX.B;>8Y)-C@  !4UMVSUA?$TX6.='$NXB(/5NVFK;T^*#K2V]JFV5L7
ML>1<4(K^6VE;%,H5X>>FXKEK6AJH]/93DNK]M#HD\?<->H87QVHV&X8>;-HX
MJ;JUF[:#3S8K/DYVAQ#.M8&2.3S(6&IUF"Y&[Y1P[/,0+Y+&'PB&DS!(H7L3
MJT6K4Q12[F'TMJ9?8A<!%X32VI22,:9[AN^.ZN$.([EI^Q/F+"^.)_I)+=<=
M1=+I:_,:G($^D[D:_P CDN=,FP2-R-[C,)R3(EUZ&/LS>8M5*T[0096^\JAU
M;E()QBTNGM9('=W >8\AZ.Z-8ZA./G^1S?'.Q'#YE,WC;<21>XQJ/8PEL/73
M]V<K##RR[$L52(#C%5;;KJVVEUYM+@$6E)OH8,@[G'3_ &:D6*^)BS,F&IBY
M.F7>+5K=F[&J),F27'3'$\3D>N"N1SIHI<KMH8QM">*.-YU]];+Z42&<EM>2
MG*)E)8K\$LPWMP]EW(FV'"_G6,X<LD++AK/>9Y3/I!T%3F"$-S[KQ-XQ''>4
M=$H(66M"Z4."=+7H.<96XSDIR?9H)(M*+QXC7_S3KMLUL5H[FC%&;=(>(QGO
MB2*(I-%<TRQEO+;K;J<P/39(%;]8OP#&6[-R3#+^T7,1-I,58(Q!SW"]U4VV
MGW%6EWK;(%1-*6*:W?LFU4UQ@[8'3<F"N[3-L5GYCUR/@[DTS%E[19 @1DXQ
MR;&E93]'Z+3ZM<D8*N-UQJ6I];BCR^96ZE:5Y)N@4>"7KE+3)D'=F(\/0GA=
MW\/C.KKLZS:Y5TN9,N-UD),TI<8K9!C,.LN?EV<SY80O3QNR VEOJUC,8[9%
M>XTN;^P[;KZFEPZ14ZW>W\5ACCTR4.LFHV3< <1C%2DQC>GW#>(>"YKSJ,GR
M_>3S6&09-Q3G21&+6.AAZDU=1Z4Q8E.Z7V&4NY"5%*UOK=R@0<DX=/>Q(4Y^
MT_V:DV5-U'E@PU,71KR!Q:N''FZ&+4J9)<3(L3XICF-$F19TWUN5VUO8XDH:
M%-BN^ZEM]M2;N;;<!,I+!?@LR+Q5,2Y19]LH-%\"J.P*<7;%!>@N=RFU>@0.
M<<38YDZ">+,\IT!I1JU^51;5209,95-Q?-M2\K;6O+6M*5,E@UAM^YV_T]?
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M*K64H8]-QIM]4VKK:F\OTIEV55</"(N&/JTZ3C+UDYX=0U QOHU*
M     &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_ -9,W=S8?PFX^4_YD3: &F39
M8
M            $ FWYQ60?F-)^^605_\ 9_ZQ)]V3]% G
M
M         (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10)P
M                                 (Z[:_)NR_\ DBH^^T@J4ORB]4EE
M[DY?67Y/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M
M     0#X=?\ A+D?\^<P^#4(%>X]TOP420X/7)^"@3@
M                 'Q.+:WO"!8U.R%&YMC@G-2+VYP3$K$*U*?;6PY,K2*+
M#"%!!ME:TNLOMK;=2O)6@GIU*E&HJM*3C5B\4TVFFN!IK:F0E&,DXR2<7T&?
M.R,3)&FQ,RQQG:V!G1TOM2-3*WI&MM2VF7W&7T3H411"8FEYE];J\VVG+6M:
MB:M7K7-1UKB<JE9\,I-R;]5O%LA"$(1W()**Z"V(KSXDNA:7=?6#)F%L?G03
M&D_R*[1!<OR$OC!1BA4FCDD;WY0F=U;002[N%%/8%M+:7F74I?2VM?L#8/-Q
MKN6B]3VV=7ZKW-A;0J)4E/8G.#BG%2>ZL,>+@+-G>4+-+"I:T=R%:;6,FN)X
M[<-K):XHP9!<;-$.64B$*OR.Q02,0UYR"W1EJ22-YM86-&T&W&O=$E'@Q(H[
M&K6EAAUWVE:4K]@8GFN=WV8UJT.6K>3JE>=2-)SDX1WI.7N<=W%8\*1<;>TH
MT(Q>['EU!)R26+P6'#PG;9GBG&&13VU3D#'4'FZEG-H<TJ)9%6.0GMIMMW.I
M>A-=D*LQ+6EWL_:5I[(\EGFN9Y=&4;"XKT(S77*G.4$_5W6L?7*E6WH5\'6A
M";7!BD\.J<P[PF&R!M;6=^B<:>FAF-2G-#6[,;8XMS6<B*Z!$:W(E:4Y,B,2
M$_:%7%VVU+M]BWDH*-&]O+>I*M0JU(59I[THRDG+':\6GB\7PX\)/*E3G%1G
M&+BN!-)I'TI8K&$+XX2=%'6)')'<DI,ZR!*TH"'MS3D4LH00X.I1%BY8230N
MVEEIAEUMM+:<E/8$LKJYG0C;3J3=M!XQ@Y-QBWPM1QP7K(*G!2<TDIOA>&U^
MN=91XAQ2W2]1D!OQI 4,Z5\O94R21!@3RA16M;:W7'/I*"QS,ONK93EK4VM:
M\GLCTSS;-:EHK"I<UY6*X*;J3<%_5QW?L%-6UO&IRRIP55_=;JQZO"?O(<5X
MPEKC<\2K',%DKM>441>Z/\287APN((I6A)-RUP0*%-2B:5KS;>=R6\OL"6WS
M3,[2GR5K<5Z5+''=A4G%8OI)I$9V]"I+>J0A*7&TF_LHY>/0J'1$I21%(G&H
MP0LK2Y63'F)K92E5;:5MMJHL;4J:T^MMM>2G.I7D%*XO+R[:E=5:E5K@WY2E
MAZF+>!-"E2IK"G&,4^))>P?ZTPV(,+:O9V.*QQG:'4Y2I=&MK9&U W.2A;90
MM8>O1)4Q296<K+I2TVXRVZXRE.2ZM1"K>7=>I&M7JU)U8I*,I2;:2X$FWBDN
MAAP$8TJ<(N,8Q47PI)8,X:%XIQAC@UP.Q]CJ#P<YV,O-=#HE%6..G.-YE]IM
M]RTUI0I+U/.,MI=7GUK3G4I7[(KWF:YGF*C',+BO7C#W*J3E/#U-YO DI6]O
M0Q=&$(-\."2QZAWX> K   !B3-F$X)G^"&8_R"D7&M94CA\S9'9E6W-,FB<U
MQ_*&J9PJ8Q1[*+,4,DCC<D94ZE.H+I7_ )MQ=]+RC#++A%/#@,M@0
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M%;%P8[98+'!:FU/J"IJ',?"<'"U@MVG%\*CQO[Z3VOBV+%X8E:8S QL
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MZ0W$/5O:]_\ 7<B]9&OO=#PBITAN(>K>U[_Z[D7K(U][H>$5.D-Q#U;VO?\
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MZ*_\C_8?]I,[]5\!'-7/7_'[3Y'_ *R9N[FP_A-Q\I_S(FT -,FRP
M
M    (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
M                                                           !
M +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ*!.
M                       !'7;7Y-V7_P D5'WVD%2E^47JDLO<G+ZR_)[P
MU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M                                                       " ?#K
M_P )<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
M
M           ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/
M7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&             'E
MG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
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MQ^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M                                         (!-OSBL@_,:3]\L@K_[
M/_6)/NR?HH$X
M                                    ! +9'Y5^GO\ :\J_VV@5Z?Y*
M9)+W2)^B@3@
M  1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)[PU^;J+_BP@0J?E'ZI&/ 9S$A
M$
M
M                                " ?#K_PER/\ GSF'P:A KW'NE^"B
M2'!ZY/P4"<
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M'-7/7_'[3Y'_ *R9N[FP_A-Q\I_S(FT -,FRP
M                                                (!-OSBL@_,:3
M]\L@K_[/_6)/NR?HH$X
M                                           ! +9'Y5^GO]KRK_;:
M!7I_DIDDO=(GZ*!.
M       !'7;7Y-V7_P D5'WVD%2E^47JDLO<G+ZR_)[PU^;J+_BP@0J?E'ZI
M&/ 9S$A$
M
M                                       " ?#K_P )<C_GSF'P:A K
MW'NE^"B2'!ZY/P4"<
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M_P!A_P!I,[]5\!'-7/7_ !^T^1_ZR9N[FP_A-Q\I_P R)M #3)LL
M
M   " 3;\XK(/S&D_?+(*_P#L_P#6)/NR?HH$X
M
M ! +9'Y5^GO]KRK_ &V@5Z?Y*9)+W2)^B@3@
M                           1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)
M[PU^;J+_ (L($*GY1^J1CP&<Q(1
M
M                                                           @
M'PZ_\)<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
M
M             ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.
MX/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&
M'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
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M6$8K'B6/&V:0S[4^9:AE%7FY&A!MQA%8)-[,<7C)O#C>'$D5M#+S'
M       WI?HK_P C_8?]I,[]5\!'-7/7_'[3Y'_K)F[N;#^$W'RG_,B;0 TR
M;+
M              @$V_.*R#\QI/WRR"O_ +/_ %B3[LGZ*!.
M
M            0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
M                                    1UVU^3=E_P#)%1]]I!4I?E%Z
MI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M        @'PZ_P#"7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M
M                       "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^
M;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
M          !Y9_%*^<;W:_:4RO\ "MP':FBOFEEWR.E\%',FI_G#>_*9_"9
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M=^J^ CFKGK_C]I\C_P!9,W=S8?PFX^4_YD3: &F398
M                                                     $ FWYQ6
M0?F-)^^605_]G_K$GW9/T4"<
M                                                 @%LC\J_3W^U
MY5_MM KT_P E,DE[I$_10)P
M              (Z[:_)NR_^2*C[[2"I2_*+U267N3E]9?D]X:_-U%_Q80(5
M/RC]4C'@,YB0B
M
M                                            ! /AU_X2Y'_/G,/@
MU"!7N/=+\%$D.#UR?@H$X
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M_M)G?JO@(YJYZ_X_:?(_]9,W=S8?PFX^4_YD3: &F398
M                                                       $ FWY
MQ60?F-)^^605_P#9_P"L2?=D_10)P
M                                                     " 6R/RK
M]/?[7E7^VT"O3_)3))>Z1/T4"<
M                 ".NVOR;LO\ Y(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_
M !80(5/RC]4C'@,YB0B
M
M                                                  ! /AU_X2Y'
M_/G,/@U"!7N/=+\%$D.#UR?@H$X
M
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M^$W'RG_,B;0 TR;+
M                            @$V_.*R#\QI/WRR"O_L_]8D^[)^B@3@
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M:6S&TS+*LXN)*-*-W2C!3E+9"&*FY1E-[(;T%&3P2EO-(N.&IC>(
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M $791N%G&71<JKE"*IM*4(]9)3;>V:X8KHDS!B)G0
M  $ MD?E7Z>_VO*O]MH%>G^2F22]TB?HH$X
M                          $==M?DW9?_ "14??:05*7Y1>J2R]R<OK+\
MGO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M                                                          (!
M\.O_  ER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M              @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_)I_!9T
M[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
M >6?Q2OG&]VOVE,K_"MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
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M:U2E-W,*;3IQ4-YX;L9M+<WW&4ISC _"?;PX\W5W(V'CNV>]N2M0-1L*RM?
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M+V8>HWQEMT3H&ZS/G?U!IV&>9W;5;2E)NZI7#A=5\*E)85JG#-/>Q>/1C%]
MEK%3]CN+=N[M#AFW9_,.!-.].W<K&2YDQ!(#HO-\G.A;U(X4D=)&\V]'VT63
M99 7AT,/=4R],W)RDZ8M!0XXY0,6N8Z?YK=&Y;F_DVTOM69M#EE*O'?IT8[L
M*CC"/05-5:<$H.+DW*3G@E$S.SEJCGGU]F^1+-K[+M$9'/D'"VFZ=6O+>G24
MIR^Z=5T:M1NI&<8148*GO2E(Z]M]!]B."._X.V*PCM1GG-^LTGR8BQSD_!V?
M9>5-ND-<&UTE)A3*HM3-3$D6R)BCKK<0X(FUM6-JU(3TIJP@\TFGHTI>Y#SQ
MT+W(,YRRQL]14[9U:-S;4^3X'&'7+&4FHRG#&,ISC.,G@H2BF>;6V7ZFY@[G
M+]3Y!G&8YAI2K=JA7M+RIRNV495.M>$8)SA"IA.,(2A*,<7.,G$ZM&9=OEM/
MQ3]W]:L"[=Y"Q9BQ8A7N+G*GF1S>6)<2XU(<X&;89A*"+I(VL\6G,A<'5.C*
M4)NURA(WJ%EY9Q)M*5KZ;FUT3IKFTR;4.=Y50N<R4DE",*<'7K-5/UBHH.4Z
M<%%R:>\I24$TT>.TO><35_._G^E=.YU<V>42C*4JDIU:BMZ"E1_5:+G&-.K.
M4HQ3CN.,'-J46?1MYA#<GA(M^O\ M)'=UMFMG,;L&P)?AQB<QG,[11=PBSR@
MC/:-C?(:NR%+6%U)?ZLK^D/=E5"Z%*W%L+MLM.*+-,ETKG.DN=*I?::N,GR[
M+<PJ6/\ =ITZ=-S4XN>]*-14H2CN[U*2@L<8PJ/'!M*?6N0:YYF*>6ZNML^S
M;-LKIYE_>Z=6K65-TY*GN0G2=:I"2GNUHNI+#"4Z224DFYF\8'=B;.>)-4<
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M;V+QV)X,F(-=FT@
M         " ?#K_PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M                        @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_
MF]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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ME2JQ<:L6TTU@TT\&FGM33V-&]H3A4@JE-J5.2336U-/:FGQ,\]?@2?/(PO\
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MQ&',9-B9YGV0<>K&"+-:MR0,Z9:Z'+V\\LDYS=#TK>BLJ61=7GFF664Y/LC
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M]7N:S_MQDG_#:'P$?%CGH_[LZB_XO<_VDC' STUD
M
M             %S/ J^6NZ?F0G?X_A YP_FD_P"VE/\ XI0_LZQU9_)S_P!V
MZG_"+C^TMS</'SO/J4
M             0#X=?\ A+D?\^<P^#4(%>X]TOP420X/7)^"@3@
M
M                            ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"
M18M3_-Z]^33^"SIW!Z^;)TS_ #.MWXW=QZ-??/+,/E#]A%'2/S;L_P RO999
M.,0,C             #RS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\X;W
MY3/X3(%#)RP@              &XEQ@O_:?WA<?^<E_] JR:-!:!_P"Z6=?_
M #G_ *NF;=U;\P\L_P#EO_3S-.T;]-1               &]+]%?^1_L/^TF
M=^J^ CFKGK_C]I\C_P!9,W=S8?PFX^4_YD3: &F398             5L<87
MYLG<S\SKC^-V@9?H'YY9?\H7L,QS5WS;O/S+]E&O%]%$_P 0=T_R-PE^.\DC
M:W/A^JY=^<K>Q3, YK?UB\_ I^S,@1OE_P"U"+E^V+JU_P"\<,C)],?]JE_P
M^Y_UQ8L\^?S^64?]6;4O&3X7C+Q#,'4?8,B;6S9_$;8XK\4/Q]Q**R8-=><N
M=,3R)>9<431M?SK*F-:A1=0ML=;J7\\I.H6])I3F_P!:5-*9ER5RV\FKR2JQ
MX=Q\"JQ7''[I+W4=FUJ.&S]7Z9AG]EOT$EF=)-P?OEPN#?$^@WP2XDV4S\ ;
MB?OF*IB5PV-K%[C'^@DSI%,$.\TZ=N=(//$[DH1NV I/VTN).;RE[V4<6Q$G
M4M-3.UU[93G=D(R2-@\Z.C*5[;^E^2)3Q@I5E#:IPPQ5>.'#@L-]K8XX3Z$F
M\0T)J6=K6]',T;CUSC2<MCC+';2ECP8OW/%+K>BDJ\N!)\\C"_\ SQ_P"G(R
MOG,_[?U/_E_AP+!H?YWP_P#.^#(QSQT&%WQMQ<L\R%]2*5S>].V&\BL5ZFWL
M>UZ8*XR@1!A*:XR]52J5$[L:ULI?7EMK<CNKS+:?:4]?-K5IW>A+6E2:4XQJ
MTY=*7*3X>#A34O7/-K:G.VU97J5$W&3IS736Y'V&FO6/1=ATMC\_B,5G<2<D
M[S%9K&V.6QEX27VF)76/R-L2O#,Y)C+:W6WIUS:L+-LK2M:5MNI4<FW%"K:U
MYVU=.->G-QDGPJ46TUZS6!T'1JTZ]*->D\:4XJ2?&FL4_71V042H:)WTI/(,
M;D&X&#L?M*I.K?L>8(HKE78YMAES:IFDQ>U[2SK;;;>>0N+:6HM;S+J\O8Z\
MF^E*4OY:]+\RUK6I9!<W4TU2JW.$>GN02;72Q>'JQ9I#G-N*=3-J%O!XU*=#
MKNEO2;2]7!8^HT6Y2W-6YVBG!<X?S]JWC)3D_,SDVX88)1%5F,I?DI6R0*;8
MIR'D)2>IC,/<2'=M.9'1(SH+E)U]"2:F=#>788;9;9@E#+M/:FYP\TI9U65'
M+U*M*,E4A33G"K3IKKIK!XISE@MKX<<$976O,XR/1UA/+*;JWC5-2CN2GA&4
M)SX(O%8/=6/K=$K(]=!QW/0W_P#9/L\]\ S'Z/>;/SA_BJ':F-^F.N/$_P##
MU?;-F'AY;.9BR[I)%=@=U&=CP?D"YSGONZ3R6/.>(&*-LC#,G9F8G%S;9\XU
M5,:96T)TYE3U)]I9U3*7VUI;=2@T]JO)LOL-1SRK3LI7-KA#<W9*K*3E!.23
M@L)8/'8EL-CZ?S*\N\EC?YRHT:^,M[%.FDE)I-J3V;,-K9+2.91PYGQAF;%B
MK+V-\C6$-%[3(5..IO%IS=&[9.B=$;8>[%QQW7T0W+:(U-R>T^XKLCL8REE:
M\R[DL5:RS#*ZM.I?4*U'&6,>4A*&]NM-X;R6.&*QPX,5QEVIW-I?4YPM:M.I
MLP>Y*,L-['#'!O#';ACPX&J;//HH_0QES48RW,O<)BF3'',[3.,-V-<==U=I
M=W0(%[ZQY!='%@).-Y.<JL;W&ME*<G07<O+3=]MSWXUHJ\R_"W;VN%7&27&H
MNFE+U-Z/JFKJ_-;A2;MKS&LEL4J>"?2;4VUZN#]0AUP5-[,H:+[BI= ,L02"
MIXID3.2S!4S5-T1BZ#)D0S47*E\&9+%T_CY"-?/6!/.S:MII#N>XT1)C^D;S
M22RZIS[_ ,XFF;+4N0/5-C5JNO2ME6@G*3ISH[JF\(2Q4);G78Q4<6L)IMXJ
MT:-SRYR3-UD-U"')5*_)2PC%3C4WG%8R6V2WMF$F\$^M:2P>^P.8C>9YXG_[
MQO\ _P#2C_\ VL.K?_\ DO\ _A_]4:!__P"A_P#^1_SS83^DZL#P\\.F*.+9
M51V%%-G\:O\ (>AH;4NK.I@V5HL1174NM+*)^W\E0\E3.6SI>9_ZES:C57,W
M5IT]63A/#>G95(Q]7?I2V?U8OUC/><JG.>GHRCP0N8-^INSC[+1S'T:"1L;Q
MPX#F=L-*JZ1//N36F1D4Z"TXMP7M\2D2(XRPLRXZ\HYF>$UMAAEMM;JEW6TY
M:64J*?/#1J4]7<I/W%2UIN/J)RB_LID_-Q4A/3NY'W4*\T_5:BU]AHV G-S;
MV5M<'AV6)V]J:4*MS<W!69:2E0MZ!.8J6+%)M]:6E)TR8JZ^^ZOL6VVUJ-6P
MA.I-4Z:;G)I)+A;>Q(SR4HPBYS>$4L6^)(\^/Z/0@62_BP,\FCA*M*Q,T#SI
M,'--:5T701MU:3H^WD+BDAEZ8DHIYE+?3FUNO*M.I92VM:\VHZHYU91M]#RH
MUL'5E5HP7X2>\\,>E&73P-": BZVJ55IXJ"IU9/U&L%CZ\D>@H_/K+%F-YDT
MD=4#%'8ZTN+Z_/;JJ)0M;,RM",YP='5R6J+RTZ- WH4YAQQIEUMA9=E;KJTI
M2HY8I4JE:K&C1BY59R48I+%MMX))=%M[$C?4YPI0=2HU&G%-MO8DEM;;XDCS
MM]KL[YEXYO$D@^+,7F+D>-E,I58YP8S*REM&N%8N1JS'*9Y@E+;6A=Q+N[,K
M8:]NOVE%-J5,E;;:FW)B.?U?D>69?S:Z0J7M[@[Q052LUAC.HUA"E%\2;4(]
M#%RGLQ9S_FE]>:VU%"UML5;;VY36W",%ME4DN-I;TNC@E';@C?OUPU[QIJMA
M+'F \1,UC+!<<L"=F;;+K2NSW9;==>J>I*^*"2R;%LBD[RH/7KSZ6VT-5*+Z
MVVVV\VVG+^;YK>9WF-7-+^6]<UI8OB2X%&/%&*PC%=!)&]LNL+;*[*G86BW:
M%.."XWQM\;D\6WQLS>+:>T               @$V_.*R#\QI/WRR"O\ [/\
MUB3[LGZ*!.
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M0HS!_BE/_P JWK[]-'U>YK/^W&2?\-H? 1\6.>C_ +LZB_XO<_VDC' STUD
M
M                                %S/ J^6NZ?F0G?X_A YP_FD_[:4_
M^*4/[.L=6?R<_P#=NI_PBX_M+<W#Q\[SZE
M                             $ ^'7_A+D?\^<P^#4(%>X]TOP420X/7
M)^"@3@
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M>UVU:,\<.#>BTU*+?0WHMQQZ&.)NG-LMHYOEU7+J^R%6.&/$UMC+^K))]/#
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MJF#QQVN%-;.+"HVO4?0,>YL\J</",UK1:FL*4,5AAP2GP\?6+J\9N C0AMH
M               " 3;\XK(/S&D_?+(*_P#L_P#6)/NR?HH$X
M  :V'%BS?M6@XBNFNK>!-E9MK[',]12),;RYQA"C>4C>]R;*$HC=90H85*AL
MN=U*- G)MZ"BU+0RTJEO/M_YPZ%YL,FTS/0.;ZESS+J-_<6-6<HJ;<6XPHPG
MN*23W4VWMW7ACP,Y8YY,_P!84^<[(M(Z<S6XRVUS&C3A*5-*2C.I<5(<HX-Q
MWFDELWHXX<*,J9#X??%&@\'E<SAW&#R!+Y-$V%TDC/&)'A-IC+*^K&1&<Y%M
M;@^&9)F!#>0MJFZ.MYK:K)^V_G+*V<X6RPUWS;7MY2M+O2E"E;U9J$IPN)3E
M%2>&*CR--MK''9.+XGB7C,^;7G<R_+ZU_8ZWN:]W1IRG&G.UC3C-P3ENRGR]
M513PPQ<)+C6!WWAC\48O-&A$\V1W%EL=B*W ,V<H-DC(UK7:V-TG16M47=XW
M(;8W'4%2[)*]&2JQMJW-22O92TFVY,19V1:19X><;FV>3ZWH:>TG2J587U%5
M*5+'%P>].,X[\G[B.YO[\Y;(OKI/=<G<>:?G<6>\W-SJG7%:E1J9;<2I5Z^[
MNQJ+=IRA/<@ORDN44-RG'KI);L5O**Y.O'JT@L(+?#X[LLFQ^<?803E0_!CS
M;CTZE]>CH<4ZVN=[G>7112XKDHCZ2IEE:4MK3DK6G]".LG+D54RYWR7Y%7,>
M5]3=PPX-ONL,.B5?K%Z 45<2I9JLM;P5P[27(OI[V]O<.SW..*X"7>4N);II
MB+!&-=EY-EFQQPKEQZNC\"F<3C,IE!3N[EHW=:I0*6IJ:#GIF5H+6)64J)6I
MTYR523<2;98;2M@Q7+>;S5N:YW<:=MK7=SBUAO5:<YPANQQBDU*4E&2>]%IQ
M;33Q3:VF:YOSJZ&R73MKJN[O=[(;VIN4:M.G4J;TL)-IQC%RBUN24E*,7&2<
M9)/81\R'QR^&SC>>*X XYP72):UN*IJ?)#!X%,Y9#FA:COH6=2DC:V<Q)($W
M/Y:6GLU'(BZM*\E_L"^V',QSA9A8J^IV4:<)14HQJ5:<*DD_O)2QB^E4W'TC
M&LS_ )@N:S*\Q>6U<PE5J0DXSG2HU:E*+7#U\8X373I;ZZ9SN]&Q^$IUHHCS
MG"=T)9@7%,GED0JR;%8+8G^9O_27N2U&9&;61A5-+\CJN6IS$K@2?T)R(TFX
ML\JV^VMM*&B]/YS9:U>2WF44K[,Z=*IO6MS*-./ GO[TE*+P33BUBI)XQ>&T
M]'.%JC(,QYO8Z@L,]K9=D]:M3W+VTA.K/W37)[D'&:Q:<9IX.+6$DGL('-.Q
MF8:<9'A_X5CNP.39E@6=:=1^6.S2Z.SRU,>4EQFOV<7U!D*5P]2J-*LD4@6L
M+>Z'VJ.><4K*LYUU;RZ5&;U<@RGZ)<]SBXL;:CG='-I0C)1C*5%>%6T72A42
M]Q%2E!8;'%OH,UW0U/G?TXZ;R&VS*[KZ=N,CA4E&4I1A</P.[FJU2DW[N;A"
MH\<6I)8O%';."9M?/YKB/=3(NT6=GZ0QG%&7^;9+\L3$]4U0:(I&9P5+2[71
M\5= TM1=2J75MI=;;6ZE*4I6M:4'EYX=,6-GFN3V&F[*%.YNK3W%"GA*I-R2
M76Q6,I'MYA-8YE?Y+GV::NS&I5M+.]_*7%5N-*FHR;ZZ;PC$S,\?2 ^'BW/:
MQ"VO69)5&FY78C<,BQW$3Y?"$=QAG0E&J#GE2S22PD\RZVA?_DWGWUOMYMM>
M46BES&:\J45.I"TI7$EBJ4Z\>4?J;JE#U>OV%\K_ ,R7-G2N)4Z52^K6L98.
MO"VGR2Z&+<G&>#Z'XO%]!$V'#B+Z?H]856X:/+:*0X#;W-H9'251IED#TYLS
MZ].+:U)&%\B*5LK*V1[*5NZ;IDBM&2>24=8;=;0NZV^N'T] ZKGJ-:3G:NGG
MDHRE&$Y1BI1BG)RC-O<E'"+PE&33::3Q6!GM7G/T3#23UO"]C5TY&<82J4XS
ME*,Y2C%0G34>4A/&4<8RBFDTVL&F1PR5QP.''C&V(V.6:7"2KI=&(K,"FN$P
MB52-7'V&9L#?)F,V4G%-Q#:S.M6IS*JI:ZJ+W5$;6I:A,5?3D&09=S-<X&9<
MJZ=G&G"E4G3QJ5(04I4Y.$MS:W*.\GA/#<DML9-&+YKS_P#-?E*HJK?RJU*]
M*G5W:5*I-PA5@JD.4>ZHQENR6]3Q=2#V2@F=LG_&3X=&/,<PK):_8AED#7D-
MN4ND4CT.8Y'(IRI2HE2E KJ]P]*UVO$*O)<$1Q%*/EC;0PTJZTNM_-J/+8\T
MNO[_ #"MET+"=.K;R2G*I*$*:;2:W:CENU-C3_%N>">W ]N9<^7-AEF5T,UJ
M9G3JT;F+E3A2A.=5I-I[])1WJ6$DU^-4,6GAB9\U-WTU<W98)"^Z^Y)(DAT/
MHCNF,;>6MTBTJBQ;@6:8C4NK*^I49QC8H[',LL6I;E"&XPJ^RAU;[+K:6/5&
MB-2Z.KTZ&>V[IJKCR<XM3A/#A491;VK%=:\)8-/#!F1Z-YQ=(Z]MJMQIJZ56
M5##E82C*G4I[W Y1FD]UX/KX[T,4UO8ID.I1QR=(&J22*/0<G.F<"(FM5()%
M*<+X?>99#VPY'=6PXZY\<%C"6L;[[BC:E*T]AR4^PFXPHR\NME]^66W,SK*K
M;T[B\=E9.JDX0N*\85'C]ZE+!\&,7@UC@TGBE@]W_,#H"C=5;;+UF&81HR:G
M4M;:52G%KA>_)PQCPX2BG%I-IM8-Y38^+_H3(,#R;8EOR\MN@D'DD<B4X;C(
M7+?=O$'Z6FKBHXG>H:4U&O'83O<W'] N36*$%]Q)EE#ND*-LLME;FIUO0SNG
MD%2T7AM:G.=-\I#DZD88;[C4WMW&.*QB\)+%/#!IN[V_/9S<W.G:NIZ5[+R=
M;U84ZL>2J<K3G4QW%*DHN6$MUX3CO0>#6]BFE6)PA.,WX6DMV(-U,WNDPV(R
M3F=KB>'$J7%#2RH5,??&=@0-:!4X8RA#!%D?2RDQ7RFK_P"?LMNY;KZ%\RE-
MC\ZO-'Y+EY5T?91I9!;V;G7;KRDU*,I.32K5)3?6;NR.SI8XFIN93GT\LP\B
M:\S"=?4UU?QIVR5O&*<)Q@HINA2A36-3>VSVKHO# LDV-XQ^C>M>0W/$C_-Y
M3D?)S$J-02"%X;AZR=KV%Q37&T7-3FZT4-<9L>&RB<SLQ$6N,5HZEW6G%EWT
MYHU]D'--K/4-A'-:%&E;Y;-8QJ5ZBIJ2?!)1P<]UXK=DXJ,L=C:-IZHY\>;_
M $KF<\EN;BM=9M3;4Z5M3=5PDN&,I8QI[T<'O14W*.#4DGL,K:B\2_4'=ER<
M8QA/(I_A!9T1KDYXRFS(OATZ(;B+[2E2]&VN-MR!_2H3;J6JKFQ4M[$K=;T_
M1TO+K=:]5<W>J]'4XW.<6Z\ F\(UJ<E4IMO@3:VQ;Z&^H[VW=QP>%XT5SK:)
MU[5E:9#=/RE".]*A5@Z5517"U&6R:7W7)REN[-[#%8X;S!QF-+<3Y+E&(FQ=
ME3-D\@ZU2W31IP/C1TR"EC"] :8G=$K@\U5,[*I,:%9=$ZNJ-0IM3J;JDWUH
M;8;87=\IYI-7YIEU/-:D;:SL:R3IRN:T:3FGM34<)26\ML=Y+%;5L:;L>=\^
M>A,FS6MDM*5Y?YC;R<:L;2A*LJ;6R2<L8Q>Z]DMURW9=:]J:7?,;\0W5+<G
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M>OOTT?5[FL_[<9)_PVA\!'Q8YZ/^[.HO^+W/]I(QP,]-9
M
M                  !<SP*OEKNGYD)W^/X0.</YI/\ MI3_ .*4/[.L=6?R
M<_\ =NI_PBX_M+<W#Q\[SZE
M                  $ ^'7_ (2Y'_/G,/@U"!7N/=+\%$D.#UR?@H$X
M
M                                  0)XI?S<>[7[-F5O@JO&3Z*^=N7
M?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_P SK=^-W<>C7WSRS#Y0_811TC\V[/\
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ME^BO_(_V'_:3._5? 1S5SU_Q^T^1_P"LF;NYL/X3<?*?\R)M #3)LL
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M>2E!-.I4J/>J2<I=-M^R0A"$%A!)+I+ Y,2$P                     $
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M*ZNZ\K6I0W*E.G&.%24).6,=N*W$DN#:6KC1!T@
M                                  0#X=?^$N1_SYS#X-0@5[CW2_!1
M)#@]<GX*!.
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M]+]%?^1_L/\ M)G?JO@(YJYZ_P"/VGR/_63-W<V'\)N/E/\ F1-H :9-E@
M
M         0";?G%9!^8TG[Y9!7_V?^L2?=D_10)P             AOF/1+
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MF5++K;/'G4UE3U'/4]*O"&8U*4:=1*"Y.I"'N8R@\5LZ$DU)8O!K%XR3YE=
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M:_-U%_Q80(5/RC]4C'@,YB0B
M
M                                                       ! /AU
M_P"$N1_SYS#X-0@5[CW2_!1)#@]<GX*!.
M
M           $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'
MKYLG3/\ ,ZW?C=W'HU]\\LP^4/V$4=(_-NS_ #*]EEDXQ R,
M /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"CF34_SAO?E,_A,@4,G+"
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MXH)+'IR?#)].3;Z9K6^S&^S*MR]_5G5J\<GCATDN!+I))&%!<3Q
M      &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_P!9,W=S8?PFX^4_YD3: &F3
M98
M             $ FWYQ60?F-)^^605_]G_K$GW9/T4"<
M
M         @%LC\J_3W^UY5_MM KT_P E,DE[I$_10)P
M                                  (Z[:_)NR_^2*C[[2"I2_*+U267
MN3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB0B
M
M
M    ! /AU_X2Y'_/G,/@U"!7N/=+\%$D.#UR?@H$X
M
M                   0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_S>O?D
MT_@LZ=P>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,
M      /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"CF34_SAO?E,_A,@4,G+"
M          !?9]'UT9Q=N+M;,9)FV.H9IC/7Z&-LQ-@[L3<I8I5.) ]T;8<B
MDR.O(G=(V@3MSBM/1&UJ2L/3$%'6&IKCRK]8\ZFI;W(,CIT<NFZ=Y=5'#?7N
MHPBL9N+Z$GC%)K:DVTT\&9UH+)+;-\TG4O8J=M;P4MU\$I-X1QXTL&VNBTD\
M5BC910<:'A7SS-2+0_W(NCU$GB8)L/M3NY8<A2S61VD*MULB:"/ID)SRH<^T
M*UV441E+#8V6TU+NZ6I]$M:'5U!+F\UM:Y<]3<I&->-/E6E5FKA12WG)O##>
M2VM<IO=##>V&QHZQTQ7O5D>XW2<^33=./(MX[J6&..#>S'<W>CCAM-5+CE:2
M8_T@W951C$+;<Q8HRU VC+T0C-IUQZ2''N[Y(X[)(DV&&WWJ:-"!\C9BI&7?
MRT3HUI1%MUU">4;MYMM1W6I-.*M?O>OJ%5TI2Z,\(QE&3Z;4L'QM-]$U?K;)
M;?)<Y=*T6[:U::J17O<6TXKI)K%<2:70*;QL P\               WI?HK_
M ,C_ &'_ &DSOU7P$<U<]?\ '[3Y'_K)F[N;#^$W'RG_ #(FT -,FRP
M
M      (!-OSBL@_,:3]\L@K_ .S_ -8D^[)^B@3@
M
M    $ MD?E7Z>_VO*O\ ;:!7I_DIDDO=(GZ*!.
M                             !'7;7Y-V7_R14??:05*7Y1>J2R]R<OK
M+\GO#7YNHO\ BP@0J?E'ZI&/ 9S$A$
M
M
M " ?#K_PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M                @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_)I_!
M9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
M   >6?Q2OG&]VOVE,K_"MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
M       #;A^BB?X@[I_D;A+\=Y)&B>?#]5R[\Y6]BF;7YK?UB\_ I^S,U@-=
M_E 8,_/%C+X:L@W/FW\*N?D]3X#-:9?^OT/ST/A(V'/I4'RP=>?V:R/UH3\:
MHYE/X!=_+/\ 5P-@<Y_\6M_DW^?(U@1N8UF               ;TOT5_Y'^P
M_P"TF=^J^ CFKGK_ (_:?(_]9,W=S8?PFX^4_P"9$V@!IDV6
M                                                           !
M )M^<5D'YC2?OED%?_9_ZQ)]V3]% G
M                                                       (!;(_
M*OT]_M>5?[;0*]/\E,DE[I$_10)P
M                   (Z[:_)NR_^2*C[[2"I2_*+U267N3E]9?D]X:_-U%_
MQ80(5/RC]4C'@,YB0B
M
M                                                 ! /AU_X2Y'_
M #YS#X-0@5[CW2_!1)#@]<GX*!.
M
M     $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/
M\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #RS^*5\X
MWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\ .&]^4S^$R!0R<L(           &S
M;]&QV;UZULF^V2[/V9L=8>1RR*XC2QE3D&4-<9)?5+0[SXYT(:[W,\BU8:@*
M7D7&TLY:V4-MY?LT&G.=[)LUS>VL8Y7;UKB5.=5RY.+ENXJ&&.'!C@\/4-D\
MW699?EU>ZE?UJ=%3A3PWY)8X.6.&/%BBWYAQ/]&GC#XS21BD^GS>]QYU;GQF
M7E["R@PQ"ZM*PE>WK+"U&232#+TRM/9?2V^RZRM;>2M*TY:# JM]SP5J4J-6
M%^Z<XM-<A':FL&OR?$9;"UYN:4U4A*T4XM-/E9;&MJ^[,[[)Y"X#>W\J8IOL
MAFC4_*,IC,?I%6)W=<Z*FDYOC]KDN=Z-I9,:FC(D,*HXN1YO.,+O,Y3*TYW)
M2E*6S)[7G-R"A*VRBWOJ-"<]Z25''&6"6/70;X$D>[,;C0V;58ULQK6M6K&.
MZFZF&"Q;PV271;-<7C68^X44-Q?A-3P\%^$5DR6SV0D9$MQ5DUZG;A9&"X\6
M8U7.R1TEDB+0(ZNO+S#+;"ZW7_:\ZM/8&V^;N[UQ<7MS'5:N5;JE'D^5IJ"W
MM[;@U&.+P->:RH:6HVU%Z?=%UG4>_N3<GNX;,<9/#::ZXVP:^
M  #>E^BO_(_V'_:3._5? 1S5SU_Q^T^1_P"LF;NYL/X3<?*?\R)M #3)LL
M
M         " 3;\XK(/S&D_?+(*_^S_UB3[LGZ*!.
M
M     0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
M                             1UVU^3=E_\ )%1]]I!4I?E%ZI++W)R^
MLOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M @'PZ_\ "7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M
M                "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\
M%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
M   !Y9_%*^<;W:_:4RO\*W =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
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M<U<]?\?M/D?^LF;NYL/X3<?*?\R)M #3)LL
M                                              " 3;\XK(/S&D_?
M+(*_^S_UB3[LGZ*!.
M                                          0"V1^5?I[_ &O*O]MH
M%>G^2F22]TB?HH$X
M       $==M?DW9?_)%1]]I!4I?E%ZI++W)R^LOR>\-?FZB_XL($*GY1^J1C
MP&<Q(1
M
M                                      @'PZ_\)<C_ )\YA\&H0*]Q
M[I?@HDAP>N3\% G
M                                                     "!/%+^;
MCW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[
MYY9A\H?L(HZ1^;=G^97LLLG&(&1@            !Y9_%*^<;W:_:4RO\*W
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M %DS=W-A_";CY3_F1-H :9-E@
M                                    0";?G%9!^8TG[Y9!7_V?^L2?
M=D_10)P
M                               " 6R/RK]/?[7E7^VT"O3_ "4R27ND
M3]% G                                                    CKM
MK\F[+_Y(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_%A A4_*/U2,> SF)"(
M
M
M                           $ ^'7_A+D?\^<P^#4(%>X]TOP420X/7)^
M"@3@
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MC_UDS=W-A_";CY3_ )D3: &F398
M                                      $ FWYQ60?F-)^^605_]G_K
M$GW9/T4"<
M                                  @%LC\J_3W^UY5_MM KT_R4R27N
MD3]% G                                                    CK
MMK\F[+_Y(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_%A A4_*/U2,> SF)"(
M
M
M                            $ ^'7_A+D?\ /G,/@U"!7N/=+\%$D.#U
MR?@H$X
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M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"!
M_?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/
M"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF
M,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&AN
MRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^
M&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>L
MC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M
M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"!
M_?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/
M"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF
M,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&AN
MRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^
M&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>L
MC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M
M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"! _?M$>LC-^&ANRXF,4/"!
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M5\TLN^1TO@HYDU/\X;WY3/X3(%#)RP@
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M]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S
MM8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO
M&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91
MW4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>
M:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#
MS M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#E
MZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<
M91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8
MO>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-
MQ#S M8O>:[]<91W4#EZO&-Q#S M8O>:[]<91W4#EZO&-Q&'-@M,< 0#"^1)E
M&(LYHG^/1XYP:U1THD"PHA58H3EVWWI53@:G.IS3*_:WVUH)Z=:I*:3>S$@X
MI+$Y'"&E.O<UQ!C:72&*NBM\D<.8GAV4E2F1)2SUZY"4>I-L3)W L@BV\RZM
M:6V6TMI_)00G6J1FTGL3"BFL3*7F!:Q>\UWZXRCNH)>7J\9'<0\P+6+WFN_7
M&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6
M+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC
M<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U
M Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN
M_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P
M+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>K
MQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4
M=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+W
MFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0
M\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y
M>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7
M&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6
M+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC
M<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U
M Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN
M_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P
M+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>K
MQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4
M=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+W
MFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0
M\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y
M>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7
M&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6
M+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC
M<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U
M Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN
M_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P
M+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>K
MQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4
M=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+W
MFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0
M\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y
M>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7&4=U Y>KQC<0\P+6+WFN_7
M&4=U Y>KQC<1$K3G5G#&7\?3-_G<>7N;FS92D470')I ]-MA3.WLD86I4]Q*
M!:04:98H<SJU,NI6^ZEU*5KR4H*M6K.$DH\1+&*:VDM?,"UB]YKOUQE'=04N
M7J\9-N(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?
MKC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%
MK%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5X
MQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.
MZ@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S
M7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>
M8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O
M5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC
M*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%
M[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN
M(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@
M<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?
MKC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%
MK%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5X
MQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.
MZ@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S
M7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>
M8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O
M5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC
M*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%
M[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN
M(>8%K%[S7?KC*.Z@<O5XQN(>8%K%[S7?KC*.Z@<O5XQN(A3Q(-*=>X5H3M[+
MH]%'-(^1S7_);PTJ393(E19"]#&UIZ8V],H<3"#[;#+:5K;?;6VO\M!DVC*U
M26K,N3>QWE+X2+%J:*6GKU__ )//X+,_<'KYLG3/\SK=^-W<3Z^^>68?*'["
M*>D?FW9_F5[++)QB!D8             >6?Q2OG&]VOVE,K_  K<!VIHKYI9
M=\CI?!1S)J?YPWORF?PF0*&3EA                                 #
M>E^BO_(_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M
M     (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
M
M! +9'Y5^GO\ :\J_VV@5Z?Y*9)+W2)^B@3@
M                          1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)[
MPU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M                                                        " ?#
MK_PER/\ GSF'P:A KW'NE^"B2'!ZY/P4"<
M
M            ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X
M/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&             '
MEG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M                         #>E^BO_ "/]A_VDSOU7P$<U<]?\?M/D?^LF
M;NYL/X3<?*?\R)M #3)LL
M                                " 3;\XK(/S&D_?+(*_\ L_\ 6)/N
MR?HH$X
M                              ! +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ
M*!.                                                   !'7;7Y
M-V7_ ,D5'WVD%2E^47JDLO<G+ZR_)[PU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M
M                          " ?#K_ ,)<C_GSF'P:A KW'NE^"B2'!ZY/
MP4"<
M                                          ($\4OYN/=K]FS*WP57
MC)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI
M'YMV?YE>RRR<8@9&             'EG\4KYQO=K]I3*_P *W =J:*^:67?(
MZ7P4<R:G^<-[\IG\)D"ADY80                                 WI?
MHK_R/]A_VDSOU7P$<U<]?\?M/D?^LF;NYL/X3<?*?\R)M #3)LL
M
M  " 3;\XK(/S&D_?+(*_^S_UB3[LGZ*!.
M                                                          0"
MV1^5?I[_ &O*O]MH%>G^2F22]TB?HH$X
M                       $==M?DW9?_)%1]]I!4I?E%ZI++W)R^LOR>\-?
MFZB_XL($*GY1^J1CP&<Q(1
M
M                                                      @'PZ_\
M)<C_ )\YA\&H0*]Q[I?@HDAP>N3\% G
M
M         "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\
MV3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@            !Y9_
M%*^<;W:_:4RO\*W =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
M                       WI?HK_P C_8?]I,[]5\!'-7/7_'[3Y'_K)F[N
M;#^$W'RG_,B;0 TR;+
M                              @$V_.*R#\QI/WRR"O_ +/_ %B3[LGZ
M*!.
M                            0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3
M@                                                   1UVU^3=E
M_P#)%1]]I!4I?E%ZI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M                        @'PZ_P#"7(_Y\YA\&H0*]Q[I?@HDAP>N3\%
MG
M                                       "!/%+^;CW:_9LRM\%5XR?
M17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;
M=G^97LLLG&(&1@            !Y9_%*^<;W:_:4RO\ "MP':FBOFEEWR.E\
M%',FI_G#>_*9_"9 H9.6$                                 -Z7Z*_
M\C_8?]I,[]5\!'-7/7_'[3Y'_K)F[N;#^$W'RG_,B;0 TR;+
M
M@$V_.*R#\QI/WRR"O_L_]8D^[)^B@3@
M                                                       $ MD?
ME7Z>_P!KRK_;:!7I_DIDDO=(GZ*!.
M                    !'7;7Y-V7_R14??:05*7Y1>J2R]R<OK+\GO#7YNH
MO^+"!"I^4?JD8\!G,2$0
M
M                                                   (!\.O_"7(
M_P"?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M       @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_)I_!9T[@]?-DZ
M9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8             >6?Q2O
MG&]VOVE,K_"MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
M                    -Z7Z*_\ (_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_
MA-Q\I_S(FT -,FRP
M                           (!-OSBL@_,:3]\L@K_P"S_P!8D^[)^B@3
M@
M                         $ MD?E7Z>_VO*O]MH%>G^2F22]TB?HH$X
M                                                 $==M?DW9?\
MR14??:05*7Y1>J2R]R<OK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M                     (!\.O\ PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M                                     @3Q2_FX]VOV;,K?!5>,GT5\
M[<N^64OA(L6I_F]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_
MF5[++)QB!D8             >6?Q2OG&]VOVE,K_  K<!VIHKYI9=\CI?!1S
M)J?YPWORF?PF0*&3EA                                 #>E^BO_(_
MV'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M                                                         (!-
MOSBL@_,:3]\L@K_[/_6)/NR?HH$X
M                                                    ! +9'Y5^
MGO\ :\J_VV@5Z?Y*9)+W2)^B@3@
M                  1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)[PU^;J+_B
MP@0J?E'ZI&/ 9S$A$
M
M                                                " ?#K_PER/\
MGSF'P:A KW'NE^"B2'!ZY/P4"<
M                             .%D$C8XJUJ'J1.B1H:TE*5/6K3:%%6<
MZZEMMM/LW7WW75Y*6VTK6HQO5>K],Z&R2KJ+5M[0L,EH);]6K+"*Q:226UR;
M;22BF^D>W+\NOLUNHV674IUKJ?!&*Q?VETV<3#9_#\@H3W*'OJ-\2)3^Q5)B
M6M]+DY_,MOH6:6;86996MEU*TKR<E:"R<WW.CH/G3RVIFV@\QHYA94:FY4<-
MY.$L,<)1FHR6*>*>&#/7G.09OD%>-OF]"=&K*.,<<-JX,4UBCN S\LX
M                        ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3
M_-Z]^33^"SIW!Z^;)TS_ #.MWXW=QZ-??/+,/E#]A%'2/S;L_P RO999.,0,
MC             #RS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\X;WY3/X
M3(%#)RP@                                !O2_17_D?[#_ +29WZKX
M".:N>O\ C]I\C_UDS=W-A_";CY3_ )D3: &F398
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M'$KOS]QH6#!FLNH6QWF\2*86;;H9$K9H0@R @;G")',-S/98C/=;XBN+?CG
MQXMMLZ-,FYM;?L5Y?8SW(^:*OG6HLUT_X?3I/*I04JCI-J:EO;5'?6[AN]%L
MUEJ3GVMM/:4R35'DRK76=1FXTE6494W#=V.7)O?<M[9A&)PZ[BQ[B-R-4O5<
M'';NU,C(-4J+B5SNJ,M))LJ89=8G2XG.4G5MLMK7FV6775_DH*T.;#2=2:A'
M5N5;S>"V17V76P*%3GEUQ2@ZD]#YUN16+P<GL725NV_6,?RKZ0;B-/@!FS]C
MW7V?S5M;\A68PS##W>5M41DV))0\LZM\@JE95,Q2IK?XU/4<?>[$*RAZ(RQ2
MSFDFD67W6TI[K;F)S66>SR._OZ%&I*ARU"I&$IPKPC)1J)8RA*,Z;E3<HX26
M%1-2:1;;S^93)8Z;IZDRS+;FO2C<\A<TY5(TZEM4E%SI-X0J1G3K*%50EC%J
M5)Q<4V7Q8\GD9RE H5DN%N%CK$,@Q2/S2+N5G,Y%S!)FI*\M*FM++S+;+S4*
MRRMUO.KS;N6G+[ TG?V5SEM]6RZ\CNW="K*G-<4H2<9+JHZ(RS,;3-\NH9K8
M2W[*YHPJTY<<*D5*+ZC173=Q-&=ZXC%>'GCO#SK.WIC;RW'(F5TTR2MT;@A*
M>*%RY]M5LM(VXG.569.N0H*UM6%4O=EEJ2[H[[+JTS[Z.JM'0'IY?W<:%&<L
M*5!TVYU,9[D<);ZPWFI2]R^LCO;4T:P?.O0K\Y_T9Y98SN*]..]6N%54844J
M?*3QCN2<MU.$/=+&I)0>#3+1QK8VZ15W3VQA.D^NDZV%G*$Q\112C4A9(FD<
M2&MSF4G?G-,ULT<:U9Z=9:2>>8?>H.,H2=V.C3GGULNM*N&3:0TO>:PS^AD-
ME+<G5WG*;3:IPBG*4VDUL6&"6*QDU''%F'Z\UE8:"TQ<:ES"+J4Z.ZH4U)1E
M5J3DHQA%M/!O%MO!X1C*6&"9%CAL<4V <1:_*C,V8[=,03G%M[ L60Q^E"22
M+GJ-/]%A!<A;CR65@,H2VNJ&J985T%_8]QZ:ZZ_^?LMIDO.%S:7V@5;5JEQ&
M[LKG>2J1@X*,XX/=:WI<,7C%X[<);.M9B'-7SO9;SGN\H4K6=EF%GN-TIU%-
MRISQ6_%J$-D9+=DL'NXQQ?7(M1&M#;X           $1=:\]YUS#.,]QK+NJ
M<EUWCF+I6@8\8S1^G">6I,Y,BIWFJ!3*&9N(B4;NC29"@CC<KJ3>>OK=:\EV
M\^G15N,RK4.29+E-E8W&59G3O[BYI.5:G&FX.VDHTVH2>_/?;<YQQPC^3;PV
M[,+TKJ/4.>9AF-KG63U<LM;2LH4*LZJJ*[@Y54ZD8JG#<24(2PQG^52QV8N7
M0Q4S0Z/DV=MV+L;9"R:[HUK@TXZ@\LG;H@;:$5<5S=$6%?(%J-!14:G356J4
MS?=85TAEEG/NISKJ4Y:T]F7653,LPH9=2:C5N*T*:;QP3G)13>&+P3>W!8X%
MOS;,:6495<YM7C*5&UMZE:2CAO.-.#FTL6EBU'!8M+'A9'W23<.#[SX*09[Q
M[&)7$8XX2611@IFF=K1:]V*XVH)3*E!E&1R=4'8Q]QU*E\AU;N2GLTH+]K'2
M=[HO.I9'?U*56XC3A/>I[V[A-8I=<HO%='88WH'6^7\X.GHZCRRC6H6LJLZ>
M[5W=_&#2;ZR4E@\=FTET,5,T   "M;,?$-\$W$4UZT%\$/;_ ,/..R)]X6/=
M_P!JO<KTRG+*;M3[A/<2Y=O.;X+N=T_;E'R]G<G1_P SRF[#RG0?E30-_KCP
MOD_ ;CDN0Y+>W]E![W*<HMW\MP<G+W/#MV:KSSG,\C<YV6<W'@7*>4;55O".
M6W>3Q=PMWD>2EO\ ZOP\K'W?!UO764C7AM0                    @%LC\
MJ_3W^UY5_MM KT_R4R27ND3]% G          (AN&Z6+6W>9BX?Y[#/[\R2#
M6T[:-%)2FN.W8R*Q^3/WG'-[.J>;Y47*;)C5[9#3:)[&:]%V)=9=V7TE:E6B
M;=>[O=#$;S;I8MX?VN$NV@S(PS^2P&%NL3:'1HQDUQUYF!ZF925MBS9>@;Y5
M*H8RFD$.#H7>?4QP*NM)I=6RV^ZE+*A&+D\%PF!=M^*-C?4O8G'^K1VN6W&Q
M.8\DXO6Y=CT<UBQK!LAG61!L?GB/.)J]+(LI09X+5(%3*88;T*0\BPB\NZIO
M.K6VV&)&,')8XI(Z/CWC$X3?LSXPP7FO7#=C3.6YM?"XGA]XVXP0WXX@^1IH
MHOM*1PN/2^,3J>M1<F7GWEE$)UER2AAQQ)=+ND.)MO8AP>&*:?J$J],=V<6;
MPPO)DNQI'<A0I;AW-D]U^R5!<J-4:9)Q%,D8YN;K9 @<&Z*2V:M'8-]KH5<G
M.L77]+R7VUMLOLNMI$A*+CP\1^\AW2Q:P[K8^T-)8)_(LT3O"\BS\L=(\UQU
M3 L>XT87A9&T[OD%W72IN?VX^2R9'5O;BD#6X\]287T]2"KZ& 0W7N[W0)>
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MY.7UE^3WAK\W47_%A A4_*/U2,> SF)"(
M
M
M    $ ^'7_A+D?\ /G,/@U"!7N/=+\%$D.#UR?@H$X
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M_P"1_L/^TF=^J^ CFKGK_C]I\C_UDS=W-A_";CY3_F1-H :9-E@
M
M  0";?G%9!^8TG[Y9!7_ -G_ *Q)]V3]% G                  #J.0/\
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M09C;WB<.$$/R*4FDKA%FI[=F$FEDORF\&WG)SE]A54#"F.LNN^UMN]O.E_\
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M>4;E*+36]&.&SH]=B3H&UC8X
M                  ! /AU_X2Y'_/G,/@U"!7N/=+\%$D.#UR?@H$X
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M#>=64XKK][=PW(3]X\<<"UY_J:PTXJ3OHU9<LY;NXHOW.[CCO2C[Y<&)6?\
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M">S=E)88/C)X#&2^            0";?G%9!^8TG[Y9!7_V?^L2?=D_10)P
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M[L'E-:TEE%TC"PN-QA@BZ*V^\TQ4EL6&5I;;<6'1(8K=P7#B3] E
M".NVOR;LO_DBH^^T@J4ORB]4EE[DU)9#_P <=O\ W_4_^];A\YN<K_N!G'_$
M:WPV<-ZW^=^9?+*OPF<.,(,6
M                                                         "VK
MA!?XW9,_-69\+8V.A_Y<?G3??\/_ -=3-W<Q?SBN_D7^MIFPD.Q3J$
M                                                 @'PZ_\ "7(_
MY\YA\&H0*]Q[I?@HDAP>N3\% G
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M[J+<9+!KB7-VH<@O]-9I4RK,$N6AM37!*+]S)=)]/:CO V260
M               "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%
MG3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
M  !Y9_%*^<;W:_:4RO\ "MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
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M_P#L_P#6)/NR?HH$X
M                                         ! +9'Y5^GO]KRK_ &V@
M5Z?Y*9)+W2)^B@3@                               ?*M0(7)/<C<4:
M5>DOO(-O2K4Y*I/>:E/*5)C+B#[#"KKTZDFPRRM:<MAEEMU.2M*5 'U
M             (Z[:_)NR_\ DBH^^T@J4ORB]4EE[DU)9#_QQV_]_P!3_P"]
M;A\YN<K_ +@9Q_Q&M\-G#>M_G?F7RRK\)G#C"#%@
M
M             MJX07^-V3/S5F?"V-CH?^7'YTWW_#_]=3-W<Q?SBN_D7^MI
MFPD.Q3J$
M   @'PZ_\)<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
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MI?HK_P C_8?]I,[]5\!'-7/7_'[3Y'_K)F[N;#^$W'RG_,B;0 TR;+
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M!II9_;<X^C;K2+US"]A'3D4]ZI)24HR3W73E3PW^4WFDH).4L4XXJ2;KGO\
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MW=W,=[U4H_?8;36?UA<@C169U<FU##3;:2O7:+D&FTE+>Y3#=?0:;D]G6XO
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M*M*3Q<5..+6$DFXRC*47A)*6]&24PABAFX
M   ! +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ*!.          5X\6M8K;^&1O>N
M0*E*%:DU=R^>E6(SS4RI,>7$7&XLY.H)NL-)-+NIRVW6UI6E?L 30]VO5,1\
M/'=34EDT T:9IEMIKHT3!HT\UF;)6U2?/&-$$D;)(@PM"4KZWR%"ZRHIT1/B
M)T*-+5E*;+5!:BV^TRE+Z5H(8HC*,MY['PE1F+,EI)W$OI6$NA<_33**6X_R
M&XP63Q>5%2&/42>:OG8PI=$GII7K&VB;LI-2ZTU&;S>D+Y:5Y;?8$[6&X9ST
M X/'#GS-P]M6L[Y>QQ.;,B9#UR@,^GF3K-IMFXL8GDKU%$KD[3 I$ES.BA+&
M:E6&7*K++6^QO)NMIRD='2ME6"(2G)2:7!B5<0[+N8X'KIB[?HK+N1,Z8GX3
M_%ORIKM$LWOLA<7Q[S9P[<B+H5C]U='Y](,,,FMS68^)D;0XGEJ4I1+_ 'I4
M_1VHKB3!/@L=WHRC]DV)^-YF^50?0=ZQCAAPO49HW9G>.=/L(7,JJIAKB]9X
M=*-SZJ1*6^IJJB0S&J1XM+5I^7H3CR+Z74Y;:U,I0778O@6TLUP5B1@P'A;$
M^$8NI6+H_B7'</QXU.+D9><Z.R2(L*%CM>'8\TT\U2[O%R*JI4;>9?>:H-OO
MNNNK6M:Q)6\7B:[G%RE_%'C.0=6%TJE.L.-M-7+B1ZYPMI;<'S3-"K8G(S,[
MY84JH FRN;(H1'(2UL)D:9K3WII:5QY7;:EMM#UB:VWFP94@H;>'>P+#.-A/
M,VXZT5?G[#<OFV-VE7E7$$=S]E3&9:V_)&*]:I',D;1EZ?PDQK3JGA"[L;4J
M)Z98C+[)0-YJE39>5T-3BS)88.6TK)CT-U/UYWLX>#5PE<_O62Y/F:>R$O;/
M',.VBFFRN.IGK/;"5SI+,WY@(D$XR$T0J6-3R2E,85MAS/8O<SKB$Q!EW*71
MZA/C)Q>_ZVPV;,EW768XG]]EUUE]D)E5UE]M:VW6W6L2^MMUMU.2MMUM:<M*
MT^P(E%<)IR<(C4[@WYMX>.O>3MRI]CFNR,F\+'A'K-M\\M8JD_\ Y&SADN/Q
M#MG F78>&-K#_P#"&TM?0]&VINRD_1J+NDO.N-OAL*\Y5%)J/!ZA8SM(MU^T
MVTWQ)KAPQ,M,&(F#>O<J.8H=<^1#/\JS%3#S"Z1DA=L)F6.9-G62IR>Q.L(Q
M?B],EK84ZIDS48IJK+HF4UN4T>H2K&4L9]!&+M4H%PZ*[<8#5<*GB)%5S+#)
M>I3;08QR'GK+^5$FX.(SV91?/U9+9D1V4QR295:;R"W="OC!!;:FO*.47DE6
M$TNL>H'O;O7K9[!M$B)2*4/I%+FY,W!PW"<FAP7-3BF\WWL=>VJU"%:1TVTN
M$2#>A5)3"CRNE(-NLNYMU.=9=6E?8K4&5*7NT1=AF@GT>9?#XHN>Y]A7MTLC
M3$K=^GXEN;$A_;10UI3E_3)+-JB+$IO9=]_.+I992ROL4MIR<@AL([U7I]0L
M*R+PQ]6<N1O$[LP9DV@QEC'%^$XGCO':'!6X&6X9CZ_&,<,>I#'I"N<44L<J
MR]Q/;Y%=TD@7K5:I8@*3](??859<!*IM<6/J$'N$/KLDFV<LJ[Q8TS1M@\:A
MD6R;"6J<-S?L%D[*23-:9@>C6C(6T3RV3-X4IT,>?7YM/:(<@Z HVQO2'KU-
MEIZ@FPHB,WLW7AB;% B4P        CKMK\F[+_Y(J/OM(*E+\HO5)9>Y-260
M_P#'';_W_4_^];A\YN<K_N!G'_$:WPV<-ZW^=^9?+*OPF<.,(,6
M
M                        "VKA!?XW9,_-69\+8V.A_P"7'YTWW_#_ /74
MS=W,7\XKOY%_K:9L)#L4ZA
M                 (!\.O\ PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
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M4IUX-[M-K=A%?>+@::PZ]-[W#BU@9@'0)B
M   0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_S.
MMWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,             /+/XI7SC>[
M7[2F5_A6X#M317S2R[Y'2^"CF34_SAO?E,_A,@4,G+"
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M?[9;^T5O2GG \0G^S5O;+>,295W:VXX1&[+EM3@F50'8N18BVPQY$,5H,.9
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MO+BI=W$G*XJSE.3?1E)MM^NV;[H4:=O1A;T5NT8148KB26"74.U"@50
M        @$V_.*R#\QI/WRR"O_L_]8D^[)^B@3@
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MJ-2FG/?E*4)1EA).?6Q:>.PR-#G3                              !
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M1!V2;=S&SL>TOD*M+I2!6J<IOO=QP)!<4+'FA&8]3=0<\:J1?".1]&=.N('
M)/M=#=48Y$?!PSX>?B&DW.SB[1/&+-1N7&MC.[,9[ZE*3EJ#V=R,,--)L_GR
MQ"#DFU+'>:,A<2//FF>W[QPY\5:*Y*PSFO;1JW(P)-<,+M>W:*RQ\PCB6".1
M[WE)_FCG$#C;L=8X9XH3;>N8W"]+>K-*)NM1&]BWW$F0BI1Q<L5' OFAFV6O
MV0MB\QZFQ"?]M]@< ,</DF7(![E9J@]R3+/F-DD<36^ZITC:*%/W;9FD2,[H
MVQR6FD=-S#K2S++[;8E/=:6]T&5F_2._F9-R/_.\_P#H56#0)Z7Y1&'X//\
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MT!XA^GN>_#U<.F/B;_2'E7OY#Z%>;+S9_B+OOX^BC0'B'Z>Y[\/5PZ8^)O\
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MQ.[R2VY"XJ0W)/E*L\8XIX85)R2VI/%+'IDA!F)E
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M =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
M        WI?HK_R/]A_VDSOU7P$<U<]?\?M/D?\ K)F[N;#^$W'RG_,B;0 T
MR;+
M               @$V_.*R#\QI/WRR"O_L_]8D^[)^B@3@
M               $5-H=(]7MRV5L9MBL2L4^,8K#RX[(>R76/3".V*32CU!#
M++XTO:9"C0J3R++SDG9%R,^ZRE32K^09-IO6.I-)5I5L@NIT%/#?CA&5.>'
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M0M#.T(4C8U-38D3H&UL;4"<M*A;V]"E+*2HD*)*5864479:667;2VVE*4I0
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M_P"2*C[[2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB0B
M
M
M                       ! /AU_P"$N1_SYS#X-0@5[CW2_!1)#@]<GX*!
M.
M                                       $">*7\W'NU^S9E;X*KQD^
MBOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\ ,ZW?C=W'HU]\\LP^4/V$4=(_
M-NS_ #*]EEDXQ R,             /+/XI7SC>[7[2F5_A6X#M317S2R[Y'2
M^"CF34_SAO?E,_A,@4,G+"                                 &]+]%
M?^1_L/\ M)G?JO@(YJYZ_P"/VGR/_63-W<V'\)N/E/\ F1-H :9-E@
M
M     0";?G%9!^8TG[Y9!7_V?^L2?=D_10)P
M
M" 6R/RK]/?[7E7^VT"O3_)3))>Z1/T4"<
M                        ".NVOR;LO_DBH^^T@J4ORB]4EE[DY?67Y/>&
MOS=1?\6$"%3\H_5(QX#.8D(@
M
M                                                       0#X=?
M^$N1_P ^<P^#4(%>X]TOP420X/7)^"@3@
M
M          ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^33^"SIW!Z
M^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P             \L
M_BE?.-[M?M*97^%;@.U-%?-++OD=+X*.9-3_ #AO?E,_A,@4,G+"
M                         &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_ -9,
MW=S8?PFX^4_YD3: &F398
M                                $ FWYQ60?F-)^^605_\ 9_ZQ)]V3
M]% G
M                             (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10
M)P                                                   (Z[:_)N
MR_\ DBH^^T@J4ORB]4EE[DY?67Y/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M
M                         0#X=?\ A+D?\^<P^#4(%>X]TOP420X/7)^"
M@3@
M                                        ! GBE_-Q[M?LV96^"J\9
M/HKYVY=\LI?"18M3_-Z]^33^"SIW!Z^;)TS_ #.MWXW=QZ-??/+,/E#]A%'2
M/S;L_P RO999.,0,C             #RS^*5\XWNU^TIE?X5N [4T5\TLN^1
MTO@HYDU/\X;WY3/X3(%#)RP@                                !O2_
M17_D?[#_ +29WZKX".:N>O\ C]I\C_UDS=W-A_";CY3_ )D3: &F398
M
M      $ FWYQ60?F-)^^605_]G_K$GW9/T4"<
M
M  @%LC\J_3W^UY5_MM KT_R4R27ND3]% G
M                          CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.7UE^3W
MAK\W47_%A A4_*/U2,> SF)"(
M
M                                                        $ ^'
M7_A+D?\ /G,/@U"!7N/=+\%$D.#UR?@H$X
M
M            0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_S>O?DT_@LZ=P
M>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,             /
M+/XI7SC>[7[2F5_A6X#M317S2R[Y'2^"CF34_P X;WY3/X3(%#)RP@
M                          !O2_17_D?[#_M)G?JO@(YJYZ_X_:?(_P#6
M3-W<V'\)N/E/^9$V@!IDV6
M                                 ! )M^<5D'YC2?OED%?_ &?^L2?=
MD_10)P
M                              " 6R/RK]/?[7E7^VT"O3_)3))>Z1/T
M4"<                                                   ".NVOR
M;LO_ )(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_%A A4_*/U2,> SF)"(
M
M
M                          $ ^'7_ (2Y'_/G,/@U"!7N/=+\%$D.#UR?
M@H$X
M                                          0)XI?S<>[7[-F5O@JO
M&3Z*^=N7?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_P SK=^-W<>C7WSRS#Y0_811
MTC\V[/\ ,KV663C$#(P             \L_BE?.-[M?M*97^%;@.U-%?-++O
MD=+X*.9-3_.&]^4S^$R!0R<L(                                 ;T
MOT5_Y'^P_P"TF=^J^ CFKGK_ (_:?(_]9,W=S8?PFX^4_P"9$V@!IDV6
M
M       ! )M^<5D'YC2?OED%?_9_ZQ)]V3]% G
M
M   (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10)P
M                           (Z[:_)NR_^2*C[[2"I2_*+U267N3E]9?D
M]X:_-U%_Q80(5/RC]4C'@,YB0B
M
M                                                         ! /
MAU_X2Y'_ #YS#X-0@5[CW2_!1)#@]<GX*!.
M
M             $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G
M<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C
M#RS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\ .&]^4S^$R!0R<L(
M                            ;TOT5_Y'^P_[29WZKX".:N>O^/VGR/\
MUDS=W-A_";CY3_F1-H :9-E@
M                                   0";?G%9!^8TG[Y9!7_P!G_K$G
MW9/T4"<
M                                @%LC\J_3W^UY5_MM KT_R4R27ND3
M]% G                                                    CKMK
M\F[+_P"2*C[[2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB0B
M
M
M                           ! /AU_P"$N1_SYS#X-0@5[CW2_!1)#@]<
MGX*!.
M                                           $">*7\W'NU^S9E;X*
MKQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\ ,ZW?C=W'HU]\\LP^4/V$
M4=(_-NS_ #*]EEDXQ R,             /+/XI7SC>[7[2F5_A6X#M317S2R
M[Y'2^"CF34_SAO?E,_A,@4,G+"                                 &
M]+]%?^1_L/\ M)G?JO@(YJYZ_P"/VGR/_63-W<V'\)N/E/\ F1-H :9-E@
M
M         0";?G%9!^8TG[Y9!7_V?^L2?=D_10)P
M
M    " 6R/RK]/?[7E7^VT"O3_)3))>Z1/T4"<
M                            ".NVOR;LO_DBH^^T@J4ORB]4EE[DY?67
MY/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M                                                           0
M#X=?^$N1_P ^<P^#4(%>X]TOP420X/7)^"@3@
M
M              ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^33^"S
MIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
M  \L_BE?.-[M?M*97^%;@.U-%?-++OD=+X*.9-3_ #AO?E,_A,@4,G+"
M                             &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_
M -9,W=S8?PFX^4_YD3: &F398
M                                    $ FWYQ60?F-)^^605_\ 9_ZQ
M)]V3]% G
M                                 (!;(_*OT]_M>5?[;0*]/\E,DE[I
M$_10)P                                                   (Z[
M:_)NR_\ DBH^^T@J4ORB]4EE[DY?67Y/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M
M                             0#X=?\ A+D?\^<P^#4(%>X]TOP420X/
M7)^"@3@
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M /!$T)ZHXO\ ( 'T=Y__ ,QYIV53OX],LI\RV'8P[T/75:?_ ,$30GJCB_R
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M'8P[T/75:?\ \$30GJCB_P @ ?1WG_\ S'FG95._CTRRGS+8=C#O0]=5I_\
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MYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M  #>E^BO_(_V'_:3._5? 1S5SU_Q^T^1_P"LF;NYL/X3<?*?\R)M #3)LL
M
M         " 3;\XK(/S&D_?+(*_^S_UB3[LGZ*!.
M
M     0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
M                             1UVU^3=E_\ )%1]]I!4I?E%ZI++W)R^
MLOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M @'PZ_\ "7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M
M                "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\
M%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
M   !Y9_%*^<;W:_:4RO\*W =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
M                              WI?HK_ ,C_ &'_ &DSOU7P$<U<]?\
M'[3Y'_K)F[N;#^$W'RG_ #(FT -,FRP
M                                          (!-OSBL@_,:3]\L@K_
M .S_ -8D^[)^B@3@
M                                        $ MD?E7Z>_VO*O\ ;:!7
MI_DIDDO=(GZ*!.
M     !'7;7Y-V7_R14??:05*7Y1>J2R]R<OK+\GO#7YNHO\ BP@0J?E'ZI&/
M 9S$A$
M
M                                     " ?#K_PER/^?.8?!J$"O<>Z
M7X*)(<'KD_!0)P
M                                                    @3Q2_FX]
MVOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>
M68?*'["*.D?FW9_F5[++)QB!D8             >6?Q2OG&]VOVE,K_"MP':
MFBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$
M     -Z7Z*_\C_8?]I,[]5\!'-7/7_'[3Y'_ *R9N[FP_A-Q\I_S(FT -,FR
MP
M            (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
M
M       ! +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ*!.
M                               !'7;7Y-V7_P D5'WVD%2E^47JDLO<
MG+ZR_)[PU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M
M   " ?#K_P )<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
M
M                   ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR
M:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&
M      'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M                                #>E^BO\ R/\ 8?\ :3._5? 1S5SU
M_P ?M/D?^LF;NYL/X3<?*?\ ,B;0 TR;+
M                                             @$V_.*R#\QI/WRR
M"O\ [/\ UB3[LGZ*!.
M                                           0"V1^5?I[_:\J_P!M
MH%>G^2F22]TB?HH$X
M        $==M?DW9?_)%1]]I!4I?E%ZI++W)R^LOR>\-?FZB_P"+"!"I^4?J
MD8\!G,2$0
M
M                                        (!\.O_"7(_Y\YA\&H0*]
MQ[I?@HDAP>N3\% G
M                                                      "!/%+^
M;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K
M[YY9A\H?L(HZ1^;=G^97LLLG&(&1@            !Y9_%*^<;W:_:4RO\*W
M =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
M        WI?HK_R/]A_VDSOU7P$<U<]?\?M/D?\ K)F[N;#^$W'RG_,B;0 T
MR;+
M               @$V_.*R#\QI/WRR"O_L_]8D^[)^B@3@
M
M          $ MD?E7Z>_VO*O]MH%>G^2F22]TB?HH$X
M                                  $==M?DW9?_ "14??:05*7Y1>J2
MR]R<OK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M      (!\.O_  ER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M                      @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]
M>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
M         >6?Q2OG&]VOVE,K_"MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.
M6$                                 -Z7Z*_P#(_P!A_P!I,[]5\!'-
M7/7_ !^T^1_ZR9N[FP_A-Q\I_P R)M #3)LL
M                                               " 3;\XK(/S&D_
M?+(*_P#L_P#6)/NR?HH$X
M                                             ! +9'Y5^GO]KRK_
M &V@5Z?Y*9)+W2)^B@3@
M           1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)[PU^;J+_ (L($*GY
M1^J1CP&<Q(1
M
M                                           @'PZ_\)<C_GSF'P:A
M KW'NE^"B2'!ZY/P4"<
M                                                         ($\
M4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX
M]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&             'EG\4KYQO=K]I3*_
MPK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M          #>E^BO_(_V'_:3._5? 1S5SU_Q^T^1_P"LF;NYL/X3<?*?\R)M
M #3)LL
M                 " 3;\XK(/S&D_?+(*_^S_UB3[LGZ*!.
M
M             0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
M                                     1UVU^3=E_\ )%1]]I!4I?E%
MZI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M         @'PZ_\ "7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M
M                        "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G
M^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
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M/]A_VDSOU7P$<U<]?\?M/D?^LF;NYL/X3<?*?\R)M #3)LL
M                                                          "
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MU/::RTW:ZFL:=2E:7<)2C"IN[Z49R@][=<EPQ;V-[,"00L1DH
M                         $ MD?E7Z>_VO*O]MH%>G^2F22]TB?HH$X
M                                                 $==M?DW9?\
MR14??:05*7Y1>J2R]R<OK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M                     (!\.O\ PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
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MF=^J^ CFKGK_ (_:?(_]9,W=S8?PFX^4_P"9$V@!IDV6
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MPTB\RE>4VM*;>R#)<ZR3GHMZ6?WRS#,*V4SJ.KR:I=;C.G&+C'8VN3X>)I=
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M"][A5[4>EFEO.>7_ +11[<>&C#OC8QIU[B_=4/1O47B%[W"KVH]+-+><\O\
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M\&)VP> N8
M   ! /AU_P"$N1_SYS#X-0@5[CW2_!1)#@]<GX*!.
M
M                   $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY
M-/X+.G<'KYLG3/\ ,ZW?C=W'HU]\\LP^4/V$4=(_-NS_ #*]EEDXQ R,
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ML+QJ551I492IQJ4Z,&H2<Z=&E&%"3<DVERB>UFRB.>CJ<
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M)K!X/A,D@0            CKMK\F[+_Y(J/OM(*E+\HO5)9>Y-"C,'^*4_\
MRK>OOTT?5[FL_P"W&2?\-H? 1\6.>C_NSJ+_ (O<_P!I(QP,]-9
M
M                        !?)P OE)9E_,>;\/8>.5_P";'YF9;_Q1?V%8
M[,_DH^?N:_\ "'_ZB@;8@X(/I4
M                     0#X=?\ A+D?\^<P^#4(%>X]TOP420X/7)^"@3@
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MT]W<ZZJX[=W#=>S:TSWZLYT<VTKS2V6NKBWMGGU[3M7&B]_DE.X2JN+6]O\
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M1RT;Y               (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
M
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M<UG_ &XR3_AM#X"/BQST?]V=1?\ %[G^TD8X&>FL@
M
M              ODX 7RDLR_F/-^'L/'*_\ -C\S,M_XHO["L=F?R4?/W-?^
M$/\ ]10-L0<$'TJ
M          (!\.O_  ER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
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M_D?[#_M)G?JO@(YJYZ_X_:?(_P#63-W<V'\)N/E/^9$V@!IDV6
M   &MC]*3^;^P_\ MBX__4KL&-O<RWSIN/\ A\_[:@:ZYS?X#1^60_LZIW'Z
M,G\W(^?M*9-^"F-10YX_G;'Y'3^%4*W-M\WG\IG\&!KP\"3YY&%_^>/^ 4Y&
MUN<S_M_4_P#E_AP, T/\[X?^=\&1NV[Z:2XNWXUVEF"LDIB4:Q39>]XZFY:2
MQ2[XYR"A2J"F*5-?+<68:3;51>F7I:7V6K6\\XBMUM;[;[.<],:CO=+YM#,[
M-XQ6RI#'94@WUT7[,7T))/I&YL]R6VSW+YV-SL;VPET837!)>PUT4VC0JB^P
M&RO#!;=Z.'+G:/.1T-S!CG(,%=8OV4::@CF07N*J$$%S'C]0KH2G6Q>:-MZ2
MQ;=9:5<O;+TYUU**$-A%>G*^59/K.>6:MRR:5Q;UH34L-LH*6,Z4\."4'CAP
M[LL5P2Q-&4K_ #'34;[3U]%\C6ISBX]!2<<(U(_>R6&/&L'PQP+7_HHG^(.Z
M?Y&X2_'>21@_/A^JY=^<K>Q3,IYK?UB\_ I^S,JWVWAV0^%%Q>%^14\?5J6.
M'YY*V$Q=::880AG>(I=)U;^9'DKL:3=SC+69>OC+@?2SG%+DQ]UMM;>9==FN
M17%IKC0:M'-*K4M>0J<<*L8J.\UZJC4BNBFNF8SFM&XTMJQW"BW"%?E8<4J<
MGCACZC<&^-,] '6+:[ VX6,&3+6 I^S32-NJ-(<X-Y"M*7*(>Y*"+#CXW-X[
M8H.7QJ1-]UU;#2#Z<V_DZ0F\TF\LV_EO.<CS/(+V5CFE*5.M%O!X/=FO?0EP
M2B^@UZCP>*-\9;FECF]M&ZL*BG3:VK[J+XI+A37%U,5M.3V+V9P=J?C1[RSG
MK(3! (@RHU:DN]T6D4>9$L2E4-M8HBQ4,[:2F1++KK;"4:,LTZZMU*UI;92Z
MZDF4Y/F6>7D;'*Z4JMQ)K@6R*?W4I<$8KHMX(FS#,K+*K:5U?5(TZ,5T>%]*
M*X9/I(\]G$[%.^,%Q=:RM+''%,PY8S:FR7-R+[JF5@. 8*N:B[R'=S36WI2G
M%MQZQHF9.=6MA2MX.3E6UI4ZV@ZJOJMMH'0?(2FG5H6SIP^_KS3X$]N#J2<V
MN%03?0-!VL*^K=6<JHM4ZM;?E][2BUPOC4$HKCDTNB;F'$RX26.^)B^8B?)S
MER:8R-Q&TS!I;B(HQL;N6[ER]9'UBDU;<\7V7$7H[H_92RA?L74,NY?L4'/F
MCM=7>CJ=>G;4*=95Y0;WG)8;BDMF''O&W]2:4M]23I3KU9TG24DMU)X[V'#C
MZA5Y]51U_P#2MS%U+A7W89I]-V:^(V_9S,9^B^P\:K=C$MHVCSO"N$WH)AN]
M_P :2[8?&^&F3"FN[F6@HP(%]C)'(5;%V&>R<AT)4LQ*94\Q1 F,+LIR6KW,
MFEE>2@P7)<LN-<ZHN%2K4[2[N)5JZQWFL93WI0CAMQ2E)_@Q>)E69WU'2N0T
M>4ISN+>C&G2>&">"CNJ3QV<,4O5:/TX97$FUPX@L*FKEB.,),236'2"Y')\1
M.RN-V2ZYDO1(36B=$IF(M,4Y1QR/5'(Z'V677)U26\LWF\\JIC6.D,WTK<TX
M7\W7MJD,8U4I;N.+QAUW!);'AT4TUT<(Z;U%EV?49RM(JE6A+KJ;PWL,%A+9
MPI\&/0:V] S)Q(,CX,QMI+LDMV">(TA@LBQ!D**$,TA4H[%,QD;W%'5+'8K%
MT*DRQ0YRMR=[B>P;4_\ /)S[:*.<5:3<;9;](VF97FH[..51F[F%Q"6,<>LB
MI)RE)]"*6.]CL:V;<<'[-17%C;9-<2OW%4)49QP?W3<7A&*Z,F^##@>W9AB:
MC_T6Z'3%QW8S1.6NU63"8IK@[QZ7++":F(3G>99"@:R(LBB^OVA"M=9$')83
M=_SJV-IMM/8NN&]>>FXMX:=M[:>'A,[M2BNCA"G-2?J+?BG^$C5'-E1K2SFM
M7CCR,+=J7%C*<=U>ONM^LSH^>^'%Q>G??7+.U49UHD.17LC8.93S',HFSMB&
M6LRUH:)6X4QDN,C<HF%Z%2UL4?2-]6]$K2]"G+3$EW$TM+Y@].5ZNT'3TQ0R
M2M>0HTW:PA4C!58M-Q7*+>C#'&4G+>:>+Q;QVXE&^T]JR>>U<TIVTJD_")2A
M*3IR6"D]QX2EP)88)K9@MA.7PP_2HO%=7J1JEW2&-^ <R?QW_CN?:+WX9SG_
M !7_ (:'ME"G"VDF_L7V F#APY6'W19N.P[($<I1=JL?._18K,FN/CWM5V-D
M@].QV<R7)V.SGE5JKIS^2VG1W&\FSM:T=+ULJIQU;+<RWPB+B\9K\9N3P7XO
MKO<[_#L]? P73%3/J5_.6GH[U[R+WEA%]9O0Q]WL]UN]/[)LF<6C">VV?N"K
MAK*6RD:46;1X$G).4<WLZ1LBY"M%%%;G/8.[*"FZ&5/9"2&QD?6)S5U0WW%%
M(DAQYU/YN^\O4.ALQR+*^<2XLLGFO(MU2Y.BVY8.24)K;/;M<9Q6.UMI+A6.
MQ=566:W^C:-UF,?_ *G0GOU%A'9'&47LCLV)Q;PZ";9D;Z-)N1C^;ZK'Z>/4
MD;&K+.%)7+WF)15>NL3KY7C.<.ZV;'.\<3JC;+G,Y@ESJ[%N1"6V^J,DQ,<9
M2E%'*/)SP:?NK;.UG].$I6-S""E)+9&I!*&$L.#>BH[K?"\4N ]'-QG%O6RO
MR1.25U1G)QBWME"3<L5QX2<L4N!8/HEK'%)W(Q]IAIUF";R62-J">RN$2F#X
M;BUZZPM]EF1)(S*F=FN:V\LVQ<H;(VH7VN+F?9S;4Z)/?]O0R\JV_"-%Z?NM
M0Y_;VU&#=K"I&=66'6QIQ:;Q?!C+#=BNBWQ8F4ZFS>WR?**U:I)*O*$HTXX[
M93:P6"X<%CBWT$O4-;GZ+!KU(UV7=B=IU[8H(AT:QZGP7''-2F_Z&\2N7R&-
MSB3%-*BXJZVY=%&2'-U%?-OLN+*?"J<EU#+N;MWGKS6C&PM,DC).XG5Y:27"
MHQC*$<>E)SEA^ ^(UUS86%25W<9G)?B8T^33XY2:D\.G%16/X2-RG(O^'TZ_
M(V3_ (D7#GZT_6J7YR/LHV_<?J]3\"7L,T*/HR?SCCW^S9D[X58W'3O/'\TH
M_+*?P:AHSFV^<+^33^% ] D<M&^0              " 3;\XK(/S&D_?+(*_
M^S_UB3[LGZ*!.                !7CQ7LASK%'#WV5R%C26/T&G$:C,74Q
M^5QAR4M#ZSJ%61(<W*#FYQ27EJ$IAR!8:3=6VZE:EF74^Q6HSSFQL++--=Y=
M89C2A6LJE2:E":4HR2I5&L4]CVI/U4:SYX\SS#)N;3-<SRJM4M\PI4J;A4IR
M<9Q;K4HMQDMJQ3:]1LI;X+^\>R2#8Q%KGN%E":Y'2;0X7BV:==97D"2K'XVP
M] E?E2YD9%3L?T]B*1(D#NG/MYUU+72,]&397I[KZ[?YW=&:>GD#U!I.VHV\
MLMO)V]U"E!1V-Q2E)1V8Q;@U]Y6Q;V8&B.8GG U33U/'2^M[NXNH9O84[JRJ
M5JCF\4IMQ@Y/'":52+_^)0PBNN;+<N+ON XZ>::3610IQ4H<R925I<0X;[74
M-O=TDLEA*BURDK9:GI>H*71*+IEJY&;2R^SMI8D*NI_.TY=6<U>E*>K-74;>
M\BGE-LG7KX^Y<(880>.S"<W&,E[QS?0-T\]6MJNB-#5[JPDXYY>25M;;ONE4
MJ)[U2.&U.G34YQ>#7**"?NBH/A.;:['XNRSONCWFS=EG(3/JMB$B0S1EDLC>
M)R9$7:-OAU)?8R-RM69:H=$-I)B6ZI5;>FJ7[%>2M!M7G/TMI_,LKR.>B[.U
MH5<SNW"G*$(T]^,X_B]YI;$]DMO!B:3YF]9ZHRC.=1PYP<PO;FAD]DIU8U)R
MJ\G*$_QFY%O;)8..SAP-DK6W8?&^UN%89GW$:EW68\GONB]SZE]:C61U,]RT
ML?86[=E-9QAIJ7F/D=4VV<MU>>72V^GL7#GS4.0YAIC.*V1YJH*_H;F\HRWH
M]?"-2.#Z/6S6/3V'4VEM397K'(:&H\E<Y99<[^XYQW)?BZDZ4L8O@Z^$L.-8
M/HE8^ZO$+QO.]>N(OB3 <XR/$L]ZL8^>:2F0LY#W"%D:>$$N11HQ9$9DUKTR
MZY38N+,LM.37E7]'7EI7DKR#8VC]!YA99]D&:YY1MZN1YG7CN1DXU%.+@YX3
MIM-888;'CM-3Z\YS,KS'36I\ETY<75'4>3VTN4G%3I.$E44,:=6+3QQQ6,6G
M@4R9?XM&8L8\,?4*&XUS9F1#MRN>D4NR)E&3LYTVLDV-'%?G-)5M6Y#R EDR
M=Y>NVB9EY";N5660CYMM]"R[K:[<RKFNRG,N<;-;O,;.TEI:,'"E1A+D]RLE
M;/%4J3@XQW74V^Y;EP8O$T5G7/-GF4\T^26.57]]'6DJBJ5KBI%U>4H2E=K=
M=:LJBE+>5+9[I*.QX)HL6VHXC&LVR&G;)*D^S6XVJ:"#9HQ7&Y1DO#\-E<(G
MLBELFQ=EER31+_H#RP*'2%.A,;7KU=UAM2+%K>BY2ZUNLK;@&F= :BT_JR=K
M++LIS.=:SK3A1KU(5*4(0K4$Y[8R2J1WXQCLQW93V\)L_5_.?I35.B*=Y'-L
M\R>G;W]O"I7MJ52E6G4J6]Q)4]DH.5*2A.<L'@I0I[-JPK^XD/$A:<S;4:[8
M6A>?MK\3ZVP8@^-YZ7XO2RF Y,D\D;I*Y-CX\LY*4\PR<75;&%+VN-4%+$A"
M@XXZTF^ZMU*YUS?<WU7*-,W^<7ECE=UJ&LU.V59PJT80<$XQEC^3VREO).,F
MDEBC6W.ESI4<]U?EF16&99S9Z6MTX7;MU4HUZDXU)1G**3_&];".XY*45)RD
MHMXEP4"XE.BNF.GV CW_ #IL+DUNF**=*,:H,RI5\]VIFC.@RE-F5<XRY'5!
M'BT#(UR)O5M+*H<.UZ<UN0D$)[C;B;^35%]S>:TU=JN^5"RL+:I1=-5G;M4K
M*G)T:<DH/&6,I0<9U%'>:G*4I88HW;EW.IS>Z%T1ELKG,,SNZ5>-5T%<IULP
MJQ5Q5BY5%A#"$9J5.E*>Y%PA&,7)Q9S>+N.?I//9XQ8ZG3=G+6Q_DZA.ECZC
M8W&Z*#L3C>LOM)1'F/C#*9@W,[<J4W5*HL<+TB2R^VO2&V6\EU:.9<R^L+&R
MG?V4K+,:%--R5I5=22PX>ME"FY-+;NQWI<29Z,H_F#T%F.8T\LS".895<UFE
M!WM!4H2QV)[\*E6,8M[-Z;C%=%I$FLN\2_4? V?'777+L\706;,4 4Y+>7AY
M8U=D+;XNF85TAYUS^1<=>K=UB1!<2E0)R#E:Q884G(+,.-LLKCN5<W>J<[R.
M.?Y50C6LYUU1C&,ERCFY*/N>A%-XRDVHQBG*3239EF=<ZVB].ZCGIC.KB5O?
MT[9UY2E!\DJ:@Y^[6.,FEA&$4Y2DU&*<FD1=:N/%H2[P&>Y.(<<N$PG'L_QU
MC=S>%..+Z7.<ARBPY3DD6O96XEZ/=#&Z]KP\\7*#%1*6XF_H+>9=4RO-R2KS
M)ZWI7U#+91M7>5Z%6JHJKP1HRHPGO/=PQWJ]/!)RQZ[;LVXC1_F(YNJV77.;
M1E>JPMKFA0E)T/=3N(7$Z>[%3<MW=MJF+DHX=:L-NS[\J<=?A]XKDON=.F.0
M)VG3.5K*\2['./G"009D>.CM.4-ATI5JVAN>U2,JM;C>T]7*RG,NI;===;6@
MDRSF6UUF=OX1&C0H2<=Z,*M51J2CT'N)2<4^ARFYPHJ9Q_,+S:Y/=>"RKW-Q
M%3W95*%%SI0EPN+J-QC-I</)[ZV/A:.R95XVW#UQBT1]S;\JO67%4BBB*;E,
M.'(>[RYX98NNL*,L<)=V;:Q-4.6)BS>52WN:I*YI.3^>3V5NLYWGRSF=UWF5
M6I3G;0M8TZKI[U>I&$9370AAO2J)]"4(N$NA)[3U9QS^<VF4T:56E>5+V=6B
MJNY;4I5)1IOHU,=R-)K[J%24:D?NHK%8RDUJWTU;VOQ'+,UXER8WW0G'M%UV
M2;Y<29#W/')3>WGNYZR9(GOL>QK:;FA,8I+7VF&H#2BC:6'5O(/M+QK4.B-2
MZ8S6ED^:6\O#*^');GXQ5<7NI4W''&6\TG'!23:Q6#3>7Z5YQ=(ZQR6MGV37
M<? +;'E^47)2H81<FZJEANQW4Y*>+@TGA+&,DH..?';U"N4R!; <9;:9DQW%
M%9R229FQ;@D]TQ6QU3TI<:>Z/4ADT8>D*:TFZAG.,;K:U+NI=2E:5H,SI\RN
MJMVG"^N<KM+^JL86]:Y4:TL>A&,83BWT-DN$U]5_F&T5O5:F76F<WV649-3N
MK>T<K>&'1E*=2G)+#;MAP;2RC6S:'!NW&-$66<!3MOG,04JC6Q=>20L;7F//
MB8HDU9'Y,PNA"1V8WA*6?9?T1Y5MIQ-]AQ-QI!A9M^O-0Z;SK2V8O*\\H2HW
M:6*VIQE%\$H23<91>'"GL::>$DTMJ:5U=I_6F51SG3EQ&XLF]UX)QE":P;A4
MA)*4)+%/!K:FI1;BTWG)R<4#.W+W=T5D(&QK1*G%Q7*C+2DR) A(,4K%:@VZ
MM+2B$R<JZ^^ZOL6VVUJ+-3ISJU(TJ:<JDFDDN%MO!)=-LR"K5IT*4JU:2C2A
M%RDWL226+;Z26UE+W#DV*R;NID[9W>>8SN3Q35B)/#IAW7?$]'AS9XC9'(:F
M*D$OR_.8^4<6F=Y2O;7!+0LY10ZQ'><L3VV_]$37V;=YP,@R[1^79;HNTH4Z
MNI:L%7NJ^ZI3WZCW:="G+AC!-/%+#>PA+[J2>B>:_4^;:\S;-N<&^N*M'2%&
M<K:RM]Z4:>Y26_4N:L,<)5'&4<'+%1;G%>XBU"+!<^W=XU>3\O3N&;)Y%TRT
M?QG+JPF)MF(#S&7)D[<[4A3A5$OE#.N9W:QWN85:-P=[E*HYM0VN"9&E1*:W
M*55N99U8Z.YG\MM+*\R^WS?65S2Y2;KK>HTUCABH24H[N\I1A@E.6[*<IQZV
M+P'3V8Z_Y^,VO<QL<UNLBT!:5N2IQMGNUZTL,<'4BXRWMQQG4WI.$-^$(4Y8
MRFNZ[%:0<2'1B/MF;]%-R]G-E[(\]LY,MUZS"O7Y;6/34Y+R$1SE'F!2<M:G
MDCLM5;:XD)&]O<DR&Z]64MI5/6MOCR#67-]K2O+)M:Y1EV7.I"6Y=4$J"C))
MO"<EA*+P76.4I0<L(N'7'OU/H#G2YOK:&?\ -[GN;9JJ52*J65RW<N49-)RA
M!MQDL7UZC"$XPQFJG6[/FXP>XFS\8X>^I.;(JIROJ1E_(>3&]OR7#&MS?89)
MV%P(@DW[>QE;7E1.A[#<_L]%2'I[;;CTO8YUUM+KO8FYJ-)Z;N==YID]TK7-
M<JM[9NC4:C4A)<I3W9KA2ENRW98<$MY$G/;K?5MIS:9+GUF[S)<[N;N,:]*,
MITJD&J-7?IO@DX;\=Z&/#'=E@9\C_"\W0?8ZR/7KBMM$IKPRMKIT':MQ/+3&
M."$E7T7.\*9-QUA-QW)R_:UNI3^06.OSD:1HUYT?1/*VH3:]TMN#P^),CMN:
M37=Q:TZ_IQG*<Z<98;LGAO)/QA8X8F+N$3LIM>LW/V[THS9F\_:/'V!VIZ7,
M6:EY!*E<FDD?F[!%"&GMW8:M<#"Y6VNZLXY"M6N-4"QE.+3GUMZ:XVY<ZFGM
M,0TCE6L,GLUEM_?2BI6Z>"<)4Y3<MW8NL<8I2C&&]&HG*..&%HYE=5:QGKK.
MM!9]F#S?+<NA-PNFDVIPJPIJ._ME^,C*3<)SGN2I2498;S=.N@?$DW-Q?EO!
M>P&Q&>LJ9/U7F.97W7C(Z><S9V?6&-.3C&(RYD25<4ZJ34K<>P%RLAW(-MIT
MIZ-H7DV\G+6HVSKGF]TCF65WN19!8VUMJ:C:1NJ3ITXQE-*<TX+=6+4MQP:X
M%*<&S2'-QSI:ZRC.LOU)J;,;R[TA7OIV5=5:LIPIRE3IR4WO-J+ARBJ)\+C3
MJ11NQYWS/$-?,+Y+SE.%',B6,H8]3%SH29;:>XEM:*\Y$TM]U;;[+W%]7U)1
MI:<E:7J#[*?RCCS),HN\]S>WR:R7]ZN:T::Z6+VR?2BL92Z29WKJ+/;+3617
M>H,P?]RM*$JLL.&6ZL5%??3>$8\<FC4 T.V\W[G?$<T]OSGG/*5^.]K+L@9K
M;,5FRU\+@U8*ZJ\Z,+0W)8B>JN1H(VED6.SS6I-S.CM0%I3"^6RME:]6:VTK
MH>RYO\V62V5MX?EG)6[K;D>4Y2*MI2;FEBYN%5*;X=YR3VXG$W-WK7G'S'G0
MR1Z@S"\\F9QRUU&W=2?)<E)W<(Q5-O!04Z+=..&&XH-;,"ZILV(RAJ)Q3C-7
M,N3N43W7;=1HK/\ 7=ZFCRMD#EB7*!%5B-\Q8@=G \U;2'.SFVWEHD?-O+17
MN3785=3E6WW:@J9#ENJN;3TDRJA3H9_D\^2NHTXJ*KT7@XUG%;.4BGC*6QRW
M*K?W"-\TM39OHKG>>D<ZN*USIC/H<M92JR<Y6UPL5.W4I/'DI2BU&.U1WZ*3
M_*-W8#3QOH                  (!;(_*OT]_M>5?[;0*]/\E,DE[I$_10)
MP                     ,5'88@:O-B+8%>B<W')+/C15B:-K'!]=U3%$X@
M[26R52JD7BQJNL?97Z;NC>V6O+F4GHN<$K&W)S#>A2V65$<=F!E4"
M     &+\SX?A6?<92G$&2"'A; 9P0W-TQ:&20O47/DD=2O#<ZNL2<W6/K6YU
M,BLO2(+FMZ16'6%N;.K4HSN4D\RVHBG@\49+(((2D$I4I)29,F*+(3IR"["2
M""";*%E$DE%TM+***+MI;;;;2E+:4Y*>P! _4           1UVU^3=E_P#)
M%1]]I!4I?E%ZI++W)H49@_Q2G_Y5O7WZ:/J]S6?]N,D_X;0^ CXL<]'_ '9U
M%_Q>Y_M)&.!GIK(
M                                                +Y. %\I+,OYC
MS?A[#QRO_-C\S,M_XHO["L=F?R4?/W-?^$/_ -10-L0<$'TJ
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MX=[AQZ' 8+IO1'H]F+O_  KEL:<H;O)[G"T\<>4EQ<&'KFP(-6F>@
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M[8SB[O9*+Z,9+:GT4TSM>XO_ +3K\/7]HE%^+=LQY=)_]_,^^0/V;(]NM_\
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MP^)9+=F"2P-/EMNG[*X-)\Q98R>38[$,M#FVY;2^PDVXFG/(3W(MQ2V^J;#
MB4@                (Z[:_)NR_^2*C[[2"I2_*+U267N36BNX+6TF:;KLM
M1:>X!01S(M:R]D1/\IR(E>TK:]U[-2$.J9NQ6ZH"%Q91M*&6DJ3RZ7?8ONI[
M([:T;_,GH;36E,OR"^M,VG>6=I3I3E3I6[@Y0BHMQ<KJ,G'%;&XQ?&D?/?G
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MZ*4<(-8J3>.&S#:KNQS*==
M                 $ ^'7_A+D?\^<P^#4(%>X]TOP420X/7)^"@3@
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MHC;Q>H<6_P#\@_WT_CZK5_WZ/_99/_EA!'ZV'_V#_'?[F/JA_P#4/^ _WPO
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M #(FT -,FRP
M                      (!-OSBL@_,:3]\L@K_ .S_ -8D^[)^B@3@
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M2NGH\E:*M3G3=U=8N4J\(SBI.E"33C476S=*BX8XU-V[\:;-_@
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M4^XRM70)6FIX/AQ,<\ ;YH+2?\AYS^N+(P+@%3W;+AA$D
M  CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.7UE^3WAK\W47_%A A4_*/U2,> SF)"
M(
M
M                                $ ^'7_A+D?\ /G,/@U"!7N/=+\%$
MD.#UR?@H$X
M                                                0)XI?S<>[7[-
MF5O@JO&3Z*^=N7?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_S.MWXW=QZ-??/+,/E
M#]A%'2/S;L_S*]EEDXQ R,             /+/XI7SC>[7[2F5_A6X#M317S
M2R[Y'2^"CF34_P X;WY3/X3(%#)RP@      6$\*#&[;ECB/:=0UX(3JVNN:
MHW*UR-72ER5:1CNQ7D.]$I+K;?8>G6>Y;HKRKJ5L-MOK9=]K=48KKB\G8Z1S
M"XIMJ?@\HIKA7*84\?6WL>D9!I:WC=:ALZ,]L>64GT]SK\/_  ED7TE#:">9
M*WE6ZV&O2Q-C#7*+PFUOBB<]04U+Y[D*&,\_>)DY)J\TE<\TCTL0MJ>^O/L2
MID]]"N9>H5=)B/-!DMK9Z;6<**=[=SGC+HJ%.;@H+B6]&4GQMK''".&1<XN9
MU[G.WESDU;6\8X1Z#E.*DY/C>$DEQ);.%FNH-L&O3<UX2>6)3N3P;=[-5\J.
M1LJ\"6-IY$\>NKV:H5JVF)2?&D@D^.&L]8JM/O4E0&<1=2:W5K??V(BL3);+
M+"4Q-M>?-=6-#3_.!EF=V4=SPFM"4TMB<HU(QJ/!>_A);W&\7CBV;ATI=5<X
MTA?99=/>Y&G*,&^A%P;@OZLHO#B6"X$C3*'09IXW8>%KL!J?Q4-"F'AF;=J"
M;<IXF9&U@AJ12^$,<FE$4AI2PC'4[Q$]+>R;BYWC>-7]JER&A:GG("*FF$GH
M52I.3SKK7*L\T3J>6L<A3\"KR<IO#>C&4\.4A52^XJ2ZZ+V=<\$U*,6]S:8O
M\JU/D4=-YM^M4HI1VX.48^XE3;^Z@NM:V[%C@XMI8PE?T4/I9,9?!]UNP8:H
M4EW$IY7@[MK)FE'<9;::48L:,G,[5(%)1-*WVF4(;+#+JTLK992G/K[:'/AA
M1_O.78W"7W-;"+?J.FW%>O+_ "'FJ\UN-7\1>X4<?NJ>,EU)I/J1)\1K$^D?
MT=G5G(F2U$K.R5GS(C35N:%<K.;6R=9BE#2G,-881"XRUT5FPS&K<ZJ+5;L?
MSUO8MM_2*E:@VB%/3%ZU]J/G8SNE9J'(Y72EBU'%PI1?NISD\-^HULBMF/!&
M*6\R^T[7)>;[+*ERY\I?U%@M[!2J27!&,5[F">V3VX=%M[J-!N:S"19#F4MG
M\O<37B63F3/TPE#N?2VTYTD4F=5;T]N)UME+;+35SDM--NI2E*4K=[ Z?M[>
ME:6].UMUNT*4(PBN*,4DEZR6!HJM6J7%:=>J\:LY.4GQMO%OUVSK(K%(VDV[
MBA:3\0BW"<8W;D.QNH4\Q.\056P2K&&1Y1/M6)8X0MT;534KR#B!<4X^YM4J
M[$H554C;KSRN=4U0ZVDV4*II:>B]1:5\)K:<A:7]K7C-2C4IQA<Q4TTU"JL-
MY+''!RP? H8O$V='4V39_P C2SF5Q:5Z3CA*$Y2HR<6L-ZGMP]5+'HN6&PK\
MXRFL#[ MAI7MW'\F8>R_@+<?+&4)SB.;8CFY$O)+I8N;'QWCTEM3I2DJ!Z:2
MI*1;=V,>L(NI7V3+#.<59E/-]G5*ZRJ&0U:-Q;YIE]"G"K"K#<Z#2E';BT]U
M\*3Z6&TL.L,LG0S">;4ZE&M87E6<J<J<M[B;3XFL5P-KV"F\; ,/     -Z7
MZ*_\C_8?]I,[]5\!'-7/7_'[3Y'_ *R9N[FP_A-Q\I_S(FT -,FRP
M
M    (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
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MK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M (!\.O\ PER/^?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M                 @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_)I_
M!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
M    >6?Q2OG&]VOVE,K_  K<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
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M3_F1-H :9-E@
M                       0";?G%9!^8TG[Y9!7_P!G_K$GW9/T4"<
M
M                    @%LC\J_3W^UY5_MM KT_R4R27ND3]% G
M                                            CKMK\F[+_P"2*C[[
M2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB0B
M
M
M               ! /AU_P"$N1_SYS#X-0@5[CW2_!1)#@]<GX*!.
M
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M>E^BO_(_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M
M     (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
M
M! +9'Y5^GO\ :\J_VV@5Z?Y*9)+W2)^B@3@
M                          1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)[
MPU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M                                                        " ?#
MK_PER/\ GSF'P:A KW'NE^"B2'!ZY/P4"<
M
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MR)M #3)LL
M                    " 3;\XK(/S&D_?+(*_\ L_\ 6)/NR?HH$X
M
M                  ! +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ*!.
M                                          !'7;7Y-V7_ ,D5'WVD
M%2E^47JDLO<G+ZR_)[PU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M
M              " ?#K_ ,)<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
M
M                              ($\4OYN/=K]FS*WP57C)]%?.W+OEE+
MX2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<
M8@9&             'EG\4KYQO=K]I3*_P *W =J:*^:67?(Z7P4<R:G^<-[
M\IG\)D"ADY80        S=KSKCFG:K*+#AO L"><@SZ07UN(;&LLLI&UMQ5Y
M=BQ^D;PKO(:8Y'6[I;>R%RTXE.76ZVWG<^^RVZW9KF^79)92S#-*L:5K#HOA
M;Z$8I;92?0239[LORZ\S2YC9V--U*\N@N!+C;X$ET6]ANAZ]:6Z(<!G#2?:;
M<"8,>2MFUJ U,P+D: AY<TC^:DYRZ$ZW0EUN0*CW.^TZB=;)UW8AMJ:^M33F
MM&H/(OYYS74.IN<[,'DF04Y4<F3QDF\$XX[)W$UBL.BJ<<5CP*<DFMPV&39'
MH:S69YM.-3,FMCPQ>/1C1B\-O0<WALX7%-HUD^))Q6]A>(S,ZERI6=CS!+ Y
M'*X#@N/.B@Z/M]]MQA:60S5?:6BNG4WHDOYG9J@DM,CMN,M0IDMIRCIMQZ0T
M/E6DK?&@N5S.:PG6DNN?'&"V[D,>@GB]F\Y8+#6^HM4YAJ&M^-?)V,7UM)/8
MNG)_=2Z;V+[E+%XU=#-#&#<+X,/%+UCGNLE.'+ORXPMN8FQM6Q''DARQ1!;B
M^?8Y<5?9B+'4N=W2VQJC4BAZTRZC2K6FITQJ,M,62<4L2E=DZ#YPM%9S:YSZ
M6Z751U)-2J1I8\I"HE@ZD4MLHS7NDDVGBVG&3PVYH_4^6U\M]'L]<%!+=@YX
M;DH/@A)O8G%^Y;P6&&#32QGF\?1JN&C/'\N=Q*4; QR)N]Y+HVQ.!97A[O #
M4)IEQ]A;6[2C'DSF"EL4EWTMI?V\-OZ.E*V&4K]M7&*?._K"UI>"UX6LZ\=C
ME.E-3QZ:C4A#'^HO4+Y/FYTW7J<O2E<1I/:HQG%QPZ3<)2P_K'';/[L</K@L
MZRRK >EI./5FP#PD7IH[ X8\$3M\;INK0W-_A.SW*SU3V=TL=^T/*;'-1V:M
MY"4B1*0@Z0Y+/DNG-5<X><PS34+JK*XM;TYK<BX)X\G0CL]UP.45@MLI2<L%
M*&9YSD.CLME8Y-R;OVGA&+WFI88;]66W@XF\7L22CM6@\XN*]W<%SLZ+%+BY
MN:Q4XN+@M.,4K%R]:?>I6+%:@VZ\U0I5*#;KS+[JUNOONK6M>6HZ>A"-."IP
M24(I))<"2X$O4-%2E*<G.3;DWBWQMGQB8E+E..E[OO/B5=LNW'@*\$>%_-0Z
M3I_<CX"O!?$NUGN,YW_1NA]T79_;#F_SG;#I.=_-]"-?\VG@OHVMS=\I\O6\
M)]]RW*2QW_ZN[N_>X='$S#6_+^6GO8^ \E3Y#WO);D<-WU\<>GTL!MS[O_5-
M<-OPY=N?=UX4-F? 9[I.G[?>;5V)C+L?I.R_^G]H/==S.T_3_:=J^A[&_P"C
M=&(9#X+Z<YOY,W?!N1M^6W?<^$8U.+9O;ON\/NL=[KL1FW+^BN7>'8\ORM;D
M\>'D>L]?#>]SCT,,-A36-@F'@    &]+]%?^1_L/^TF=^J^ CFKGK_C]I\C_
M -9,W=S8?PFX^4_YD3: &F398
M                                    $ FWYQ60?F-)^^605_\ 9_ZQ
M)]V3]% G
M                                 (!;(_*OT]_M>5?[;0*]/\E,DE[I
M$_10)P                                                   (Z[
M:_)NR_\ DBH^^T@J4ORB]4EE[DY?67Y/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M
M                             0#X=?\ A+D?\^<P^#4(%>X]TOP420X/
M7)^"@3@
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M3_F1-H :9-E@
M                       0";?G%9!^8TG[Y9!7_P!G_K$GW9/T4"<
M
M                    @%LC\J_3W^UY5_MM KT_R4R27ND3]% G
M                                            CKMK\F[+_P"2*C[[
M2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB0B
M
M
M               ! /AU_P"$N1_SYS#X-0@5[CW2_!1)#@]<GX*!.
M
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MB;0 TR;+
M                    @$V_.*R#\QI/WRR"O_L_]8D^[)^B@3@
M
M               $ MD?E7Z>_P!KRK_;:!7I_DIDDO=(GZ*!.
M                                        !'7;7Y-V7_R14??:05*7
MY1>J2R]R<OK+\GO#7YNHO^+"!"I^4?JD8\!G,2$0
M
M
M           (!\.O_"7(_P"?.8?!J$"O<>Z7X*)(<'KD_!0)P
M
M                           @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L
M6I_F]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D
M8             >6?Q2OG&]VOVE,K_"MP':FBOFEEWR.E\%',FI_G#>_*9_"
M9 H9.6$      "06J&;4NMFRV"\_+8\HEJ3#V3XCD)3&4KB6T*7TF,.Z9S,:
MR'0U&X%(#5EI',H;<0;2RM>6MM?L"UYYETLWR>YRN,U3E<494]YK'=WEACAB
ML<.+%%PRJ]679E0OY1WU1JQGACAC@\<,=N!M@_6N\?\ H5S'X[F7R:#1WT'W
M7G&GW%]\-I_2E;^)S[HNT/V3?2NL;W*"+5>F$W(27'%6J3DV9V%4H)3UOMH<
M:0F-QZC+4G%E\M;2[CBK;[J4I6^VE>=2#YD+O![N8TW+#9^*DOL\H_887.E;
M8[;.>'YQ=J9<WVCNI/&<X9>2=V< QJ]NS-KXQR>2DN[PQ-3/DYE\&32FE60L
M0S^K2L7E2%L70-1>X-%A:M586J-2FI;K:FJDQO@TQ6SWF]UC1TYFD\<ONI1C
M@I-TWRCW:=6&*6ZU/K9;%L4E+@BUZ\]IY5K#3=3.;".%Y;QD\6DIK<6].G+!
MO%..V.U[<&N%IZ+0Z5-(F[SK_P 3+@/Q/ V$HKD6!XF49!C6(L;1^=J%NFYK
MZL/F3-#65NDYRM[IC171X4FO:8^XQ5TIO9%]:F<^[G<M><<UT=SFU\SN:]I5
MKJTG7J2AA=[JW'-N."Y18+##9@L. W38:DT/2L:-*XA2\(C2@I?W?'KE%*6W
M<V[<=O1,N^M2^CV^+W#O^2(WR6#P>A/.K\;<?MG_ .-/7Z4:!^+H_LW_ .@=
MX@/&?X&V*7A3(L74BF-I L;#F58^0'4Z20YX5LZA4C7*&E2YQW';<M/;#UK<
MG.O(NOJ5<:07?6VMUEM:>:ZYO><F^IJE>\I6I)XJ,[F,TG@UCA*HUC@VL>'!
MOC*U#6.BK6;J6V[3J-88QH.+PX<,5!/#%+9TC1^W$R)%<O;<[399@JXYSA&4
M-C<WY$ASDI1*VU0X16:Y,D\ECRX]N7E$+D!RMH<R3+B#K+#2KKJVWVTNI6@Z
M0R"TKV&0V5C<K=N:-I1IS6*>$H4XQDL5L>#3VK8S2V;W%*[S:ZNJ#QHU;BI.
M+PPQC*<FG@]JV/@(Y"[%N-M*':R:,X_WR58*5ZW-;W ^%+I3DW839^32@PE]
M0[0Y7:X#C&3&UE;:XMZM+>T1IRDRA2B1*C36Y0:2<46BM0$UL5:,N,YU+=:8
M69QO)1N<\S&G0MXQZUVU)SJ1ZUIIXR44FTE))IN6\]FU:.6Y)0SUV3ME*AE=
MG.K6E+:JTU&#ZY-<";;2>Q[5N[JVUH\1IXPML[JUK)OKBS7: ZPRV:Y0S+@+
M+T!Q@E1-L$D#M T$1E4+F#,U-S0R)2%YC%(5*=P/J3TR@ZEEMUUU";;JYAI*
MGF.39U>:8O;NK>T*=&E7I3J-N<5-RC.#;;>&]%.*QP2QXS'-0SL\RRNVSVUM
MZ=M5G5J4JD88*+<5&49))+;@VF^CZQ2V-AF&@    &]+]%?^1_L/^TF=^J^
MCFKGK_C]I\C_ -9,W=S8?PFX^4_YD3: &F398
M                                                $ FWYQ60?F-)
M^^605_\ 9_ZQ)]V3]% G
M                                             (!;(_*OT]_M>5?[
M;0*]/\E,DE[I$_10)P
M         (Z[:_)NR_\ DBH^^T@J4ORB]4EE[DY?67Y/>&OS=1?\6$"%3\H_
M5(QX#.8D(@
M
M                                         0#X=?\ A+D?\^<P^#4(
M%>X]TOP420X/7)^"@3@
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MB^MW<=K;5]"[M[&RHRMH6=A%3W*6]O3<GNN<YX;%CLP6+?#CQ&OT-IF!
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M'_K)F[N;#^$W'RG_ #(FT -,FRP
M                                      (!-OSBL@_,:3]\L@K_ .S_
M -8D^[)^B@3@
M                                    $ MD?E7Z>_VO*O\ ;:!7I_DI
MDDO=(GZ*!.
M !'7;7Y-V7_R14??:05*7Y1>J2R]R<OK+\GO#7YNHO\ BP@0J?E'ZI&/ 9S$
MA$
M
M                                 " ?#K_PER/^?.8?!J$"O<>Z7X*)
M(<'KD_!0)P
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M :9-E@
M                 0";?G%9!^8TG[Y9!7_V?^L2?=D_10)P
M
M            " 6R/RK]/?[7E7^VT"O3_)3))>Z1/T4"<
M                                    ".NVOR;LO_DBH^^T@J4ORB]4
MEE[DY?67Y/>&OS=1?\6$"%3\H_5(QX#.8D(@
M
M
M       0#X=?^$N1_P ^<P^#4(%>X]TOP420X/7)^"@3@
M
M                      ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-
MZ]^33^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
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M&2%D     -Z7Z*_\C_8?]I,[]5\!'-7/7_'[3Y'_ *R9N[FP_A-Q\I_S(FT
M-,FRP
M                (!-OSBL@_,:3]\L@K_[/_6)/NR?HH$X
M
M           ! +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ*!.
M                                   !'7;7Y-V7_P D5'WVD%2E^47J
MDLO<G+ZR_)[PU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M
M       " ?#K_P )<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
M
M                       ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?Y
MO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&
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M$L,7P)/;M;P1C><Y_?9VX1N%3IVU+'<ITXJ,(8\.'1VX+A?J)$%1DI8P
M#>E^BO\ R/\ 8?\ :3._5? 1S5SU_P ?M/D?^LF;NYL/X3<?*?\ ,B;0 TR;
M+
M             @$V_.*R#\QI/WRR"O\ [/\ UB3[LGZ*!.
M
M           0"V1^5?I[_:\J_P!MH%>G^2F22]TB?HH$X
M                                    $==M?DW9?_)%1]]I!4I?E%ZI
M++W)R^LOR>\-?FZB_P"+"!"I^4?JD8\!G,2$0
M
M
M        (!\.O_"7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M
M                      "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;
MU[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
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M\R)M #3)LL
M                     " 3;\XK(/S&D_?+(*_^S_UB3[LGZ*!.
M
M                 0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
M                                         1UVU^3=E_\ )%1]]I!4
MI?E%ZI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M             @'PZ_\ "7(_Y\YA\&H0*]Q[I?@HDAP>N3\% G
M
M                            "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$
MBQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(
M&1@            !Y9_%*^<;W:_:4RO\*W =J:*^:67?(Z7P4<R:G^<-[\IG
M\)D"ADY80      ,UZWYK=-;\^8@SVR,B"2.^(,@QG(+:P.JA0D;7A9&7,AS
M(;URE)2JHA,JO(I;?<7]O2E?8%NS?+H9OE=QE=23A3N*4H.2VM*2PQ6.S8>W
M+KV677]&_A%2G1J*23X'@\<&;(OUJ[8'T4L.=<YM]R&HOH1RKQZX["!L3Z4+
M_P 5H]E(?6KM@?12PYUSFWW(/H1RKQZX[" ^E"_\5H]E(Q3G?Z2QG'.^#\RX
M/=M:,4L+5F7%.1,4N;XW2V7J7!F;\AQ!XB*UV0)U)=$RA8W)GBXXJPS[2^^R
ME+O8K4>[+.9_+<LS*WS*G>5Y3MZ].JHN,<&Z<E))])X8,\M]SC7M]95K*=M2
MC&M2G!M2EBE.+CBO4Q-:4;@-<&]RPX:QOQV^$-@B/,$W98CL5@!HCT8+>''I
M5I,3RS HR1#WMHF[<WW'N::&9;CJ1.YV'D6''):*$JBRQ1>D.2&<SU<PO.;/
M7ES5JTY5,INI2E@MF]2G+?3@WL<Z4FXX/!/"2Q6\I+>%.SMM<:3H4Z<XPS"@
ME'%_<U(QW6I);=V:P>S@Q3VX-&NA+> ?Q4HO*#HTDUJI,">R[4S?*(ED_$ZF
M+NI9AM"2UI*QZFK&X-22XROL]LTJ TNRG/OLMLY+J[9H<Y^B:U%5I7G)O#%Q
ME3J[RZ6"A)-_@N2XF:^JZ%U12J\FK;?6.R49PW7T]LDU_62-C_A.<+EIX4,'
MRQNONE.(@R9%18Z=DBU*V.-KI%,.XW+-0O4@HI?*D66R.?R9:V)4MI;=8867
M;91(D-6&+;J6ZCUSK2IKBYH:=T[3J2M'633:PE5J;5'K?N813;Z[\*2BHFP]
M*Z9AI:A5SG.9PC<*F\<'C&G#A>WHR>"6SU$WB:4^S69E>Q6Q6<<\+4E[>;E[
M*T[R&2UF4*I>T()5)'%W:V:O0WFV7=IVU24EI=SS+KJ%<MU]]U:W5Z)R;+XY
M3E-MED7BK>A"GCQN,4F_7:;]<TWF5X\PS"O?26#K593PXE)MI>LMA@X7(\)O
MKPM?QTW!F:7=@6\*-;<GA[8=<Z*%,N4OY$;*9D+<6:^+2;[SRBBFV\HA1=?=
M0JVE:65^UK2@YAN(\VD:DJ=59XL:CV=9N[V+>Q>KBUT3>=&6MY04Z;RM]8MO
M78X8);7ZFQE&/&T\^CW,:]^>'YEW:WM]D7W">:AVP[8=F]KXAV_]VO9OL=A]
M!V+V#S?_ %/IN7^0;+YN?1KEKOR!Y1W]VGO^$X888SW=S#H\./K&$ZS\M\E;
M^5_ ]W>GN\APXX1QWOL8>N:^PVF8$     ;TOT5_Y'^P_P"TF=^J^ CFKGK_
M (_:?(_]9,W=S8?PFX^4_P"9$V@!IDV6
M                                           ! )M^<5D'YC2?OED%
M?_9_ZQ)]V3]% G
M                                       (!;(_*OT]_M>5?[;0*]/\
ME,DE[I$_10)P
M   (Z[:_)NR_^2*C[[2"I2_*+U267N3E]9?D]X:_-U%_Q80(5/RC]4C'@,YB
M0B
M
M                                 ! /AU_X2Y'_ #YS#X-0@5[CW2_!
M1)#@]<GX*!.
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M]?\ '[3Y'_K)F[N;#^$W'RG_ #(FT -,FRP
M                                              (!-OSBL@_,:3]\
ML@K_ .S_ -8D^[)^B@3@
M                                            $ MD?E7Z>_VO*O\
M;:!7I_DIDDO=(GZ*!.
M         !'7;7Y-V7_R14??:05*7Y1>J2R]R<OK+\GO#7YNHO\ BP@0J?E'
MZI&/ 9S$A$
M
M                                         " ?#K_PER/^?.8?!J$"
MO<>Z7X*)(<'KD_!0)P
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M3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M                                                     (!-OSBL
M@_,:3]\L@K_[/_6)/NR?HH$X
M                                                ! +9'Y5^GO\
M:\J_VV@5Z?Y*9)+W2)^B@3@
M              1UVU^3=E_\D5'WVD%2E^47JDLO<G+ZR_)[PU^;J+_BP@0J
M?E'ZI&/ 9S$A$
M
M                                            " ?#K_PER/\ GSF'
MP:A KW'NE^"B2'!ZY/P4"<        /\K7D^S_R\G_IP!6KMUQ<=#]+%;A'L
MMYG1/.0VT@\Y;B[%[>JR//&RI!A)%2Y,@CW3M<&N,.4%V%]OEC7:==?2A=;J
MC),HTEGV=)3M*#5N\.OGUL-O!@WME_53+5>YSE]ABJT\:B^YCM?VO7*1EWTK
M>!2"7H(MBW4%<J3.SC8VMTCS+L+&<0-!5Z@ZTA*I>U:7'L]96%'=?=RFG*G
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M9]8@1
M   "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG^9
MUN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@            !Y9_%*^<;W
M:_:4RO\ "MP':FBOFEEWR.E\%',FI_G#>_*9_"9 H9.6$        +7=-.#!
MO9NC:TR&+8TOQ9BIRZ!19EK,M%\-C2YN,,LY5D59[T*J73.PTCGU(.;T!C?>
M87T9BLFM>48/J'G"TSI[>I5ZW+WR_P!%2PG)/BD\5&'34I;W14695D^CL\SC
M"I2I\E:O[NIC%-?>K#>ETL%ATT;#L6X7O!\X43 V9&WRS#'<VY0+1U=&A@R6
MGLO:G4XDZA=AT%ULBY\B?)2FJ?6B<TUZO?&XN^[I+^Q:4YUFJ:^M-?:XJRM-
M,6\[:RQP<J?"OP[B6[&/&E#<ET%O&?TM,Z2TM35QGE:-:YPQ2GP/\&C'%RXN
MNWEZA!;?SZ187E_%.1=8]0L#MF/\-SR!2?%#W-,CITA<E4P66,#E%7QNAF/(
MFLLC4'Z5G7WEIE!ZYTNL+,Y:)DYMMM;<ETOS3.POJ6<Y]=.KF%*K&JH4\=W?
MC)23G4DMZ>U;4HQ_":+)GW."KNUJ9;E-!4[.I3E!RGP[LDXM1A'9'8]C;?J)
MFK<-TFL22FJNHV>]T,J->(-?H,NE\E67$GN[E?0Q'%86RF'VDGR:;2&XHQ''
MV))6M>6^_G''WTH4G*./NL*NL^=Y]E>GK&5_FM14Z*X%PRF_>PCPRD^HN%M+
M%ERRO*;[.+I6EA!SJ/A?W,5QR?07L\"3>PW-,98&X??T>G!Z;,V;Y ARWMI+
M&AQ2,SJG0(39_*7*]'T3C$,*1A:>;?!H&DZ>TAU?E-]AA]IO_2CZ=,E;;>?+
MS,]4\ZN9/+\M@Z&14Y)M8O<BL=DZTE[N;X8P7!AUJV2F;@MK'(= 62O+V2JY
MK-/!X+>D\-L::?N8]"4GP]%[5$U0^(-Q+MB^(ID.DDRL[TCF.6!<>;C?"D:6
M*Z06#)KK#4Y2TVPWHC)3,U*0ZZU8]++.R#:F7EIRTB3HTA6\-*Z/RG2=IR-C
M'?NY+\96DEOSZ7WL,>""V+8VY2QD]6Y_J/,-07'*73W;>+ZRFO<QZ?WTN.3V
M\6"V*O,968^ !?AA,O@R9QE\(Q-C;2+B%Y(RO+;V]H01V)9(@YYSJ\WDEVKU
M15#9>0G;&8@REYYZI5>0E1I;;C3S"R[+[J:PS%\X66V]2^O,RRJC8T\6Y2IS
MV+H+W&U]!)8MO8DV9W9>A][5A:VUEF%2ZG@DHSCM?1^ZV+HMO!);6=%XRFM7
M#_U0DV*\2:G.,BKFQOLD"S8R(.4].R.CQT:>CC]8O$7"0D)2F$N7)%MSC1:D
M2G''$6V65/H70PGI/3S?9QJG/*->^SQ0\G/=5":AR;J;9;TE''>W6MW!M)/;
MAC@\*&K\MR'*JE*TRIR\-6/*Q<M_<X-V+?!O<.*7!T>@4DC8QA8    !O2_1
M7_D?[#_M)G?JO@(YJYZ_X_:?(_\ 63-W<V'\)N/E/^9$V@!IDV6
M
M  ! )M^<5D'YC2?OED%?_9_ZQ)]V3]% G
M                                                          (!
M;(_*OT]_M>5?[;0*]/\ )3))>Z1/T4"<
M                       ".NVOR;LO_DBH^^T@J4ORB]4EE[DY?67Y/>&O
MS=1?\6$"%3\H_5(QX#.8D(@
M
M                                                      0#X=?^
M$N1_SYS#X-0@5[CW2_!1)#@]<GX*!.      !^1QQ*<DU0H-+(()+O-...OL
M****+MK>8889?6VPLNRRVM:UK6E*4IRU#A>"X6'L6+X"B>09PV*XJV19GB'3
MO(#]K[H; )(NA68-TH@821DW.\F9%26LAQWJHZTO,LCT:267U3JYGT9EMYG+
M5)TA5O0K<VI6F7:6H4[S-J:N<]J14J=O)8PI)K&,JR]]A_HY='!-<5@=Q<YM
M6G0LWR=A!N,JG1DUPJGQK'HHUC_I ,&Q5J!D_#>BVM4$;<<XI8<5,68\B.:<
MOLV;YAR3+)/-F= ^Y1FZZT^2S@^,M,=O,046*;TR,]V54(*+MI9;9M'FZJ7.
M;V];/LRDZEU*KR<%]S2BHIN,(KK8)X[<%M,3U+&E:5H9?;12A&.\WPR>..UR
M>W#H+H&NWR?R\M:?^BKR#9IC*>'JFYU]%)VEG;PNV"U!DKTYO4)BT6:\QXP0
M+3SE"6&77R>K!D)I;*FU,M2-LB<I.V+K4UE;"K%9:HZEM3%!MPTESL910I^#
MYQ2BHUIU)4YOWSPQBWZB36/J&>Z1NYR56SEMC&,9+U\<=O4-M#.FN^#MF8.O
MQOGS%L+RM#%Y9]M6:9,2)VM0*#R:D5<V)<<7VRCKX07=_,KT!R9:1=2EQ9MM
MU*5IJ.RO[W+JZN;&K.E671BVNJN!KI/%&7UJ%&YI\G7BI0?'_DXO6*:GQMV'
MX,!Q$HCTAR%M%PNRE2--,H;)E9\RSYI.U*#4#.W2"#/JM11TR/@=FYQ1*AGN
MLO5LB2VAI7VMBD]1EU-V&L<:$HT[34[VQE%*%*X>W9+@C"ITUACU"QS5WDV%
M2+=7+<>N3]U37&NC)=)EZ,&G,/R9#XQD#'\D:)?"IFQ-LEBLF85A2]H?6%X2
MEK6US;U9-UUAR94F-MNI7V*TY>2M*5I6E,*JTJM"K*A7C*%:+:E&2:DFN%-/
M:FNBF7^$XU(*I3:E3? UM3]1G:;Z<MEU*^QRTY/8KR5_])7_ )12DE*+3X&3
M%$O 3B[#(-!\FGO+8D7*LH[1;1+,@*CR"KSY2K<Y89'%JEW,OLNN6FGL:(E-
M=4WG<I9=+?L#.==59PS^BXO\A:V^Y][A!2V=/%ME@R",*N73WDGRE6IO=/[G
MV$C]=^X!!M .%29IQJLWN3/=G&6MFGV$&9\DCK(74J1;69!>:RZ[MPXJ37=8
MH(99+(%::G24J49:792MMM*5I#(KBYU!JE9SF;4YT(.XJ-123C0@L-B6"X(K
M'H^J5<PC3L,L5G;+=C5FH1Z3F\'+;T%MQ^R= UJ@;7P\N+0@UL94U$V(MT=+
ML/%0)85<2F0FY>TK@O@Z=VLANMNY"5RS%K91T67V6UZ<U47===?=2[F^C,KJ
MIJ/2KS&IB[NRO*CFWP\G<2WDO6D_672/):THY9G/@JV4J]"/J.=-;O5<?79$
M'=;7^999WZXG>8,+EFE[)Z<8^X?VT6!5J0Y00>N?,;Q?(+C,86H[$K8H<6R=
M02Q>CN0<ZA2U9:EM-Y;+:T%TR/,H6639;:7;QRR\JW5&K%X;N$]U1F\=BW9-
M-2Z!2OK>=3,+FXHK&YI4J4H;,7BFVULVO%;,"7KEGZ(;1<1[@K;#0&IMD6RU
MJSN--&U$I-).6,RASQO%;G6..1B:M4]SQ&':BAO6='6MEJI,92VM:4I46>&7
M5LMT[G=A<;:M&ZMH\6.$YX2PZ*DFL.,]?A4+N_LKBG[B=&JU@_O8XKU4UZQW
M3@$0F,33A$0%N?VM*K)S#)-E?"0=2RPI7*SW[+4^A[HM=U5MO2K7!3'&Y.DJ
M<96Z^A)!=M*\VRVE*>OZLJ&L*DJ3W>1C2W,/N5&,6L/7)\BA"IE*BTFIRGCT
M\9-,B%Q$X1"N'[LEP+(9@3$>3\FPO!4PV_I",000^^;90DI#LQ8Y<%;3'S)$
MXIC'E<4MD:A3R'*+>8E*NMMKR66VB[Z=JU]06&=U+VM1I7%>%%RJ3PIP34FM
MN&"6.'KGBS*G3R^YLH4(2E"FY[L%M;V+8L>B6)9#VXFFS^D?$*22[3[9_5BR
M':D9D/0J]B8BSQ=/-;GS%&2;5">*7M+V\]FG,-&BRY;0SH^CM6$<G.YU>2PV
M^30RG/<O<;NUNE.[I;*,U/=Z^/NL.#AV>H>VI>U;NQN%4H5:.[1D^O6&.Q[$
M4CRS>B2K.#!A[5>9Z:YLQOCS(6!L+8)KN!FZ'U/U5BR1Y)C32AR^>Z0<J:2Z
MB%+>38MCYES8295RHENK6VZWFUS2GD%.GK2MF].\MJE>C=5*RH4Y?CI.#<N3
M4<>%\#2V\)97F,YY3&TE;U8TW&,54FEN<*PECQ<3-NC7W'27$&!L*8E0R"Z6
M(L7XEQUCM'*;[+"[I*EA409XVG?[BRSU5EE7@IMHHY*&F4ITGL7W?9KJ:_N7
M>7U:[E'=E5K3GAQ;TF\/6QP,QHPY.C"FWCA%+'CV&7AY"J      !3#N#Q].
M&WHMGJ5:V;$Y.EL9RM#$,<<7UH:X&[/B(A)*F%!)&8PIR2&4).J>U.15]U*4
MI6RZM:5^P!#$C%]:QX-GCMGOQ6/_ -U %U6I>UV&MV,$P[8[ 3TXR#%L[[:U
MCCJZM1[*N4T9G58S+JG-RFZ\XBEBY"92WEK]M;2E?Y0(E=VW7'XX;.CV<9)K
MOL)D^71K)\42MBUX:6R!.SVC)3NZ>JE#>6X)#*$F](33EK2GLT %B.INUV'-
MU<'Q38? CPY/V,)I5;2/NSJU',JQ7:WJ*IE%][>HOO.)MH;;6E.=R5K_ ,@
MDB *6=N./YPU](<Z2K7383)TOC648:0TJ7MJ;8$[/:(HAZ0%.3>82XI#>A.H
M:F.I6M.2E;:\M !8=J+MOA;>#!D7V+U^>G.0XMF"EW2,+L[-![&L5&,B\UM7
MUN;E-UYQ5EBLFZVVM:_;4IR@"O/;OC]<-G1W.\LUOV&R;,(QE2%)F)6^M+;
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M1;#Q6/2"+(YBPS3)F)':$0YY9'),F6M9K<]N"LPM0H<T:NPTDJEG.N+KR^P
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M1XE/%^P9PVGG',1E\5>\K3[("-W>CH3"GYB;WF)1ANO2ID,AD=CI4RJ1'(G
MXXAOI6VE5-R)36VO(3<,ZTAH+,M7TZU>WG&A:TFEOSC)J4GBW&.'"XK!RXL5
MQF*:CU;9:=G3I5H2JUZB;W8M)QBN!O'C>Q<>#XBRW$N04>6<58SRHW-ZEH;\
MF8^AF04+4M-*/6-B.9QQMD:9O5G$4H0<I1$.5I9EUGVEU]M:T]@8??6LK&^K
M6,VI3HU9P;7 W"3BVO5P,DM:ZNK6G=134:E.,DN+>2>'V3((\I7
M      (!-OSBL@_,:3]\L@K_ .S_ -8D^[)^B@3@
M
M    $ MD?E7Z>_VO*O\ ;:!7I_DIDDO=(GZ*!.
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M>B6EC?9N4
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M>M_G?F7RRK\)G#C"#%@
M                                                    MJX07^-V
M3/S5F?"V-CH?^7'YTWW_  __ %U,W=S%_.*[^1?ZVF;"0[%.H0
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M+L[_ &/B;]6T=$ ;XWT6GYF/7#^WLG_#-P &PX /(M^E2?/4[*?DOA?]5D9
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M.#%0    #>E^BO\ R/\ 8?\ :3._5? 1S5SU_P ?M/D?^LF;NYL/X3<?*?\
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M-3^!$DH+.7$               @$V_.*R#\QI/WRR"O_ +/_ %B3[LGZ*!.
M                 %7_ !G_ )L;;'\DHA^M""C9'-%_W&RO\[/^QJ&I.?7_
M +3YS^9I?^HI%37#BX5GA[THP+EWSW]UL7>[5@D"[W!8QRQ[GX)'.P9O*&?L
M:/,_:\[L%.I[7=D&6\ZO.4'&7?RC:'.!SF>0]87V5>1LGN>1J17*UJ&]4GC3
MA+&<L=K6."Z21IOFNYG_ $CT%EV=>7\^M.7IS?(T+C<HPPJU(X0C@\$]W>?3
M;987C?A0:]:>1C8W.Z&597S=G:1X7RJVG95S=*$DHD#4A<H4YIW.UEM0M+44
M6X.B),6G4+E=5B^J>EY)1Q1!II5^!YASGY]JRYR_))TK6SR2G>47R-O!PC)J
MHFM[&4MD6VU&.[''!M.236R\KYG-,Z(M,TU%3K7F8:AJV%Q%W%U452<5*E)2
MW<(QZZ223G+>GAC%24923CE]&N@$.:M+)[D9%'FLJ=2S.LL87Z5]AD5?%T?C
M<7@U[&P7N71]E496U4XJE!2;G=':H5&F<G.O&0?S"WUW5UA0L)U).RI64)1A
MB]U2G.IO2PX-YI)-\."2Z!B_\K&6V-'0ESFE.E!9A6S&I"=3!;[A"G2W(;W#
MNQ<I24>#>DWT3">*YA!,"?2$]HWC:=W9XFX9+QM87@*?3U6D:(W;:],F-"(Z
MF9GYXN1M:$]7#(\Y1].IH9;SE:12W6WW''767W?,[2]SSF(RVEIJ$ZM.WN/[
MS2I)RGULJSDY1CBVE4E"JUA[F4:F&"Q5AR>^R[3G\RV;U]7SA1J7=K_<ZU9J
M,.OA04%&<L(INE"=%2Q]U&5+%RE@\T_2',Q:_.^FS;B4R30Z8YND>4X*ZXOB
M;"[-3]+V4Q <OL?I35L;E"ER;VA5'3U350VZRVU0I7EEV4ONY>9:.8;*<]I:
MMEFBIU:634[:I&M.491IRQ2W88M).2GNSPZ"BV\.C??YF,\TU6T-#)G5H5\_
MJWE*5O3A*,ZD,&]^INQ;E&+@Y4\?NI326/0B9*,'1*2;8ZZL6-]ZY3J+Q18=
MJK@N 9289SC9W<8=.I8T8&AMBVQNF;K5ICMSJ[L1M"U*&ZQW*6')>2P@I60;
M;=E%MG-U;Z7OZV89+2S7FVJYG<U:,J=6*J4X2N:F&-..]/=C+:I?BW%2VR<9
M+##;O3]E=:RRRWRO4-;)>=RAD]I1N(5:$I4JM2-G2QW:LMV&]*&R4,*BDX[(
MQG%XMB\[;QZ7[':JL6^[9I%OXFDTW2HH$N+Q1"G#.T"LK(8=1>YPRE(/"5T
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M-E1OZ%*$;RZN*[JS26]/<JRIP3EPM1C%**QP3<FEC)XWF#3!T$
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MVB5O/;)H,<X;/"+KU-55]BBUD04*+OH50VXL1W>L:Q3?";<@B40
M  (Z[:_)NR_^2*C[[2"I2_*+U267N34ED/\ QQV_]_U/_O6X?.;G*_[@9Q_Q
M&M\-G#>M_G?F7RRK\)G#C"#%@
M                                                          MJ
MX07^-V3/S5F?"V-CH?\ EQ^=-]_P_P#UU,W=S%_.*[^1?ZVF;"0[%.H0
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M:::=23336QIK:FMC1M'*H3IY7;4ZB<:D:%---8--02::>U-/A1((6H]X
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MO*GB7RJ7.;3VWD!B$U:Y/%Q1))B]:82D()+N/-K9SZQ(2EO/$QC+-&%#?O\
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M!BP
M                                    6U<(+_&[)GYJS/A;&QT/_+C\
MZ;[_ (?_ *ZF;NYB_G%=_(O];3-A(=BG4(
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M_P C_8?]I,[]5\!'-7/7_'[3Y'_K)F[N;#^$W'RG_,B;0 TR;+
M
M  @$V_.*R#\QI/WRR"O_ +/_ %B3[LGZ*!.
M
M0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
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M7\7L2[D!Z*:6\VY?^ST>T'HWIWQ"R[A2[4> K"/B<Q7\7L2[D!Z*:6\VY?\
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ML&Z=.$&UPX-Q2;6.W [D+D>\
M                   @'PZ_\)<C_GSF'P:A KW'NE^"B2'!ZY/P4"<
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M;2WDY*4H+=5R?**U7EZUK;3KX^ZE2@Y<?"XXGMAF.84J?)4Z]:-+B4Y)=1/
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MZ_X_:?(_]9,W=S8?PFX^4_YD3: &F398
M                                           %?J$\HKB,/)9E]+;U
M.$BB"*5I6O2&VW-2FME.2E:4K0E/?=[/)3[7_EY!7_V?^L2?=E@0H$X
M
M                   ! +9'Y5^GO]KRK_;:!7I_DIDDO=(GZ*!.
M                                           !'7;7Y-V7_P D5'WV
MD%2E^47JDLO<G+ZR_)[PU^;J+_BP@0J?E'ZI&/ 9S$A$
M
M
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M_L/^TF=^J^ CFKGK_C]I\C_UDS=W-A_";CY3_F1-H :9-E@
M                                                          5U
M_P#S2+_S)/\ X%#T?[/_ %B3[LL4'G)P
M                                                        " 6R
M/RK]/?[7E7^VT"O3_)3))>Z1/T4"<
M                    ".NVOR;LO_DBH^^T@J4ORB]4EE[DY?67Y/>&OS=1
M?\6$"%3\H_5(QX#.8D(@
M
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MP4<CRZWJQK4H-3CP=<_;+;*4Y*<@Q<NY_H
M                            ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2
M+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@
M9&             'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?
MPF0*&3EA                                 #>E^BO_ "/]A_VDSOU7
MP$<U<]?\?M/D?^LF;NYL/X3<?*?\R)M #3)LL
M                                                "NO_ .:1?^9)
M_P# H>C_ &?^L2?=EB@\Y.
M                                               0"V1^5?I[_:\J
M_P!MH%>G^2F22]TB?HH$X
M            $==M?DW9?_)%1]]I!4I?E%ZI++W)R^LOR>\-?FZB_P"+"!"I
M^4?JD8\!G,2$0
M
M                                          #B)!_P%[_LAR^\CA%<
M)!\! /AF?X#RW\[C]\#8$*]S[M>I[9+#@+$QYR<
M
M                 ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?
MP6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&
M    'EG\4KYQO=K]I3*_PK<!VIHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M                              #>E^BO_(_V'_:3._5? 1S5SU_Q^T^1
M_P"LF;NYL/X3<?*?\R)M #3)LL
M                                     "NO_P":1?\ F2?_  *'H_V?
M^L2?=EB@\Y.
M                                    0"V1^5?I[_:\J_VV@5Z?Y*9)
M+W2)^B@3@
M1UVU^3=E_P#)%1]]I!4I?E%ZI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M                              .(D'_ 7O\ LAR^\CA%<)!\! /AF?X#
MRW\[C]\#8$*]S[M>I[9+#@+$QYR<
M
M      ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/7S9.F
M?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&             'EG\4KY
MQO=K]I3*_P *W =J:*^:67?(Z7P4<R:G^<-[\IG\)D"ADY80
M                     WI?HK_R/]A_VDSOU7P$<U<]?\?M/D?^LF;NYL/X
M3<?*?\R)M #3)LL
M                          "NO_YI%_YDG_P*'H_V?^L2?=EB@\Y.
M
M                     0"V1^5?I[_:\J_VV@5Z?Y*9)+W2)^B@3@
M                                             1UVU^3=E_\ )%1]
M]I!4I?E%ZI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M               .(D'_  %[_LAR^\CA%<)!\! /AF?X#RW\[C]\#8$*]S[M
M>I[9+#@+$QYR<
M                                                   ($\4OYN/=
MK]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGE
MF'RA^PBCI'YMV?YE>RRR<8@9&             'EG\4KYQO=K]I3*_PK<!VI
MHKYI9=\CI?!1S)J?YPWORF?PF0*&3EA
M    #>E^BO\ R/\ 8?\ :3._5? 1S5SU_P ?M/D?^LF;NYL/X3<?*?\ ,B;0
M TR;+
M                 KK_ /FD7_F2?_ H>C_9_P"L2?=EB@\Y.
M
M              0"V1^5?I[_ &O*O]MH%>G^2F22]TB?HH$X
M                                       $==M?DW9?_)%1]]I!4I?E
M%ZI++W)R^LOR>\-?FZB_XL($*GY1^J1CP&<Q(1
M
M
M        .(D'_ 7O^R'+[R.$5PD'P$ ^&9_@/+?SN/WP-@0KW/NUZGMDL. L
M3'G)P
M                                           @3Q2_FX]VOV;,K?!5
M>,GT5\[<N^64OA(L6I_F]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.
MD?FW9_F5[++)QB!D8             >6?Q2OG&]VOVE,K_"MP':FBOFEEWR.
ME\%',FI_G#>_*9_"9 H9.6$                                 -Z7Z
M*_\ (_V'_:3._5? 1S5SU_Q^T^1_ZR9N[FP_A-Q\I_S(FT -,FRP
M
M   (&/3>E1<1"(J4]E;37; :EP775ONNH8J+=I.U67VVW5K0NE$383;S;>2G
M+;6OV:UJ*Z_5W^$2?=D\Q0)P
M                                                "">RR<JW9G3!
M52VO3'2B?)S+N=7DJ4F)B!A-M+>7FTK;>KO]G[->7_P4%>G^2GZQ)+W2)V"@
M3@                                                   1UVU^3=
ME_\ )%1]]I!4I?E%ZI++W)VC7A.4FP)A4LFVMMEV*H HK2MU;OYU7%FM4?=R
MUK6O)<<==6E/L4Y>2GL"%3\I+U617 C,0D(@
M
M
M     '$2#_@+W_9#E]Y'"*X2#X"&G#R9T#9K:SK495Q:B0RN5O#I?<:890Y>
M0OL8"S;+;[JVDVT;&--9S;.2VM;*W<G.NK6M:X>-3UB$. G$*!,
M
M                             $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\
M)%BU/\WKWY-/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,
M0,C             #RS^*5\XWNU^TIE?X5N [4T5\TLN^1TO@HYDU/\ .&]^
M4S^$R!0R<L(                                 ;TOT5_Y'^P_[29WZ
MKX".:N>O^/VGR/\ UDS=W-A_";CY3_F1-H :9-E@
M                                                   09DGSA./_
M -G9;\)YL*Z_5W^$2OW?K$YA0)@
M                                                   "#.S'RD=*
M_P KLB_>L'%>G^3GZB)9<*)S"@3
M                   1UVU^3=E_\D5'WVD%2E^47JDLO<G;L ?X#X3_ #1X
MW^!K,(5/=R]5D5P(RX)"(
M
M                                                  !Q$@_X"]_V
M0Y?>1PBN$@^ B/H%\F*&_P!KS'X4.@JU_P JR$. F>*),
M
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M^V/6?<-/^(=HS_FTP'W_ (>2,V\5N.YS[4>4+#X^CV<?;'K/N&G_ !#M&?\
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M-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\
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M6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@/O\
MP\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"
MP^/H]G'VQZS[AI_Q#M&?\VF ^_\ #R1FWBMQW.?:CRA8?'T>SC[8]9]PT_XA
MVC/^;3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\/)&;>*W'
M<Y]J/*%A\?1[./MCUGW#3_B':,_YM,!]_P"'DC-O%;CN<^U'E"P^/H]G'VQZ
MS[AI_P 0[1G_ #:8#[_P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/^(=HS_FTP'W
M_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6
M'Q]'LX^V/6?<-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q
M#M&?\VF ^_\ #R1FWBMQW.?:CRA8?'T>SC[8]9]PT_XAVC/^;3 ??^'DC-O%
M;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\/)&;>*W'<Y]J/*%A\?1[./MC
MUGW#3_B':,_YM,!]_P"'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_P 0[1G_ #:8
M#[_P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0
ML/CZ/9Q]L>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\
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M8?'T>SC[8]9]PT_XAVC/^;3 ??\ AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\
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M?;'K/N&G_$.T9_S:8#[_ ,/)&;>*W'<Y]J/*%A\?1[./MCUGW#3_ (AVC/\
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M/6?<-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF
M^_\ #R1FWBMQW.?:CRA8?'T>SC[8]9]PT_XAVC/^;3 ??^'DC-O%;CN<^U'E
M"P^/H]G'VQZS[AI_Q#M&?\VF ^_\/)&;>*W'<Y]J/*%A\?1[./MCUGW#3_B'
M:,_YM,!]_P"'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_P 0[1G_ #:8#[_P\D9M
MXK<=SGVH\H6'Q]'LX^V/6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]
ML>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\ B':,_P";
M3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\ #R1FWBMQW.?:
MCRA8?'T>SC[8]9]PT_XAVC/^;3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_
MQ#M&?\VF ^_\/)&;>*W'<Y]J/*%A\?1[./MCUGW#3_B':,_YM,!]_P"'DC-O
M%;CN<^U'E"P^/H]G'VQZS[AI_P 0[1G_ #:8#[_P\D9MXK<=SGVH\H6'Q]'L
MX^V/6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@
M/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\ B':,_P";3 ??^'DC-O%;CN<^
MU'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\ #R1FWBMQW.?:CRA8?'T>SC[8]9]P
MT_XAVC/^;3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\/)&;
M>*W'<Y]J/*%A\?1[./MCUGW#3_B':,_YM,!]_P"'DC-O%;CN<^U'E"P^/H]G
M'VQZS[AI_P 0[1G_ #:8#[_P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/^(=HS_F
MTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGV
MH\H6'Q]'LX^V/6?<-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[
MAI_Q#M&?\VF ^_\ #R1FWBMQW.?:CRA8?'T>SC[8]9]PT_XAVC/^;3 ??^'D
MC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\/)&;>*W'<Y]J/*%A\?1[
M./MCUGW#3_B':,_YM,!]_P"'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_P 0[1G_
M #:8#[_P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/^(=HS_FTP'W_AY(S;Q6X[G/
MM1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<
M-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\
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M6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@/O\
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ML/CZ/9Q]L>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\
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M-/\ B':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\
M#R1FWBMQW.?:CRA8?'T>SC[8]9]PT_XAVC/^;3 ??^'DC-O%;CN<^U'E"P^/
MH]G'VQZS[AI_Q#M&?\VF ^_\/)&;>*W'<Y]J/*%A\?1[./MCUGW#3_B':,_Y
MM,!]_P"'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_P 0[1G_ #:8#[_P\D9MXK<=
MSGVH\H6'Q]'LX^V/6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^
MX:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\ B':,_P";3 ??
M^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\ #R1FWBMQW.?:CRA8
M?'T>SC[8]9]PT_XAVC/^;3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&
M?\VF ^_\/)&;>*W'<Y]J/*%A\?1[./MCUGW#3_B':,_YM,!]_P"'DC-O%;CN
M<^U'E"P^/H]G'VQZS[AI_P 0[1G_ #:8#[_P\D9MXK<=SGVH\H6'Q]'LX^V/
M6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\0[1G_-I@/O\
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ML/CZ/9Q]L>L^X:?\0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\
MB':,_P";3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\ #R1F
MWBMQW.?:CRA8?'T>SC[8]9]PT_XAVC/^;3 ??^'DC-O%;CN<^U'E"P^/H]G'
MVQZS[AI_Q#M&?\VF ^_\/)&;>*W'<Y]J/*%A\?1[./MCUGW#3_B':,_YM,!]
M_P"'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_P 0[1G_ #:8#[_P\D9MXK<=SGVH
M\H6'Q]'LX^V/6?<-/^(=HS_FTP'W_AY(S;Q6X[G/M1Y0L/CZ/9Q]L>L^X:?\
M0[1G_-I@/O\ P\D9MXK<=SGVH\H6'Q]'LX^V/6?<-/\ B':,_P";3 ??^'DC
M-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF ^_\ #R1FWBMQW.?:CRA8?'T>
MSC[8]9]PT_XAVC/^;3 ??^'DC-O%;CN<^U'E"P^/H]G'VQZS[AI_Q#M&?\VF
M ^_\/)&;>*W'<Y]J/*%A\?1[./MD+>(WQ#= LAZ&[=0: ;R:>SF;2S .26&+
M0Z'[,86DTIDKXXQM:G;V:/QYEFJUV>75>HOH62G3$F'&WUI;;;6M>09)H[*\
MRI:JR^I5MZ\:<;NFVW3FDEO+:VU@D634M]93R"\A"M2<W;SP2G%M['P+$DCP
M>OFR=,_S.MWXW=Q1U]\\LP^4/V$5-(_-NS_,KV663C$#(P             T
M/N*YQ7.(/@'B#[*X@Q!LK)X3C>$R>,(8M%D,8QXN2-"1=CR'O"LDE6\0]Q<C
MK3G)Q/-K4T\RM*F5I2M+:4I3IG0^A]*YII6SO[^SA4O*D).4G*HFVJDTMBFE
MP)+8C1VJ=4Y_89_<VEI<RA;PDE&*4'AC"+Z,6^%OHE>7KON*CZ7\RZG8I[PA
ME?T<:)\0I]G5[<L'IIJ?QN?8P[4>N^XJ/I?S+J=BGO"#Z.-$^(4^SJ]N/334
M_C<^QAVH]=]Q4?2_F74[%/>$'T<:)\0I]G5[<>FFI_&Y]C#M1Z[[BH^E_,NI
MV*>\(/HXT3XA3[.KVX]--3^-S[&':CUWW%1]+^9=3L4]X0?1QHGQ"GV=7MQZ
M::G\;GV,.U'KON*CZ7\RZG8I[P@^CC1/B%/LZO;CTTU/XW/L8=J/7?<5'TOY
MEU.Q3WA!]'&B?$*?9U>W'IIJ?QN?8P[4>N^XJ/I?S+J=BGO"#Z.-$^(4^SJ]
MN/334_C<^QAVH]=]Q4?2_F74[%/>$'T<:)\0I]G5[<>FFI_&Y]C#M1Z[[BH^
ME_,NIV*>\(/HXT3XA3[.KVX]--3^-S[&':CUWW%1]+^9=3L4]X0?1QHGQ"GV
M=7MQZ::G\;GV,.U'KON*CZ7\RZG8I[P@^CC1/B%/LZO;CTTU/XW/L8=J/7?<
M5'TOYEU.Q3WA!]'&B?$*?9U>W'IIJ?QN?8P[4>N^XJ/I?S+J=BGO"#Z.-$^(
M4^SJ]N/334_C<^QAVH]=]Q4?2_F74[%/>$'T<:)\0I]G5[<>FFI_&Y]C#M1Z
M[[BH^E_,NIV*>\(/HXT3XA3[.KVX]--3^-S[&':CUWW%1]+^9=3L4]X0?1QH
MGQ"GV=7MQZ::G\;GV,.U'KON*CZ7\RZG8I[P@^CC1/B%/LZO;CTTU/XW/L8=
MJ/7?<5'TOYEU.Q3WA!]'&B?$*?9U>W'IIJ?QN?8P[4>N^XJ/I?S+J=BGO"#Z
M.-$^(4^SJ]N/334_C<^QAVH]=]Q4?2_F74[%/>$'T<:)\0I]G5[<>FFI_&Y]
MC#M2V#@NZDZ[<6V5[I[%<13&39LYFBV38+0TG<H=9)%E]$J>"2&*DD]K\</4
M,9.2R/PEJ3<O8O+S4=MU:\^Z^Z[5O.=2IZ3=A9Z>7@UM.%5N,>NQ:E!KW>\^
M&3Z/1,]T+5GJ!7=QG#Y>M&5-)O9ABI+[G!=!=0O<^KZ\';T(8-U[S+Y21JOT
MFSWQB78P[4S_ ,BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJ
MR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'
MI-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]
ML?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-
MGOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?
M5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GO
MC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]
M>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$
MNQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#
MMZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQ
MAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ
M$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAV
MH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,
M&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\
MBY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z
M]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY
M7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]Y
ME\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\
M2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\
MI(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2N
MK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(
M>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+
MVQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>D
MV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ
M]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>
M^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7
MUX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,
M2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX
M.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]LB6^<#;A3I=SX;C1/IY#2X,Y84
M52=='Z33+-4ZA]+?Y4DL<;E%V0*K[3+4Z FWFVFT+Y+*?:\M:UK56I,[Y%R\
M(EO;W%'M27R+EF]AR*P]67MDM/J^O!V]"&#=>\R^4D4O2;/?&)=C#M2;R+E?
MQ*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7
MRDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*
MZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RD
MAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZL
MO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ
M39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;
M'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39
M[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U
M?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[X
MQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7
M@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+
ML8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[
M>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8
M=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A
M#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J
M/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!
MNO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(
MN5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO
M>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5
M_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9
M?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$
MKJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*
M2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJ
MR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'
MI-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]
ML?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-
MGOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?
M5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GO
MC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]
M>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$
MNQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#
MMZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQ
MAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ
M$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;(EYVX&W"GBF<=68M']/(:VL$\DDV
M12UM*FF632GI*UIXI>@)/-49 .4$43W.!U:5)O+K7GUY:UY*<E6&I,[<)-W$
ML5AT(]J2O)<LQ7XE=67MDM/J^O!V]"&#=>\R^4D4O2;/?&)=C#M2;R+E?Q*Z
MLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDA
MZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO
M;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ3
M9[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'
MU?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[
MXQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?
M7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ
M+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@
M[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L
M8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>
MA#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=
MJ/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#
M!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/
M(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!N
MO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N
M5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>
M9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_
M$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?
M*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$K
MJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2
M'I-GOC$NQAVH\BY7\2NK+VS">QW <X2<+P=DJ4QC3&%-+^R1LY:UN1,WR\<:
MC56J$UEIUA2K(9Z>^M+;ZTY+[+J>S]@3T]2YXYI.XEAC[V':DLLERM+\BNK+
MVSLF'. ?PB9)B'%<B>]+(2O>G_&\'>G=>9.,P%F+71TC#6N7J[RR,BE$67J5
M9]]]:66VV4K=R4I2GL"$]39XIM*XEAB_N8=J162Y7A^175E[9DCZOKP=O0A@
MW7O,OE)$OI-GOC$NQAVI'R+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH
M\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&
MZ]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\B
MY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]
MYE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7
M\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE
M\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2
MNK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I
M(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK
M+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>
MDV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+V
MQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV
M>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]
M7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^
M,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7U
MX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2
M[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.
MWH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&
M':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH
M0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':
MCR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P
M;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR
M+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;K
MWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E
M?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF
M7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q
M*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7R
MDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*Z
MLO;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDA
MZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO
M;'U?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ3
M9[XQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'
MU?7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[
MXQ+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?
M7@[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ
M+L8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@
M[>A#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L
M8=J/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>
MA#!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=
MJ/(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#
M!NO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/
M(N5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!N
MO>9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N
M5_$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>
M9?*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_
M$KJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?
M*2'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$K
MJR]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2
M'I-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR
M]L?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I
M-GOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L
M?5]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-G
MOC$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5
M]>#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC
M$NQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>
M#MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$N
MQAVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#M
MZ$,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;'U?7@[>A#!NO>9?*2'I-GOC$NQA
MVH\BY7\2NK+VQ]7UX.WH0P;KWF7RDAZ39[XQ+L8=J/(N5_$KJR]L?5]>#MZ$
M,&Z]YE\I(>DV>^,2[&':CR+E?Q*ZLO;.->?H_G![3,[JI(TC@Y9Z=M7'DF4G
M69*UL-*2FF%WTI=DBMM:VWVTK[-*T!:FSW']8EV,.U(/)<KP_(KJR]LC?ISP
M,.%%DC D8EDVTZAK_(ESE)B%;FHFN6DYIQ2%_7I$MEQ2'("5-;0E,5;;3DLI
M6M*>SRU]D5*VI,[C4:C<2P]2/:D(Y+EC6VBNK+VR47U?7@[>A#!NO>9?*2*?
MI-GOC$NQAVI-Y%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E
M[8^KZ\';T(8-U[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2
M;/?&)=C#M1Y%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8
M^KZ\';T(8-U[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/
M?&)=C#M1Y%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^K
MZ\';T(8-U[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&
M)=C#M1Y%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\
M';T(8-U[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=
MC#M1Y%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';
MT(8-U[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#
MM1Y%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(
M8-U[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1
MY%ROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-
MU[S+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%
MROXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[
MS+Y20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%RO
MXE=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+
MY20])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE
M=67MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y2
M0])L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=6
M7MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20]
M)L]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67M
MCZOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L
M]\8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZ
MOKP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\
M8EV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOK
MP=O0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8E
MV,.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOKP=
MO0A@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8EV,
M.U'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOKP=O0
MA@W7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8EV,.U
M'D7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOKP=O0A@
MW7O,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8EV,.U'D
M7*_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOKP=O0A@W7
MO,OE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8EV,.U'D7*
M_B5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOKP=O0A@W7O,
MOE)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8EV,.U'D7*_B
M5U9>V/J^O!V]"&#=>\R^4D/2;/?&)=C#M1Y%ROXE=67MCZOKP=O0A@W7O,OE
M)#TFSWQB78P[4>1<K^)75E[8^KZ\';T(8-U[S+Y20])L]\8EV,.U'D7*_B5U
M9>V1'WVX(_"SPCI9M%E[%FH</B&1\;X2R!,83*$<RRLM5,$E8V!6N:G5.D=9
MZO;5!J-45;?;8>0:5=6G)=;6GL#(M(Z@SBXU184*U>4J4[JFFL([4Y+'@B67
M4>4Y=1R&[JTZ252-O-IXO8\/5+(^#U\V3IG^9UN_&[N+=K[YY9A\H?L(]>D?
MFW9_F5[++)QB!D8             >9CQOOG4=O\ \LH=^JF!#L3FX^9-A^;G
M_:S.;]:?.>[_  X_ B54#-S%@                                 W0
M_HHG^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M
M     (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
M
M    $&=F/E(Z5_E=D7[U@XKT_P G/U$2RX43F% F
M                                CKMK\F[+_P"2*C[[2"I2_*+U267N
M3MV /\!\)_FCQO\  UF$*GNY>JR*X$9<$A$
M
M
M     XB0?\!>_P"R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428
M
M                                    ($\4OYN/=K]FS*WP57C)]%?.
MW+OEE+X2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?Y
ME>RRR<8@9&             'F8\;[YU';_\ +*'?JI@0[$YN/F38?FY_VLSF
M_6GSGN_PX_ B54#-S%@                                 W0_HHG^'
M^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M                                                           (
M,R3YPG'_ .SLM^$\V%=?J[_")7[OUB<PH$P
M                                                           !
M!G9CY2.E?Y79%^]8.*]/\G/U$2RX43F% F
M                          CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.W8 _P'
MPG^:/&_P-9A"I[N7JLBN!&7!(1
M
M                                                        .(D'
M_ 7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_P"59"' 3/%$F
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M\YG%*$M[\7)K9L;X,<-F+]<V+;#+#*<MEU+J?\M/_2?_ (*C#\3I/ _L"
M                             $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\
M)%BU/\WKWY-/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,
M0,C             #S,>-]\ZCM_^64._53 AV)S<?,FP_-S_ +69S?K3YSW?
MX<?@1*J!FYBP                                 ;H?T43_  _W4_+'
M"/XER6.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,VXAHDVL
M                                                     !!F2?.$
MX_\ V=EOPGFPKK]7?X1*_=^L3F% F
M                                                      (,[,?*
M1TK_ "NR+]ZP<5Z?Y.?J(EEPHG,*!,
M                     !'7;7Y-V7_R14??:05*7Y1>J2R]R=NP!_@/A/\
M-'C?X&LPA4]W+U617 C+@D(@
M
M                                                     '$2#_@+
MW_9#E]Y'"*X2#X"(^@7R8H;_ &O,?A0Z"K7_ "K(0X"9XHDP
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M.Q.;CYDV'YN?]K,YOUI\Y[O\./P(E5 S<Q8
M        -T/Z*)_A_NI^6.$?Q+DL<]<^'ZUEWYNM[-,W'S6_J]Y^'3]B9MQ#
M1)M8
M               "#,D^<)Q_^SLM^$\V%=?J[_")7[OUB<PH$P
M
M              !!G9CY2.E?Y79%^]8.*]/\G/U$2RX43F% F
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MH]N/.;UM](/"'QL0/N^'IUHGSQE7[70[X/2_2?G3+OVFCVX\YO6WT@\(?&Q
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M&FN%'.#U'H
M  XB0?\  7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428
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MR#/9^W*+O]GDY?MK:5]GD]@:<9V,N _<"(
M   ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_ #>O?DT_@LZ=P>OFR=,_
MS.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,             /,QXWWSJ
M.W_Y90[]5,"'8G-Q\R;#\W/^UF<WZT^<]W^''X$2J@9N8L
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MV?V'DF*;]K-D([?C%^S5DEXQ[?'V(K+-61BNA;A)5$;N9F>K:G[%2U3= GZ
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M>T:^<6N_RU*#;E3Y.:ISWMF"W9M1>WAV$A183)@
M               (,[,?*1TK_*[(OWK!Q7I_DY^HB67"B<PH$P
M   <5>^LA;L4PF/+58^GD55$LM[@DM=CDU+3+JJ"FZIU%AA%+2;Z\^EE;>2V
MOL^Q4 <J                                    (Z[:_)NR_P#DBH^^
MT@J4ORB]4EE[DU(7O_C3O_:CA]]FCYMZ]^?6=?\ %KS_ -14.$]7?.O,_P#B
M%S_;3.+&)F/
M                                              &T[PX?D8X;_P#-
M#_6K.1WSS*_]LLL_^8_]77.R^:CY@6'_ )__ *FL3?&TS8@
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MY)5?8J65997^7_FVTI]G_P!(,4-E+@/V
M   $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\
M,ZW?C=W'HU]\\LP^4/V$4=(_-NS_ #*]EEDXQ R,             /,QXWWS
MJ.W_ .64._53 AV)S<?,FP_-S_M9G-^M/G/=_AQ^!$JH&;F+
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M85U^KO\ ")7[OUB<PH$P                                    &FI
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M/
M                                    &T[PX?D8X;_\T/\ 6K.1WSS*
M_P#;++/_ )C_ -77.R^:CY@6'_G_ /J:Q-\;3-B
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MF7[1F1K*\LA6K?K56.,MF&&UM=%]!X_Y-A;G2G)2E/\ D&!&9'^@
M      Z])6!+(FM0@4VVUH9;7DK=;2[DKR5_DK[%?LAMPP3:?0:X4^,;,?Z/
M[!1CM9PY,>SF<L^1E494$2B,WN!C4\L5]6]7?1>5<0?V>54A0@7UI9R7%WG%
M&&%WV\MEUM:U&Q-/<XN?9-7MY3EX4[980Y1O@^SM-$Z_Y@= ZY=:YO*$K:\K
M/KIV[5-R?#BUNM>R1',TP;DJK_IBR7GE%^Q<27<VE<^VGL<MYM6TRZGL4]FE
M*?\ I:#:=;^8G4=1MQL[=5G'!5-YXP]2.&W'U4:;H_R;:0MI)RS7,JM!O%TW
MN+!+H*6&/V"46']:2T%Q;=&XY5O)4^PK7&6]D.:VMM;/ME2TRVY2HI6ZG+S:
MUI92OV*#4NH=8Y_JFJZ^<W,IM/'<6*A+U5CLPX.!G06A^:_2'-_9SMM.VN'*
M+KYU&I5I=-5%%./K= N"PKB-)!&M.:9;;<HYEU*TO+ISJ775I=6O+6G+]D81
M5FIRWD;3I1<([K)!BB50                               ($\4OYN/=
MK]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/7S9.F?YG6[\;NX]&OOGE
MF'RA^PBCI'YMV?YE>RRR<8@9&             'F8\;[YU';_P#+*'?JI@0[
M$YN/F38?FY_VLSF_6GSGN_PX_ B54#-S%@
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M26/&\.%]-[3* \1Z0    "#,D^<)Q_\ L[+?A/-A77ZN_P (E?N_6)S"@3
M                                   :T^BD(FC3Q[N(++G2(2AMBCQB
MG)"=HD[@P.R./.AY^2M>3R2&YZ4)"VU<<<2C.OMM*-NNNM*OK2G);=R=#ZUO
M+.KS(9%:TJM.5U"ZI.4%*+E%*C=+;%/%;6N%=%<9RKS>9??T?YB]2WM:A6A9
MSLZZC4<)*$FZ]DTHR:W6VDWL?0?$;%L\+,.@\R**LO---BDB++++MNO,,,O:
M%EMEEEEM*W7WWW5I2E*4Y:U&@;)I7E%O8E5C\)'3V8IRR^NEM;HS^"S2GUMQ
M9DY#P&^(?$EN.9XDE3SL!AU8SQE5$) GD#JD33[7$Y2J;68UNL<5R9.4B.NO
MO*+NMLM)OK6M*6W<G8.H<SRV?/;D-U"XH.VA85U*:J1<8MTKO!.6.";Q6QOH
MKC.#=+91FU/^7;4UG4M;B-Y4S*V<:;IS4Y)5K)MQCN[S22>+2Z#XC9*X?.(V
MN?<*S V$\KQIP*9)IKZX0.;QEW1GM;J6UR/M\UN:4U,O3VJ6YPL2+*WE7W%T
MO),I;?2G+2@Y[UWFM6QYS+[.,KJ1=:C?JI3G%J4=Z&[)/%/!K%;=N#6*.I>;
M7):.9<S^79!G-*2MZ^6RHU:<DXRW9[\9+!K&+P>QX8IX,U:XEKIN5)Y?%^#+
M((I-2<+QK=*03E_RL7''U.RW0%M9^A6.S<[G)RV"R,&Q=.X2-"F,4<JAW<BB
MO_'<RT=*76?Z2MK2ISN4*M%YQ4R>-.-'?BY<JY;(N..]O[[C2DTMD(-\&+.1
M;+3&N;N]H\Q=S1KK(J6?3JSN-R:CR,8X.49-;G)\FIUX1;ZZI-+W6"-[*,QM
MBAL;C\0B[8E9(S%61JC<=9D-E2T30Q,: AL:&Q&7====8E0-Z4LHNE:UK2RR
MGLCBNXN*UW<5+JYDYW%6<ISD^&4I-N3?3;;;/H7:6MO8VM*RM(*G:4:<80BN
M",()1C%=)))+I(YL43T                                     09V8
M^4CI7^5V1?O6#BO3_)S]1$LN%$YA0)@           *>^,CKUF/)>)=?-C-<
MX;=DG..AVS>.-JXYB\BZG;3*L.A9J@O(N.6$NI!MY[\]LQI2D@HJM%:BB&\A
M):8L-3EW09/!I-I\#6!&[8#B$<!K=+#L1G.ULNQ1D-3CZQ[6LF"LH,4GIGV$
M35V3MZ*304K#[?85+CYH8Y-1#:;8G*4HC51%.B47%?SM6PBHU(O84]ZLY^R;
MJ/P].)!D3$&%K=46]]XID.CZYAGV+/=BITLP'EA@QDJ;I[(,3R#ML0\R'&T.
M=FLJU"M+4$4<E=E]Y-UEO1 3R2E))[=G5.<XA>8-0%2?3V5PGB6;([YRF";L
MZL91RK)9/D=JDVN>#<;-<Z5V26?3!CQ#CG'V%L=NZUX<"$360Z44O9",TTM/
MR$6GWW!%/;L2V%G>JNV> -"=U>(_C[;S*,9PZW[1YS:MR];<SSY28SXUS?A?
M(,%CJ$MOAD_4IZ,:Y=C9:C+0&(#%%AUUQU]4I9I99E]!*TY13CT%@?'PS]M<
M690WMX[&X;8WO4;P43$-(9XTR9SBD@:'>8XMQ1A?/S,HRPFC;@D(D"IHFK7"
M5#JRTJC3J%C.:CNZ'I+ZUO"::C&/1VE\&N.PV+-KL*0+83";VLD>+<E-[@YQ
M%Z<&5UCJQ>C:WQTCJPP]F?$B%U0W%NK.?92TXJRZZVVEU*<VZE:Q*;33P?"4
M#YEVWPKI]](3E\UV <KH1CB<<.#&^-U&75K<L4Q''3\ZYQ=WYALGKNC0J;8I
M%Y<ICER"QQ47EI+'2J,HWDM-Z4J'1*B3E2V<.)_F1Y1#^*CQ*6]PTLFR.88T
MURT*VNQ)E'9>)$+S,:'92VABON.QIBMKG21,25)G:*6JZR:_L Q4G2VV'4MO
MM4V&64<(VPCUW"V=JX<W%)TGU+T(Q9KYM9DMEU;V$U$@UF(LTZ_9#:G1FR:F
MEL*5+6^YSBD40M9RK(960$Y93PF4,='"P_MC2XR_G5NNJQ$HRE)M;4ROJ!8O
MR- ,*\(N89(A#UBQ7L9QWWC9B(8FDB#M2_XRQSEM9.G&$1=V9[;;"6A2H94-
MCG:ELMLZ$EQLMOL+,I>7:)L4W+#H1-J6"[@8(R/L[F_3^)R9Q79WUV8(3)LJ
MQDZ-/R%N9&?(3 PR:+*$<E5H"6%Z,6L\E2&7EI%!MY-QE;3*6W6W4I$HN+2W
MN@RN3CWXCFN2M.,83**J<LIF'6[;[7W9#+)N"#BBLRHL.P%PD+//))C*T]M>
M4UTR@2*6ER-"8<D5$(SFBBHTHPLBZVL&3TWA+U45-9%8- <^N6O&(\6<5[B@
M<1"<Y>S9BU5#L!Q79?&<PLCM8[(D,I,R[E)M>]9[2,?17%-C?:Z+[W6U$O+L
M*NZ(OEL-N*$_7+%N*2+7.&^453B<\<HZA9=#C,V:C%&&TLMH;>43@%SO*+O,
MI3G7%E7'WUMI6O);6^[D^S4.B23]Q'UR.NM>NT<VUE_TB'6V5436M68]E*PL
MI:JLJ84R/J_#;>;%9+;;:6==V3%I0G1N)-:67UH<EMKS:\G)41;P47TCHG"A
MG\]W^V6P-DC,D?=V]UX3FI[CK--4<C;5R5=3>J?R9]Q1EE])4KBZHEZQOPIA
MM(:NJF^W3JI72RZXODN)!":W5@NB_L&T,(E(          CKMK\F[+_Y(J/O
MM(*E+\HO5)9>Y-2%[_XT[_VHX??9H^;>O?GUG7_%KS_U%0X3U=\Z\S_XA<_V
MTSBQB9CP
M                                          !M.\.'Y&.&_P#S0_UJ
MSD=\\RO_ &RRS_YC_P!77.R^:CY@6'_G_P#J:Q-\;3-B
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M=B<W'S)L/S<_[69S?K3YSW?X<?@1*J!FYBP
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M=^L3F% F
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M-;3.G+;)*]2-6K0Y3&44TGOU9U%@GMV*>'JHS\,O,F
M                                  XB0?\  7O^R'+[R.$5PD'P$1]
MODQ0W^UYC\*'05:_Y5D(<!,\428                         _P K3EIR
M?8^Q_P"W %;G$^SMEC7K C!+<,=JKYJ[9'BT82)7=C;7].OL=E%Q54-B)S*-
M(M.5WTM+MOIR7V\[V*T$\.F0>PP5EK><]\TTQ/GS#%(^PS209ZQ!B?(K(Z1M
MI6KHLX/DFM8)]%EK<Y(KZI%I!G+0L[F6W='=;?96EMU!-NMO'H!-<1);$&5Y
M7+]V=FL)/A;$H@&,8?CQVB: J.-!"M(MD!5USH8J<24E%2KIKJ<MM#+ZTM_D
M$N'6XD<>D1-8-UY^X[MM#?<V12_3&59AE>J[ ]W,3/V73-,6A2234=ZO=$U%
MUS<[N9]$1%+KZI[J=+7_ )Q5:B+6S#HC$SI*<\3UKWRFN!D=(];CICUJ=,EM
MJ&^+LUZJR5IT"L\E2:ZW(JJSTQ9A5*]!=?<7R?R?R"&&S$8] C!K\]\2K/.O
M;3L-!LU86-3R$V7'(\8/V(6-"2YD1&5R".5;%LC0VE5IVQJSW5M-M*^UH93E
MK6O*)E)QV1;3PV-<*Z?JAI-[5C'BZ!9=IIGE/L=A!HG2J/IHC+VYT=XAD",H
M;:%IV&<Q=9<V2)&DI_SNQ.SR;JE\ZM:\WV*UKR<HEG*I+94G*3PX7PDL:=.'
MN(I>H2QMIS;:4IR4Y*<GL?8_\/\ ],2$Q_H       "K;B\WN*35F%.;':ZF
M/Z7;S29M;4K+)ET17/"65[68CB,ABU[X@6(KT[7,8V^JVI;:;=<GO2+#*&V7
M6<M!% P5GB0Y*?\ B0<*EIFF+GK%+&Y2S:@AP3H,LIG]EFUL3UPD$EC3;(6&
M,*DB!S*BTA2$N"*JXL^TE52EY=+;_9 E,[P1!99Q?]C45BMUN:T>A&JLI1,Q
MCV\&L"*3R;.>UL=D$B1,1BZ]F2/CVQ0AI2*E99%IYR=N(LNNK0N@$2'UZEVP
M5L!O;P\KW*2+%&V*&%Y\U%=G&12%Q=F>+YS5MV$,XQ.)+C5)SBF:=8YDPJ9N
M4F3F7=IV=ZLNK2Q,65;0"^6(15HA$88HBP$&IF2.-:)G:R#UBQP4%HD"<M,G
MHH7N*A4O6J*EETK><<:8:9=6MU]UUU:UK B5/[4NR/4/?G7/:M_>7A%@?/D%
MRCK'F5,J=GE7$X=EA T4S)@S(Z5@JI,9VISE#- I3%%RJTLFJP]:TD5NN-Z&
M@CTR!FAK+=M>=*7Z3U:)3;E;+SNZ2CW-%&/<FD+)E;9Z>UMCD*:T1R@YT[18
MD<9\C:B24UI78S,Q5,YEO,,J!$Q#PP\@S6-:V9VUTD/N]E^3=)<EY Q7%TF4
M2')%DZ;XG6LY.4M:7656.1IRY2X/&,98WLIBRE>8I6M"FZS_ )M0('R:58_Q
M[M-P[L+[!YAG4@?<HY^P9'\K96SFWS9UB<NQMD62,5C_ #M%!7LI<2DQ0UX;
MEUJIK1-J4LI WVM%+%A)]W95QP/C.^9CF+SD'B=85U0GZE>V8"OT_P F;#LC
M G<ES&VYLS1',N0B K(^_K$BA&;*&7#\%D%KF9'Z&7I%*B2$+5A!W8*6XD\2
M.PF]",2XYARW(S+&>RBVF6T;#7Z#7R!6MCC!:8TFLM?<_'S%1ML11OZ%)2IY
M*6A"=0<3<=2SI;C;[A J+U:AS?/>!E6Z3N\N6/3_ *_YRE:^8ES:5DSPN5-J
MK(%&F4(IIVWND:1]9ZMJ:J4^U1_-4(LI2G-IS:P(G'*\J3. /D-T"WB=763Y
M%19=P<Y:B;+JKUD7;-LL5M.:<>HGJ-2)W83F=L(V;AL*,6IYG'RJ%)Y&RT->
MDB6Y&<K)2Q(=,[3NY9)T_$[T?9(C W7*224ZK[H*7_%:?(QT!CLK61!XP+[E
M71ZN5K"V!0MCALC6%)#32JGD4<#JV74MNOI4%M+;<%,:6,8BQ]'4J-R;;6:+
MLZ)0T/#TOD3JQKK4))JYB7O;HI6.3DH9%9MZ6IJ@TPZM"J<^ZMU*U$")ED
M                      $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\
M-Z]^33^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
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M_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M                                                    (,R3YPG'
M_P"SLM^$\V%=?J[_  B5^[]8G,*!,
M                                                      09V8^4
MCI7^5V1?O6#BO3_)S]1$LN%$YA0)@
M                    (Z[:_)NR_P#DBH^^T@J4ORB]4EE[D[=@#_ ?"?YH
M\;_ UF$*GNY>JR*X$9<$A$
M
M                                                    XB0?\!>_
M[(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_E60AP$SQ1)@
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MS>%<NE+Q()#(U3RZNIRHQ8K6J3CKSJW5OK2M (F1P
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MNI^6.$?Q+DL<]<^'ZUEWYNM[-,W'S6_J]Y^'3]B9MQ#1)M8
M                                                          "#
M,D^<)Q_^SLM^$\V%=?J[_")7[OUB<PH$P
M                                                         !!G
M9CY2.E?Y79%^]8.*]/\ )S]1$LN%$YA0)@
M                         (Z[:_)NR_\ DBH^^T@J4ORB]4EE[D[=@#_
M?"?YH\;_  -9A"I[N7JLBN!&7!(1
M
M                                                          .(
MD'_ 7O\ LAR^\CA%<)!\!$?0+Y,4-_M>8_"AT%6O^59"' 3/%$F
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M=NE3:@3HSW2K(S%DM#1<O,(J;5,DL+3$UNYA5EME+;: =I
M          ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^33^"SIW!Z
M^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P             \S
M'C??.H[?_EE#OU4P(=B<W'S)L/S<_P"UF<WZT^<]W^''X$2J@9N8L
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M;K>S3-Q\UOZO>?AT_8F;<0T2;6
M                                      @S)/G"<?\ [.RWX3S85U^K
MO\(E?N_6)S"@3
M                                      $&=F/E(Z5_E=D7[U@XKT_R
M<_41++A1.84"8
M    ".NVOR;LO_DBH^^T@J4ORB]4EE[D[=@#_ ?"?YH\;_ UF$*GNY>JR*X$
M9<$A$
M
M                                   XB0?\!>_[(<OO(X17"0? 1'T"
M^3%#?[7F/PH=!5K_ )5D(<!,\428
M
M      ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X/7S9.F
M?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&             'F8\;[Y
MU';_ /+*'?JI@0[$YN/F38?FY_VLSF_6GSGN_P ./P(E5 S<Q8
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MM_5[S\.G[$S;B&B3:P
M                             $&9)\X3C_\ 9V6_">;"NOU=_A$K]WZQ
M.84"8
M                              @SLQ\I'2O\KLB_>L'%>G^3GZB)9<*)
MS"@3                                                    1UVU
M^3=E_P#)%1]]I!4I?E%ZI++W)V[ '^ ^$_S1XW^!K,(5/=R]5D5P(RX)"(
M
M
M                           !Q$@_X"]_V0Y?>1PBN$@^ B/H%\F*&_VO
M,?A0Z"K7_*LA#@)GBB3
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M=O\ L\_@LDYP>OFR=,_S.MWXW=Q-K[YY9A\H?L(IZ1^;=G^97LLLG&(&1@
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ME>0=.Z53CI?+8R6$E86_]E T;G[3SV]:VIW=;^TD1!%^+0
M ;H?T43_  _W4_+'"/XER6.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,VXAHDVL
M
M         !!F2?.$X_\ V=EOPGFPKK]7?X1*_=^L3F% F
M
M          (,[,?*1TK_ "NR+]ZP<5Z?Y.?J(EEPHG,*!,
M                                     !'7;7Y-V7_R14??:05*7Y1>
MJ2R]R=NP!_@/A/\ -'C?X&LPA4]W+U617 C+@D(@
M
M
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MGV^S]M;['V?9I['\OL^S['L5$<&,4?URTK]CV1
M                     0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_P W
MKWY-/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C
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MFM_5[S\.G[$S;B&B3:P
M                              $&9)\X3C_]G9;\)YL*Z_5W^$2OW?K$
MYA0)@
M                             "#.S'RD=*_RNR+]ZP<5Z?Y.?J(EEPHG
M,*!,                                                   !'7;7
MY-V7_P D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(@
M
M
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MJ5NM,*,LK6TRRZVG+2MM:TK0>#H[O11[D\5BN ^D
M                 ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^33
M^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
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M0_HHG^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M
M      (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
M
M     $&=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
M                               ".NVOR;LO_DBH^^T@J4ORB]4EE[D[
M=@#_  'PG^:/&_P-9A"I[N7JLBN!&7!(1
M
M
M   .(D'_  %[_LAR^\CA%<)!\!$?0+Y,4-_M>8_"AT%6O^59"' 3/%$F
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M^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M
M (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
M
M$&=F/E(Z5_E=D7[U@XKT_P G/U$2RX43F% F
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M0C'##=Z?"3?&TS8@
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M)8X)U(1DTL<7@F]F+;P-59G:PL<RN+*FVZ=&O4@F^%J$G%-X;,6EM,%BY'A
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MJ1Q>ZWT&FXOH/'8L\TUJZQU#%TDN2OXK%TV\<5[Z#V8KC6":XL-I;X,",L
M #\CCB4Q)JA0:4G3IRC#CSSC+"B222K*WFFFFWUML+*+LMK6ZZM:4I2G+412
M;>"VMD&TEB^ U+MPOI."3%N=Y=CK5[#\'S+C.&'=H;\H2>3/C<EF$E0GJ"GQ
M?$$[*34D^'$'4M(1K+[[JK^BO4%_]',)K7>>0<S<KW+*=WG5Q4M[RHM[DXQ3
M<(OW*EC]WT6ON<<'M3-5YOSDJUOIV^6485K:&S?DVMYKA<</N>@GT>%;&C9+
MU%S6Z;(:OX%SX]LB"-N^7\60_(#DP-2A0K;6=9)6A,Y'MZ%2KI14>F37GUML
MN,^WK2GLC4.?9=#*,YNLKIR<Z=O7G!2>QM1>&+PV;38N4WLLQRRA?SBHSK4H
MR:7 L5C@B/7$#XFVMG#GA[,[YB<'>13J7E*S('B6$E(5TVDI*.ZA*EY4VKUB
M%NCL52*[K2C7!8;92^_G6)BU)I=Y5+KI;1V;ZMN)4\O486U/#?JSQ4(X]#8F
MY2:VJ*7JM)XEOS[4F7:>HJ=XW*O/W-..#D\.CMP2CTWZV+V&O?7Z3IL;.7%T
M<L/Z"(G>'LU_*X\LPG4Y<4*>SG&U-='F+P1G:VJ\Y+96_FWIK[2O9KSC*4Y:
M[5^AO*;:$87^:.-Q+@ZR$$_44IMO;T^H8#])68UY.5I8)T5P]=*37JN,4EU"
M=>D'TCK7#9?($:Q#G#'#UK+/):XHV".OZ^4HYMBQSD*LVU&C;'.47,T4=X@J
M>%U]EB;LQN-0E7W\P];9R6W7XSJ3FDS?)[6=_EM:-Y:TTY2BHN%116UM1QDI
MI+APDI<4>*^9+SAY=F5Q&TO:<K:O-X)N6]!OB<L(N.+X,5AQR-BU6K2H$JE<
MN4IT2)$G.5K%BLXM.E2)4Y=QRA2I4'76%$)R"K*W7WW5I;;;2M:UI2@U-&,I
M248IN3>"2X6S8+:BG*3PBC61VM^DRX,QK/'#&FJF&7O9UR;W+M)?/5$F,@\"
M<W0M1>0?9"4J6-2B3SE'4VSH2E'0-A"F^[I4UZ@BA=YVY,CYG<RO+57F=W$;
M*#6.YN[\TOOVY1C!]%K&37 TGBEK;-.<BRMJ[MLKHRN9)X;V.[%O[W9*4O5P
MBGPK%<,=HE]* R-")<WL>T.C3G$6=<:2<K4Q*5OL?ES:TWWEVF.#?#LAQA*E
MDIMM*7\PNYT:RKZUI2IUO)6MUUK\S-I<T'4R7,HU*BX%*,91;XG.G)N/8R?2
M+?2YR[BC54,SLG"#][)J27&HSCM[*/JFT5K=LEAS;/$,7SA@J8(YE 923?0E
M432J9T979-0NCI&9,T&U[,89*S'&4L4I#J4NI2ZPRRMY)A1M^F,WRC,,BOYY
M;F=-T[J#X.@UT)1?!*+Z#7J;&FELS+LQL\UM(WMC-3H2ZJ?14ET&NBG[#3.\
MY+RCCC#4->,AY8G,5QU!V!/>I=Y3,7M P,J.RPLPVTJY:XGD%&JS[2KJ$D%\
MXX^_[0NRZZM*5\UG97>87$;2QI3K7,WLC!.3?K+H<;X%T2O<W-O9T7<74XTZ
M$>&4FDNJ_8Z)0=P_^.6_;V;WO^M$>Q!%V'#MZ/*3]!LA5=7^DT>HQ#3ZW19P
M=V%846WMJR0-EY9RDBGLIK[ZV4K6MM:UV?JGFVI:9TS#.*MQ.688TXSIX1W%
M*?NDI+:U%[$^CPF"Y#K:>>9Y++:=&,;3";C/%[S4?<MK@6*VM= V+1J8V"
M             09DGSA./_V=EOPGFPKK]7?X1*_=^L3F% F
M                    " .^'$;PGP]&S&3IF6)98EA65W22-$;3XJ88D^JT
MZN+IV10NHZE2J<0JTJQ3:_$VD=CW*;K[K;Z76V<EM;LYT3H#.->5+FGE%6UI
M.UC"4W6E.*:FY);NY3J<&Z\<<.APFM^<3G0R#FTI6E7/:-Y65Y.<8*WA3FTZ
M:@WO<I5I88[ZPPWL=N.'1AIZ^7 _H=\1+_+Y#?+ ,N^A+._.V0?M53O!@WUB
M=.^8]3_L=+]Y.V3[C:8)Q_K8T;./6 ]GF*+/&<7#!">(3B&0Z%SVL@;H$AR
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M/+>?D5^<I_VD34]>_P#C3O\ VHX??9H^<NO?GUG7_%KS_P!14.&]7?.O,_\
MB%S_ &TSBQB9CP
M                           71<'/_P!>7._]AP+[_E(Z<_EL_7LV_-6_
MPJIO_F&_6\R_-T?9J%[0ZP.D
M                                      XB0?\  7O^R'+[R.$5PD'P
M$1] ODQ0W^UYC\*'05:_Y5D(<!,\428
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M)_F3UCJ#6-AI_-;++8V%W=0HSE1A<1G%5)*.^W.O53W,<<'%)X;6MK.U<?\
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M .SLM^$\V%=?J[_")7[OUB<PH$P
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M_P"HJ'#>KOG7F?\ Q"Y_MIG%C$S'@
M                                          NBX.?_ *\N=_[#@7W_
M "D=.?RV?KV;?FK?X54W_P PWZWF7YNC[-0O:'6!T@
M                                                       '$2#_
M ("]_P!D.7WD<(KA(/@(CZ!?)BAO]KS'X4.@JU_RK(0X"9XHDP
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M                "#,D^<)Q_P#L[+?A/-A77ZN_PB5^[]8G,*!,
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MO4,=&V5KJ:R\ S.VHPH<GRD:F,*4(PC4;@VHN:CBX8MQX&3+&)&<@
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M6"X?51:5+>U#(^.3]'>U;Z9:1T;LE0&G\O/)M,+^W$.B)-.*2X46G")(
M      19W7^2_E?^SF#X81X4:_!#\]2_M('EO/R*_.4_[2)J>O?_ !IW_M1P
M^^S1\Y=>_/K.O^+7G_J*APWJ[YUYG_Q"Y_MIG%C$S'@
M                                                        NBX.
M?_KRYW_L.!??\I'3G\MGZ]FWYJW^%5-_\PWZWF7YNC[-0O:'6!T@
M
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MT\(349-+HN*:7&4\TT[G.3K?S"A*%+WRPE'LHMI-]!/!](@\,D+(
M  ;H?T43_#_=3\L<(_B7)8YZY\/UK+OS=;V:9N/FM_5[S\.G[$S;B&B3:P
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MR3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
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MU)X8;SX,,<=ID&0Z1T]IB=6>1V_(2K**G^,JSQ4<</RDYX88O@PZ9G<989(
M
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M*4I3V*4I2GLUY*4Y/9K7EK_Z>M1;CVG^@
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MHG^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M
M   (,R3YPG'_ .SLM^$\V%=?J[_")7[OUB<PH$P
M
M   !!G9CY2.E?Y79%^]8.*]/\G/U$2RX43F% F
M                              CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.W8
M _P'PG^:/&_P-9A"I[N7JLBN!&7!(1
M
M
M.(D'_ 7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_P"59"' 3/%$F
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MC@]FW M>H[*\R_(<KM+^#A<P=SL;3:3G3:VIM8;<5MZ)1\-D&%
M&Z']%$_P_P!U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M
M         09DGSA./_V=EOPGFPKK]7?X1*_=^L3F% F
M
M        (,[,?*1TK_*[(OWK!Q7I_DY^HB67"B<PH$P
M                                  $==M?DW9?_ "14??:05*7Y1>J2
MR]R=NP!_@/A/\T>-_@:S"%3W<O59%<",N"0B
M
M
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M[TVY3?"WPL]ZC%+=BDH\2)=4IR4I3_DI2G_IA B?Z
M                   @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_)
MI_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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M;CYK?U>\_#I^Q,VXAHDVL
M                                !!F2?.$X_P#V=EOPGFPKK]7?X1*_
M=^L3F% F
M                                 (,[,?*1TK_*[(OWK!Q7I_DY^HB6
M7"B<PH$P                                                   $
M==M?DW9?_)%1]]I!4I?E%ZI++W)V[ '^ ^$_S1XW^!K,(5/=R]5D5P(RX)"(
M
M
M                             !Q$@_X"]_V0Y?>1PBN$@^ B/H%\F*&_
MVO,?A0Z"K7_*LA#@)GBB3
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ME,#=H>^?4^T,9\0\)W$$]&['772/>4P-VA[Y]3[0QGQ#PG<03T;L===(]Y3
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ME,#=H>^?4^T,9\0\)W$$]&['772/>4P-VA[Y]3[0QGQ$..(;D#=-ST5VY09
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M[FZKW2V3J0K-/IR?))_86'L<=0GT;_W4^LZAON?[,[4^"/+ONY[%Y_0>Y;M
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MP8XOAZ&#YU;Y!0Y+R'7K5L=[?WX[N[AN[N'6QQQZ['AX$0*&3EB
M -T/Z*)_A_NI^6.$?Q+DL<]<^'ZUEWYNM[-,W'S6_J]Y^'3]B9MQ#1)M8
M
M        "#,D^<)Q_P#L[+?A/-A77ZN_PB5^[]8G,*!,
M
M         09V8^4CI7^5V1?O6#BO3_)S]1$LN%$YA0)@
M                                   (Z[:_)NR_^2*C[[2"I2_*+U26
M7N3MV /\!\)_FCQO\#680J>[EZK(K@1EP2$0
M
M
M     #B)!_P%[_LAR^\CA%<)!\!$?0+Y,4-_M>8_"AT%6O\ E60AP$SQ1)@
M
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MLPQ_4RR6WN5EF44:D)6TZD*DYO&522:CCPX)1<988;J>/N45:C-#&
M   #=#^BB?X?[J?ECA'\2Y+'/7/A^M9=^;K>S3-Q\UOZO>?AT_8F;<0T2;6
M
M           @S)/G"<?_ +.RWX3S85U^KO\ ")7[OUB<PH$P
M
M            !!G9CY2.E?Y79%^]8.*]/\G/U$2RX43F% F
M                                       CKMK\F[+_ .2*C[[2"I2_
M*+U267N3MV /\!\)_FCQO\#680J>[EZK(K@1EP2$0
M
M
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M!VG4\,IJW7E3*KAUHW52I.<)1W94I-J6#XTW)[NS#K7UTN$JW&:&,
M   &Z']%$_P_W4_+'"/XER6.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,VXAHDVL
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MP
M                         !!G9CY2.E?Y79%^]8.*]/\ )S]1$LN%$YA0
M)@                                                   (Z[:_)N
MR_\ DBH^^T@J4ORB]4EE[D[=@#_ ?"?YH\;_  -9A"I[N7JLBN!&7!(1
M
M
M                          .(D'_ 7O\ LAR^\CA%<)!\!$?0+Y,4-_M>
M8_"AT%6O^59"' 3/%$F            ^)6Y-Z"WG+EZ)%;]GG*U1":WD_P#1
MG7V4%2G1K57A2A*3Z2;]@I5*]&BL:TXP73:7LG'$2F,*K^C32-A4&5]BA9#N
MWFW\O_)S2U%UPKSL+ZFMZ=&K&/3A)?Y"A3S'+ZKW:5>C*7$IQ?L,YVVZVZE+
MK:TNMNI2MMUM:5I6E?L5I6GL5I4>3@V/A/8FGM7 ?Z
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M3^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
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MG^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
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M;SE9[E%._:2K;8S2X%./#ATGLDET$TB?PQ<OP             09DGSA./\
M]G9;\)YL*Z_5W^$2OW?K$YA0)@
M                                                  "#.S'RD=*_
MRNR+]ZP<5Z?Y.?J(EEPHG,*!,
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ML3]'PXAC_C/*!3I+<&2\]L)FR=J2&IFG+N&U;BL*BN7H(B6J>PTTYB5:J/\
MHMRBZTM84N:35-+#.R[<XS&SRGG4TI&\LMVGF=-/<Q>VE526]2FUM<);-N'
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MMV<E^6=JT_4526[]ER+'S8.?DNYB_P GX0L/5W%C]A(VDAI8V:
M   $&9)\X3C_ /9V6_">;"NOU=_A$K]WZQ.84"8
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M>A4G,Y:!"C+1NA%_0K#4ROD,I2A7+2M*".#X>(D,!
M   "+.Z_R7\K_P!G,'PPCPHU^"'YZE_:0/+>?D5^<I_VD34]>_\ C3O_ &HX
M??9H^<NO?GUG7_%KS_U%0X;U=\Z\S_XA<_VTSBQB9CP
M
M                 !L7<(KY-LV_/?)/@'C4=H?RZ?,FZ_XK4_L+8ZIYCOFG
M<?\ $:G]C;EIPWX;F
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MNONNK====6MUUUUU>6ZZZZO+6MU:UY:U'1222P6Q(Y.E*4Y.4FW)O%M\+/\
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M^VXN_FFVW64U7FO.#IO*;QV-:I.I7@\)<G'>46N%-MI8KHJ..' ]NPZBT/\
MRG\\6O-/T]2Y?:6UIEE>"G1\+K<E.O!K&,X4U"<E"2]Q*HJ:FFI1Q@U)RKQ=
ME2!9GAC9/\;2)))8PZ]+82M36G$'I5:>M+53<YH%19*UL<DEUU.D(/+L,I2Z
MVZE*V76W791EF:6.<6<;[+JBJ6TNBMC37"FGM37136/1X&C2NLM%ZFYO]05M
M,:MM9V><4,&X2P:E&7N:E.<6X5*<ON9P;BVFL5)-+(0]YBP   :G7TNGY%6M
M7[49/ZI\B#9?-A_%[CY-_GQ,7U5^IT_SO^:R$WT/G_$C>K\B,#?C[*(N_.E^
M0L_PZGL0/'I/\I7]2/LR-YX:=,T.LS291;'4/E60)R^MT7A<(CKU+9;)7<^B
M5J8(U'6Y2[O;RY*+J5H2A;&U(8<;=R5Y++*^P*E*E4KU8T*,7*M.2C%+A;;P
M273;)9SC3@ZDWA"*Q;XDN$\=?8G(BO9;:C.F68\T+3%VP&P.3<B,; 450URO
M5Y5R,]R5L:"R"+;:&K;CGZPFEEEM.<9[%*#J>QH++\MHVTVL*%"$6^AUD4F_
ML&IKBH[FZG5BMM2HVE^$V_\ *>P;B6)*X#BK&4$7GV*ET*Q]#(DM4E64++4*
MXY'&UG4GEV4,.I98<<CNNI2E]_)2OV:_9'+=S55>YJ5H[%.<I=5MFUZ4'3I1
M@^%12ZB,@B@5  /&=V6^4=G_ //9E7X=OPZMR_\ 4*'YF'P4:CN/UBI^'+V6
M>S$.4C;@ $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KY
MLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #S,>
M-]\ZCM_^64._53 AV)S<?,FP_-S_ +69S?K3YSW?X<?@1*J!FYBP
M !MP<>#YK[A2?D;C_P#]!ZB T5S9?/3//SD_[>1M?7/S:RO\"/\ 91-1\;U-
M4&PY]&3^<<>_V;,G?"K&XU3SQ_-*/RRG\&H; YMOG"_DT_A0*I^(C\X#O/\
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MZMJ:0C%SS!72HT_O]]KDI=)3C*,NDGMPP.\<CUOE&;:&I:[G-4\KE9.O4_\
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MW]?3^>VN::$N')TJ-.?*RI5-].G*4HMP53DL85E%0<Y*+<5N)*] :7.@P
M                              @SLQ\I'2O\KLB_>L'%>G^3GZB)9<*)
MS"@3                    &O\ [T8QVJP7Q0,.<27'.K3QO%A>+ZJO.N[S
MBZ".L;+R_@F4*Y^Y3%7EG&,3D-4]LF>)$T.%&FZ]OJ8X&(SUR=0801V)6Z!4
MBTX;C>#Q.*:-NN&SOUNAJ4LG]=EM,-[M>YH[2+#F-\_8HKKQE.?HY$RN$?DF
M)Y0X2:,S2-RJ)2)/=>75D2/B)U4*:UM0W\Z\^VX-V48O@<6?U"MI^*;MUN#O
MGK3KU(M:,&8HU/S&W1!/GK(&+9;D24JD[RQ)'*/0%AA::;L4>>WJM42Y4].R
MLXNQ(D/1E$)NE-J:&T;L(Q3>+;"KB);-1C6GBEX:VDQ_A4_<K0#"JC(?;-@8
M75\UZV#QO-X,]R7&L^30N1+Z.I2915GO1R-H,4] 4JOMM*OLK>:G3!NK%->Y
M9'S)>UV-,4[\<+7;;8J3P[%,&+X262,ESAP1HZL\9:%LG8X([5C\/CR>]6L-
M,6NSG:A9FA)10K/,O)3$6F&76TJ)L.M<5[XGSBK?[.JO6O/?$UV#BD:Q#I&T
M8F59.UHP4E0%.FP\XAB=OM51R<Y4FED@70R..^6%)B>QBCC>F,["L<D]5B^M
M2K^R!(XK%17NB'DJWXXC>+,,5WAF.=N'/,X2S1=)E7(>@L+<S2<G1O$MZ<A]
M?6.(9N/R J42;.,0B5UQJH@YFL9U*\A24F*-I1,68Q)MV+>[@\>,V,<?3F.9
M0@4(R7#EESC$<AQ"-3F+.%Q=2;ET<EK,B?V-9<3=6MQ5RIL<"KZVU]FWG<@B
M4GLV';P                 $6=U_DOY7_LY@^&$>%&OP0_/4O[2!Y;S\BOS
ME/\ M(FIZ]_\:=_[4</OLT?.77OSZSK_ (M>?^HJ'#>KOG7F?_$+G^VF<6,3
M,>
M                                     -B[A%?)MFWY[Y)\ \:CM#^7
M3YDW7_%:G]A;'5/,=\T[C_B-3^QMRTX;\-S
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M)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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MZ]^?6=?\6O/_ %%0X;U=\Z\S_P"(7/\ ;3.+&)F/
M
M               &Q=PBODVS;\]\D^ >-1VA_+I\R;K_ (K4_L+8ZIYCOFG<
M?\1J?V-N6G#?AN8
M      #B)!_P%[_LAR^\CA%<)!\!$?0+Y,4-_M>8_"AT%6O^59"' 3/%$F
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M;L_S*]EEDXQ R,             /,QXWWSJ.W_Y90[]5,"'8G-Q\R;#\W/\
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MWH]8WZY+P;&,Y
M     XB0?\!>_P"R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428 #
MS^MKH?(X%LSGN*2PE04^MF6IV8J,4VW6F."9SD2]W:WFRE_VUR9^:5Y"TFZO
MLWDJ+;OY1]>^;W,K+-]#91F&7M.UGE]!)+[EQIQA.'JTYQE!KH.+1\)>=?*,
MQR+G+SW+,U4O#89I<2;EPSC4JRJ0J>I4A.-1=*2,^Z&;]SS2.7/)B-IMF^,)
ME<EOFD#/75;C#%R$LPI#(HXY5)5%M3ZF*-J4;SBC"5B?D+-MYUA)I.(\[7-%
ME/.CEU-5*G@N?6V/(UU'>6[)IRIU(XIR@VL5@U*$ML7@Y1EG7,9S[YUS,YG6
MC&EX;IB[:=>V<MU[\4U&K1E@U"HELEBG&I%*,L&HRC:(EXMVAD7DBO+<*TR?
M$.;%]J@Q9([8QBU@4&JUQ=;%YONU;G1S>J&K*7W6FGVMMAIUMUW/_P"==0:%
MG_+OSM7]G'3V9ZDI2TQ!K=I\K=5$E'W/XB48PV="/*8+!8<".G(?S6\QN77T
M]4Y1I2XCK&HGO550LZ4FY>ZQN(U)3V]&7)XR6./"T5.Y"W;F68=P87M/DELJ
MH3PJ;PUZ9(*SK*VI&.(0Y](=TD6:%BLODN/.YAMYRHRRG3*S[S*V6VUI9;T)
MD_-;ENF^;>ZT%DE3"I=6M:$Z\UMG6K4W!U9I=!;$HI];"*6+>U\L9[SUYKJS
MG=L><[4-)NWL;RA.G;4Y;*="A44U2A*22<GM<IM+>G)O!+!*V*8<:/5K(:M(
MOG^EMLY7-Z>Y(@63#P=R96B27F5.O2I%#U&UIR9/>==6^MEE;;:W5Y>3E'/>
M7?RQZ^R>$J64ZE5K2F\9*CX334GP8M0G%-X;,6=3YI_.-S89Y4A5SK2=2\JT
MTU%UU:57%-XM1=2,FDWM:6S$JC6[>-B+!LJQ;"X>LC+XMW7OVPASP0I0%,T8
M;T<>O:&&)6-:,@BZU4U*K"C+#":V$6EETMMMI[ W_1YM[BIJFWSW,[F%>TCI
M?R36@U)SJR<]Z=7>;>R:Q33QEB\6SF2MSQ6-'1MUIS)K.K;7T]9^6Z$TX*G1
MIQCA3H[D<.N@TL-W"&"P6!AN7SC'*L_,:^.JYPX.&2*+R$-SZPL34E*+6Y.B
MTYJI7412AZ/3FT11^\KF654<IQE/MJ6\MPY$_E__ )(L_P"9SG4L^<[,\]M+
MV=*%TJMO3HU(X.YHU*?6592Z[<E-8N4(;R3>">P^J7\ZG_YW;27\TW\M5[_+
MKDFC+_*:,JV62M[ZK>T:N,<OJTIM5;>%&.YRL(/=W:T]QX)XK%J\CUS&!<A,
ML.@,LTW>\IGMUC0W,C(^70R8]D/A:$MI*-969RCKG?VQ64NN++H394ZZAG,I
MR\O)7.'_ "T:NR:YN<WL=24+"$]^4YPY:CA!RWVISC./6KA>+PV8G)T?YP-"
M:@M[7([[2=WF56.Y&G2FK>OC4W5!.G3E&;WGP+!;VW#HG;8;PK[=GM@GO9O,
MT!2Z\8:E9\5>([K&SEMJ*6U2M$.C;.:EE)D:3-K)"4#VY-AJP](FMN=*]D7E
MGVI#^==6WYAS]RT+HZEH;3-V\XU);JK"IF<W*5'&=:I-.DJKE.M*$9*$9RPI
M=:G#E(8%UR[^66ESD:_J\Y.L+&.1Z3N>0G2R>"A&O^+H4H-7#HJ-.A&I*$IR
MIPQJ]<U/DI[Q??%8I&H/'6>(P]B:XU&(^A(;&5B949*!L;$":REA*9(E3VV%
M%%VTI[/L<MU:UK6M:UK4<EW]_>YI>5,PS&K4KWU:;E.<VY2E)\+;>UG;F6Y;
ME^3V%+*\JHT[?+J$%"G3IQ480C%8*,8K8DCL \A[0 /P5=D53**(ZE45U(-[
M%J?SN@HHZ.[H*G<SEOZ*AO)SN3V>3[ FAN;ZY3'D\5CAPX='#IDL]_<?)X<I
M@\,>#'H8](J9PA*L$,;QJNDB$?@CGFX^J>/97-0/RUNS_',A.<&DY.1C<X,R
M!C4."IG42(F^R[W2*R"S74Y,:DLNN+(N&_-39?JBZM\]J9A6NJ>F5C4M5*$9
M6-2WC7INW5E.4U%35-I_W:,FJ2G&HTI21SSI7,=)6]QI^.74;2IJMX4KMQG*
M-_2N96]57+OH1@Y.#J)K^]2BG5E3E33:@SA,9[/;$2&%Y+D;E.88IEK5KODW
M(,O@)*QI>Y+A#*;(G)-CL;411JQ^T'Q!.RN%5;<J:Y0Y+U[A>BM4)KSB[5%]
M?1G6B=(VF96=G1M;F.7U,WMJ%&NU.%.]M9MJI4565>2JN<=RI&I;4X0IJ;A-
M1>XCSY%KK6=YE5Y>U[NUEF=/);JXKVZ<)U;&[@DZ=-TH4(.DJ<M^E.E<U)U*
MC@IP<EOLRA.,KY]Q<P928E.0_==>UW:V2%3DR0ML.A=F-XSEYWE;/D)=>L31
MI?&$$<CYT/M,2+7) NHT%.=QRR\\A+6X63+,ATIGEW8W-.S\'4_*--6U.5:M
MX15M(4IV\<'4C4E4J*MA*%.<.5=-1IJ,IX%]S34&K\@L[ZVJWJN=QY;4=S4A
M1H>#4KN=6%S)M4Y4E3INCC"=2$^155RJN<*>)U9!/6Z<M>%Y-M!*H%-L"-^2
M,PM!$[5N3>\8H>GI*SL2;%CCE-_K%XAC9Y3H[[Y.WI',M);'U;I8AJ5?V;>7
M;3W5,JKY77S*RT10NK;5<[*TFZ"C*%U"#G-W4;6GRE6Y@WA;5)4W+EXTG5WE
MR:;+?#-;?-J.67VO+BSN](0OKR*KN49VDYJ$(VLKNIR5*VFHXW5.-11\'G55
M%Q?*M([7$WA\N+9(UKS-B8'A')VTLC8<<R2*L3 ^M7@V38,62:9&XV+>T+BQ
M)8XOS5'GF]K5E$G(*VW7&);3$=Y-+O#?VUJI5;W5UL[K4UED=.=Q3JSG"7A#
MO53HJXW)1FZD;.I156#:GC@IN-12PN.675S.%.ST9=1M-*WV?U*=M5I4Z<X>
M#*Q=2L[7?C*FJ<KVG6=*:C*FUC*FI4I0QQS.]EL\,T7Q62YY'C4 ).@.6#U>
M2Y,HB\-1Y#R9CS)2N",S*:0\PB7M3@N5,;71S41MF(1.KO>NOJWW6%I+[*7?
M*]&:6N;Z^E0LJUW)7=JE;TU5K.WMJ]NJ\YXPK4I1BIRY.-Q6E.E24%RJ;J)E
MES36VK;:PL(W%]0LXNRNV[FKR5&-Q=4+ET*<&IT:L)2<(<K*VHJ%6LZCY)J-
M-HM8AJU\<HC%G&3)D2.2+XXR+9 D;:+J-R9[5-B8]U3H*.B5"YT1$KKS+2J*
M"23Z64ITEEM_+;31.8T[6CF%>C9.4K.%::IN6[O."DU%RW6X[SCACNMQQX&U
MM-_Y;5NZV76]:_C"-].C!U%'>W5-Q3FH[RC+=4L<-Y*6'"D]A7O#,[XS>M0,
M.QB#Y'QK,)]'H=JJCD$01OD4E[XS6VS;$4<?[WB+WGN2E"K:5"ZXNIIY%IB)
M92R^E;#K+*TVUF6EL[MN<',;W,[.]M\JK7.9NG5<*M*$_P 3=5(;E3"*DI*.
M."EA.&*VQ;-/Y/JS([GFXRRRRN]LKG-J-KE:J454I5IP_'6E.HYTL9.+@Y88
MRCC">#V22,7R.9Y'Q MR:ZLTW2QUER1N3/F:?90E*J"0Q-#F!CQTW*X@R7S=
M]A$@C[*G=UQ"=K2K'A(K+LL(M3$W%J%5M];[:9;D^H*5E0N+65:YLM.6\Z%M
M25>LZU2==JK/D85H3FX1<JLH491;;<Y*4(-&/7.9YWINM>W-"[C2M+[4]S"X
MNJKH450IT[=.C3Y:="<(*<E&E&=:,TDE"+C.:98IKQ*9/-<-0:43!V99 ^.Z
M%Q.OD$>-O/:) UDO;FECS^E/JR1PA1>]QXA*J-,3(B$1AQM]R:ER>I5UVG]7
M6-EENHKJQR^G4I6U.45R=39.G)PBZE-K?J-;E1RBE*<II)*>$]Y+=&CK^^S/
M35K?YC4I5KJI&3Y2F\85(;\E3J)[E-/E*:A-N,(P<F^3QANMUXP1U@T=V!:;
MVHN%3[(SSLAE7FL5U#89MA!%#HTSRQXOR00W.DA)FV%$#3T78!B^C:V%M"AI
M4E\]42E+NV]FE#-+S2515_";3)Z>36O7K"ME==1G0W/!W*--T;R4L>44.4J.
MK&O!X0E-K3655\IL=8TY4/!;S.JN>776/&CFUNYPN-_PE1E45>RC'#D^45*E
M&C*WJ)NI&FGVF!YUD$UQ))W=RS<UY$R"OPH5,LE8848Z9U!&$L@G/+:G<H6X
M*&YFM3QGW/+%*IHJQ2DQ6\N%S?583=6PI36O@S;2UIEN?T;>AEE2SRF.9.C;
M7BN)IWE!0DXUHJ4\:G*)0J\O;*-&GRG)R6+@7#)M6WF::<KW-?-*=[G4LK5>
MYLG;0:LKAU(J5"3C#"ER;<Z/(73E6J<ERL6TJC.;9\]9K<MIG*"*I;#F@M%F
MU?"B\-.KTUE2!9AQ)&[W!+/VZ'H8"OGARAV(LM=R)"<\EQS[:K;?0L_['FN=
M*Z;HZ'AFL+>XJ.661K.\C"3IJ\=3=="565>-!*+QI2H*D[C@K+>CP^NUU=J>
MOKNIE%2XM:;AFLJ"LISBJCLE2WE<1I1H2KMS6%:-PZRML<:#W9\'"QO,VR[#
M$44YODRC+<@GFK&SF6(]CHV%L36B;,@8<?\ ':3'C,P^YMO1/KC[H$<V.3N"
M=0>>8M4E%W)J)_\ Q=?5>Z;T7=9A/*U067VEKGV6VM2XY:<I2M[N%P[B<^4D
MZ<>3=&,J<HQBH1;4][A/)::FUS:9;'-77>8WMUI[-+NG;<A",8W%G4ME;0I\
MG%5)<I&O*-2,I2<Y)."AP'U/N?WYKQE('/&VS[+F5F*EF)&R5Y74M,2B[7B1
MNEM'"^3*%^0T,/<<7HK'!4D1)>Q5S>K6Q3MI:<Y5H5<1=;3M=)VM?.J5#.,D
MJ9;<NWNITK53JU97<J6[R:C0E5C<O=3G+>A4C"ZY)QH]=O)U+K6%W;9%5N,F
MSVEF=JKFSA6NW"C2C9QJJ7*RE<1HSMEO25..Y.G*=IRRG7>[NM2OU4F\RR!B
MPU_F,EC<UYDQEK5%YG%EUCJWRB)-;G5(UN)[V@C$2C;^O3*+%",QP9DE&I?1
M+:>1=7I+J6X'KO+,ORC/%:9?1K6S=M2G5HU5NRI591QE%0E4JU*<6MV:IUI<
MK#><9+8L=@Z S7,<XR&5YF-Q0NEX56A2K4GO1JT83PC)SC2I4ZDD]Z#J48<E
M/=4HMXLDF,,,V  HUX]O#3<.(=J)19C)H*<MD->5+W/L/)*5H6KE[8X(D=F0
M<7)CKJ5+M631N9DA[?2_F6&/#8C*O,*)-.,IF&B]01R+-,+AX6%?",_O6O<S
M_JMO'[UM[7@67/,N=_:8TUC<4]L>GQQ]?H=-(T!^')O[F3AB;2-F9H8VJG-N
M*[*A&:,1/1ZIE1SV&7K;*/,:<Z&D&'L,H87%+:J;%M2;C6]Q3TM-+-3&*DI^
M[,^R2TU#ESM*K2E[JG-;=V70:XTUL:Z*>S!X-8-E]]6RVY5:"Q7!*/&N+I-=
M#B?2Q1Z>^EF_.K^_F,DF3-<,CMDELL3)[I7!7$U,UY)QZXG665,:9O#[U)K@
MU&EG75+*5E],W+:VUN2J3[/MASQFV2YCDEP[>_IN/%);827'&7 _4X5T4C9%
MG?6U]3Y2WDGQKHKU5_1<1,L6H]9_-UUMEMU]]UMEEEM;K[[JTMMMMMIRW777
M5Y*6VVTIRUK7[  K1C_%VT/E^Y[-HK#\TL\MS&],[V<G>X]>D<L7VS-EO3&^
M"FR>D+:MCAD=P;*JE1*1):H26W(349JDMQN)1FY!/3&=4LI><U:+C:IK8]D]
MU_=[O"H)X+%X/:FENXM6Z.:V,[Q64)IUFGM7N<?>X\?M88X["S 8^7$   /*
MMX]WSNNZ?Y;PC]4&.QTAHOYL6GX$OAR-9YY_%:WJKX*/1!X2'S8NAW[+F(/@
MBW#1FI_G#>_*9_"9GN5_PVA^:C[!8B+$>\      #4Z^ET_(JUJ_:C)_5/D0
M;+YL/XO<?)O\^)B^JOU.G^=_S60F^A\_XD;U?D1@;\?91%WYTOR%G^'4]B!X
M])_E*_J1]F1O/#3IF@        >,[LM\H[/_ .>S*OP[?AU;E_ZA0_,P^"C4
M=Q^L5/PY>RSV8ARD;<  @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>_
M)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
M       >9CQOOG4=O_RRAWZJ8$.Q.;CYDV'YN?\ :S.;]:?.>[_#C\")50,W
M,6          )?:N:&[7;EVRI9KWB-YF4=@R90JF,T5K6F,PF.]BH^V!B%7*
M9*O:FE4^5176FVMJ4Q0XW%74,H1T?+?2PYUJ?(]/[D<UKQIU:CPA!)RG+;AB
MHQ3:6.S>>$<=F.)=\LR/-,XWI6%)SIP772V**Z.&\VECAT%B^D?-III+L!OA
MEFS$&OT:1NKRE;3'V3220+KV:%0B/EG%I:O<L?+$JXY(F-6'V$D$)TZI:I,N
MY"2#.;?6V.H-1Y7IFQ\/S6;C3;W8QBL9SEPX16*QV;6VTET6MA#)\EO\\NO!
M+"*<TL9-O",5QR>WUDDV^@BQK;3Z/IO1JIBMXS'V3B_-L.B3.L?IX1B-ZDJN
M3P]F:TQJQX?U4>ED4BY[S'6M(74TTYOO5*BBK3#34Q1)=QHQ+(N=336=WL<O
MPK6UQ4DHPY5149M[%%2C*6$F^!2P3>"3;>!D.:Z"SO*[5WF-*M1@L9<FWO12
MX7A*,<4N-8OHM);2C ;*,(/L;G!6TN"%T;S>QU[:L2N"(_HRC>A5HS[%"8WH
MCK#"3.C.+MKS;[;K:\G)6E:>P)9QC.#A+;%II^HR:,G"2G'W2>*]8VCLS[;Z
MKY&QCLMD75'$VTDGWJXL< B>-''$#AC=X<8=%"FNJ=)F9PQ2ZM[34R>LL@,:
M%5MMR)6\*2U91-YA3<58I)MTME^19W:7MG:9Y7LH::R.K*HJJJ)3ECMI*JF^
ML<<5PJ"P;2<W@S9MYFN5W%M<W&5TKJ6=YK3C!TW!N,</RC@TNN3P? Y/'#9%
M8H@3Q;G;#N'676GA_8"C.:6R!ZM-N2)E))IGG'TEQA.<I9#S@\,KHXR,J(3"
M.Q1]3Q=I:HP0G;5-S:A+/+.O+ML.L(L5'Y1H2GF&85+S5.:3MW<WLJ<(PHSC
M4A3IT4TH[\)2CO-R;DMYX8)[,7%6+5<[2SA;9#81K*A:J<G*K!PE.=1IM[LE
M%[J223P6/3PQ=+8V&8:          ;H?T43_  _W4_+'"/XER6.>N?#]:R[\
MW6]FF;CYK?U>\_#I^Q,VXAHDVL                  %07'BGLBQ_PLMG%L
M8-4I5TE1X]@2Y>E,N+N21V;9.A\?E)1U+2KZ&)GJ.K%3:9;6XNE;5O+SJ\G,
MNSWFRM:-UK6RC6P<8.<TGT90ISE'J22EZQB6N*]2WTQ<RI8J4E"+?2E.*EU5
MBO7(U[40]S@'T<:R+8L)LZ=#I=KHI6WI[32[5K(]JL6/>6'>ZQ,;==;>Z1]S
M>5AE.=<7SC;N=RV<O+>,DN(77.WRU[P/,:^'2:Y14EZTE!>L6[-*,K?F\Y*U
MX59TO73W'-^NG)DLN!ZHA)_"VU.L@IJ Q"FBDI3O]B&ZG/(FU,ARXZ9E.%E?
MYXM?=(3CS+J7TISB[[+[.4JXNM;%SD*Y6M+[PG'><X[N/O.3CN8=+=P__#B7
M713HO3-KR&&ZH2QP]]ORWL>GCC_^ IFXD6_.^NNA>-I5O#PZN'G,&4V:2E!@
MM;D),U9BDC>K0VMKB[/<:;#9_(G2,W]B(FN]<K3E)K:']BV7W4OZ&E-@Z1TO
MIC-N6H:;S;-:=3DXNLJ>-*+3Q24GN14MKE@FWLWL.B8?J+/<\R_DZN=9?E\X
M;\E2W\*C6&#;2WFX\$<6L-N'2,C\5;Y]WA/_ /F0_K[EX\FB/^V>>?\ F_V$
M#TZH^?&5?U/[61M8C2)M UJ-L=$XIL%Q#)KG?AY\0F$X#WZCT<*LR[B4IP2O
MJ@XB,M$=A*UZ>4#,K6.D?0WM%[.D=&]:RNZ%8HJ2HNM*.K6IFW\CU-7RK2E/
M+-5Y54NM+SG^*JX./NG*:2;24GCON,E.,DL5M7!KG-<CI7^H)WV09A"AGL8_
MC(8X\"46VEM2PW5).,DW@]C(];*;%<>#AR0E'EC:TW5;<# S7(F=GDSP3%V&
M]*WGO*RY(T&+28]$L,21G6+3%'8:5P[4KT9"FI=%%IEQEM#KME&4\V6K;EV.
M1^&V&9R@W%;TL7@L7AO2JQ:7"X[T6UCAAALM^8YAKC3U%76:>"W=BI)-[JV8
M\&.$:;6/ GNM)\/#MLAR)Q4M@&[&^M&2-4N&CES:7&^<\#Q;*1SI!IBZQ]%C
M![<E3@V+L6.!3+AF<(5R^-5;.3LFPU(6:7=;<610NMMUV(VFB<KG=WEGGF<4
M+*\MKJ5/"<%)U$DFJBQJP:4L>#!X=%XF17&I[^-M;7.5Y;5NK>O0C/&,FE!O
M%.#PIR3:PX=GJ''Y*S'G;?GAP;2Q+..'FGAC3.:N;=B",*=H\E*T,4>&)U.B
M;R]/9TC=\>0%0G)>F6]T:DZ8E$JJ:I*K_.4MK?0N:SR_+-+ZNLJ^6W$LYMZ<
M75EX-33DI+>26ZJD^![LFVU@GP<<MS=WV>Z>NJ5[166UIM4X\M/K6GNMO%PC
MPK>BE@]IA[#?"EWC;=<,9LL:XNV18PZ1''K(@Q*TX,B[,EU[01Y(V([HD10U
MI<F5SR4RN;<24=>\J2[#E/9-QW1'?;5/N&8:WTW/-ZU2MD-*<*E5NJZTFZ[D
MV][A35-IXK<6Q888KH>2STOG<<NIPIYM4C*%-*"IQ7))8=;P-.::^Z?#CC@^
MC^W"?XD4DV0UOW!C/$-=<>OJ;45]:XKE++3Q'VND#G<"EMTL9[BY>R)&6R,.
MZAK=(6L+4'IT)!"U L25-2VFT,.40UQI&CE&;V%;2D:L7?Q<J=)2>_"<=U]:
MV]Y8J:P3;:DI82PP2CI;453,<NNZ>?NG)6DE&=1I;LHRWEURPW7@XO%I)--8
MK':YD9+B^Q&=<18;E/")V>USP)@8YBG]2;46&HS(H9)W)3)324RZ():1!>VQ
MHIKDR-XHNI8AK0Y:=>884;=2ZE<?LZV4Y9?W%#7EE=W69[T.&K*,XK=VJ;WD
MY8Q<-WKMB6":+O<TLPOK2C5TG<V]"QW9?Z-.,GCPQZUI8/>QV</090WPUW*1
M8;:>-5IU*H@I4;^H\#;%Y%E6=&&8*92U9&=8NQRAC;4K&1VE:;8U>FFV4$KJ
MF-I;1<[7NAE59*:]"4G+V;J^%+,*FG=04*B6EG=4*<:,H*+IJ4HMM[7O=93<
M7T([JW6U)MX-IR52SAG.458?_7E0JSE54MY3:32PV+#KIJ2Z,MYXI;J1<#]'
M;/AAW"RPV7%ZHZOB6<9G(R/1+6VI])G=DZ1J4-''FUK6BSP>*&&MO.Y*]CU*
M_DY*UP+G75PM:W#K8\FZ=+D\?><G%/#I<IO^OB9;S?NB],4>2PWU.IO_ (6^
M\,?ZF[ZV!%*%6*5WTDS98_#/8W;%!IQ4C*JI);9<WVRBZ&8I(9['4SFFI*G%
MNE8Q:=;=R?SI-:7TK?9?07NY:CS0V:S#'<>8?BD^'=WZN.'1X.4PZ3]0M='&
M7.+<NSPWE9]?Q;V[##'U]SJ':OHQAS#YEF;4AM;O"<GVGFE^3+'*\R^355'0
M7'EC,<[W*K[UUR<RY.LM+J9[%5=BO_ZYTE:T>>15?2*VDOU-V4.3P]SAOU,<
M.AQ>MN]# J\VSI^1JR?ZRKJ6_CP^YAAC]GU\3B=E[4:WZ2=HG3'=I5\L:M;9
M,9EHUOISB4S&9%-B[4ULCZ/G$V+KX^N(M*J=;2_D/0<E>7H.2?)]Z/-#F?A?
MY"5Y'DL>B]ZACN]+>3X.*73)<RPESBV/@_Y56\N4PXMVKP]/!KJQZ1S/&B6*
M<8[Z\&;-\1J:FF]NQSKC9QM175*72*%R&98=;')@N466G&%IU#/*W=%6EI1G
M+:[7\M*\E+;J?-Y%7FF-0Y=7VVW@BJ+'@C.,*K4NK&+X?N43:Q;ML]R>]I?E
M_"'!].+E3374E)?UC9!&HS8@                   !!F2?.$X__9V6_">;
M"NOU=_A$K]WZQ.84"8
M                                           @SLQ\I'2O\KLB_>L'
M%>G^3GZB)9<*)S"@3
M         1UVU^3=E_\ )%1]]I!4I?E%ZI++W)V[ '^ ^$_S1XW^!K,(5/=R
M]5D5P(RX)"(
M
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MM*5^R-,:WL;3+L^E;65.-.@J4'NK@Q:VF;Y%<5KG+U5KR<JF])8LN[&(%Y
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M-IR2REYYMAM]+(\X/-YE.G<CIYODSJQJT:D(U-Z3EO*6Q3^]DI8;(X1P>Q+
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M'%3PQXGOP2]5)8]':3GX>_"^Q#H%9D:4M<UG.;,WYD46J<JYJR<I)52*1_\
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M77ZN_P (E?N_6)S"@3
M                                           $&=F/E(Z5_E=D7[U@
MXKT_R<_41++A1.84"8
M         ".NVOR;LO\ Y(J/OM(*E+\HO5)9>Y.W8 _P'PG^:/&_P-9A"I[N
M7JLBN!&7!(1
M
M                                         .(D'_ 7O^R'+[R.$5PD
M'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428     QU*<08EG)UZB;8NQU,5!E*
M4,/E,)C4A.OI3EY*7FNS8KONI3E_EJ+Q8:BU!E45'*[Z\MHK@5*M4II=A)%C
MS'3.F\XDY9OE]C=2?"ZU"E5;]7?A(QX5J%J:0?V41J_KN2IYW.[(*PIC4L_G
M<O+SNFLC5#.=RTY>7E%ZESB\X,X<G//<Y=/B=[<M=3E<#'Z?-9S84JO+TM.9
M#&N_NEE]HI=54<3*D8QOCN$W5NAL"A<2NK9T=;HQ%F-ANJ7_ .X5JU(4E:V?
M^#[ Q^^SG.,S6&97=S<+''\;5G4V\?729E&7Y'DF4_PNSM;;9A^*I4Z>SBZR
M*.Z"VET                                             . D\4B\U
M95D;F4;8);'7&SHG!@D[.W/S*O+]G^;6-;JF5H55GL_8O+NH)Z=2I1FJE*4H
MU%P--IKUT2RC&:W9I./$]I J5\(WABS1;>X/>BFLQ2HU58M-OCN+(W#2S5%A
M5"><8GAZ1B3F6&TISC+*V5+-,K4R^EU]:W5O5+4^H:2W87EQAAT9N7PL3Q2R
MK+9O&5"GCTHI>Q@9DQ+H?I1@=TL?\-:F:ZXUD11M#BI-$</0-HE!-]*VULH5
M)D[':^E%%76\MA=JBEEEU:UMI2M:UKY+G.<WO8[EW<UZE/BE.374QP^P5:5E
M9T'O4:5.,N-16/5PQ)8"VGJ     (_R[4W5C($C=)C/=:-?YO+GPTH]ZE,NP
MUCJ22-W/(3$HR#G1\>8XM<W TE&F+*LN--OK:67;;3[6VE*>ZEF>94*:I4;B
MO"DN!1J227J)/!%"=K:U).<Z=.4WPMQ3?5P.M^8YI3Z'VK?^7[$W>D)_+&;^
M-7/=9]L2^!6?Q-+L8^T/,<TI]#[5O_+]B;O2#RQF_C5SW6?;#P*S^)I=C'VA
MYCFE/H?:M_Y?L3=Z0>6,W\:N>ZS[8>!6?Q-+L8^T9Q@6.,>8KCY<2QA X9CB
M*DJE*XJ,P*+L</CY2U;=;>L6%LT>0MS=8J5WVTJ:90NEYE:4K=6H\=:XKW,^
M5N)SJ5,,,9-R?5>+*T*=.E'<I148\222^P=S%(G  QYD;$>*,PM:%CRWC''F
M4F5L7T=6UHR-"XW-VMN=*)SDE')"WR9M<TB1?1(I,*Z8NRTSHS+K>7DNK2M>
MA=7-K)SM:E2G-K!N,G%M<6*:V%.I2I5ENU8QDEQI/V3B\;8&P;AH]V4X@PSB
MC%*E^*2$/JC&V.XA!CWHAOO4&("78V,,[68XE(C%9MQ-IU;Z%U,OK;R5NKRS
M7%[>7:2NJM6JH\&_*4L,>'#%O A3H4*.+I0A%OAP27L&5QYBJ        $95
MVE6FSHM6.3EJ5K*XN+BJ4+G!P78&Q8K6KEJLZ]0J6+%2B*F'J52D\RZ\PR^Z
MZ^^^ZM:UK6M:BX1S?-8I1C=7"BE@DJD]GV3S.SLV\72IX_@Q]HDT+>>D "!/
M%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N
M/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@            !YF/&^^=1V__ "RA
MWZJ8$.Q.;CYDV'YN?]K,YOUI\Y[O\./P(E5 S<Q8          W9^,MK!F3B
M':(\//8W62%/.7%\1@B9Z=H7"4E%LAOC&<<=XV=53R@8NRSURN^,/T!3H5:(
MFY0M37K*\ZRMI)]Y?.G-]G.7Z4U-FN49S4C0C4JX*<WA'>HU*B2<L,%O1FVF
M\$\.FL=SZORR\U!D>7YAEL'5E"&+C'AW:D(/%+AV.*36UK'I,[5FK'DEX=_T
M;UUP]D@FV-Y=F43319^8;E]ERHF79ZR_=(G^*G*$2@Q,:XQC&[JL3JRR+S"#
M+FTVE+C++JW74,NNZ.K.=R.86?7V%.IO1EALW:%+=C+;MPE42:QV]<N!E6\M
MZFG^;MVESUMW.&ZUC]U5J8N.SHQ@VGALV,A/]'%X>^>VW8U-N=E''$KQUB>-
MXL=;L3N\O:'"/*,FO&4&E(B:WV)-SC1&K>(1;!')8KM=J%7H%5RM+V+>=SK[
MR<CYV]597/*7IZRK0JWTZZY51:ER:IMMQDUBE/?26[[I82WL-B=EYO,@OHYA
MY8N:<Z=K&D]QR36^YK8XI\,=UM[W \5ACT*'.)#D=MRUOQM]/V542N8WK8')
MB=B<$U;*IW%B89*NCK(Y$76?:WDN+6TDG6W?9NM,I6OL\HV;I&TG8Z7L+6HF
MJD;6GO+BE**DUZS;1@^HKB-WGMW7@\82N)X/C2;2?KI$*1D1938'PC'N-YQ3
M->X=K&UNTP<]3FNV-HZS_);-'L<P%R8XL<07&TSWDFD;2S?+S7%EB DRB-O[
M?*;%)))RDNZ\@DPK5F95>;C16:U,YG&FL\EO/<IN52:<O=84]YPI.2;VRW%@
MVD]K3SZRIZTU/80RV+F\J6'7S2A%J/!C/#>J*.' MYXX-\".B<<=T5.66L6I
MLE[NL>W>SD639#@^=HKCV&D0O$6O%T:<(M9'<?0Q"WISD*]_421;)"WU0>N.
M=ZJ&XFQ:F0UL*)N]7-M",+&N[/+96&33=.=&52>_5K[REO3FWM4=U4]Q**CA
M)N+EBV4-:R<KJDKF]C=YE%3C5C".[3I8..$(I;&\=_>;>]BEO*.Q%&8V280
M         ;H?T43_  _W4_+'"/XER6.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,V
MXAHDVL
M                 !!F2?.$X_\ V=EOPGFPKK]7?X1*_=^L3F% F
M
M                  (,[,?*1TK_ "NR+]ZP<5Z?Y.?J(EEPHG,*!,
M                                             !'7;7Y-V7_R14??
M:05*7Y1>J2R]R=NP!_@/A/\ -'C?X&LPA4]W+U617 C+@D(@
M
M
M                 '$2#_@+W_9#E]Y'"*X2#X"(^@7R8H;_ &O,?A0Z"K7_
M "K(0X"9XHDP
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M$DEUT5BC$=6Y5<6.9SOYRISL[RM5J4IPDI)Q<][JI3CCT'T&RIH9R8J
M     ;7OT;15LFGA6V5,"-T"7)+I3B.LEK,[S;#2U-&F?]K*(.C7(^4NXJI_
M2<M+O9I;]@<_<]O)^%9?RF/Y.MP>K3-P\UV]X/>8>_I^Q,V:^V7$5][^#?Z9
M3W;&C/[O]\;5Z\=LN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=
MLN(K[W\&_P!,I[MA_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]_!O],I[M
MA_=_OAUX[9<17WOX-_IE/=L/[O\ ?#KQVRXBOO?P;_3*>[8?W?[X=>.V7$5]
M[^#?Z93W;#^[_?#KQVRXBOO?P;_3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_?#
MKQVRXBOO?P;_ $RGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=LN(K[W\&_TR
MGNV']W^^'7CMEQ%?>_@W^F4]VP_N_P!\.O';+B*^]_!O],I[MA_=_OAUX[9<
M17WOX-_IE/=L/[O]\.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O
M]\.O';+B*^]_!O\ 3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?P;
M_3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_ 'PZ\=LN(K[W\&_TRGNV']W^^'7C
MMEQ%?>_@W^F4]VP_N_WPZ\=LN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP
M_N_WPZ\=LN(K[W\&_P!,I[MA_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]
M_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O\ ?#KQVRXBOO?P;_3*>[8?W?[X
M=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?P;_3*>[8?W?[X=>.V7$5][^#?Z93
MW;#^[_?#KQVRXBOO?P;_ $RGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=LN(
MK[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_P!\.O';+B*^]_!O],I[MA_=
M_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_
MIE/=L/[O]\.O';+B*^]_!O\ 3*>[8?W?[X=>1I>%FWU=KHJ>N:<8VYDMQ*HL
M9TA)AWN6OA?;J25-.57=LJWT=:+ZJJ4ITM*<REGVO_+47(\D^'<Q^R0Z[>Z9
M);MEQ%?>_@W^F4]VQ3_N_P!\1Z\=LN(K[W\&_P!,I[MA_=_OAUX[9<17WOX-
M_IE/=L/[O]\.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O\ ?#KQ
MVRXBOO?P;_3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?P;_3*>[8
M?W?[X=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?P;_ $RGNV']W^^'7CMEQ%?>
M_@W^F4]VP_N_WPZ\=LN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_P!\
M.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]_!O],I
M[MA_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]_!O\ 3*>[8?W?[X=>.V7$
M5][^#?Z93W;#^[_?#KQVRXBOO?P;_3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_
M 'PZ\=LN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=LN(K[W\&_
MTRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=LN(K[W\&_P!,I[MA_=_OAUX[
M9<17WOX-_IE/=L/[O]\.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/
M[O\ ?#KQVRXBOO?P;_3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?
MP;_3*>[8?W?[X=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?P;_ $RGNV']W^^'
M7CMEQ%?>_@W^F4]VP_N_WPZ\=LN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]
MVP_N_P!\.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*
M^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]_!O\ 3*>[8?W?
M[X=>.V7$5][^#?Z93W;#^[_?#KQVRXBOO?P;_3*>[8?W?[X=>.V7$5][^#?Z
M93W;#^[_ 'PZ\=LN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=L
MN(K[W\&_TRGNV']W^^'7CMEQ%?>_@W^F4]VP_N_WPZ\=LN(K[W\&_P!,I[MA
M_=_OAUX[9<17WOX-_IE/=L/[O]\.O';+B*^]_!O],I[MA_=_OAUY&G,:S;XS
M+^NADY:<8D3<I^EM<7DLYAU6E2XW$1OMU;(:W.1UUI%A=$O1<EY?LUO]FO\
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MWOX-_IE/=L/[O]\.O';+B*^]_!O],I[MA_=_OAUX[9<17WOX-_IE/=L/[O\
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M67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M                                         (,R3YPG'_[.RWX3S85U
M^KO\(E?N_6)S"@3
M                                        $&=F/E(Z5_E=D7[U@XKT
M_P G/U$2RX43F% F
M        CKMK\F[+_P"2*C[[2"I2_*+U267N3MV /\!\)_FCQO\  UF$*GNY
M>JR*X$9<$A$
M
M                                         XB0?\!>_P"R'+[R.$5P
MD'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428
M
M            ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?P6=.X
M/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&             '
MF8\;[YU';_\ +*'?JI@0[$YN/F38?FY_VLSF_6GSGN_PX_ B54#-S%@
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M"4NA:=2Z;>02HU(U>4MKA2<-Z$H36[NXJ<)<#ZY=/8\4BJP9L8N
M ;H?T43_  _W4_+'"/XER6.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,VXAHDVL
M
M         !!F2?.$X_\ V=EOPGFPKK]7?X1*_=^L3F% F
M
M          (,[,?*1TK_ "NR+]ZP<5Z?Y.?J(EEPHG,*!,
M                                     !'7;7Y-V7_R14??:05*7Y1>
MJ2R]R=NP!_@/A/\ -'C?X&LPA4]W+U617 C+@D(@
M
M
M         '$2#_@+W_9#E]Y'"*X2#X"(^@7R8H;_ &O,?A0Z"K7_ "K(0X"9
MXHDP
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MV6_">;"NOU=_A$K]WZQ.84"8
M                                                 @SLQ\I'2O\
M*[(OWK!Q7I_DY^HB67"B<PH$P
M                $==M?DW9?_)%1]]I!4I?E%ZI++W)V[ '^ ^$_P T>-_@
M:S"%3W<O59%<",N"0B
M
M                                                <1(/^ O?]D.7
MWD<(KA(/@(CZ!?)BAO\ :\Q^%#H*M?\ *LA#@)GBB3
M
M                    ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]
M^33^"SIW!Z^;)TS_ #.MWXW=QZ-??/+,/E#]A%'2/S;L_P RO999.,0,C
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MN_O;ONHQX=V7!CP&J<RR7-,GW/*5%TN4QW<7%X[N&/ WP;RX>,BF+V6H
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M!,
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MS-EZ-U9;ZQRRIF=M1G1ITZ\J6[)IMN,(3QV=#KTO6))C-C+
M
M XB0?\!>_P"R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428
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M;336#36QIKH-/A1W%"<*L%4IM2IR2::>*:>U--<*:X&?N)28
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M&D%RNM82K_E.4K/;[[=GQ]%;7ZV/0/0X'*9OXT;/I4K6QD;3:U/*:Q);(W'
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M.>\HRQY+=IX[KV57"2PVI;"9PQ$SH
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M*TDK:J5.5F6EEW)RU!5UAEP*,DVMF.!D7+/%KQ)C_8?-VH\$P%M)L'LO@]=
M"G?%N%<>QF1GO[#/<:1[)])Z@?EDY;FJ-P"*-LM;&QS7R&YF,,>UY25O(7_;
MF6,0H/!2;23)%:4[P8VW=AL]>X?#LG8IG.(,@+\59EPOFJ,IHAE'&,];4"%R
M,;'YF1.CRA/;')"OL.;UR=282K*I?3D+-+-*+B0E%Q]0F>!*          19
MW7^2_E?^SF#X81X4:_!#\]2_M('EO/R*_.4_[2)J>O?_ !IW_M1P^^S1\Y=>
M_/K.O^+7G_J*APWJ[YUYG_Q"Y_MIG%C$S'@
M                                                V+N$5\FV;?GO
MDGP#QJ.T/Y=/F3=?\5J?V%L=4\QWS3N/^(U/[&W+3AOPW,
M                                                           '
M$2#_ ("]_P!D.7WD<(KA(/@(CZ!?)BAO]KS'X4.@JU_RK(0X"9XHDP
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MG?\ M1P^^S1\Y=>_/K.O^+7G_J*APWJ[YUYG_P 0N?[:9Q8Q,QX
M
M    -B[A%?)MFWY[Y)\ \:CM#^73YDW7_%:G]A;'5/,=\T[C_B-3^QMRTX;\
M-S
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M*I*V6J2369_B!K*VG.I!7/HUG/#1(Y$<TGWW5I2M34AE;.=2MUM*>R,*R_\
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M%8[9/%8/2#NNNONNOONK===6MUUUU:W77775Y:W75KRUK6M:^S4='&ES_ (
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M@GBHXJ,$^-0BHPQZ>[B9#EN191E"_P#I]"%.6'NMKD_ZTFY8=+' EX+"78
M   ^1>A2.:%:VKR;5"%Q2*4*Q/==?;:>D5DWIU!-UQ=UAEMII)E;:UMK2M.7
MV*T$T92A)3CLDGBO51"45*+C+;%K A[K9P]M-]0)4^S?6_!S%BZ4R:/UBKZ[
MM3]-'8YPC]SDA=ZMIA,EDKVD+*JXMI!O.++L,Y2Z4YW)6M*W_.-5:@S^A&VS
M>YE6H0GO13C!82P:QZV*? VBT9=D&4935E6RZA&E5E'=;3D\5BGAM;Z*1,T8
M\7@KVV0X56@&V$@<)CFK6V'.\Y=;S%#G.8LMDF.)<ZKK[.CHY/SSCUZC)TG<
M++.2E#'2BVO);;2M*TMI2F591K?5.1TE;Y=>5(VT>"$E&I%+BBJBENK\' L&
M8Z7R'-:CK7EM!UWPRBW"3?&W!K%^KB8=QAP,N%SBIZ2R)IU<9)4\(E/9*4W)
M<QR#D=ILI2A/,(.B,ME3G"UY)9A5;Z=DMQU_+?=2MU;>2VEPO><K6E]3=&I>
MRA3:V\G"G3?91BIKUI(\=MHG3-K-5(6T933^[E.:[&4G%^NBU]N;F]G;T#2T
MH$;6U-:-*W-C8W)2$3>W-Z(BQ,B0($2:PI,D1I$Q5I911=MMA=EM+;:4I2E!
M@\YSJ3=2HW*<FVVWBVWPMOHM]%F51C&$5""2BE@DMB2701T3*^'\69UA+ICC
M,F/HCDV"//,N<(M-6)O?V<T\FE]$RXI*X$G42.:*XRMR=434M2GOKSBK[+N2
MH]-C?WN67,;O+ZM2C<QX)0DXOU,5PI]%/8^BBA=6EK?47;WE.%6@^&,DFO5V
M]'B?"N@56J_H_P!PI%;]5\KK8X)R;SKE!S DS+FY.PFFWU,NOY$]F0^SDQ-3
M+^=0HA0439S:6VV4L^UKFT>=+6\:7)^&)OWSI4=[^SP]=IOUS%WH/2SJ;_@S
MPXN4J8?#QZC+*L#ZUX#U@B5\&U^Q+",31A0<4J<$$.9$S<H>EI!52"7"1.U:
M&O$D<BB*\RU2O4*3Z6?:\_D]@8AF><9IG-?PG-:]2O66Q.;QP7%%<$5THI(R
M.QRZQRRER%A2A2I=%16&/3;X6^FVV9O%M/:5X;)\*/A_;9R1=-LU:X11UGCE
M?<>Y3F)N<HQO*G=9=;6RKA('+'SY&J2IPZ.O-Z5UL6W\VEM/_4;>;E>4:XU3
MD5%6V77<XVJX(24:D4N**G&6ZNE' Q_,=+9#FM1UKRWBZ[X91<H2?3;BUO/\
M+$Z=@[@S<-;7V0M\N@NK\4=)6UJ2UK<_9'>Y=E,U M3GU4(ES>TY D$AC;:O
M0&\VXA0F1$GEW66W4OY]*7#T9ES@ZOS6DZ%S>SC0DL'&FH4\5T4W",9-/HIM
MHHV6C].6%15:%M%U4\4YN4\/44FTFN-+$M &&&3               $&9)\X
M3C_]G9;\)YL*Z_5W^$2OW?K$YA0)@
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M]_\ &G?^U'#[[-'SEU[\^LZ_XM>?^HJ'#>KOG7F?_$+G^VF<6,3,>
M
M      #8NX17R;9M^>^2? /&H[0_ET^9-U_Q6I_86QU3S'?-.X_XC4_L;<M.
M&_#<P
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ME\                    (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
M
M                     $&=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
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MR
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M]U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
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M$2OW?K$YA0)@
M                                    "#.S'RD=*_RNR+]ZP<5Z?Y.?
MJ(EEPHG,*!,
M  !'7;7Y-V7_ ,D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617 C
M+@D(@
M
M                                  '$2#_@+W_9#E]Y'"*X2#X"(^@7
MR8H;_:\Q^%#H*M?\JR$. F>*),                          !KM\0_A
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MBV]K;?"V^BV76$(4X*G32C3BDDDL$DMB22V))<"/U$I,
M     ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^33^"SIW!Z^;)TS
M_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P             \S'C??.
MH[?_ )90[]5,"'8G-Q\R;#\W/^UF<WZT^<]W^''X$2J@9N8L          >B
M=G3AFL?$QT"T @SYEUUQ&5C+#.(Y80XM4/1S QW,=\+1-GN1&IE<AC]J.PBV
MSI*7TO,K=7V.;3[(Y/RS6-31VJ<TN:="-=UKBK'!S<,,*TGCLC+$Z"OM-PU)
MD5A0G5=)4J-.6*CO8XTXK#A17I]5$Q_Z:DQ^)%E\I8ROZ<+KS=3[L^]E@^BV
MW\<GW-=N/JHF/_34F/Q(LOE+#Z<+KS=3[L^]CZ+;?QR?<UVYJ2;(XH3X&V(S
MW@U(]G25+AC-&4L4)I&H0V-BA_3XZG+[$"7L]M*4K2V\YU+9Z'W$6G&VE7&5
MMI?=2G.KO7*+YYGE-KF4H[DKBWIU=W''=Y2$9X8X+'#'#'!8\1JG,;56.85[
M)2WE1K3ACAACN2<<<.ACAC@8I9D!;J\-36<L);BG)R0H#7!3S>QT):Q44GO6
M'\Z\JWH4UIE;[N6ZVG-MK[-/LCVU).%.4TL6DWAQX+@/+"._-1;P3:6/%B;
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MR^D\[UA6SN&VPLJ?(4Y="53![^'&H[\TWT<8M=+81&JS/@
M     "#,D^<)Q_\ L[+?A/-A77ZN_P (E?N_6)S"@3
M
M       $&=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
M                                 ".NVOR;LO\ Y(J/OM(*E+\HO5)9
M>Y.W8 _P'PG^:/&_P-9A"I[N7JLBN!&7!(1
M
M
M     .(D'_ 7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_Y5D(<!,\428
M                         .!D<5B\P;36:6QMAE+0?;=:>U2)G;WMN.MN
MIS;K34+DG4IC*74]BO+;4>NSO[[+JRN<OK5:%PN"=.<H27J2BTUU3QW^79?F
MEN[3,Z%&XM9+;"K"-2#]6,TT^H16D?#XTHE1YJEWUIQ70\^M;C36A@I&[[[J
M_9NK6.'-7L_^&@SVRYW^<[+XJ%MG=_N+@4ZG*?VBF:US#F,YH,TG*I>:=RMU
M)/:X452;]>EN'5D/#&T.;SJ'D:WPTR^E>7FKW*7.A/\ Z5,YR-6GK3_P<WD%
MPK<^?.Q7CN3SNY2^]C2@^K&FG]DM-M_+CS(VL^4I:=LG+[^5:HNI4JR7V#-D
M+U-UBQV<6IA6 ,11Y63=2\I<B@4<JX%7V_8,+7GMYRPLSV?^=2^E:_\ *,6S
M/G UQG,7#,\WS&M3?#&5Q4W7TG%22P]8S7*.;3F\R"2GDV297;U$\5*%M24E
MZDMS>75) $DDIRBR$Y19!!-EI91))=I111=M.2VPLNREMEEEM/L4I2E*#$I2
ME.3E-MR?"WM;,UC&,(J$$E!+!);$ETD?H)28
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MT/Z*)_A_NI^6.$?Q+DL<]<^'ZUEWYNM[-,W'S6_J]Y^'3]B9MQ#1)M8
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M.RWX3S85U^KO\(E?N_6)S"@3
M                                                 $&=F/E(Z5_E
M=D7[U@XKT_R<_41++A1.84"8
M               ".NVOR;LO_DBH^^T@J4ORB]4EE[D[=@#_  'PG^:/&_P-
M9A"I[N7JLBN!&7!(1
M
M                                               .(D'_  %[_LAR
M^\CA%<)!\!$?0+Y,4-_M>8_"AT%6O^59"' 3/%$F
M
M                  "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$BQ:G^;U[\F
MG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&1@
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M0=V@W*/O_L#&7$/#ANSZ*S1UO0=V@W*/O_L#&7$/#ANSZ*S1UO0=V@W*/O\
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M0=V@W*/O_L#&7$/#ANSZ*S1UO0=V@W*/O_L#&7$/#ANSZ*S1UO0=V@W*/O\
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MQ#1)M8
M                 "#,D^<)Q_\ L[+?A/-A77ZN_P (E?N_6)S"@3
M
M                   $&=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
M                                             ".NVOR;LO\ Y(J/
MOM(*E+\HO5)9>Y.W8 _P'PG^:/&_P-9A"I[N7JLBN!&7!(1
M
M
M                 .(D'_ 7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_Y5
MD(<!,\428
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MG[$S;B&B3:P
M                      $&9)\X3C_]G9;\)YL*Z_5W^$2OW?K$YA0)@
M
M                     "#.S'RD=*_RNR+]ZP<5Z?Y.?J(EEPHG,*!,
M                                               !'7;7Y-V7_P D
M5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(@
M
M
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M%W65K;=7DNMK2OLTJ//*,H2W9IJ2Z#V,J)J2Q6U'WB4B
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ME]U+#&+QW47.#0J6LLOR",HJ4=UU&MW"/!A3CPIM;-YX;O06.#6H2-\FI@
M              -T/Z*)_A_NI^6.$?Q+DL<]<^'ZUEWYNM[-,W'S6_J]Y^'3
M]B9MQ#1)M8
M                     "#,D^<)Q_\ L[+?A/-A77ZN_P (E?N_6)S"@3
M
M                       $&=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
M                                                 ".NVOR;LO\
MY(J/OM(*E+\HO5)9>Y.W8 _P'PG^:/&_P-9A"I[N7JLBN!&7!(1
M
M
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MREY1I1ME;K#"C++J5MNI6M*TKRT&!--/![&C+4TUBN _40(@
M!!F2?.$X_P#V=EOPGFPKK]7?X1*_=^L3F% F
M
M (,[,?*1TK_*[(OWK!Q7I_DY^HB67"B<PH$P
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M2Q>/J&Y.;+5^:ZOL+JYS5454HUHQCR<7%8..+QQE+;B6 C;YLX
M
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MX=/V)FW$-$FU@             \Y2#?^U#BW_P">LY#_ /0E9,.M;G_M2O\
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M<=.J-_K_ #6=U6WJ>16R>"];%17'4G@G)_<QZ/N<>-^BO_+!V&_9K/\ UH0
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MS0             @S)/G"<?_ +.RWX3S85U^KO\ ")7[OUB<PH$P
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M-ZN^=>9_\0N?[:9Q8Q,QX
M              +]>#U_AOF+\MV'\0F#KO\ EN_@F9?*J?\ 9G3',3_";_Y1
M#X!<..D3>X
M                                           <1(/^ O?]D.7WD<(K
MA(/@(CZ!?)BAO]KS'X4.@JU_RK(0X"9XHDP
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M_-2^"SS&^"C\ZOH[^>UJ_$[R.A=6_-N\_,OV4:XR?^)T?PSUB!S2;0
M                     @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>
M_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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ML::V/ TIG->E<YQ=W-![U&I<U91?'&4Y-/;MVIXD9A>"V
M&Z']%$_P_P!U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
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M\RSHY@.:1#-T9><MP/B]X:T:S!FC%S Q(8=L-C!5(CE=F0&"+NS8O(BS!E^
MO38><4G*3&IUQ*FB?L:VE"2V(W$I/'@W<23Y;YO)M_Q.N)9J1#MPY?KCK5K6
M;J/(+';&T1@#GE]&KR[KHRR)# 8!(Y5'G1#%HN_RE$^OKZXJ$SFYWJ$Z)&DO
M2)3%-+Q+UL8J6&+>))+A:YFSZOR9OMIUL)EUSV$D&E.;H+%X7FZ11]@C<OE^
M-LK8\3S6+M$R21I*B;'.2Q6Y&H*4./16FK*G4K=6O-IR$0FE@I+9B7"")(
M        19W7^2_E?^SF#X81X4:_!#\]2_M('EO/R*_.4_[2)J>O?_&G?^U'
M#[[-'SEU[\^LZ_XM>?\ J*APWJ[YUYG_ ,0N?[:9Q8Q,QX
M                                       +]>#U_AOF+\MV'\0F#KO^
M6[^"9E\JI_V9TQS$_P )O_E$/@%PXZ1-[@
M
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M ,7M?E-+X<3S7OZG6_-2^"SS&^"C\ZOH[^>UJ_$[R.A=6_-N\_,OV4:XR?\
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M>7N5P,\^69#EMSHVZSBM!N_I2FHRWI)+!0PZW'!\+Z!KW#:A@
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MN=,9S2S6W6]&.,9PQPWZ<O=1]B47T)*+>.&!TUGV3T<]RRIE]9[K>V,O>S7
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M8I)NZH:[,R             "#,D^<)Q_^SLM^$\V%=?J[_")7[OUB<PH$P
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MCK-#%'-=VQ62R)BK2B6Y1%RL<&*+6PVY':J+HX-B%<@5W&64/5$W)ZE6O_\
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MM,XL8F8\
M %^O!Z_PWS%^6[#^(3!UW_+=_!,R^54_[,Z8YB?X3?\ RB'P"X<=(F]P
M
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M=7T=_/:U?B=Y'0NK?FW>?F7[*-<9/_$Z/X9ZQ YI-H
M         0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_P WKWY-/X+.G<'K
MYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #S,
M>-]\ZCM_^64._53 AV)S<?,FP_-S_M9G-^M/G/=_AQ^!$JH&;F+
M &W!QX/FON%)^1N/_P#T'J(#17-E\],\_.3_ +>1M?7/S:RO\"/]E$:,?^TU
MN]'Y99?_ !7AX-2_]W\L_-TO9JC)/^W-[^'4]BF:CXWJ:H
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M5W^$2OW?K$YA0)@
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M-%-481@GP[J2]@J4Z5*DL*48Q3XDE[!]HJE0
M
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M'ZUEWYNM[-,W'S6_J]Y^'3]B9MQ#1)M8
M                                           "#,D^<)Q_^SLM^$\V
M%=?J[_")7[OUB<PH$P
M                                          !!G9CY2.E?Y79%^]8.
M*]/\G/U$2RX43F% F
M         CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.W8 _P !\)_FCQO\#680J>[E
MZK(K@1EP2$0
M
M                                        #B)!_P !>_[(<OO(X17"
M0? 1'T"^3%#?[7F/PH=!5K_E60AP$SQ1)@
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M=Y'0NK?FW>?F7[*-<9/_ !.C^&>L0.:3:
M$">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\SK=^
M-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #S,>-]\ZCM_\
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M11/\/]U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M
M    09DGSA./_P!G9;\)YL*Z_5W^$2OW?K$YA0)@
M
M    "#.S'RD=*_RNR+]ZP<5Z?Y.?J(EEPHG,*!,
M                              !'7;7Y-V7_ ,D5'WVD%2E^47JDLO<G
M;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(@
M
M
M  '$2#_@+W_9#E]Y'"*X2#X"(^@7R8H;_:\Q^%#H*M?\JR$. F>*),
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M6+4_S>O?DT_@LZ=P>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ
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MX^:W]7O/PZ?L3-N(:)-K
M                                09DGSA./_P!G9;\)YL*Z_5W^$2OW
M?K$YA0)@
M                                "#.S'RD=*_RNR+]ZP<5Z?Y.?J(EE
MPHG,*!,                                                   !'
M7;7Y-V7_ ,D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(
M@
M
M                              '$2#_@+W_9#E]Y'"*X2#X"(^@7R8H;
M_:\Q^%#H*M?\JR$. F>*),
M
M$">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<'KYLG3/\SK=^
M-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #S,>-]\ZCM_\
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MBI1DL4T^BFFFGQ%EJTJE"K*C6BXU82<9)[&FG@TUQI[&<"*I3
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M^N$:[R \(EQ1Z@W%TQZNO$OC'SGUPC7>0'A$N*/4&XNF/5UXE\8^<^N$:[R
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M%=\/1]*5QXG#NC[0?6N\@^A9#?CM>_)L'T'VOG&IW%=\'TI7'B<.Z/M#5ZV
MRNHSSGC-F<E;*3&E>9\N9(RNJCB9=>YIV!1D69/,O.92'(U,B,<"6HQXJ1:?
M<25<;:72ZMEM:\VFZ,KL5EF66V6QEOQMZ%.EO88;W)P4,<,7ACACAB\.,UG?
MW3OKZM>N.ZZU6<\,<<-^3EACT<,<,3$8]QY               #=#^BB?X?[
MJ?ECA'\2Y+'/7/A^M9=^;K>S3-Q\UOZO>?AT_8F;<0T2;6
M                                                          @S
M)/G"<?\ [.RWX3S85U^KO\(E?N_6)S"@3
M                                                          $&
M=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
M                        ".NVOR;LO_DBH^^T@J4ORB]4EE[D[=@#_ ?"
M?YH\;_ UF$*GNY>JR*X$9<$A$
M
M                                                       XB0?\
M!>_[(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_ )5D(<!,\428
M
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M.G[$S;B&B3:P
M                       $&9)\X3C_ /9V6_">;"NOU=_A$K]WZQ.84"8
M
M                        @SLQ\I'2O\KLB_>L'%>G^3GZB)9<*)S"@3
M                                                  1UVU^3=E_\
MD5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(@
M
M
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M%$_P_P!U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M
M     09DGSA./_V=EOPGFPKK]7?X1*_=^L3F% F
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MD].YA:7DH+&4:52,IQ7!C*&._%8O#&44L3/@L9D8
M         !!G9CY2.E?Y79%^]8.*]/\ )S]1$LN%$YA0)@
M                                     (Z[:_)NR_\ DBH^^T@J4ORB
M]4EE[D[=@#_ ?"?YH\;_  -9A"I[N7JLBN!&7!(1
M
M
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MZJ8$.Q.;CYDV'YN?]K,YOUI\Y[O\./P(E5 S<Q8
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M[A!@)EH             09DGSA./_P!G9;\)YL*Z_5W^$2OW?K$YA0)@
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M:E9TK><7@W&E-K@Q,>Z@?.A\;/\ -'L_^L!L'OU7_P!M]'?*K/\ LF6S1/\
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MR<BSGFSG:4[ZE5?AL;-Q\'E3E4IJ--JD^24JD'7C4C'!J.XVD]UFYV.1CNH
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M-5'Y.P^D3G!_Y/NOVI?NX]-M:?\ +-Q^T+O \[C;#^'[./C51^3L/I$YP?\
MD^Z_:E^[CTVUI_RS<?M"[P9%URVMEF:LEY$Q7.,)+L.2G'3&R/+H@<IG9)EM
M_;ZB8]$F.2EQ5@L1](W+25%M]#3>=892G-H+UHOG S#4^>7N09KE<\MO[*E"
M<HRK<K+\9@XIKDJ>&,9*2>+V/@+II76=[G^;7639CE\K"\M:<)24JO*/K\&D
MUR<,.M:ECB]C)I#9QGP
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M5^)WD="ZM^;=Y^9?LHUQD_\ $Z/X9ZQ YI-H
M   0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_S.
MMWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,             /,QXWWSJ.W
M_P"64._53 AV)S<?,FP_-S_M9G-^M/G/=_AQ^!$JH&;F+
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MUB>B*.4#H              (,R3YPG'_ .SLM^$\V%=?J[_")7[OUB<PH$P
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M2:YB^V=*QQ-QDC,BDSR5_.UZ1J8E*PIT<;.0@SV22KZ?:7?\E0!VT
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M2_);/^PH&K<A_P"Z6>_)[7^RI%BXW0;2
M                                             #B)!_P%[_LAR^\C
MA%<)!\!$?0+Y,4-_M>8_"AT%6O\ E60AP$SQ1)@
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M_-2^"SS&^"C\ZOH[^>UJ_$[R.A=6_-N\_,OV4:XR?^)T?PSUB!S2;0
M                     @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F]>
M_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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ML&L$DUCMP/0.7Y=F><5/*2C5G"FY1C/:I2WEBVG[K!=!X\.+3P-XR8Z7ZAY
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M[]8G,*!,
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M$Z?[1 L6J?FQF7_#[C^QF6;4?S>O_D=;^SD:CE/L4_\ 1#YH'!+X0
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MM[@K4FEE([+*].8LO*M)_G:V4#H$JQW]G#B9.X;".<-_#UT@19)N75G"75'
M9,AM=:GW/!2RS&,:H6G>KE5MJJ]\3).C+6U-YQM55IE;[KKN6ZL1+W3PX,2;
M $H                %=&&/G&-Q_P A\/\ P(A(TOIG_O1J7Y+9_P!A0-6Y
M#_W2SWY/:_V5(L7&Z#:0
M                                 <1(/^ O?]D.7WD<(KA(/@(CZ!?)
MBAO]KS'X4.@JU_RK(0X"9XHDP                            >+C'K:X
M]RHQV2E-996#Y ;+9&D-M5F%VUC4C)H[IC+4=Z==?9;V$9;6A5Q9M:?\VMMW
M)6G64_Q]L^3^[@\/76PU!'\756]T);?69[1)!Y"H@E2F.*4)E!19Z=0098<0
M>0=90PHXDTNMQ9I1I=U+K;K:UI=2O+3V!R<TT\'PFW^':N _40
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M?T43_#_=3\L<(_B7)8YZY\/UK+OS=;V:9N/FM_5[S\.G[$S;B&B3:P
M       :V_&'X+>>>(SLS!LW8NRIB*#Q^+8*C.*UC3/C)E8\*'ADG^3I:H<4
MU([%WM%VL-13A.59SC;3>E),Y;*6\VMVW= <X>6:2R>KEM[0KU*L[F51.&YA
M@X4XX==)/'&#Z&&#1KO5VCK[4.90O;:K2A3C04,);V.*E.6.Q-88218-MEHQ
MD+8#A:7:(QJ70QFR)7$^ND ]U[Y<^4A?;+#<JQ6_/JWG(&E8^=@NB:!J;$G_
M $3I.><7TEME.=6W%<CU+:97K7TFK4ZDK3EZ\]R.&_A5C4C%;6HXK?6.WH/
MO^:Y)<7^F/(=.<(W')4H[SQW<:<H-\"QP>Z\-G$8HX-'#9RKPVL9YGA&5)WC
MZ=.&2ITP2IJ5X^OD=Z- C:6 QH.3N%9&QL9]%)A]_.MZ.R^SF?9K2OL#W<X.
MK['5]Y;W-C2JTH4:4HM3W<6W+'9NMGDT?IRZT[;5J-U.G.52:DMW'9@L-N*1
M<R-?&8&I'OC]&K?,S[$RO*^I.0\38DQY/?\ X8GO&TU(E2-)&)NN5*C)#;"R
MXO'7M&FB+K?6Q62CNZ&B \XT@BRU-:187O73'._3R_*86.>TJ]>[I=:JD-UN
M4$EN[^])/>7 WMWDDWUV+>J<\YN9WF82NLJJ4J5O4VN$M[9)\.[NI]:^'#H/
M%+9@7Y<-35>8:4:3X6UDGTAC4KEN,_"-VV?XA<Z71U?[L\LSS("#M=<]-[6Y
MU[%;9622=TI!?\^7?S>=9S;JZOUAG=OJ+4=QG-K"<*%;D\(SPWEN4H0>.#:V
MN+:V\&!G>G,KK9-DU'+:\HSJT]_%QQP>].4UABD^"6'!PE9_$F^C]89W+FC[
MG'"$S)U^S?)#CW*9)3F.Y\QAD9[/-O.4/KPUHE*)VB<H<3#><L<4-51"JMG/
M,0W*##5%^8Z0YT\PT_;QRW,J?A66PV0>]NU*:]ZFTU**Z$7@UP*6"2,;U%H*
MSSBM*]LI^#WLMLMF,)OC:6V,GT6L4_>XXLJRCO"3X_.!&NR 89VT/)@:&SL9
MI;(#M3D9CBC:D(J9818SQZ4-,>HP=,6;RW6I$Q=*UMISJUYEE:9K5UUS79I/
MPK,+%>%/A<[:FY-].47+>]=F,4]*Z[L8\A9W?XA<"C7FHKU%)+#UD=@QQ]&N
MV]SCD*S(&]VVK2HHL.LO?E\>DTWS;EM^1DG7F7(#Y?D5O9&MF./N.,N+4W&/
M5I-;N=5/?6ZZVE*[YW\ARVT\%TS826'N5*,*-*+X]RFVWZG68\94M^;K-KVX
MY?/+M;>%IRJ5'TMZ:27J]=ZAMFZTZT8;U'P_&,'8)B2>(P.+EWWED4-O6.SX
M\*K2NVTGDSL=_P!)>I&]'%4O4J#.2GL6EE6EDEE%6:,SC.,PSV_GF69U'4NI
M^LDEP1BN!1707KO%MM[4RW+;/*;2-E8PW*$>JWT9-]%OHOJ;,$9Z%L/<
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M&F2             !!F2?.$X_P#V=EOPGFPKK]7?X1*_=^L3F% F
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MFE7&4O*I?0>;)K/+89_1L-5*YH9>ZJA6W<*=6DGLWFJD)X*#:E*+ABXII8/
M]F?YAF]33%QFFBI6ESFBH.I;J:=6C6<>NW$Z52FVZB3C"2G@IM-XK$Q]H?N-
M"MY]<(AG6(IK65S5&*8UD.&W'W*%,%R(R%IJR"-G'W6%W*$M2U9"U"=6VVX]
MN6$7WVV&77EV>[6VD[S1>H*N2W3WZ:2G2J<"J4I8[L\.@]CC)="49)8K!NV\
MW>N+#G!TO0U#9+DZK;IUJ6.+I5H8;\&^BMJG!]&$HMI/%*8XQ,S@
M               (,[,?*1TK_*[(OWK!Q7I_DY^HB67"B<PH$P
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M63AQI\,SO,N?LV;"9)VNVOSECFS$$HSSD%CB,.*B^*TQQBY+C[&&,X,A;XC
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M+6<?R"=/]H@6+5/S8S+_ (?<?V,RS:C^;U_\CK?V<C4<I]BG_HA\T#@E\(
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M^^A@BRNVVVRVVRRVVRRRVEMEEM*6VVVVTY+;;;:<E+;;:4Y*4I]@1)3^@
M              %=&&/G&-Q_R'P_\"(2-+Z9_P"]&I?DMG_84#5N0_\ =+/?
MD]K_ &5(L7&Z#:0
M                            <1(/^ O?]D.7WD<(KA(/@(CZ!?)BAO\
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MJ7P6>8WP4?G5]'?SVM7XG>1T+JWYMWGYE^RC7&3_ ,3H_AGK$#FDV@
M                    ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]
M^33^"SIW!Z^;)TS_ #.MWXW=QZ-??/+,/E#]A%'2/S;L_P RO999.,0,C
M          #S,>-]\ZCM_P#EE#OU4P(=B<W'S)L/S<_[69S?K3YSW?X<?@1*
MJ!FYBP                                 ;H?T43_#_ '4_+'"/XER6
M.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,VXAHDVL
M                                               !!F2?.$X__9V6
M_">;"NOU=_A$K]WZQ.84"8                       -;O4M2JRK]('WIE
M\NH<>JQ!AB^'01 JYQI;(A3*,/Q@I:W776D]C6+6XQQ.K92RZV^YW.NYU:_;
M7=!:HC'+.8O);2UP4;N\Y2HU]TVJ\\'QX/=7]1'+>C)SSC^9/4-[>XN=E8\E
M13^X2=M3QCP88QWWAA_I)/'HO'+F>@BGTF8M?E,]*F12O%S21@]6[5M*3$+W
M'7I'&B2$!YUJ<JQ4Z2!LDJ)/3G&U-5*NALKTE]MMMPIJ=U_+KR>6)N=*YEX0
MH\+2NG/%K;LC%T9/@PBL7L6+M=65.S_FN53-VE3K6D5:N6Q)RLE323>"QE.-
M>*X<92W5M:2VBAS:=<&M/F;=C2UJU?XCF4.'# $T,SU (NRL>2LM0?&A,.[+
M-RGF1MQ^?*&^8-UMU7E=9>YNKVWJ[:4NL[$N5V76<VMU.ALHT?J^KJ33^6\X
M%=ULDKU)2HT*E9U,.1H.JH.F_<K9"G*/WRBTSE7/=>Z$HZ2U1F_-=;*AJ*VH
MQA7N*5!4L?"+F-%U(U8^Z?75*L)=#=<TUAB93X6_"^TAE>D6'<I9-P["<Y9&
MSA#*SB<SF=EJ9,ML<)$K<#3&)C[+6G)XV=&2C.P3CD5"%AJT@PXTRIE:<RV\
MY/.1K*UUE=Y;EUW6LLOLJW)TZ=/""P@EUTL%C/?]TE+&*BTDL.&\<T7-)H"\
MT#8YOFUC;YAFF84.5JU:V-1XS<NLABVH.G[AN.$G).3>/!5#-& O3+9OBVZ0
M85>7A9K9(M,,FS\F!*'9P?$&/9'7&,.FC8?V2N/7JBE3(7*%;+0XX[IUB)6D
MHK,./)*NILZTKO5VG-+:RSB$%J&GF]&ERJBHNK#EJE-[$DL);D:F"6$91GNI
M1;-.7ULM"ZLUIH#(:DY:6JY%7K*BY.:HSY"E5B\6V\8<I*EBWC*,H;[E**9+
M[A*<*#5G:/1[$V<-HVN8YH=)19D9DQU&G#(T^BT6Q##8YEJ?-)[+$FV$R*-W
MU4OLQ(=7I9>I-4)[SW#[4FR^AMYN*\Z7.?J736L[K)M-2I6=*GR4JLU2I3G7
MJ3H4I*4W4A/9&FX4XX)/".UM8)9MS,<SFD-7: LM0:NA7OZU;EX4*<J]:G3M
MJ4+BM%QIQI3AMG552K+>;BW/9%/%RX#23 F,^(AQ+]_9CMRUWY';]6I@1BK#
MV&)@Y.=T?8(LTS:?0=D+4,!:I%8N20MEQV44K2G%U1JG5Z-6*BKU)E+Q7UCG
M>8Z"YN\CM-+2\'J9G1=:O<4TMZ4Y4Z526$L'@ZDJK<9)[T84U"+45@>;0.G,
MJYS>=;4E]K2'A5+**ZM[:UJ2EN0IQJUJ4,88K%4HT4I1:W95*LISBYO$<:+6
M'"_#Y(UIW7TW8FC7O,C!F]NBAS' 3E+-'Y4V5B\AE%KBHBA:NK06A;[XO5M<
MR4Y!2=S1O525MIMO,H'-#J/-]=RS'1^K9SO\IG9.:E5PE*#WX0P4\-[%[^_!
MMMPE3Q@UM'/MI+(N;6.5:]T-3AEF>4\PC3<*+<85(\G.IO.GCNX1Y/<J**4:
MD:N[44E@=%U^U;QIN9QH]\HSG)#)56.61"?D*0XI3OSY'&N9O1#WC@EB89^8
MR+6AR<F.,N3E5;5!6I=ISBE3W&?:%7E&>W/=2YCI'FAR2YR65-9A.7)0K.,9
MRIQ<:N]*EO*24II;N]MPBY);6FK=IK2.5:ZY]M16FH(U7E=.+K3MU.<(U9*=
M!0A6W'&4H4Y2W]S9C.,6]B:?9.)'JQA313?;A<Y)U-BEV$W?*.:S(_+VV(.C
MJ2PK4L4GF%V?GD-RM:KHDI(X]DIP;G8@NZU(O1\VTPJMUQUQOGYOM2YQK71&
MI<OU15\,I6UGO4W4C'>3G2N)<*2QW)48S@WUT9<#X,/7SI:0R'F]YQ=(YKHV
MCX!7N[_<J1IRDH-4ZUK'9%MX;\*\X5$NMG'!..V3??\ *K_I?*>))L5+676;
M9GBB9W9;DL+F4&]P$%EVN6#5#(>BCON?;NWI-J4I5'S&(]OO-=$)Z#LZBJXH
MZ]08>9;X,LH:OMN;[+[6MF.7:;R2>-2G4Y6I"[N5).>\]UXX2WE+"$E+=W<4
MHJ*+CG%SH2[YTLTO:&4YMJ[45/"E5I<C2J65HX-0W([ZPQAN.#=2#AO[[C)R
M<FHHRXB30?BW</"7,VC;;PZBIM-8JRDPR)2^$JC\B,+G+3(_)GEYC&-T3.Q0
MLM:U/IS0<@,36GJT]*WF776W66%Y/:RMKWFMSZUK9U+/W1HSERDZ=1*E)0WH
M1C.JY2J82BIJ2>$7L6W%O#KV-WE_//IF]H:?AIA7%Q3BJ5.I2;K0E4W*DI4Z
M"C"EC&;IN#CC*.UMK!*:$=:*\-'CBF-!-*,^N7$:;5?:>VX^TMI:<GO[QV<0
M@+LK:5;1S;\LW7HTA%O(2E:I@5;;SKK.;;B-Q5^D3F9Y5]?J#3\EO;.NE1C'
M!OU'0ZZ3X7.@^#$SNUH?15_, Z$>LTOJB#W=O6QKSEBET.NC<8QBN"-.Y2VM
M'1=<VV_B3<4?;'=9WMO=\#:B11]QS@ZXTZAK8X2)N9Y#'H:X-ME:5M5-QUMC
M_+K^2[I$:]R0<ZG)=2E/;J"HN;WFURO1]+K,[S6K&K<\:@Y1E43XG^2H<4HP
MF6[2])\Z?.YG.O:_7Z=R6C.A:;>ME.,9PI./'%_CKE]&,YT^,H\6_,NQO_YZ
M!-O_ $%+'XW+#_N]4_\ X;I_^MJF@:G_ &)I?_Q;5_\ W?1-GO-_"0U0P+J)
MLWG1Q:)EDS:B-:L;.RN1[!S3).07&1RZ>2+!&0T,M?7".4D9$),2N=[TKH26
M:V&'E%7V<\XTZVIUW..3<Z6I\[U5EN2TYT;;3-3,[.$+6G2I*$*<+FDX14]Q
MU,5NQQ:FDWC@DMAUGG_,OHW3FBLVU#5A7N]84LGOZD[RK7K2G4K3M*RJ3E#?
M5+"6]+!.FVDUC)R6\\P< ?YL;#7Y79A_6A)Q:>?'_N-=_FJ']C O?\N/_:>Q
M_/7/_J*A6G@V%S?*W%&XV&.\3RA-%\B3K7O+L+A,GJK-3)V:6O#I!6-N-.<T
M-AZQI['=#>B-5D67J4-W.-+LJ:5;;78>=7EGEG-MH^_S2DZMA1OZ%2I##%RA
M%5)/8\%+&.U1>R7 W@S56G["_P XYW->Y9DU94<SN,LN:5*IBTHU)2I0CC)8
MN.$MCDDY0X4L5@8#P'CY_P!,L,J<&[?\"=[SXI2*I1=+]BX?'V[*,I<T#FYN
M"Q&8GD###IF5%B&)I.+1D+&B3-15"DY9M2[5-YAIE\SR_H:NS=9UI36L+&+4
M.3M:DG1@G%)/&,JE/?<I8R<9T9O%M8N*26.:<RVYT+D3T_K;F\J9C.+J<I>T
MX1N*DE*3:PG"E55-0BU%2IUZ:PBG@IMMVR<":1:FF8DS1"]6,D9_=FUFG#/(
M97A[89/&$LAQ0YOZ)Q1VGQFV)EF-*QADQC(84:=:H,.JH;><>2G,,Y#-7\]5
MOJA9I9WFIK>QC4G1E&%>U<W&NHM/K]_KE*&\FE@EA/8Y);-R_P O-UHUY+?V
M&D+K,ITH7$9U+:]5-3MY34EC3Y/K7"IN--[S>,,91BWMPYP=U2G'W$+XM>!6
M.PRF.V[-#C,F-!;4PM#'%J?)60&LI B3TZ0JRJQF>2$]YE;Z7F%M)7L>Q7FW
M?G8C&_T'I;.ZV'A\K-4Y/HS7)4GBWTI1;PZ#FRQ<R$YY;SEZST[;X^3(W\JL
M%T(-5ZT4DN#;&23?"U3CZVR$.?3J0                       (,[,?*1T
MK_*[(OWK!Q7I_DY^HB67"B<PH$P
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MC3@\>AM;V;"5XV"9F
M                              '$2#_@+W_9#E]Y'"*X2#X"(^@7R8H;
M_:\Q^%#H*M?\JR$. F>*),                            &O]Q^^%,X\
M0W7MHR-AEH3JMI=?TSLXP=OI<G2G90@:ZWLR3XMO5G=%91ZN5IBU[!>>90@M
M=:<FKT=J\P\K-M$ZDCD5\Z%V\,MKX*3]Y)<$_4Z$L.A@_N<'8L]RQW]!5**_
MO-/@Z:Z,?\JZ?JFAUH%OWL7PN-D%.2L<HSRU!!Y\)S5A::$N#0TSAD:W(PMS
MB4I0FD6N<:E,><RC+D*ZTFBUJ76WVWEFD&*DBC<V=Y)8:CL/!Z[V>ZIU(X-Q
M;6R2? TUPK@DN)X-838WUQEMQRE/U)1?17$^)KH/H/UT>B[HWQK=!MZ6%G+A
M^7V#%66%9"0IVPAF1X:81.4KP=;2TU#%U+HL(8,BI:GTNJ2<RJ51U2>;<H3I
M3+JE6Z)SC26=9--\K2E4MEP5*:<HX<;PVQ_K)=)OA,_LLXL;V*W)J-7WLMC]
M;H/UOL%M(QDNA"S;+B(:::1QQR?=C<]06%.:%":L18_3.R=_RE(C+2^<G1Q[
M'+(8ME:^]8;=870^Y,4A(J9;>H/)*YQEMVRS(LUS>HH6%&<XM^ZPP@O5F^M7
MJ8X\2;/'=7]I9Q<KB<4^+AD_42V_Y"ISAL?2',.[^[;Y UN=\?WX20OW-5:O
M.4F>B%3[DDEF1'FR6.S.T@RYF8YTX)T]SFV(D1JA/<EL/254'*"2C%639_H:
MZR3+(7\)\M*/Y9);(8\#CT7%<#;P>.#P2;PM>79]2OKJ5NX[B?N,7M?&GT$^
MBEZWJ[&PP,R    /&;NNMLV+NOONMLLLS56Z^^ZM+;;;;9URW7775Y*6VVTI
MRUK7[ ZM_P!@_P#)_P TU'_I_P"O_E/8M\)F-_&#".M;#^'CECP>O[R?4?M&
MV>4I^^750\)F-_&#".M;#^'AX/7]Y/J/VARE/WRZJ'A,QOXP81UK8?P\/!Z_
MO)]1^T.4I^^751W!*J3+4R=8C4$*T:L@I4D5I32STRI,>7::0H3GE77E'$'%
M7TNLOMK6VZVM*TKR"DTT\'L:)^':N _<0  &A5]+W^4?J!^9*<_#LD;HYK_U
M"Z_/1^"81JO]8I?@/V2TCZ)-\W%FK]MK(_ZB=;ACG.;_ !ZC\CC_ &E4N6EO
MX?/\\_@P-HT:Z,E       BWO'\BG<']EO8']4TM%QR?^+VORFE\.)YKW]3K
M?FI?!9YC?!1^=7T=_/:U?B=Y'0NK?FW>?F7[*-<9/_$Z/X9ZQ YI-H
M                     0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_P W
MKWY-/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C
M         #S,>-]\ZCM_^64._53 AV)S<?,FP_-S_M9G-^M/G/=_AQ^!$JH&
M;F+                                 !NA_11/\/]U/RQPC^)<ECGKG
MP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
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ME=D7[U@XKT_R<_41++A1.84"8
M                ".NVOR;LO_DBH^^T@J4ORB]4EE[D[=@#_ ?"?YH\;_ U
MF$*GNY>JR*X$9<$A$
M
M                                               XB0?\!>_[(<OO
M(X17"0? 1'T"^3%#?[7F/PH=!5K_ )5D(<!,\428
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M^JF!#L3FX^9-A^;G_:S.;]:?.>[_  X_ B54#-S%@
M              W0_HHG^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/
MV)FW$-$FU@
M                     (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
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M!G9CY2.E?Y79%^]8.*]/\G/U$2RX43F% F
M                          CKMK\F[+_Y(J/OM(*E+\HO5)9>Y.W8 _P'
MPG^:/&_P-9A"I[N7JLBN!&7!(1
M
M                                                        .(D'
M_ 7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_P"59"' 3/%$F
M
M                           "!/%+^;CW:_9LRM\%5XR?17SMR[Y92^$B
MQ:G^;U[\FG\%G3N#U\V3IG^9UN_&[N/1K[YY9A\H?L(HZ1^;=G^97LLLG&(&
M1@            !YF/&^^=1V_P#RRAWZJ8$.Q.;CYDV'YN?]K,YOUI\Y[O\
M#C\")50,W,6                                 #=#^BB?X?[J?ECA'
M\2Y+'/7/A^M9=^;K>S3-Q\UOZO>?AT_8F;<0T2;6
M                                                    @S)/G"<?
M_L[+?A/-A77ZN_PB5^[]8G,*!,
M                                                   09V8^4CI7
M^5V1?O6#BO3_ "<_41++A1.84"8
M                  ".NVOR;LO_ )(J/OM(*E+\HO5)9>Y.W8 _P'PG^:/&
M_P #680J>[EZK(K@1EP2$0
M
M                                                   #B)!_P%[_
M +(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_E60AP$SQ1)@
M
M                       @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F
M]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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M>'9WXHNR7MCUC'TA_P#@KP;X]HSY0@\EZ7\?EV#[4>'9WXHNR7MCUC'TA_\
M@KP;X]HSY0@\EZ7\?EV#[4>'9WXHNR7MCUC'TA_^"O!OCVC/E"#R7I?Q^78/
MM1X=G?BB[)>V/6,?2'_X*\&^/:,^4(/)>E_'Y=@^U'AV=^*+LE[8]8Q](?\
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M\.SOQ1=DO;'K&/I#_P#!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_\
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M/#L[\479+VQZQCZ0_P#P5X-\>T9\H0>2]+^/R[!]J/#L[\479+VQZQCZ0_\
MP5X-\>T9\H0>2]+^/R[!]J/#L[\479+VQZQCZ0__  5X-\>T9\H0>2]+^/R[
M!]J/#L[\479+VQZQCZ0__!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_
M /!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_P#!7@WQ[1GRA!Y+TOX_
M+L'VH\.SOQ1=DO;'K&/I#_\ !7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/
MI#_\%>#?'M&?*$'DO2_C\NP?:CP[._%%V2]L>L8^D/\ \%>#?'M&?*$'DO2_
MC\NP?:CP[._%%V2]L>L8^D/_ ,%>#?'M&?*$'DO2_C\NP?:CP[._%%V2]L>L
M8^D/_P %>#?'M&?*$'DO2_C\NP?:CP[._%%V2]L>L8^D/_P5X-\>T9\H0>2]
M+^/R[!]J/#L[\479+VQZQCZ0_P#P5X-\>T9\H0>2]+^/R[!]J/#L[\479+VQ
MZQCZ0_\ P5X-\>T9\H0>2]+^/R[!]J/#L[\479+VQZQCZ0__  5X-\>T9\H0
M>2]+^/R[!]J/#L[\479+VQZQCZ0__!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO
M;'K&/I#_ /!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_P#!7@WQ[1GR
MA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_\ !7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1
M=DO;'K&/I#_\%>#?'M&?*$'DO2_C\NP?:CP[._%%V2]L>L8^D/\ \%>#?'M&
M?*$'DO2_C\NP?:CP[._%%V2]L>L8^D/_ ,%>#?'M&?*$'DO2_C\NP?:CP[._
M%%V2]L>L8^D/_P %>#?'M&?*$'DO2_C\NP?:CP[._%%V2]L>L8^D/_P5X-\>
MT9\H0>2]+^/R[!]J/#L[\479+VQZQCZ0_P#P5X-\>T9\H0>2]+^/R[!]J/#L
M[\479+VQZQCZ0_\ P5X-\>T9\H0>2]+^/R[!]J/#L[\479+VQZQCZ0__  5X
M-\>T9\H0>2]+^/R[!]J/#L[\479+VQZQCZ0__!7@WQ[1GRA!Y+TOX_+L'VH\
M.SOQ1=DO;'K&/I#_ /!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_P#!
M7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_\ !7@WQ[1GRA!Y+TOX_+L'
MVH\.SOQ1=DO;'K&/I#_\%>#?'M&?*$'DO2_C\NP?:CP[._%%V2]L>L8^D/\
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M\.SOQ1=DO;'K&/I#_P#!7@WQ[1GRA!Y+TOX_+L'VH\.SOQ1=DO;'K&/I#_\
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M_EE#OU4P(=B<W'S)L/S<_P"UF<WZT^<]W^''X$2J@9N8L
M                  &Z']%$_P /]U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]
M7O/PZ?L3-N(:)-K
M                           09DGSA./_ -G9;\)YL*Z_5W^$2OW?K$YA
M0)@
M                           "#.S'RD=*_P KLB_>L'%>G^3GZB)9<*)S
M"@3                                                    1UVU^
M3=E_\D5'WVD%2E^47JDLO<G;L ?X#X3_ #1XW^!K,(5/=R]5D5P(RX)"(
M
M
M                          !Q$@_X"]_V0Y?>1PBN$@^ B/H%\F*&_P!K
MS'X4.@JU_P JR$. F>*),
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MP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M                                            09DGSA./_P!G9;\)
MYL*Z_5W^$2OW?K$YA0)@
M                                            "#.S'RD=*_RNR+]Z
MP<5Z?Y.?J(EEPHG,*!,
M          !'7;7Y-V7_ ,D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]
MW+U617 C+@D(@
M
M                                          '$2#_@+W_9#E]Y'"*X
M2#X"(^@7R8H;_:\Q^%#H*M?\JR$. F>*),
M
M            $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<
M'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #
MS,>-]\ZCM_\ EE#OU4P(=B<W'S)L/S<_[69S?K3YSW?X<?@1*J!FYBP
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MP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M                                            09DGSA./_P!G9;\)
MYL*Z_5W^$2OW?K$YA0)@
M                                            "#.S'RD=*_RNR+]Z
MP<5Z?Y.?J(EEPHG,*!,
M          !'7;7Y-V7_ ,D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]
MW+U617 C+@D(@
M
M                                          '$2#_@+W_9#E]Y'"*X
M2#X"(^@7R8H;_:\Q^%#H*M?\JR$. F>*),
M
M            $">*7\W'NU^S9E;X*KQD^BOG;EWRRE\)%BU/\WKWY-/X+.G<
M'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C             #
MS,>-]\ZCM_\ EE#OU4P(=B<W'S)L/S<_[69S?K3YSW?X<?@1*J!FYBP
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M'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M
M(,R3YPG'_P"SLM^$\V%=?J[_  B5^[]8G,*!,
M
M  09V8^4CI7^5V1?O6#BO3_)S]1$LN%$YA0)@
M                            (Z[:_)NR_P#DBH^^T@J4ORB]4EE[D[=@
M#_ ?"?YH\;_ UF$*GNY>JR*X$9<$A$
M
M
MXB0?\!>_[(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_E60AP$SQ1)@
M
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MG^'^ZGY8X1_$N2QSUSX?K67?FZWLTS<?-;^KWGX=/V)FW$-$FU@
M
M  (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
M
M $&=F/E(Z5_E=D7[U@XKT_R<_41++A1.84"8
M                           ".NVOR;LO_DBH^^T@J4ORB]4EE[D[=@#_
M  'PG^:/&_P-9A"I[N7JLBN!&7!(1
M
M                                                           .
M(D'_  %[_LAR^\CA%<)!\!$?0+Y,4-_M>8_"AT%6O^59"' 3/%$F
M
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M(:)-K
M                 09DGSA./_V=EOPGFPKK]7?X1*_=^L3F% F
M
M                (,[,?*1TK_*[(OWK!Q7I_DY^HB67"B<PH$P
M                                          $==M?DW9?_ "14??:0
M5*7Y1>J2R]R=NP!_@/A/\T>-_@:S"%3W<O59%<",N"0B
M
M
M              <1(/\ @+W_ &0Y?>1PBN$@^ B/H%\F*&_VO,?A0Z"K7_*L
MA#@)GBB3
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M8F;<0T2;6
M                     @S)/G"<?_L[+?A/-A77ZN_PB5^[]8G,*!,
M
M                    09V8^4CI7^5V1?O6#BO3_)S]1$LN%$YA0)@
M                                              (Z[:_)NR_^2*C[
M[2"I2_*+U267N3MV /\  ?"?YH\;_ UF$*GNY>JR*X$9<$A$
M
M
M                  XB0?\  7O^R'+[R.$5PD'P$1] ODQ0W^UYC\*'05:_
MY5D(<!,\428
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M_11/\/\ =3\L<(_B7)8YZY\/UK+OS=;V:9N/FM_5[S\.G[$S;B&B3:P
M
M      $&9)\X3C_]G9;\)YL*Z_5W^$2OW?K$YA0)@
M
M     "#.S'RD=*_RNR+]ZP<5Z?Y.?J(EEPHG,*!,
M                               !'7;7Y-V7_P D5'WVD%2E^47JDLO<
MG;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(@
M
M
M   '$2#_ ("]_P!D.7WD<(KA(/@(CZ!?)BAO]KS'X4.@JU_RK(0X"9XHDP
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M4IR4K?2E?LT CNRW=_![J>&/0Q>."]5X/J,_0"
M  0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_S>O?DT_@LZ=P>OFR=,_P S
MK=^-W<>C7WSRS#Y0_811TC\V[/\ ,KV663C$#(P             \S'C??.H
M[?\ Y90[]5,"'8G-Q\R;#\W/^UF<WZT^<]W^''X$2J@9N8L      !]K8XJF
MAR;W9#?0I<UKDCBC-NLL-M+5(CRU*>^XLREQ9E+#BJ5K;=2M*_8J)9PC4@X2
M]S)-/U&31DX24X^Z3QZA=;]8>XJ/CNAWQ+8H[U!KOZ*-$^+5.[5>V,S^D#4_
MQT.YP[4_9/\ 2%N*RL4$)$F9HHJ5*CBDZ9,GPCBL]0H4'WVE$D$$E1*XPXXX
MRZEMMMM*W775I2E.40?-5HB*<I6\U%?_ !JG;!:_U0W@JT&W_P##AVI=?IK+
M_I'VUU6>22G(,*UKQ4XT)55FV9,$XV;I*O;3K:7T41?%I<4(E[H::3?8:1>X
MT9V]25=SBU=WL4KKK4%#FCR/>HT*52\OELW*5:HXI_?5-[=73W=^2?#$S/)Z
MW.'FF%2K4A;6K^ZJ4H)M?>PW=Y]+'=3XS3=S8E<T.9LMHGIUM?GE'DZ>I79\
MM0$M5KRYIY4ZDKW6UK3&')VVUQ567G43EWW6$\_F6UK2E*CH#+I0EE]"5..[
M3=&#2QQP6ZL%CT<%LQZ)J&]4HWE6,WO3566+PPQ>\\7AT,>(LGX9>Q,21L.6
MM+\[:M9+V\UTSFK9\ANL'PFU.+KFC&,Y@")403E;'1+<J;>2Y,QJ^@=*GK$)
M-$Q)?2*+4U52=5B&L<IKRJT-0Y9>T;#-K9.FIUFE1J0F_P E4Q3Z*QC@F\6\
M%CNN.1:;S"DJ=7)[ZUJ7>7UVIN---U(2C]W###H;'BULZ.&*<E<B;'Z-ZLZL
M997<.#5_:.]WV:8)1KG(=Q-FFY%[G8S$7QM3G9%QOC%RC2M7'S)HYL2@JU07
M0MN6IBCRE5UZBPHDNMGM,HU)G>=T(ZNO;+D[.4:\;6W;WI23_%U*BDE+<4L<
M/=)X.."Q;+E<9ADF6975EIVVNMZYC*D[BLMD8M=?"#6S>:X>!K%/;@C7V&TS
M 2\[8G7C-NU7#NX<N9M;8)*\N0#"6+\EX'RK \9,Z^8R/%N54.5Y%(W.1O\
M$8Z4N=DZ;)3(ZH5]RLM+=8426GN5F65/3\[6N4YMEN2:LS?+\WJPH75S6IUJ
M<ZC4(U*3I1BHQE+!?BVI1PQVO'=6QF;YAE][FFG\OO,NA*K0HTITIQ@G)PFI
MMMN*V]>FGCAQ8\*/GBF!<PZF\([=Q\V4A\BQ27MCD35F#Z_8[R$W*HW,GR18
MPG[GD>99"3PY\L2OK0TD0@DY"0KO3%U6EJ;J\ZA-":G35\SL,]UWEM/)ZD*[
ML:5S.O4@U*"C4@J<(;ZQBWOX-K'9AQXX0I6-WE6E+V>8PE25U4HQI0FL)-PD
MYRGNO:EN[,<-N/%AC1R-D&$FS^P-NM&FN(\%6[_\07B/NN=,NXAAF4TN"-9L
MK2%J9<-P&9MU'&&M\H4R!S,*O>K6<@LJI!2Y+V/?TEE$5Y%"%=^F:L\XU!?W
M/HME641RRA7G3=:XI1;JS@\)N.ZN#';BXO'9UV.,5LNG'+<GM*'EZ_S%WU6C
M&?)49M*G&2QBI8OAPZ&*P][A@R!'$[Q(6SP+7_8#"NXF<=N=/\XJ9LFQXJSO
M+Y,^3_%V1X,:@02^'3%I>:(6U.\F(W N].L3-Z"Y246=_-=CVIU*K)]&7W*7
M5UE68Y?;6&?VRARG(PC&%2G/%PG!K%X8K:G*6#PVXXJ-BU+:;E"A?V=W7N\H
MKN6YRLFY0G'!2C)/!8[=C26.W9A@W3N,_,1   #=#^BB?X?[J?ECA'\2Y+'/
M7/A^M9=^;K>S3-Q\UOZO>?AT_8F;<0T2;6
M                                              @S)/G"<?\ [.RW
MX3S85U^KO\(E?N_6)S"@3
M                                              $&=F/E(Z5_E=D7
M[U@XKT_R<_41++A1.84"8
M            ".NVOR;LO_DBH^^T@J4ORB]4EE[D[=@#_ ?"?YH\;_ UF$*G
MNY>JR*X$9<$A$
M
M                                           XB0?\!>_[(<OO(X17
M"0? 1'T"^3%#?[7F/PH=!5K_ )5D(<!,\428             (S;I%]+J#M%
M9R\G+K_EVO+R<O\ S8&^W_\ T^:/+>_J=7\W+V&9US8/=YR,@:\\V?\ ZBF0
M7X$7S9>#ORDS1^N6<CQ9'_#H_A3^'(VS_-O_ -]\V_,67_HK<P!IAB!2Y<:?
MB&Y_QZ31/A!CC#;C!:[-EM>T4BR](V/"K[.6I(?92J18LCTKBCT8X\RM;R%A
M]EM>3GW4'GLZ6]G->O2QY"*W>DY-0;P]1IX]-LR[G.U)2H_RO:+T?G#<M5U;
MB=TH3]W3LZ=2^IT)M/:HU*5:BJ6.R4(M]!%][NTMK\V+F9X2%+VMR3&HUR(_
MG=$I3'6UL-),YMUMW-OMKR5Y*TJ+\TI+=? SD2WN*UI7A<VTG"O"2E&2X4UP
M-&NIPJXP0\;^<16/2-YEDI8<#Y(+8,2LDGF,HD#5"$!\[G2<SM,B=G=4FL44
M2,B4FPV^R\PLHNMMEU*7WTNQ_*HJ=Y7<L6H3:BFW@L)27^0[3_F!OI6W,]HF
M^LJ5O;WF;V3J7DZ5&E3G7DJ%N^OE"";6,Y2:32;>+6Q87_9/A<;GL(?X]*FP
MMU:SFU>?0F\Y2GO(5%H%5A"Q,I2')U*96FZ6M2S++[;K+O9I6E:4J+[4A&I!
MQEP8''N1YG?91FE&]R^;IW"G%8X)XK>6*::::>&U-8-%%? 49C)CB_.&09X^
M2B>S6+YR>X3'Y%,Y1()*N9H\T,J.PE VU=W)62D+/N7&7&ULLMN-K6G.K7DI
MR67(UOTIU)XN:G@FVW@DEQ^J=8?S=W$<MU!E63Y32M[/*Z^44Z]2E0I4Z49U
M9SEC*6Y%.36ZL,7LZ'"S82%^..#6YXB,);(YQ..'[!XNY2J+PO-3T97*$2CL
MRE;-'9C>VR?GEF.S0WO*=$9>I*NZ)1S;+.G*^U,YU/8&/9C!0S"WC#%1G)8I
M-X/;Q';?,QFE:\YA]99K?4[>XS3*Z2\%K5*-*=2COTL&H3E!R6#VQVO=>U8&
MQJT-+<PMB%F:$A2!L;4Q2-"B(I6A*9,3;S2B2Z5K6M+++:<E/9&0)**P6Q(X
MJN+BM=5YW-Q)SKSDW*3X6WPMG(B)1  KRW0.F>3IYK?@C!^0YA%,G-^;H/F+
M(BB#O)J!%'<&0RCM657Y-[%I_/L$T4JB&ML;332KW!P-M.MM-)1GTI;+Z4ZE
M:E;4)25934Y8/@@L<=[I/@2?"]JV)FX^;)97D659WJO5-G;7.13RJO9VZKPW
MI5+ZMN<EX+CP5*"4JM6JDU3IIP;C*K L-%S-.'\&F6$E&'&5YI95EYE]U?\
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M77QM[6I4H4,/NGRL>5>' XW,&MNTV2J5I6G+2M*TK]BM/9I49&<1G^@
M                 ($\4OYN/=K]FS*WP57C)]%?.W+OEE+X2+%J?YO7OR:?
MP6=.X/7S9.F?YG6[\;NX]&OOGEF'RA^PBCI'YMV?YE>RRR<8@9&
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M&,EM3V/H-)II;0RS,K3-[*%_92WJ$UT=C37#&2Z#3X>JFTTR0 M9[P
M     (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
M
M    $&=F/E(Z5_E=D7[U@XKT_P G/U$2RX43F% F
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MG6K5LES)UIRFU=4_=-O_ $?3.E.8RK5JY3?.K*4FKB'"V_N.F6]CHTWF
M
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ME&??RJ_]\<G_ /F/_3U"=FJ?R8]?/S,XV^"+2/9:?JE+\W'V$:FYP?GUG/\
MQ.Y_MIF?AZ#$#7LP;_[47[C_ +)<<^#6IHL%+YP5/S7^2F=E:K__ )*=,_\
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M#ZYSGS[Z"?-SSH9GI^E%K+)5>7MFULE0KK?BEQ\G)RI-K9O4V3\'N-0
M                 0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_P WKWY-
M/X+.G<'KYLG3/\SK=^-W<>C7WSRS#Y0_811TC\V[/\RO999.,0,C
M     #S,>-]\ZCM_^64._53 AV)S<?,FP_-S_M9G-^M/G/=_AQ^!$JH&;F+
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MI[G*T)JJZ\!R#-+6XO6FU3Q<*DL-KW85%"4L$L7NIX+:]A,<8F9P
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M^?6=?\6O/_45#AO5WSKS/_B%S_;3.+&)F/
M                           !?KP>O\-\Q?ENP_B$P==_RW?P3,OE5/\
MLSICF)_A-_\ *(? +AQTB;W
M                                                        #B)!
M_P !>_[(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_E60AP$SQ1)@
M   BWN^J+1Z<;2*#;Z666X"RL76ZM:4]D^%/!%E/9Y*?;7F4I_Z4>6^>%G5_
M-R]AF>\U<'4YR\@@EB_+%I]BO!_Y"#/ ;6)E/#1PX00<68<W2W,J1:79?;=>
MG4&98ES@64=;;6M2[[D:XHRE+N2M;+Z5^Q6@\61_PZ*^^G\)LVS_ #<TYPY]
M<TG--1G;V3CTTK.C'%>O%KU4R/?'KC"7,[+IKKS!TELASQ-]C4:Z+L37;V8_
M-\#MBK\T2Y\5ID]IJE P$NSBU'''F4M*K:CONY:]#=S?/GB554:%-8UW4V)<
M6#3?J8X8^ITC,?Y1<PJ:7N]3:SS67(Z1M,CE&K4GLIRN'5ISHTTWLE4<(U5&
M*V]>ELWEC?K'6GM#'V)CJI,6=I69L::JS?\ QJKM<B(1]DF>S6O2']#SJ_\
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M"27 DEP)'/BD5            (,R3YPG'_[.RWX3S85U^KO\(E?N_6)S"@3
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M4P         "+.Z_R7\K_P!G,'PPCPHU^"'YZE_:0/+>?D5^<I_VD34]>_\
MC3O_ &HX??9H^<NO?GUG7_%KS_U%0X;U=\Z\S_XA<_VTSBQB9CP
M                                            7Z\'K_#?,7Y;L/XA
M,'7?\MW\$S+Y53_LSICF)_A-_P#*(? +AQTB;W
M
M           #B)!_P%[_ +(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_E60AP$
MSQ1)@             P1L+@!@V3Q\[8LFDPG\>@DE0JVJ7L<%=&-COEK4LJG
MNN;79X6QQX?4:2RI'V&Y4AN,M,NM-N,LK2VE"XH*XAR<I24'PX8;?7P]@RS1
MNK[S1&<4\_RRVLZV;4)QG1G7A.IR,XX]=""J0IR>W_20J)8)Q2>TA)BOA'X,
MP,4K28)SAMYAQL<%?9KDRP3.AZ)E<%-2[2KSU38X1MR37J+R[*4J92E#.2E/
MMO8IR>2GE=*C^2G5BN)2P74P-J:A_F,U;J^4:FK\JTYF=Q".[&I<6"<XK''!
M3A4@\,>AP=(EOAW4/!^$I2ZY$CC$]R;*\@16MT@R]DV727).3'9#;0NVB&LH
ME[DZ*&=LK:39RHVVQ$CK6WEZ+G5K6M>A8V]O)U()NJ^&4FY2]3&3;PZ2P1KC
M4G.+JK5%A3R:]K4J&GZ,MZG9VU&E;6T)/%[W)48P4Y;7U]3?GT-[# D6ZHE#
MBVK4*1U<&-2J3FD$/#58VF.+<89;6VU6B+>&]V:KU!-:\MM%"8\KE_YUEU/8
M'J:Q37!_3IF%T*D*-:-6I3A5A&2;A+>498="6Y*$\'T=V47Q-$!,&<-C"^N&
M4)IF/$4_SA'9_DI0:HR2ZKIC'9,EG?9+U?(%-CZSRB%O#23<<Z'&7VG(24:D
MBTV^PDTJR^ZE?!1RVC;U76I2FJDN%XIX[<=N*XS;^K.>[5&ML@M=,ZDM,JKY
M/812M81HU*3M\(<FN3G2K0F\()+"I*<9-)RC)I$X)M%KYI%GB+6R20Q4M[1F
MMZIZB]S*6^$HE-E25A",Y^97]O3W*TU]Q=QO8U3B[;JW%7EF4MOM]M2'*0<,
M7''HK[>)JK*[]99?TK]T:-PZ4E)0J[^XY+;%R5.=.3P>#PWL'AA)-8IUFXKX
M/.M>"3711@S)VU6'5+Y1/1Y48^SR],M7:J2MUR>YQ(N;%21;<36^[FU,+NY*
M75I]BHMU+*;>@\:,JL7TI88^KQ^N;UU!_,IKK5RIQU;8Z?S.%''<5QE].>YC
MP[K4HR6."X&2+P]H_!\2Y>*S@NRYL3F2>H(F^PQ@5YQRH?/&Z+M$E7LZ]Z,C
MS91H:4R!P759"2KCN2^O05OMY/MN6GHIV5.G7\(<JDJBBTMZ3:2>&."]9&%:
MEYU,UU'IUZ6I9;DN691*XIUJBL;16\JLZ49QARDM^;E&/*2:CLZ[!] QML?P
MP->]K\EM&6LU2C,[Y,XN64GA*QDGB.()H.C3.=SPB2QI-%XXU=#<C<KNEL4J
M;E*ZZ^VVMY]];;>2G<9;0N:G*U93WTL%@\,/4P7V^F7S1'/SK/F\R*KIW2U#
M+*.5W#;KQG;NLZ[<=R3JNK4GCO1V.,=V"6.$5BS])#PXXY*&)9%GO;;>Y?&'
M).:A<V!3L<M/0.3:I)O3JVQ9>;&KUQJ)6096R^WIN6MM:\E:<H2R^$X<G.K6
M</PWM]4EL^>N]L+J-_:Z<TE"_IR4HU%EL5*,D\5))55%23VI[I/F*QEGA<8C
ML/CR7L)@BS(U1UE1])>;5*U,R$AN0$7&F5N,-N*2I[:5ONK6ZZM.6M>6H]T(
M1IP5."PA%)+U$:AO[ZYS.^K9C>2WKNXJSJ3>"6,YR<I/!;%BV]BV(YX3'D
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M2WI.6*>$-CV=%F;Z4RW/,MMZL,\KNO5E-.+=2=3!8;5C+@V]!%MPP4RL
M       "#,D^<)Q_^SLM^$\V%=?J[_")7[OUB<PH$P
M                !7AQ%.'I%N(C 8!CV890F&-6B!RY9,+*Q1"W.=CVO4LY
MS.GL<D;H;8FKVO(4FW$F4I6^RIM]*<E+J\N>Z!UY<Z"OJ]_:6U*XJUZ2I]>V
MMU*6\\&MNW!8KI(UESG<VEGSFY=;99>W=>UHV]9U/Q:C+>;BXK>4MFQ-X/A6
M+XROF,<!9UA+$W1:&<1_<:(QEH+,):8[&)(I8&)L).4&JCBFYH:I&D;T19JH
M\PRZTLNVEQE]UU?9K6HSJYY[:5Y7E<W>G\IJW,_=3G!2D]F&V4H-O8DMKX#6
MMI_+K6L+>-I8ZHSRC:06$84YN$(IMM[L8S26+;>Q<+;.]D\$A0XX]S/C6?[X
M[2Y3C68X QP=4@R$\WRAOC)[#E_%F6TDH9VIZ?'!!<^T/QC1LH9=9;=8C<U'
M-NY:\E?$^>*-._L\QL<DRRVN+2O*HG2CN.:E0K4'"4HQ3W<*V_A[Z$2XQY@Y
M5<LOLJS+46;WEK?6T*35:7*1IN%S;W*J1C*<EOXT.3QPV1G+:9R;.$QCQLRS
MH[EDO+<S-<='L7Q+%\5:;V1CHBG*")'OIZ=TD!]+^G;E:NK[?2^Q-RV6]'3D
M^S46:ISH7]3*\YRMVM%4\YN9UIRWI8TW/=QC'H-+=V8\9D%+F:RREG.G\Y5[
M7=73]I3H4X[D,*JIN;4IOABWOO%1V;#M.^'"TQ'O%-,899-F\OPAFO%BHCM/
ME?&I#?9)7!J;U?;9B;W$Q3T)G946?J=F-:PLVP]'<:?;3G4,MZ/RZ)YRLTT9
M9W.5JC2O,GN4]ZA6;W%)K=DUAT)QZV<6L)81?0V^SG$YHLEYP+^TSEW%?+\^
MLVMVXH*.^XI[T%+'#;3GUU.2:<<9+;BL,(O/":RQ$\_239_5[>N7:[YER='4
M+7FUV.P3C_*,6R4_%ID%KW++8,^OK+'(^XRAW;K7145T2PHAR/47H^Q2C:$V
M7FCSH97=9'3TWJ3):5_E%M4<K>/A-6C.C'%[L.4C&4Y*$7N1>,6X**GO-8NP
M5^9K.;/4E75NDM0ULLSV[I*-U)VE&XIUYX+?J<E.<80E4E'E)+"24W)PW(O=
M6.<S\#ASV"=H_E3+>^^PLQV6C3\UN+%E]9'8@W1V+M#*K-=FQF@N,(\:RIH0
M8B?S.SRST+M878IY;[2*77775N&4<\U/(J53+,KR.PI:=J0DI4%.HYSE);KE
M4K2WG4QCUK4H8X;,2UY[_+]6U+6IYQG6H\SKZKI5(RA<N%.,*<8O>C&E0@XJ
MEA/KTX5$E+;NXO$O QQ%G*#8\@<)>9:^S]XAT,B\6=9W*#*'26:N4?8T+2NE
MLB-MOOM-?9(J27+%=U+JTN4'7UY:C3>87-.]OZ]Y1I0H4JM:<XTX>XIJ4G)0
MA][!/=CTDC?V5V=7+\LMK"O6J7->A0ITY5JFVI5E""BZDW[^;6]+IMG<QXSW
M@                                  $&=F/E(Z5_E=D7[U@XKT_R<_4
M1++A1.84"8             *O\U\)_ ^4,Q2W8#&&6]I--LQ9(L2TRM,]-\R
M5Q!3*YZ*MU4SGD*+.4;F,(?GRRM]UU[AVL*6GF75,--O-K6\0P)U-I8/!KIG
MR84X/VH.#,UXGV78JY>FVR&+9-D"6*\^99R@[9*ROE5SR-C%WQ([)\L2R2)E
M*N0,[1$GB_M6B0T;$R%59:;;96MQU#6 <Y-8= [BG8];^$M@;,$Y2HLV2*"Y
M'V$G6;)6WQR*O.8IL?D_-S@0K<T$>CL(CJ=>GCBAS;"B$M#B[BD=QMO9"JEE
MU;[7 0VS?K& .!WIXKU9U*?YE+,8J</Y+VJRS,]@Y%C%U*-L?L3P:1K:H<+X
M;<:*TZ5S06X]QHC1<]M566'M:]>K3WV67VW66D1J2QETD=KR5P<<"S')64<B
M8SS]NCJHCSM(UTQSGC'5;8 W%>*,N3!Y++(D<JE,24162&-S_*4UEQ;FI953
M3>MH:9<9RF75O# *;PP:3,_SSAK:=S[5"#Z8*L5E1K".*KF9PQ&FA;T[QR9X
MIET>5+')FR+ YVE57R9HR(G>')4M/=KSSE#@I5J;EO9-JD^TR)#>>.]T3%&$
MN$[A+%F9(7GK)><-NMQLEXKM7W8:=MR,YG9C;<.K'1,6B7O6/XXCC428$LE4
MI2K;:NBY,O<;;[;#;3Z'%E&60P(N;:P6"72*U->>&PESYO!Q4,O2R5[=:HY$
M+VL(;<79XU[GDDPA*9KBQ_Q_'U+^P)USS'WV#Y)@1\B:$ZBE3VQ?8D7IZ7D&
MDF<_G,"9SPC%;&L"S%LX1FI;;J7G74.XS*[Q'-G7A))]@<Q2:?WRC87+4N1O
MK/("95,,EO[2XVKG6U8R%6VEV(2T1-AI]2B"S5!QE[ EWY;REQ$O\X:O81V1
MP*]:UYMA:6?XE?F!K8%S(Z'J"%Q5&*U+5B>VMZ;;T3DR29D5HBE*1>C,(4)U
M!=+[*T]FE8DJ;3Q7"01Q]P<,"QW(..9WEO8'=;;IOPW(4,OQ!C#;38=7EG$N
M.)<T6FEQ^4,T+(C$;)>GZ-DG5L0*'LYUO3TI;6G+=;;=2&!,YO#9@C/^=^'I
MAS/&S.+-NU,\S[B?.>+(JSX]*D^"\NO6,R9]C!EGOA*(Q;DY VIE)4NQZMEA
MAIZQMNJ26ML.K8=6^EA71Q(*32W>@8IS1PG\,9/R_.<X8WSUN+J%.<M&I5F:
M::AY[5XGC>8G9&D*;B)#.8JY1V8,=)11M(M(N<VHEL7WTK>9<;4\TXTR&!%3
M:6#2:Z9VX[A::G%Z]X/UE8V69Q?&N!L^0G9B-',\L,52Z49AA3\YR>V4Y$E4
MC0OSE+5,F?7<\]UN,J6:=2MA1)A!)99=K AORQ;Z+1G_ !=J?B_$6QNTVT44
M42HS)6W_ ($/"N0[.R-9&$W@ @CACR"^Y)K):DBMGZ9@<S*K^G5*^R%')?9T
M5M.96)!R;2700PYJ?B_!V:MG<]0M1*C9QMI)H#+,I%/;LC7,2=TQQ$S8;'K8
MH@3M2)0TI;V@VM5%AQZNXP[[:VZRGVH!R;27$29 @          1AW-2G+-8
M\M%$6TNOL9FM5=2MUMO(2ADK(M47<MU:4K6Q.GNK2GV:UIR4]D23A*INQAP\
MI!^M&<6_L)GGN82G2W8\._!^LIQ;^PBA!OX>6T\U0(9E'H2SJV"6HTTF8U1L
MTBB4Q2SOQ-CJV*#$JEV+4)KSD2NRZI9EMM]E:\EU*5I6@XTU;S-Z^S3569YG
M9VM*5G<9A<U8-UJ2;A4K3G%M.::QBT\'M71.6]0\UNL\PS^^O[6WIRMJ]Y6J
M0?*TUC&=24HO!RQ6*:V/:C[/5F;?^\%DZ]P[NR,?^@SG'\4I=WH]N6CZ(M=>
M*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX^B+77BM/NU+MQZLS;_W@LG7N
M'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]X+)U[AW=D/H,YQ_%*7=Z/;CZ
M(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX^B+77BM/NU+MQZLS;_W@
MLG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]X+)U[AW=D/H,YQ_%*7=Z
M/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX^B+77BM/NU+MQZLS
M;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]X+)U[AW=D/H,YQ_%
M*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX^B+77BM/NU+M
MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]X+)U[AW=D/H,
MYQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX^B+77BM/
MNU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]X+)U[AW=
MD/H,YQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX^B+7
M7BM/NU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]X+)U
M[AW=D/H,YQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW>CVX
M^B+77BM/NU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K,V_]
MX+)U[AW=D/H,YQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?Q2EW
M>CVX^B+77BM/NU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2[<>K
M,V_]X+)U[AW=D/H,YQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z#.<?
MQ2EW>CVX^B+77BM/NU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK3[M2
M[<>K,V_]X+)U[AW=D/H,YQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=W9#Z
M#.<?Q2EW>CVX^B+77BM/NU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HBUUXK
M3[M2[<>K,V_]X+)U[AW=D/H,YQ_%*7=Z/;CZ(M=>*T^[4NW'JS-O_>"R=>X=
MW9#Z#.<?Q2EW>CVX^B+77BM/NU+MQZLS;_W@LG7N'=V0^@SG'\4I=WH]N/HB
MUUXK3[M2[<MHX<^O&5->87D=FRFR(V1?(I0U.;44C>FEZM/1I6F]*<9>:TJU
M99%UIU>3FWUI=7[-*<@Z&YE]&Y_HW++VVS^E&E6K5X2@HSA/%*&#VP;PV\9N
M[FJTMG.ELON[?.:<:=6K6C**4XSQ2C@_<MX;>,L9&Z#:H
M
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M]Q+'S-)W]A;3R_MBU"U.G),I_P VZH\E>_M+:3A5G^,2QW8IREAQ[L4Y8=/
MS/(>;?6NI+#RKE=C/R2Y;JKUITK:A.6.#C3K7$Z5.I-/AC3E*2Z*1S6"MI,
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M2;6
M               @S)/G"<?_ +.RWX3S85U^KO\ ")7[OUB<PH$P
M
M                !!G9CY2.E?Y79%^]8.*]/\G/U$2RX43F% F
M                                           CKMK\F[+_ .2*C[[2
M"I2_*+U267N3MV /\!\)_FCQO\#680J>[EZK(K@1EP2$0
M
M
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MFWO*JY?.JJH44L7"+4IX='&7N([.BM_II%L.0N,/PVN&+B=JUVP',\@[6R.
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MS=;V:9N/FM_5[S\.G[$S;B&B3:P
M                                      $&9)\X3C_]G9;\)YL*Z_5W
M^$2OW?K$YA0)@
M                                     "#.S'RD=*_RNR+]ZP<5Z?Y.
M?J(EEPHG,*!,
M   !'7;7Y-V7_P D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617
MC+@D(@
M
M                                   '$2#_ ("]_P!D.7WD<(KA(/@(
MCZ!?)BAO]KS'X4.@JU_RK(0X"9XHDP
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MLZ=P>OFR=,_S.MWXW=QZ-??/+,/E#]A%'2/S;L_S*]EEDXQ R,
M   /,QXWWSJ.W_Y90[]5,"'8G-Q\R;#\W/\ M9G-^M/G/=_AQ^!$JH&;F+
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M]U/RQPC^)<ECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M                                                           0
M9DGSA./_ -G9;\)YL*Z_5W^$2OW?K$YA0)@
M                                                           "
M#.S'RD=*_P KLB_>L'%>G^3GZB)9<*)S"@3
M                           1UVU^3=E_\D5'WVD%2E^47JDLO<G;L ?X
M#X3_ #1XW^!K,(5/=R]5D5P(RX)"(
M
M                                                          !Q
M$@_X"]_V0Y?>1PBN$@^ B/H%\F*&_P!KS'X4.@JU_P JR$. F>*),
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M5[S\.G[$S;B&B3:P
M                           $&9)\X3C_ /9V6_">;"NOU=_A$K]WZQ.8
M4"8
M                            @SLQ\I'2O\KLB_>L'%>G^3GZB)9<*)S"
M@3                                                    1UVU^3
M=E_\D5'WVD%2E^47JDLO<G;L ?X#X3_-'C?X&LPA4]W+U617 C+@D(@
M
M
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MZ?L3-N(:)-K
M                       09DGSA./_ -G9;\)YL*Z_5W^$2OW?K$YA0)@
M
M                       "#.S'RD=*_P KLB_>L'%>G^3GZB)9<*)S"@3
M                                                   1UVU^3=E_
M\D5'WVD%2E^47JDLO<G;L ?X#X3_ #1XW^!K,(5/=R]5D5P(RX)"(
M
M
M                      !Q$@_X"]_V0Y?>1PBN$@^ B/H%\F*&_P!KS'X4
M.@JU_P JR$. F>*),
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M\2Y+'/7/A^M9=^;K>S3-Q\UOZO>?AT_8F;<0T2;6
M                                                    @S)/G"<?
M_L[+?A/-A77ZN_PB5^[]8G,*!,
M                                                   09V8^4CI7
M^5V1?O6#BO3_ "<_41++A1.84"8
M                  ".NVOR;LO_ )(J/OM(*E+\HO5)9>Y.W8 _P'PG^:/&
M_P #680J>[EZK(K@1EP2$0
M
M                                                   #B)!_P%[_
M +(<OO(X17"0? 1'T"^3%#?[7F/PH=!5K_E60AP$SQ1)@
M
M                       @3Q2_FX]VOV;,K?!5>,GT5\[<N^64OA(L6I_F
M]>_)I_!9T[@]?-DZ9_F=;OQN[CT:^^>68?*'["*.D?FW9_F5[++)QB!D8
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M[$S;B&B3:P
M                     $&9)\X3C_\ 9V6_">;"NOU=_A$K]WZQ.84"8
M
M                      @SLQ\I'2O\KLB_>L'%>G^3GZB)9<*)S"@3
M                                                1UVU^3=E_P#)
M%1]]I!4I?E%ZI++W)V[ '^ ^$_S1XW^!K,(5/=R]5D5P(RX)"(
M
M
M                   !Q$@_X"]_V0Y?>1PBN$@^ B/H%\F*&_VO,?A0Z"K7
M_*LA#@)GBB3
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MECGKGP_6LN_-UO9IFX^:W]7O/PZ?L3-N(:)-K
M                                                 09DGSA./_V=
MEOPGFPKK]7?X1*_=^L3F% F
M                                                (,[,?*1TK_*[
M(OWK!Q7I_DY^HB67"B<PH$P
M              $==M?DW9?_ "14??:05*7Y1>J2R]R=NP!_@/A/\T>-_@:S
M"%3W<O59%<",N"0B
M
M                                              <1(/\ @+W_ &0Y
M?>1PBN$@^ B/H%\F*&_VO,?A0Z"K7_*LA#@)GBB3
M
M                  ! GBE_-Q[M?LV96^"J\9/HKYVY=\LI?"18M3_-Z]^3
M3^"SIW!Z^;)TS_,ZW?C=W'HU]\\LP^4/V$4=(_-NS_,KV663C$#(P
M      \S'C??.H[?_EE#OU4P(=B<W'S)L/S<_P"UF<WZT^<]W^''X$2J@9N8
ML               <JQOSY&'=OD$:>76//S0I+6M3VQN*QI=VQ85R]$K;W)
M<G6HE)?+]J87?;?3^2HDJTJ=:FZ5:,9TI+!J2337$T]C)X5)TIJI3DXU$]C3
MP:]1K:B3\QWWW>R%#S\?SG;K9&60M8C-;G*-/^9\@.;4\MYUE2S4#^G5/YE'
M]&877DJ4MJ?9R?R"RV^F--VEPKJVL+.G<)XJ4:4$T^..$>M?36!<ZV>YU<4?
M!Z]W<3HM8-.I)IKB>W;Z^)$L7TM(             ;H?T43_  _W4_+'"/XE
MR6.>N?#]:R[\W6]FF;CYK?U>\_#I^Q,VXAHDVL
M                                                 !!F2?.$X_\
MV=EOPGFPKK]7?X1*_=^L3F% F
M                                                  (,[,?*1TK_
M "NR+]ZP<5Z?Y.?J(EEPHG,*!,
M                 !'7;7Y-V7_R14??:05*7Y1>J2R]R=NP!_@/A/\ -'C?
MX&LPA4]W+U617 C+@D(@
M
M                                                 '$2#_@+W_9#
ME]Y'"*X2#X"(^@7R8H;_ &O,?A0Z"K7_ "K(0X"9XHDP
M
M                      0)XI?S<>[7[-F5O@JO&3Z*^=N7?+*7PD6+4_S>
MO?DT_@LZ=P>OFR=,_P SK=^-W<>C7WSRS#Y0_811TC\V[/\ ,KV663C$#(P
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MI7:U_'IB_OI#T>S_ ,1O.XU.U'EC*?&K;ND.V'GFZ?>E=K7\>F+^^D/1[/\
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M2NUK^/3%_?2'H]G_ (C>=QJ=J/+&4^-6W=(=L//-T^]*[6OX],7]](>CV?\
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ME=K7\>F+^^D/1[/_ !&\[C4[4>6,I\:MNZ0[8>>;I]Z5VM?QZ8O[Z0]'L_\
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ME=K7\>F+^^D/1[/_ !&\[C4[4>6,I\:MNZ0[8>>;I]Z5VM?QZ8O[Z0]'L_\
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M:W?!Z@?A*>B=^G;9;RR!]*.NO'OT-OWH>@FE/%?TM;O@]0/PE/1._3MLMY9
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M>G'"*Q;P7JO:S* \1Z0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
B                                          __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>moa.jpg
<TEXT>
begin 644 moa.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" *(!( # 2(  A$! Q$!_\0
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MIUV1)8/JL+2/ZGJW<CVKTD\&N3!5.>ERO>+<7\O\U9D4W=:A11176:!1110
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MU\2^+?V4-)_9/\;>&?B!X$GV>*?$'AZ"6_AV.?[2GN=\D]QNFD>./<5!V*H
MVX&,U]V_'JPTWP=^S3XNMQIAO-*@TBY$MF)W3?&RMO\ GY8 !F)/8#M7PO\
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M3OPNM[:6L^A_VN=+^T106=V8S]HSYB[&AB;ALG;@Y!.?-/A3\"8OVQ_ .C>
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M\U0V=I7VW9[8IT\SIII=%;IY(VJX64T[;N_5]_\ (^3/@AX+O/B'X4T+X/\
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M7;S7PA ?BI\2-?\ ^%XCQM?:?H.A3PSQ>&K76+N+3[J,D6LRS6O*-_JV= )
M-[9/7%:/P A^,GBOP#\4_'-WXEN]0GOM;N;;P]I<&HWTL=G:O=6<T?[DY*.L
M32K^[;: <#C)K)Y<U#F<DK?GV-/KD'-06M]3[#F\<VL?CV'P^5E-U-:RW:N
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MJ,;R7]7L?2/A/XK7?B;XHZGX=D\/:Y8VVGPRRIJ-Q8-%:7&R81A4EW$,6!W
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M\/\ 4M%UOQ%=ZO-J.C7FFF\DOVN)UDF?*2!WA!!520&P2,# -?07@#XCZ?\
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MX=_\*-L;K7_^$IM/#FOWS1MI&JWVI?8],L3&T22BZFVJZ!U<(NP_,S8/!K[
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MLMPVO.KWK/+Y?EX);[5'EBV3Y8S]T9PK8BAS\KM;5_/H*C2Q"@W]K1?)[O\
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M!(EC3;"(8Q$N\2W+$-G)$9XPU=SK865GHGKZ=+_AL<GL\3&2WY>O?RM\SG=
M^/'Q$U#XD6EXDFGV&CZ?K5U;W2!KF*VNI1;3CRB-^UF&Y'VG!_=AOX17E'PF
M_:OUGXPW7C.35O$,NKV_C+0IX(]&-^]PFB.BBW\SR&D80!PY8M\V[.?:O>;'
M]C#Q[INKVNC_ -KZ1+X8N]:GU2_N'NK@ZC&S6\J*T3>5Y88N(@Q8<JT@SDBN
M=^&G[!?C+0/&?BFPN-%^%ND^'UTIK?1]2TBSG@U:ZFD5&87,IB",BONV[!D
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M GQ"^,?Q"\-)X=N?#2^&2\ZZH^H27(O;-2D.PVI1&1&+*^[=U&W'.:[;X>_
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MQ#\3^*;;6=#UZ.*\M8CJ=_<2:9)=7-NR1J)"B11J@90H8D;\ D$UV7_!,_\
M:&U?Q3J^L>#M6\1W/C1M-\GR]6?4'U$-O6YF.9F<YZ!/NC[F.V:I:9^R7\<?
MB=X<UCPY\0=3\$W_ (:TZ%=/T:RBN=0ECO$@FA\B:[CGC*/)Y8D)9 !O5,
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MG5W0^%&97HHHKA- HHHH **** "BBB@ HHHH ***0G:.: %HH!R** "BBB@
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M7+G6_P#6I\O_  :_9,\6?#[P-XET_4+NRO+[4]-EM4G$LTAD9A)MW,T8) W
M=#TKFG^$?QR^#WB_2_#?@AO#C^&_$]BESJ]_>'4#<:;=QB1ML,D*JD:-A%PX
M+$9'I7V+NHW&J>9U'+FDD[F?U*'*EVO9^NY\-7G[$_BBW_: U_3++P=\/#X?
M;3UNK;Q'-I,O]K2S[84\MKH1;"%PQ50,C8OI7UU\#?"%YX ^$FB:-?M&]W81
M/'(4+%?OL1C< >A':NKW'%&:RKXV=6*@RZ>%A3GSQWV"BBBN(Z0HHHH ****
M "BBB@ HHHH POB?IIU?X<ZS"F?-%J\L6.N]!O7'XJ.E4_@WXC_X2+P#:ASF
M?3U2RFR>=Z1INSR3U/?'TKJ)(5N(VC<920%6!'4'@UYI\,O,\(_%W6M ?*P7
M_P!HU2$<@?-*J@#H.BGH/QKAK-T\3"ITE[OZHREI),],HHHKN-0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;+"MU"\3C*2J48$=
M0>#7%?"G6!:>)/$?A]B$_LR[+P*>,K*\LO SV!'0#\>M=O7E_C9C\/?C5IFL
M_=L]7\W[41P/W<"HF>@ZMW)KBQD_9.G6Z)V?I+3\[,RJ:-2/4**5AAC25VFH
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 % .#110!PUK8IX+^-MU,=L=OXCM@JCH#)%Y"*.PS\[>I^E=R1@U
MP/Q]26RLO#^K0YW:5J:23$9XAP7?..W[L=2!ZUVFAZHNMZ'97B$%;NWCFX_V
ME#?UKCP[4:M2BN]U\]_QN9PT;B6J***[#0**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HILLJ01EY'6-!U9C@#\:\?^)O[4
M&GZ;XS3PG9F6*\U(^5;W[;5MF;8KX6029+?-M&%/S$"KC%RV$W8]5_X2.Q_M
M067VNW-R06V"5<C&<\9SV-72,5X-IQN;#5OM,DMP]T02978DG/7:>N.M>H>"
M/'0U8&&Y90X VL3UR>^3]*TG1:5T9QJINS.IHH!R/Y'UHK U"BBB@ HHHH F
MB_U8IU-B_P!6*=7=#X49E>BBBN$T"BBB@ HHI5^\/K3 KOJUI'J26375NM](
MGF);&4"5TY^8+U(X//L:DN+J*R0-/+'"I.T%V"@GTYKYO^)?QWMM$_;2T^SA
MU#=?6VBR11Z3Y!'VDK+.#)YQ3"X ;C_8]ZS]*_:$\>>(]-TB7Q-X?_LL0+-/
M?V_VZWGP5D4)\T:#_EGN/R_WN>17S[XCPB<X-ZQ;6SMIUO\ ?]Q]9#A#&3A3
MJ*UI13U:3UOLG9O;=:7:5SZC0^:@9?F5AD$<@BFW$JVD#RRLL44:EW=SM5%'
M)))Z 5\K>)?VW?$O@#2IDU#0OL/G3,^DG[;%+]JL\J(W^6([>,\/\WK7H7PC
M^-6O_&[Q_P")]'O]'_L_PM<Z;C3+[[7'+]I8A(Y1Y:JLB[69OO'G'%=.'SW
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M**7 ]:.#W_2@!**7 ]:,#UH RO&NA+XE\(ZE9E0S3VLJQY&<,4901P?6N9^
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MP@_="3/\('_+0R=>?PQ7UI7S_P#\$N]'?0_V(_"<4@PSS7SD9Z?Z9,/7VKZ
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M (S7E]%?1_5*/\B^X^L_U#R#_H&7WR_^2/4/^'A?QO\ ^AB_\D+#_P",T?\
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MZO\ 20?V;A^S^]_YGAW_  R1K_\ T/O_ )1(_P#XY1_PR1K_ /T/O_E$C_\
MCE>Y>4WI2&,BCV]7^D']FX?L_O?^9X=_PR1K_P#T/O\ Y1(__CE'_#)&O_\
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M*;BLZ\U38OUK*53H:1IV*_@;Q/J%J]QX<UM]VJ:5M2QDVJ/MMK\R(^$&U/\
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MY:7,4S;%?=$UI<*PPQ']X=#FN=7E))D6LCT5/B?X88L!JO\ JV*-_HTO!'_
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MCSY9A(N"TK?(%/S8SP#4_P"SI^P!\1?AYJ^F6?B_XE?\)/X7\.:A-=:58?\
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MK<]2.3R5YZQI=_R/D.+,3&7LLMYFO:7E+E=G[.-E+7I=R6O8Z+P%X<^)=O\
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M\<^(O^"G.N^/-6TV_P#[(\'>#--6\T(^1%<?:;IX2"/F$,JXDMY?]8&4[NF
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MQ<(Q=GB__)9?Y']4PR?.IQ4Z> JN+U3M'5/9_$>)?;H?[_\ XZ:3[9!_?_\
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M 2TU-$ZG,W&_K["J.J'<PSZ?XT^)^146H]12W#9%:K.DQ+<7GEO]R0$'^?\
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MY.(U?<& _<XQ\U<T;.27=I?>KFGM4X\R[7/M#8:"N*_,;Q;_ ,%%_C1JFO\
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MH'[(_P"VOX0^%6IIXFB?7VTTR7%O96;V$:75R\69)995=0 N6(7@#(K\TO\
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M61#EI V=HP%;&,8/J6:6*X>V??&S(XZ%3@UJG9W _/3_ (*%_M Q?$']J?\
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M\&RXZU%,I84[S.*1SQ7+*#:.F+L5VCSQ36M<=JL8YIRIA?6H]D[&RJ,^>?\
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M[B2P&03Y9P*[K]IK]H.#1+X_#7P;H4'B"\5TCEU5[(7=O9(_E3LQFB?*91I
M"4QE,= 37M58KWN=VDK?<?T55QK<:<(0OS7O_A5DW?YH\K:#4]3^&4)U>+.M
MC3[>/[0ZO_I&&C+,[-\[.3O)/?KZUU?PE^%LW@GP-''//:B[M@TTA=S\VUW8
M9RH/1A7?^&?#WV;P9I\FKZ?:W0^SQ;SY&\ E!P-PZ9_G7F_[2_Q.L?%.G^&=
M.\+:C;6-[J^I"VU%HKA8OLUNWR$DQL2OW@06!'!-$L)!15:4M"H3>D%\.UT:
MGC2ZNO WP(\>>+)A)'9BU@M=ZY$;.^H6;?*3@=#_ 'NE;?\ P0-\)#0/V"M'
MU09']L/+][J?*O\ 4%]!Z^IK!_X*0RGX=?\ !*A=+L9OM%[J=YI5MY\;[GNF
M58Y&;<,%\B$MG!SU^GU;^R/\$K+]G3]FGPSX2L8?)BTXW1VE%4_/=32\X5/^
M>I_A']:Y922PC7\TOP2_X)^'<28KZQF,II:+3[CT@S[6SQ3_ #..M0<$>]"M
M7FV/$+$K9MO\^M80:MEWS:'_ #WK$S@FM*9,R57R*EMSUJLC8-6;8Y%7+8E$
MM%%!&[I6)1S?QQ\8I\._@OKNI,_EL]I.B$MC)$,I]1_=]:_*_7-<E\2^*=7U
M"9B[7E[+*I))^5G+#J3_ 'CWK[J_X*H^/#X6^$6BZ+;RE)=1O989%5L$J86'
M8C_GH.QKX)M8_)MT7N% /N<5]_X?9>G*OCY=6H1^6_XZ'Y?QOC.?$QPZ^RK_
M 'DE%%%?II\.%%%% !1110 5]7_\$<_^2C_$/_KQL_\ T*2OE"OJ_P#X(Y?\
ME)^(7_7C9_\ H4E?-\6_\BJK\OS1[W#/_(TH^K_])9]1_'3]JC2_@1XYT'0[
MZSO;F77()9UDAA1TA"#^(F1<9P<<'-?*&C?\' /@;Q=I-BVC^$_&5W?ZII4V
MI6MLNEV\CNR7$MNL>U;LDLSQ\*,Y##G)Q6O_ ,%-]'\:ZI\;]+\1^']&O=0T
M+P?HR+>Q16D\LUW)<7$\2B%4&Q]N%9MQ4A2#SG%?F7\.OV>_&_@F%9+[P)\0
M=-LK32IK5;O3]$N(;RSB,S2L\+E $D4EV4] <'U-?@F%Q,IUJM)_9U7H?TEG
MF4X?"Y;@L51=Y5(OF5[^]>ZNNGNV^\_8'X;?\%)['7_ L.H^(?"_B+P]J4\$
M5Q%I][IJVEQ,LGS#;$\Y8X0HQP> P/0BLJP_X*Q>&Y/BEK?AFZ\.>)[630K&
M>YGGDT^)(C+#-Y30AC<?ZSJ=I .!VKY3T?X/>(OC1\,O!NJ>'/\ A9MR_@W2
MH8%DUSS7O=4:6&.)_/,:MYIC,;A>5V@#.>16;\8_!GC#Q!X/O?&.C^"/$2:O
MXM^)CV4D!T><21:?<H\QD=5!81!B 3N* ]B>:,)B*U3$5(36B;2]+VO_ %V\
MR,[R["8;+<%B<-*\ZB?/_==DTOFM?PZ'VO\ L_?\%-/#OQ[\7>&]%M]"\0:=
M>>(Y)HXUO+**'R3&')W@3L1D)QP>HK;\1_M_Z#H/@#XC:]_9>KS1_#C6I=%N
MXDMHV>>2.Z@MBT8\X;EW3J<DJ< \<8/QOX<N;O\ 9?\ VJO"VNZGX*\7SZ!I
M]Z(M^G:.6$9GB6$'+;$ $DP).>@;J>#E>*_C"_BGPO\ ''P%:>!_B-#K7C[7
MKKQ'I5Q_8VVW>V?4[24 L&+%RL#GY59<?Q8SC15*DH.:[/\ !)H^1I5)->_W
M_"Y]+>%O^"K4UIX2\*ZIXO\ A[XS\-CQAK<&BV,5WH)LW#222HTC"6X^XNQ2
M2I;&]>.:;XH_X+'>%/".K^+H+KPSXK\GPK$TAE73H=EV1>Q6H$;&Y <GS=^.
M/E4GM@_,O[9/[+'Q2^$_P_\ A'X>\-7_ (P^(,G@V[U#Q)JUYK\]WJTIBMYX
M95BA>.-?WSBX8*KA0WE8W#;DLLOV?O$WQA\ ^#;U_".LVE[XP\5/INK0W.E2
MI]GM1I-U?^9(NQBJ?:88DW/N7>RC&XAAWOWJO+';;]+_ )A[1P<;]4W^J7W6
M/U5\*:W_ ,)/H%O?&":V\_=F.9-CIABO(R<=,]>]?.6O_P#!3KP]X=^*7C7P
MY-H'B,P>"Y8[>XU);&+[$TIN+F!D$IG W P*2"%($J?WL#TD?M8Z!:W\5C#H
M/B=6D<1ILL8Q&"V/23ID\\>M?GA^U#I'BWXL?'/XEZ!X2\$>,M)T+Q!]GGU>
M^ET:: M*M_>RQS6DD09,R%<2.X)9/+ ]:PJMWYJ6VO\ P#>Z5-N3U5OSU/TA
M^ O[0NG?M#6^LWVBV]U_8^FWILH+UXU\F](@@D9HI$=E=0TS(2",-&XQ\O.I
M\=O^22:O_P!L?_1R5\^?\$C?A_K/[.OP-UGX1^(4URXU+P/K=P(]4U!7<ZI#
M/!:W@D\YPC2[6NVBSL4#R"O.S)^@_CM_R235_P#MC_Z.2NA)*<>7LOR,J]_9
MSOYEK0#CX2Z/_P!@N'_T2*Q(>V*V] _Y)+I'_8+A_P#1(K%C& *TANQP^%>A
MG?$/6W\.>"+N\0G>I1$QU)+KGN.V:N_#W0!X6\)6EIC$D>\N<=?G8CL/6LKQ
MI&FOZMI>A'!%Q)]IE7_8$<N,]?X@O45U;3!I6(&!V%>?&//BYU>D4HKUW?Z%
M0UG<MVUZ;699!U%?"'[;OP,O_@3\0-?O_#K06/ASXE6XTV1;<M%(9([:.)4P
MB*GS;YSC+$X''WA7W*T@"U\>_P#!5.37_'?QC^$'@70)O)>ZUB69BSR*NX/9
M(A.S/ -P?X?I[_:\'3E_:2A>T6I<U^R5_P TCP.+:?/@&XJ\DX\OJVE^5SZ*
M_9MT.#PS^SAX'L[<Y,.C6:W&2-PF%K"&W8 YX&<\UV:2X%>"_L0>)==\,7GB
M;X=>-)5&NV%\'TPLTF)K;:Z93S2'9?\ 17/RIMY^N/<P_/->5FV'='%S@W?J
MGW3UN>CE>)=?"PG)6>S79K0L_:.:4W !JMNH:3 ZUYW*>A<LBZR::UQDU6\[
M::;YQ,E'*',3M)Q56>2E:?!_QJG>W.T]:TC$ALP_B=X;7QK\)_&NCL!(=2\/
M7UNBD9!9X&0=C_>]#7YE:79^.X_A9KGPAEA>TN-9\4:A'I%K$EQ')/;VHM'$
MFSJRE83AD0@[6Z <?HO\=?B))\/-&TRU@>%=1\3SM8QASCRD(VLQP0PY>/GD
M>W2O*/V?/ 2ZO^T;/XC\2V=K)J.A!K?2=L.8V#K=+++^\&[<ZLN60C.T9Z5]
MUD&(G@\OJUYQ33UCZK2_WGQ6<^SQ68T<+%ZI^]Z-7M\T>WR:'!X66/3;7;]G
MLUVIMQCYB7/0 =6/:HRV*6:1V?+'<QZDG.:C8X/UKX[5ZR/J7Y$]I,D<^'42
M12_NY4(R)$/52.A!'8U\?7OPIB^ ?[1_AOPS-X@6^TI-6M+JVMI;X2K L+0W
M,FY"JJN2<C YQDXZU]=V8\V_@7LTBC]:^"M:\+ZQ^T;^WIXRM8]8GM9=#M$N
M+=1=NA@;^R&EZ8<J&,(SC&0?Q'U_"-+FEB)3E:$87?WI+[KGRG%',XT/9+W^
M?3Y)M_?8_0RRU%+UXYX65K>:,/&5.5VGD8QQTK5@N=K5X'^R%\6IO$V@7OA?
M4&+ZKX9E>S9W)+3+ (8BP+,6(+$G.!]!TKVN&<[NM?*YC@I8:O*C/I^1]+E^
M+6)H1K+K^?4W;:XW5M:3-O4_2N8LKG(_I6_HTV%_G^=>74CH>G!FINYI2>*8
MIWG_  H)POXU@;)C@V:<IP:C'&,?C3D)=P/4XIV*N>6?MZ_#JX^+7['7CK0;
M&7[-J-Y9)]BGW%#%,DT<B,&"LP.Y%Y49].:^3_V'=$U;QE^U)X"T75+W4-9L
MOAMX5VW]S<3/<6ZWT,,EB\0=@1N'VC=M8*V#DX^Z?8?VD_VC4^)?Q;F^%^@:
MQ#;7?D2@B"[V33L;5+E"NQR6V[23\G SCUK5_8/\%6G@;1/$MNT,<FM-J5PU
MY>L@,TC?Z.'!DP&(+KNP>_)YK[_#JME^13IU5K/WDNJ4E:_S2/@Y5J.89W"=
M)Z4[J_1N+O;Y-GT(UX9G+'O5C3)0UV!WP>G2J&[MS5K1_P#C^'^Z:^!LK'W3
M-A.#].:^!/VL]<F^(?[1=U !*/[)\VU1@#@@33]\GT]NM?=GB;5%T7PY?W;L
M$%O;R29)QT4G^E?(?B70+77?B+)J@A1FO9))M^P'=N+MUP?[WKWKYGB*K:@H
M?/[CWLAJPH2J8F>T49DW@*35?#,]I N19122-@>Q.>!_M"O+_"W@NV\#ZIJE
MXR;[V[F+&7 +1X9Q@' (X;'X5[9XKUX^ 7O[""1)I;J(J[AMP = .H(]!VKR
M75[LAI,X)=BQSZYS7R/LN6FHO?J?6993G[*+EON_5ZLP]1O=C/G&237.ZDFX
M-UZ5=U:\W.>>A_/K6?).)5.>]<<SWS(NM)-PW3@TMCI?V:7&.E:+2+$PSR ,
M4N]3\WK2AN5?0=9KM/>G75_A:@DN/*'!J*8[U%;=-#(D6Z+GVJS =S51 Q3[
MW4O["\.WUZ5WFU@DE (SN*J6 [>E0J<I22(G-03D^AVG@GX8G71_:>KF2VT1
M.FWY)+G.Y?DW*4;#@9YX!]:Z37=7-S*))=N5&VWMU_U5LG.T!?X67IQT%?/G
MP3_:OU*Z\5/I>L,KZ4TK_9XG+%(%_>-C#2;5YV]!U%>P:YKD>E%][B64Y*C(
M;/7'?U%?JN3Y?2PE"T?B>[_KH?C/$&9UL9B/?TBMD0:[JJZ; TCE7<*<*>>?
M<5Y)X]\0W/A_Q=HWB<*4%C=O'O (P&@G7&<C^_ZUU?BSQ)9^%M!NM:\07L=I
M8V<9E<23+&T@'&U=Y ))P,9ZL/6OE?XP?M*>(?C+XML;71-'FTGP)873>9=W
M5I+!+?R(DZH8W1VBD5@\3#/)VL1T%=E?6)Y^$C:HF?<7B?QY!J.OZK;0G;]A
M$>X9 SO0'L?:O-_'GQ)@T*V8O)OD+ +$C N_)Z#<,]#^1K,\8ZO>W'Q)O-+\
M.PRZSKFOO#;VUO9HUP5DV* 76,[\?,3P"<*3VKZI_8N_X)DS6.IVWC#XG^5J
M5W- S0Z1)F:VA\V-"/,@N(,AT+RCAN, >M>)3C*IHCZ23C35V>(?L]_L ZE^
MV9XNT[Q3XGT?4-#CT52;>:^M&MIF5YHQ((VDADR?]&4\$=%S[?H/\!?V5/!W
M[/6C"'1]*M)+Y]KS7LUM ;AG";"?,6-2<_-U_O'UKT'3=*M-$LUM[&UMK*W3
M.V*"(1H,DD\#CJ2?Q-3UZ$*:@K+4X9U7+R'*Y+CZU_+/_P %G;:70O\ @L?\
M;8'MIF?4-8AEM@(R?-'V&%VQTS@-SC-?U+I]\?6OQ$_X*(?"/PKXH_X*3?$?
M5=8T:TN]2M+Z$P226D,A.^RC5LEE+?="XP>U>YD^;QR^HZTU=--'GXS+7C:?
MLD[6:9S&F+Y-TG8@ ,/0Y%>]_!8";4;96Q@R#KTZM7@UF"UR&.<L^3^)KV_X
M-7(75;7)X\U<\^[5\@OC3/HZOPGZ6?LRW*M\-;:)<?NU0?+TXBB%>B5Y+^R9
MJ2W/@L0J<X&[W^Y$*]:KV&>+$****DH**** "BBB@ HHHH FB_U8IU-B_P!6
M*=7=#X49E>BBBN$T"BB@=: .8U3XT>%-%\:0^'KKQ!H\&M7"JT=G)?0K,VYS
M&,(6W'YP1TZ\=:Z97#IN!!7KN!XKXM^/FEV7A?\ :&U/5(;SPYJ4US!+$'DE
M6;5M,G:YD;,1&#$D9'R\Y5S65HOQ0\;>#OANNHWOC.+4(([B 6WE:O/*]P#<
MA9 V6 8?-C /3.:^P_U756C"I0GO;?JWV]#[W_4OVV'IUL-4UERZ-;M]O3S/
MN&PU*#5!*;>191!(8GVL&VL.H.._-(NL6;ZF;(75N;U4,C6XE7S548Y*YSCY
MEY_VAZU\I_#KXK^*]5^,'A_4(=0T^#P\;9VOK))YE>ZG,4OSF,-L8Y:,DL<_
M)["O:[#PLFE_M17>K?;;V5]2TJ6/[*\VZ"$*;(95,<'@<Y/4^M>9C<E>%J.G
M5E]EM6[KH>/F'#LL%5=*M+[#DK=UT?YGSM_P7(\ _$_XD_LE3:3\,6U%+VXV
M_:FL3=B<;;RR=-OV<$]%ESD=,X[U^2OQ"M85T=9Y_M1U&V21&FFQYA5AN.6/
MS?P)^0]J_>7]M#XTV?P2^!FJ:A-<6,=[(8OLL-S(H\_%Q"KX4LI; ?/!XXS7
M\^&H_%F[^)?ARY%[IATRZLW5GS;&'SE97SU8EL!5_.ON. *J]E*E*/6Z9^6^
M(F69K4R%YMA*G)1P]XS7\ZJN*_#0R9?BQJNA^!-0\.6LTD=IJMP+ARKN-Y4H
M1G# '[@[&LCX;:?9>)O'B:=<R+Y%K +QX]RYE42*"H!R"2&/&.?6M;0O"'GS
M)J5SY<D,>0EMU9U(X(4C!^\._P##[5Y'XP\82>'/B;/JND2M D*QHJ[BH90%
M<J0I&02.F:\#C[,W@ZL*OV'-<R^7^1^H^#/"^+QF58:OFGP4HM4T_P"5OF_,
M[[XB^(+>V^(-SI]M<3M81R&.WMYI!BV"J,@*#A>1V'84:'J$FD:FOE$!&ZCL
M1D?X5YUI=AJ_Q2\0W.H6I'VR9_,*_/M!8'. ,GH#WKTWP9X3D\5:8EQYZP2I
MA?+9]KD@ ],'UK@X(S^57,:CLU3FWRW[?\ [/&KP^KXW#PKY?&]7I;=6\SN[
MJ]NM>^&;Z-IZQR-K3)970<$@123!')VYX$;.>01QR,9K]O/^"1/P?L?@G^Q;
MH.EV.H1WPNTM[Z58YUE%M(UC:*8QA5V[=@^4C(SUK\//A%<,;T+\Q.0#CHN=
MV/I7W;_P0:U3XOZ_^UAXD75O% NOAGIMKJ*PZ7)J5Z\B3+);)"5A;, 54=1D
M8(P<<5]]QK@N?!>V3ZW_  /P[PNSJOC<OED^D88:+D^\W*3_ "V/U ^+OP!\
M*?&_PW=Z=KVBZ=<B[C>,SM9PO,FZ,QY#.C8(!XX[#TK\W?VJ/^",%Y_PN'1]
M$\$_:GT#Q MS<75Q+N*V+*2Z+NAMMD8("@ @YZ"OU4)R:0H"X;:-PZ-CD5^;
MY3Q#C,OE>C+3MT/?SOA; 9HE]8CKIJMS\ROAG_P05?4H-5C\6:ZRI+"([1K*
M]PZ%MP8DRVG'\/2OMK]E+]C/PA^R?X*L=/T6PMGU&W@ABFU&2"$W4YCA$66E
M2)&;^,\CJ[>IKUS.:*,SXDQ^.CR5YZ=AY1PMEV6M2PT/>77=A1117A'T(444
M4 %%%% !2J,L*2J7B/51H7AS4+UF"_9;:249.,E5+>WI0VDKL3=E<X'7IX_%
M'Q8DNA\T>@0" =,!V:=6]><!?0U;W^_ZU@?#LR3Z9JE_+DOJ]_)<J3_SS.UE
M_#YCW(K9#9<4\KBW051[R;?^7X6,8O2Y8#\5#J!XJ:.H+Y>*]&UAMZ&:TO-.
MBE^;K4<HYIJG!K4Q,3X^> X_BI^SSX_T%XUE>_\ #U^D*E<_O6MI8UP,-S\_
M89KY._X)7_$'_A$OV=?B?HNJ,[3_  W\6-IHB<Y9(]L%LO#$$#,+=E'!X[#[
M9L+H1S$.-T3C9(IY#*>HQWKY"OO!VB?L;_MVR:;?LK>"OCS]HUN]\PQF"VN;
M=KVX*G<(XEYGMQAA(W Y'RD]%&SA*G\_N._ 584\1"I55XIJZ\CD;K6IO"7Q
M>\1>(M)\N]T_4--.]%S)$4B2$,%"D#D@YYY-9G@GQ+:V-_J&HM;+:17TQOY(
MA&(SNEW9.,_3OVZFO6OB%^RWJ'@#QG::1HIFN](F<13RW&Z1HXF\LODI&% .
MYNHQ\O/2N,^*WPXBT/QK;:5;QJPEL(T"PJ,NR/+N. HSP!VIJGS0<X[']#9;
MBJ6)@I4)?$OP7?T/+O@/\ ](\8?$WQ#\0;N[O([U[-K=M-,J"SC\M;<B01%"
M0Y"#YMW0GUK;O-/O[O7X]/\ #5AL2WFGD'EP,#.TA,CG]W][#%ST[\]ZL:EH
M'B30=)B>RTVYTEM?D\JXB:WE@-LK9B)*@#;Q&K<YX.>]=WX&U9O UM;1PVL$
MNL6L**);B+<)V*?.P(PS<$\_3-7*FVDI.SZG;1P,(05:@DV]?F6(?"VL^,]]
MUK6HBV2T!Q#)<.@^7G&UP?4C\*E\+:CI-M.]W;I;M<WJ,+F9U0SL%5E7+#D\
M$@9[5<M_$FI3:*3K=A!#;/%YCRP0,KE2O+;G..FXYK&\0?LYW&E_&'PH-/\
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M_9UUR#T_@I/^&?\ XA?]"U?_ /@NN?\ XBK^O8;I47WD_4L0M'!_<<Q7U?\
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M41MM*Y&!P=I(SZ'%<5_PU%X(_P"@S9_^!=O_ /'*/^&HO!'_ $&;/_P+M_\
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M ("O\CW_ .,'QK\<6A\(^3XDU2$3>'+.639J%PN]R'RQPW)/K7)?\+T\>_\
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M[@#WIQJ.4G",M5YBJ9>J<(U9T[1EL[;G?_\ #/\ X*_Z%C0?_!;!_P#$4?\
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M)KJV'CRS=N5$,HQZ_NQ[U]PMUKU*7\-,\6II-H2BBBK)"BBB@ HHHH ****
M)HO]6*=38O\ 5BG5W0^%&97HHHKA- HHHH **** "BBB@#C/V@_A?-\9O@_J
M_ANWNY+*;4?)VS)*8RFR:.0_,%8C(3'0]:_#G]H[X'ZY\,O'NGZ#J%S'=7OA
M=FN)%CDD=9BXAF4G<H)P#CH,;B.^:_?N-MK5^+?_  4P_8\^)?P0U?Q!XIO]
M9&IIXJG@L["Y:[NIFMO+LBLFYS&NW+*I&TG(3D<"ON>"L>J=2IAIO22T7FOZ
M9Y>8Y?/$5*-6G4C!QDTW+;DG&TG\K)KS/B_XWZY<ZUK<<T=LB20P""15C(4L
MKMSC/^T>M9=A=3V@@E2TBF>>,VR 1%MI+D@>Q_QKN_$W@XZ9\*],U:XE@GO;
M<>5J"LVYY7VP#<H(R06=SECGCUS6,D-MX*ATU8R;]Y-1CN9-Q$OE1CY3Z8^Y
MGT^;WK[3,L+2Q=-04=8Z?J>APJL;DF(K8O&X_G56,73MM*+GRMI=URZV,2U\
M+V@B2:X^SPW0DE:ZA?"L"S';A2,].>:?\,O&&H>+/B!IW]O.SZ5I\T1126((
M21<<.2OW2U-^(=FVO>-Y]2MG:&VGVXBC.T-B-5.5&1U!/6NGT#0=-GOY)(_]
M$CTXF":.7;&[LA&YP,<@^IQTK;+<GPV#HQBU9R7]?F>!Q1QIGV<9E4I9)#FA
M@)\LE_/>3LVO+E9TEO>V5W/>7^AVL]B-@:>!HEBWX4A %3KT/4]Z_9G_ ()*
MZ%/H_P"R#82W-M);2:C/'> 21E"ZO96IW#(Y!P>>>G6OQ[\">!?%'C/PQ%HF
MB:/'?>,KZ:.&2VL[265H=TW#.B R@>5N;..BD]!7[K?L>^"[_P"'_P"RWX T
MK588[?5;3P]IT=Y&B,FR9;2)) 0P# AE/49]:^>XPQ,(992PWVF[^=EL&.P-
M;$<9X[,^:])<JCKHY.$7)Q\NAZ11117Y:?1A1110 4444 %%%% !1110 CSI
M:QF21@J+U). .U>2?!^>;7[[5?$4V[.K"%$)ST0,C8SG^Z.YKI_CWXH;PYX
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M2X&/?I4L\_[PY//UJM<7/[NG/4]%&/J/R!@?>LNZA\VV8CT[5H:O-O8>F/\
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M<8 Y- 'G?Q/T\>*OBOX?L&.^UL[>66X7JO[P,%R.1UB[C_ZW022^;+N-<_\
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MTUY!M5TSGN3_ (5@FKFE]##C.:FC/-3Q>$+M&R98_P#OH_X5,GABX4_ZR/\
M[Z/^%7S1)CIN0QFK5L<+3DT"9?XT_,_X5*FCRJOWU_,_X5+:*OH1]<U#$NZ0
M]:NIIDB+]Y<_6FQ:1+'_ !)^9_PJ;A?08J[5JK?H9'4#J?\ Z]:']FR_WE_,
MU3UR[B\*Z5-J-V5\JW SR/XF"CKCU]:7M(P]Z6R%=6U/@7_@M9\8[:ST[PAX
M8@G+-_:4DUPL3@_((8_O -TQ-W'_ -?X;C\664<:KE\* !]WC]:_7WPU^RCX
M2^.WARTUWQIHMIJVHS;]IN[.&<QX8IQYL;,,K&G?L/05?_X=X?"+_H3]$_\
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M\$>E<?\ \)?IW_/Q'_W\7_&OU-D_X)^?"V=E,OAVRFV+L3S+"T;RU'11^YX
M]*3_ (=\?"C_ *%?3/\ P6V?_P 9K^O\BXKH9=EU# <G-[.*C?O;J?Q3GW#>
M-S+,J^8:1]K-RMVN[V/RS_X2_3O^?B/_ +^+_C7U3_P2$^(>@Z)X^\?S:AK.
MEZ='+9V:H;N[CAWG=)G&X\X_K7U'_P .^/A1_P!"OIG_ (+;/_XS1!_P3_\
MAOIT[R:?ISZ2THVR?8;>U@\P=MVV'G']36F;<74,;A)8;DM>VM^SN<^6<*XW
M"8J&)O%\O3Y6_4]%_P"%U>"O^AP\+_\ @U@_^*H_X75X*_Z'#PO_ .#6#_XJ
MO/O^&%/!/_/?6O\ ON#_ .-4?\,*>"?^>^M?]]P?_&J^)Y,/W/M?:8[^1?>>
M@_\ "ZO!7_0X>%__  :P?_%4?\+J\%?]#AX7_P#!K!_\57GW_#"G@G_GOK7_
M 'W!_P#&J/\ AA3P3_SWUK_ON#_XU1R8?N'M,=_(OO/0?^%U>"O^AP\+_P#@
MU@_^*H_X75X*_P"AP\+_ /@U@_\ BJ\^_P"&%/!/_/?6O^^X/_C5'_#"G@G_
M )[ZU_WW!_\ &J.3#]P]ICOY%]YZ#_PNKP5_T.'A?_P:P?\ Q5'_  NKP5_T
M.'A?_P &L'_Q5>??\,*>"?\ GOK7_?<'_P :H_X84\$_\]]:_P"^X/\ XU1R
M8?N'M,=_(OO/0?\ A=7@K_H</"__ (-8/_BJ/^%U>"O^AP\+_P#@U@_^*KS[
M_AA3P3_SWUK_ +[@_P#C5'_#"G@G_GOK7_?<'_QJCDP_</:8[^1?>>@_\+J\
M%?\ 0X>%_P#P:P?_ !5<M\;/B_X/OOA=JD47BWPP[OY. -4@/29#V:L?_AA3
MP3_SWUK_ +[@_P#C517O[ W@;4K1X)9M:\M\;@7M\<'/_/'VJHK#J2:9%26-
ME!QY%KYEBV7_ (3+Q-X0TU#YUII>D66HO@[E#QOM/J,X/H#[UZ=@]3WZUQ/[
M/N@B2QU+4L'!FEL[1G'/V?$;)CCI]#CT%>@'3V+=1CZUXF7^]&5>6\W?Y=#T
M,.K1(5'%8GC!-UNGU/\ *NC%B1W%9^N>')=40!&1<>I([?2O2A))W9M+56.+
M6++#CM4P7)Z?D*VA\/KL'_6Q?]]'_"GIX!N4'^MC_P"^C_A75[6/<QY68NS'
M:E6+BMH^ [K/^MC_ .^C_A3AX'N-F/,CS_O'_"E[6/<.5F \>3T[^E4O'WPU
M\)?&GPG+H?C?PSH?B?3)8S&$U+3H;TQ91DRHF5E!"N^..-Q]376)X'N%ZRQ_
M]]'_  I4\%7"]9(O^^C_ (4O:QZ,.6^AY+X!_8O^%WPOL8+/3=%$UG;L62WG
ML[1HOO%L%5B P68YKTJTB@TZRBM=/MH-.LK=0D<%M&(8U &!\J\=,#\!6F/!
MTV/OQ?\ ?1_PIZ^$IE_CC_[Z/^%77QM2L[U9M^IG2PU*E?V<4KE!KB6?[\DC
M8Z!F)IT:9ZUH)X6E!Y=/^^C_ (5*GAQU/+)^?_UJYW-6L="1Y[X[^64?7^@K
MGXV)KT#Q;\,+_76!@G@7GG<[#L!V4UCQ_!'5D'_'U:_]_'_^)KNI5Z:C9LY:
ME.3E=&%"<KFK,#X6MN/X-:FJ\W-O^$C_ /Q-3Q?"/44ZSV__ 'VW_P 32=:G
MW$J<C*3[M6X.*U(?A=? <SP_]]M_\35A/AQ>(V?.A_[[;_XFLO:P[FBBT4;,
M\U=3K5J'P+=1'F6+_OH_X597PE.#_K(_^^C_ (5G*I$T29GU7UFPTWQ18"TU
MW2=-UVT#;EAO[5;I4;!!(5\@'!(K:_X16;^_'_WT?\*:?",W_/2/_OH_X5,:
MB'8QM$\/:#X9 &D^'="TU1T%O81P[>,<;0.W%7PS3MOD9F8]R<U;3PI,O\<?
M_?1_PJ5?#<H'WT_[Z/\ A2G4YG=L<(J*LD58EJ:V^8CZU870)5'WT_,_X5)#
MHKQMDLOY_P#UJR;1HF)MRA]ZHRC]\1[UK"P;9C(S59]"D9R=R_F?\*$T.Y5B
M^^*\\_;!UVV\/? >YFN&566\@:,$@9)..Y';=TKT^'1) XRR_F?\*\#_ &O?
MAIK'[3EI/X*\.WT5E<6JQW+S23/'$&BE9&4M&KG/S#C;^5>7G$F\-*E#5S]U
M?,=/D=6,9NR;5_3J?'D6JF\A\Z1BTK_>).3QP*8MR9L\]Z]9M_\ @ES\1(8M
MI\0:+T_Y_KG_ .,5+:_\$O?B%"QSX@T;GG_C^N?_ (Q7RD<JQG_/MGZ%_:^"
MV4U8\3U"1A-U(Z579R5')KW"\_X);_$*X;_D8-&_\#KG_P",5"W_  2Q^(A'
M_(P:+_X'W/\ \8IO*L6_L#6<X/\ G1X-J,9+=.E1Q0[8O:O>Y_\ @E;\0Y&;
M'B#1.<];ZY_^,4B_\$JOB$(\?\)!HO\ X'7/_P CUS/)L;_(SIEGF!Z5$>"Q
M6I9LXJ[!98E&1^E>Y6O_  2N^(,77Q!HO_@=<_\ QBK*_P#!+CQ\)=W]OZ-_
MX'7/_P 8K&&28WFUILS>>8/^='B6E)&+YFE#"")3YA4?=&< GL.2!GWKY$_;
M=_;^N?BSI%[X1^&-U-I>CP0RB^U"WD,#W<4L &T26\S*^"\G#+@$#T-?KQ\%
M?^">3>$X[L>)+BQU+[;!Y#A9/."_-$X(\R$<[D/X'WK\Y_B-_P &Q_Q2L_%V
MJ?\ "'>,O#5MHERL:0+=:O=I+CRP'W"*QV??W8QVQGFO3HY)6C&_+J<W]N8:
M<K.>AY1_P2;^-%U\($U+PYK5_>ZG8^([P7CR7DYF:.1;=BV"[*!DJG8DXZ]*
M^^KJXAER%Y3\*^??@C_P;N_&3X;ZA#<7GC/PM*T/3R]7OFZQE3ULQZU]>Z#_
M ,$Y/B%::/''=Z]H[S@DLRWMR0>3CDPYZ5RU<HQKG=4V6LWP7_/Q'E5Y/B<K
MCY0:S;BW$C'(KVB7_@F[X\DD+?V[I'/_ $^W'_QFF#_@FOX\\PDZ[I'/_3[<
M?_&*/[(QG_/MC_MC!_\ /Q'C+6N\JA P<Y&*P/B/X;O]8\+-IFC;VU/4IUBM
MUCW%_ES*V @W?=C;H#^7-?1<7_!-[QNLZL=;TC SG_3+C_XS6_\  7_@GUXF
M\!_M Z;XD\0ZGI=_H6FV\Y6U2YEE9IW1XP=CPA,!9#SD&MJ&38AU8^TA97.>
MMG6'C3DZ<[NQ]&_ ;X0V/P(^%6F>%].2-+?3O-QL51G?,\O\*J.KGL/ZUU]5
M='@N+>Q5;IP\_P#$021U/KSTQ5JONK)>['9'P,I.3YGN%%%%(05RGQR\.#Q;
M\*-6T\IY@G\GY=N<XF1NF#Z>E=708%N4*. RMU!&0:J.X7MJ?@MX9+?V%;*Y
MP\4:QL/0A1FNE\-/B^BY_B']:P(K!]&U_7["7(DT_5KBU93_  E&VD<_3T%;
M'AZ7;J47^\*\>>Y[W0^B_@%<8U.$-N(V-PO7[HK]'?A3J+:EX+MY"0?O8QV^
M=O\ "OS4^!-UY>KP\A?W;<D\?=%?H5^SAJQU'P?LSD1].?5Y*[\([TVCQ\5I
M43/1****W,0HHHH **** "BBB@":+_5BG4V+_5BG5W0^%&97HHHKA- HHHH
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MW.QT/18O#NCPV4/$<&['7NQ;N3ZU:I6;<:2NNR2M'9%A1110,**** "BBB@
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MCN&,]A@,9K2KZ>3;TC)>:>C79GAX?VF"Q'L9.\9?<?HY10PPU%?O!] %%%%
M!1110 4444 31?ZL4ZFQ?ZL4ZNZ'PHS*]%%%<)H%%%% !1110 4444 %%%%
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M=GMD?_!0?XP,^/M'_D.R_P#C-2'_ (*!?%\#_CY_\AV7_P 9KQ&/X@V)?_\
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M/Q*S_K__ !RU_P#C52#]L[XDD?\ 'Q_Y#M?_ (U7DX\8VI_R?\*>/&-KC_\
M7_A1_KAGG_074_\  A_6Z_\ .SU9/VS/B2>L_P#XY:__ !JG#]LKXD9_U_\
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M^O\ PIKC#//^@NI_X$/ZY7_G9Z>O[7WQ#9O]?_XY;?\ QNI/^&O/B#_SW_\
M'+;_ .-UY<GBRU+?_K_PJ3_A*K;_ #G_  I_ZX9W_P!!=3[P^MU_YF>GK^US
M\06_Y>/_ "';?_&Z>?VM?B /^7C_ ,AVW_QNO,$\56Q7_P#7_A4B^*;8#_\
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M-#:SBU&#\TPAD=!]UAU3N,>M?ESXF\:3^,/&6I:[+']HUKQ-=27ICW!,@L6
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M_P#(TG^-;-%'LH?RK[E_D')'L8P^'NBC_EQ_\C2?XTO_  K[1?\ GQ_\C/\
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ML9?_  A.D_\ /G_Y%?\ QI?^$+TK_GT_\BO_ (UIT4>RA_*ON7^0<D>QF?\
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M$]-_Y]?_ "*W^- \*::/^77_ ,B-_C6A11[*'\J^Y?Y!R1[%#_A%M._Y]?\
MR(W^-'_"+:=_SZ_^1&_QJ_11[*G_ "K[E_D')'L4/^$6T[_GU_\ (C?XT?\
M"+:=_P ^O_D1O\:OT4>RA_*ON7^0<D>Q0_X1;3O^?7_R(W^-'_"+:=_S[?\
MD1O\:OT4>RA_*ON7^0<D>Q1_X1C3_P#GV_\ (C?XT?\ ",:?_P ^W_D1O\:O
M44>SI_RK[D')'L43X9T\_P#+M_Y$;_&@>&=/'_+M_P"1&_QJ]11[.G_*ON0<
MD>Q1/AG3S_R[?^1&_P :!X9T\?\ +M_Y$;_&KU%'LZ?\J^Y!R1[%+_A&]/\
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M+H]E(+GV917QG_P_Z_97_P"BI^$O_"ETC_Y+H_X?]?LK_P#14_"7_A2Z1_\
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M"3V1]D1?ZL4ZN*_9X^/OA?\ :@^#VD>.?!>IVVL>&M<\[['>6]Q%<1S>5/)
M^'B=T.)(G'#'!!!P017:UVQ^%&+/Q:_X1+3O^?6'_OTO^%))X2T[8?\ 18?^
M_2_X5I4C#(K[=/4_F\77_!%C;:7I%S]EC\JYMS@^4N-WG2KZ?[-9W_"):=_S
MZP_]^E_PKU<^##XK_9=TW4;=/,NM*O)?,VC+>4GG2'H">K#N!7F\+^9$I]1R
M/0U\OPSG5/'0Q%*+]ZA5J4Y+TD[?>CIQ-#DY7W2?X%#_ (1+3O\ GUA_[]+_
M (4?\(EIW_/K#_WZ7_"M&BOI[LYC._X1+3O^?6'_ +]+_A1_PB6G?\^L/_?I
M?\*T:*+L#._X1+3O^?6'_OTO^%'_  B6G?\ /K#_ -^E_P *T:*+L#._X1+3
MO^?6'_OTO^%'_"):=_SZP_\ ?I?\*T:*+L#._P"$2T[_ )]8?^_2_P"%'_")
M:=_SZP_]^E_PK1HHNP,[_A$M._Y]8?\ OTO^%'_"):=_SZP_]^E_PK1HHNP,
M[_A$M._Y]8?^_2_X4?\ "):=_P ^L/\ WZ7_  K1HHNP,[_A$M._Y]8?^_2_
MX4?\(EIW_/K#_P!^E_PK1HHNP,[_ (1+3O\ GUA_[]+_ (4?\(EIW_/K#_WZ
M7_"M&BB[ SO^$2T[_GUA_P"_2_X4?\(EIW_/K#_WZ7_"M&BB[ SO^$2T[_GU
MA_[]+_A1_P (EIW_ #ZP_P#?I?\ "M&BB[ SO^$2T[_GUA_[]+_A1_PB6G?\
M^L/_ 'Z7_"M&BB[ SO\ A$M._P"?6'_OTO\ A1_PB6G?\^L/_?I?\*T:*+L#
M._X1+3O^?6'_ +]+_A1_PB6G?\^L/_?I?\*T:*+L#._X1+3O^?6'_OTO^%'_
M  B6G?\ /K#_ -^E_P *T:*+L#&U3PEIZV;2I;1![?\ ?(1&N05!(QQ7T_\
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MTH_\LCQ_L)_\377"/:<8%+$/F^Z!^%:K 4?Y5]QA];JIVYF<H?A1I3?\L?\
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M#L:6UM58Y*MCYH%^Z?P/;YW/(_V[C:<:T-8Q?WZ6//RW SRW-/KL'[DH6O\
M,O\ _!!'9K__  3 ^*%Q=74]Z]_\2;JX)EE\S&ZUTIN,Y[_S->5?'OPO)X!O
MC))=6LL@8++;I*6EMQY88%UP-H(&<GUKI_\ @C%\1_#O[,/@K7_A3K^KPQ:)
MXAU*YUNWO+BZB5(Y?+M%5'=V1 =EJW 0G)'..GS1X/\ C%J'Q*^.OQY\0>.A
MK6E:-X9T*UU"&UN]T"RE++<ZPI,Q4L1&> 1RW)YKIX*E+)<54AB5:+E^#7_
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MG#,_4,3^HK[T_P"#0SXJQC]I'XA?#*[.;?4=+U/7XXF(VNPN-*C& 6P3A#_
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MOT0'2KR278T0DR"TK,.X7[JCO1I/[)&O_LJ>&7O9?$E_?VR(SL)=0DEZ$_\
M3-!UD_2O//'/QQMKJ/R;V[$VV;E7E# 8#=BU>?P]P#@<:L7CO;<\6VDUY+_,
MZ,ZXNQ.!Q&&HQI\LFDY)^;L?N#_P3"L9M,_8;\$0SDM*GV_<22<YU"Y(Z\]#
M7OE>)?\ !.>]BU']C7P=-"0T;_;<$$=KZX':O;:^VRO_ '*C;^6/Y(^/S/\
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M*\DBDMW22>0EB?+$:;6)7:!W)'6N"\'>#=:^(\5S)HEHTL5DH:9Y(I&7D-@
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M8[DCVJXCDBM_+M H:%!'$#TP#[>WI3]+\.:;X>MS%INFV&GJW!%M;K%GK_=
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MNC]3 ?4_"?P=\(Z!J5IJ%Q=7\5PZ^(4\^%X[:WWEU( VE<QJ3^\.#CTKZ_\
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M7NIR31GS-L$,&K))AAYAZVZ?Q@<<D8&/YZ-#LY-7>&&+[\@P,^RY_I7[^?\
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M[3=/\HW"W !F?=A%(F&=RJ2,%QVKYW+7[+$_%S19\=EM*=IWGS1OHSY"&H+
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M_P" ?G-^WC\/Q\)OV]?C/X<C96ATSQMK<,6TY 6/49XQV4=%[ 5+^Q%XOO\
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M 7Q!\!_%/P/X;U[Q]=_V7!X#NO[0M].\JXG^T2&Y,B#S80I7]Y#$<D,/FQC
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M:>=JVCW5U:0KYMRN^(6R7*KF%&49;?R03^@KQS]F+]EGXH^)?%,NJ>$O#_\
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M  4<\<^.+*VT#X<^(;CS]$\):D+^UE\NW7S'>(2,,(-P_P!<PY<].GI]E_\
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M\,=,\;P^#]-O(-]Q=)=/??.XW\%X^C #  ^Z?K6AHGA>R\?^(_#OB_5/#O\
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MGR,NUH=B?QL&ZPO_  C\>,Z2Q%.#/6C1G.)J_&/XBZ7\+_@AXEU/PY#]EO\
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M]8QVBW&V0^2SRP$MM 9CC<YQGMUY%>;0PE&GBXR?P=>[.FI6J.DX_:Z'/_\
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MQL\?W?AJ>U_LW7II;33HYO-2;S)+J5E2/:'5!G"G=G V\D9-?6/[4G_!$/\
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M= N_#'_!/?X?V-]=?;+J#^T=\WEB/?G4KIA\H) P"!U[5]'U\3_\&ZZW2_\
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M4^):^3^YLOML%QM^5NBQJ>2V>QKT;QM\1[ZQM+.UF3;<6-K'L?*_,I.T' 7
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M\=W>G>$9_L6A>#K!UO6V-)]IN;:15D.)=CKN21.%+ 8XR<T_]FBSMQ\)]?\
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MI6I_\([\.HI9M^E_9[&[^S0G3[MX%\YH4F;YX@<YSSSQU_-::XVFOM#_ ((
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M!$?]9GY<=/FS7SS=7=SJM_\ :;V?[1-LV;]@3Y<YQ@<=2:]4_9-_:WO?V/\
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M?_@LW^S?XQ\'>);*WUY=+_L&R::]M[FS$^[,=M SB1W0)_&V,?W3D\5]N?\
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M^PEI_AWX9>$O$"^)]4\3ZDFGWJ-?6EZ^G6[DDR2")XVCYNUPS(1@'CIGS/\
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MN^P[:$Q%20\$_2H4DWT_>4Q]:U6IB3*=A]Z]._8T-W%^TQX>>S6)FFGA6?S
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MZBOJ.OU:,J<DI4=8]/3I^!^;3512:K?%U]>OXGXUT445]J?S:%%%% !1110
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MS!YL?4JR_,K+PR-V(/8CUK.U"*XU:>2:_O;[4KF<;9+B[F,TIXVCYFYZ8'T
M]*V5B+'\:K7%MC( _2L*M'FU-(3:T3/J+_@EQ_P4*M/V:_B7/X9^,5WKOB'X
M/7^ERP&QCE%VT$ZF!K<+'=3);*JBW4=,C/R^V!X?_:9UW]K+_@IY\.O'UX&T
M]K[QEH0L[:,21+;[)K.)]J%WV[C K<-R>?0#YW.FQW6$GA26/KAT!&?QKJ/!
M&M7?@3QAH'B+2\+?^&M2M]5M1\P!D@D$B@[2#C<HZ$'W%<]/+;\WFGITN_\
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MJ9MI(8F+;IL1N8Y6P>H!PV.N>:],\0:IX;\3N=6L]/\ M7BNS1EEB@@B<!F
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M(GC+_P $ES_\11[2'</J>(_D?W,XVBNR_P"&<_B%_P!")XR_\$ES_P#$4?\
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MC[F615.'>!JD\)%NOB.7GTN[N_3?8_$S_@HAXO;6_CSXQ:"020?VK.(V#9!
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I%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795893072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the maturities of the Company's operating lease liabilities were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,052,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,023,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,951,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total remaining lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,897,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: present value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,412,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,764</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,074,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,409,922</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Annual Future Minimum Lease Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, prior to the adoption of Topic 842, annual future minimum lease payments under non-cancelable operating leases were as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,756,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,052,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,023,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,952,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,653,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6795896048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:   </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,599,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,842,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,067,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528,736</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972860688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary of intangible assets by major asset class</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following sets forth goodwill and intangible assets by major asset class:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Useful</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Yrs)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite lived:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,802,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,742,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,248,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,219,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:24px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">CELLECTRA</font><font style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:inherit;font-size:9.5pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,106,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,106,270</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,106,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,679,190</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GHRH(b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioject (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,100,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,175,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,924,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,100,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,882,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other(d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,050,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,356,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,050,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,131,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">918,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,717,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,024,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693,851</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,717,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,957,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,760,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total goodwill and intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,231,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,024,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,207,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,231,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,957,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,273,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and GHRH are developed technologies which were recorded from the acquisition of VGX.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</font></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of finite-lived intangible assets, future amortization expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization expense related to intangible assets at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is expected to be incurred as follows: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,414</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604,445</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6973011456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Goodwill and Intangible Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following sets forth goodwill and intangible assets by major asset class:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26" rowspan="1"></td></tr><tr><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Useful</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Yrs)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite lived:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill(a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,513,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Definite lived:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,802,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,802,528</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,742,079</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,449</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Licenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,248,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,657</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,323,761</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,219,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">104,404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:24px;font-size:9.5pt;"><font style="font-family:inherit;font-size:9.5pt;">CELLECTRA</font><font style="font-family:inherit;font-size:9.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174;</sup></font><font style="font-family:inherit;font-size:9.5pt;">(b)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,106,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,106,270</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,106,270</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,679,190</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">427,080</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GHRH(b)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(303,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioject (c)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,100,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,175,556</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,924,444</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,100,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,882,222</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,217,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other(d)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,050,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,356,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">693,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,050,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,131,250</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">918,750</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total intangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,717,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,024,022</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693,851</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,717,873</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,957,728</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,760,145</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total goodwill and intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,231,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,024,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,207,222</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,231,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,957,728</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,273,516</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill was recorded from the Inovio AS acquisition in January 2005, the acquisition of VGX in June 2009 and the acquisition of Bioject in April 2016 for </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$400,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and GHRH are developed technologies which were recorded from the acquisition of VGX.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from the Bioject asset acquisition.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other intangible assets represent the estimated fair value of acquired intellectual property from the Inovio AS acquisition.</font></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Aggregate amortization expense on intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. Amortization expense related to intangible assets at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is expected to be incurred as follows: </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">520,414</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">492,818</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253,333</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,604,445</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,693,851</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> impairment or impairment indicators present and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> losses were recorded during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6604327536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-term Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Short-term investments at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> consisted of mutual funds. Short-term investments at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consisted of mutual funds and United States corporate debt securities. Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's debt securities are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses are included in non-operating other income (expense) on the consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.&#160;During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, gross realized gain on investments of </font><font style="font-family:inherit;font-size:10pt;">$594,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and gross realized loss on investments of </font><font style="font-family:inherit;font-size:10pt;">$118,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, was recorded. No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive income (loss) for the years ended&#160;December&#160;31, 2019,&#160;2018&#160;and&#160;2017. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">4</font><font style="font-family:inherit;font-size:10pt;">&#160;available-for-sale securities in a gross unrealized loss position, of which </font><font style="font-family:inherit;font-size:10pt;">2</font><font style="font-family:inherit;font-size:10pt;"> with an aggregate total unrealized loss of </font><font style="font-family:inherit;font-size:10pt;">$11,000</font><font style="font-family:inherit;font-size:10pt;"> were in such position for longer than 12 months. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of available-for-sale securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:   </font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66,599,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">754,709</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,911</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturity&#160;(in&#160;years)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross&#160;Unrealized</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Market&#160;Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">---</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,842,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528,084</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US corporate debt securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less than 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">224,633</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(652</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,067,588</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(528,736</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794155744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Reconciliation of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income (benefit) taxes at statutory rates</a></td>
<td class="num">$ (25,370)<span></span>
</td>
<td class="num">$ (19,908)<span></span>
</td>
<td class="num">$ (30,872)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount', window );">Foreign income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">25,457<span></span>
</td>
<td class="nump">20,898<span></span>
</td>
<td class="num">(20,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeTaxReconciliationStatuteLimitations', window );">Research and development tax credits</a></td>
<td class="num">(3,838)<span></span>
</td>
<td class="num">(3,170)<span></span>
</td>
<td class="num">(3,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncomeTaxReconciliationFairValueWarrant', window );">Change in fair value of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="num">(282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
<td class="nump">846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits', window );">Expired NOLs and credits</a></td>
<td class="nump">616<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits', window );">Limited NOLs and credits</a></td>
<td class="num">(616)<span></span>
</td>
<td class="num">(2,176)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">831<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (257)<span></span>
</td>
<td class="nump">$ 2,170<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ComprehensiveIncomeLossTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Foreign Withholding Taxes, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationForeignWithholdingTaxesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationFairValueWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Fair Value Warrant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationFairValueWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationStatuteLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Statute Limitations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationStatuteLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972620512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 9,632<span></span>
</td>
<td class="nump">$ 8,313<span></span>
</td>
<td class="nump">$ 6,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">1,575<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 11,204<span></span>
</td>
<td class="nump">$ 9,632<span></span>
</td>
<td class="nump">$ 8,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6810848784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2009</div></th>
<th class="th"><div>Jan. 31, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">24,717,873<span></span>
</td>
<td class="nump">24,717,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(21,024,022)<span></span>
</td>
<td class="num">(19,957,728)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">3,693,851<span></span>
</td>
<td class="nump">4,760,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, Gross</a></td>
<td class="nump">35,231,244<span></span>
</td>
<td class="nump">35,231,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, Net Book Value</a></td>
<td class="nump">$ 14,207,222<span></span>
</td>
<td class="nump">15,273,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_InovioAsMember', window );">Inovio AS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_VgxPharmaceuticalsMember', window );">VGX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 5,802,528<span></span>
</td>
<td class="nump">5,802,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(5,802,528)<span></span>
</td>
<td class="num">(5,742,079)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">60,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(1,248,104)<span></span>
</td>
<td class="num">(1,219,357)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 75,657<span></span>
</td>
<td class="nump">104,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_CellectraMember', window );">CELLECTRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 8,106,270<span></span>
</td>
<td class="nump">8,106,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(8,106,270)<span></span>
</td>
<td class="num">(7,679,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">427,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_CellectraMember', window );">CELLECTRA | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_GhrhMember', window );">GHRH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 335,314<span></span>
</td>
<td class="nump">335,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(335,314)<span></span>
</td>
<td class="num">(303,630)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_GhrhMember', window );">GHRH | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(2,175,556)<span></span>
</td>
<td class="num">(1,882,222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 2,924,444<span></span>
</td>
<td class="nump">3,217,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, Gross</a></td>
<td class="nump">$ 4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(3,356,250)<span></span>
</td>
<td class="num">(3,131,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 693,750<span></span>
</td>
<td class="nump">$ 918,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of intangible assets by major asset class</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_InovioAsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_InovioAsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_VgxPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_VgxPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_CellectraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_CellectraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_GhrhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_GhrhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972926128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Narrative (Details) - Fair Value, Inputs, Level 1<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares', window );">Number of shares held in an affiliated entity (in shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability | $</a></td>
<td class="nump">$ 7.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract', window );"><strong>Marketable Securities and Fair Value Measurements (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="nump">395,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities and fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MarketableSecuritiesAndFairValueMeasurementsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of affiliates held for management investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAndAdvancesToAffiliatesBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792290992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance Of Convertible Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">$ (18,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(2,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">78,500,000<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">(14,082,302)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(1,938,206)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">1,700,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">64,180,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">15,578,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount on the liability component</a></td>
<td class="num">(6,764,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(255,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccretionOfPremium', window );">Accretion of premium associated with the bonds</a></td>
<td class="nump">227,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">38,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">8,824,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">4,067,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentAccretionOfPremium', window );">Accretion of premium associated with the bonds</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 4,017,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentAccretionOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Accretion Of Premium</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentAccretionOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtinstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtinstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794081296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years 2 months<span></span>
</td>
<td class="text">8 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto', window );">Number of lease agreements entered into | lease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 31 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 19 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Number Of Lease Agreements Entered Into</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeNumberOfLeaseAgreementsEnteredInto</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6809616144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">24 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 05, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare', window );">Convertible preferred stock, shares issued upon conversion, conversion price ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion', window );">Daily market price triggering mandatory conversion ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ConvertiblePreferredStockThresholdTradingDays', window );">Number of trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays', window );">Number of consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod', window );">Warrants exercised in period (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 902,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,901,320<span></span>
</td>
<td class="nump">$ 10,654,622<span></span>
</td>
<td class="nump">$ 13,070,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 31 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,265,390<span></span>
</td>
<td class="nump">8,752,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 918,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value for options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm', window );">Options exercisable, remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber', window );">Number of options expected to vest (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,265,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expirations in period, weighted average exercise price ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.27<span></span>
</td>
<td class="nump">$ 5.17<span></span>
</td>
<td class="nump">$ 9.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expirations in period (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324,502<span></span>
</td>
<td class="nump">119,091<span></span>
</td>
<td class="nump">200,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="nump">$ 4.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">910,000<span></span>
</td>
<td class="nump">519,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">5,900,000<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 970,000<span></span>
</td>
<td class="nump">302,000<span></span>
</td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">952,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months 31 days<span></span>
</td>
<td class="text">1 year 8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value of unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber', window );">RSU's expected to vest (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.09<span></span>
</td>
<td class="nump">$ 4.31<span></span>
</td>
<td class="nump">$ 6.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion', window );">Average daily trading volume triggering mandatory conversion (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock, redemption price ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberofVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PreferredStockConversionNoticePeriod', window );">Notice period for mandatory conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementAgentFee', window );">Agent fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedSalesAmount', window );">Stock sales agreement, remaining authorized sales amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | ATM Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,937,406<span></span>
</td>
<td class="nump">3,911,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.41<span></span>
</td>
<td class="nump">$ 5.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="nump">$ 32,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under a share-based compensation plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,214,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan', window );">Number of shares of vested restricted stock outstanding under the plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,497,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,767,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Authorized amount</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Average Daily Trading Volume Triggering Mandatory Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockAverageDailyTradingVolumeTriggeringMandatoryConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of vested restricted stock outstanding under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberofVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberofVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Conversion, Daily Market Price Triggering Mandatory Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PreferredStockConversionDailyMarketPriceTriggeringMandatoryConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PreferredStockConversionNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock Conversion, Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PreferredStockConversionNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment  award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrants Exercised In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockIssuedDuringPeriodSharesWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Agent Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedSalesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Sales Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedSalesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_PriorATMSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_PriorATMSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6703793392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | investment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | investment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized loss</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6971305552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly financial information (unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (unaudited):</font></div><div style="line-height:120%;padding-top:6px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Statements of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">617,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,770,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,014</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous revenue, including from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,488</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">866,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,003,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,137,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,486,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,389,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,696,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,681,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,850,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,975,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,700,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,818,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,336,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,364,917</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,421,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,951,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,200,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,535,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">587,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625,535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,668,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,428,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,194,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,315,105</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551,453</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,681,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(750,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,512</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before income tax benefit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,235,146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,536,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,685,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,351,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,147,382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,536,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,579,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,288,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">445,759</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,662,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,090,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,387,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,219,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Statements of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,372,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,813,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,385,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,289,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,817</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,448,761</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,365,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,851,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,462,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,577,751</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,636,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,791,693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,189,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,698,015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,001,788</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,643,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,651,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,275,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,499,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,642,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,203,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,746,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380,987</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,523</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) from investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293,741</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,017,359</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,092,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,380,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,962,205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,015,672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,639,125</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,181,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,962,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,015,672</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,639,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,350,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791811968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">2.73%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.71%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in estimation of fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972972400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">GeneOne Life Sciences </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company owned </font><font style="font-family:inherit;font-size:10pt;">1,644,155</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in GeneOne as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to GeneOne. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2010, the Company entered into a collaboration and license agreement (the &#8220;GeneOne Agreement&#8221;) with GeneOne. Under the GeneOne Agreement, the Company granted GeneOne an exclusive license to the Company's SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> universal influenza vaccine delivered with electroporation to be developed in certain countries in Asia (the &#8220;Product&#8221;). As consideration for the license granted to GeneOne, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, and is entitled to receive research support, annual license maintenance fees and royalties on net Product sales. The GeneOne Agreement also provides the Company with exclusive rights to supply devices for clinical and commercial purposes (including single use components) to GeneOne for use in the Product. The term of the GeneOne Agreement commenced upon execution and will extend on a country by country basis until the last to expire of all Royalty Periods for the territory (as such term is defined in the GeneOne Agreement) for any Product in that country, unless the GeneOne Agreement is terminated earlier in accordance with its provisions as a result of breach, by mutual agreement, or by GeneOne's right to terminate without cause upon prior written notice. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2011, the Company entered into a collaborative development and license agreement (the &#8220;Hep Agreement&#8221;) with GeneOne. Under the Hep Agreement, as originally executed, the Company and GeneOne agreed to co-develop the Company&#8217;s SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> therapeutic vaccines for hepatitis B and C infections (the &#8220;Hep Products&#8221;). Under the terms of the Hep Agreement, GeneOne will receive marketing rights for the Products in Asia, excluding Japan, and in return will fully fund IND-enabling and initial Phase 1 and 2 clinical studies with respect to the Hep Products. The Company will receive from GeneOne payments based on the achievement of clinical milestones and royalties based on sales of the Hep Products in the licensed territories, retaining all commercial rights to the Hep Products in all other territories. In 2013, the Company amended the Hep Agreement to grant back to the Company the SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> therapeutic vaccines targeting hepatitis B, along with all associated rights, from the collaboration in return for certain remuneration including a percentage of license fees. In 2013, the Company further amended the Hep Agreement to in part provide exclusive patent rights to IL-28 technology for use with the Hep Products in Asia, excluding Japan. The Hep Agreement shall terminate upon the later of the expiration or abandonment of the last patent that is a component of the rights or </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> years after the effective date.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2015, the Company entered into a Collaborative Development Agreement with GeneOne to co-develop a DNA vaccine for MERS through Phase 1 clinical trials.&#160;Under the terms of the agreement, GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> milestone-based ownership interest in the MERS immunotherapy asset upon achievement of the last milestone event of completion of the Phase 1 safety and immunogenicity study.&#160;The collaborative research program shall terminate upon the completion of activities under the development plan, unless sooner terminated.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the Company and GeneOne amended the Collaborative Development Agreement for MERS to expand the agreement to test and advance the Company's DNA-based vaccine for preventing and treating Zika virus.&#160;GeneOne will be responsible for funding all preclinical and clinical studies through Phase 1.&#160;In return, GeneOne will receive up to a </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> milestone-based ownership interest in the Zika immunotherapy asset upon achievement of the last milestone event of the completion of the Phase 1 safety and immunogenicity study. All other agreement terms remain the same.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company completed the sale of certain assets related to its compound VGX-1027 to GeneOne for a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from GeneOne for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> consisting of</font><font style="font-family:inherit;font-size:10pt;color:#ff0000;"> </font><font style="font-family:inherit;font-size:10pt;">patent, device maintenance and licensing fees was </font><font style="font-family:inherit;font-size:10pt;">$127,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$342,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$551,000</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses recorded from transactions with GeneOne relate primarily to biologics manufacturing and were </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$128,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </font><font style="font-family:inherit;font-size:10pt;">$511,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$372,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to GeneOne and its subsidiaries. At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$284,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$381,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, of prepayments made to GeneOne were classified as long-term other assets on the consolidated balance sheets.  </font></div><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plumbline Life Sciences, Inc.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company owned </font><font style="font-family:inherit;font-size:10pt;">395,758</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock in Plumbline Life Sciences, Inc. ("PLS") as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and one of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue recognized from PLS consists of license fees. For the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from PLS of </font><font style="font-family:inherit;font-size:10pt;">$111,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$107,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$589,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$478,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to PLS.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The Wistar Institute</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Two of the Company's directors as of December 31, 2019, Dr.&#160;David B. Weiner and Dr. Morton Collins, were directors of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar. Dr. Collins retired from the Company's Board of Directors effective January 14, 2020.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the Company entered into collaborative research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company will reimburse Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> during the </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year term of the agreement. The Company will have the exclusive right to in-license new intellectual property developed in this agreement.  </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the Company received a&#160;</font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;">&#160;sub-grant through Wistar to develop a DNA-based monoclonal antibody against the Zika infection, with funding through July 2020. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the NIAID, with funding through February 2020.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A grant funding liability recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as contra-research and development expense from Wistar. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to the Bill and Melinda Gates Foundation and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$1.5</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">$1.8</font><font style="font-family:inherit;font-size:10pt;"> million, respectively. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$616,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$258,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, and an accounts payable and accrued liability balance of </font><font style="font-family:inherit;font-size:10pt;">$219,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$554,000</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to Wistar. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$843,000</font><font style="font-family:inherit;font-size:10pt;"> recorded as grant funding liability on its consolidated balance sheet related to Wistar.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797963088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
<td class="nump">$ 42,220,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">88,017,319<span></span>
</td>
<td class="nump">95,257,876<span></span>
</td>
<td class="nump">98,572,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,203,156<span></span>
</td>
<td class="nump">29,315,159<span></span>
</td>
<td class="nump">28,290,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">115,220,475<span></span>
</td>
<td class="nump">124,573,035<span></span>
</td>
<td class="nump">125,862,987<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(111,108,545)<span></span>
</td>
<td class="num">(94,091,138)<span></span>
</td>
<td class="num">(83,642,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">2,605,981<span></span>
</td>
<td class="nump">2,264,747<span></span>
</td>
<td class="nump">1,836,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,948,539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,933)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInFairValueOfCommonStockWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">360,795<span></span>
</td>
<td class="nump">806,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss on investment in affiliated entities</a></td>
<td class="num">(3,090,557)<span></span>
</td>
<td class="num">(1,988,567)<span></span>
</td>
<td class="num">(6,982,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">496,200<span></span>
</td>
<td class="num">(1,343,856)<span></span>
</td>
<td class="num">(197,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit/(provision for income tax)</a></td>
<td class="num">(120,809,112)<span></span>
</td>
<td class="num">(94,798,019)<span></span>
</td>
<td class="num">(88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (provision for income taxes)</a></td>
<td class="nump">257,335<span></span>
</td>
<td class="num">(2,169,811)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
<td class="num">(88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">1,192,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (119,359,219)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic ($ per share)</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted ($ per share)</a></td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (shares)</a></td>
<td class="nump">98,717,999<span></span>
</td>
<td class="nump">92,539,997<span></span>
</td>
<td class="nump">81,777,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (shares)</a></td>
<td class="nump">98,717,999<span></span>
</td>
<td class="nump">92,539,997<span></span>
</td>
<td class="nump">81,918,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,636,945<span></span>
</td>
<td class="nump">$ 29,860,785<span></span>
</td>
<td class="nump">$ 28,407,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">235,649<span></span>
</td>
<td class="nump">449,524<span></span>
</td>
<td class="nump">765,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Miscellaneous revenue, including from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">237,536<span></span>
</td>
<td class="nump">171,588<span></span>
</td>
<td class="nump">10,474,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_GrantwithAffiliatedRevenueMember', window );">Grants and miscellaneous revenue from affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,572,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInFairValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInFairValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_GrantwithAffiliatedRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_GrantwithAffiliatedRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972622928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases approximately </font><font style="font-family:inherit;font-size:10pt;">82,200</font><font style="font-family:inherit;font-size:10pt;"> square feet of office, laboratory, and manufacturing space in San Diego, California and </font><font style="font-family:inherit;font-size:10pt;">57,360</font><font style="font-family:inherit;font-size:10pt;"> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms of </font><font style="font-family:inherit;font-size:10pt;">3.9</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">9.9</font><font style="font-family:inherit;font-size:10pt;"> years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all of its leases and determined that, effective upon the adoption of Topic 842, they were all operating leases. The Company performed an evaluation of its other contracts with customers and suppliers in accordance with Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</font></div><div style="line-height:174%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the maturities of the Company's operating lease liabilities were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,052,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,023,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,001,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,951,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total remaining lease payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,897,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: present value adjustment</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,412,236</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;Total operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,764</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,074,842</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,409,922</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average remaining lease term</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2 years</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average discount rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease costs included in operating expenses in the consolidated statements of operations for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the fourth quarter of 2019, the Company entered into </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> agreements to sublease a total of approximately </font><font style="font-family:inherit;font-size:10pt;">13,500</font><font style="font-family:inherit;font-size:10pt;"> square feet in its Plymouth Meeting headquarters through periods between December 31, 2022 and March 31, 2025. </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2018, prior to the adoption of Topic 842, annual future minimum lease payments under non-cancelable operating leases were as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:83%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Year ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,756,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,891,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,979,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,052,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,023,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,952,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,653,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6604846544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables reconcile the components of the numerator and denominator included in the calculations of diluted net loss per share:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Numerator</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment for decrease in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator for use in diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89,012,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Denominator</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding (denominator for use in basic net loss per share)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,777,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for use in diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,918,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,752,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,694,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069,936</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688,017</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,585,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2019 Bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,799,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2019 Bonds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,737,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,449,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,937,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used to estimate the fair value of stock options</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.45%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.71%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of New Accounting Pronouncements and Changes in Accounting Principles</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 840</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Topic 842</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,518,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,518,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797736160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,551,777)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,598,388<span></span>
</td>
<td class="nump">3,747,183<span></span>
</td>
<td class="nump">1,850,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">1,066,294<span></span>
</td>
<td class="nump">1,249,584<span></span>
</td>
<td class="nump">1,618,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">851,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfCommonStockWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(360,795)<span></span>
</td>
<td class="num">(806,819)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">1,763,652<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">10,901,320<span></span>
</td>
<td class="nump">10,654,622<span></span>
</td>
<td class="nump">13,070,962<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">5,230,954<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfPremium', window );">Amortization of premiums on investments</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">72,561<span></span>
</td>
<td class="nump">319,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">5,397<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(150,027)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Loss (gain) on short-term investments</a></td>
<td class="num">(476,368)<span></span>
</td>
<td class="nump">1,342,005<span></span>
</td>
<td class="nump">215,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">5,889<span></span>
</td>
<td class="nump">14,529<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss on equity investment in affiliated entities</a></td>
<td class="nump">3,090,557<span></span>
</td>
<td class="nump">1,988,567<span></span>
</td>
<td class="nump">6,982,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Tax benefit from other unrealized gains on short-term investments</a></td>
<td class="num">(266,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Unrealized transaction loss on foreign-currency denominated debt</a></td>
<td class="nump">471,172<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">2,616,288<span></span>
</td>
<td class="nump">2,686,844<span></span>
</td>
<td class="nump">9,818,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts receivable from affiliated entities</a></td>
<td class="num">(593,461)<span></span>
</td>
<td class="num">(251,964)<span></span>
</td>
<td class="nump">261,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(178,008)<span></span>
</td>
<td class="nump">1,194,316<span></span>
</td>
<td class="num">(851,847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">70,665<span></span>
</td>
<td class="nump">725,202<span></span>
</td>
<td class="num">(333,583)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(2,026)<span></span>
</td>
<td class="num">(30,644)<span></span>
</td>
<td class="num">(526,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,337,829)<span></span>
</td>
<td class="nump">550,407<span></span>
</td>
<td class="nump">2,829,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="num">(1,622,037)<span></span>
</td>
<td class="num">(2,940,128)<span></span>
</td>
<td class="nump">2,243,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="num">(248,063)<span></span>
</td>
<td class="nump">50,849<span></span>
</td>
<td class="num">(145,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(180,450)<span></span>
</td>
<td class="num">(1,016,836)<span></span>
</td>
<td class="num">(13,689,322)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties', window );">Deferred revenue from affiliated entities</a></td>
<td class="num">(1,800)<span></span>
</td>
<td class="num">(140,535)<span></span>
</td>
<td class="num">(319,876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StraightLineRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(398,357)<span></span>
</td>
<td class="nump">3,608,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(1,733,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">1,899,364<span></span>
</td>
<td class="nump">4,165,848<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">816,342<span></span>
</td>
<td class="nump">27,083<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(48,507)<span></span>
</td>
<td class="nump">87,333<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(97,850,136)<span></span>
</td>
<td class="num">(73,550,156)<span></span>
</td>
<td class="num">(63,208,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(100,950,301)<span></span>
</td>
<td class="num">(88,155,046)<span></span>
</td>
<td class="num">(95,700,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of or maturity of investments</a></td>
<td class="nump">92,893,232<span></span>
</td>
<td class="nump">132,659,976<span></span>
</td>
<td class="nump">77,162,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(987,926)<span></span>
</td>
<td class="num">(2,085,022)<span></span>
</td>
<td class="num">(10,293,902)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(9,044,995)<span></span>
</td>
<td class="nump">42,419,908<span></span>
</td>
<td class="num">(27,831,144)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuances of convertible senior notes and convertible bonds</a></td>
<td class="nump">97,443,617<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Costs related to issuances of convertible senior notes and convertible bonds</a></td>
<td class="num">(3,314,757)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock and warrants, net of issuance costs</a></td>
<td class="nump">9,089,010<span></span>
</td>
<td class="nump">29,227,776<span></span>
</td>
<td class="nump">94,347,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsfromStockOptionandWarrantExercises', window );">Proceeds from stock option and warrant exercises, net of tax payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,809,526<span></span>
</td>
<td class="nump">1,342,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards, net of proceeds from option exercises</a></td>
<td class="num">(780,406)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">2,960,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">105,397,595<span></span>
</td>
<td class="nump">31,037,302<span></span>
</td>
<td class="nump">95,690,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(1,497,536)<span></span>
</td>
<td class="num">(92,946)<span></span>
</td>
<td class="nump">4,650,107<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">23,693,633<span></span>
</td>
<td class="nump">23,786,579<span></span>
</td>
<td class="nump">19,136,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">22,196,097<span></span>
</td>
<td class="nump">23,693,633<span></span>
</td>
<td class="nump">23,786,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">559,646<span></span>
</td>
<td class="nump">1,254,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">2,717,585<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_EquityComponentOfConvertibleDebtIssued', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">15,752,698<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 14,634,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AmortizationOfOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AmortizationOfOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the fair value of common stock warrants, which are revalued at each balance sheet date subsequent to initial receipt or issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EquityComponentOfConvertibleDebtIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Component Of Convertible Debt Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EquityComponentOfConvertibleDebtIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period, excluding the portion taken into income, in the liability reflecting services yet to be performed by the reporting entity for which cash or other forms of consideration was received or recorded as a receivable from a related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInDeferredRevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change during the reporting period in the value of prepaid expenses and other current assets from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsfromStockOptionandWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Option and Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsfromStockOptionandWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of purchase premium on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StraightLineRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between actual rental income due and rental income recognized on a straight-line basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StraightLineRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792541184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity Summary of RSU Activity Under Equity Incentive Plan (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (shares)</a></td>
<td class="nump">1,688,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">1,491,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(1,003,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (shares)</a></td>
<td class="num">(106,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (shares)</a></td>
<td class="nump">2,069,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785482832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity Summary of Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value ($ per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value ($ per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813826960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th">
<div>Mar. 11, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th"><div>Dec. 26, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37,662,038)<span></span>
</td>
<td class="num">$ (23,090,693)<span></span>
</td>
<td class="num">$ (29,387,226)<span></span>
</td>
<td class="num">$ (29,219,262)<span></span>
</td>
<td class="num">$ (119,359,219)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (88,205,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="num">(620,426,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,089,010<span></span>
</td>
<td class="nump">29,227,776<span></span>
</td>
<td class="nump">$ 94,347,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent', window );">Expected number of positions to be eliminated, percent</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,693,851<span></span>
</td>
<td class="nump">4,760,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,159,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,159,000<span></span>
</td>
<td class="nump">115,007,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,783,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,783,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,634,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,484,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,484,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,600,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,578,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,578,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ino_VGXAnimalHealthIncMember', window );">VGX Animal Health, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,315,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Number of Positions Eliminated, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RestructuringandRelatedCostExpectedNumberofPositionsEliminatedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of current assets and current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_VGXAnimalHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_VGXAnimalHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806601984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impact of Recently Issued Accounting Standards - Impact of Adopting ASU 2016-02 (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, non-current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,518,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">13,783,009<span></span>
</td>
<td class="nump">$ 14,634,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,074,842<span></span>
</td>
<td class="nump">1,733,600<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 20,409,922<span></span>
</td>
<td class="nump">22,484,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,065,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,518,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Impact of Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,065,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, non-current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,518,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,634,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,484,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806123232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 58,067,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(528,736)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">57,538,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">57,842,955<span></span>
</td>
<td class="nump">$ 66,599,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">754,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(528,084)<span></span>
</td>
<td class="num">(15,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">57,314,871<span></span>
</td>
<td class="nump">$ 67,338,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember', window );">US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">224,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">$ 223,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual maturity</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DomesticCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806482896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio incurred a net loss attributable to common stockholders of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$119.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. Inovio had working capital of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$62.2 million</font><font style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$739.8 million</font><font style="font-family:inherit;font-size:10pt;"> as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. During the year ended December 31, 2019, the Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.7 million</font><font style="font-family:inherit;font-size:10pt;"> from a private placement of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> from the private placement of </font><font style="font-family:inherit;font-size:10pt;">18 billion</font><font style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> convertible bonds due August 2024 (the "August 2019 Bonds"), net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> from the private placement of  </font><font style="font-family:inherit;font-size:10pt;">4.7 billion</font><font style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> convertible bonds due December 2024 (the "December 2019 Bonds" and, collectively with the August 2019 Bonds, the &#8220;Bonds&#8221;) and net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;"> from sales of common stock under its At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp; Company (the &#8220;Sales Agreement&#8221;). As described in Note 19 below, the Sales Agreement was amended subsequent to December 31, 2019. From January 1, 2020 through </font><font style="font-family:inherit;font-size:10pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">43,148,952</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Sales Agreement, as amended, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$208.2</font><font style="font-family:inherit;font-size:10pt;"> million. These proceeds, in addition to the Company&#8217;s cash, cash equivalents and short-term investments of $</font><font style="font-family:inherit;font-size:10pt;">89.5 million</font><font style="font-family:inherit;font-size:10pt;"> and long-term investments of $</font><font style="font-family:inherit;font-size:10pt;">6.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, are sufficient to support the Company's operations for a period of at least 12 months from the date it issued these financial statements. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements and/or future public or private debt or equity financings including use of its Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, the Company announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, the Company reduced its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">28%</font><font style="font-family:inherit;font-size:10pt;"> and discontinued its Phase 1/2 clinical trial of its immuno-oncology product candidate INO-5401 in patients with advanced bladder cancer. In the third quarter of 2019, the Company incurred a personnel-related restructuring charge of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with one-time employee termination costs, including severance and other benefits, all of which have been paid as of December 31, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s consolidated financial statements as of and for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;"> have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. ("VGX"), and records a non-controlling interest for </font><font style="font-family:inherit;font-size:10pt;">39%</font><font style="font-family:inherit;font-size:10pt;"> of its subsidiary Geneos Therapeutics, Inc. ("Geneos") as well as </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> of VGX Animal Health, Inc., a subsidiary of VGX. All intercompany accounts and transactions have been eliminated upon consolidation. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Reporting </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment operating primarily within the United States.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. After the adoption of Accounting Standards Update ("ASU") No. 2016-01 on January 1, 2018, unrealized gains and losses on the Company's equity investment in its affiliated entity Plumbline Life Sciences, Inc. ("PLS") are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. The Company&#8217;s investment in GeneOne, an affiliated entity, is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) from investment in affiliated entity. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds and equity investments in the Company&#8217;s affiliated entities, PLS and GeneOne, at December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. Investments included mutual funds, United States corporate debt securities and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fixed Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful lives ranging from </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">18 years</font><font style="font-family:inherit;font-size:10pt;">. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or </font><font style="font-family:inherit;font-size:10pt;">17 years</font><font style="font-family:inherit;font-size:10pt;">, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective as of the acquisition of VGX in 2009, all new patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#8217;s intangible assets resulting from the acquisition of VGX, as well as the acquisitions of two other companies, Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowances against the Company&#8217;s deferred tax assets were </font><font style="font-family:inherit;font-size:10pt;">$137.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$115.0 million</font><font style="font-family:inherit;font-size:10pt;"> at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Topic 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company adopted ASU 2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;Topic 606&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantRevenuePolicyTextBlock', window );">Grants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that as of January 1, 2018, accounting for the Company&#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, </font><font style="font-family:inherit;font-size:10pt;">which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra- expense as opposed to revenue on the consolidated statement of operations.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options, restricted stock units and warrants and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. For the year ended December 31, 2019, the dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 10) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016&#8209;02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Topic 842&#8221;) on January 1, 2019. For long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC&#160;840, Leases (Topic 840). See &#8220;Recent Accounting Pronouncements - Recently Adopted&#8221; below, for more information about the impact of the adoption of Topic 842.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur. </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Recently Adopted, Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements - Recently Adopted</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-02</font><font style="font-family:inherit;font-size:10pt;">. In February 2016, the FASB issued Topic 842,&#160;which requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets and to disclose key information about leasing arrangements.&#160;The Company adopted the new lease standard on January 1, 2019 using the modified retrospective approach. The Company elected the available package of practical expedients upon adoption, which allowed the Company to carry forward its historical assessment of whether existing agreements contained a lease and the classification of its existing operating leases. Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its consolidated balance sheet of approximately </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company also classified deferred rent of </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> as an offset to the Company&#8217;s operating right-of-use asset upon adoption. There were no adjustments to the Company&#8217;s opening accumulated deficit balance upon adoption.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 840</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Topic 842</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,518,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,518,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-07</font><font style="font-family:inherit;font-size:10pt;">. In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;"> that simplifies the accounting for stock-based payments granted to non-employees for services by generally aligning it with the accounting for stock-based payments granted to employees. The Company adopted the standard on January 1, 2019 and there was no material impact to its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-13</font><font style="font-family:inherit;font-size:10pt;">. In August 2018, the FASB issued ASU 2018-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements (see Note 6 for more information about the Company&#8217;s fair value classifications). ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its disclosures.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements - Not Yet Adopted</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-13</font><font style="font-family:inherit;font-size:10pt;">. In June 2016, the FASB issued ASU 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</font><font style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. ASU 2016-13 is effective beginning in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-18</font><font style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued ASU 2018-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:inherit;font-size:10pt;">, which clarified the interaction between Topic 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. ASU&#160;2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the financial statements.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU 2017-04.</font><font style="font-family:inherit;font-size:10pt;"> In January 2017, the FASB issued ASU 2017-04,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its consolidated financial statements or related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972622928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The Company</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Inovio&#8221;), is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. The Company's DNA medicine pipeline is comprised of three types of candidates, DNA vaccines, DNA immunotherapies and DNA encoded monoclonal antibodies (dMABs). In clinical trials, Inovio has demonstrated that a DNA medicine can be delivered directly into cells in the body via its proprietary smart device to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's novel DNA medicines are made using its proprietary SynCon</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> technology that creates optimized plasmids, which are circular strands of DNA that can produce antigens independently inside a cell to help the person's immune system recognize and destroy cancerous or virally infected cells. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio's hand-held CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> smart delivery devices provide optimized uptake of its DNA medicines within the cell, overcoming a key limitation of other DNA-based technology approaches. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Human data to date have shown a favorable safety profile of Inovio&#8217;s DNA medicines delivered directly into cells in the body using the CELLECTRA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> smart delivery device in more than 6,000 administrations across more than 2,000 patients.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio's corporate strategy is to advance, protect, and provide its novel DNA medicines to meet urgent and emerging global health needs. The Company continues to advance and validate an array of DNA medicine candidates that target HPV-related diseases, cancer, and infectious diseases. The Company aims to advance these candidates through commercialization and continue to leverage third-party resources through collaborations and partnerships, including product license agreements. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine, The Bill &amp; Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency&#8217;s Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Inc., Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its collaborators are currently conducting or planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis (RRP); glioblastoma multiforme (GBM); prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus).  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6798041712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 11, 2020</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,803,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,656,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972964480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">401(k) Plan</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> of its employees&#8217; contributions, up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">6%</font><font style="font-family:inherit;font-size:10pt;"> of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.2</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$822,000</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797964528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (120,551,777)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax', window );">Unrealized loss on investment in affiliated entity, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,452,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="nump">1,001,475<span></span>
</td>
<td class="num">(180,496)<span></span>
</td>
<td class="nump">7,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(119,550,302)<span></span>
</td>
<td class="num">(97,148,326)<span></span>
</td>
<td class="num">(89,650,745)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">1,192,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (118,357,744)<span></span>
</td>
<td class="num">$ (97,148,326)<span></span>
</td>
<td class="num">$ (89,650,745)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Investment In Affiliated Entity, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6639131872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders&#8217; Equity</font></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preferred Stock</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Outstanding as of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares      Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series&#160;C Preferred Stock, par $0.001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The shares of the Company&#8217;s Series&#160;C Preferred Stock have the following pertinent rights and privileges, as set forth in the Company&#8217;s Amended and Restated Certificate of Incorporation and its Certificates of Designations, Rights and Preferences related to the various series of preferred stock.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Rights on Liquidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company (a &#8220;liquidation event&#8221;), before any distribution of assets of the Company shall be made to or set apart for the holders of common stock, the holders of Series&#160;C Preferred Stock, pari passu, are entitled to receive payment of such assets of the Company in an amount equal to </font><font style="font-family:inherit;font-size:10pt;">$10,000</font><font style="font-family:inherit;font-size:10pt;"> per share of such series of preferred stock, plus any accumulated and unpaid dividends thereon (whether or not earned or declared).</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the assets of the Company available for distribution to stockholders exceed the aggregate amount of the liquidation preferences payable with respect to all shares of each series of preferred stock then outstanding, then, after the payment of such preferences is made or irrevocably set aside, the holders of the Company&#8217;s common stock are entitled to receive a pro rata portion of such assets based on the aggregate number of shares of common stock held by each such holder. The holders of the Company&#8217;s outstanding preferred stock shall participate in such a distribution on a pro-rata basis, computed based on the number of shares of common stock which would be held by such preferred holders if immediately prior to the liquidation event all of the outstanding shares of the preferred stock had been converted into shares of common stock at the then current conversion value applicable to each series.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A Change of Control of the Company (as defined in the Certificates of Designations, Rights and Preferences) is not a liquidation event triggering the preferences described above, and is instead addressed by separate terms in the Series&#160;C Certificates of Designations, Rights, and Preferences.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the liquidation preferences are in excess of the par value of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share of the Company&#8217;s preferred stock, these preferences are equal to or less than the stated value of such shares based on their original purchase price.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Voting Rights</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of Series C Preferred Stock have full voting rights and powers equal to the voting rights and powers of holders of the Company&#8217;s common stock and are entitled to notice of any stockholders&#8217; meeting in accordance with the Company&#8217;s Bylaws. Holders are entitled to vote on any matter upon which holders of the Company&#8217;s common stock have the right to vote, including, without limitation, the right to vote for the election of directors together with the holders of common stock as one class. Series C Preferred holders are entitled to </font><font style="font-family:inherit;font-size:10pt;">368</font><font style="font-family:inherit;font-size:10pt;"> votes for each share of Series C Preferred Stock held. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Holder Optional Conversion Right </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holder of any share or shares of Series&#160;C Preferred Stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the Preferred Stock into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing (i)&#160;the aggregate Liquidation Preference applicable to the particular series of preferred shares, plus accrued and unpaid dividends thereon by (ii)&#160;the applicable Conversion Value (as defined in the relevant series&#8217; Certificate of Designations, Rights and Preferences) then in effect for such series of preferred shares. As of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the Conversion Value was </font><font style="font-family:inherit;font-size:10pt;">$27.20</font><font style="font-family:inherit;font-size:10pt;">, such that the outstanding shares of Series C Preferred Stock were convertible into </font><font style="font-family:inherit;font-size:10pt;">8,456</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock. The Company is not obligated to issue any fractional shares or scrip representing fractional shares upon such conversion and instead shall pay the holder an amount in cash equal to such fraction multiplied by the current market price per share of the Company&#8217;s common stock.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Company Mandatory Conversion Option</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has the option upon </font><font style="font-family:inherit;font-size:10pt;">thirty</font><font style="font-family:inherit;font-size:10pt;"> (30)&#160;days prior written notice, to convert all of the outstanding shares of the Series&#160;C Preferred Stock into such number of fully paid and non-assessable shares of common stock as is determined by dividing (i)&#160;the aggregate Liquidation Preference of the shares of the relevant series of preferred stock to be converted, plus accrued and unpaid dividends thereon by (ii) the applicable Conversion Value (as defined in the relevant series&#8217; Certificate of Designations, Rights and Preferences) then in effect, if the following triggering events have occurred:</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:66px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(i) the price of the Company&#8217;s common stock exceeds </font><font style="font-family:inherit;font-size:10pt;">$72.00</font><font style="font-family:inherit;font-size:10pt;"> per share for </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> out of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days; and</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:65px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(ii) the average daily trading volume (subject to adjustment for stock dividends, subdivisions and combinations) of the common stock exceeds </font><font style="font-family:inherit;font-size:10pt;">6,250</font><font style="font-family:inherit;font-size:10pt;"> shares for at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> out of </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Common Stock</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2018, the Company entered into the Sales Agreement with Stifel, Nicolaus and Company (the &#8220;Placement Agent&#8221;) to sell shares of its common stock with aggregate gross proceeds of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">, from time to time, through an &#8220;at-the-market&#8221; equity offering program under which the Placement Agent will act as sales agent. Under the Sales Agreement, the Company will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that the Placement Agent will be entitled to compensation for its services in an amount equal to up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. The Company has no obligation to sell any shares under the Sales Agreement, and may at any time suspend solicitation and offers under the Sales Agreement.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">3,340,678</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Sales Agreement. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$2.78</font><font style="font-family:inherit;font-size:10pt;"> per share resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company may sell up to an additional </font><font style="font-family:inherit;font-size:10pt;">$62.8 million</font><font style="font-family:inherit;font-size:10pt;"> in shares of its common stock under the Sales Agreement. The registration statement that registered with the SEC the shares that may be sold under the Sales Agreement expires on June 8, 2021.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As described in Note 19 below, subsequent to December 31, 2019, the Company and the Placement Agent entered into a first and second amendment to the Sales Agreement to increase the amount of common stock that may be sold under the Sales Agreement from </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company also sold shares of common stock under the Sales Agreement subsequent to December 31, 2019.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company entered into an At-the-Market Equity Offering Sales Agreement (the &#8220;Prior Sales Agreement&#8221;) with the same placement agent. The registration statement that registered with the SEC the shares sold under the Prior Sales Agreement expired on June 5, 2018, and no further sales can be made under the Prior Sales Agreement. The Company sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,911,104</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Prior Sales Agreement resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$32.1 million</font><font style="font-family:inherit;font-size:10pt;">. During the period from January 1, 2018 to June 5, 2018, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">314,950</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Prior Sales Agreement. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$5.07</font><font style="font-family:inherit;font-size:10pt;"> per share resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">. During the year ended December 31, 2017, the Company sold a total of </font><font style="font-family:inherit;font-size:10pt;">2,937,406</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Prior Sales Agreement. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$8.41</font><font style="font-family:inherit;font-size:10pt;"> per share resulting in aggregate net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$24.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Warrants</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December 31, 2018, warrants to purchase </font><font style="font-family:inherit;font-size:10pt;">284,091</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock were exercised, with net proceeds to the Company of </font><font style="font-family:inherit;font-size:10pt;">$902,000</font><font style="font-family:inherit;font-size:10pt;">. As of December 31, 2019 and 2018, there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> common stock warrants outstanding. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Options and Restricted Stock Units</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, restricted stock units and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. The maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan may not exceed </font><font style="font-family:inherit;font-size:10pt;">16,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares, provided that commencing with the first business day of each calendar year beginning January&#160;1, 2020, such maximum number of shares shall be increased by&#160;</font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock unless the Board determines, prior to January 1 for any such calendar year, to increase such maximum amount by a fewer number of shares or not to increase the maximum amount at all for such year. On January 1, 2020, the maximum number of shares to be issued was increased by </font><font style="font-family:inherit;font-size:10pt;">2,000,000</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">16,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock reserved for issuance upon exercise of incentive awards granted and to be granted at future dates under the 2016 Incentive Plan. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">8,214,032</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock available for future grant under the 2016 Incentive Plan, </font><font style="font-family:inherit;font-size:10pt;">2,069,936</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding but unvested restricted stock units and options outstanding to purchase </font><font style="font-family:inherit;font-size:10pt;">4,497,736</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive Plan generally vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years and have a maximum contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had options outstanding to purchase </font><font style="font-family:inherit;font-size:10pt;">4,767,654</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years and have a maximum contractual term of </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$12.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.8</font><font style="font-family:inherit;font-size:10pt;"> million was included in research and development expenses and </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> was included in general and administrative expenses, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of total unrecognized compensation expense related to unvested stock options, which are each expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$4.3</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, of total unrecognized compensation expense related to unvested restricted stock units, which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">1.6</font><font style="font-family:inherit;font-size:10pt;"> years and </font><font style="font-family:inherit;font-size:10pt;">1.7</font><font style="font-family:inherit;font-size:10pt;"> years, respectively.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and restricted stock units granted to non-employees for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$970,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$302,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$201,000</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, options to purchase </font><font style="font-family:inherit;font-size:10pt;">952,500</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock granted to non-employees remained outstanding.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes total stock options outstanding at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted    Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48-$3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">848,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3.01-$6.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,066,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,844,977</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.01-$9.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,454,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,210,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.01-$12.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.01-$15.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,745,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of options outstanding was </font><font style="font-family:inherit;font-size:10pt;">$918,000</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of options exercisable was </font><font style="font-family:inherit;font-size:10pt;">$881,000</font><font style="font-family:inherit;font-size:10pt;">, and the weighted average remaining contractual term of options exercisable was </font><font style="font-family:inherit;font-size:10pt;">5.7</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the aggregate intrinsic value of unvested restricted stock units was </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> and the aggregate intrinsic value of restricted stock units which vested during the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$3.5</font><font style="font-family:inherit;font-size:10pt;"> million.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, options to purchase </font><font style="font-family:inherit;font-size:10pt;">9,265,390</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock and </font><font style="font-family:inherit;font-size:10pt;">2,069,936</font><font style="font-family:inherit;font-size:10pt;"> restricted stock units were expected to vest.</font></div><div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity under the Company&#8217;s equity incentive plans during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was as follows: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,752,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,040,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,491,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,003,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106,634</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average exercise price per share was </font><font style="font-family:inherit;font-size:10pt;">$6.27</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">324,502</font><font style="font-family:inherit;font-size:10pt;"> options which expired during the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.17</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">119,091</font><font style="font-family:inherit;font-size:10pt;"> options which expired during the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$9.67</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">200,501</font><font style="font-family:inherit;font-size:10pt;"> options which expired during the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share was </font><font style="font-family:inherit;font-size:10pt;">$2.19</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.86</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$4.33</font><font style="font-family:inherit;font-size:10pt;"> for options granted during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value was </font><font style="font-family:inherit;font-size:10pt;">$3.09</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.31</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.66</font><font style="font-family:inherit;font-size:10pt;"> per share for restricted stock units granted during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company received </font><font style="font-family:inherit;font-size:10pt;">$113,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> in proceeds from the exercise of stock options during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. The aggregate intrinsic value of options exercised was </font><font style="font-family:inherit;font-size:10pt;">$25,000</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$910,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$519,000</font><font style="font-family:inherit;font-size:10pt;"> during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785659056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,003,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,665,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liability (Note 10)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,646,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,646,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,591,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,052,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Changes in fair value of the financial liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Initial fair value upon issuance of the August 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,055,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,763,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Level 3 liabilities held as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806818544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the Notes at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount on the liability component</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,082,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,938,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,700,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,180,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the August 2019 Bonds at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,578,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,764,346</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the August 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,946</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,824,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the December 2019 Bonds at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,067,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the December 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,017,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum payments due under the Company's convertible debt instruments are as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Notes (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">August 2019 Bonds (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 2019 Bonds (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,290,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,051,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,021,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,236,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,308,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,463,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,645,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,390,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,498,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;"> per year. </font></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> at maturity.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785670816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense (benefit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are presented in the following table: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> statutory tax rate for December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> statutory tax rate for December 31, 2017, is as follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (benefit) taxes at statutory rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,370,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,908,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,872,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income tax, net of federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,457,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,965,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,838,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,456,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(282,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,332,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,537,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,268,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">846,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired NOLs and credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,176,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited NOLs and credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(616,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,176,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,019,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,093,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> are shown below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,300,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,408,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOL carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,788,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,399,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development and other tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,737,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,432,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">985,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,013,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,408,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,852,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,722,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,413,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,693,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,229,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,250,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,159,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115,007,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,070,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,243,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(142,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right of use asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,894,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,862,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible note</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,381,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,121,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock', window );">Schedule of operating loss and tax credit carryforward expirations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Federal NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">State NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Federal R&amp;D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">State R&amp;D</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of unrecognized tax benefits rollforward</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to the Company's unrecognized tax benefits:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,632,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,313,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,855,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,575,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,319,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases (decreases) related to prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,204,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,632,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,313,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>368</ContextCount>
  <ElementCount>551</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004001 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Company</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Short-term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestments</Role>
      <ShortName>Short-term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Major Customers and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk</Role>
      <ShortName>Major Customers and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Convertible Debt (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNotes</Role>
      <ShortName>Convertible Debt (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2119100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2120100 - Disclosure - Investments in Affiliated Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/InvestmentsInAffiliatedEntities</Role>
      <ShortName>Investments in Affiliated Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2121100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2122100 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401KPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2124100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2125100 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2126100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Short-term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestmentsTables</Role>
      <ShortName>Short-term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShortTermInvestments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Major Customers and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables</Role>
      <ShortName>Major Customers and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRisk</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssets</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebtNotes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2317301 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2319301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/Leases</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2321301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2325301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesCalculationOfNetLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Impact of Recently Issued Accounting Standards - Impact of Adopting ASU 2016-02 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryOfSignificantAccountingPoliciesImpactOfRecentlyIssuedAccountingStandardsImpactOfAdoptingAsu201602Details</Role>
      <ShortName>Summary of Significant Accounting Policies - Impact of Recently Issued Accounting Standards - Impact of Adopting ASU 2016-02 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Short-term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Short-term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Short-term Investments - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShortTermInvestmentsSummaryOfAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Fair Value Measurements Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Fair Value Measurements Marketable Securities and Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FairValueMeasurementsMarketableSecuritiesAndFairValueMeasurementsFairValueOfCompanysDerivativeLiabilityDetails</Role>
      <ShortName>Fair Value Measurements Marketable Securities and Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Major Customers and Concentration of Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskDetails</Role>
      <ShortName>Major Customers and Concentration of Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/MajorCustomersAndConcentrationOfCreditRiskTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsSummaryOfGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2414403 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillAndIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Convertible Debt Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2415403 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt - Balance Of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2415404 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleOfMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AccountsPayableAndAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/AccountsPayableAndAccruedExpensesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Stockholders' Equity Summary of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryOfPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity Summary of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Stockholders' Equity Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Stockholders' Equity Summary of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity Summary of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Stockholders' Equity Summary of Stock Option Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryOfStockOptionActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity Summary of Stock Option Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Stockholders' Equity Summary of RSU Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryOfRsuActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity Summary of RSU Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2419402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2419403 - Disclosure - Leases - Summary of Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryOfMaturitiesOfOperatingLeasePaymentsDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2419404 - Disclosure - Leases - Summary of Future Minimum Lease Payments Before Adoption of Topic 842 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/LeasesSummaryOfFutureMinimumLeasePaymentsBeforeAdoptionOfTopic842Details</Role>
      <ShortName>Leases - Summary of Future Minimum Lease Payments Before Adoption of Topic 842 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2420401 - Disclosure - Investments in Affiliated Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/InvestmentsInAffiliatedEntitiesDetails</Role>
      <ShortName>Investments in Affiliated Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/InvestmentsInAffiliatedEntities</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2421402 - Disclosure - Income Taxes Summary of the Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSummaryOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes Summary of the Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2421403 - Disclosure - Income Taxes Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>Income Taxes Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2421404 - Disclosure - Income Taxes Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2421405 - Disclosure - Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSignificantComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2421406 - Disclosure - Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesExpectedExpirationsOfFederalAndStateLossesAndCreditsDetails</Role>
      <ShortName>Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2421407 - Disclosure - Income Taxes Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2422401 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401KPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/A401KPlan</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2424401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2425402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2426401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ino-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ino-20191231.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ino-20191231.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ino-20191231.xml</File>
    <File>ino-20191231.xsd</File>
    <File>ino-20191231_cal.xml</File>
    <File>ino-20191231_def.xml</File>
    <File>ino-20191231_lab.xml</File>
    <File>ino-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972972400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fixed Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consist of the following:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Depreciation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31, 2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,007,935</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,996,777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,011,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,229,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,048,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,944,293</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,781,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,996,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,939,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,166,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,773,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,909,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,464,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,444,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,031,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,425,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,606,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,198,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,767,653</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,808,824</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,341,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,466,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,948,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,999,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,949,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation expense for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2017</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented.  During the year ended December 31, 2019 the Company disposed of fixed assets with a net book value of </font><font style="font-family:inherit;font-size:10pt;">$6,000</font><font style="font-family:inherit;font-size:10pt;"> and accumulated depreciation of </font><font style="font-family:inherit;font-size:10pt;">$432,000</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972987552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Agreements </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ApolloBio Corporation </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font><font style="font-family:inherit;font-size:10pt;">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product designed to treat&#160;pre-cancers&#160;caused by HPV, within the territories of China, Hong Kong, Macao, Taiwan, and may include Korea in the event that no patent covering&#160;VGX-3100&#160;is issued in China within the </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years following the effective date of the ApolloBio Agreement.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the ApolloBio Agreement, the Company received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$19.4 million</font><font style="font-family:inherit;font-size:10pt;"> in March 2018, which comprised the upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;"> less </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> in foreign income taxes and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> in certain foreign non-income taxes. The foreign income taxes were recorded as a provision for income taxes and the foreign non-income taxes were recorded as a general and administrative expense, on the consolidated statement of operations during the quarter ended March 31, 2018. The Company also incurred advisory fees of </font><font style="font-family:inherit;font-size:10pt;">$960,000</font><font style="font-family:inherit;font-size:10pt;"> in connection with receiving the upfront payment from ApolloBio. These fees were determined to be incremental costs of obtaining the contract. The Company applied the practical expedient that permits a company to expense incremental costs to obtain a contract when the expected amortization period is one year or less and recorded the fees in general and administrative expense during the quarter ended March 31, 2018. No additional advisory fees are due related to the ApolloBio Agreement. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the upfront payment, the Company is entitled to receive up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in the United States, China and Korea. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the terms of the ApolloBio Agreement under Topic 606, and the license to VGX-3100 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the agreement consisted of the </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment.  The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain at this time. Future potential milestone amounts may be recognized as revenue under the ApolloBio Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> year after the effective date for any reason upon </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days written notice to the Company.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under Topic 606, the entire transaction price of </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;"> was allocated to the license performance obligation. The Company determined that during the quarter ended June 30, 2018, the transfer of technology occurred and accordingly, the performance obligation was fully satisfied. The Company has recorded the gross upfront payment received from ApolloBio of </font><font style="font-family:inherit;font-size:10pt;">$23.0 million</font><font style="font-family:inherit;font-size:10pt;"> as revenue under collaborative research and development arrangements on the consolidated statement of operations during the year ended December 31, 2018.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AstraZeneca</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 7, 2015, the Company entered into a license and collaboration agreement with MedImmune, the global biologics research and development arm of AstraZeneca ("AstraZeneca"). Under the agreement, AstraZeneca acquired exclusive rights to the Company's INO-3112 immunotherapy, renamed as MEDI0457, which targets cancers caused by human papillomavirus (HPV) types 16 and 18, with the ability to sublicense those license rights. AstraZeneca made an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$27.5 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company in September 2015. AstraZeneca may be obligated to make potential future development and regulatory event-based payments to the Company totaling up to </font><font style="font-family:inherit;font-size:10pt;">$125 million</font><font style="font-family:inherit;font-size:10pt;"> and potential future commercial event-based payments totaling up to </font><font style="font-family:inherit;font-size:10pt;">$115 million</font><font style="font-family:inherit;font-size:10pt;">, in each case upon the achievement of specified milestones related to MEDI0457 set forth in the license and collaboration agreement. AstraZeneca will fund all development costs associated with MEDI0457 immunotherapy. The Company is entitled to receive up to mid-single to double-digit tiered royalties on MEDI0457 product sales. Under the agreement, AstraZeneca can also request the Company to provide certain clinical manufacturing at an agreed upon price. The Company determined these options did not represent material rights at the inception of the agreement. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Within the broader collaboration, AstraZeneca had rights to co-develop up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> additional DNA-based cancer vaccine product candidates not included in the Company's current product pipeline. The Company has received notice that AstraZeneca intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457, that were covered by the collaboration agreement. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2017, the Company had recognized all of the </font><font style="font-family:inherit;font-size:10pt;">$27.5 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment as revenue, as all identified material performance obligations had been met with respect to that payment.&#160;In both December 2018 and March 2019, the Company recognized as revenue </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> in milestone payments from AstraZeneca triggered by AstraZeneca&#8217;s initiation of the Phase 2 portion of ongoing clinical trials in the second and third major indication, respectively, under the agreement. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized total revenues of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> from AstraZeneca primarily for manufacturing services, for which the Company determined it was the principal in the arrangement as it controlled the product supply before it is transferred to the customer, and the milestone achieved as discussed above. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accounts receivable balance of </font><font style="font-family:inherit;font-size:10pt;">$161,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the collaboration agreement with AstraZeneca.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Coalition for Epidemic Preparedness Innovations </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April&#160;11, 2018, the Company entered into agreements with CEPI, pursuant to which the Company intends to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI is to conduct research and development so that investigational stockpiles will be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplate&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI has agreed to fund up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$56 million</font><font style="font-family:inherit;font-size:10pt;"> of costs over a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company received funding of </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, related to the CEPI grant and recorded those payments as contra-research and development expense. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had a grant funding liability balance related to the CEPI grant of </font><font style="font-family:inherit;font-size:10pt;">$5.0</font><font style="font-family:inherit;font-size:10pt;"> million recorded as grant funding liability on the consolidated balance sheet related to the CEPI grant.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813166400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (87,764)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (106,771)<span></span>
</td>
<td class="num">$ (62,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,169,811<span></span>
</td>
<td class="num">$ (257,335)<span></span>
</td>
<td class="nump">$ 2,169,811<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxBenefitsExpired', window );">Tax benefits expired</a></td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">483,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">186,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">149,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">68,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">80,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Benefits Expired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791902832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution to 401(k) plan</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813653552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,668,837<span></span>
</td>
<td class="nump">$ 2,428,671<span></span>
</td>
<td class="nump">$ 2,194,783<span></span>
</td>
<td class="nump">$ 656,248<span></span>
</td>
<td class="nump">$ 7,948,539<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,315,105)<span></span>
</td>
<td class="nump">$ 2,551,453<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,938,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,938,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,082,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,082,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,578,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,578,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,764,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 18,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 982,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage', window );">Debt instrument, convertible, required bondholder approval, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Debt instrument, convertible, carrying amount of equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 10)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage', window );">Debt instrument, convertible, required bondholder approval, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember', window );">Initial Conversion Price | Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0002110595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember', window );">Initial Conversion Price | Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0002147766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price ($ per share) | $ / shares</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember', window );">After January 2, 2020 Conversion Price | Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0003517658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_EventOfDefaultMember', window );">Event Of Default | Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember', window );">After July 2, 2020 Conversion Price | Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="nump">0.0003579611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | After January 2, 2020 Conversion Price | Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price ($ per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | After July 2, 2020 Conversion Price | Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price ($ per share) | $ / shares</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Required Bondholder Approval, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleRequiredBondholderApprovalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_InitialConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJanuary22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_EventOfDefaultMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_EventOfDefaultMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=ino_AfterJuly22020ConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806882528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 25,939,475<span></span>
</td>
<td class="nump">$ 25,948,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(13,166,458)<span></span>
</td>
<td class="num">(9,999,919)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">12,773,017<span></span>
</td>
<td class="nump">15,949,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,598,388<span></span>
</td>
<td class="nump">3,747,183<span></span>
</td>
<td class="nump">$ 1,850,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposed of</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1', window );">Accumulated depreciation written off due to disposal of property plant and equipment</a></td>
<td class="nump">432,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">15,007,935<span></span>
</td>
<td class="nump">14,909,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(4,996,777)<span></span>
</td>
<td class="num">(3,464,444)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">10,011,158<span></span>
</td>
<td class="nump">11,444,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">4,102,467<span></span>
</td>
<td class="nump">4,031,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(3,229,357)<span></span>
</td>
<td class="num">(2,425,854)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">873,110<span></span>
</td>
<td class="nump">1,606,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,048,053<span></span>
</td>
<td class="nump">3,198,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(1,944,293)<span></span>
</td>
<td class="num">(1,767,653)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">1,103,760<span></span>
</td>
<td class="nump">1,431,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">3,781,020<span></span>
</td>
<td class="nump">3,808,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,996,031)<span></span>
</td>
<td class="num">(2,341,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 784,989<span></span>
</td>
<td class="nump">$ 1,466,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated depreciation, depletion and amortization as a result of sale or disposal of property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792261312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,538,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">$ 6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 10)</a></td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">US corporate debt securities</a></td>
<td class="nump">67,338,017<span></span>
</td>
<td class="nump">57,314,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">76,003,102<span></span>
</td>
<td class="nump">76,591,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 10)</a></td>
<td class="nump">8,819,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">8,819,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">8,665,085<span></span>
</td>
<td class="nump">19,052,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">67,338,017<span></span>
</td>
<td class="nump">57,538,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">US corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability (Note 10)</a></td>
<td class="nump">8,819,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">8,819,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,349,729<span></span>
</td>
<td class="nump">9,646,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">2,349,729<span></span>
</td>
<td class="nump">9,646,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">67,338,017<span></span>
</td>
<td class="nump">57,314,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">67,338,017<span></span>
</td>
<td class="nump">57,314,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813898368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">30,737,956<span></span>
</td>
<td class="nump">10,449,150<span></span>
</td>
<td class="nump">8,937,494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">9,265,390<span></span>
</td>
<td class="nump">8,752,677<span></span>
</td>
<td class="nump">7,694,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">2,069,936<span></span>
</td>
<td class="nump">1,688,017<span></span>
</td>
<td class="nump">1,234,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
<td class="nump">8,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024 | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">14,585,653<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,799,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds | Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CommonStockEquivalentsAbstract', window );"><strong>Summary of common shares that were excluded from the diluted net loss per share calculation because of their anti-dilutive effect</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">1,009,450<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CommonStockEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CommonStockEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811454144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 11, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 29, 2017</div></th>
<th class="th">
<div>Aug. 07, 2015 </div>
<div>product</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 2,502,624<span></span>
</td>
<td class="nump">$ 2,000,868<span></span>
</td>
<td class="nump">$ 24,448,761<span></span>
</td>
<td class="nump">$ 1,529,644<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
<td class="nump">$ 42,220,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,165,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,065,212<span></span>
</td>
<td class="nump">4,165,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod', window );">Territory expansion option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromCollaborativeAgreement', window );">Proceeds from collaborative agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementAdvisoryFees', window );">Advisory fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Agreement period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_MedImmuneMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_MedImmuneMember', window );">AstraZeneca | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones', window );">Agreement anticipated development and regulatory event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones', window );">Agreement, anticipated commercial event based payment receivable milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumberOfAdditionalProducts', window );">Number of additional products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized', window );">Agreement, milestone payment, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,300,000<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Deferred grant funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | ApolloBio | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementCorporateIncomeTax', window );">Collaborative agreement, corporate income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementForeignNonIncomeTaxes', window );">Collaborative agreement, foreign non-income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Commercial Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedCommercialEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Anticipated Development and Regulatory Event Based Payment Receivable Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAnticipatedDevelopmentandRegulatoryEventBasedPaymentReceivableMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementTerritoryExpansionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Territory Expansion Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementTerritoryExpansionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Advisory Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementCorporateIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Corporate Income Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementCorporateIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementForeignNonIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Non-Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementForeignNonIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementMilestonePaymentRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Milestone Payment, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementMilestonePaymentRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfAdditionalProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Additional Products</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfAdditionalProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromCollaborativeAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Collaborative Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromCollaborativeAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_MedImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_MedImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792699536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity Summary of Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">9,265,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in Years)</a></td>
<td class="text">6 years 5 months 31 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price ($ per share)</a></td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">6,745,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-average exercise price ($ per share)</a></td>
<td class="nump">$ 6.37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember', window );">$1.48-$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit ($ per share)</a></td>
<td class="nump">1.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit ($ per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">903,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in Years)</a></td>
<td class="text">3 years 4 months 31 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price ($ per share)</a></td>
<td class="nump">$ 2.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">848,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-average exercise price ($ per share)</a></td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember', window );">$3.01-$6.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit ($ per share)</a></td>
<td class="nump">3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit ($ per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">4,066,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in Years)</a></td>
<td class="text">7 years 10 months 30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price ($ per share)</a></td>
<td class="nump">$ 3.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">1,844,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-average exercise price ($ per share)</a></td>
<td class="nump">$ 4.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember', window );">$6.01-$9.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit ($ per share)</a></td>
<td class="nump">6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit ($ per share)</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">3,454,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in Years)</a></td>
<td class="text">6 years 31 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price ($ per share)</a></td>
<td class="nump">$ 7.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">3,210,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-average exercise price ($ per share)</a></td>
<td class="nump">$ 7.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember', window );">$9.01-$12.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit ($ per share)</a></td>
<td class="nump">9.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit ($ per share)</a></td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">220,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in Years)</a></td>
<td class="text">5 years 9 months 30 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price ($ per share)</a></td>
<td class="nump">$ 9.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">220,880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-average exercise price ($ per share)</a></td>
<td class="nump">$ 9.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember', window );">$12.01-$15.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit ($ per share)</a></td>
<td class="nump">12.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit ($ per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (shares) | shares</a></td>
<td class="nump">620,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Life (in Years)</a></td>
<td class="text">4 years 2 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price ($ per share)</a></td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (shares) | shares</a></td>
<td class="nump">620,043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted-average exercise price ($ per share)</a></td>
<td class="nump">$ 12.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788394368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 26, 2019</div></th>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 64,180,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">8,824,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember', window );">December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">4,017,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2020</a></td>
<td class="nump">5,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">106,308,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">127,498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2020</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">5,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">81,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 101,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | August 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">20,021,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 20,645,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2021</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">5,236,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 5,390,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleInternalRateOfReturn', window );">Debt instrument, convertible, internal rate of return</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleInternalRateOfReturn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Internal Rate Of Return</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleInternalRateOfReturn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813983296">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="2">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(231,366)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="num">(312,310)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">231,366<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 312,310<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Upon adoption of ASU 2016-09 on January 1, 2017, the Company elected to remove the forfeiture rate from the calculation of stock-based compensation and recorded a cumulative catch-up adjustment to accumulated deficit with a corresponding offset to additional paid-in-capital of $312,000.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Upon adoption of ASU 2016-01 on January 1, 2018, the Company began to measure and record equity investments, except those accounted for under the equity method of accounting that have a readily determinable fair value, at fair value and began to recognize the changes in fair value in its consolidated statements of operations, instead of recognizing unrealized gains and losses through accumulated other comprehensive income (loss), as done under the previous guidance. The Company recorded a $231,000 cumulative effect adjustment to reclassify the cumulative unrealized gain, net of tax effect, from its investment in PLS from accumulated other comprehensive loss to accumulated deficit.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794083648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020</a></td>
<td class="nump">$ 3,891,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">3,979,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">4,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">4,023,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">3,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">12,951,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">31,897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(9,412,236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">22,484,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,074,842)<span></span>
</td>
<td class="num">$ (1,733,600)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 20,409,922<span></span>
</td>
<td class="nump">$ 22,484,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years 2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6973045984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Financial Information (Unaudited)</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the quarterly results of operations of the Company for the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> (unaudited):</font></div><div style="line-height:120%;padding-top:6px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br clear="none"/>2019</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Statements of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,523</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">617,427</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,770,712</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,665</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,014</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,390</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,579</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous revenue, including from affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,422</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,614</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">279,488</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">866,863</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">135,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,829,905</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,003,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,137,209</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,486,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,389,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,696,586</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,681,441</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,850,101</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,975,029</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,700,541</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,818,650</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,336,367</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,364,917</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,421,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,951,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,200,694</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,535,012</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">587,679</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">637,438</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">755,330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625,535</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,668,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,428,671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,194,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(656,248</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,315,105</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,551,453</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss on investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,681,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(173,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(750,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263,571</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,512</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before income tax benefit</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,235,146</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,536,452</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,685,847</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,351,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">87,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62,800</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,147,382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,536,452</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,579,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,288,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to non-controlling interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">485,344</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">445,759</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191,850</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss attributable to Inovio Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,662,038</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,090,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,387,226</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,219,262</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.23</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quarter&#160;Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">June&#160;30, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">March&#160;31, <br clear="none"/>2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Consolidated Statements of Operations:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,372,600</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,813,287</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,385,852</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,289,046</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue under collaborative research and development arrangements with affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">184,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,319</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148,008</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miscellaneous revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73,817</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,590</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502,624</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000,868</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,448,761</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,529,644</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,365,647</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,851,858</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,462,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,577,751</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,636,141</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,791,693</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,189,310</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,698,015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,001,788</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,643,551</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,651,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,275,766</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,499,164</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,642,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,203,169</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,746,122</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(169,300</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">380,987</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">396,681</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,523</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of common stock warrants</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">228,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127,841</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) from investment in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293,741</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,017,359</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,092,608</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,380,423</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss before provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,962,205</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,015,672</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,639,125</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,181,017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,169,811</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,962,205</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,015,672</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,639,125</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,350,828</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net loss per share</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.36</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788220464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value ($ per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value ($ per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">101,361,034<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares (shares)</a></td>
<td class="nump">101,361,034<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6973080880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Affiliated Entities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Affiliated Entities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Investments in Affiliated Entities</font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company held </font><font style="font-family:inherit;font-size:10pt;">1,644,155</font><font style="font-family:inherit;font-size:10pt;"> common shares, representing a </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">7.8%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in GeneOne as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">395,758</font><font style="font-family:inherit;font-size:10pt;"> common shares, representing a </font><font style="font-family:inherit;font-size:10pt;">15.0%</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">15.1%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in PLS as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. Please see further information as discussed in Note 2 and Note 6.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.3A-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355119-122828<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6968863584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_IssuanceOfCommonStockForCashFinancingCosts', window );">Issuance of common stock for cash, financing costs</a></td>
<td class="nump">$ 4.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IssuanceOfCommonStockForCashFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for cash, financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IssuanceOfCommonStockForCashFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>75
<FILENAME>0001055726-20-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-20-000012-xbrl.zip
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M#=)1C3RM#&IXS7W:K^&TQ1$-+TB23HT+L3BBX05IVOVK^05^1-,+1L/[-2^
M$0TO&-Z#O[P>$;-A3:\:/VSPHNF@JM?4T;.2A''W37?0NZWS$.?/:R;7QQ#%
MTYJ)=6I\^JQV4FUX-7M<,W4XKM@:*";"P]IICXV?G#ZOG_Q88PAGCVNF/OU9
M/^_ISZI)MX]ONGTP'S6ZH'A<.[4"R/G$2@CA2;T-F#ZLF98T34MJI]7KQ^G#
MFFGC;B-:)H^KIM['W0H7;C+-/ZJ:DLS)O>2!PP,_')>&UX<-^<.::8T1Q\*
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M_Z^_^>F3B.BA\RF^_6[RNI_N)^F<9)"^*7+H/WP;^ISDY*FGP7]\/TP>'OL
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M9F$==%<G-^O5Y 1EET[[0DDN ',D4I^#W,L-Y#XW'\NR$7I@D_A"?,)FT=\
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MW_+<D(5%W2:C.GM8FT-U BM#0Y!P[ R1E%)9'/L*HZ"\K3WCQ<W6\_+UEVM
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M[PYOJ5; 'R-"AT%(0EBD\6P/LBH)Q@H\_?H0:=ME[1.@)NIH((KT#2 YIXJ
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M&07@H2M67)(3F/*M2Q#X@^&C<J_P5.PX+]CTI*K%:C/3*1PI\%<@IJ""!-)
M@&&+;*2,7!DJBC6HCCJ@UJYOKZ U,Z#A0@6@ VP@0%DSA4RAK1V&G\IMNS'H
M0\K/ [0U=WEH'EI0W1ADAL@((9JW\#80UD2Z?!L&5@LZ;W^ ->ZM+.]>EL*)
M#:+CP#$*;@&QH.D8Q)407T2" 4%=9&6Y+X5O(P]#=!V@VZVV'NI)U6#2*UHS
M0LCR870?9WFIQS1HJ:H%V?J.'!E$' F'P%\RX'KHD.F"@<'[+FE0"M"K6GNP
MZZJ/@8=F06:"A:%!5BCKE*"*\"C'@S$:116>+YA+1"X1$6M,4&@F9\84AR#;
M(J4YP85)!1-4"KS>2#2[)NSP>$@&585IE259ZWD?(FF!K0C#".R1L(X(D5_9
M2)@)14GV:[1;XYKV!,@:YD5:*)!DP9E2$+=A9 JW :2;E=(B2\7<IP!GC4[&
M5E(+_BB'$-EW I8\3TJYB-*HG+%4$"05US =$)SU9;$;Y,"Y$0B,# K!6;7&
MHL#E#5$,<&-05X*T^P(/ >*:BW.83R/X"S^<LQAT2907+ULB(L)*B9"%XN7S
M G/-#:G(6*-#&S#'=: (%J+(10I$1(F2"@O*:@S&#G .A^/.H+M\6YJ_<[4S
MO)\5#KETN.'NXU+J#;.0XR!@H2:"^RK*H%"+1#)9<M>97DB];;ZN I*W,5B!
M>-H3]</MQ$6:=Y\*)V68/EV;;G(%S<H9:*,T*'+E@BB$8-=*WQS/=R2BQ%KL
M%O5[WW\66'$*Q*9+6@9AV?4S0-CT]FUGT/M]T(NSR>\V >'-8G,6?Q$ZL\@R
M?QU0)**0*FI\D1FR_KJP15$:_GD[RDNX%X%8OZB] #$[/!A#@#D< ;^"J8?H
M<_PP[D^OI'C, ,1)IF/A7+WO-9'"%Q<RQ1_[SP_I>'3_+H[],C[&@\'PN?_4
M&22=YE-7X+Q)KB(:A."G2,0PXA$RTEK!X-]+=P].<<4E%9>-J\^=09#$=ZGK
M])/;-%N+(DG\254FG&;^.N%(*?#]C03G04*\O>3;35&D?%I]-Q3-FD1/+ASY
M\-<@SH;WR>.73G:W$J5-N[V2=YWG [1,JVT"11SX^Q&Q_A@9#P))BNA6$+Q\
M0=7\U&X1N#?"MAL"Q&_XU\[@B BPR!E_DR)X@MA?JPO&+,]<\!!+4GT*?RL$
MO$\'7NLWUO2O=YA Y6F"0PHZW(;:2A497=R=ZU3Y$%?.KM4?WW9I:ZYI#8*(
M.(T)H43Z)#?/[]<TDFF-2A79>UW:&A=:"N> J2W101@*;G@>VH!FC+ K.2><
M4*0YVVB!N5F<W[H%>JDW[H[*-T#P2:<$>=INN2ML3_R6!'/69^XH,[[DO+A>
M!.NE2T0?IV#-O()ZP%=1\S$=P5*23G_: "V_N>)_XAXX0H6#--&8D^<3&?(5
M%H#EB=+_V.^4FWJ(B8;$=(8!/VJYGZL?!9ZE__13[!^O0X8D"FD7.A-)1 UE
MRN*BNZ'3(&L5G?"6K@?8([RK*)R^Z</MWX$!?=IP.,J2[BAO1O9A/!KZJZW
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MB=>B*""'GY?K1RJ+1P^(O!?39^8J3XW:*/65F@M\,?WPV@3"*L(X#RSH21Y
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MTU[ :##?$%)(H6GHNRYQHW2H>%X*;QUHJ1(8F(+;RMA+X? !U>=.OY/MB/T
MO"*'(FVP")7F%H(+DH<3)**J7);G=W;)LI]4L89=5MF 7!Q(BVDDP9NF(E+@
MA.;)(/AM:&5)\2DMI-)RRU56W_[SV(\G1XT&OF@#*/$_TPL3\HN _"$_'S?Y
MKF>/I38P:YOV2(VTBWB@G0V)=B@T>4XF %%6I?! ^_]@O0377E9]-$S,#T_6
M3;//I>*?:)P!&L:93R)$R3?_4X6I7%(J.,*, Y,X8&@>6H29+-K$ 1>56SM(
M(06GUX;8R751OL?(S<-CECY-;U=KQJP.0VNB@(:AI!&1G,TZB+E01[C4HH$R
MP=B*GKL"S'X =Z8;ST8TX]27RUA0MXB&3B%C(Z5(P:VA<R5GGS!P<OG5X;1V
M[/2,)PQ?P[LJ5!:%BCEJ0V<C<):8*_",<%1JV4DHPUJH2\5S4[+!&2V9-"XP
MF$42S"K.I3@@6-!R S"*A6#\DE%Q+,NCM8P8=41$-'("_!.3)\[!P36DW(M'
M,T;TQ5J>71&[@^7Q)5U(A4*')+0\TI1S4U0_1&"$RI>B@A<HY;5A=DO+PR@-
MI*#$A(:YR17(LW:Z%1J1$N!5?G4X?;'EL2X(M*%6",!Q:+ADI+A/VTD<EOQ1
M KR+*#XK/$\+PFO?C+?N,","O[$CP!P#'@C8(X>8,]@ZQSG!Y99Q;++1LS-.
MUJV_!C5-78"K&Q*OVROVE>2*X8#JB/FH3Q4GX:R!$+"4*7C#)Z7!E7!OLKB]
MPM7@4R##"9%4,:T"(@$0'A7%51!^E3O0,NDOR=H/6//[(#M)[V906W/00!84
M,7!^K./^Y+*S$.2P/,= 0X[+6W422:D9\.D"!-7+V&FE37OSD2"84@/@",Y,
MI'PGT\E*&>(5K19!V0@FI-IVI?\:3[M9#[^D->-7>KW[&\=](^11\K4?!_'7
MK2]T1\HR"[PB9&##$,M0<S!(% E#"4>VG.#FDA.A%YEH#ZL^%A;*!W::>^=7
M?WV-@0\550$FANH081LRYC2P3Z2EL(*4KY Z#XQ6=_OY%,-GALFHN)9OVLSF
M4]Q-[P:3M]0T.FON LI0X @%D#DB\$,H69 G;D,3.53:;\3^(G@MR'88>@E$
MYX"]8_"J\3<$(DN#*-)\<M%TT<,P]+N>%2GTZZ)$<Q-8S[Z1%*'#+G+&EZ&Y
M(N49:5.^Y  C?TR+7!GVCL''1'#'0B?]7Y'UF]6N"*I<B***1O5:*;(4J;:4
M6*7$IWC4209Q+^QD_@CHFGA+,D09-Z#3L0XT%4KH8F/%7Q]8RA6\H90*SJ^%
M LU>F!!&AB%"VFK0)1%F$*)$ @>6,*EMQ>8)T@A#;'9=V#N&)A&$$Z0I-X*X
MD'))+$:>$I@%2MIR31A&4G.&:$N)!DKX$E??A3?M]T&13&Y\CH=K\F2&64D"
M23$#&QL% ED2>$(X9@D-RMOD&$(R?"J%WN^G71]%5W?AS:] 6>OH32/N&4K]
M.85)4J4H5 $TA@^/_?0Y7E>A$E G T40 P8V@5!,HGQ[2UN#RF<E82W+>9Z-
M -H'"M2A4.! AU**G;2@4"%@=X'+=P4,9LB4[!%%Y$0HT(?C @D.JJ.*.\5#
M3#D7>0H4S(LH%\AHB?: @K]\/Z@HS8)T_'5T.^Z7JVPVK9I9Z23,L)&^_#YD
M0:!L:&Q1HQ[80*FJFPIV6M8>X6GLC*R%$U@(*QP5.#3@J6I3-.L(A:HZ;O5R
M>!:2LQ]N01%W!G<^8S"]C6GK:WY8 #I:LX!QHDE( A$5VT-,R_)]C%CX:SH7
M7;[&Y;QDX6LN[=,N#$THI;_>/0H@ L8X+U47(HS*1VT(TURQ8RR\V4^T9E(S
M[RLKF>3:%ROGIVJ( A^EW'L!"0$$VFGA@U'22_ICWU?]<]P=9Y/C0^&W;G_<
MBWO3BZ@>'L>C_%5%D%!<8%?5-6<]1_D:/AUQCB3WC;%LA(HKZ3G'G%9U"U>^
M#>L2B/M8^-$P,?=67_85^US]@I4F1$LYPOFHE1.0_J$OALW&DX9LLV;[X@>.
M%M[Q.1XD:?8^'<7#8!P31%BS2Q<HPPBGPC"&0/ (99I$$/D@!^J<+9TR*JB+
M6KH>@:[C.W"5O?)9>)%-![TU(3\."#<A1*HZHA0%%MSSG)X,U"BIDM:6GD>@
M9P N@!^W/469%AP<9>,(T% KS<#4Y!1%G 2NI>C+*5I])6J-/8RHE2'%@:(.
M12QBF@:%/11<5]U5H!@7+4DV($D11"U<7]9,# <!) ]!0A R6D;>9LF"&$&H
MJB[4D,(?$FE%9!-Z;'S-R7+5N6]^'@CL(" $!Q$9G'?$XR( ^E30Q/L=>*G$
M]$)HTAS3B( P3+0QOG1"A8(%IN!.B@BM:KF/$6,:\PMD3W5Q-OFEOK-0 681
M$;X]IHT"IV1$IY:9,XR6TJ$7;)DOD*Z[^LZ&V(@')@!2!BR40OAF&1-Z!ASI
M5^)I71X]=_>=(VLC?T4Z=I-K[)$2F$\I*D %FRH%W%+T@+ZS,)8'0@D2^GXS
M\/^^S#!WURS\[]7XSB<@R=:^L[\LT2KE#^IRC$'ID;#P3IC"JNI*,.7+XI9*
M-%IZ[-5W]L4QELLHB'2D%9%::E;01$A,JCQ& 33$%TB3YK0Z#ZB%6,Z2D!CP
MHR/"BM. 7 @MJXPQ*'HJ]26J"WUQ-OFEOK/6G&L@K-6  $TLUPA-+3-UFK/*
MT(AQQ9>/)[?D/3,76BN*G8_[,9-2D( XFI-5&F)DE?X"D=7@H;54/6='6C(=
M,<=]Z8I51D5<2I8GH9UOY5:9R4":76(BX[1TW<:=5D@;IBVV2 ;^/CPFBY;U
MWENH#&\NTYT^ 4FV=J>UM(B%X*E81PWB+(J*BT X\[VVFV[5;NEQ&'>:.&M]
MOTF'">4X8&IVL)<+:2N]C-E]VX>C2469R9I3>1X(P[#CU/+0WY*"J2S:*E&)
MR[7(%&-,R5)=3[F:I&8=#6?NC,2A IR&7(%!,!),?=$/EX _ATOK8%1SS)=Z
M$-6L8Y>V31$S'"(#2QU7A!/K>S+ERZ&&1Z5#2THJ#&$$6UU-5556\Z(:<"3@
MXU0IO_T$N$$11'!YA9^Q+$+E;D;^\DPM],:+BCI)-BEW#9)AMY\.QUE<B;5Y
M^X9B@GV>_?B?29SY=MG/;^.GN+_<[:$8<S, MAY.!N 5!V/AE>_BCE^"=S2B
M;'(Y6?>Y^GT+(WU)', '@K+FQ+AO\*N QMI?.A9A@UUQ'#42-BH?W-.(^]M(
M5Y%9@;/S0"PY$6)=Y! 8)1MI+(23OGT1RT_/8J'+S7:XY)ZIR<4@EIX(L8'0
M$:'8AI1%@0AD&#A4'$N.$"H=>SH^JQY68"._*69 5IU6?KM3.5* ;P-9*O&6
M LP&D0?D*_TZ-*'B%BRN1@Q,A9(4T<*L6,HU>#,E6R<$1ZKD )PM7D^E"",$
M49,TX%@%+@HCS%U0W$[BB"WW?A$2K/MROO6\$7LJ18@,N-TB"A %R\V$$:'.
M@],(25QNTWM 15B#T</*JP2(D3(NP( %HB)%\];K5#)3=I6E0(ABM+4B?.HD
M?7^R($HSW]IE.2VTT$SDERP=#G\?9'&G[Z\,_:63#&Q\FV;QMHU; FP-=9;#
M:ED$,(9!F"?FHY"2\OGT1;KN8[''@7[. \F@,^@FG7Y%/NW=>#3N]*/QVO09
MT1QD00CP"HS TM&@V&ISUD2V=$;@E>)LEIZ<79Z4/:89?*LJF5F;BE2,.(1]
M;QU?5*60PM/S"!:A('"O@?_TOODO@)@=<P$NOE)&F  QEQ\$5Q*K\D6#DC,(
M"<X0<;[UT6YJRU)  &.8@K'W36ZY=H4Y"J7 I5P!)^!EB9>C8&G%QT'!?GDG
MY-2R($#",0G>$1&<VT+>))&E@ 80AY;.9;TBQ.U%@3&L!'+<.9_7,(8;Y'#!
MB4;;TBEJL11U7P@V]Z["@.L"B64DB PT1)4F-+G;H4P([F6YA9/&^'1XFY[I
M\X=SAR/;&2;;Y7LC9+FRH)B=93S0D=]/SUDD4 J7G$>ND+\/1&T,;VEY>P=M
MSPX4X5)0&?A+^X(07% L"P,&D)>S*MQ["7JIE<G9(V0ORL6WZ9-.02!!E8B0
M]O<&Y9SCA-7E+@.$B:4+^$Z*IKUK#>7Q ,X,%@%CD:8&%==)^7NQRDU<A.!:
M$[RYZ[,50N;SEM^RE6X@EEDD%,!%. DX130@A3W6-"RU5J[(W&ZXK+V!\AKR
M;\*ZT 2,A*'ACCK%@KS5 4A<:$5C:X!+QO>I\G((,XJ-[\+H;!A1%S(^PS?B
MO!3F$4*U:C#X%X7T4^7L:"2=OX$(!<CZC?+ (%X@74:LZD+ZL\+W09$#;$<Q
M!C?$,:--A)7)6V1:AC$Q);_]C#AR'Z8T O,<A3:$,# RQ-'_S]Z[-K>5W.K"
M?V57OCNG&WU!XU2=7=77')^:&3LSDYW*I[<X$FTSD4EO4O+$^]>_:'(M6623
MBQ>1DNQD4O&,;4H"T&C@ 1J7@-W*5<^ G,%GZW>4U Y?M #. KGJ!)^Z "83
M(AC&7JH? ")D7=KWLO3B[!#+@I&YL@]:9N1@E>.Q#IH3:&@,]98'E!,$T(_<
MK?..KI>[*1:O5SM[K\/=[4^SV[^-;^M<L:/GX$I(FE&C8-IS2%888?MI+JSP
M6Y8+&K[]#Y@YE+#S,#/<?^JB,=G&V@AMO?"1KVZ__A6M36T8:<AJ^UR\#/<#
M *-W[6-=B6R\<W5%<+>KQ;.74D,+44]C8_'!3Z_KO^H8O<^LEG6"WFK_.[N*
M+:/X]@V\9QPNK,@EY%0TF1B+N:^=$NUAU&G,:BTV.XBF,S QM().@Y<95&'[
MGS(8#J)4/[6_(H?6UDFR@O#L3'R/15#GM<N"(8J("G5$&93*K&5][2-*AG:#
M%^9 D?_[G 9AQ8^SZ?C+CZ/Y/\:WAP"LA"DX6]!;D[.+UO:E,QS5AW8"6K75
M1NR]6M_,L5TZTCSO]2*;C/)>:_*!"JJ@3>FB 0!MVO>D!@[_^[B>Y9;YN@5"
MIY)R",HK$_J*4BVRDDV]S_=C%B^=5#AS6%&]5DDA\A5+1,"'1'WE;UCO)/OW
M.;V(BV5L5J8&'!P$1Q1L&/MV<BQ)?@,']@)O04ZD.>3A*X!&!A&$I[X+NK88
M-"#NQ7J9EZRYF!DC4Y#1&LSH$@3=U\(+HU/CRI\=>'UC)<WGO1)2",.>FAS4
M?R,J-%U_3<7,NHFCG]'.?&_G=*)C$%HIFZK[9M#E2TJECVNL"+G-&2A-"/3=
M'-NS ^6CKI<.WBAC;1W5ETT&FW37XI<Y"FW3_&TZ]]_']1RWS-:T@9,^*Y7Y
MOQ@DW^-EDU1JR@*^'[/X['CYJ/N%*:&-M0(\<A0#Q2E=^KX 97R3Y?GW.3WS
MQ2)#/B^;UY(F([T4V#=>V41IJ*'OA1S8"[P%EC(CZ!#J-1!*^)3[]E-EZZ[X
M;\;+O&3-%0Y4]+**%6H7EO?],+&<V.ZT#]-G UZ;KSO3ZU\^S.:WOX[G'U]/
M/X^['5![7YY>F;7E4P8C6TZ,*3A%(4?JWIF]UT$U#LZ1$>N[<PZG; \_7V=1
M=!):_X,'GVQ9M .3 P3$)%0V5/C4="20V#W7<D!JFTLA22JK'_;./HK6"S*-
M VN<7<E\X^L>:42CI"FRPYN44/DMT0$ZCM/IY3,]\!;L#!$?:5V>%#/:[&7J
M9L5$Z4J[97O[6_!+9'K@[5B1R*S;PC+RR<!!(*E^ 5K)J!I'NOWM^/F97NV>
M>SV]FK-%'Z?QZM_\^YN[:S;I^9]7'T;3]^.?1[?C_.[=^.KHC3N8E+11DY00
M-;!L0@\1@32U#X$U&R4W\U%/Q]Y+$NR>>AAG%5@PK@HL. YHJ8N1:DE6:2KX
M7A$+W/Y;KOMJ<YQ6+J6@P9.(QB<*T*_ LMZV[2JO) ,-HUZ&9&]&B\6;=W\=
MS>>CZ>V;^<^3]Q]NWW#,<CN:UJ\^<B.>),41GM2,MHPRH4["$!*<AAQD4%L7
M4CQ$*'N(>1SA@ZOO5,)@K4DB,ZS(?);9=5UI?+11;9L&?"KALX\?)RN<5<$E
M4\D?8-R\NQ'B:Q]K*M$$E";G5-._0MM^'% $UTRM^8]_+B;_>SJY^3]_8# ]
M_L-__*^3R: U,H2-7CNCM%0^U^4.MM\Z$E(V>7,6QUXR9M/5E+G;#]W0L,6^
M<[R/"-[>C*8_C3Z.OT[N!"&0=9_YFGP>U[]N@X3UDS<9'%F7"5#S_<TF)MUO
MY00;MJFL1HO6/&CRW,O%A5F6]BB694J)+ZKU(>?H0$K7-Q,2*:)M<^$TFZRU
MAN!367X[FK^9+U>)7B^CJ'Y0W)&&AD^ XR%M&#(CFQCA(W3/(([9<AOA4/]#
M^-+^40BYE8M=A#V:CT&[ YERW1%O<XDYH\S&]W;'NN9*7X"/U;GYNUN. VLG
MU[$K4$LD#EG .U_G< HGK>GI%QS#;5$E*[I_MI*_2<_)9 ]O.DU\?UES0BQ0
M9WBX(KM+[U0._L)DOUXL[HZ6M&,EY^B(KV=67K'ZYWX((GM<VKINA1 8[<DA
MBE>DG$3MH("E#UHF98M7@HI.IG_U\A@#;A]P+3B>ET)MMZL'DWLZ>+$Q. Q,
M<[0A"P\J]^L9G,6X=<KO 1+>;Q(/<P"[Z0[L=$6$[%WM@.20.MJ^-<4K9[=Y
ML$-DO9_P_SJZ"EPDX74P2D4.0$((&%4W;LK'8F-3)5/EN]WI_%=3*+V7KH'@
M/.5$GMC?.T:PT8)*_:NZE4:H+:O=J_P.)NS3?/QA/%VP>UZMTOYI?/OF73,X
M8']H;#"!5  9P%DJJ*6U]Q%<A"8)^,K5W7"HS1JENZ@YF>CAL).M:R;*4?"5
M<E&%R""[(UJ**-KPB.H29+5Q[F<G>CBF2P H5%(<T@4DJC:ABY5E <;>;4PG
MG:ICP?4YJ?:W'/+]=G=;NX-^G?TTFU8NYK.;&[Z3KYD?OJ5'IU>2RG4[H- )
M$SL3X8+HNV( 8OOV( YBZ!!*+\KTL X&K[V-I5 RBOAR:X.B9]H$]ZTR/:S#
MF7TO&"00F6,9%'5/6\\TEM3F>Z0D,,8]->_WJ8JW=9K ;'H)K3<V%0+"G!6P
M&5+>0=<_%:V1JKW/1UG.4SAX4N$,WPZHR8_L4E36YV215+]L)B(;BR8??YR%
M?O'"V=-YITS(4I3L^-9@?:&Q7806%4?135-XO46&,</#6887E<XR\I\OYZ__
M/%G\@^.]^@>C]V.Y<XGJ8G[[__TX^OML'N\6MTS,?/$UFW!SLXSG[_]FXXVV
M^7GA2QA/KSY\',W_L3&Q_O-X>C=>38BO7W!U^]?)[8?^^^[_MK]^^31>7Q/1
M?6GSV3;? 6L5# $#"N1[[I(V4D+?>5BS!VOIV>G=\AO5Z/KA"]N B"]Z%)_X
MV&=A,OOFCR (CDV4Y+ U%5]<(-MG.8PNL#98X<$1B.<_@C1^QY=V[*\_C_@;
MUQS\N);\O)W/_CZ^NEWXFC']DOS/;_TW?T;"8IWPDL&+4 IC0VO[Q=[6*V.V
MGA'HYS^C_SM[]^[C:/K#Z.?9U8?Q-W\.03M&YD!UP7VIE1#.]IW>&'&MY^'K
M.<@7< X_CJ]??_QX-_WVCP!9Y%Y*88%Q$0I3=/\81!PVA+CU"!YN9KOH$7R[
M<G4V6&NEY##$L%$!'8/O>Z1RR6&+7.43N 'W+PB*/+ I4<N'NT# 9Q)%K^)*
M>U6V>V1X 4?QW8 B-B]@G2/!!M\0$M%]Z1=RZ+G=X:)Y_B/X%P)%2EA%@2,^
M@]YJ >"P'Z!H(U^:9P*N^\_H.P-%H$)U@*&0TTGF@$YWU:\&5+(O]QP>#8K\
MU57=H%9KIL>3SS4K\(21LPH)9%VJB,I*[Q!U%SGK$G*&K5(G]QU(_<4H?G8&
M:J&>";9HY%C9]&][!K2D;9")H[*+0U'WK4/1["%+5P))7=?XB2A%_]:;&/&[
M9X*B]"\(17.Q5@0%/B 5((JQQ#[Q -'M2#Q<'(H><!3?#10%*[(+0I.*6@1;
M)V7=NU?KXG/EY_8?P;\0%/6I;E-"R<<CM %/1=QO.T9,VYWQ2SBC[PV*EJ)3
M]#&3#,#>.7E%?=BF,;W<N_)C3/%;1*%U=9I@E7<BEBR%J0C(.1"0?2FHMRN^
MQ1<@\&\9^T,0R@M"1D>& 5&4T,W9]SH+D?"9@.<32/W%6)I@=2IH*C:5J%!F
M[&;L^5I YW<DB"X>?M&WCOU9HZUP'J-@J"ESDB9TN4^OT:=M<CT9^S=L+M<:
M_C3>ONE[J=>QWOGQ_--H?OMEK=!_EV97N;QYYVOOR?MQTS0=&:2.?JMCO2>?
MQP\^U,IHK=^X%/+6:QVM5;)$Y4WNG@.KD]--][2"ICAZ-_.G"XE>E) ">I^%
M3<I8E8.0/OI>2 RDH6TQ/Z.,?IB,?IO<3&Z_G+(ZWBAMO0O9)%G;XF,4IMLB
MJ*AHOVV]A$$<)GR3H,<S,#2).>B0C$J""1-U)5*\K^<2&F)35$K\.74A^FN1
MS@EGP&C>)25=3%K6.2A>=JMW@U+@<,M*+X%T* ]?:3H+&P,G88N-#EPH0LL,
M,I'JFHD"!"W:[D=V9L8>JDHGL-&Y&<9,L_?3MC5D>S7<VJW&5(((#'FD5RI3
M<*9_F(GL*G(S$$^J Z[U;OK.R5E;RO9*/4SHNJI8C*.CQ'IA1-&VOS6NA/;:
MDSH?8Y_'\]O);ZL54L.#$^LGMHQ7\?:/#(:^?J-?QM/);/[3[':\2'?CNB1N
MWZH&/DF-A402!";IG"7[?Z\DZ6#LX"B;=?+/S=F#[Q%F>P>;L+76UDC(T4LH
MOG9SIR+Y* UEX=W@+H!'\$&7/Z%8:O&+0S"LH8)!FM6P.B'/_K0UB59+)Q28
M)V/PN(/2S $6MAV28CVDNB)Z=5!U"+UJABTO.Z4-P;'LO)V/WXWK/H>F4^HO
MGV;3U0<7#%6'65[V#%9NNV[FY3=;0TF_C.>3\2*N_[A]S:8"Z[)97]C6@,Y8
MD+JY[MY79=W6G>2TL5ME<"BC:W):K;9D7+?J?G_S[J?Q[UUD7<MNYY/IU>33
MS?CU=-5(SR#Q>O;I=E-<JSDN\O^-IG)G9X4QD4/FA%HD,AB#[CG-I-GR#-W+
MDXF\+*NM<M3! PR19A]9X./:/+Z6L+B^GM1O-[JI"T5>3[O5(UM0]$.O9(5G
M- >J-K8GSW#:EMJ7F1TJ1G:EN29*PKI7^A<3WIK%)%7?L)QQDA(1^I!6/1X^
M99%SX]%9=DI^?[+[>7P[FDS'UWDTG_(/W+<6TV4O0J9D8H@0:UER!X,J]K:-
MPKWZEY7:VCT-*AJ.&;/1GE16;.XP\CWU**" "5O%]K(OJALVZ'70=;3 T:43
M*4218I\#9=L$T SG^@98/=8F?=T,O7IU;AM9]ERUS'(C\ECGZ4)"1;8K^4Q.
MA7;?Q"N^:,K:?PNRN7TR%ZM]C)2 '612X,GS[0M"U]%QHK'T59+?Q.V[J*FW
M.12.>:W*CDT^,?AVW<:NXD-)3=_?=ZI^1UIZDVN3,Q1-021&$09J]RSD(KU@
M>-ON^KR0JBTS/V5\/9Z/;GX=_7.YPFXQ#N/I^-WDH!;0-:XX]- )8G06ZHZ#
M(DR(_0Z]3#"TWG4/*8^B>DLV:NW>:](Z2"=UYL\R3C:^ RM\]55H8N(GHGI/
MIDGPC4M1%/0@HX.48NBK%6H@W QZT!OZ<S3AL_EX\G[Z>"5A1"/L,BDKLK71
M9(S]BC^M]?#>N&%2'D7U'B51)=2UQ4A9:ND);<S]"! 9I&^W*TH46R5^"=KW
MJ$KM.8LR15NB$=9BS*8KJ# R9Q@<"7XTU2M7^W@U\='(:!&$MZ849=F:J&[K
MK0&-@WNT!BEY#,U[E 2MEPJ94",U&#8GVG4/#JSO6#;GMNU4D@M0OD=%5( 4
M5$I*..>]K5-#?/_.IC@(:?*"CR-[Z5/]]/J'V=4Y_(X51K*&%PJI."NLJRN3
M5[JB8VQC]);T88+.P,$>S4D2LTA4'*,C0!4<N\S.<QHA:#!S_D0<[/-'IDX"
M5S9KA.(*&>?*UW*6W/BCS<#U2";6T\</,IC]GE?_L6*A-^]^_3#> &X-XJ,_
M*W_W7N[-O=^]OUO<UL]O3U+??_T/L^G[V_'\8_T^;4G%>L)YS^IO4,%(56>K
M2P 7O/6UH2G:Y8"?=G,4RHV'LD>(Z3!IWV>$&7)>;1:S;'G87*L[JZ-3V-@$
M3SE"L3'9+ )&#EPUK@]<6QO-9_ZHW"$L;M#V>(8>*DNMD?BY5C$L3W=5+O7/
MR<>[CQO*4'_2UV\:OOQE.OGO.S[ZQ=5\L@3D7_7K'2L-AQYWH_F7&AR(#5JV
M?./GT]*U+A;O$6(.6%<H>*@_.["6AI1T,$ [1RS"'_5!JGK1<SS^G%XS,Y/1
MS;=R.EXBB2"# Q?Y4KD @>KI\*^";+*[3D?_\3!#<J'3T6E\!?9BU^SNYA%W
MC$E;?NYI;UF626G*.N6@I22!=4]]D.@Q0C/>_L7<LNX<G_::/<L!Y:RB$))/
MQ7)8I;55]:(%42BS<TOB>2_:S[66<OV 5JA.EO%ODGZL71W[(="!Y0=GDBX^
MS'.CMS8Q4F#7DH5Q.A:&F#&0=2HA;.\*D,XX\7#$V,&".I=TET[F1$?S30$"
MN89;C?"!8W?,BJ0+2@K">EC&,6Z-85<+1PV<T9KCP-W+.:]O !BLG5(MI74*
MO1,>0E39I@C+4Q($RN'VUE<^)9!2&'K.6W6R4_F6G/_:6644RN?L414M+22@
MHOFL8LK&FP+;VFF[&X5DI?P6S^J;  !KAX0U5Z8E6*'0*AF-E;0\))^TH;1C
MYDN]4!KQX:/8>0_IUP_S\>+#[*8NH5B,K^[JL]&O\U&=B9A&7Q8[.U"&5CI0
ML"&ZI(B$%@*+%"(XZ?BW',4_S.%?C[[\X3_5(0!G'YG'\?JU8Z0KM%MJSZ_S
MR?OWX_GQ'"-Y$65)AHISF 36>1D!$_+9B@C;6UK4,5P/$GP<[P^D=CRG,=0*
M_P(02\1L=<)E5B851EP8UE+!R[.%H\[V 6F[>6(ZQJO$U),5R6X,UP^(.@-+
M@N.K8K,26-NV&7DZ3RDVS[/H-G<![F+HV9D^D]W;6+*!'/< FS"E2)#1IN3N
M,3($HMWR^N.S2FP/Y-K-KJYUQ"GXH"!;,)"7Y6[61TA&F=*\-TACL&Z!><',
M7D0MC/0V:QMELL!>$11J[QQY%(Z-"CQ\6?_'_'>6D^M7@+QDO;B(J"0QHL.(
M,M6BT@S2^J6H" (H8]HFG]4%>MX;M!]E#3A4#M^MXR@Q*&&EE@X5.U2;V)0D
MCA:;6FXM+-J'P_]?(+<7T0PK4U8VNV"C05-'9DKIG$\!&7E ILU+I+&_0R]<
M-RYSCZ0,#,+)L->FJ(I(F@&;SU8845 VGDC+RXEJ)2EYWM3:P*:H!%Z86DQC
M;*UAE$%7X"8#F]J@VJZEBSKAB_!^$8WQI4!=1(?!"X^UQUA4RUL[GV3&T#Q<
MGT=L_:3YKTLCZVJY^Q!@[SOJ6D451JD#>.^E\D9SL.D<1V.&7 HRF.V3)*3:
M"4?VT'9>IEZ(-UXKX\F%K4442>J4P!)"K"]FD<,\@ +;PWB@G;[I1<GSR>SR
MNH::)$J=LU?[L+,#)U5D]^6*K%76M#TQ8N&B$EVM\!L6YQ.8;1==49$U+7GV
M6*Y6&8)S+A+[L-JMM4,V.].O0RR>3S O.QZ-ON208S(6ZSX\H66_#B%PK&9V
MC/)Z^3)]CL@D%E0,J9*S!H4N@FS(4GH7!!O(+'?HYT'.Y1E%^4SP%#59H"P@
M(F!2T100SDD):!%MV?$P]ES"?&( BZH8$SD03M*QG\V@:W$8LLQ,A"C5"[NU
M+Z]T<"/[0E9EGT@E+$%+4'45I*.Z@@2Q2/\2=6W+8]$+NKQ@M:.4P1>3-6LH
M0YH:6R94RA2U?5S8N07Z\_AZ_''Y4+9\']AE!@_)]!-XG4L0T>MHO1&*V>.X
M 4Q,J2Z_W?:FL8N9G63MYN0OT]''NI+K?\;7:;*XVIEIV#U!2[$CTN2!K84J
M-GI/JL8](J).L33M1M+9P=SB%H(>3_VE)WK(Y ,8DI*Q8D2J/KGFT:@NH41!
M31Y-:N%@;7?:2Q#"$:GXA\R7Z"-#YDPF.U_?:5;,>[9NI0[;;=H6T&JE=SZT
MGI7WE^<>UBX/L=ZX4NJ06PXX6&Y0<@URO;1DMO2JX.8,IJ-%]\OXZFX^N9V,
M%_[S:')3IVV6V?R7T?)5^W8RO9O=+?XRG8]'-_6[_#!;+-[.%LN!#1)^Y$]\
M6+R95P&,YP]Z?>O']EN-M>A>IN*<\E:2<@$L7YHN-M V1M/TGTG9L'TQ3BXG
MLI^6!OS-N_[O]PMM\WU"!HQ2@&=XYBP:C_VT4E<G9#R0VH35<'%;E>(/_PF7
M$ES#S^&B^[G[]G\:3::MT]S7XA5$5H'=)?L9Y5@>J'4_M9'_W[8[MY?F,,K.
MQ<^>MIW(SM([YDF \<F$J/J]'QIEU,T$!D/ZR1AJ[_8!L^5<3)!$PFRT\5%G
ME356HP:!OS2)II.JF2UW.&WGXFC?3#EK@K54&.%@ABA %EARY&6FD-JGP>4S
MZF49VGY)'VMD(#%[@:V,@A@8G1I!_;1/EUD&.XR,/I37 ZE>%\-J'E;7*7UT
M=^M7J*)%R<(JF?A:62/8?O9MST*Q#=DXQ?_XYV+ROZ>3F__S!W:PXS_\Q_\Z
M!U%[;%NPR-&,LB9ZHL)*)U5OVP+#A>;M;$W'#J'H'#SLLV>4; @:DB*O*#HE
ML5^$*FRQ#2)\!59MW):3.9E,ZXZ$.%O<+G:-UMT]$E-D%UGF&;52B$XS$N-8
M1COI@P'9Q#+@&K.UE8I3";UTV()LG8W B!RD6*_8":5:844H?'&RM"- Z\IL
M89^/WQ,C%$+@&%MJ7[+.QH!%Q4[(!AF%R9;: <;&2&>>C<WC*CK6BLD9&)I4
MYQQ+;:QW[(6HUG-HY1E70-.O;TY7W]4P@G,-&D@,:=(RBY"M-?RK\?T0>)$B
M#0TM.8RB<_"PQW)3U,D;"B%$(87/); )65GN5&([..Q9>-@W@L!;=CL&E6,4
MZK.W(5/?0.X@7.8<SJ5$I$D4:1B;.1%4H9SZ&<W"IQ2')L;N(>515.]1&R^$
MKENYT)NH#;$MEMW<!$E0XB%J<PFJ]XTS,=+G;)PG9PEBRIFPW]/C_&;;^("+
M/X7V?A@SH\M=.P9V#JME)4&&?=XXI:6,2MHNU&*-X2"E<05ZHR=@D)1'43TP
M?=PDDU.J@].E"L78X%('"FT=(MQHM@*A'T?US[5TG/\]V5I1M#:;RU___6X5
M!2SX[F^,P)I-^3^OEJ.[FE%QW8=^N1U-KT?SZ\5?/EV/;AFV2"M@3^(,K/>8
M.4CA2\)W!.NL$2D#^)CKJH(685*;==YD=%@,I^P?R+780M7)ZB&I7&=P4#=B
MW5O)H7X[--X:Y7"(R"U3^X^@=4#%/-]:9S$7BEA2D-;>[Z=+(JNF FM0E"=3
M^5"_EEWG'%]VD]_N>\\?_MF]ZNW!1<KFPF@^IYHN"EHYD3B2-X9\MEHU"997
MESR)0WC\Y6H\'<TGL[?S\>?)[&YQ\^7G\:?9_'9\O0?I.N&44^Q,7%&%L3HD
MOV(4*65J,F/GXO/4Y1">L@E&"T6J#@]B8]PE- -!"HT7J3L*0 R2NWV7PG$4
M#UP31M,%^*YHEQ)E+YTS_9RZ( HT>:#!:_)(6B]U65S.F=UX4#4M'T&ST6(=
MJFTE7FQ9G_#J\J=RR2O#KJ3N_W4$4F(.%$O0*W:]0/[U[#JX-E_I; &4(E)6
MLU)*!N])D(+0[[8LMMW1LT4O#Z'K?/SL&_6''#-)-@TH,[%/"NR-NOV#B7D:
MFB;V//SLP<L< $(Q#%:R)Q^<YO.Q_29>D73STG=&?OA#RVU+BW48N-=0K]&?
M2:;@0-4]Y$%BC"2ZV6@EIZR:\86T+-!NF=A!S*/H'GIHC(E"ME(K\"JQ\;)6
MBNY>D->Z?9DWPIZ1\/GD\W) [-<LSY9T_)#<.3(,*0ME&#ZZB(IC0N6C*(81
M9>1;<8#>#)-S#@:&#L :8%0N,\O5>$%U!T_L&' QMP.=I3.P[P".9>-/\ZT/
MU$-R3S&$$@QZ);+V[!Z4Z"(NCM(MM*E1R9'8]@ACG8Q3"!V2KP3GDA%:)Q&*
ME:7H?MPOHWCO6T(U'P@]EM#74P[MKL:+1;^+F.U2&G\>W\P^?3P$!*ZQH%7.
M=>2B*IAT)LN2#%T&Q ;,;>.J%IN/:\>1=U[6ADXG6 HEL^U7FA('[7R-;<<:
M6KX,36U,^Q!Z5M;Z][IC;T.)Q!\1"-$[G9Q&TGRIA?8I%R6'IC,/$7$ZL4,R
M-RX:H;2M0[J4,#Y%(U?$%EE7U[3KE?:XJD,I/B07M9[Z4T#>1V>,CDRL]?=I
MG<QZ0XWB2]#;DV@/23B>Q,%"G9J%Y&!,\U74M@A=_=!JEUJIF;\&'0O<H\#[
M2'SS:5P75$[?U^?AY83,=[/Y[S4_=)QP YBZ29FBA*(R54WH\ZJHBFT0BZ,Z
M1V.0]-VDG8VC05>J*-2G55(UZDQ1&J(NO\WV,#084O*%=7LLY:DLU>T.QYV'
MDCD'XSA \0S)T!6.LGHK'RFWCZN6]BC[DHA3R!P$C&!45*%NS'71838JN7Y\
M='!M[RK?C/.0R;][A+;'K(NQH)=-#81!NQX&Q,1&I=T4JM4>F+65J'.P,23]
M6D5<4"!:[3DL-ZF47OI('IM+*^O*Z'/SP?_1_UD77=5YO/SOY29D]K==L+58
MS@X,H\7X^N$'ZK/ID7X@:B^\42XJM-6LUO?G;E-3B;&Y&FHO #H#"T\OHD$_
MY%,A5Q)CJ42 ["_[Q]7L!=C&#RDP>[SZTXNH(K8Y0PG^WO[J:G['7#[,'1VG
M,Z74:C2Q'.YB%!3KM>I7HK$IV"QE^D_^=GOLU-$$7YK](7WP 41)D+!P,%/
MD>[9+Q&HC>N?CO'_&MW<K53HYF;V>ZVC.#+B9[BE='0B.@DQ^5#0]1GFPF:[
M-8&LZ'ML8$O3HUD8CGIB=$$%ZZV.4)=A]LM</%]AV20M9%V*N =['<S"@[?-
MXP1O0K IQ&1(91%BX9B_7^9"1LJV2FBS"'<;":<0.9S/XEM<-["[#*!<L,)V
ML7*MX,K-M=_MY8\B<E415$?5?]T:?Z1X91*FMFB!$4&0DAS,>.>T%E[S[]NM
MMWNIWDK3V5@9.@0-D<-*E)244EB<=&A7K!BE??OZ+.NKX_YC.)&A/\UFU[]/
M;F[86+V>WO(7UF*Q/G)=__VQ43_#])IM]$&&6)NW=9_SQ>!TF[K3ARC;$>1>
MF/>A(TX<9TEBO40;BP<=C;3]/<ODVH=4NS/LO13O7],2KZ?UQ8G9F\]N;L;7
M_MT[_LCH]E@#Z!$T6SJ53<F*D!TL];9%%Y<:VW*(_3N R MQ.G2Z2@%1T$$)
M53<T1I-DCR9EG15^M"TZ"YMOYS..QF^_O+T936]91>HND!/2J8X]A'4&P.CD
M &7F<+9#AD6KL"6&@D.LTT[JSLK8X*E)L,%;6;-DEF10B>*]@W:Y\2!.[ P!
M3N"K+A:L#5+SR6]WRQ9;_GP- GX>7\W>3VL_P]&/MFCX(^PW@B%)@3%<--WC
M%)D [>9T!XV!W4_5&=C8T^T#UHM<EPYJ1GPIR4"N4SC2F* M<X(VR?TD?&QY
MHWW(1P:V"74!*0,_[T&5U'>^D/8ZMDV)E^(C?_QT,_LRGO\XNKWZP'A@[>]7
M3=W'-YH+@Z).83$%36UO8##>97)KZZ#:,8G [N7N &+/P_*;=\N_/)YSL#)R
M=!RE5Q9K[4:2';"/LNYDV<JY.0?C'<GK_'^:,YVC9NWI#H.QM@9=,%0.D.LP
MN1B3+0;[)!]'P:9- #M3AV _Y.3K#S^<J/;ZK]7/>,Q6"2)-V<12$JINWQZH
ME%Q#E$*-'%H]EJCVT!\2E91DSK%$$RC6UDJ-W9%[!NVQ28<J0TXY=PA1_>/S
MOA#N)?:;QSH<&"F:ZEY<\DGJZ!RQY<Y2:=&^YK0-3EO8?Z1\RF@RK]'].'RY
M_\__.QG/Z^/FEQ_JT^8:Q_>?>3W]='>[6'Y [N$[:7(:$GDO33':!LU_@ R,
M*,GD=-./NF6%VTOF>]NW_'$\6MS-ES%DF8__^VX\O?JR_?L]^.3BY]JV.6=C
MMF?D@TS>LG-7I9BB4W36=57T'MDN#7=:O$A)PC-)DK4PZ<  UA7EZFS[^IBW
MDF0684_CTXN4I'HF2?JL=$3+M]P(GR#6)]%.DK6TN$%OSG%\#^K)Y'E1YB%'
M ':+2-:ATEHXBWUC<\+</G:?A_D3R[ZQ*GNJC>9L1V1BW%VGCF$1@<T)M>OJ
M]RG]KGK;(RD>*/OF:ZJ=3Y25\BXE2SE@1W%$06WH>9!\=]!]-_YUMGRU_'F\
M'$KR=C2OG^X*\3E$W2/V>XUZ\/5??IV/I@MFI?;6AR\/_^8>D?QI/!V_F3*!
M[\:_7$U8/\=;VDTW E@P0$51*"KGX!WX[A7&"I*F[4O"C0#V"%;/)R)Z2A$Y
M;^J8?9>*$(E"4$IV+0Y6HO2-KIO-43>/$='6+SGJJA;T024!GN,+YT/*I=^F
M#5%PU-'4%2 BP0;Y6\DXE=B!6XKL A($13'P?X0BK>Y?<$+,NLFGU$H)H/,1
M>[FK^>N'\5\GB]O1O 82D]N[V_$^M6/KJIF]9)0SX'UQ?>[>) ^JP17&Z%;M
MSJ5QE[N/1\O%1M804:!N/9 E8 #7UX.GS!)J'ODD/58N>32?L@-?],LFPV@Q
MN3HD]'^XU[(Z1I/JO :71;2AB'YRB>-(INQ<//I*_E$\"&NWTG("L>[/\L^[
MB0T.K3",P"P'7=("2+NZAVQ* G.QDUCQ1V4O02P,$"L$<CSH,02 @%CJ@)B.
M6"/C9@'U&K$/NX#.1ZP:(-8"@Q!1EU^%)(RO27#7$YO-(+%P$6+U +%):XFD
M0+,USACK-$O?$<O!([@A-= 7(7;@@H$BB!A]B1[YEC&J2YW!Q)*#V:VS?,',
M^8FEX0LF%>/Z6/CB9TI2LAG#OA(TNLTGGG7)BDL0.W3!JA,VA-%%LM::1+;K
M@@["1[U9 _\$Q Y=L*"U*H5#<L@ZD7; (*=+L>KH]9!D'\+]\Q$[=,%DC"HD
MIB_+DK)*BE%._TB-00[:V0LXA38EN[8"O=@LD2GE:)SU(6/J/2^'4;CI>=<N
M&,A'$)LF-PP+#GJ<6U,$R((-K=%(21DH,F#O< T&LW-C>[4'M)O<CIJ3"!YV
MNBQ:XSVY0@S-M6-K!GTF":W=S.T>['0?1_"075B.78\E2$_1%N"PH2]E4@D3
MX9#C'=#>QQ$\9!M4W4Z308(146)469CN!0U-(#]TW8:<[^,('K(/F,E&3.@Y
MJ&1X(,EW1>$<(KDH!BWO@ -^),%#3EAD%4F 2$J Y'@YV\[Z.FN4&+(10T[X
M,00/.V)26K#] JT"UO6"0:LN[Q:-D'GGNOD]ONUQ! ]=.D+)%B**+*U*5G%@
MB'V!O2:S&2(_$<%#EXZ#>%$?J@UY683D>.)^J!.@'O1Q<#&5&+IT.<J8.:*@
M8(+-1I&_K]#T*&!WI#;LE!])\%!HJ;-,[#ID-+5:E#68.K/FG+4X%%H..>9M
M!"^W!+UYE_]Y]:$6.-:A^V^F<;3X4/]?"V\^CVY66>_%[7QRQ5]>_X(CZ_4_
M>/#)8Y_0;1:DZY#=$FV2VFH/MEA-5H90^U '4L\7H/[)A3/\E"]2UBH"ICK=
M1 D+H<!*.%&P_@[EY;\'X0R7%$3#&A(L$:#1T6E&@:X3#O]-V\JKD>,R>#H)
M??QM?'T]OO[ZT%#G/=>NOC?3]N^:/M#]-T=29&8#!VP<*1?&;L)2,;&PK^8P
MOPP-B#J:MC,S-JSUAN-\1!WJ2VR64I9(H6.,O4X:- G/S%@+3M8T%OD>,V>J
M:!<<(U?RP"%WJFDC%^Q0Q?WS,[8)8M;FJM5IW";69UZMO>:X(:858Z $B:90
M^44QM@EVQ%K0Z;W.L4C4S%N)SI)?,29,\+)YP*B#:K51+XF]36CTD#T&R\I+
ME!Q::R<*1JT[]J3*6Z8AO-)*&KF&[)^?OP%+$C0RLD89BQ90F_,82:TLB=9*
MM$.+7DFTRAIX:?R]Q-(UDD9@D<9HZ^N.'6#O6TO7-* 0QK0]99NE:X\4[;+6
M<_S+>/YY<C7>WA+ZTVS9!3"^]LL>XU]GMZ.;S9;1GV:W?QOO+%+>5MK_4 B:
MN74VZOK\DYEWC'V7M\L4<N.#S6:%\L7X>#YA?9TH6K]1HV5?P=,OM[.K?_R%
MY;/X^9>_[-$V1)_JP+%<FP 5VRE474<V>DQM=ZW9+!C\W@0]-#8_2I5<#2(%
M&N6234%TP[O) K0KP)3^_H5U$:U,A<%WL:!L,J&.CDE]+8D3MI3&O^C-:4+?
MMJ#?LG6>U?GBW1\M5Q+M1OM?]3-Z75ST+ J^UHSTB6STEOTR7V^'X@__^5;^
MS?TH(3V!I+8R\?+$]SC]_8KX!((#&6HO&F8IHG)]TTDL2N5.].+?DG\ +K^F
MPR%9623#1Z/8\QN?^O&XZ!E@ZJ7T\$<E_RV^%KL^3G$E%4S*A^*M5]Z@M/U(
M%J]"2;04O7TQHO_ON\GMEQ_'MQ]FUU];4=_\/AW/%Q\FGX;6-%^Z7G2M;S[K
MD'4R@J26IMAD(0H1+&MW+DD^]%\/6M#P85;\4$:?7SIO;YB%F\DQ\@G> Z 6
ML39.*A5-IGNE4T#;=L&*/W*$_'SRN70I[=KHBX#L2@38*)<^A6]H]];F@2'Y
MCK7=:+Y)Z9R@/3XD=J\!21;(617^;=\  98,[= >\2SR8?& ^+,LX]] 7$!&
M]]_RE[O?%LMFB]O\F7]I_,'&WP]+V&D;,42H QM+,38EA3X"^V83HZ8=$B8Z
MBX2_;M0KGW^:'%7$K=AW"531L?%E2PLB0]\=DIQKUX>0%H:DVB1[G8*3*/P>
MFM^LJ\-;A142D+(Q_/ON15J#Q,WJUF]%FL_5 *=%G?XH?> H+;(@4RQ=#5NM
MK,#!9Z67*,?G:G]SX+10B54PA_HXQ]ZR+[;-1K4S!)]*CI?M^6,VJ0A&2U9F
M6T=AVUYYZNZ3)DUWH:LXM"\$G"^*7 *K0"#&4#JG;+,,K7I;)8TR]@(4?@^F
M-QLG* 4(H4AMO%5)]?M;L]@RD>K;D.9SF5Z/QA)0=BZ38",L0K=T,2@#@H8V
MS[U(.3Z7Z668;5R4D4,V,,NU@WW8EC$7VTP7>"HY7I1I67>I"F&M@TB1G?C]
MV ]EA,I-N_715W$;<7^=W'[XRW3V6YW.65=*KPZ_9D6F5\LQ6QPMW--?*\,7
M?;?ME_ZQ[_7TZN;NNJ[OZ O6CGWEM84P5G/N&+$8Y(-7MK;Q1Z%C 6A?(C<?
M>9^,LPN*\_5B<;?9_'Y #55"Z95GE))];5:@@'DE.H4QB0:DH#!&H;R8Z%9<
MG$-,BQT_8?F]C@K63&2%\76/1^$+YA"-2YUZ83";C0=KUN0BQ#^#=(:&P&5+
MVA3A0-2\!O]/$(B@95':U">&K9WXXDF%-&$"QC],/H\WASS^93%^=W=3LQ4[
ML]?+[6:U//!^K]F/HW]./MY];#/4RJ@<C<Z!!*24L@$9@[%>D=1\H6J&VOWM
M =\'D'5)-OC;;6-#06(_6=*RB2G[Y#5CD24;!I%O K,!+X>+OXXG[S_4Y/UG
M1B;OQPTWZ#PQ.F6C9B&9B $E>PF9.#+1A:/<>BCRA;/S%1[L_&$+!A>CO\_F
M\6:T6-SGX\)D]O?QU6TC%*B5%%+9''+@,PW"B[ 2"A90>2F4EW[&)PLECF]N
M6"CS42,6'^OT$*F<=Y)18K"1EKHB J-R'PJ+Y07=W_-*Y4\?YA\:@6BPY PE
M,M$!!_*ZCAE>#2YUX U^MY?GOEQN<C6>+NH Z/?S\0J--T)*1KK@M=0VUZR9
M%4F6E=8XI0B70A+?LY"6LU V/]VZ%0N9*-:]8C;Z.IVP6R3"'H;_0KPP[WA^
M,;T=W6[5'P^Z;MS)2H,O(!E?>KW2G^2D+>99]><2#+-+QD0I"=#LD%&2Y3C-
MBZR$J'9WJ0EX$887_NKJ[N/=\N7*?YS-;R?_LV68Y9YP@-551I"9@T@LR'&!
M3%U;;T1(L1U$3L3 "=PA#.TB\ +LG0M4["B\CJ0C%@:0T5L'N6AS?]N#;+=D
M2N> __E>9-1@C!W1=Q6,!9O0%:\RDA-=]C22L*')1:-%XN#I>Y'20\RQ(R%J
M!%AMB[2. 5D-N/L-((E4:8<F*:&L^B[D<P "V9$&]!Q_$CF)&$2416OG>O/$
M +_=KPN2.++[GF0V"$AVY'@4Y#KB@,BRA9)&.,K]MC:M?#LS6:HZ=>![DMJ&
MN][Q.%R*YF"1_V^RC1A%-%UE>5(EM;O9#>HZ _,ER6EH7%V0F3C$"=$8AB>2
M4C=YRL<H4#7M4+7X28N7Y;;HXJX]B&+ V>38LR>RAF)ODQF[R@;_@$1C'KXS
M?-LR.M2U1UT ,14V*BE$]N^YEY*L^T^;K*@4%O!%&93'2.D UZ[JC8J.O*N#
MOX6QIK>X-8YN[II21DG]/<CG9-<>(]O84#Q(0]8&-L']'IF8(8GF>5B"9K7Z
MKF1V@FN/FF*)J$7.3N5@O$ZV#T4\;7'MRM@7YMH?*[7#7'MR-K"IDB$EO9P%
MK:B'0#76;5R[$V">)JQ]\"7=/DC_[G8\_]MX-"_\!4?Y>$!9A//%R6!LR(EQ
M2S>I3^:<H5W98876VAS&YAY"3^?W)V;OU]_'-Y_'/S*O'_9OUUIC6:.0,3'
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M9D(W0S (*?,3$CGX_E92[=2,GAV49$_-$4J'@DQ4,C2'?CDBARXY2Q)CB=D
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M'>]&2)JZ7[KMCJBKK8GNEJQ6S^Q\VD"3AQ)L$M +@.J6?_UF N=0 .K@X$(
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M'"@OURFN,ME-:-LS8]T^B6; L2DR -\N9JNIY\T43@K^LBC4."'&NGT:D4D
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M\*5XATN8WE:C_O#JEVKRYGH'_8[6.B4<H&WEO#?4V*;D,6#_4J'?6LCEJ'$
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M&!.2&-;,U -\E_5)<E/>$X2;'B37U]./6GR!A[RZ&H?%7U;>"BP-%1&"Y)@
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M@5+JW#;/A2=,"_ 7+B4-V$<VA6 >=*;<CE/NGMR5I(-:;9864FC!%8_8_Z
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M-Q.**4:.07=7B0:$.% / W&.$T +22A1EZ;SZ'*9\X+!2/B_H^A)5QT'<=%
MKAZ4,8$Z&EW(KJ8[X!S+EH'+2@)O1Z&[L^/8*JH4)_C4HP6SX+IKNS32EJ\>
M5C*IS7R1SJ'H[BYX2M& *\D!,*7T6&WK4S-94PDJRJ CN+'&'$%/NJNB;%;!
M>A=$TLK8$+45]40@%B&5*%N"F#!@F$>1=Y==)NX$R])"[IEH2E)JWVR;X=Z6
MK9?44JX9L<>@N\LN(4T.!GR'XM9I"589C*KKJY05J<4/$L*ME$>AN[/I,@;0
M$DI<\DR'+*2OT;[&1>V%?AN<V<3ICO*>C.XN)].='.%C;_2AK8:\5(\%X*("
M3SD)KG'NC8J:V@A_<I8Q1EW+NR%;'GS11L4BE8O54'.+4&)UW;_L;_<\9!0@
M$O!\@6,GAV7!LR8^*NE(<:_V$F(CSF/@"Y:XCJ2',M U%HM2?*D-#C)L*HS'
MFHMFV)15Y:JREYI;;:1:5.WM&)@NLD4(&;#H#JA ^!CNQI/A;35*?U[>W.%8
M,NRE@O^[VF'_&N?)!N^<,"'9)%60J4XE=!2A+&(#9,;P-7*>I:V)/!"/]>77
M?PU'S4^/OXY)N+F9K=%IOK+FXD]GHFB6)F/57,!;E/J:R1HE<UF: *&;SO<G
M/1&I?!K>W Q]?[CF75,I%J=Q1P:."UM$TS0AF8JJ:X/!TY #V-YT?MK59VR4
MOVH<^=O1\+^JR\G8?8"L_$MT[]ZZ-<_VA "B"Q:TA <NO;.DN7[#+0G%L[V%
M[[-,/S5Q_<?P^OJV-_BI]VYX^7'-]BL6HH'$TT9EM "T'FCS)BXE5>5>%$6)
M9E(\-9'\7%V]OKV]&ZR11@Z:HO_PC$3(; //N9E]&[%'NPS:3%FM^<F* TSD
M"C#$FU&];?WKK18VI?T!'^VNK_LW?8QP]>]>\V@L$R87S"I-4DK96]E<6S!'
M?0EKI&:<TZ<GH'H.Q:*(TF R72:V9F4GSY#0R!032YHF"CC)-$N!-2WW9V@E
M%]K%GH*(FON_J1ZM>;-VWC&;*'B:%.!_C<SV7AS*E%,TB="X1^5I"J36FS5>
MUPOGK>-<9IQ&'W6*KAG=G*DODUXCL%SVQ'2D^Z+0:Q=UEHZ:3+)/FF%7^2RA
ML$+8<BB$!*<B3BRRS%@\G*?(E!K)C2):4^R?LZ2IR7,VQ+(D21A ]T]+1%L9
M!M95>MP$ V%8<*EXT_WE7$Z0^Y05/A",Q(FE.YM*I/ZB&US57YVF0&N;#)RT
MS-(<I<M&4UVO)_><!0!LY6B&A8'*IR&>SL6(.*V.>!X2 ,WHL36MAF!",6++
M)W*L4-3JQ!#&C,>#^8U@#?A*8]"Q!H'K)>K'#(>I7SGT!2<NG5@\72>AK=R&
MU8PE0XV1RBL(J4*E^]IFQ4.1V.'EMS3RQ"X$-A7)+GXCTN <2Y)K\!/1:^5]
M@TEUSB4F/46WT74=#Y@2AZ1F1JD2%&PB^[HB7S.?7;G?D^ UV<F%4GY0KY$"
M[AZD&C>? @:WDC73UV2$B%(6>0A[FEJP)[=AM#.@+PJ2>,.9%EK*QFUX&F2)
M-@SES)S8?="F$MG%:X@D+:@& (VL<4<TO5^RPBWUY219\!HG%XB['L,<QWP\
M0_9%E.&:@+['IIB!F1)-,4F88B>7HXA#>@UE)22J^/* (Q"XX$DWGE41(0NO
M(0&FG9R)=$MH*Z<A8M**>P:?'!R1!C)VV11D6%GFM8QKILC)N='-)+*+T[!2
M WB(WGF#"^45)\V5,AB;<<4EJN:&GI["="YACD3P&+G4R0;-(2^MT;<.2NCB
M]@8;8^E"%]7I\+C'1SDB28 PD31NA70<GV)M\Y0@?#D 0.%NZA.[.M] *)N]
MR>D< N%$)4%!"M%XH06Q.:J4N2.F+),KAB(_#7'LZVD.8HMRU%'AF&?2">Z;
M5@ZKLRA[,Y^<H+9YE N1 S2-V'_J%*'>Y_J2!U?/DMRU>^QI"&/#YS@?A%&9
M S3/@MH X+P93R5E=*4<E)%$G" \.]AK7$H R:.F&2 &P#$6K&FV4$^]S=-1
ME(/<KC,?19BVYN/6'B)BT_"+P\[*Y3="0(KSQ+1GBW<XI27Q266=&>?.6Y)4
MLWE2*5+VRU!-Y>D].>WQ%8Y8D:BP'C(_+[F)D=S/=9.X8+F<1H\/-4:>EDBZ
MRX(-).UY.K^%2B\8";YVH1[024KES:AAUI*39/%@?L)EE<&3$HL]Q8EE^%-N
M)H529XH>$RFE/K';]'42VB[#M51[K%9FG&9)?:2F:3)W@=+R5D1KHNF)7:9O
M*I'='N&4X(D$&1,SGKM@ZFXY3XRTJ7 <7-$3"RO=-?G!!FIH4(8X97F*GIH:
MC&</27VY0(KCFH=3Y/!P=^G&)TN3B!E@>@)8D7@S%DIG+<K6<\I/[2I]G82V
M>[C'N5 X9R%!WNL3EQ!0:WE(FLNWA>E4^*<ICUT\1N".0AQ.4NND> K"T6;!
MB,O)=NWK.0W1=+V]8<DYS2(1\!E>X #99AI6#HS&(G<'N&G4R1W^89_>A)(A
M"$:92UQG<!AU&ZLGH "ZB!B2D],+&7M\>4O46HXCXSUN)LW*:-ET?5E(8EO*
MCK4XM4+L306RB[]@,4$NPD$>DG(3K"3U1B5PISA<O>PN X=Z<@BLLP\M1\6R
M8@ MB=#@$16O0696(90[HQC.[#^Q;-0>]N4-L+>UTH1$F8Y>:D"7S>8)@Z6"
M95ZBU,EE;GM\>8LI9!43)&?":)NYR*QIN<26UW+TDQ&2G5R<.=S#6]398-L>
MPT:^P&0BS6L]X9#AEFF)Y:?VX-#= YHA\Z92"8GK#B6-VK+[&ZR@67FA1W&F
M^TFR.-6 ,+S#"?V?<-#$+[W;:I/[\84F4QLIR"'A,F25E838&663A22M"]3-
MRR;3IR&0V3ODW%=;!#,_3S_BAI7L2$X)C,(D%II-*X$Z$HOX::D^9;GLYX%6
M)1Y(2(HRZW64&I1&-7V"DI3+E5 H\O3\YWX>:&,."J*KLMHY[0%W!KP!Q ?:
M)+#;Z^0SLF.]S$JG0C:94!8%SX:%X'73:RM8N7_]R0EJJY=9:YU(,5#&!<=5
MX;)9<B AMROWKCTY86SX,JLBUPR;5"+1@$U5AO2DE@/WVI4KGRF@=WUR"=SA
M7F8Y[@AG#JP& HZD3OAF\8%6?,5 M:<GG8<D-VZZ=8JJI E$:R5);,H*K<JA
M?'SC /Q.[M5E;X^S/(3 <"(8SC;V &Q9,S/.:(A(9?TZUY*?6-_3IN+8*-E3
M.E%/I':29&8\KF5O2AN\@Y!4OK%P9<5!TM^Y>7#]MDDPQY@B.@]N0=**6*FG
M&[JDM(XVM5**L2P*Z ))TRIPN\C:COP?8_#G//\&5WG9B -U+&0](C)5JX8"
MR= B"'/!3IC_MS_]VKOWG17ZSG7)#04P!J=N5)0A ) GP;K[\P^^[.,@*Y.;
MO?!_C/F:\_S[@!/\(K&0OG@>C'+-NLE N&SI8V&GS/_VY\\\H\%E;ZW/VCB5
M26Y :(BY=(V4[F+__0\?)V^N?QO/5L&_^7TV&>GU !SG1YP%G8>C-Y^J46\"
M/G0ZQ_VG?N]W8&/UT-#5(_<(9\+ZH%RD,D>"FZXS5<ISGV6985"AN-!J'@SL
M3NP\S_6F<MPU_<L='@&N+>^-JO'K\?@./V[N.!>8!!X9^4_ZU]Z _HQ)%J7E
M:L-PTQN/ZT]?"(=A>'L['$S_?7;P7W_V[O=Q]7_N<$H9G-BD&*"^]/66G^Y?
M]7NC+W-\W:L=_ALD@:.J6C]VWC(;C0[,T!"M#!"!%7.!@M'1:,C"V/GQ5%[?
M_2AP3Y:=[[#<1K@K#N7M")##VVHT_;ER.)B>FT/_4+&O%AP0,1RY]S^O$R!;
M\%C6.TN-3U)0K_&1*QK#IW%<Q[24+C4<?O>C>36_'V^5)':3ECV*M+:1DG($
M3)Y#0,V69.,2B*:^:1"&Z;1*2NR5-@>0TFQ@'OLK),/R1/6*"FQOA90R.Q>-
M\SSAE!#0*PU.5*BX2F+RU7R+UCXEAF[PN;C >4E'RW.VT1/GK<B61YR_ *D]
M\S:JJ%;JIGAEVWW@:DGC/W@(45>X!A<2I5X1;C88'(C?PA.9SJ^UB7FPI3I'
M\!X[4<H2+ES6H.9I;:5C=TKO#^7UX!(2L'NE^&EX.?VY^V-)MY]NAE^J=6\?
M@'N%9@: @]&4 "0&[:\31  2O"Q2 U$L/GX\"H?W=P( >T>]&S>X<E>W_4%_
M/$%T\KFJYY&N85X+7*RN/:5:ZBQM#DT*:"AEM)B2H>DI\=XYB74=YSZGE"SN
MW-4L<$^,9LUUM.6A> 26RYL*]L?YFD'2)&-;<< *+Y,(YTG(IHDG9EW> !)(
M914[B 6:PUA@B$)YFRDSX#UH"JFYX[1)T?*1#5<@'O8LCFB!U#L%2:@A$ UL
MXD[R6#^F.4(D+1RL6%[E\JB\/\0"O9;<4478U!2UC:PI]W,06,HR WDXO[NF
M7(#S3+A*D4&R&*U@.=83R' />2HGD!%+*&<'I'3?%DBEQ6F<S.B<E<M*&MW,
M+W!!NB)SMH=SAELPN!\#A(.*%E51!46"LQS'.=>!0*MR-#(_M!H>S0"M#S))
MXQEVS ;@G5'?],KBB]/!#-"-1GB9,EOG]O5;WO:^X#^Y/WJCJ^E__:T:XT4+
MH-O^\(JNE1=N_UJH]G 0)S1($6_#/E?XY6+1& ["5ACPA>4JLJ3N=^PXXJWE
M2XO&]LG/2<F)JFXY49R-#1E #%YHK44FM0]T("3-Z*G+"3?"3;[@MJ#1W70[
MY&PWX,?>X,VGZ:UJ'HZNJ_X$+Y!FOW>M&*>?6R22TW'[_4OXH&EZ]AM8T/C=
MK[^5IOCZE[Q0V"T2P_HKB"JX6AC^UBR5Q?70K.5J#(">XF(/,M]>-L<YDNES
MY_AQSD-R+10^@T%D,(Y8*>LU!BZ:[!8V[-V?!_:[:7J, UF4S&.<QM\KO"JO
MKMQG"+T?JND7(P2JW.N/_M:[N5NYQVI?QS5_J6)%T#JF$*VS+')!=#/M4X>@
MEG>Y?KU44:_F][^<C.B>R'F:@YUG,)I82 BC<]KR9%0S+@R"LE5:K[XDXX]@
M?L_E//?K3N?/T^"&/:8AD(4H"0LTV'HKI'7,.;;J//FK^3U')R.ZXYSG+\/!
M9Q!V=35[Y>I>^+[7V ?)G<+W4Y<,6*"R3C398(R*6=D6^]1T3](Q#FM)+B=R
M&/90AY&(P<'WQF5IN/!2Y'L@0L)BD4)S&(PH .5'B6R/<AA_F_[&Q\&%)!"O
MF =801/U6H28:]M(1%IO6G$ZX6Q^X>:Q)+.7T[CW>FX\OKN=_1J\7D#)Q?[G
M_E4UN'H'WK%ST\'[_@0?K%X/KO G[GHWQ075&"\P^B/XV&'3?K#F )N?G![?
MC/]UA\=4\BX&+1/$G4RT#J2^<13@V/1\(]Q@JL\+A=<'%^%3."\P^,4[Q?V?
MDDZ,>2<%AQ.!M"M:X44S-L1:2[_M4S(G9U73E6B.8"]=5%+Z8.Z'R$?EF3N?
MURE855!"<.X=8X G<C9*W _C\3Y3^6V?DCTYJU(^09KD(X6<UTB2I9>-527K
M%W+@\WD]FE5%,"NIA8W<X%#WJ'4]\@NLRE+V[&/5WX8W\#%8_WJZ&'#AIM!R
M;[DA4A.:#98%-U4?(AL16=MYO9H?274$*3Z-0SN(<<T?E; T,,423<I)233-
MR@;PA30S%9UN-:U7=A_W14_HJ$X!#<X?&I> ,7SB7./=A-'.)=M@0<Y5*\IX
MI=?6*GV#AW9P^[)1IL1)E' Z) 5MX$]3^](,XYAO/ZI]7&,\H:,Z!5PX?V@X
M@$4&I2Q3N&L7$'VS:$0$2MP*^SHTY'B*AW;X^&5TT"Z')+F 2,:3I!KMBV1.
MG)>M:?$K\TSLZUU__-]Y5%6O<=!*-9Z<+CH4\Q6)V0LF+3.$<DD@X])-J:W(
MG*K6G.L58>LK_?8HQ:=P9 >QK?F#DH FDL [0ILR(/@0X3]H6[CX0=)V&$^8
M.!30.,&#.@5D.']DFO(@10B0,7//$JY(XXUMT9CXBB,[6.[U5(_LX+:EHK7>
MX3SB1"#M8@#ET]2VB,1Y"6;50>VC\N*)'-0IH,+Y(V,A>6IC9,D%D[C5RC=W
MA2$P<G:'CXD)YP^*)Z8SDR$X2C2-EMLI)M19Y<PC6^4$Y\>1/(V#6NS,=G>3
MC\-1_W^JJ^["B2T*DU>^SPMG>2 "P+82Q"5(D>H+"$,B4[:U=F5Y9=;>V3Z>
M3%&DZC_9S[TOE.]3KD;P##KJXW2Y9; IT=QTH5%&VVN"GJ1</_?Z-[W?;W#4
MP[3TZ^ JRZU3,EN"=YV<&<E-\][MF'1<M8C6,"H(WX?[7L/\7@3\IDE!J]%E
M?US=%]J]'TYZ-^!Z1OW!N'_9636\<H9)3I'@J'@!QJZ])LSH9M];-(X4 ^0D
MM?M1R2V8>GPAEAVF"T+$Y;PL*D=!?D*D3**H6Z!,!-#7,M!S3W;]I(18-@DN
M3M/BBNI$>-(B"F."9*$QXY0S+7KHF'SB,OS4'TU_IJ-#HS3>I6A-;6*.!<ZY
M3[C<DM];;V(\B];B1LA*]I%KK.;CZ&(JS7,I0N@,DDF.2*FDRH[39HJ_]0!U
M?%OP!3]GGYF82@-<$I-02L7D66 Y)LM2M+4V@5W&U%:;R0%;DWW$T>.(J6[$
MNAM-L\J]" U$)1D+"I)])50R+C<OXA)?RMO0!R.":+./^N)-V3JJ#)?J_QO'
M.AVTLHE\%P8VP?<PS4D.D(L3F2F8;R-=*>U2<_'\8!VQCY?L?;"\3]DO-EK\
M^V@X7CD&K\/,5:24"@!ZU$6?& 321J868FI;JR23%I1['V\KJQDYG)QV[K5;
MI94 ZY1B.E)E*!J["+()NX&)Y=DG"_U5^[B.?<2NF_WVOJU\6O>>ZAR4Y-&'
M&#PH:VXF6]BPH*%+ \CVZ56?LGR[O6K$I9*99YQ42FR2D TWLWL< =U>+5^Z
M1Z_ZB/)]<S<93WH#'#O<T1W645RJ+4A+1ASS)KRS.C5#9Z237+<!2MRLI?0^
M.KQ6\7!D =E. 46:5"!*D* M#2"CT,REMYPOC$9N!&09V+O=8T9W @+:>,Y,
M<7/>(5I!("\.!M2/D@BH2&O:7'=%"-)MHL6](D]0LILCR1:+G7=XB2GFM ^4
MV4@$%9PT&ZMP>IDPJQR>>L7W\72P'6<G(4R[6I@\2.8CU<D2[CUW1I%[YT<%
M\:LQ^5X*%0\HS/&V=T3[3'4(EY[PJ$1427"'>P5((U;/$E\=E-=/BSP4CWN6
M[@-3R6[0'E,DG$40IJ"$69J3E,V<2A[2RJ$(]I7:)FKOF<O3DG W;!?"4U1:
MXI2/*N=LFQ8IFX)<WITQ[QBVZGQ_UA+N]A%9.I$H=RX(7*;&$^?-Q#%EE)*K
MXQA[+A+NS!H>)%RG- W9JPQP"9P)LS*9>P=,EW=*S4_9X-MD1?MC<+U<E]][
M?QM< =E?JRWP>76\\)GOD,R?AG]4H]F?^K?]R<IJD ;=/N"7^R_EK[]'Q=._
MO;E>^(YQ[G]>BY$-D\9X$20@8V)"#HDT&#D3:U;.>:?LU?JWD?T(]1L]O.%=
MR_+4I?M)2A68HA3,RP"YHC&NP9<T>+8RC-CSV1WT[-ZT+:-;:N<42M'HO68Q
M)QVRHJF.3XX:+^U*NWLEUEXNGX]N]Z-[_W&T_F(A)F$XN$?)L,;#<!Y$_0 O
MX1SMR@1$G>WNL(?W1\L*U:7A!-HGR:4"[$T=YS3J5.>.0I*@R6KH\N2/KBG
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M6=0!0(%460M^+3.K?0K:-HY-@DH47O@Q5 !"5\OGA3M(G :3/1B"SISAF.'
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M8([QN4G_-0!A02CZ#*M<D:7P>1@!);)H 9/=,QXOZ"> PF8H8)^UC\;*K98
MK6AT$M:VZ$&K6Z=WPVA>_R@@B@A,JF2&SB3)T7BR7 )R%+'J?WCJ7@@#X5@
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MB0X05Y?+D"/NAAG)P$HDAE'PFRI7> S_B+EA [ /)!D88.(<KL>=A.,L7F#
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M74J&0VR"<HT%ZU"SDUZKIW8G:ZO&TM_(=F+DG-D.@?<LL>AAHBX#IF[$PLT
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MH:0X^W/R"C8,-ZEH>3Q%?JS#QJ8CVXN^!2 HUX1VZ I33O2<PA7(7!7D=.4
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MG_[[O_Z8#XF\>QMO^.8?@6L[JVP481Q\^,1F/Y[=7B,2_;WWKR_79X;GPA>
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M;I,RE$;'[AY)B];.[5U22[3/5<.G4?!I"CDI:^E6WYYK:#W9-OM65W>-U:Q
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M?2GWUTTBC%#K9*Y32.9ZG-'*O__X?<(O[FQ[^3XM[9L$[H<LRVM"25[7'G<
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M!.'"<XQ[SYYZOA>O!$TOEB)'U!9)]7!P>1*]3(DW0%LPKD*0M,$*TS'A.4K
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M+"TX8.LSC6JGA&K*&M5H5-.H]CBJ;58#Z98GNV'EE?#!OJ\%)P\(PF,@YL8
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MQ0QN[:30^*/Q1^//\520G$I.V.ZE)2<853_O#+H'20S;Q),C2L1]IVW )MF
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MMW+>$Z5L++8P2V' XP![Y.I%!/+@MM()-F2]Q7ZBX0SY2T8KJZPZKA0:<\C
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M4-@6MVRLP&6LGDA3EO.E-@-5X*):^^8HUN&VY?!.SUS_VWVOZ]$B46N<CCY
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MOF7Q[NY,W ;P$0516Z8/6R=63H=[ML=[W9U5V2"Q(K':?['RN.OVN-LSUP*
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M+#[H[JR'!\D4R=3^RY33YUV#/AO)%,G4H<O4D=OEGKNS0OSDD!WJWIWZN%8
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MD D"U+"X7CYP-/*X&@@BOTS0/F/3/)G&*5QT%$3P($0LEL+_P/S-81YPY10
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M@!J?!* 4 &>62GW^=EA$"2Y&M*8#YW<K[5<E;95"%3MC.$=ON)TC=4#)*AK
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M-O$0+R%>0KR$> GQTGZ2_2)VOU;BMK7F@&B3V'++7EM_/#3BJD/$52T"J!L
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M?*SQ%97RVC_BY#YCZ5.165=QF)^*;*N20WM-+2:H!=0":A&]L4$JLDC%0N.
M??FG7*1]>Q5L5_(YH 3KP-K*"*NYY@X:!XV#QD'CH''MT+BV[^C_)8G9BS8H
M4HQ:G^O$-EV?JEVF;4)I;IT*;$UBV0'QS(V7 -MR6@3R26 ", &8 $P )F@9
M$U2PZ4:5^007@ O !> "&5R Q:%UZ851/J+1UHF%%G;C=#UB63[1#:_R9*DJ
MRE&U!58(8\J9YA8B#"VE 3% #$8," /":HLP&#%T;=]6?I_B)Y;EY1[3,-9H
MOU]T8V$]C7]4M/2H!'--ZX7K$LMPB.6XTH#7DEZXR)0"54 54 54U=I-!*Z
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M!<TG=.(8%K&\;9JRO?GTJDRGN Z'@8 *0 5;J8#4 SE4F4]P ;@ 7 "W %0
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M-)/C>\3%Z0!(S6(WQJP^QO*(;6$K!C !3$RN\QR'6!8.5@(F@(FIG3 =$;X
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MPB(=?0!7""0*$CW6?C.+.)9+;.=@(1Y(%"0*$CVZ3H)$)9)H0-RBLNA@QS:
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M;:JB69YE2ROVP-9O+/ !4[9#/.=@6[^!*6"J\9@R H/XCK15=6 *F&H]IMR
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M2_4&2W]3)^"2OXA:0:2JGUGR#D([;(RJBLHA!W5LIP94!ZK;A.K,BK8$@.I
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M8,?;8,?E[993?>KW)9JV[ZT7*3;C]&^NQ$0;*%B^?)0A%YOHKDN"0%I3%%6
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MICPN+B*K8AETF&1AT6ICEYQ %1M?MXCPJZ@"=#RI*%-%&:HVW;#0C4:%901
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MNV_5(D9@$]_S9(%/E8FNVL;!E%6,A*-&P]):\@ .K8%#<XV$2WQ')_96+52
M"J"BV49BJU9<@ /@T&PC89K$= /B>8 %8 $K,;G. 1SV3D$IE$^N4K!7G=O?
M.E78DN9T*3QDME@5M:C:_"B$KGK9I>I@U98%&4 ,$(,5 \0 ,5@Q0 P0JR_$
M6FC% A+X%@E,::4# !@ IH#@E+%A\M9;&X^LMI>UW2;=QVWZE31W&:H"QT^5
M2:[:_,#*-'@="K@ +E"V %P %[ 7P 5P 7NQ:RVTH7O$=% +#53 6DRNPZGP
M^V>D%,K^5KH#,XJT).=_)UH8=Z.1&*9&^_TP"FG.>AJ+\S /65:%M7FONVR#
M%F<,C^CR:D]W%IPJ6E>U=5,(O/4R>\>#Y%&7=LRCRP_(!#)A.)?C.\L@MKP]
M3( GX G#*=%P'EU\ ": ";NY=)TX%CX@A@6  J#'!ZBBH#RFY0R.+KZF +/M
MQ8;%R51:*O>0M$6MLKA6]9+1?<3V.OE+%8G):]:[J93JP$@V,0R#!):\XP#>
MDXXJ^E"U:P /H#YD4\%BK,0#-C85U%8M=56!H;2^_<!;?? &XWZ8?(!.;-\@
M?B!O>R"L.]BF;FP#ZP[K#KS!NC?,NMLF,4V=Z+X+ZP[KWEJV@757W[K/9>N_
MSRE__I7?7_'ZQ^]'V>D#I</SK]U'UAM%+/O2OTSB+HOSE.9A$G_IWX;9GQ<O
MXM\;VLV3](X_\464=/_\^:]_^7%Z.7L8\&MNV3#A\Q0__)9$8?>E_'=Z 1=E
M+.1UR_H_G=Q<F;H1_&[_<7=UHH4]_@&_^^FUZ5G!Y:41^!?7YE7G1K^Z]/WK
M*^>FT[DT TL_^?F5_.=E>1<.6*;]RIZUVV1 UX-\[O(HC-GI(RNTP_#L#POJ
MX7)=J&A^R[?BZ^=ASF_?+>\T%J,VE:/VI@JL>Q!3?_]!BO=AS,DP/[>$ULO4
MW"]#)M2'CS\KGRC3:,KX-(O*]W[(>AK-N#8,AMRTB#\F?8W&HBR>I<,TS)A&
M[Y-1KCT_AMU'?HLAY7=C6B_,NBGC+_IA3.-N2",MC/M).B@T50OYCSS1,!(
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M11)6IH[+'%KF/IOB1?A*1.3.(^%=/;%QIJ@0SA*Z2N=GSFP5G\Z;K<+UJ@:
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MY$=2U,T%J1BLE=>O7JM$.3ZZ$!$^DDO%'LR$$+YB24_L]5??]\^4N2\P:D2
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M/4,X%*U>%X5]BH:*JZ<XK^:/>G:5\CB,=RUE^PM7BG$BH\D0#=% L-<0B?.
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M7>++OPA'/2^[2DIS1?75-;Y,CP1G5C!V.1K)$;FXN9&7M#?#:U#YM;>7W[&
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MJ$%;\7SMZU/3L$-03TRTR_=N^@[AN[L $!]8APR5C(SK09U,9I_*I8"'<^^
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M0[M:/41># ;L:0GYH)F]*,>.PFRZP$&8I#C*>15#=D3H4H,Z*^TEYR0$0..
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M PZ39Y;SK'UJX6,[,U]'KRP=< @&6D/[CG?]Q?W/K+Y<SA>SVU27+/>7LVG
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M[]L/PT08-&OP7D_*9KZ4'QZ[\Q__\O\!4$L#!!0    ( "5_;% VRX(NE(D
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ML*L, 40.%_-HV#SA0#J"I520<"@H=HC4PB#':?M0X]Z.H+OKI>@=I];^@NU
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MF@SEKAL6XN$WV8MW\R"*FMY5:"Z^%NKR,I_E ;['(YRT/'@(>G)?B1 $6XN
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M8M$\7J5%OXFRF(>)#5MI@658$(W$!B]BC!LR[?Y@$$L_)-@;SM(_E*..<3F
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M$)*P__<2^1H5QLP("X.,B5EQ4!T!UPZ7!CG<,$CK&('*08<P=QIRC&O_AJ0
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M>=A23^^JC(UI?;_/I[+X1S99+M15-I_<6_7YDSJHQU.[270 A!)%'07.><N
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MG-W[?)[.)WDZ>S>_+,J;]3A^FZ=A)ET^WOAXIM>?.R+<YHOTZJK,KC;:V:Q
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MSA]=0?:K,,RH[OA1\TDKGHXTC]6AL&NIE^.U1X/QF'E!13Q /<?:0**+*$P
M'>\U [YB%$B+R.>MHE.3A.^7LWRI/OYV!BG+A@3'1)R=Q4 HK8@P$DI73)HQ
M5K_*='?I@-V0M$64>LM;^3%9WE2(]7WR7*#6$@L(%L)+Y[6VVNAB+1CZ^E;+
M\]M=#R[@-4&FMSOZZV29Z<DJY9[>I?:%DQWNRZ3:;#-.]/W#,^\G]]L:'VEA
M#ZM;W%2.(NGB<T$+H8'T2<^*@&KB./![9*/>!/"X!<>:7/)<"!@/L'^R;GL(
MCU*$O6".'893K[/5>CF;KO=^K$^16JOK#Y].^HE*QP5D#>-&"N>8,]"E)H6%
M' )3T](1RLN#DOQ%S?_VP.V+D=XLIOE==G"SOTTT30B62V@EHX*.PB8Q$ C(
M*?.84D]5L4ZD<'VEBU^>O-8>3@/SP\F[K'1<D%Y%Y(P6$"&-N-5,H&*MSAHY
M;GFJ%2I6XXQ&>/W</#)*P65\K-&*U<;=?9OG]UEY ["G#P7D(8$"2,P!5!Q"
M#P$H4IX)'&/*54M YRU!TJ/LF,5O?8V"C\V^9_/\6UJ]^R.)3\<I?L;HP!2@
M0,9U8RBL(P(P?5AW%.;K)P5T9J1KEQ6ZPZHO'OE'MLB6DWF<N+JYBW2(@NVV
MCD95+JDT/F!#B8846<2-H$ XIN&A2H("]1NA=%96JQL^Z0*MFB?_NWQ1Z?!_
M\5R (EYR4;WA!'E +:"2':9GG:^_Z3NK1-7^^=\4E=YR])Y$P5YG-]G=M[3T
M]U%]S=YGRZW*7+*]*XT/ $$BO.)1ZP7:>^H<+ 0@#%"#5I*]Q!N_;5S,I0N4
MAN&0]Y/EU7*[46Y^G\PWY[/(L1<$"J!03A-+A6>>:?E@Z\-&P_I28R]ARFWS
M2$LPU3W[-VGE^>WO^3I;E9#XZ+/!.8(4@ P+'+4>;H VIIBF-'2$%WH[U&P+
MD9J$,_GB>[9<SS[/LZ?\M)W#ZLUJM<EN/GW+%[L'DV;[\+=39WZ['PC.$A[E
M&!#%7AXE7I3:91> :*GZ#&KOG44&@[&_E)6S%UARA=1X6T"*2>H],AI;"B47
M!AX.2AHIUF,XZ"#W2?>8U0X$>CR;AZ^_R]<[OI[EKS4/KCHT.!CO12"==UQ3
MPQ6"13(X(TK0^NK'^6$BO9\K'0#4,I7M9#:__VVR_%>VWIYC'Y>S+U_BO!9?
M?ILL;A(I[DN/A-;>'2#%@#,*B6)*8P>PHJ*  6-87T0YWSTU&C[I$L&V19J/
M<= J%7G]N)RD!NIV<O^:I_+L=P1IC%1 ."0092*E%;/"/TN$4_7]#V+\C-$E
M4ITQ0'QBE4TWR5#6!B^\_KH097=@G9/,6DF8TXC(XG(DQN/ZX8?R9V"+5D!K
MFT-4_/'D2[8]U?:S^CV?;^YJW3HM?R5X1SFW#@HBB.< ^$,H0=Q&UC;(1P,7
MS%"]@%DW"V$K/C\-L][U6E6;]==\F=H&J+M\LU@?8:'J+PB0  >YE-@;+$D4
MTP!AQ8(XL@V<J".WF7:*4WN$5U_B'SX[9B<I&1&XHI[2*"YA9BEP &A5\"HU
M'C:HOC%R4V>[P#2EY:/OQ[]]F:RSPG#W6$,^1=]J;PF*.0:UM50)!K&UT-D"
M*JHQ:1",>P$&T6[!&B#EL*IW[-B0(#"!1ANA" &I^B[CRA8K9)XW.-U';OQL
M&9GVSX#WRWR:93<K'P%([#A93(N)GG\4E+PL2*BIHTI3P".W$R"]+)1GJ@!H
M$&(]<@-E;YBU=]E?9PF?*'H^B!^[!\X4]LK?$Z1B5B#A+65,6$$!Q(?[#Z &
M75?A!9@NNX:K"3?L[B6[2=K'SHBZNZ_^F;H*+=8K]T>VG,Y6V<V;1:G]NM[+
M@O#*8@ X<BE!ESN$#RX>JCUJD(Q^ :;*7C#K+YCBX7#;S[V8>FFU^Y)A@2'-
MN".":8^]E$([5X0G,2 HJ\\=([=7=H!.;^[1'0#[V5XMKV=?OJZO-NO5>K)(
M)H\R7^B)H8%K;*"7BA.D.=66.%$D+3%!&W1#@",W5':$T&AR3H\EL.UTJ*N]
M#O5P5Y8I)FU_*\3[ESEC#+?QI%68>%^4O(_4 @TR!M'(K9EC@;11J-?5[?M\
MG2JA3^;/I^'S92&&?UK<[-6T%^M,B9.E 6*M?"%0KJ)VB+5"43/$$B'K"FM?
ME 59@TKU%V 5'0[(NK)S^O[GDBWQ^?[AD<=;XLUBNLSB#]\LGMJ'2L^VCK\8
MM)/0(H(4]T(SY3CU!\B,]_6E<'0)9MO1 'MIU_&C]L#_2/)(#[?R\T\&Z2!P
M1L>];BT7D=@ J(/  T6#6DDCMSZ/#-F&=_1N$E>WOV>K=7;SK,C (P%W>_A7
MN)'/?E]@W%KKH/5,8^RU ;;HC1)_PTB#?+Z1VZW[A*V_&-U#;?2K]=>]N+"J
MJ(6>&ALD,MQXX7S4L)2@"D7QM5BS)Z1^S@\:N7V[*XA&?_%M_TB;XF"D@UU<
M=J]\)G!B-+,J*DB06\ZMAZJP]D65B3?0"T9N.1\!FDV4@SHSWD>"F'RQ7DZF
MZ\UD_C%;WI4I!.U])4AA@ ..1SH)9KWS#!8>*"X<K._'1Y=@BA\4S&'/O[-/
MLF"I@! B*@QG4;<A\?(_K$[%/^JSRH78Y5O!I2^J%]G:'[+E]]DT>WWN[U+
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M:LY!(8@1RA(J-/!2.G\0\@6$IGY,67<>L.%YIR&*0_+,T68NIP<%X)!D\0_
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M8SMN=684O%")/QM#_BLPVRCUI9^2QP9RK-U]F^?W6?:HGM7)8+NC8P(G4$"
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ML<D5Y(]K:P\<(]8C9^3#X=MG+-AJN7[$O/%?SQDW_FBKY>Z+51SQY[SR5#"
M: V%\ P 2AQCB!:+1E30^OZ7CJ.^>B)UWA9R-46_<RE_U"S]ZG,!61+5(@^C
M9D0M\\QZS(LU:*!&6HNO$35>IV@C/"Z3MJ/R+PQ'TOY(^2&*D9/E+'^_S*(T
MNEG-[Z^S;_ERG=T<-=Q4&1:<EEHX:X"-AQD3 &!##CAY63]'MW4]JB&%\LY
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MC(ZZ /1, XR<$T19KMDAZT1A!!J<,Y=HYFT?L;XXY7AS[$JL4F5XP(P#IX6
M3FF-HXPO5>%%58C1^@8[>(EFW@X@&YY95N^RLONH?&#@!ANE(+7..TDE-+@H
M5<*UY@T2N.$EFG1;!:L_+^-M%F_$FX^3/W9335U2)EMR%/=IJ7OQY.B A'+6
M1?D=>,M5/$*=+^#4\4AM8+B[1"MO^XCUQ2D'6?QM-EEEU[,O7]=7M_'HVRZC
MA$=*QP5-E5-68P"(8U )X7TAA\7SDS2(,;U$LVZ;6 W#%V]GD\^S>53S*W/$
M841@"'*BD*+0&P&BTB])44K%:&WJRZ;HD@RT[:+4]SURG9JTQ/\OC7A\^7
M4B"O/7;2Z0B0I\@6*)GX7WU9$UVBR;4Q0 ]D_Z^_/<,FSNY?VU^\\O/].Y[
M]./'C[_.%OGW6?[7:7[WMRU"'S9W=Y/E_=7MA]F7Q>QV-DT(/.2=YO/9=):M
MBO]_.K7LCW6VN,ENBOEU/HV'IY*[3,?-=&/RNV_98K6[=U>KS=TV)W)E4V3I
M_-A\>_"K)A?>RPDNERFU(7&6OG]XY/WD?ELS\,=D>7/@N#)O:^.7!^P$,%HY
M"!&B3'F"4[:HH@I)HZ&NY!?I"+E#\N/)9:Z.K7.;'5D&8%O?2$9,%L5_Y+2%
MS"D(:&JFL,418R\;Y)B>?=9-YO/C)UR?+//<P3T0V-N#,Z%UL_[/Z3R/;_S[
M7];+3?;PPWRQCD>"FV^__?>_K':6Z<[2MC[.U@F%-XN;V??9S69RK/OUT6>#
MQA0I)2B.T@)CUB8*[ $@PND&6OK9W%8SH;DW%LC;Q;++=+X7\_OG;/UUZ\A/
M-]G7V;>/N8O7X/IX+^(:;PD0*+0-9*11#+$N-:=GQ?H-H"-M']D"/<LXHQ/,
M?CW>&89G2K*WQ\LRK41LN;MO\_P^RU+@J9TMLVF$N[RR:\F($-_N!'/8<B*Y
M 9Q"2O93EHJ@D25Y=T:0O NT:A+X7;XHYE!*UA?/!1F798ERP"!'D_(*4VC7
M=GJ*(SNRS.\^B-D4H]XB$;92S_W)EEI/G@M1+C(2 8\8Q=03A41J.;9;BZ>B
M_M%\/KTO1$1L \?>PK5K8_.PNL5-,G-5ZM#0Q><"IAHI(GSJ] P=3@@7>U8A
MZN4X!<^&7/)<)QX/L'^R;GL(CTKN_0DX=AA.+:2#K9'YJEH5RJ-C N:04L@\
M<B1U%2""&+E?H_9"]]K,IF+%XT%)_3R7JB5@NU3"JY<D1"@U@\."<PVI,IQ+
MIXHY2X;KI\F='T9^(=)9$_PZIWGE<G="6^9VZP04.^>HM\6\J8!JG#)/3>R/
MU+VKA\'ET'!4EW^_I.N/9#5*%GH)!$>>6F6<LX!C>[@F%)$CLV;50OUXR<*S
MUMXIW<XN64@Y<=8YY!V!Q!-IA"@$5:-Q@X(WG9<LK$6W!FNO:5-\%"WQ:94"
M7=UJ/;O;7N=7MWXR6Z9XQB(U>2=YK=3GU7HYF1[+[FWRRL"5M ZJR*O("6NM
M0ZJPPAE/FX0@#R8HM^]4[QGET1@'CB%Y6.XC4*YGJW_Y998]KO73131-U6\'
M)Z0"$*I(T:AC&R*COE)@3J3OM8=1.6?WQU[GFA=Z)L)%,GZ1\?][GAPF*<2T
M3]9__>M!2NHY)I)&T4,2ZUG$?X^[I5S65WE;O\=_#N9OA0R]LO_GTRO_?,[*
M4]4E>(KK._EH8$(BRCVVJ4R8<I3&:[U V7-0WT#<>IF 89E]#.A?]!%ODW\\
M6]P,<< __G:(^B3BVC/F$*>4<105S0)S!UG]BN2M%SOXN8[W!D0814;!UAI<
MED^PGUOZ(QT%_^<__C]02P,$%     @ )7]L4+<]&J[0.P$ ;;@0 !0   !I
M;F\M,C Q.3$R,S%?;&%B+GAM;-R]>9/<.)KF^?]\"F[-KDVF6:B2%PBRK+O'
M0!"HUIA2TDK*JNY-6W.CPAD1K/0@HYQT'?WI!^#A[G&X.TZ2FJK*+$4HPM_G
M?4#\<!#'O_S/;_<;YTNQ;<JZ^M<_>7]V_^04U76]+JO;?_W3;Q]?H8_X]>L_
M_<]_^V__\G^]>O4?Z8<W3E9?[^Z+JG7PMLC;8NU\+=L[Y^_KHOG#N=G6]\[?
MZ^T?Y9?\U:O^EYSN#YNR^N,O_%^?\Z9POC7E7YKKN^(^?U-?YVT7^ZYM'_[R
MRR]?OW[]\[?/V\V?Z^WM+[[K!K_L?^OD3_"O7HT_]HI_ZY7GOPJ\/W]KUG]R
M6(95T\46"#+^^+=G/_\UZ'[:2Y+DE^YO]S_:E"_](/M8[Y?_^/7-QR[/5V75
MM'EU7?SIW_Z;X_1V;.M-\:&X<?C___;A]4EUR2_\)WZIBEON]_MB6];KCVV^
M;=_DGXL-D]%]VMVVN'GY(S;;[:-/X XEW"$OX@[]]PL?W'Y_*/[U3TUY_[!A
M]ORBH5]!</M<K"UUG0EO542><_7I!QK6^XE5W<*LXN<?:5AS_Z"1:FWC^7WZ
ML8:UFY5L]<FHVWQC^,EX]I$G-6_X3[UA?QI^D'_Z&?QVP0>H'GUP\:TMJG6Q
M[J#YZ*.=<OVO?V)_6NV:5[=Y_K!ZS5JM^^)3_BTKF^M-W>RV!?K<M-O\NET%
M%& /9ZY+(0HR $&"(@P"%_M10A(/KKJ/7!75J]\^C@*Z;YD+\2<9'YX[O"V:
M>K>][ILGIHVWSKW<?^M5.4R6<]#E_#XJ^___Y9=#/H]LK*]?>BXZ/3=Y\[D3
M-:3.Q'G)+\6F;<;OO.+?>>5Z0RO[WP4\>NIL?6W4V=ZH#>]/U-OA67STR*#M
MM5-OU\66]7/&7\JWUQ=*9/B)7ZYKUG@_M*\>%0[O[UC(I#;_W/7NL&1><N99
M9<*[[99U\?:!R;>'HFJ*M*B*F[+%==66U8YU$=\]%-NN^];L!8'(HX1Z&:0I
M %X216$8#X(0I,A;M?OFY6*%LRA#ICZV)QK$,Y5R4/Z7DY5O<MO%$+<0Q^4(
M.(AVCD@XZ'9^&I3_?.4<Q#L'];-Q4MWH,QB=H/260=DI$JTGKQE*C*8%\SK?
M/%.T"I,0IFX:)&$<9DE&PC1SQZA9A$(%$"O'LDS;09<2;-7]DR+J)-:I87.0
M]C(W9Z'B*;,NHT_;YD7Q33^;ER%FR"5)4GULV1@2L>$Y,_>%V(GG83_V<1BF
M?H@SQ"2@,79 ,A5>:4:T3*U.G1*S=)V4(M>$)JKQJQ/HY-7:Z20NB&/GK;M,
M,T/6+XIIIG)ZF6Q&'9/MB=7;HKRMGD>-*,34]Z#/B)JY 0%)L(^*4I^J],14
M8]GNB?6ZU'IBRO[)]<2FL$ZQ)]9+6Q#!3IDET!/3M7E1U-+/YD1/S(Q+9N;U
M5A%@7(S\ -/(IR$,<.9G0] T!BA9M?L7 )HS21=#27'JQ&L)@1I7]E-&+:MP
MQ5CA/E^J<%:L-3$_9]15\W-P2YIA4YY%$_9X4?S23D9J-DS2(U%Z9<5-P<*N
M5>;@_ 1BDF#&4QJR_P:4[$>V:90F4GTPFSHL]\]&Z9(O)JPZ+T:^I9@NA\51
M]0_U;D+#ZC-8G:( E\'<23*MIZ\>:K0>)AM/-14Q]$(_2</$I3&B89BP#N\8
MG&3$5P&S9L@EOJTPY:8<;"<T4I&KX\N+Y?0[Q;P3 *4A\Y?%1%-)G<"?4<]D
M2?=H\O&4! C"S'-3 %R 0A<2+XGWL(W#R%7AG9' RWO;8=97.?)-;JDB_YZ^
M_%@>!T6<%*"AT0)9%A/-IG:"C!;\D^X)]I.=IX(#Y!*8A!!&@";0AS[PQZ6,
M*7:)$ADU0R[Q;8DI-R5[@M,9J=H3'%Z>+(^ Y[T3Z0F:,7]9U#.5U*F>H$G/
M#,U0KC!&44Q\OK@&NAGU@LQ+AZ@8(IC)O&#1C67Y#<N^7II[Q:+MKI&91J/&
M6IA-7-1<H?I\H+#-RZ*:=C9R\WJ2+HER[.3XV8M %*=>2#V( S]F?<*1FCAC
MG489?JG&L,RMU\9PI6RB&*:F\$\.3\NADCR-=-U<!H6TLSBU\TS+%5'J#*\F
MJMLW==/@?+O]?E-OO^;;=?,I_[PI5DE,4.3#!( 0$4(S#P.OCQJ$+DJDMI;I
MQK(\,MS+<[@^YY% Y_=.XNF7@G;,%:/2E+[*T4G+4BN4NN#5&5J9<GD9U#*6
M36WG692C&*,E9AVVLCV.B+Z5S2HB& ,_QCZ!U/52WP,8C/$""( ,O]2C6"87
M;_U[98^JF/,[%R?)+ TKQ6@UC8MRG%(TT JA3OISADWZGBZ#2@;RJ$T_;09(
M]#:_+[+Z/B^K51R#%'F)EV01^[\D"$@Z1@49HJDVCR1BS4.E*X=+='[O19J@
MDXR]&HRRY*P14HF:.AVQ#F[)<DO!YP732R4;$88INR1*L@]%4["?O?NUN/]<
M;%=A!%# >VZ1[X4N3KR8AF,0%]-,!ER2'VV94Z,:YT3=DB.4K&UB0++HF!Q_
M+IGE_-Y+G!A!C_TY0QQ%(Y<!&%7QM9&'27$Z&^W:NWI;MM^[7A=&+O(00AE&
M*$$ABHE+QF QIE)+3Q5#6,;)T8SL7I?22$S50<FI;'OF*<]D"_MF=R+[D3,B
M\]AJ5BZ#+;I)G)K%UO%$G35CSPA@-P(X(1B!)(E($*;9& YC%^K11C#(++Q1
M&EVI^ZC*' L6FJ#.+,.H4^Y(D4?2T*6R1S:-B_11\D5X"1(+UK3E-:YW5;O]
M/O2K<.Q#E_HQ133":<A/NQBGNJ/,);'4VDJE"+:74BIMJE'S2@PP]FV2H\NH
MYRE?9ADCO6C.N<5"6F8N@RR:.3Q=&&3 $5&F/%H[_K]VV[)9E]=\#^$0U0]A
M"#//2U.<N'[D)QY.QJBQ#Z3F8W1C6>:,PC86;??$>#.E<7+D>;I'Y5C<3/RY
M8-89$IFR>1E,,I9-;>=A-+6 Z$U9%:_;XKY9(>![-":AR_X%713B8%SX'41^
MA@TM(A*/-^M"(B[3Z70:6TTDX;08UZ8V68YM^OY.O+1H;YK2\B)YRY?!.:,9
M"2\S4G5+=KL)'UPV3=$VIZ7@^OZAKHJJ/1S[@#TO] (:I91X+DE0&  X:B(T
MD)J0LJO$,B/)MX=R/'.EOG'.56E^5,LH7^1\ECF*37!XNI@2DQS&CGM@NF%L
MI_S*:)%9W2:CY/:Y<?$DI;@,AD^4ZXD-.%,X?(G[956?:6TZC+&_**OVKGA;
M?&L_?2TV7XI?:_9UL\(PB:,D3ET70YB@#,-Q:W< $]8JB=#>9GS+C/==WQ6C
MM%63S[-Y*?Z:ZP)?.:-JIZP<IMOAPIU>N=-+7T"QK(<[+;M.P.*+YY':^8OI
M28/)7.I:0<\?VD -VUYH^:8HA'G;NTDRK*=[I,VV;9^^UO]9Y%L6/@RAGX1^
M2J,88!1YB>^/X7$<!"8;-.&@]ELQSRPNQ>TTTW19<=)6>\7$.IW:N3PWVRY9
M\=YV8W2Y#$RU/Z,]&HV.M,,_1DLCGY9D\Z+HF[$VA3TY12\ 9A%KQTB"XSA-
M4^BEK(W;"R"AT!X]"V'MMRN^8<9)6&JH9;'CIK6VA<NUTKI(.&^X?;%3 M9;
M&(&2,-;&["W2:67D??Y!VAF%Q&1;&E7O3+4UE#VP0WP_@DF61,@/<12X*$KA
MOJV#*$M,-C7B4>VW-(%9WDD8:J:AL>.EK7:&J[71S$C8;K:5L6._[49&H!A,
MM3%[@S2:&'F3?XP61B$OR09&U3EC[4OY96C?/(\&+DA\X@>  IKXP W&^-1-
MA=[OFX]JOWT)#8-.W%!#[8L5+ZVU+TRME?9%W';#[8L5^ZVW+Y>+P5C[,AJD
MT[Y(F_R#M"_R><FV+XK.Z;4OKZMU<5-695MLOA__Q8KX*,QB$H2>'WM,3(*\
ML9&+,Q(86%:@'-IR2W/090)\Z@;K-#J3>&NRY3D6K' PAJTR,-$"35(6-IHA
M^3+1:XE.&27='&D[ON0V23\YH8;)D(?Z.SQ6:>A%7I90UO;Y(,-A0/UQJ5V<
M1 3)G$VM$4:JU9$_GOH3_Q53>S4N>W:^<9G8+G,-R5(V8YQ9V6O TV4LVS61
MB/"."TEOE#=:O'@,VF'9+R$40#_U"(BX#)JZ!(TJ(IP)K4VR%=MRM_C)9HH3
M1W,9W#RA6Q1BB)NS%.2X]^(&"9UBF&9#Q'D_SX#25LDL@Y[6LKNTS<&HBR*3
M#R\&/+\"%?HLH)N .(X2UX,!";/QM(.8!K'P#+>%T/:GN26V,]BP]O*TP\RN
MRE'SY%FV)O<OV"@'\:F'F<M#;>K!1KF(3#_(FW5B^L&BZ_-//]A,KI[DR376
M/NV7L"9N1D&2!"2#Q&4/%<)PW!81QZXO/"-N*I[]EDAB2X(Q$[6;'RO^66AS
M%/8@&#/96-MBQ6R+#8J930>"IJ@U'-*6+KZUD,](O(E0=,M$N\ 7G Z-4@!#
MD*4N1M@+H\PC'D;C&]LDPF*G,!H.:;]UD-A88-)*_0;"DHLVVHAN!;OAT8B4
MV^9:"DNNVVPL1-PWT5X<K%%L,A2\77ZKH9*41,.A[)F!MH.O)1UB$R_T@R")
M(:((IB@*0#*^3DV2Q!/>[6PNHOV60V*C@$$CM1L.2QY::#>Z1>F&FPT9JXVU
M&I8LM]AHB%AOH,TX&*/69"@8N_@60R4G\09#V3$3[<5^;6B84ABG(? RC$($
M$$G0./V5 )2ZIIH+X8#V6PN)9?_F;-1O+*PX:*.M4%CG;\YG<RV%%;]M-A1F
M%O:+VJ+83$B[NOQ60CXEB49"T2_E-N+XS\=+-E<DAI"U2FQD@P,OBXGGN_$8
MWP5$Z#AL\U$MMQ8J2_<-VZK8<$SBJ*'6X_BK1XO$9S-=LQ69Q'S#38E\(2BW
M)J?LD6E2M"U>:+NBG]>EQL60<UIWBZ-[?AG-"@<$\K5A* @)\4D2L>AC1)HB
MJ97X.G&D6I%)EN)KN7:^R9C:,$.-1*]L 7>$]T+.K#,U8>PRUI0:R43D7G E
M=\3O!-_D;;%^GV_;[Y^V>=7DW04S1TM4 R]*"$4NA)2%@PE.AB6J<01(>FD-
MB;$X]FK5(,WIM#G'XF9;UWW)K3,5S)C1RZAEYM)Y=F6V49]$ZQOYYZYLO_]:
MM'<UZV!\*9J6=U.;K&RN-W6SVQ:?BF]MRASX8Y7$88@S$H:9#X ;Q D.PU&
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M$W%/C1)&F[+#2T2:>C)G4:;ID0["7C?-C@5,4YP"+T%! D@6XPS@#(X!@S1
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MT]^9YW@;HT4ATL1,6N0+:V6FS?U40S-#"6BV-=W;,52MW[""W.Q_IFA6P T
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MV@UE1Q?;:JAG=+G-T'1+<T[J;5VMB_6.#>4_;XKA'7^W2#G-FV*-ZWO^G7X
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MV?FUVUT;QIJM]JYPTKI:2[[?G*E$[;9=TQ7F8MJNJ^[F;_XP3'S#BI4RLM"
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M4\&HLHM6V,D>1S:F]/T(9W$4X01&'L5IZOJC#C] KC5Z"D6WST_?(C_%#+9
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MCH9[RZ",3@*UL2=)AR"8]=ANZVWY7]UI7[\6]Y^+[0I2?HP&\%PW3%P?4@3
M< ZAYX,XD-J";2#<9(1IG-^SFL\2:/%%S5(5WEAW4Y4_ D9.0)^7[!&FD9:W
M2Z237D)G:67 *_GQWPL=+UI6['MEOOG8,D5<'<X?NE,,WY15\9I]JUF%E$8Q
M 3#+$ 9^D@$WA8.L($4T4!L;6A(SX;CQY>',E;-/P]GGX8R).+_S5)PN%^5Q
MI:URE!US+J (U<>C]DK/\GA5S76AL:SE ET&XZ=+]^08>!*?+[4/956O?LVW
M?Q0M'WQ_Y(?6=JM24+5^Z>C;YE/QK=WEF_W)GC3QTPC!-*#0"[S(QQ$(1S4!
M^PNQ]]RV55A_W7T0[QS4.WFU=H[NQ3[.P/EIR.%GD0-MIRVR\RW DLI*#OS_
M1Q72NK[>\=_LNHX_1&$]4JQ2:,WC0CNZ/.S^*(4_BS;)S)NNG?7\H975-.N%
MQG4J^^=M4R?+LI[VH5:='VI>5TP*6G_I;B_[5*.;F^Y8^*+9M_DY>^)7<1P&
M6>:[J1M'"?0 Q $:=(1>#%*UZ2)3T2V/H=[N^&B7GW#<='J<NV+37763L_^-
MDM<.2XA?9/H3^XO^YWY6G6(R5BJR,TYS%(CZ!%17 FMGE.NTM7,0O!\P73F]
MZ+FFJ00]%9JU,ET^RQC@6,SOY)R6'2?E ?SN:U6L'X<$49*@- 4>H@D@U <X
M&&?5$@HCJ0/_M0)-C=6:2W1^TH2GBJ.RG+1LIO([P4[78LCWW"4AR&F8NS2>
MZ:1R$EW:_HA2*BNVY1<V!/JRW[W >JXK#+S(!32%F8MQX%*2XF@?*X!8;KN
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M\PD8\4,R%EB4#.H1+ .""^.'>#P&A>0QVYH>7@;&-/:I<L/$2=I"Y#AIPPF
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MCE=%[@MA?!'?+7_+_/PF%PL^*[*+LS_S<FC$3:'UU]%]*?9[TF([ 83I6I$
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M-^M9_;(6WGC5\4OZ/<T/*:&&HR)O&FW]*ZOOT*&JJ4B7IQ(=V\#QH44B:#D
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MX%?/IP0M($DMX"5*3 TT<"2M!V_1HU41VL$Y-$&0L76I@BCX5W1!B@.>PV!
MO>1_I";E=?8]9</]D=Y?I^7&<8@;>@!X@0]BU_>;RY&ZH5PSY&H%,6D [<4S
MEF\,N 0VIJ:Q]O99[2R$B4G&"UP9?[>H.+5U&FG\!ZVSD"=WIBI%(L_1Z6LV
MOW)*.IFBY0]$IYM0*)PR0F)K!B\.%5K$AFX0.D%@^P$= ?G=4!B&@.MP<](
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M-OHG^D5DO[\=\?+FK[2JT]T7^M\RV]9=+]+1Z7BSN]#L(_A!',?8BHD/'8=
M9,:HC\%![+NV^.Z^>@SS1RSZT_<&OE$.^-NWEXWB:,$HADW<N=?@-_Y]^F4=
M)K4K?PP8]*<6MW$$WEV^-X+>;<W+[<!K<([X?ONR3IJZNS[EL5*SER[,WQL[
MY_K\L?P:= 8;7]@5U\TH=Z5J<7]?Y.VH= Z6':Y1:5EDHP"1$)/ @R#T@$V(
MTX]+7!>)+02GCS=C?-PV8+MGMG^J7WQTE:SJ%/B";WDVKQ/$8EZ+K>]RU, ;
MWCQ:KL3U+<+.U;@J(WL=*Q>%]IQ6N2IF2OL>6O,?IN##*U'6)G 1]&- G, *
MXB"(B07ZEYX"A /. J)%H&E7U@Y/_[HM5=ALT,T'[FQU&;=IWOC2[:_9-[N:
M_S%ZCXN]';KPYM8+OM"QH37%Y>L(!<N8KFKC:CK_W(4F,O"Z:PY0D==ELJT/
MR?Y;6MYOHA"9V,2!A<S0CPDFOM7W0@I";#G\6UAS(],>7D: C,<TH9DYA24;
M91;Q'6?]R$J=)A%CC#=B#.QBC/%"C!FN>1G[G1FU8@<+UH6LU-$3:D&,%VI(
MDZ=)137ZW$/G<"-I/'[?>7P[\CA[R*?MFBFF^ES%QP(.77Z';3'+3RL[%F-_
MVDIT$WNA95FV%Z+ MT'@$A\.@P'Z'Q5KRC<'T1Z^QXN)L3ZH6!6^3>&4]9U2
M[N17:D-T/,[J"^,S?3Z3ZL[ /QG<N?N$OTB7\&**F]\U+XOXC>!:X ARPJM
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MZZB>FNSK=>C,@O:KJJ-2Y FMQ53/,0X7SWW,ZS++JVS[5[(_I!O3<6*:=P;
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MQ](%FE/GB=;K&/G\<>Y\9 6S8"6G(6M@0L75C%J\HS?I.<G6WH). H"QY>'
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M,J-FH*;O14D0++\3I8E4M?M0';]=\>^WLS3/M@WUC#G!32AYYM>B>DIMXMB
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M16)8(QEXZX#->@V?]5*K<8 G GOUUUH?U%X+&VX[,;F=3[/):;#I%C-4KWH
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MF%6L](T8U5E*C]0HOZ1&T[3;X.EFO 8S.[W\:).)N<E#:XO.?K+0ZZWXY&"
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MADS+=E#+=JQ!MF784Q5N0\3IDFX.3YMXR_ Y5+X-\:I;P,7X59?P PU2(J[
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M'UN@UAZI=025K33N,^M#7EC_.TLW2I/P#T"US"3] [@SVTG\R.<KJW/7ZN^
MW.4)IOKIF_E2*# ]0N&..*-0X4=B[50H\2/AGW&H\>J?)-E#7G!7VYI58 %
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M'[N)'X5.(C/):#1K> KA2*WM'NJ5E79@/]Z7FX_;E.^9;%K U@-#+#=;Z&P
ML;E@(N[EE+ZF_>L1[? $[1U6Z^<^VHTHN#B)/?ILH"7FH;XF'"N-]V(3ROFI
MW&X7)*:08#NP7:;7-$8V]5P&('"@'3D 2V6)T6CV_PCE%&L G<JIG7N3RLG!
MSE$Y.:[!RBG5$C^2<LHYIJ2<"MSI4<[?BLT1A,_E-N<Q<7=:WOU^NT# <5W
MT+FA1X*0( !#%-,0(S]P*99*)3D.(L-ZVP#B2^.#Z%IY8:76PX;AMG9[-ZPU
M__US"URGZFIK/!V"/$6[&=#J@QNU6EL=\"OKT.)[9^:DY8+\*\N\[O;]$68
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MTTWU_7:3%MMTR<'@7489Z[?E\9_#NVV=+&,1HL2C +!)UV6S+&2@DJ ^9G>
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MR0=(X^K6259Z!&H8B_-0HH$^E#K[E9RV=*%%<PV&!Q=OUOM) CWV/S:F<4B
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M_6QH;'/=96G_W#S1.>Y0M^7K[K0'ES@1]'T:!8@D81@A&N.D Y< G R+AXQ
M&B6&,A<FF6DFU=!J\A8:KIQU8-M6&VB]F*>8ZF%?*LPSVKSS$.ZQG;X83H[
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MYA&=FG:R''4$B"GV=E,M;O-JG=W<7Q>K_"5?[=(U_):S!:GK.Y!%SVYDVT&
ML>NYS [TH1-[$4F$-ES4OVXZLN6@^'/$ RSK#PY,\#[$ -KZY7$<QB2C7'FR
M1%2-N7JD:.QW;]7L+!<GA&HX;]-JD ;\I:X>-$ Y?L^KQR_9NMDG?LR?;TM2
M5'GU'9=/:5XL@ T=[$,7^#%),($T=(,. ;)%LQ28L"PS>I1>2I\:1'\QS-8Q
M:'Y6VL"V_FB #]&CH8VAH%0CMH(&#;M$L3D5Z^=)5-\TL3U#Y=/E69\F:F5/
M9.^0/#VOR^]9MH7%"K/5]Y+1O6VOC+$^0Z* N#CTXA#9H0]\K[460\_Q1#<1
MA]@P''/MH=4)WO?@Q/?+!O%W>6=Q+.KDA.L,:PKW=P?1)[[O.!:-:AN0RG2*
M;$;VN'YF5U('6=-O3VKQHM3;A>0V+#N+]2/FF[H@16O/#8'O@X ZQ'/B"'B1
MA^+67D*CQ)'9DU2W8EB:FZIH#:*1[QB<Y:1G-VHXC_/8<-+@1ZF[AXF',W"[
MW3TU7>:W;;:Z+LBVRI]J.;ZYIVF^J?.8WMP?8=G"NVVU29?5(H0Q)@#Z&#HD
MPA@3!_HM'$19Q"6V$C0.P_BR\.ONZ8EGHN2%S ^.6#N>)9DM!K/&E\RJ'C/K
MGCECO7!OWA7/$8\"S+;:Y2AK-LTE%X8=P;8X;K:.M [(K9M[BV-ORN7PW[U2
M5.N/S@.)<,UL0XG'<[-I,+6 #[X=57G1C:HVA6_/L/K[H'!P"'-GXL51&F/Z
M@'(<-\N1.[E"]K=WY9&.,N8GWP]_I4VH#_G=ISW<(Z>^Y-L_Z2;+NC0[]4D2
MB6)H P!1 B#UD1>SP*##[<4TE"I$-SE:PR$RQ_3QGH$ZI/B6/W*?GB71DG63
M S4WE1\7HCCV[K@:A77W_73!"N[CU?%<?^3GE<4]M;BK^^3C$QS^&V^[GI79
M?/K-/%9X,^+C5 ['>2";;EKDCT^75;;Z1\F/ =9Y];U&'L<^#5TO]G&,8@_3
M@'G0(L=^&&.Y[,]S0&Q\'=OALE[VP":<&E7;=8+)<80&G<WTN.\D!V=_]/GQ
M=/.--4,.[#S_@G/D4$9,SI):6DMJGGQ7>^H]\CL9Y+?9Y@DL@BAV_)"Z&! ;
M0^+[P'$ZP#2T8X7I<1J@X\V*Z_R>+QRM[UDJ>N(] WYDYL/YM^#\ID'NXP1S
MGY&FNC3E3=L_9C3334S$J0EN#FTSZ?H/\RMA6;%JYF,$G3"A04"<T/>#T$&$
M=+@)".@,5G]2>(W/<AT:ZWN>K07?/\Z'GBD7?<;:<7YSW;Z3_(LL^(Z;;NSE
MGE*WF=$4. \^QECJ#6@IB2*0J]VR@L6JS4]?5[EJ;_U$B>_1P/9@ J%-(QO8
M'JVK:?BQF\04RQSQ#3)D^'3NEWR[S-;L1UFYVUJ;)E__%5MQM15(FLJOZ?T]
M6W:G7(XR?M4[SR378L.X%IMH1J-9;HYH8=779EM@5U8-;:+B%WT\]0BR%GKG
MH:5Z7'E?LU,7/Z(*]B7;9NSO/O+;OFSDKLMGKJUM8M"%[Y.(^, +0<QD,P8(
MH+BS26(@E=YVF"73-PQ:</406QW@C3NL>BGJ&5=ZJ)W'P-+D2VFB\\D-+5Z"
M?I.NF4FX>LJ+G-]8XH_).ZL$!6% 0.Q2%$<D\FGDNYW5V'83F<$UU);AX=7"
MJT=7^@K@N /L DT]0TP7P?,89-J\*<UT0\7,E4UBZ[KF-0I=Z-JA#9,PM"D@
M"8T[2UZ,(ZD$>RK?-SR@ZNRS=5S=9JP<_>W("5)ZAL\0"N<Q9 9Y<"X5I3(;
M4K47LVW5&-K;740(QP2&,"34QL2&- [LSEJ$(U^ZYJ*"#<-#9'\+,*]Q35 =
M\#TG/2-D*(OS&"6#O3A5!7 P*VJCI9VTZHS+Q/5B#R6.'Z$$N@!YS!8-('&B
M& %/ZB&BLI&QQ@L/TLIZ<Z$9.5=6(9IS?CB18OLTHW HMT>SIZ^ME_*A1?63
M5*YW$^ISH$=8?A08G:/^J+C1*T#*O C5'WWDN]W7Q=&3%U0^/95%_?#E]Y3O
MAE?;14+LR*,8\[1CGA<X 8R\5OK\P!>+;#6:,ZQ*#4I^?>?U4[%E#;5],?97
M"W98P4<A/DX,(0-D3O\*3+=#I;&.)YMLX"Y;K;(5SC;Y2[TV_3G-"QZ!WQ3O
M_XP/=-]W'.0GH>U!U_.<$(44=#B<F"1R5Q+TVS=^Q>#<$%SM85KK/+WKOW=N
M*'^!))D]$Z"YAIG'S&C0OW=Y$,PR*3.7MOIR7;RP.9QO^6ZO"[@_B>2'S6GQ
M?0&HGP0D=GP_( !Z,8@2U-E/&!+9*56/U3&VD.I*11U*/L1ECFEE9E4A2BY,
MKGIIG<\<J]FO$U.M">:$=V?Y4O+7LBA?;WIU6\)N3",?>BZ)O!@&)/0=V*WD
M?3=VY#9JAYDR/.!NCM;4UH=LOSSL6UV;V;KMI:EO%U</O_.8$'4Y\W9O5R='
M0\O3 @0=0@,?Q! #X$(OB?W66I 0)UP4V0-7 -&=*S4K0N,J;L;5,2")O9=]
MB=HV9_^/6IA6E,IY#*'!7@@6II5C17@IF&X*-CZWG[--=[DP7]99[]8[U@7W
M*4:H&T$6H$("$N!XP(=.L+?N4FQ+9:'39-/P5,5+X=4%\)B(65L.5&[_5QNU
M8MO!4[ JMSO<(>1%09NKW%=6C;)-A5GC%$E5968=+<9?W^I9<PO,0]^T>_5V
MI6R$->'7//E#D=_GR[2HX'+):[8Q+)_+=;YDB[[;[%N5,"[^7#ANZ-&$!)38
M891$?@QLMEAW;>2C(*!R23@UF32L?D=Y 8\ 6P?$5@=9\KV-)L+%1'$"KN4T
M\0*WUA\<I%6C'%D/Q:CKD4/-W,]##74[]?8-B G.A+5P=[?-_FO'[X2^\.V1
MO?2R%5KB>2%T$F([-K43.X:U.4##((Z$GVFK?M_@\-M#LAI,DX4?Y\CI&V!#
M^9S)D!KLQMM!I(<7U6%S&*9N$D?(1F$, AH!CR_4XLY>Q)9R4E&#LA7C@<*;
M(209#ZBSIZ8Z9H@;+#O3S?/G^)%0'GE.YRD]"GY<T!Y59A3%YS:]6V=LJ12$
MOAL&-@AA!(*(V@%N3!&4^*'4HTLE R-+#AL]')9@;NMAU"F)CG[6ANG-1<+&
M4)H:@KC(R'$X2WV1=*%?6E3X4%253WF175?9TW81)$'@^@1B@$@('!]#3%H1
M<T#H2QU4*AL975TX-*O&-DQB)'A4DADS% Z5&A'VQM";/3OBFB-/Z"QU1\&-
M?NU1Y458?Y:/V6K'J^7!Y7_M>)UXFA=YE7W*7WAN_(IUN)RI']QNLRKY_DOZ
MSW*#UNEVVV@BQ&X(0>+B&-LX<",O<9J\OS;R$")2#[;-(C&M9"UXOHG;P;<:
M_!]K!ZR#!U;M D^R4SMAU5XH!E9F6T]0&F?3<)+Z:;S-S&CM$+K[!'F49IR)
M:H_CZUMI'Y%AX91":<47SUWEL-BS;>*RV-:E=N*%S*#=VO"![4JF>Y7[MLQ
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M#/")2P-$8Q(G$"*4 -^N<ZV[-O3<2.I&N%$@A@^TC^\SIBUZZ[F!7P^_M''
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M1@$B7CH8@R@4_B*/AHF))&9WA,;E9B=S2T>'O^LG%1-1IZ@S)ZP-L*8A3OR
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M<')E+GAM;.R]69?;2)(F^CZ_(F_.<U;ZOO3IFCF^5NNV4J$K*;MFGG H$J%
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MDM'+\C?:1$*KC.U+@:R"TJ_-GH8;5H-9$@ZDY@(%2\TBY1Q&0KL-'[CWGD4
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M2QF5,0&4QB;,VT-/"RSM;=?:-%-\3*?^D"[JM\;=-2Q1GC!FM?+0&LF)LT*
MBE*"7$RQC\8YS6\//"VR]GP@^I1.RS.7CZ.B6:OE(S,DW% &+ =(, >4":XC
MXA7]SI 8%WR B<M= ZL-'O>%L559ZZSJIQSVYG67\J<<.H"O&J.3L'=3( DQ
MVD-<QC0HJB*AA!,<DUO2N'#,VU-;[7/XQ$C?\X7,JY54=*X65.8QJ^OK;)J5
M^'>S1;9XV(&>F.D2#Y&UUBG.+<.&<$>V^ST!+*HU0N.<X+<#IQY9?I; 0-V
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M+&B:_2N=[.K^^[3;I5N55*_HVF/R=_&JA',,-=:*$@P5A,Q"@"LF:125O3-
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MDZWB9X&"\;A(2QE<77\LTMML>;O7)CX\+,'"6&.\%\'%(TH3[*2K%E]6\HP
MQ0 OQK8%B0Y8&X&+[-DJENGDP('_T3&) 0 R41Y*<VNH(E3I+9P]BD+$ &^L
MMHV(MOC:U_;R/I]]^Y(6MT<N13U]+&% ,&]0J?-,L,.@%8Q7E! .8DR1YO='
M.^\&V?8V$L'*_L]G/XR*8E5OXE(.9)$%T#&@@K\@L>).<K,)85GD!*W5>'NH
M![)0*\@0Y]R%5WCMA,&@HHU)&I5]-4S-'2/@&@>RS1AZHLJ>%XLG( E_>PF0
M\*/DTVCV+=US]OKL]PEFAA+% 6 $>$,- DA4:[;0QECY P7!R5++X_G7N<SW
M1KQ?/%&&YHRGU.!@2@"/D0'!R-RL6]M+Z9URHJQ>2OHDGG4IZ]]&W[/;Y>U!
M:3][)F&0&HZ#PVF]*8.OU#JV63M&2O1:T+ '>3>56-X.W_J,':Y-KWF0A7[X
M?9;]<QF,KOFXR%;UNVKDW1P=GR M#8$*\&">@K 7!B=$;&E'*J9]Z1LYP&BZ
M-W3)W_-@JW9VSJXA"5<@?'N66\4\,S(06J6[64PEK&4^#U_K="3U@Y@ZF<DG
M!H[>E5?]1]/'!7PLLO%^<^/8D(0XC*BSV C@.%/4&K%=M T[]"4CXQ39Y9WP
M]=1DG.O LO]W-%N.B@<4K"C0!!;U!B>< 4TED@;8LA*;](CJ#2%$2QF3V#?0
MS:<U@'3"X1.AXNY75QIL>CU:3O>WD]CW: *MP)822I&U5CCL,/35(IV/:B$Q
MT!2<UF#0 C^C],-R>JIR.#@R09YS98F!U#G,'!#0;7%+[:459^U ,[3)WCX/
M'A:;,/B7\.8C#LZNQQ,!R^-Z(R@TRFL->)G,5F$?ZYA<SX'JDK;\F1;8>2Z@
M''5>=@](%*(>(&Z 0M([P;%2E9E.J5,7YKK$"?@(6D[B:%]X>7&"5:/]YX[G
M$P"!UM8RHASPDFBG&*YH8^K2.IK'"OA5#]!XEKZ9ZVT(E?G- DB.O%**"U-I
M8,JYCW%K!FJ\M!E3BV+F6[S>9@TC#C$(C(!6AO\&6BL*%<47&"8Y5<1UK[<U
MX^C K[<)A""R$DO M%)EZ:(JL]DR0?2%G.JT)]-3KK<UX_' KK>%;P4'L\T%
MU] *ABQ0@E:+ET[$U($::!2M/8"TR]L!7F\35CLL:>"(()PI4!X_5 1@92^L
MZ5*KX&B=NV_O>IO@P<A71GI?-NN!@6=P2Y]6]J(3?]NT9$_EZ%N\WJ:@Y8 P
MRS4!0&$@E*I4)K?47[0Y>X*<ZUYP:\;6\P"G2FS_-%JDJUI7DX]I,2X%^:U^
MXNJA21+-;=AVI0C*55&"*"#;_9@S!V.VL\';.FV#JT5&]P6WCT4^3M/)O"SV
M_ECR[,A%A?V#DC(U Q)' R>U-AC!8.-55&+F+_JT(!Y.K3'V/-KJB4WW>$KV
MJ90CK*VL#LR12,F\0H@Q9S"CB'$/P/83TBSF=&'P8<"V=55[?!X0UE8GLI%8
M6\^1A,^,<PN8A,YYY27PJ$J"%13 &$4V>$.]%ZR=Q.>S8^U+>,N\K#+ZN+-O
M2H^NZ/E29-^^'3P)BYPY\=1:38AUGBHGA6.D/&A<\PLQ'6.O#;"O9&^X[(3[
MPT'KEV)4%K&VHX?Z08LC\R0*<8V\#B((;A0US!HM'GGA8BY!#;"#9/](/)W7
MP\%=67@\'2_+RZU/R#EIASXV9Z++KBIA!Y$:$:>@LG#K8(7?L)@:J -L!]D_
M'MOA^WFP^2F=I+>KVP0K=7Y"$&7O# D&)+AF%$-.PK?(*:*VVA.DQ?7*R+^=
MSHO=XJXM+I^CLH,?9<6Q-J [GT\$(EH@B0 M6Z4A@36O4L9D>4(6$^ =8'O#
MMB'4!E/[4TMM59HJ.425H%YJA8"BA-DJ)UUR#6/*;#;O7?CV0-,.6\^SF[5=
M]HX:*JA%DCB+;-F#"9'JNJ[TA$9!Z8<[!(AG\/F/FMSU=3HN#;W(TZ8=\R2(
M&*J4TPH2Y2$C6L(J0U5*1Z).,W^ (X(NF=T7\*I5N^]EN^Q#T'KQ9$*Y1= )
M)LJK=D (+H2KZ(&01#7L_0&. .+8>29X'#F,W/%T J6G&FD#M0ZVGN5*;V]Y
M*0-L5 .#'R!Z'\_2D_/V]@0A5BN:C::EGKNZ_I0NEL6NS/#&<R2>"J$YM<(Y
M2RWA!FZ/'Q1G- HI%QQ/[YK1;>/G4_K/91;$4*8:KGO$J;N[(K\?30]:.-%S
M)EYY!AS A&.GG504RBW9A/.8XQIXP5'ROAE_]HBY&17%0S;[MLY-N[K^<I.N
MFQB6W9KS6=K PVLT:V*!Y&7_9H>TILPQ#U45)E% J"AS_$<.F[?.^OX@6F3W
MJW*D[[/1UVRZ:F9_$'P[GD^<D%!B["GE4@N!E-:59:DP!E$AA1\B*A[/U+X
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M!(;$8Z"=)XA7_72TQ1S$V"*#3WB,!$?KW'U[%:.LE^$#0)81":QB!(KJ,GZ
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M\(IJ0-DF6:/\UBWJM>YS+W"-150^&&'T!>O?\EGZ\-NH^$>Z\,M#Q8(/#TB
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M?;9E/:;H' !Q[3D2KBU AC)D)!7 .8% Y1$*R***20S13>X-,B^KH78DD+Y
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M[DQ=HJ@U)I_==+I:W*3%JCG:4635GB/AU <6*(L=5DQ! #41&QX(P92+ -H
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M\RAU C\S)=,TL#+>WN;%781BM^6G[;Q.#,HIS0-F0C-!I40 6XHHQW8W&>I
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MWPB?M88C7ZMBZ'O/V^3\;[+G[6D9F.?&(\A17&X68$<EWLU7:91C[A]AM.^
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MBD-#=C-V%.4DE1BA?_PH+M]-P>__O/OTUZRXUI/[5)AL7:Z^GOKTMEE(494
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M:\=+704I5;R02 \I@@X[R""2%2*8X9R3=OS6K%YX=SK*8^.=2D:1%LGWHK]
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MQ!YA<<A.:-$FP$.<0E\G]^L0R67D\S3J=RFYW[M!^?4;!Z>)5H@X"[$@-@)
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MQ$8JAB -:KG9=Z0Q'JC.>$A-/%34D4K)G",8"L^M$<@K#ZK91FWYPN+]6^=
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MYPW>TUGY8UK^7U?EPT9*:_!2 8HHK<WA\G7U\#"9/WZZ>5D<P!;+R?1^\7*
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M1%UXX!@@'B&+#4[^C1LY2&Y85@3\/XMQK(LQEP?GOQ['>#\$C! .-9(( RL
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M_&&]6FY @>V7UM>] J(IJ !AIC!@A@,K8+TYDLQ=FYNB)PX<8EHVWH.Y+^J
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M,C Q.3$R,S$N>'-D4$L! A0#%     @ )7]L4-X E94].   368" !0
M         ( !9ZP" &EN;RTR,#$Y,3(S,5]C86PN>&UL4$L! A0#%     @
M)7]L4#;+@BZ4B0  -H\& !0              ( !UN0" &EN;RTR,#$Y,3(S
M,5]D968N>&UL4$L! A0#%     @ )7]L4+<]&J[0.P$ ;;@0 !0
M     ( !G&X# &EN;RTR,#$Y,3(S,5]L86(N>&UL4$L! A0#%     @ )7]L
M4)FG%#AFQP  :> ) !0              ( !GJH$ &EN;RTR,#$Y,3(S,5]P
<<F4N>&UL4$L%!@     &  8 A $  #9R!0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>76
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W%39.Z;W^Q\87P:&'7W<Q? %02P,$%     @ )']L4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M8_F^/;PQ/!P,_>;X-G1V>B5[\S]02P,$%     @ )']L4-GD!TA# @  N@<
M !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6R-E=N.FS 417\%\0%C<R<1
M02JIJE9JI6BJ3I^=Q EH#*:V$Z9_7]LP%(PG21[BV]['ZX#QR3K*7GF)L7#>
M:M+PC5L*T:X!X(<2UX@_T18W<N5$68V$'+(SX"W#Z*A--0$^A#&H4=6X>:;G
M=BS/Z$60JL$[YO!+72/VM\"$=AO7<]\GGJMS*=0$R+,6G?%/+'ZU.R9'8(QR
MK&K<\(HV#L.GC?O)6V\]J Q:\5+ACD_ZCDIE3^FK&GP[;ERHB##!!Z%"(-E<
M\183HB))CC]#4'?<4QFG_??H7W3R,ID]XGA+R>_J*,J-F[K.$9_0A8AGVGW%
M0T*1ZPS9?\=73*1<D<@]#I1P_>\<+ES0>H@B46KTUK=5H]NN7XF2P68W^(/!
M'PU>>-,0#(; ,(">3*?Z&0F49XQV#NO?5HO4H?#6@7R8!S6IGYU>D]ER.7O-
MTR@#5Q5GD!2]Q)](_+EBNU0$_X, N?\(X5LA?.T/IA"QW1]8_8'VAU-_8B31
M2Q(M:;0$/D'H&8G<4\U80BM+N&1)#99>$DUV\6#_,W >$,Z((BM1M"1:&431
M8B,_,%AN2F84L94B7E"LC'2+^#[%3<F,(K%2)$L*XPP4R4,GY9YJQI):6=(E
MB_%A%>DBW1C:C\HCRAG3RLJT6C(9KZ!860ZE%\0>#$*#::E<);X?I=X'2+(<
M6*\HN(0*S3L*/DQED7Z !2:7J*IJ/Q [5PUW]E3(^UC?FB=*!991X9.,5\I"
M.@X(/@G5362?]=6D'PC:#I42C.4Z_P=02P,$%     @ )']L4+?*2:56!0
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MV@XS,Y9]8^TG6G3#1T,T?KFL_@%02P,$%     @ )']L4&%'BCG%!0  5QP
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MHX1!0P@TDH"4(V02770^2 A<GR3M&QLXDJ SB20@(9 $9:(\1)T@[)O"P"$
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M\L'\A+8=UVQTO.FF%\3F9YS_!5!+ P04    "  D?VQ024Y PK4!  #2 P
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M^;.9QFPR'/;S#V++-R[^ %!+ P04    "  D?VQ0?E]W@;4!  #2 P  &0
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M_:\1'7@INRL_0JW_8(NAH';A^,F?S31FD^&PGW\06[YQ\0=02P,$%     @
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MCS#5\XF2J?AO< 7EPX,2GZ- 9>-*BMXZU!.+EZ+%Z[C+-N[#>,/W$VP=P"<
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M@4'X[0*W(&4@\C)^3YQT3AF R_,+^Y=8NZ_E+"S<HGQL2]=D=$])"97HI7O
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M?[#%D%"[<+SU9S.-V60X[.<?Q)9O7+P#4$L#!!0    ( "1_;% *HJC;M $
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;'U386_;(!#]*X@?
M4!*2K5ED6VHZ39NT25&G=9^)?;91P><!CKM_/\#4\U:K7X [[KU[=QS9B.;)
MM@"./&O5V9RVSO5'QFS9@A;V!GOH_$V-1@OG3=,PVQL0501IQ?AF\YYI(3M:
M9-%W-D6&@U.R@[,A=M!:F-\G4#CF=$M?' ^R:5UPL"+K10/?P?WHS\9;;&:I
MI(;.2NR(@3JG=]OC:1_B8\"CA-$NSB14<D%\"L:7*J>;( @4E"XP"+]=X1Z4
M"D1>QJ_$2>>4 ;@\O[!_BK7[6B["PCVJG[)R;4X/E%10BT&Y!QP_0ZKG'26I
M^*]P!>7#@Q*?HT1EXTK*P3K4B<5+T>)YVF47]S'='!)L'< 3@,^ 0\S#ID11
M^4?A1)$9'(F9>M^+\,3;(_>]*8,SMB+>>?'6>Z\%W]UF[!J(4LQIBN&+F.T<
MP3S[G(*OI3CQ5W"^#M^M*MQ%^.X?A8=U@OTJP3X2[-\L<2WFPW])V**G&DP3
MI\F2$H<N3O+".P_L'8]O\C=\FO9OPC2RL^2"SK]L['^-Z,!+V=SX$6K]!YL-
M!;4+QUM_-M.838;#/OT@-G_CX@]02P,$%     @ )']L4-VE"1RS 0  T@,
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M?S;3F$V&PW[^06SYQL5/4$L#!!0    ( "1_;%"_+[87M0$  -(#   9
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M:&5E=#(X+GAM;'57[6[;(!1]%<L/4!N<^*-*(C6=IDW:I*K3NM\T(8E5VWA
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MJ='P@[:OA7F7PSUZ:&C1C]\(R?2ALOD+4$L#!!0    ( "1_;%#\0BQTVP$
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M%Z\+ 8WUTZ.;Z_DMSPNKAJ5-R?JO*/\ 4$L#!!0    ( "1_;%"(LU!UN $
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M_&"+H:#VX?@1SW8:L\GPII]_$%N^<?$74$L#!!0    ( "1_;%!>P@;\M0$
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;'53VVZ<,!#]%<L?
M$"^&MM$*D+*IJE9JI56J-L]>&,"*S5#;+.G?US:$T)2^V)[Q.6<N'N<3FB?;
M 3CRK%5O"]HY-QP9LU4'6M@;'*#W-PT:+9PW3<OL8$#4D:05XX?#>Z:%[&F9
M1]_9E#F.3LD>SH;846MA?I] X530A+XX'F3;N>!@93Z(%KZ#^S&<C;?8JE)+
M#;V5V!,#34'ODN,I"_@(^"EALILS"95<$)^"\:4NZ"$D! HJ%Q2$WZYP#TH%
M(9_&KT63KB$#<7M^4?\4:_>U7(2%>U2/LG9=06\IJ:$1HW(/.'V&I9YWE"S%
M?X4K* \/F?@8%2H;5U*-UJ%>5'PJ6CS/N^SC/LTW6;+0]@E\(?"5<!OCL#E0
MS/RC<*+,#4[$S+T?1'CBY,A];ZK@C*V(=SYYZ[W7,N5)SJY!:,&<9@S?8%X1
MS*NO(?A>B!/_A\[WZ>ENAFFDIULZ_X] MBN018'LKQ+YFQ+W,.F;(&S34PVF
MC=-D285C'R=YXUT']H['-WF%S]/^39A6]I9<T/F7C?UO$!WX5 XW?H0Z_\%6
M0T'CPO&#/YMYS&;#X;#\(+9^X_(/4$L#!!0    ( "1_;%"F$CI&Q $  #<$
M   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;&U4VX[;(!#]%<0'+ F)
M-U%D6]IL5;52*T5;M7TF]MA&R\4%'&__OH"]KIOR8F XEQE@G(_:O-H.P*$W
M*90M<.=<?R+$5AU(9A]T#\KO--I(YOS2M,3V!E@=25(0NMD\$LFXPF4>8Q=3
MYGIP@BNX&&0'*9GY?0:AQP)O\7O@A;>="P%2YCUKX1NX[_W%^!595&HN05FN
M%3+0%/AI>SIG 1\!/SB,=C5'H9*KUJ]A\;DN\"8D! (J%Q28'V[P#$($(9_&
MKUD3+Y:!N)Z_JW^,M?M:KLS"LQ8_>>VZ A\QJJ%A@W O>OP$<ST91G/Q7^ &
MPL-#)MZCTL+&+ZH&Z[2<57PJDKU-(U=Q'*>= YUI:0*="70A'*,/F8QBYA^8
M8V5N](C,=/8]"U>\/5%_-E4(QJ.(>SYYZZ.W<D?W.;D%H1ESGC!TA=DN".+5
M%PN:LCC3_^@T3=\E,]Q%^FY-IUE:8)\4V$>!_3\E9G<EIC"/:9,L:9(E! YW
M)BG,\<Z$K"Y.@FGCD[6HTH.*[;**+EWQ%%\*^0N?6NHK,RU7%EVU\\\G7G*C
MM0.?RN;!Y]+Y+EX6 AH7I@<_-]-;GA9.]W.;DN5?4?X!4$L#!!0    ( "1_
M;%!W=O7+Q0$  #<$   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;&U4
M[8Z<(!1]%<(#+(HS[72B)CN[V;1)FTRV:?N;T:N2!;& X_;M"^A:.\L?X5[.
M.?<#KOFD](OI "QZE:(W!>ZL'8Z$F*H#R<R=&J!W)XW2DEEGZI:800.K TD*
M0I/D Y&,][C,@^^LRUR-5O >SAJ944JF_YQ J*G *7YS//.VL]Y!RGQ@+7P'
M^V,X:V>15:7F$GK#58\T- 6^3X^GO<<'P$\.D]GLD:_DHM2+-[[4!4Y\0B"@
MLEZ!N>4*#R"$%W)I_%XT\1K2$[?[-_6G4+NKY<(,/"CQB]>V*_ !HQH:-@K[
MK*;/L-2SQV@I_BM<03BXS\3%J)0PX8NJT5@E%Q67BF2O\\K[L$[SR2Y=:'$"
M70AT)1Q"'#('"ID_,LO*7*L)Z;GW _-7G!ZIZTWEG:$5X<PE;YSW6F;T4TZN
M7FC!G&8,W6#2%4&<^AJ"QD*<Z#LZC=.S:(99H&=;.CW$!791@5T0V/TG<%OB
M>TR6)?$@^VB0?40@O0D2P]RV@FPN3H)NPY,UJ%)C'\9EXUVGXIZ&B_\'GT?J
M&],M[PVZ*.N>3[CD1BD++I7DSN72N2E>#0&-]=N/;J_GMSP;5@W+F)+U7U'^
M!5!+ P04    "  D?VQ0>M>D'[8!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6QU4]N.VR 0_17$!RP)=MI59%O:;%6U4BM%6[7[3.SQ10N,
M"SC>_GT!.ZZ[=5^ &<XY<V'(1C0OM@5PY%5);7/:.M<?&;-E"TK8.^Q!^YL:
MC1+.FZ9AMC<@JDA2DO'=[AU3HM.TR*+O;(H,!R<[#6=#[*"4,+].('',Z9[>
M'$]=T[K@8$76BP:^@?O>GXVWV*)2=0JT[5 3 W5.'_;'4QKP$?"C@]&NSB14
M<D%\"<;G*J>[D!!(*%U0$'Z[PB-(&81\&C]G3;J$#,3U^:;^,=;N:[D("X\H
MG[O*M3F]IZ2"6@S2/>'X">9Z#I3,Q7^!*T@/#YGX&"5*&U=2#M:AFE5\*DJ\
M3GNGXSY.-X<;;9O 9P)?"/>1P*9 ,?,/PHDB,S@2,_6^%^&)]T?N>U,&9VQ%
MO//)6^^]%DF29.P:A&;,:<+P%6:_()A77T+PK1 G_@^=;].3S0R32$_6].0_
M NFF0!H%TK]*3-^4N(4YO G"5CU58)HX39:4..@XR2OO,K //+[)'_@T[5^%
M:3IMR06=?]G8_QK1@4]E=^='J/4?;#$DU"X<W_NSF<9L,ASV\P]BRS<N?@-0
M2P,$%     @ )']L4$^U\E;< 0   04  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL=53;CML@$/T5Q <LOB7>1K:ES595*[52M%7;9V*/+UHP+N!X
M^_<%[+BN2U\",SZ7&<*034*^JA9 HS?.>I7C5NOA1(@J6^!4/8@!>O.E%I)3
M;4+9$#5(H)4C<4:B(#@23KL>%YG+7621B5&SKH>+1&KDG,I?9V!BRG&([XF7
MKFFU39 B&V@#7T%_&R[21&15J3H.O>I$CR34.7X*3^?4XAW@>P>3VNR1[>0J
MQ*L-/E4Y#FQ!P*#45H&:Y0;/P)@5,F7\7#3Q:FF)V_U=_8/KW?1RI0J>!?O1
M5;K-\2-&%=1T9/I%3!]AZ>> T=+\9[@!,W!;B?$H!5/N%Y6CTH(O*J843M_F
MM>O=.BWZ=YJ?$"V$:$<@LY&K_#W5M,BDF)"<SWZ@]B\.3Y$YF](FW5&X;Z9X
M9;*W(HZ/&;E9H05SGC'1!A.N"&+45XO(9W&._J%'?GKLK3!V]'A+CP]^@<0K
MD#B!Y*\6TUV+/LRCW^3@-3EX!-[M3#R8)/";'+TF1X] N#/Q8?YSWJG7)/4(
MQ#L3'R;9F9#-%>0@&S=\"I5B[-W@;[+K?#]%[@K_@<^/PQ<JFZY7Z"JT&01W
M76LA-)A2@@=SJJUYC]: 0:WM-C5[.4_E'&@Q+ \.65^]XC=02P,$%     @
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M4,$$"[E=,&N Y)R@( P)'.@ #G0P"+1/?6L #1-T^K*\^7J56 ^)3QPQWHE
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M)')75K>AOL^;XVWS4*JC.;I[[?\'BW]02P,$%     @ )']L4)"HF_G] @
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M4O.-U$.JQOUX,1HG4G3VTI=,-\_%/U!+ P04    "  D?VQ0>GX<F (#  "
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M.]><"R;M@V\R55O9#K>#G*V%>HWE>]7TA,U \)WI=X.VZ9[\!U!+ P04
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M-7-_T0V"\B!84;Z>*22C21;/50->]0>$;]">!XW%%[-D7!, 1#1',^Z#8'-
MY :9>M#UAR,H81D:%T6F'RXCA,4HFRD+MAP$><[<:<->@NA_J!KV"@29Q435
M4[? .$G)'!7L%@BRBXE2IWXQXWT(=@H$6<5$@6PJK'3.D1#L*"B_15;Y1"P8
MDYS-_?^$K0<#UD-FC@7#-H'1[5+!\-W&P-TFH]NQ!D D'ZLZ&@PGE5 '-\?I
M8"M/M1LB![O]K/C@1L7H'=X-FM^X.A2U#IZEL2.2&V3V4AIA:XGO[/<]VMFV
M7Y1B;]K7S+ZK;L#K%D8V?GB-^@EZ]1=02P,$%     @ )']L4(?WA<V2!
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MT7::F;F<_J!IH<4P7PYXN:'*OU!+ P04    "  D?VQ0$ *0%/@!   -!0
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M7PI[=&O.%6@[P8-NN=5OTQ)0J)79IGHOIALZ!8H/\^.#EA>P^ =02P,$%
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M+';HVJP(D,&*SW3&J**A5)&)9<-HG5'IN=,P$F:HB@KFS@"=SK 6Y%(D@LL
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M+Z8':PH4'^:W&"Q_"/5?4$L#!!0    ( "1_;% ?KECJ-0(  +8'   9
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M26WCMEQLMG\'M\^;JERVO=2N+&?_[E[GJ^WK:]O_6S/<0+<-]+Z!5KT-3-O
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M3^)<$0HI#4:0RQ'HQ)JQ699)VDR!T.FNL.L5(9L":%,2;5 DR09%;(X(V11
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M$,8N8%8T[[M4IEE"66&4&6+91<R*G)R(%Q/#*#/ LI9$",PIRQZGC&-0>?P
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MPCQ+P#/95DRJ3'[BA "3*M&:ZF)F1<M/,TYR)C'1$A'M<F9%"\Z(+9;$.$N
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MP!8J!PQ@F!,?!@,80H016I %6'SS0Q3)S-]3H^A=9@A0BPOJ%0KV^0VD&!<
M^%4K5"[]DWC5@6'98<C?I#"L.P@0P#D*(H\HAPG%"V'%:Q0,BQ0#P5*)B?@"
M)UZB8%BC&/)+1U2$/$XV.]+<I>2[Z(YEHY-G9>SIV)]A!Z6,M [!K75XLO>@
MJ5/)@W%-:MO=<!D8.D:UXT4GFVY;FW]02P,$%     @ )']L4*=6-!0! @
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M965T<R]S:&5E=#<P+GAM;)55T8[:,!#\E2@?<([C! *"2#VJJI5:"5W5]MG
M0J)SXM0VY/KWM9U<!&$I] 5[[=GQ[)*Q%ZU4K[H ,,%;)6J]# MCFCDA>EM
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M=ZC $P)OJ  ) 1HJ\(7 'RH(A" 8*@B%(!PJ /9EYNQO">J6-),-!O=RF6X
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MBIES^YZ5YIX=()N;%&\I_\O..T91GZ+J&TH.XH1H-<?4Z7]02P,$%     @
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M7 CA2'CTGD0[:W'LS!N,+EPN4[&FX_ =-YSTT[D"YL.M^ ]02P,$%     @
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MF),!-\?(*Y>B\/(9X(C3!IDXS'-.U_/J"K-:JTPHZQ285]%6OX&D6<9H!#F
M)$LK'^2&"TF=;)"6/D(DIU(<R:6T!&"M"9R1&0T@Q;+.8?]<,J8POR79K',I
M(V7 N(':GL<Y@$Q];P!HHDHRB-TB+O&"2;F . [75!HDUN3?- $CDBEQ WTP
MYS< (;8=[^3P .=2DC8V =P732'*/&'Z>=]F #%>A23W/\!%Q3-?R()T04-K
M Z8T2;\T^?ALG9Q)03H ) <I;>5&.02@#'B?(U/4,1UJ!23/(SZO;/XATI[,
MPG&"SL\3M,R<^PTDG)"U@M0  T1RE,G,:@BK#(9D@C!"8*CEAY%.!$##"7G(
MA 4@=:WN9-Y^BZIDB<R[4Y3NE)/$X<?*<\ I[*5*RKD@EQ_-$.MI)Q/O.2)9
MV=394<$8"D<,&IPQ:"DO-13P3D:8 >#88))444/$<4J>&T+.?3$NR@UL"CB;
M/,D-8X;JTX9S'=G#.219VMK2]!;$NP;J70ZSKW.Q^,5$,AR1I(!'*(-UJD-R
MDA&:?.V94L9AE-OWTO#&L*]<+>LD>=0+:V4W9FLFZ74 ]=XDWGVEUZ'VE8ZU
M-TNK *@F%>O$/ N\@.7LJSXKD,H>H9$UD0LGPVH;1T'<ZUS=)SG@OLXE9 Q!
M2J4!P*2J!PB+AB"]> 0X3U$ZT_CS%F\^1VX_1R8 X=R8HYV,4U- $LMRJ3YF
M9]<X_[![[44N*'<-I+N6TETC6<J;;> P(!<:BG<< :#2=B$I>58YPBC%&/,(
M<$3].1$ H*4( -!"!(#M&Z>BO+.:HE%Q!.!4+X1L[T4BWB?/"BQ+P9"*_S@"
M%&2\!CI>'D[V=2YN:Q4G;S$&B+,NR!1G"#B==)2G@"/ \7S(19ZBZC3',7EF
M/P-@-K,?(>W[T(*")Z#@M3P9::"V"07/&8,\]A@@E.KL+3N4'D(TF1B(I+MA
ME 4_^>P2$Z#UW92K<3'#B"W8,$(_MF$J:'HZJN;3"\Y$A7LN*DAF I)9RSO.
M!HJG759?\Q6#F,S*AX7:Y$*=0XT+E#S.+/1,'E=@K#[2/_V378CC/LA#;H3I
MKR3/W3 F?7]>P H77%10]P34O;3M?@-]NOH0DYO(L%";7/USJ'&!RE8?]RQ;
M?8AEZK/0:+;< $/+#;%\N3%6.,RAPOD#@?.'TAD;%60KN2SH%%]54$&;4:[-
MLG<5#=-Z0A"MD]%D #BO WAI SA+V2$OP"@$%;*[% 2:0#X[*X4#T8:RPU)4
M8ZV0HTPO)ZA*BDE)T3H%8'V9F+)[%-1VBEZ%F%DB(*-5G"^78D]!@Q&X8:6"
MR*="BD_Q_S#&0B9(>2:8&R.XT7'9>?  82R1K31%<*.C39)9(&S4R5ND,<(X
MGY(// #&_I1DJ[> \RI[BS%!U5F6JE((-%S;39RW60*5<]8F)Z\HYH +WIT*
MD/;+L$*R:D"R>K)5M>LHI%\F3[^*QF<*Z9?)TZ_,^!JFY<3YG<P 8#IQB)/:
M%'#2\E"+7IKQ&% <!>1AT W R"7YJ !3\D "4*F%'2>]=_*:=%5M'P_OIG>=
MN\W/];Y>L)-OW]]F?SL\S1;?]_7%1(/OI_IB?GQY_;OZXT/P/Q;;Q^?UKO-C
ML]]O5H>'J@^;S;[BWJNO["U/U>+^_<.R>MC7OP;^?7M\@'W\L-^\-(_+>^\O
MW*__!U!+ P04    "  D?VQ03G%4]1$#   P#0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970X,"YX;6R55^MNFS 4?A7$ P1\ >PJB;3>(VU2U6G;;YHX"2K@
M#)RD>_O9X+* #RW+CX#-]WWGPCFVF9]E]5KOA5#>6Y&7]<+?*W6X"H)ZO1=%
M6L_D093ZR5961:KTL-H%]:$2Z:8A%7F PS .BC0K_>6\F7NJEG-Y5'E6BJ?*
MJX]%D59_KD4NSPL?^>\3S]ENK\Q$L)P?TIWX+M2/PU.E1T&GLLD*4=:9++U*
M;!?^%W2UPL00&L3/3)SKBWO/A/(BY:L9K#8+/S0>B5RLE9%(]>4D;D2>&R7M
MQV\KZG<V#?'R_EW]O@E>!_.2UN)&YK^RC=HO?.9[&[%-C[EZEN='80.*?,]&
M_U6<1*[AQA-M8RWSNOGWUL=:R<*J:%>*]*V]9F5S/;=/(F1I, %; NX(*/Z0
M0"R!3"502Z!3"9$E1/\(]$-"; GQ5$)B"<E4 K,$-I7 +8$/"$'[_IJ"N$U5
MNIQ7\NQ5;4T?4M,ZZ(KKDEN;R:;"FF>Z)FH]>UIRG,R#DQ&RF.L6@WL8UL?<
M0!C>Q]P"&!+V,7<NAO01]RX"]Q$/@$;4ASP"KL1]R KR%G680&>U2RT&4XL;
M =(3P+   05((T OXV!TD(T6$S>8LC42,AZB05X?7!SF&"=),@C[$1"DA"8:
M#+M.0=>IXSH-(U@@ @6BZ<F+08%X0O)B-U84FA]L* $-)8XA3@@LP$ !-CU4
M#@IPQX.$#GKBECNAMI&.!HM">+T( 6-DV.@0:)C\3T!]9T86+P3DWK'3@MAE
MZ<\2-F((;F6$ 4,C]8S@9D9D^FM&<%,AMZN<%WUM0;U.CX9OVJ[9 /23HH";
M%45 >N+ARMZ"H@MKE"#*>#26!;BQT83.OD-N:^.0X8]"@[L;0>WM6$N<$J,S
M/A86O H@YAAB8_L-@M<!Q*>7&(;;&[M-R8;G@7L 1-%@LW^ E$:=@=L;0^V=
MC$B,[,'_L0ECN'&QNPT[*5D!($Z&:TQP<2@SWQ+?TFJ7E;7W(I4^WS6GL*V4
M2FC!<*;[9*\_7[I!+K;*W";ZOFK/\.U R8/]/@FZCZ3E7U!+ P04    "  D
M?VQ0;$K7?8L"  "1"0  &0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6R-
M5MN.FS 4_!7$>]>86TA$D'835:W42M%6;9\=X@2T@*GMA.W?US9>FC@G45[P
MY<P9S]C(/OG ^)NH*)7>>]MT8NE74O8+A$19T9:()];33D7VC+=$JB$_(-%S
M2G8FJ6U0& 0I:DG=^45NYC:\R-E1-G5'-]P3Q[8E_.\+;=BP]+'_,?%:'RJI
M)U"1]^1 ?U#YL]]P-4(3RZYN:2=JUGF<[I?^,UZL<:03#.)730=QUO>TE2UC
M;WKP=;?T ZV(-K24FH*HYD17M&DTD]+QQY+ZTYHZ\;S_P?[9F%=FMD30%6M^
MUSM9+?W,]W9T3XZ-?&7#%VH-);YGW7^C)]HHN%:BUBA9(\S7*X]"LM:R*"DM
M>1_;NC/M,$;2S*;!":%-"*>$++B;$-F$:$K ^&Y";!/B*2$VFS4Z,5NS)I(4
M.6>#Q\?3[8G^B? B5IM?ZDFSUR:F=D>HV5,QC^8Y.FDBBWD!,'%PB5F-F/ "
M@R<,4AHF(2$H)#0$\05!Z B!,)$C9,2D!M,9C"-U#;'$L-0(E!H](!7"N%)'
M3')'*L22P%)C4&H,$*0P00(2) ]XA3"NU^3*ZZ<PPE&:.HXAKAN.4U!P"A#,
M8((92#![P#&$<1W/KAU'6'EVSQCBNO$[9J#@[ '!$,85G%T)!D\(HKIQ0G-0
M[QP@R& "',"75O" 91#D>K:@\^L"/"20[,8I8?>FO8S"UQ^^?RM92Q!H?D,%
M?'?A^U>*70< )8&S#CI[8EK*#^;U%E[)CIW4N6>S8X6PTA6"?J*<^6>,%RL,
M191A%0G!2*0BIMQ _Q<?BY7OA!_J3GA;)M6K:1ZN/6.2*F?!D_J]*U4?38.&
M[J7NSE2?CT7".)"LMP40FJJPXA]02P,$%     @ )7]L4(,".WN3W0  W&8#
M !0   !X;"]S:&%R9613=')I;F=S+GAM;.2]:W/C1I8F_'G?7X'P*V]+$1#-
M^\7NZ0BYJFS7M*M*6RK;.S.Q'R 2E- F 35 2M;^^CVWS#R92)!4V3TSNQ,;
MV^,2@41>3I[[><Z?FV:7[,OB[_O\5;4O=__TQ6(R^"+Y;;LIFW_ZXGZW>_CZ
MJZ^:Y7V^S9I>]9"7\,NZJK?9#OY9WWW5/-1YMFKN\WRWW7PU[/>G7VVSHOSB
M+W]NBK_\>?>7U]5RO\W+79*5J^1-N2MVS\G;DD<HJC*Y3'ZZ>9V<GUW\^:O=
M7_[\%;[$+PZ&R;NJW-TW\-8J7X4_O\Z7O60T2)-A?[ (?WR7U;UD0#\.^^&/
M_[PO>\EP'G_SV'3_[>JVV=79<O>_.M_\]/R0MQ;3O_QK^+<K>'I%;WRWR>["
M7]?9IFD-8[]QG==%A1-<):^S7?LYV9S_[[_]MX.+_*YHEMDF^9<\JY/OX(]-
M^.0I;\M<HN]_]R_A7V1//^9W!6XD#/,^V[86\/;]AY_??DBN?[CZ^.[JU9N?
M/KU]=?7C39J\??^JUS'B*YA2#=-Y"]3R6_+7_#E\KM_O#_J3R6PX#7]YM:_K
M<#NZMO;R<C"\' TZ)O%=L<GKY!6\=U?5K1E<+9<Y_ Z_KOC)KJ54VRW0VLVN
M6OZ:)C?W69TWR8?]KMD!519EBU;DM5_RS>;RU[)Z@E?SK*E*^,S;IMFWO_.^
MZACB>G^[*99 D%6VZYJ<;-;'_*&J=S ;F&>V:Q_]O^2M/\D(/U<;8#19+=O5
M]=C--MMLDF_W35'F3==#;[9Y?8>3^+ZNGG;WN'4/6=G:>3/D/6Q1US.OJK*I
M-L6*CN?;;).5RQS?R'=--Y?2;&C>15=9T\ @7[=^SII[XC-+_(_\[_OB,=O
M\ZVUWMS#3E_N\GJ;%.5CWNRVL:> NI"!-TF=+W,8ZG;3(M[((\FZKK9)MEX7
MFX)6GN-6%>W#NZ[SAZR WW\#(=  0>+,J]T]T/O26^=GOWCR5#Y5.[BFA[_Z
M7?$;C,"_I4F9M\CYK=M)V-53/OL6B+:\*W#3#HS[?56MGHK-)OS[AP>\^4BJ
M&[B<>5(7=_>[RVI]N6_RCC5\H$V*_\9[$/_-T!VLYQ86A6MI$9\EA8?LF>@
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M.+8D="@"H[P62?**6]4^A5-XG^D8=H>.BC[+'^%JTV=R:IF\##N\MKXYH:?
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M?'1D1'O%GCPZC"RA*&+1.&6"^>JUULUYFRYET(5E##P-DD=L6URA@E&( W&
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M5X@ 9\.10JDB@-&P/[=)VO+@N!CBRO^\P:<Q+Z"HUB^96$YD./+\^FFP![#
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M =?XEHOLT[9C&(SO&3#\Z4PNTB3Y7A@\2('%-!U/Y\ I1@L[XBHY'P^)QUP
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MC-<LVV"1@2FD$-<O/VCA/3@1^]GVP,*00E520:4!V&,O@J5B;XY_:L(!#2(
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MXJPW_Q(1C8$CW1</#JX//OA]7N8?RE;/@EBDW8^?XP^CQ00N^OS(-#!2Q/.
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M?#CK (N&0D?*^ MH2DQ*(BRK&+A>"CB<'$4Y=1+_WCEK+_]0DZ)SLQXPQTD
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MPQ%2M*AV(,R+?3.C/<WH(8)=_68AELD9)WS,>:C<\K%[8K$]/%Z]=7;1[<6
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MG1O? O2>@8@X4,)*!67 H[?M8D?%5HRYC52^&/;Y.QA]GAUZZ7?H1-RRUVP
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MX6DV'9&(L4?OHNO0@93 ([#3([@8!B6->52A[C8#Q7E>D[ (MTT%M\Z,YE7
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MBR7%NY+0_ZP:SE56T;-I6)EV+"009APA(494CF\@E8JJ;/*</3PZ@2YO-::
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MZ]5J_57<DR=LRV7Z8.7F\ OI=QVDSM?=09!7;8.W5+0P[2&.[#F2 ?.Y^<V
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M(3 JUD.]ZW)8/S7[L+U-FF-O8OL'<4%&%D)]*O1VN)V;-P!?2YR0I9TODTJ
MIJ,LHZN/E*2<8;>9)Q,&!R:<C-$Z#Y@+2>XTSQR52!NPA&"!I2+1IN6G1-D4
M+]7Z."V30S5W6ZCYV'5.,<<2T4W1^NS_SU7^QXI[P[^7;+\J3<%'U&@ZA!:(
M[+=!Y* -(EMQ)D=M$'G> I'#(WPU7UMDKQ6%#%Y9I%>V:QL]X59'6%G!K"!4
M$5[*G9,XQDZ/:<E#^,WT^G2K+ZL;0XU7:*9_8;?X.C;&"2JHNC9;M,X0UN,O
M1G@PJ%9-*T0(Z_%7')."V3\8K_Y/GOP!4$L#!!0    ( "5_;%"EJF,B'08
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MK[8%;%N^VQ; ;?ER6T"WY=MM =Z6K[< O86OMP"]985G;?2PS==;@-["UUN
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M_/%^_SJ?S?^+OWP"4$L! A0#%     @ )']L4!\CSP/     $P(   L
M         ( !     %]R96QS+RYR96QS4$L! A0#%     @ )']L4"?HAPZ"
M    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"
M% ,4    "  D?VQ0O*!:^.\    K @  $0              @ &9 0  9&]C
M4')O<',O8V]R92YX;6Q02P$"% ,4    "  D?VQ0F5R<(Q &  "<)P  $P
M            @ &W @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M "1_;%!<=IZXN0(  ,L*   8              "  ?@(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    "  D?VQ0+"7K\N4%  ">'0  &
M            @ 'G"P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ )']L4-GD!TA# @  N@<  !@              ( ! A(  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "1_;%"WRDFE5@4  )\9
M   8              "  7L4  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    "  D?VQ0(D/8'ZL"  #%"   &               @ $'&@
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ )']L4&%'BCG%
M!0  5QP  !@              ( !Z!P  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( "1_;% FV%IUO0$  -0#   8              "
M >,B  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  D?VQ0
MF3-P-N,'  "**0  &               @ '6)   >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ )']L4*>0=(ZP 0  T@,  !@
M     ( ![RP  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M "1_;%!)3D#"M0$  -(#   9              "  =4N  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ )']L4'Y?=X&U 0  T@,  !D
M             ( !P3   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    "  D?VQ0$H1I.:\!  #2 P  &0              @ &M,@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "1_;%"R?"\@M $
M -(#   9              "  9,T  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ )']L4",$*?JU 0  T@,  !D              ( !
M?C8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  D?VQ0
MIM0O:K8!  #2 P  &0              @ %J.   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( "1_;% 58<_5LP$  -(#   9
M      "  5<Z  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ )']L4"VEQ]2U 0  T@,  !D              ( !03P  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  D?VQ098)9E[<!  #2 P
M&0              @ $M/@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( "1_;%#V R,2M $  -(#   9              "  1M   !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ )']L4'>-35FU
M 0  T@,  !D              ( !!D(  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    "  D?VQ0"J*HV[0!  #2 P  &0
M@ 'R0P  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "1_
M;%#=I0D<LP$  -(#   9              "  =U%  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ )']L4+\OMA>U 0  T@,  !D
M         ( !QT<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    "  D?VQ0\VQ(0K4!  #2 P  &0              @ &S20  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "1_;%!?3HN[M0$  -(#
M   9              "  9]+  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ )']L4$JNF2&T 0  T@,  !D              ( !BTT
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  D?VQ0.K[_
MH+8!  #2 P  &0              @ %V3P  >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( "1_;%"- V%DW@(  +0,   9
M  "  6-1  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M)']L4/Q"+'3; 0   04  !D              ( !>%0  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    "  D?VQ05R._[[8!  #2 P  &0
M            @ &*5@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( "1_;%!,2;IUQ $  #<$   9              "  7=8  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ )']L4(BS4'6X 0
MT@,  !D              ( !<EH  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    "  D?VQ07L(&_+4!  #2 P  &0              @ %A
M7   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "1_;%"F
M$CI&Q $  #<$   9              "  4U>  !X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ )']L4'=V]<O% 0  -P0  !D
M     ( !2&   'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "1_;% _X5$KM@$  -(#   9              "
M 6%J  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ )']L
M4&_POZ0Z!P  (BL  !D              ( !3FP  'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    "  D?VQ0I#J#3ZD#  !+$   &0
M        @ &_<P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( "1_;%"0J)OY_0(  $@,   9              "  9]W  !X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ )']L4 ZL"'>8 @  ;PH
M !D              ( !TWH  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    "  D?VQ001ZEP[P"  "%"@  &0              @ &B?0
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "1_;%!Z?AR8
M @,  ( +   9              "  96   !X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ )']L4#0IB]6B!   ]1<  !D
M ( !SH,  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    "  D
M?VQ0Y9E9QQ\"   8!@  &0              @ &GB   >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "1_;%"C&\_)ZP(  $T+   9
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M970U,RYX;6Q02P$"% ,4    "  D?VQ0#/'J*=P#  "-$   &0
M    @ %#G   >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M "1_;%#<F4M-QP4    @   9              "  5:@  !X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ )']L4$H#/$ D @  208  !D
M             ( !5*8  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    "  D?VQ0Z/8)$! "  "-!0  &0              @ &OJ   >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( "1_;%!'G^16#0<
M /(K   9              "  ?:J  !X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ )']L4 SA]FH, P  @@P  !D              ( !
M.K(  'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  D?VQ0
M:WR\>A $   G%@  &0              @ %]M0  >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( "1_;%!O&<B"*@(  !P&   9
M      "  <2Y  !X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ )']L4!^N6.HU @  M@<  !D              ( !);P  'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  D?VQ0Y$8Y.V '   Z+
M&0              @ &1O@  >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( "1_;% 7W?:"600  '86   9              "  2C&  !X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ )']L4(/CH IL
M @  S@<  !D              ( !N,H  'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    "  D?VQ0AUIX1 L"  !]!0  &0
M@ %;S0  >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( "1_
M;%"S"SU7R@(  +@*   9              "  9W/  !X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ )']L4'0ERTFH @  >0D  !D
M         ( !GM(  'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4
M    "  D?VQ0IU8T% $"  # !0  &0              @ %]U0  >&PO=V]R
M:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( "1_;%!K?'_3- (  +@'
M   9              "  ;77  !X;"]W;W)K<VAE971S+W-H965T-S N>&UL
M4$L! A0#%     @ )']L4+M%-PM( P  L@X  !D              ( !(-H
M 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  D?VQ0=SZ2
M>S<#   S#0  &0              @ &?W0  >&PO=V]R:W-H965T<R]S:&5E
M=#<R+GAM;%!+ 0(4 Q0    ( "1_;%"M$,^+M@,  .01   9
M  "  0WA  !X;"]W;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @
M)']L4 9DF;M_ P  I0\  !D              ( !^N0  'AL+W=O<FMS:&5E
M=',O<VAE970W-"YX;6Q02P$"% ,4    "  D?VQ0 H/P%48#   6$   &0
M            @ &PZ   >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4
M Q0    ( "1_;% ,5Z/^2 (  .@&   9              "  2WL  !X;"]W
M;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @ )']L4/P?F, + @
MI@4  !D              ( !K.X  'AL+W=O<FMS:&5E=',O<VAE970W-RYX
M;6Q02P$"% ,4    "  D?VQ0C[I?TT,$  "5%   &0              @ 'N
M\   >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( "1_;% &
MVB38&@D  .TN   9              "  6CU  !X;"]W;W)K<VAE971S+W-H
M965T-SDN>&UL4$L! A0#%     @ )']L4$YQ5/41 P  , T  !D
M     ( !N?X  'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4
M"  D?VQ0;$K7?8L"  "1"0  &0              @ $! @$ >&PO=V]R:W-H
M965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( "5_;%"# CM[D]T  -QF P 4
M              "  <,$ 0!X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0
M   ( "5_;%!CGE< C0(  #0/   -              "  8CB 0!X;"]S='EL
M97,N>&UL4$L! A0#%     @ )7]L4*6J8R(=!@  834   \
M ( !0.4! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "5_;%!<Y9VVAP(
M &@P   :              "  8KK 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( "5_;%!G_9"@)P(  !\O   3              "
M 4GN 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !: %H J!@  *'P 0
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972987552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level&#160;1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level&#160;2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level&#160;3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company did not have any transfer of assets and liabilities between Level 1, Level 2 and Level 3 of the fair value hierarchy during the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,349,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,315,356</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,003,102</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,665,085</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67,338,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liability (Note 10)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the Company&#8217;s assets that are measured at fair value on a recurring basis, and are determined using the following inputs as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value Measurements at</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">in Active Markets</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level&#160;3)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,646,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,646,507</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mutual funds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,314,871</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">US corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223,981</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investments in affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,405,913</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76,591,272</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,052,420</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,538,852</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 assets at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consisted of money market funds held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investments in its affiliates, GeneOne and PLS. The Company accounts for its investment in </font><font style="font-family:inherit;font-size:10pt;">1,644,155</font><font style="font-family:inherit;font-size:10pt;"> common shares of GeneOne based on the closing price of the shares on the Korean Stock Exchange on the applicable balance sheet date. The Company accounts for its investment in </font><font style="font-family:inherit;font-size:10pt;">395,758</font><font style="font-family:inherit;font-size:10pt;"> common shares of PLS as an equity investment with a fair value based on the closing price of the shares on the Korea New Exchange (KONEX) Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> consisted of mutual funds. Level 2 assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consisted of U.S. corporate debt securities and mutual funds. Level 2 assets held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2019, August 2019 and December 2019, the Company issued the Convertible Notes, August 2019 Bonds and December 2019 Bonds, respectively. The carrying value of the Notes and Bonds approximates the fair value as December 31, 2019. See Note 10 for additional information.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Level 3 assets held as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 liabilities held at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> consisted of the embedded conversion option contained in the August 2019 Bonds that met the criteria to be bifurcated and accounted for separately from the August 2019 Bonds (the "derivative liability") (see Note 10 below for more information). The derivative liability was recorded at fair value of </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> upon the issuance of the August 2019 Bonds, and is subsequently remeasured to fair value at each reporting period. The derivative liability was initially valued and remeasured using a "with-and-without" method. The "with-and-without" methodology involves valuing the whole instrument on an as-is basis and then valuing the instrument without the embedded conversion option. The difference between the entire instrument with the embedded conversion option compared to the instrument without the embedded conversion option is the fair value of the derivative, recorded as the derivative liability. There was no derivative liability associated with the issuance of the December 2019 Bonds.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the August 2019 Bonds with the conversion option is estimated using a Monte Carlo simulation approach. The key inputs to valuing the August 2019 Bonds with the conversion option on the date of issuance and as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> include the Company&#8217;s stock price on the valuation date; the expected annual volatility of the Company&#8217;s common stock, and the discount yield, which was derived by making the fair value of the August 2019 Bonds equal to the face value on the issuance date. Fair value measurements are highly sensitive to changes in these inputs and significant changes in these inputs could result in a significantly higher or lower fair value. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents the changes in fair value of the derivative liability for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">: </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Initial fair value upon issuance of the August 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,055,371</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Change in fair value </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,763,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,819,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Level 3 liabilities held as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6973059520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Basis of Presentation</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inovio incurred a net loss attributable to common stockholders of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$119.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. Inovio had working capital of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$62.2 million</font><font style="font-family:inherit;font-size:10pt;"> and an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$739.8 million</font><font style="font-family:inherit;font-size:10pt;"> as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;">. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. During the year ended December 31, 2019, the Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.7 million</font><font style="font-family:inherit;font-size:10pt;"> from a private placement of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2024 (the &#8220;Notes&#8221;), net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;"> from the private placement of </font><font style="font-family:inherit;font-size:10pt;">18 billion</font><font style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> convertible bonds due August 2024 (the "August 2019 Bonds"), net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> from the private placement of  </font><font style="font-family:inherit;font-size:10pt;">4.7 billion</font><font style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">1.0%</font><font style="font-family:inherit;font-size:10pt;"> convertible bonds due December 2024 (the "December 2019 Bonds" and, collectively with the August 2019 Bonds, the &#8220;Bonds&#8221;) and net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;"> from sales of common stock under its At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus &amp; Company (the &#8220;Sales Agreement&#8221;). As described in Note 19 below, the Sales Agreement was amended subsequent to December 31, 2019. From January 1, 2020 through </font><font style="font-family:inherit;font-size:10pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">43,148,952</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the Sales Agreement, as amended, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$208.2</font><font style="font-family:inherit;font-size:10pt;"> million. These proceeds, in addition to the Company&#8217;s cash, cash equivalents and short-term investments of $</font><font style="font-family:inherit;font-size:10pt;">89.5 million</font><font style="font-family:inherit;font-size:10pt;"> and long-term investments of $</font><font style="font-family:inherit;font-size:10pt;">6.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, are sufficient to support the Company's operations for a period of at least 12 months from the date it issued these financial statements. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements and/or future public or private debt or equity financings including use of its Sales Agreement. However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2019, the Company announced a strategic organizational restructuring. In order to reduce operating expenses and conserve cash resources, the Company reduced its workforce by approximately </font><font style="font-family:inherit;font-size:10pt;">28%</font><font style="font-family:inherit;font-size:10pt;"> and discontinued its Phase 1/2 clinical trial of its immuno-oncology product candidate INO-5401 in patients with advanced bladder cancer. In the third quarter of 2019, the Company incurred a personnel-related restructuring charge of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> in connection with one-time employee termination costs, including severance and other benefits, all of which have been paid as of December 31, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. Inovio&#8217;s consolidated financial statements as of and for the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2019</font><font style="font-family:inherit;font-size:10pt;"> have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these financial statements.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidation</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its subsidiaries. The Company consolidates its wholly-owned subsidiaries Genetronics, Inc. and VGX Pharmaceuticals Inc. ("VGX"), and records a non-controlling interest for </font><font style="font-family:inherit;font-size:10pt;">39%</font><font style="font-family:inherit;font-size:10pt;"> of its subsidiary Geneos Therapeutics, Inc. ("Geneos") as well as </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> of VGX Animal Health, Inc., a subsidiary of VGX. All intercompany accounts and transactions have been eliminated upon consolidation. </font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Segment Reporting </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment operating primarily within the United States.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has contracts with certain of its customers that have represented more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's total revenues, as discussed in Note 7.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair value of Financial Instruments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s financial instruments consist principally of cash equivalents, short-term investments and investments in affiliated entities. The carrying amounts of cash equivalents approximate the related fair values due to the short-term maturities of these instruments. Investments are recorded at fair value, based on current market valuations. After the adoption of Accounting Standards Update ("ASU") No. 2016-01 on January 1, 2018, unrealized gains and losses on the Company's equity investment in its affiliated entity Plumbline Life Sciences, Inc. ("PLS") are reported in the consolidated statement of operations as a gain (loss) on investment in affiliated entities. The Company&#8217;s investment in GeneOne, an affiliated entity, is accounted for at fair value on a recurring basis, with changes in fair value recorded on the consolidated statements of operations within gain (loss) from investment in affiliated entity. The Company carries convertible notes and bonds at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds and equity investments in the Company&#8217;s affiliated entities, PLS and GeneOne, at December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">. Investments included mutual funds, United States corporate debt securities and an equity investment in the Company's affiliated entities, PLS and GeneOne, at December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> allowance for doubtful accounts was deemed necessary at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fixed Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Long-Lived Assets</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> recognized any losses on long-lived assets through December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Intangible Assets and Goodwill</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are amortized over their estimated useful lives ranging from </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">18 years</font><font style="font-family:inherit;font-size:10pt;">. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Historically, the Company has recorded patents at cost and amortized these costs using the straight-line method over the expected useful lives of the patents or </font><font style="font-family:inherit;font-size:10pt;">17 years</font><font style="font-family:inherit;font-size:10pt;">, whichever is less. Patent cost consists of the consideration paid for patents and related legal costs. Effective as of the acquisition of VGX in 2009, all new patent costs are expensed as incurred, with patent costs capitalized as of that date continuing to be amortized over the expected life of the patent. License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2019 and 2018, the Company&#8217;s intangible assets resulting from the acquisition of VGX, as well as the acquisitions of two other companies, Inovio AS and Bioject Medical Technologies, Inc. ("Bioject"), and additional intangibles including previously capitalized patent costs and license costs, net of accumulated amortization, totaled </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2019.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not more likely than not that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company proceeds to perform the two-step test for goodwill impairment. The first step involves comparing the estimated fair value of the reporting unit with its carrying value, including goodwill. If the carrying amount of the reporting unit exceeds its fair value, the Company performs the second step of the goodwill impairment test to determine the amount of loss, which involves comparing the implied fair value of the goodwill to the carrying value of the goodwill. The Company may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the first step of the goodwill impairment test. The Company performed its annual assessment for goodwill impairment as of November 30, 2019, identifying no impairment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;9 for further discussion of the Company&#8217;s goodwill and intangible assets.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowances against the Company&#8217;s deferred tax assets were </font><font style="font-family:inherit;font-size:10pt;">$137.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$115.0 million</font><font style="font-family:inherit;font-size:10pt;"> at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaboration Agreements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses whether its collaboration agreements are subject to Accounting Standards Codification ("ASC") 808:&#160;Collaborative Arrangements&#160;(&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808, the Company assesses whether the payments between the Company and the collaboration partner are subject to other accounting literature. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of Topic 606. However, if the Company concludes that its collaboration partner is not a customer for certain activities, such as for certain collaborative research and development activities, the Company presents such payments as a reduction of research and development expense.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company adopted ASU 2014-09,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">&#160;(&#8220;Topic 606&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">using the modified retrospective method which consisted of applying and recognizing the cumulative effect of Topic 606 at the date of initial application. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</font></div><div style="line-height:174%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Fees</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Supply Services</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Milestone Payments</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Royalties</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Grants</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has determined that as of January 1, 2018, accounting for the Company&#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, </font><font style="font-family:inherit;font-size:10pt;">which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. Beginning on January 1, 2018, all contributions received from current grant agreements are recorded as a contra- expense as opposed to revenue on the consolidated statement of operations.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Liabilities</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as derivatives requiring separate recognition in the Company's financial statements. The result of this accounting treatment is that the fair value of the embedded derivative is revalued at each balance sheet date and recorded as a liability, and the change in fair value during the reporting period is recorded in other income (expense) in the consolidated statements of operations. In circumstances where the embedded conversion option in a convertible instrument is required to be bifurcated and there are also other embedded derivative instruments in the convertible instrument that are required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument is expected within twelve months of the balance sheet date.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign Currency Transactions</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are remeasured at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Expenses</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies and DNA immunotherapies and vaccines. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of studies and other events. The Company follows this method since reasonably dependable estimates of the costs applicable to various stages of a research agreement or clinical trial can be made. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Net Loss Per Share</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of common shares outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options, restricted stock units and warrants and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. For the year ended December 31, 2019, the dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 10) has been considered using the "if-converted" method. The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables reconcile the components of the numerator and denominator included in the calculations of diluted net loss per share:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Numerator</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss attributable to Inovio Pharmaceuticals, Inc. (numerator for use in basic net loss per share)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(88,205,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustment for decrease in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(806,819</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator for use in diluted net loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(119,359,219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(96,967,830</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(89,012,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Denominator</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average number of common shares outstanding (denominator for use in basic net loss per share)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,777,493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive potential common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">140,529</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator for use in diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,717,999</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">92,539,997</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,918,022</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.09</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.05</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,752,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,694,870</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069,936</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688,017</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,234,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,456</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,585,653</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">August 2019 Bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,799,071</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2019 Bonds</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,009,450</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,737,956</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,449,150</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,937,494</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2016&#8209;02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;Topic 842&#8221;) on January 1, 2019. For long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determined the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior period amounts continue to be reported in accordance with the historic accounting under the previous lease guidance, ASC&#160;840, Leases (Topic 840). See &#8220;Recent Accounting Pronouncements - Recently Adopted&#8221; below, for more information about the impact of the adoption of Topic 842.</font></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company incurs stock-based compensation expense related to restricted stock units and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur. </font></div><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.20%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company adopted ASU 2018-07 on January 1, 2019, which generally aligned the accounting for stock-based compensation for non-employees with that of employees. The fair value of the stock options granted to non-employees was estimated using the Black-Scholes pricing model.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.73170731707317%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.45%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.71%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.42%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99%</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life in years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements - Recently Adopted</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-02</font><font style="font-family:inherit;font-size:10pt;">. In February 2016, the FASB issued Topic 842,&#160;which requires lessees to recognize most leases on the balance sheet as lease liabilities with corresponding right-of-use assets and to disclose key information about leasing arrangements.&#160;The Company adopted the new lease standard on January 1, 2019 using the modified retrospective approach. The Company elected the available package of practical expedients upon adoption, which allowed the Company to carry forward its historical assessment of whether existing agreements contained a lease and the classification of its existing operating leases. Upon adoption, the Company recognized an operating right-of use asset and operating lease liability in its consolidated balance sheet of approximately </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$24.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company also classified deferred rent of </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> as an offset to the Company&#8217;s operating right-of-use asset upon adoption. There were no adjustments to the Company&#8217;s opening accumulated deficit balance upon adoption.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The impact of the adoption of Topic 842 on the consolidated balance sheets as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 840</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Topic 842</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Impact of Adoption</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,065,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,518,207</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,518,207</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,634,769</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,733,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating lease liability, non-current portion</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,484,763</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-07</font><font style="font-family:inherit;font-size:10pt;">. In June 2018, the FASB issued ASU 2018-07, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;"> that simplifies the accounting for stock-based payments granted to non-employees for services by generally aligning it with the accounting for stock-based payments granted to employees. The Company adopted the standard on January 1, 2019 and there was no material impact to its consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-13</font><font style="font-family:inherit;font-size:10pt;">. In August 2018, the FASB issued ASU 2018-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">, which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements (see Note 6 for more information about the Company&#8217;s fair value classifications). ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The Company does not expect the adoption of this standard to have a material impact on its disclosures.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Accounting Pronouncements - Not Yet Adopted</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2016-13</font><font style="font-family:inherit;font-size:10pt;">. In June 2016, the FASB issued ASU 2016-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments (Topic 326)</font><font style="font-family:inherit;font-size:10pt;">, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses on certain types of financial instruments, including trade receivables and available for sale debt securities. ASU 2016-13 is effective beginning in the first quarter of 2020, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. This standard includes the Company's financial instruments, such as accounts receivable and investments that are generally of high credit quality. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. The new guidance requires the Company to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for its financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU No. 2018-18</font><font style="font-family:inherit;font-size:10pt;">. In November 2018, the FASB issued ASU 2018-18, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</font><font style="font-family:inherit;font-size:10pt;">, which clarified the interaction between Topic 808, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Collaborative Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and Topic 606, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. ASU&#160;2018-18 is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on the financial statements.</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">ASU 2017-04.</font><font style="font-family:inherit;font-size:10pt;"> In January 2017, the FASB issued ASU 2017-04,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&#160;</font><font style="font-family:inherit;font-size:10pt;">("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020, and it believes the adoption of this guidance will not have a material impact on its consolidated financial statements or related disclosures.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6960938048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Notes)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Convertible Debt</font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Convertible Senior Notes </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 19, 2019 and March 1, 2019, the Company completed a private placement of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;"> convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$75.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year, beginning on September 1, 2019, at a rate of </font><font style="font-family:inherit;font-size:10pt;">6.50%</font><font style="font-family:inherit;font-size:10pt;"> per annum. The Notes will mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate will be </font><font style="font-family:inherit;font-size:10pt;">185.8045</font><font style="font-family:inherit;font-size:10pt;"> shares per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of Notes (equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$5.38</font><font style="font-family:inherit;font-size:10pt;"> per share), subject to adjustment upon the occurrence of specified events.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company may not redeem the Notes prior to March 1, 2022. On or after March 1, 2022, the Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price on (i) each of at least </font><font style="font-family:inherit;font-size:10pt;">20</font><font style="font-family:inherit;font-size:10pt;"> trading days (whether or not consecutive) during the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the Notes and concluded that the embedded conversion features meet the requirements for a derivative scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet, and that the cash conversion guidance applies. Therefore, the Notes issuance proceeds of </font><font style="font-family:inherit;font-size:10pt;">$78.5 million</font><font style="font-family:inherit;font-size:10pt;"> are allocated first to the liability component based on the fair value of non-convertible debt with otherwise identical residual terms with the residual proceeds allocated to equity for the conversion features. The Company determined that the fair value of the non-convertible debt upon issuance of the Notes was </font><font style="font-family:inherit;font-size:10pt;">$62.2 million</font><font style="font-family:inherit;font-size:10pt;"> and recorded this amount as a liability and the offsetting amount as a debt discount as a reduction to the carrying value of the Notes on the closing date. The debt issuance costs associated with the Notes of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> are allocated to the liability and equity component in the same proportion as the issuance proceeds. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the Notes were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the Notes at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,500,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount on the liability component</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,082,302</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,938,206</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,700,833</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64,180,325</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the Notes was equal to the period through November 1, 2023 as this represents the point at which the Notes are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through November 1, 2023.&#160;The effective interest rate of the liability component is </font><font style="font-family:inherit;font-size:10pt;">13.1%</font><font style="font-family:inherit;font-size:10pt;">. For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> of interest expense related to the Notes, of which </font><font style="font-family:inherit;font-size:10pt;">$4.4 million</font><font style="font-family:inherit;font-size:10pt;"> related to the contractual interest coupon. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there have not been any conversions or redemptions of the Notes.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">August 2019 Convertible Bonds </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 1, 2019, the Company closed a private placement of the August 2019 Bonds with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">18 billion</font><font style="font-family:inherit;font-size:10pt;"> Korean Won (KRW) (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) issued to institutional investors led by Korea Investment Partners (KIP), a global venture capital and private equity firm based in Seoul, Korea. Net proceeds from the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$14.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company also announced its intent to pursue a listing of its securities on the KOSDAQ Market of the Korea Exchange (KOSDAQ) in the form of Korean Depositary Receipts (KDRs) representing shares of common stock. </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The August 2019 Bonds, which are unsecured obligations of the Company, were issued on August 1, 2019 and will accrue interest at a coupon rate of </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly. The August 2019 Bonds will mature on July 31, 2024, unless earlier converted or repurchased. The outstanding August 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. Commencing on August 1, 2020, the August 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock, if KDRs are not listed on KOSDAQ at that time or the converting holder requests delivery of shares of common stock. The initial conversion rate is </font><font style="font-family:inherit;font-size:10pt;">211.0595</font><font style="font-family:inherit;font-size:10pt;"> shares per KRW</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> in principal amount (equivalent to an initial conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of July 30, 2019), subject to adjustment upon the occurrence of specified events. The conversion rate is subject to reset on January 2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed </font><font style="font-family:inherit;font-size:10pt;">351.7658</font><font style="font-family:inherit;font-size:10pt;"> shares per KRW</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> (equivalent to a conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$2.40</font><font style="font-family:inherit;font-size:10pt;"> per share based on the exchange rates as of July 30, 2019). </font></div><div style="line-height:120%;padding-top:6px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The August 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including July 31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the August 2019 Bonds to be repurchased plus a premium in order to provide an internal rate of return with respect to the August 2019 Bonds of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. In addition, upon the occurrence of a fundamental change (as defined in the August 2019 Bonds), the Company will be required to offer to repurchase the August 2019 Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon but excluding the applicable repurchase date. Upon the occurrence of an event of default (as defined in the August 2019 Bonds), with the approval of at least </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the bondholders, the Company will be required to offer to repurchase the August 2019 Bonds at a repurchase price equal to the principal amount thereof plus a premium in order to provide an internal rate of return with respect to the August 2019 Bonds of </font><font style="font-family:inherit;font-size:10pt;">8.00%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the August 2019 Bonds and concluded that the embedded conversion feature is considered a derivative requiring bifurcation from the August 2019 Bonds as it does not meet the equity scope exception due to the fact that it is denominated in a currency other than the Company's functional currency. The fair value of the conversion feature at August 1, 2019 was </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;">, which was recorded as a reduction to the carrying value of the debt. This debt discount is being amortized to&#160;interest expense over the term of the debt using the effective interest method. The conversion option is accounted for as a derivative liability, which is revalued each reporting period with&#160;the resulting change in fair value reflected in other income (expense), net, in the consolidated&#160;statements of operations.  </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the August 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the August 2019 Bonds at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,578,211</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,764,346</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(255,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the August 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,322</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,946</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,824,948</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the August 2019 Bonds was equal to the period through August 1, 2022 as this represents the point at which the August 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. Accordingly, the total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, inclusive of the fair value of the embedded conversion feature derivative at issuance, is being amortized using the effective interest method through August 1, 2022.&#160;The effective interest rate of the August 2019 Bonds is </font><font style="font-family:inherit;font-size:10pt;">29.4%</font><font style="font-family:inherit;font-size:10pt;">. For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">,&#160;the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$982,000</font><font style="font-family:inherit;font-size:10pt;"> of interest expense related to the August 2019 Bonds, of which </font><font style="font-family:inherit;font-size:10pt;">$65,000</font><font style="font-family:inherit;font-size:10pt;"> related to the contractual interest coupon. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, there have not been any conversions or redemptions of the August 2019 Bonds.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The derivative liability is valued at </font><font style="font-family:inherit;font-size:10pt;">$8.8 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">. The change in fair value of the derivative liability was </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">December 2019 Convertible Bonds </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">4.7 billion</font><font style="font-family:inherit;font-size:10pt;"> KRW (approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were approximately </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2019 Bonds, which are unsecured obligations of the Company, were issued on December&#160;31, 2019 and will accrue interest at a coupon rate of </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly. The December 2019 Bonds will mature on December&#160;31, 2024, unless earlier converted or repurchased. The outstanding December 2019 Bonds will be repaid at maturity at a price equal to the principal of the outstanding bonds to be repaid plus a premium on such bonds to provide an internal rate of return with respect to such bonds of </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. Commencing on December&#160;31, 2020, the December 2019 Bonds will be convertible until the date that is one month prior to maturity date. Upon conversion, the Company will deliver KDRs, if the Company has any such securities listed on the KOSDAQ at that time, or otherwise shares of common stock of the Company. The initial conversion rate will be </font><font style="font-family:inherit;font-size:10pt;">214.7766</font><font style="font-family:inherit;font-size:10pt;"> shares per KRW</font><font style="font-family:inherit;font-size:10pt;">1,000,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of Bonds (equivalent to an initial conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$4.00</font><font style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of December&#160;19, 2019), subject to adjustment upon the occurrence of certain events. The conversion rate is subject to reset on July&#160;2, 2020 and on each three month anniversary thereafter until the maturity date to the then current market price if the current market price is lower than the conversion price then in effect; provided that the conversion rate will not exceed </font><font style="font-family:inherit;font-size:10pt;">357.961</font><font style="font-family:inherit;font-size:10pt;">1 shares per KRW1,000,000 (equivalent to a conversion price of approximately USD </font><font style="font-family:inherit;font-size:10pt;">$2.40</font><font style="font-family:inherit;font-size:10pt;"> per share based on the exchange rate as of December&#160;19, 2019).</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The December 2019 Bonds will be subject to repurchase by the Company at the option of the bondholders from and including December&#160;31, 2022 up to the date that is one month prior to the maturity date at a repurchase price equal to the principal of the December 2019 Bonds to be repurchased plus a premium on the Bonds in order to ensure an internal rate of return with respect to the Bonds equal to </font><font style="font-family:inherit;font-size:10pt;">6.00%</font><font style="font-family:inherit;font-size:10pt;">. In addition, upon the occurrence of a fundamental change (as defined in the Subscription Agreement) the Company will be required to offer to repurchase the Bonds at a repurchase price equal to the principal amount thereof plus accrued and unpaid interest thereon to but excluding the applicable repurchase date. If certain bankruptcy and insolvency-related events of default occur, the principal of, and accrued and unpaid interest on, all of the then outstanding December 2019 Bonds shall automatically become due and payable. If any other event of default occurs and is continuing, the holders of at least </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the in aggregate principal amount of the December 2019 Bonds by notice to the Company may declare the principal of, and accrued and unpaid interest on, all of the then-outstanding December 2019 Bonds to be due and payable.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the accounting for the issuance of the December 2019 Bonds and concluded that the embedded conversion feature does not require bifurcation from the December 2019 Bonds. Although the embedded conversion feature meets the definition of a derivative, it qualifies for the equity scope exception for instruments that are both indexed to an entity&#8217;s own stock and classified in stockholders&#8217; equity in its consolidated balance sheet. The December 2019 Bonds are denominated in a foreign currency other than the Company&#8217;s functional currency, which would typically violate the settlement provision criteria when analyzing whether the conversion option is indexed to an entity&#8217;s own stock. However, per the terms of the agreement, the functional currency rate required to be used in a conversion scenario is fixed as of the date preceding the date of issuance of the Bonds. Therefore, the fluctuation in functional currency doesn&#8217;t impact the settlement of the conversion option. Further, as there is no cash conversion feature or beneficial conversion feature on the date of issuance, and the Bonds were not issued at a substantial premium, all of the proceeds were recorded as a liability. </font></div><div style="line-height:120%;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that all other features of the December 2019 Bonds were clearly and closely associated with a debt host and did not require bifurcation as a derivative liability, or the fair value of the feature was immaterial to the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of the December 2019 Bonds at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:27%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,067,644</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance cost</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of premium associated with the December 2019 Bonds</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued interest</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Net carrying amount </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,017,644</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the expected life of the December 2019 Bonds was equal to the period through December 31, 2022 as this represents the point at which the December 2019 Bonds are initially subject to repurchase by the Company at the option of the holders. The effective interest rate of the December 2019 Bonds is </font><font style="font-family:inherit;font-size:10pt;">6.2%</font><font style="font-family:inherit;font-size:10pt;">. For the year ended December&#160;31, 2019,&#160;the Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> interest expense related to the December 2019 Bonds. As of December&#160;31, 2019, there have not been any conversions or redemptions of the December 2019 Bonds.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, future minimum payments due under the Company's convertible debt instruments are as follows:</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ending December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Convertible Notes (1)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">August 2019 Bonds (2)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 2019 Bonds (2)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,000</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,290,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,103,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81,051,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,021,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,236,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">106,308,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101,463,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,645,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,390,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,498,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) Amounts represent contractual amounts due under the Notes, including interest based on the fixed rate of </font><font style="font-family:inherit;font-size:10pt;">6.5%</font><font style="font-family:inherit;font-size:10pt;"> per year. </font></div><div style="line-height:120%;padding-top:6px;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) Amounts represent contractual amounts due under the August 2019 and December 2019 Bonds, including interest based on the fixed rate of </font><font style="font-family:inherit;font-size:10pt;">1%</font><font style="font-family:inherit;font-size:10pt;"> per year plus a premium on such bonds to provide an internal rate of return with respect to such Bonds of </font><font style="font-family:inherit;font-size:10pt;">6%</font><font style="font-family:inherit;font-size:10pt;"> at maturity.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6973045696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consist of the following:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Depreciation</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">and</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Net Book</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31, 2019</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,007,935</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,996,777</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,011,158</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,102,467</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,229,357</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">873,110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,048,053</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,944,293</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,103,760</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,781,020</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,996,031</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">784,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,939,475</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,166,458</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,773,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,909,341</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,464,444</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,444,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,031,965</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,425,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,606,111</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,198,803</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,767,653</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,431,150</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and other </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,808,824</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,341,968</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,466,856</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,948,933</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,999,919</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,949,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6796047328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of preferred stock authorized, issued and outstanding</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Outstanding as of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Authorized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares      Issued</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series&#160;C Preferred Stock, par $0.001</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of shares authorized under stock option plans, by exercise price range</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes total stock options outstanding at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Options Exercisable</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual Life</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise&#160;Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares Underlying Options</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted    Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$1.48-$3.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">903,257</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">848,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$3.01-$6.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,066,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.90</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,844,977</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$6.01-$9.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,454,212</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,210,448</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$9.01-$12.00</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">220,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$12.01-$15.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">620,043</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,745,317</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.37</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options, activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock option activity under the Company&#8217;s equity incentive plans during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was as follows: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,752,677</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,596,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.39</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,040,786</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.49</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,265,390</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.72</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock Units Award Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:9px;padding-top:6px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;"> was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:85%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,491,771</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,003,218</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancelled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106,634</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,069,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6703793392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsTextualAbstract', window );"><strong>Goodwill and Intangible Assets (Textual) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 547,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">520,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">492,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">275,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">253,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,604,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 3,693,851<span></span>
</td>
<td class="nump">$ 4,760,145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972931264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements Marketable Securities and Fair Value Measurements - Fair Value of the Company's Derivative Liability (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at beginning of year</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Initial fair value upon issuance of the Bonds</a></td>
<td class="nump">7,055,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">1,763,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at end of year</a></td>
<td class="nump">$ 8,819,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6794501792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 2,502,624<span></span>
</td>
<td class="nump">$ 2,000,868<span></span>
</td>
<td class="nump">$ 24,448,761<span></span>
</td>
<td class="nump">$ 1,529,644<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
<td class="nump">$ 42,220,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">22,003,955<span></span>
</td>
<td class="nump">19,137,209<span></span>
</td>
<td class="nump">22,486,266<span></span>
</td>
<td class="nump">24,389,888<span></span>
</td>
<td class="nump">26,365,647<span></span>
</td>
<td class="nump">21,851,858<span></span>
</td>
<td class="nump">22,462,620<span></span>
</td>
<td class="nump">24,577,751<span></span>
</td>
<td class="nump">88,017,319<span></span>
</td>
<td class="nump">95,257,876<span></span>
</td>
<td class="nump">98,572,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,696,586<span></span>
</td>
<td class="nump">5,681,441<span></span>
</td>
<td class="nump">5,850,101<span></span>
</td>
<td class="nump">6,975,029<span></span>
</td>
<td class="nump">5,636,141<span></span>
</td>
<td class="nump">6,791,693<span></span>
</td>
<td class="nump">7,189,310<span></span>
</td>
<td class="nump">9,698,015<span></span>
</td>
<td class="nump">27,203,156<span></span>
</td>
<td class="nump">29,315,159<span></span>
</td>
<td class="nump">28,290,369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,700,541<span></span>
</td>
<td class="nump">24,818,650<span></span>
</td>
<td class="nump">28,336,367<span></span>
</td>
<td class="nump">31,364,917<span></span>
</td>
<td class="nump">32,001,788<span></span>
</td>
<td class="nump">28,643,551<span></span>
</td>
<td class="nump">29,651,930<span></span>
</td>
<td class="nump">34,275,766<span></span>
</td>
<td class="nump">115,220,475<span></span>
</td>
<td class="nump">124,573,035<span></span>
</td>
<td class="nump">125,862,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(30,421,053)<span></span>
</td>
<td class="num">(23,951,787)<span></span>
</td>
<td class="num">(28,200,694)<span></span>
</td>
<td class="num">(28,535,012)<span></span>
</td>
<td class="num">(29,499,164)<span></span>
</td>
<td class="num">(26,642,683)<span></span>
</td>
<td class="num">(5,203,169)<span></span>
</td>
<td class="num">(32,746,122)<span></span>
</td>
<td class="num">(111,108,545)<span></span>
</td>
<td class="num">(94,091,138)<span></span>
</td>
<td class="num">(83,642,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">587,679<span></span>
</td>
<td class="nump">637,438<span></span>
</td>
<td class="nump">755,330<span></span>
</td>
<td class="nump">625,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,605,981<span></span>
</td>
<td class="nump">2,264,747<span></span>
</td>
<td class="nump">1,836,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,668,837)<span></span>
</td>
<td class="num">(2,428,671)<span></span>
</td>
<td class="num">(2,194,783)<span></span>
</td>
<td class="num">(656,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,948,539)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,933)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest and other income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(169,300)<span></span>
</td>
<td class="nump">380,987<span></span>
</td>
<td class="nump">396,681<span></span>
</td>
<td class="nump">312,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInFairValueOfCommonStockWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">228,665<span></span>
</td>
<td class="nump">259,971<span></span>
</td>
<td class="num">(127,841)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">360,795<span></span>
</td>
<td class="nump">806,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="num">(4,315,105)<span></span>
</td>
<td class="nump">2,551,453<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,763,652)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss on investment in affiliated entities</a></td>
<td class="num">(1,681,401)<span></span>
</td>
<td class="num">(485,841)<span></span>
</td>
<td class="num">(173,212)<span></span>
</td>
<td class="num">(750,103)<span></span>
</td>
<td class="num">(3,293,741)<span></span>
</td>
<td class="nump">1,017,359<span></span>
</td>
<td class="num">(2,092,608)<span></span>
</td>
<td class="nump">2,380,423<span></span>
</td>
<td class="num">(3,090,557)<span></span>
</td>
<td class="num">(1,988,567)<span></span>
</td>
<td class="num">(6,982,664)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">263,571<span></span>
</td>
<td class="nump">140,956<span></span>
</td>
<td class="nump">127,512<span></span>
</td>
<td class="num">(35,839)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,200<span></span>
</td>
<td class="num">(1,343,856)<span></span>
</td>
<td class="num">(197,544)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income tax benefit/(provision for income tax)</a></td>
<td class="num">(38,235,146)<span></span>
</td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="num">(29,685,847)<span></span>
</td>
<td class="num">(29,351,667)<span></span>
</td>
<td class="num">(32,962,205)<span></span>
</td>
<td class="num">(25,015,672)<span></span>
</td>
<td class="num">(6,639,125)<span></span>
</td>
<td class="num">(30,181,017)<span></span>
</td>
<td class="num">(120,809,112)<span></span>
</td>
<td class="num">(94,798,019)<span></span>
</td>
<td class="num">(88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">87,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">106,771<span></span>
</td>
<td class="nump">62,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,169,811)<span></span>
</td>
<td class="nump">257,335<span></span>
</td>
<td class="num">(2,169,811)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(38,147,382)<span></span>
</td>
<td class="num">(23,536,452)<span></span>
</td>
<td class="num">(29,579,076)<span></span>
</td>
<td class="num">(29,288,867)<span></span>
</td>
<td class="num">$ (32,962,205)<span></span>
</td>
<td class="num">$ (25,015,672)<span></span>
</td>
<td class="num">$ (6,639,125)<span></span>
</td>
<td class="num">$ (32,350,828)<span></span>
</td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
<td class="num">(88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">485,344<span></span>
</td>
<td class="nump">445,759<span></span>
</td>
<td class="nump">191,850<span></span>
</td>
<td class="nump">69,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192,558<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (37,662,038)<span></span>
</td>
<td class="num">$ (23,090,693)<span></span>
</td>
<td class="num">$ (29,387,226)<span></span>
</td>
<td class="num">$ (29,219,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (119,359,219)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic ($ per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted ($ per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 184,523<span></span>
</td>
<td class="nump">$ 617,427<span></span>
</td>
<td class="nump">$ 64,283<span></span>
</td>
<td class="nump">$ 2,770,712<span></span>
</td>
<td class="nump">$ 2,372,600<span></span>
</td>
<td class="nump">$ 1,813,287<span></span>
</td>
<td class="nump">$ 24,385,852<span></span>
</td>
<td class="nump">$ 1,289,046<span></span>
</td>
<td class="nump">$ 3,636,945<span></span>
</td>
<td class="nump">$ 29,860,785<span></span>
</td>
<td class="nump">$ 28,407,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember', window );">Revenue under collaborative research and development arrangements with affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">55,665<span></span>
</td>
<td class="nump">53,014<span></span>
</td>
<td class="nump">71,390<span></span>
</td>
<td class="nump">55,579<span></span>
</td>
<td class="nump">56,207<span></span>
</td>
<td class="nump">184,990<span></span>
</td>
<td class="nump">60,319<span></span>
</td>
<td class="nump">148,008<span></span>
</td>
<td class="nump">$ 235,649<span></span>
</td>
<td class="nump">$ 449,524<span></span>
</td>
<td class="nump">$ 765,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Miscellaneous revenue, including from affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 39,300<span></span>
</td>
<td class="nump">$ 196,422<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,614<span></span>
</td>
<td class="nump">$ 73,817<span></span>
</td>
<td class="nump">$ 2,591<span></span>
</td>
<td class="nump">$ 2,590<span></span>
</td>
<td class="nump">$ 92,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInFairValueOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of common stock warrants which are measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInFairValueOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI http://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LicensewithAffiliatedEntitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806430960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes Summary of the Provision for Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,170,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">2,170,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(263,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">$ (87,764)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (106,771)<span></span>
</td>
<td class="num">$ (62,800)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,169,811<span></span>
</td>
<td class="num">$ (257,335)<span></span>
</td>
<td class="nump">$ 2,169,811<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6793025344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Expected Expirations of Federal and State Losses and Credits (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2021</a></td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2022</a></td>
<td class="nump">6.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2023</a></td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2024</a></td>
<td class="nump">282.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">186.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">483.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths', window );">2020</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2021</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2022</a></td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2023</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2024</a></td>
<td class="nump">148.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">149.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths', window );">2020</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinThreeMonths', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFourMonths', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2024</a></td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths', window );">2020</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2021</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinThreeMonths', window );">2022</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFourMonths', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in the Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringintheNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Indefinitely Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsIndefinitelyCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Carryforward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardCarryforwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFourMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Four Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFourMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Three Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in the Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringintheNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6960963024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Accounts Payable and Accrued Expenses</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consist of the following:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,919,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,043,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,967,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,466,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued subcontract costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,076,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,540,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,237,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,134,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972964480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">Major Customers and Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Major Customers and Concentration of Credit Risk</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Customer</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ApolloBio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AstraZeneca</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,850,424</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,269,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DARPA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,983,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,107,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other, including affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">917,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,859,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111,930</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,481,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,220,086</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from various license fees and collaborative research and development agreements. The Company has determined that as of January 1, 2018, accounting for the Company&#8217;s various grant agreements falls under the contributions guidance under Subtopic 958-605</font><font style="font-family:inherit;font-size:10pt;color:#333333;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Not-for-Profit Entities-Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#333333;">,</font><font style="font-family:inherit;font-size:10pt;"> which is outside the scope of Topic 606. Beginning on January 1, 2018, all contributions received from current grant agreements have been recorded as a contra-expense as opposed to revenue on the consolidated statements of operations, as discussed in Note 2. During the year ended December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue from various license fees, collaborative research and development agreements, grants and government contracts. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$469,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">67%</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$161,000</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">23%</font><font style="font-family:inherit;font-size:10pt;">, of the Company's accounts receivable was attributable to MCDC and AstraZeneca, respectively. As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, $</font><font style="font-family:inherit;font-size:10pt;">3.2 million</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;">, of the Company's accounts receivable was attributable to AstraZeneca. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972622928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition  </font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized total revenue under collaborative research and development and other agreements determined to be contracts with a customer of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> from AstraZeneca and </font><font style="font-family:inherit;font-size:10pt;">$917,000</font><font style="font-family:inherit;font-size:10pt;"> from various other contracts. The Company defers revenue when a contract is entered into with a collaborator and cash payments are received prior to satisfaction of the related performance obligation. Of the total revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$293,000</font><font style="font-family:inherit;font-size:10pt;"> was in deferred revenue as of December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. During the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> that was included in deferred revenue at December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. Performance obligations are generally satisfied within 12 months of the initial contract date.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791124320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of major customers and concentration risks</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:32%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Customer</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">%&#160;of&#160;Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ApolloBio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,000,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">AstraZeneca</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,194,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,850,424</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,269,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">DARPA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,983,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Roche</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,107,254</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All other, including affiliated entities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">917,053</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">631,473</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,859,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,111,930</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,481,897</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,220,086</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791124320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses at December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> consist of the following:</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Trade accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,919,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,043,816</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,967,897</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,466,821</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued subcontract costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">273,508</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83,812</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,076,772</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,540,284</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,237,258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,134,733</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6608515568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 1,066,294<span></span>
</td>
<td class="nump">$ 1,249,584<span></span>
</td>
<td class="nump">$ 1,618,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6813473296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers and Concentration of Credit Risk (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 2,502,624<span></span>
</td>
<td class="nump">$ 2,000,868<span></span>
</td>
<td class="nump">$ 24,448,761<span></span>
</td>
<td class="nump">$ 1,529,644<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
<td class="nump">$ 42,220,086<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioMember', window );">ApolloBio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_ApolloBioMember', window );">ApolloBio | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MedImmuneMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,194,877<span></span>
</td>
<td class="nump">$ 6,850,424<span></span>
</td>
<td class="nump">$ 22,269,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MedImmuneMember', window );">AstraZeneca | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">53.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MedImmuneMember', window );">AstraZeneca | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember', window );">DARPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,983,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember', window );">DARPA | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_HoffmanLaRocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,107,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_HoffmanLaRocheMember', window );">Roche | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,053<span></span>
</td>
<td class="nump">$ 631,473<span></span>
</td>
<td class="nump">$ 3,859,132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MCDCMember', window );">MCDC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_MCDCMember', window );">MCDC | Accounts Receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_MedImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_MedImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_HoffmanLaRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_HoffmanLaRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_MCDCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_MCDCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811570784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Affiliated Entities (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne Life Sciences | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="nump">1,644,155<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="nump">395,758<span></span>
</td>
<td class="nump">395,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6808433904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 09, 2020</div></th>
<th class="th"><div>Feb. 07, 2020</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 11, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,089,010<span></span>
</td>
<td class="nump">$ 29,227,776<span></span>
</td>
<td class="nump">$ 94,347,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember', window );">Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementAgentFee', window );">Agent fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember', window );">Sales Agreement | Common stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Authorized amount</a></td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,148,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 208,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share ($ per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementAgentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Agent Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementAgentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6807972768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="nump">$ 7,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">110,788<span></span>
</td>
<td class="nump">89,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Research and development and other tax credits</a></td>
<td class="nump">11,737<span></span>
</td>
<td class="nump">9,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,255<span></span>
</td>
<td class="nump">3,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDerivativeInstruments', window );">Derivative liability</a></td>
<td class="nump">1,852<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetInterestExpense', window );">Interest expense</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in affiliated entity</a></td>
<td class="nump">645<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">4,722<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,413<span></span>
</td>
<td class="nump">2,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">145,229<span></span>
</td>
<td class="nump">116,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(137,159)<span></span>
</td>
<td class="num">(115,007)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">8,070<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investment in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(2,894)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount', window );">Note discount</a></td>
<td class="num">(2,862)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Convertible note</a></td>
<td class="num">(1,381)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(805)<span></span>
</td>
<td class="num">(1,121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (24)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Financing Arrangement, Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesFinancingArrangementDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDerivativeInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDerivativeInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6788238864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2010</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Full payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Long-term other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,672,024<span></span>
</td>
<td class="nump">2,669,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember', window );">GeneOne (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Payment received for license granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_MilestoneBasedOwnershipTarget', window );">Ownership target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Full payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,000<span></span>
</td>
<td class="nump">342,000<span></span>
</td>
<td class="nump">551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Accounts payable/accrued liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511,000<span></span>
</td>
<td class="nump">372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Long-term other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">284,000<span></span>
</td>
<td class="nump">381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember', window );">PLS (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,000<span></span>
</td>
<td class="nump">107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,000<span></span>
</td>
<td class="nump">478,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">616,000<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_ProceedsFromSubGrant', window );">Proceeds from sub-grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="nump">$ 554,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_MilestoneBasedOwnershipTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone-Based Ownership Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_MilestoneBasedOwnershipTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromSubGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sub-Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromSubGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611322-123010<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-12C.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611225-123010<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12.Column B)<br> -URI http://asc.fasb.org/extlink&amp;oid=50485924&amp;loc=d3e611133-123010<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637345&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_GeneOneLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6811920768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_NumeratorAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (37,662,038)<span></span>
</td>
<td class="num">$ (23,090,693)<span></span>
</td>
<td class="num">$ (29,387,226)<span></span>
</td>
<td class="num">$ (29,219,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (119,359,219)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (88,205,772)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AdjustmentForChangeInFairValueOfWarrantLiability', window );">Adjustment for decrease in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(806,819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Numerator for use in diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (119,359,219)<span></span>
</td>
<td class="num">$ (96,967,830)<span></span>
</td>
<td class="num">$ (89,012,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DenominatorAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding (denominator for use in basic net loss per share) (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,717,999<span></span>
</td>
<td class="nump">92,539,997<span></span>
</td>
<td class="nump">81,777,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Effect of dilutive potential common shares (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">140,529<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for use in diluted loss per share (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,717,999<span></span>
</td>
<td class="nump">92,539,997<span></span>
</td>
<td class="nump">81,918,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted ($ per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic ($ per share)</a></td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (1.21)<span></span>
</td>
<td class="num">$ (1.05)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AdjustmentForChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment For Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AdjustmentForChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791970176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 279,488<span></span>
</td>
<td class="nump">$ 866,863<span></span>
</td>
<td class="nump">$ 135,673<span></span>
</td>
<td class="nump">$ 2,829,905<span></span>
</td>
<td class="nump">$ 2,502,624<span></span>
</td>
<td class="nump">$ 2,000,868<span></span>
</td>
<td class="nump">$ 24,448,761<span></span>
</td>
<td class="nump">$ 1,529,644<span></span>
</td>
<td class="nump">$ 4,111,930<span></span>
</td>
<td class="nump">$ 30,481,897<span></span>
</td>
<td class="nump">$ 42,220,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_MedImmuneMember', window );">AstraZeneca</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember', window );">Other Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_MedImmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_MedImmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_OtherCounterpartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_OtherCounterpartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6785757248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Lease Payments Before Adoption of Topic 842 (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 3,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">3,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">3,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">4,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">4,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">15,952<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 35,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6792974272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity Summary of Stock Option Activity Under Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning Balance (shares) | shares</a></td>
<td class="nump">8,752,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares) | shares</a></td>
<td class="nump">2,596,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares) | shares</a></td>
<td class="num">(42,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (shares) | shares</a></td>
<td class="num">(2,040,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending Balance (shares) | shares</a></td>
<td class="nump">9,265,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning Balance ($ per share) | $ / shares</a></td>
<td class="nump">$ 6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted ($ per share) | $ / shares</a></td>
<td class="nump">3.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised ($ per share) | $ / shares</a></td>
<td class="nump">2.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled ($ per share) | $ / shares</a></td>
<td class="nump">5.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending Balance ($ per share) | $ / shares</a></td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972940096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Trade accounts payable</a></td>
<td class="nump">$ 6,919,081<span></span>
</td>
<td class="nump">$ 10,043,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">8,967,897<span></span>
</td>
<td class="nump">9,466,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedSubcontractExpenses', window );">Accrued subcontract costs</a></td>
<td class="nump">273,508<span></span>
</td>
<td class="nump">83,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">2,076,772<span></span>
</td>
<td class="nump">3,540,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 18,237,258<span></span>
</td>
<td class="nump">$ 23,134,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedSubcontractExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontract Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedSubcontractExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6972953584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;7, 2020, the Company entered into an amendment to the Sales Agreement, which amendment increased the amount of common stock that could be sold by the Company under the Sales Agreement from an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> to an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;">. On March&#160;9, 2020, the Company entered into a second amendment to the&#160;Sales Agreement, which amendment increased the amount of common stock that could be sold by the Company under the Sales Agreement from an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$200.0 million</font><font style="font-family:inherit;font-size:10pt;"> to an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;">. Under the Sales Agreement, as amended, the Company set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales were requested to be made, limitation on the number of shares that could be sold in any one trading day and any minimum price below which sales could not be made. The Sales Agreement provided that the Placement Agent is entitled to compensation for its services in an amount equal to up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds from the sales of shares sold through the Placement Agent under the Sales Agreement. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From January 1, 2020 through </font><font style="font-family:inherit;font-size:10pt;">March&#160;11, 2020</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">43,148,952</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under its Sales Agreement for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$208.2</font><font style="font-family:inherit;font-size:10pt;"> million. The sales were made at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$4.92</font><font style="font-family:inherit;font-size:10pt;"> per share. As of the date these financial statements were issued, there is no remaining capacity under the Sales Agreement, as amended.</font></div><div style="line-height:120%;text-align:left;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 20, 2020, the Company entered into a Debt and Share Subscription Agreement with PLS under which the Company will receive shares of PLS common stock in exchange for a portion of the outstanding accounts receivable balance due from PLS. Following the issuance of these shares, the Company will hold a </font><font style="font-family:inherit;font-size:10pt;">19.9%</font><font style="font-family:inherit;font-size:10pt;"> ownership interest in PLS.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6806700112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,196,097<span></span>
</td>
<td class="nump">$ 23,693,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">67,338,017<span></span>
</td>
<td class="nump">57,538,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">700,073<span></span>
</td>
<td class="nump">3,316,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">1,332,044<span></span>
</td>
<td class="nump">738,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,584,598<span></span>
</td>
<td class="nump">1,406,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">1,050,140<span></span>
</td>
<td class="nump">1,120,805<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">94,200,969<span></span>
</td>
<td class="nump">87,814,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">12,773,017<span></span>
</td>
<td class="nump">15,949,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entities</a></td>
<td class="nump">6,315,356<span></span>
</td>
<td class="nump">9,405,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">3,693,851<span></span>
</td>
<td class="nump">4,760,145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">13,783,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,672,024<span></span>
</td>
<td class="nump">2,669,998<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">143,951,597<span></span>
</td>
<td class="nump">131,113,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">18,237,258<span></span>
</td>
<td class="nump">23,134,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">729,729<span></span>
</td>
<td class="nump">977,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">4,049,727<span></span>
</td>
<td class="nump">5,671,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">92,353<span></span>
</td>
<td class="nump">223,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredRevenueFromAffiliatedEntityCurrent', window );">Deferred revenue from affiliated entities</a></td>
<td class="nump">31,775<span></span>
</td>
<td class="nump">33,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,065,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,074,842<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">6,065,212<span></span>
</td>
<td class="nump">4,165,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">708,425<span></span>
</td>
<td class="nump">27,083<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,989,321<span></span>
</td>
<td class="nump">35,299,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">101,567<span></span>
</td>
<td class="nump">150,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">8,819,023<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,518,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">20,409,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">24,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateNoncurrent', window );">Grant funding liability from affiliated entity, net of current portion</a></td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">36,943<span></span>
</td>
<td class="nump">87,333<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">138,546,739<span></span>
</td>
<td class="nump">44,080,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2019 and December 31, 2018</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2019 and December 31, 2018, issued and outstanding: 101,361,034 at December 31, 2019 and 97,225,810 at December 31, 2018</a></td>
<td class="nump">101,361<span></span>
</td>
<td class="nump">97,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">742,646,785<span></span>
</td>
<td class="nump">707,794,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(739,785,655)<span></span>
</td>
<td class="num">(620,426,436)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">472,608<span></span>
</td>
<td class="num">(528,867)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">3,435,099<span></span>
</td>
<td class="nump">86,936,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">1,969,759<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">5,404,858<span></span>
</td>
<td class="nump">87,032,407<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">143,951,597<span></span>
</td>
<td class="nump">131,113,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">64,180,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="nump">$ 12,842,592<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredRevenueFromAffiliatedEntityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable from related parties as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredRevenueFromAffiliatedEntityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6968345376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are presented in the following table: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(263,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax expense (benefit), using a </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> statutory tax rate for December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">35%</font><font style="font-family:inherit;font-size:10pt;"> statutory tax rate for December 31, 2017, is as follows:</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (benefit) taxes at statutory rates</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,370,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,908,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,872,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State income tax, net of federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,457,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,898,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,965,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,838,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,170,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,456,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of warrants</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(282,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,114,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,094,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,332,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,537,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,268,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">846,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expired NOLs and credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">616,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,176,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">454,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Limited NOLs and credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(616,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,176,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(165,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in tax rates</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,019,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(102,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,093,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(257,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,170,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax benefit recorded during the year ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> is principally due to a requirement under Accounting Standards Codification ("ASC") 740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Accounting for Income Taxes</font><font style="font-family:inherit;font-size:10pt;">, that a company must consider all sources of income in order to determine the tax benefit resulting from a loss from continuing operations. As a result of the requirement under ASC 740-20-45-7, the pretax income which the Company generated from other comprehensive income was a source of income which resulted in the partial realization of the current year loss from continuing operations.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> are shown below:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capitalized research expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,300,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,408,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NOL carryforwards</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">110,788,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">89,399,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development and other tax credits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,737,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,432,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,506,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">985,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,013,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,408,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">889,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">912,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Derivative liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,852,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,122,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease liability</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,722,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,413,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,693,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145,229,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,250,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(137,159,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115,007,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,070,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,243,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Acquired intangibles</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(160,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(142,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investment in affiliated entity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right of use asset</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,894,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Note discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,862,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible note</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,381,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fixed assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,121,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$483.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$68.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$80.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The federal net operating loss generated in 2018 and 2019 of </font><font style="font-family:inherit;font-size:10pt;">$186.6 million</font><font style="font-family:inherit;font-size:10pt;"> will carryforward indefinitely and be available to offset up to </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of future taxable income each year. The federal NOL carryforward began to expire in </font><font style="font-family:inherit;font-size:10pt;">2020</font><font style="font-family:inherit;font-size:10pt;">, and the California and Pennsylvania NOL carryforwards will begin to expire in 2028 and </font><font style="font-family:inherit;font-size:10pt;">2021</font><font style="font-family:inherit;font-size:10pt;">, respectively, unless previously utilized. </font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, as of December 31, 2019, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$17.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</font></div><div style="line-height:120%;padding-top:6px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Federal NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">State NOLs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Federal R&amp;D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">State R&amp;D</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.4</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2024 and thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">282.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">148.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indefinite</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">186.6</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">483.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">149.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis, regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2019. As a result of the analysis, the Company estimates that approximately </font><font style="font-family:inherit;font-size:10pt;">$10.6 million</font><font style="font-family:inherit;font-size:10pt;"> of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the activity related to the Company's unrecognized tax benefits:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of the year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,632,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,313,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,855,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases related to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,575,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,319,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,532,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases (decreases) related to prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of the year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,204,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,632,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,313,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of December&#160;31, </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</font></div><div style="line-height:120%;padding-top:6px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2016 and state and local income tax examinations before 2015. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not currently under Internal Revenue Service (&#8220;IRS&#8221;), state or local tax examination.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6797763968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">74,062,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="nump">$ 123,378,420<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 74,062<span></span>
</td>
<td class="nump">$ 556,718,356<span></span>
</td>
<td class="num">$ (434,838,235)<span></span>
</td>
<td class="nump">$ 1,327,968<span></span>
</td>
<td class="nump">$ 96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,437,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs of $4.9 million</a></td>
<td class="nump">94,347,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,437<span></span>
</td>
<td class="nump">94,332,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">857,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">1,342,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,341,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13,070,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,070,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(88,205,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,205,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on short-term investments, net of tax</a></td>
<td class="nump">7,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax', window );">Unrealized loss on investment in affiliated entity, net of tax</a></td>
<td class="num">(1,452,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,452,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">90,357,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">142,488,809<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 90,358<span></span>
</td>
<td class="nump">665,775,504<span></span>
</td>
<td class="num">(523,356,317)<span></span>
</td>
<td class="num">(117,005)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,669,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs of $4.9 million</a></td>
<td class="nump">29,227,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,669<span></span>
</td>
<td class="nump">29,222,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,199,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">1,809,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,199<span></span>
</td>
<td class="nump">1,808,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,654,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,988,277<span></span>
</td>
<td class="num">(333,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(96,967,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,967,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on short-term investments, net of tax</a></td>
<td class="num">(180,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180,496)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax', window );">Unrealized loss on investment in affiliated entity, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">97,225,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">87,032,407<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 97,226<span></span>
</td>
<td class="nump">707,794,215<span></span>
</td>
<td class="num">(620,426,436)<span></span>
</td>
<td class="num">(528,867)<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,340,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs of $4.9 million</a></td>
<td class="nump">9,089,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,340<span></span>
</td>
<td class="nump">9,085,669<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">794,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(780,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 795<span></span>
</td>
<td class="num">(781,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of issuance of convertible notes</a></td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,752,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">10,901,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,795,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos, net</a></td>
<td class="nump">2,960,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,960,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(120,551,777)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,359,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,192,558)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on short-term investments, net of tax</a></td>
<td class="nump">1,001,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax', window );">Unrealized loss on investment in affiliated entity, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5,404,858<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="nump">$ 742,646,785<span></span>
</td>
<td class="num">$ (739,785,655)<span></span>
</td>
<td class="nump">$ 472,608<span></span>
</td>
<td class="nump">$ 1,969,759<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Investment In Affiliated Entity, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OtherComprehensiveIncomeLossUnrealizedGainLossOnInvestmentInAffiliatedEntityNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
